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The most intimate mechanisms of cardiac arrhythmias are still quite unknown to 
scientists. Genetic studies on ionic alterations, the electrocardiographic features 
of cardiac rhythm and an arsenal of diagnostic tests have done more in the last five 
years than in all the history of cardiology. Similarly, therapy to prevent or cure such 
diseases is growing rapidly day by day. In this book the reader will be able to see with 
brighter light some of these intimate mechanisms of production, as well as cutting-
edge therapies to date. Genetic studies, electrophysiological and electrocardiographyc 
features,  ion channel alterations, heart diseases still unknown , and even the 
relationship between the psychic sphere and the heart have been exposed in this book. 
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The book Cardiac Arrythmias contains a spectrum of different topics within the 
subject area presented in chapters written with a magnificent scientific rigour. Some of 
the topics include: the most prevalent causes of cardiac arrhythmias and their 
mechanisms of production; some emergent or almost unknown electrical cardiac 
disorders; ionic diseases; mapping and ablation techniques; and some original insights 
on psychological disorders related to cardiac arrythmias as well as some pathologies 
which can affect the heart in different ways, and vice versa. The book also includes the 
most current treatments of Cardiac Arrythmias.  
It is my opinion as the editor that all the authors in this book have done an excellent 
job writing their chapters, which resulted in the publication becoming a proper 
textbook. I fervently hope that reading it will be as enjoyable and informative for all 
the readers as much as it has been for me. My sincere congratulations to all the authors 
for their work.  
 
Prof. Dr. F. R. Breijo-Marquez,  
Titular Professor of Clinical and Experimental Cardiology, 
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Novel Genomic Approach  
to the Arrhytmogenic Sudden Cardiac Death 
Maria Brion, Beatriz Sobrino, Alejandro Blanco-Verea,  
Montserrat Santori, Rocio Gil and Angel Carracedo 
Genomic Medicine Group, IDIS, CIBERER-University of Santiago, FPGMX 
Spain 
1. Introduction  
Unfortunately, most of the common diseases in cardiology do not show traditional 
Mendelian genetics, they usually are complex genetic diseases resulting from the 
combination of multiple heritable and environmental factors. However, one of the 
cardiology dysfunction that can affect apparently healthy young adults or with any 
previous heart disease, such as sudden cardiac death (SCD), could be the first symptom of a 
Mendelian disease such as cardiomyopathies or channelopathies. 
In many of the SCD cases, especially in case of young people, the cause of death cannot be 
explained neither after autopsy nor after laboratory tests. Inherited heart diseases such as 
hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and primary electrical diseases such as long QT syndrome (LQTS), Brugada 
syndrome (BrS) or catecholaminergic polymorphic ventricular tachycardia (CPVT), are the 
main cause of death in young adults with no previous clinical history. Most often these 
inherited cardiac disorders give rise to lethal ventricular arrhythmias and show an 
autosomal dominant mode of inheritance. 
Genetic screening of the genes described as implicated in the different pathologies may help 
to determine the cause of death and to evaluate the potential risk of the relatives. Today we 
know which are the main causes of sudden cardiac death in young adults and we also know 
which are the genes responsible of these diseases in a high percentage of cases. The aim of 
this article is to present to the reader the estate of the art of the use of the new next 
generation sequencing technologies for the study of arrhythmogenic sudden cardiac deaths. 
We will discuss the different available technologies, and the different applications: 
Candidate gene resequencing. We will describe the interesting genes to be studied and the 
different strategies available for their enrichment and sequencing 
Whole exome resequencing. We will describe the application of this approach to those cases 
were we need to look for new genes. 
2. Inherited arrhythmogenic diseases 
There are various arrhythmogenic disorders, with different electrocardiographic patterns, 
which are not always present or are not evident in carriers of mutations implicated in the 
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pathology. In general these are diseases with low penetrance so the genetic study is of great 
importance in patients with personal or family history of sudden cardiac death. 
The term inherited arrhythmogenic diseases typically includes cardiac diseases caused by 
mutations in ion channels and ion channel-controlling proteins such as the long-QT syndrome 
(LQTS), the short QT syndrome (SQTS), the Brugada syndrome (BrS) and catecholaminergic 
polymorphic ventricular tachycardia (CPVT). Ion channels are integral membrane proteins 
that regulate the flow of ions across the cell membrane. They consist of multimeric units 
generally encoded by different genes. The α subunit forms the pore and mediates ion current, 
while the β subunits are regulatory. Defects in these channels due to mutations in genes that 
encode proteins, or mutations in proteins associated with these channels may lead to an 
electrical disturbance in the heart linked to the development of channelopathies. 
2.1 Long QT syndrome 
The Long QT Syndrome (LQTS) is characterized by prolongation of the QT interval on the 
electrocardiogram, which indicates ventricular repolarisation unusually long, due either to a 
decrease in the K+ flow of repolarisation or to a delayed entry of Na+ into the myocyte. 
The estimated incidence is between 1:2000 -1:5000 people (Hedley et al., 2009), and its 
penetrance  is variable, ranging from sub clinical phenotypes with a QT interval at the limit, 
without arrhythmias or syncope (Napolitano et al., 2005; Priori et al., 1999; Vicent et al., 
1992) to sudden cardiac death, being a major cause of sudden death in young people. To 
determine wheter the QT interval is prolonged the corrected QT interval (QTc) is used, 
which is calculated using the Bazzet formula QTc = QT / √ RR (Bazzet et al., 1920) Are 
considered abnormally prolonged QTc values when exceeding 440 ms in men and those 
over 460 ms in women (values corrected for heart rate). It is estimated that a patient with a 
QTc interval of 550 ms has a 63% higher risk of suffering a cardiac event that an individual 
with a value of QTc interval of 450 ms. (Zareba et al., 2008). 
The LQTS shows a congenital form of the disease in about 85% of cases and a sporadic form 
which corresponds to 15% [85]. There is also an acquired form of QT prolongation caused 
mainly by drugs, both cardiac (e.g. antiarrhythmics) and other medications (e.g. 
antidepressants) or derived from an electrolyte imbalance. The congenital form shows two 
basic patterns of inheritance, one autosomal dominant called Romano-Ward syndrome and 
another autosomal recessive known as Jervell Lange-Nielsen syndrome, which presents 
with congenital deafness. To date 12 genes have been described in the pathology. The most 
common are genes that encode K + channels, KCNQ1, KCNH2, which represent about 40-
55% and 35-45% of cases respectively,  and the SCN5A gene coding for Na + channels which 
represents a 2 - 8% of cases (Hedley et al., 2009). The involvement of each of these genes 
leads to defined clinical phenotypes, so KCNQ1 gene leads to LQTS type 1 (LQT1), KCNH2 
causes LQTS type 2 (LQT2) and SCN5A leads to LQTS3 (LQT3). 
2.2 Short QT syndrome 
The short QT syndrome (SQTS) has been recognized as a clinical entity characterized 
recently by a shortened QT interval that can lead to arrhythmias and sudden cardiac death 
(Gussak et al., 2000). Although there is no established consensus, it is accepted that a value 
between 320ms and 340 ms are considered short (although it could be considered normal 
340ms) if there is a history of cardiac symptoms such as syncope or aborted sudden death. 
Nevertheless, as in LQTS, the transition zone of normal QT intervals to pathological 
intervals is difficult to establish (Schimpf et al., 2007). 
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In SQTS, mutations in genes encoding K + channels: KCNH2, KCNJ2, and KCNQ1, cause a 
gain of function of these channels and give rise to SQTS1, SQTS2and SQTS3 respectively. 
However, mutations in genes encoding α and β2 subunits of the Cav1.2 channel, the 
CACNB2 and CACNA1C genes, cause loss of function of these channels and give rise to 
SQTS4 and SQTS5 phenotype respectively  (Hedley et al., 2009). 
2.3 Brugada syndrome 
Brugada Syndrome (BrS) is characterized by ST segment elevation in right precordial leads 
(V1-V3) of the electrocardiogram and can also be associated with an increase in PR interval 
and bundle branch block. Penetrance is also variable, and can trigger polymorphic ventricular 
tachycardia and / or ventricular fibrillation and sudden death. The distribution and incidence 
of this disease is difficult to determine because it is a syndrome recently described and because 
electrocardiographic manifestations are not always present. Campuzano et al. (2010) estimate a 
prevalence of approximately 35/100000 persons / year and they say that, although symptoms 
usually develop around the age of 40, sudden death can affect individuals of any age. They 
estimate sudden death affects 75% of the affected males, and between 20 and 50% of the 
affected people have a family history of sudden death. 
The dominant pattern of inheritance is autosomal dominant with expression probably age 
dependent and incomplete penetrance. Today we have described more than 100 mutations 
in 7 different genes that give rise to the 7 types of BrS. These genes encode proteins of both 
Na + channels and other ion channels. The mutations affect the proper development of 
phases 1 and 2 of the cardiac action potential (Hedley et al., 2009b). It is estimated that 20-
25% of BrS patients show mutations in the SCN5A gene (Schott et al., 1999), which also 
represents 5-10% of mutations found in cases of sudden cardiac death in adults and children 
(Hedley et al., 2009b) . 
2.4 Catecholaminergic polymorphic ventricular tachycardia 
Catecolaminergic polymorphic ventricular tachycardia (CPVT) occurs with a characteristic 
pattern of bidirectional or polymorphic tachycardia related to stress without structural 
cardiac abnormalities (Coumel et al., 1978). These clinical manifestations often occur during 
childhood and adolescence. 
The CPVT has two modes of inheritance: autosomal dominant and recessive. The autosomal 
dominant form is caused by mutations in the gene encoding the ryanodine receptor RyR2, 
which is a large protein that forms the calcium release channel in sarcoplasmic reticulum. 
The recessive form of the disease is caused by mutations in the cardiac isoform 
calciquestrina gene (CASQ2), which binds to the ryanodine receptor and participates in the 
control of excitation-contraction (Ylänen et al., 2010). The steps of the molecular 
pathogenesis of CPVT are not entirely clear, but Mutations of the two interacting proteins, 
RyR2 and CASQ2, seem to result in inadequately controlled Ca2+ bursts into the 
sarcoplasm, with concomitant risk of delayed afterdepolarizations and triggered 
arrhythmia. 
3. Genetic screening of arrhythmogenic diseases 
The importance of knowing the molecular substrate in patients with inherited cardiac 
channelopathies is recognized and highlighted in the guidelines for the prevention of SCD 
developed by the American Heart Association, the American College of Cardiology, and the 
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European Society of Cardiology (Zipes et al., 2006). Screening for mutations in genes that 
encode cardiac ion channels associated with LQTS, SQTS, BrS, and CPVT is primarily 
sought in clinically affected patients to tailor risk stratification and management and to 
further identify family members (Priori et al., 2002a, b, 2003). However, genetic analysis is 
not yet available at most clinical centres and it is still mainly performed in finite research 
laboratories. 
Our present understanding of human inherited arrhythmia diseases has become 
increasingly complex. Several clinical syndromes have been identified as human inherited 
arrhythmia diseases and at least 21 genes are known to cause these diseases. These genes 
and the associated syndromes are given in Table 1. Mutations associated with inherited 
arrhythmia syndromes occur in ion channel pore-forming proteins, associating subunit 
proteins and channel interacting proteins ,Ca2+ handling proteins, components of the ion 
cannel macromolecular complex, and regulatory pathways. Although most inherited 
arrhythmia syndromes are rare clinical findings, sometimes with just a single family 
described.  
Several studies have been published trying to determine the effectiveness of genetic 
screening (Bai et al., 2009; Kapplinget et al., 2009) in terms of efficiency and cost. Bay et al. 
(2009) showed that the current cost of genetic testing for inherited cardiac channelopathies is 
reasonable for those who have a conclusive diagnosis and that these patients should have 
priority access to genetic screening (Fuster et al., 2008) However, until now these studies 
were limited by two main drawbacks, the reduced effectiveness of the techniques of genetic 
determination employed and the high cost of the same. 
 
Gen Symbol Locus CPVT LQTS SQTS BrS 
A kinase  anchor protein (yotiao) 9 AKAP9 7q21-q22 x 
ankyrin 2 ANK2 4q25-q27 x 
calcium channel, voltage-dependent, L type, alpha 1C subunit CACNA1C 12p13.3 x x x 
calcium channel, voltage-dependent, beta 2 subunit CACNB2 10p12 x x 
calsequestrin 2 CASQ2 1p13.3-p11 x 
caveolin 3 CAV3 3p25 x 
glycerol-3-phosphate dehydrogenase 1-like GPD1L 3p22.3   x 
hyperpolarization activated cyclic nucleotide-gated potassium channel 4 HCN4 15q24.1 x 
potassium voltage-gated channel, Isk-related family, member 1 KCNE1 21q22.12 x 
potassium voltage-gated channel, Isk-related family, member 2 KCNE2 21q22.12 x 
potassium voltage-gated channel, Isk-related family, member 3 KCNE3 11q13.4 x 
potassium voltage-gated channel, subfamily H, member 2 KCNH2 7q36.1 x x 
potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 17q24.3 x x 
potassium inwardly-rectifying channel, subfamily J, member 5 KCNJ5 11q24 x 
potassium voltage-gated channel, KQT-like subfamily, member 1 KCNQ1 11p15.5 x x 
ryanodine receptor 2 RYR2 1q43 x 
sodium channel, voltage-gated, type I, beta SCN1B 19q13,1 x 
sodium channel, voltage-gated, type III, beta SCN3B 11q23,3 x 
sodium channel, voltage-gated, type IV, beta SCN4B 11q23.3 x 
sodium channel, voltage-gated, type V, alpha subunit SCN5A 3p21 x x 
syntrophin, alpha 1 SNTA1 20q11.2   x     
Table 1. Genes related to arrhythmogenic sudden cardiac death 
Today, with the development of the next generation sequencing strategies, these two 
problems are being overcome, so that on one hand, we managed to sequence as many genes 
as we want, detecting both, genetic variants already described and new variants not yet 
known; and on the other hand, we have significantly reduced the cost of each genetic 
screening and we hope that this reduction will still see increased in the future days. 
The new next generation sequencing technologies are allowing us sequencing large number 
of DNA fragments or genes, using target resequencing strategies, in a fast, reliable and 
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effective way. The selection of the genes will depend on the researcher's own interests, so 
that in our case, we could focus on those genes previously described as involved in 
arrhythmogenic heart diseases or we can make the sequencing of all genes and search 
exome mutations also in genes that have not previously been associated with the pathology.  
If we consider the aforementioned 21 genes as candidate genes to be sequenced, It would 
involve the sequencing of approximately 400 exons, accounting around 120.000 base pairs of 
coding DNA. This work, in terms of time and cost of each analysis represents a major 
handicap for the routine work of many small laboratories dedicated to genetic diagnosis of 
these pathologies. An indicative example of this type of analysis is the Familion test for 
Long QT syndrome (Kapplinger et al., 2009), a  bidirectional DNA sequencing-based assay 
that comprises analysis of 73 polymerase chain reaction (PCR) amplicons to analyse the 3 
major LQTS-susceptibility genes (KCNQ1 [LQT1], KCNH2 [LQT2], SCN5A [LQT3]) along 
with 2 minor genes (KCNE1 [LQT5] and KCNE2 [LQT6]). Kapplinger et al (2009) evaluated 
the Familion Test in 2500 unrelated LQTS cases and they found 903 positive genetic tests 
describing 562 putative mutations absent in 2600 reference alleles.  They reported that 
despite the passage of 14 years since the first LQTS-causative mutations were discovered, 
still one-third of the mutations being discovered today are novel; therefore, this study is 
further evidence of the need for genetic screening strategies that allow us to detect both 
known mutations and new genetic variants, such as the sequencing. In addition, the study 
highlights the need for functional studies providing evidence on the possible pathogenicity 
for new genetic variants that are being described. Here we describe the implementation of a 
new research strategy using next generation sequencing,  that allows the simultaneous 
study of the sequence of all the genes described in relation to arrhythmogenic disorders at 
risk of sudden cardiac death (candidate gene approach), or the study of the complete 
sequence of the human exome (whole exome approach), searching for genetic variants both 
in genes previously associated with sudden cardiac death and in new genes whose 
involvement in the fatal event is currently unknown 
4. Next generation sequencing 
Capillary electrophoresis based in Sanger sequencing is the technology widely used for 
analyzing genes involves in different pathologies. However, over the past five years, Next 
Generation Sequencing (NGS) technologies have became a reliable tool for massive parallel 
sequencing, overcoming the limitations in throughput and speed of capillary electrophoresis 
(Shendure & Ji,  2008; Metzer, 2010; Glenn , 2011) .   
On this chapter we will focus on commercially available platforms: 454 (Roche), Illumina 
Genome Analyzer (Illumina Inc.), SOLiD and Ion Torrent (Life Technologies) (Table 2).  
The 454 Genome Sequencer (Roche) was the first NGS platform available (Margulies et al., 
2005). Small fragments of DNA are attached onto the surface of beads and amplified via 
emulsion PCR. Millions of beads are deposited onto a picotitre plate. Sequencing is 
performed in parallel by pyrosequencing, where the incorporation of a nucleotide by a DNA 
polymerase results in the release of a pyrophosphate, which initiates a series of downstream 
reactions that ultimately produce light by a luciferase. The light can be correlated with the 
nucleotide incorporated, because the nucleotides are added following a sequential order.  
The Illumina Genome Analyzer (Illumina Inc.) relies on bridge PCR on a glass slide  to 
amplify small fragments of DNA. In this approach, forward and reverse PCR primers are 
attached to a solid surface, and as a consequence, amplification products originating from 
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any single template molecule remain immobilized and clustered to a physical position on 
the array. Sequencing chemistry  is based on sequencing by synthesis with reversible 
terminators (Fedurco et al., 2006; Turcatti et al., 2008), where all fluorescently labeled four 
nucleotides are added simultaneously to the flow cell channels, along with the polymerase, 
for incorporation into the oligo-primed cluster fragments obtained after bridge PCR.  
The SOLiD system (Life Technologies) is based on sequencing by ligation and the use of 
two-base encoded probes (Valouev et al., 2008). A universal sequencing primer is 
hybridized to templates and a pool of fluorescently labelled octamer probes containing all 
possible combination of A, C, G and T at positions 1-5, interrogates the sequence of the 
unknown template on each bead. Only the probe homologous to the first five bases of the 
template will be ligated to the universal sequencing primer.  Up to ten cycles of ligation, 
detection and cleavage record the colour at every fifth position. Templates for sequencing 
are prepared via emulsion PCR.  
In the case of the Ion PGM Sequencer (Life Technologies), sequence data are obtained by 
directly sensing the ions produced by template-directed DNA polymerase synthesis using 
all natural nucleotides on the ion chip. The ion chip contains ion-sensitive, field-effect 
transistor-based sensors in 1.2 million wells, which allow parallel and simultaneous 
detection of independent sequencing reactions (Rothberg et al., 2011). As 454 and SOLiD, 
template preparation is performed by emulsion PCR. Unlike the other technologies where 
the throughput is determined by the equipment, the Ion PGM throughput is determined by 
the chip used for sequencing (Table 2) 
Very promising NGS approaches are the ones based on single molecule sequencing like 
Helicos Biosciences (Harris et al., 2008) and Pacific Biosciences (Eid et al., 2009), where 
sequencing is performing directly on the DNA, avoiding any amplification step. However, 
these platforms are not commercially available so they are only mentioned.  
 
 





454-GS Junior 400 50 Mb 10 h 
454-FLX+ 700 900 Mb 23 h 
Illumina-MiSeq 150+150 > 1 Gb 27 h 
Illumina-GAII 150+150 95 Gb 14 days 
Illumina-HiScanSQ 100+100 150 Gb 11 days 
Illumina-HiSeq1000 100+100 300 Gb 11 days 
Illumina-HiSeq2000 100+100 600 Gb 11 days 
SOLiD-5500 75+35 90 Gb 7 days 
SOLiD-5500xl 75+35 180 Gb 7 days 
Ion PGM – 314 chip 200 >10 Mb 2 h 
Ion PGM – 316 chip 200 >100 Mb 2 h 
Table 2. Comparison of NGS platforms.  
5. Target resequencing strategies 
For some applications, it would be not necessary to sequence the whole genome, but 
sequence specific region or regions. This is the case of the study of: i) a disease phenotype 
previously mapped to a specific region of the genome, ii) candidate genes involve in a 
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pathology or pathway, iii) whole exome. To reach these purposes it is necessary the 
combination of methods for targeted capture with massive parallel sequencing.  
Methods for capturing the regions of interest are commercially available, but it is important 
to remind that, due to this field is in continuous and rapid evolution, before designing any 
experiment it will be necessary to check for latest approaches, in order to choose the more 
cost-effective strategy for each project (Turner et al., 2009; Mamanova et al., 2010).  
Even considering the different capture strategies, the workflow for targeted resequencing 
for either candidate genes or exome sequencing is very similar. Genomic DNA is used to 
construct a library, which consists in small fragments of DNA flanqued by adaptors. 
Depending on the method used for capturing the regions of interest, the capture occurs 
before or after creating the library. Once the capture library is created, is clonally amplified 
followed by massive parallel sequencing.  
During the process of capturing and library preparation it is possible to barcoding samples.  
This process enables the user to pool multiple samples per sequencing run, taking 
advantage of the high-throughput of the NGS platforms.  
Capture strategies can be broadly grouped in two main groups, the first one is based on 
PCR, and the second one in the use of hybridization probes (Table 3).  
1. PCR approaches:  
When a specific region has been previously mapped, long-PCRs using high-fidelity 
polymerases are used to analyze large kilobase-sized contiguous intervals (Yeager et al., 
2008). 
Different strategies for amplified simultaneously hundreds of fragments of DNA have 
been developed over the last years. Access Array System (Fluidgm) uses a microfluidic 
chip with nanoliter scale chambers, where the simultaneous amplification of 48 
different fragments in 48 samples is performed. By incorporating the adaptor sequences 
into the primer design the amplicon product is ready to go directly into clonal 
amplification (Voelkerding et al., 2010).  
Microdroplet-PCR technology developed by RainDance involves the use of emulsion 
PCR in a microfluidic device, creating droplets of primers in oil solution. The primer 
droplets that are targeted to different regions of the genome merge with separate 
droplets that contain fragmented genomic DNA and PCR reagents. These mixed 
droplets are thermal cycled in a single tube. The encapsulation of microdroplet PCR 
reactions prevents possible primer pair interactions allowing an efficient simultaneous 
amplification of up to 20,000 targeted sequences (Tewhey et al., 2009). 
Illumina and Life Technologies have followed similar strategies for capture regions for 
MiSeq and Ion PGM Sequencer, respectively. Illumina has launched  the TrueSeq 
Custom Amplicon Kit for multiplex amplification of up to 384 amplicons per sample, 
and Life Technology has recently developed a multiplex PCR for amplified in a single 
tube up to 480 known as Ion AmpliSeq Cancer Panel.  Currently, only the cancer panel 
is available, but it has been announced by the company that custom panels will be early 
available.  
Halo Genomics has developed two different strategies based on amplification methods, 
Selector and HaloPlex. The first one, Selector Target Enrichment system is based on 
multiple displacement amplification. This strategy produces circular DNA that is 
amplified in a whole genome amplification reaction. The resulting high molecular DNA 
product is compatible with all next generation sequencing library preparation 
protocols. For achieving this, DNA sample is first fragmented using restriction 
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enzymes, secondly the probe library is added and the probes hybridize with the 
targeted fragments. Each probe is an oligonucleotide designed to hybridize to both ends 
of a targeted DNA restriction fragment, thereby guiding the targeted fragments to form 
circular DNA molecules. The circular molecules are closed by ligation and then 
amplified. Next step is library preparation (Johansson et al., 2010).   
In the case of HaloPlex technology, PCR products are ready for pooling and direct 
sequencing, it is not necessary to create the library after the capturing because the 
probes also contain a specific sequencing motif that is incorporated during the 
circularization. This motif allows the incorporation of specific adaptors and barcodes 
during the amplification.  Currently, this product is optimized for Illumina.  
2. Hybridization 
Other strategy is capture by hybridization of specific probes complementary of the 
regions of interest. The first hybridization approaches were based on-array capture 
(Albert et al., 2007; Hodges et al., 2007; Ng et al., 2009).  But to avoid the disadvantages 
of working with microarrays, currently methods are based in-solution capture. 
Fragment libraries are hybridized to biotinilated probes in solution and subsequently 
recovered with streptavidin-magnetic beads, amplified and sequence in the platform of 
choice (Gnirke et al., 2009; Bamshad., 2011).  
All the vendors (Agilent, Nimblegen, Illumina and Life Technologies) offer kits either 
predesigned for specific application such as exome sequencing, cancer, etc or custom 
panels to be designed for the user (Table 3). There are different kits for different sizes of 
the region of interest that go from less than 100kb to up 60 Mb.  
 
Approach Method Kitsa NGS – Compatibilityb 
PCR 
Long-PCR 1 1, 2, 3, 4 
Access Array System (Fluidigm) 1 1, 2, 3, 4 
Microdroplet PCR (Raindance) 1, 2 1, 2, 3, 4 
AmpliSeq technology  
(Life Technologies) 2
c 4 
TrueSeq Amplicon Kit (Illumina) 1 2 
HaloPlex (Halo Genomics) 1 2 
Selector (Halo Genomics) 1, 2 1, 2, 3, 4 
In-solution 
hybridization 
SureSelect (Agilent) 1, 3 2, 3 
SeqCap EZ (Nimblegen) 1, 3 1, 2, 3 
TrueSeq Enrichment Kit (Illumina) 1, 3 2 
TargetSeq (Life Technologies) 1, 3 3, 4 
a Custom (1), specific gene panel (ej. cancer panel) (2), exome panel (3) 
b 454 (1), Illumina (2), SOLiD (3), Ion PGM Sequencer (4). 
c  Custom early available 
Table 3. Capture methods for targeted resequencing.  
5.1 Candidate gene resequencing 
In dealing with arrhythmogenic diseases at risk of sudden cardiac death, we can analyze 
those genes previously associated with the pathologies that explain a high percentage of 
cases, variable according to the pathology (Hedley et al., 2009ab; Kapplinget et al., 2009). 
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Therefore, as it was already used for SCD associated cardiomyoapties  (Meder et al., 2011), 
the strategy with the arrhythmogenic diseases could be to capture the 21 genes mentioned 
above in Table 1. As it is shown in table 3, there are a great variety of strategies available. In 
addition, all commercially available kits have developed tools for designing specific primers 
or probes to capture the regions of interest.   
For selecting both the capture method and the NGS platform many factors have to be 
evaluated: size of the region of interest, the coverage and accuracy needed, the number of 
samples and barcodes availability and DNA requirement. There is no an ideal method for all 
the situations. 
5.2 Whole exome resequencing 
The targeted resequencing of the subset of the genome that is protein coding is known as 
exome sequencing. This strategy is been a powerful approach for either identifying genes 
involve in Mendelian disorders or rare variants underlying the heritability of complex traits 
(Bamshad, 2011). Therefore, arrhythmogenic diseases such as the LQTS, the SQTS, the CPVT 
or the BrS, all genetic diseases with Mendelian inheritance, are appropriate candidates for 
this type of study. 
All the vendors of in–solution hybridization methods have developed commercial kits for 
capturing whole exome. (Agilent, Illumina, LifeTechnologies, NimbleGen) (Table 3). Due to 
the throughput needed for obtaining enough coverage for variant calling, the platforms of 
choice for this application are Illumina GAII or superior and SOLiD 5500.  
This approach has been successfully used since 2009 in at least 29 diseases, in which the 
genes involved in the disorders have been identified (Bamshad, 2011).  
6. Genetic variant versus mutation 
It should be kept in mind that this kind of genetic tests identifies the presence of a 
probable/possible arrythmogenic disease causing mutation for which the probability for 
pathogenesis and even the likelihood of sudden cardiac death is influenced by many factors, 
including rarity, conservation, topological location, co-segregation, functional studies, and 
so forth. According to Kapplinger et al. (2009), fewer than 25% of the previously published 
LQTS mutations have been characterized by heterologous expression studies to demonstrate 
the anticipated loss-of-function (LQT1 and LQT2) or gain-of-function (LQT3) conferred by 
the mutation. The rank of a new genetic variant detected in an afected individual as a 
pathogenic mutation must meet the following specifications: 
a. The variant must disrupt either the open reading frame (i.e., missense, nonsense, 
insertion/deletion, or frame shift mutations) or the splice site (poly-pyrimidine tract, 
splice acceptor or splice donor recognition sequences). Considering the acceptor splice 
site as the 3 intronic nucleotides preceding an exón (designated as IVS-1, -2, or -3) and 
the donor splice site as the first 5 intronic nucleotides after an exon (designated as 
IVS+1, +2, +3, +4, or +5) (Rogan et al., 2003). 
b. The variant must be absent in a representative cohort of healthy unrelated individuals 
with a minimum of 200 individuals and 400 alleles with a common population origin. 
c. The variant must have been absent in all published databases listing the common 
polymorphisms in the studied genes and previously published reports or compendia of 
rare control variants. 
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Many of the possible new genetic variants described, although they meet the requirements 
listed above, may not have any pathogenic effect and the only real way to check would be 
through functional studies that prove this effect. Due to the difficulty in performing such 
studies in many of the functional proteins involved,  during the last years several “in silico” 
tools have been created allowing us to infer the probability that a genetic variant is 
pathogenic or not. Unfortunately, different prediction algorithms use different information 
and each has its own strength and weakness. Since it has been suggested that investigators 
should use predictions from multiple algorithms instead of relying on a single one, Liu et al 
(2011) have developed dbNSFP (database for nonsynonymous SNPs functional predictions). 
It compiles prediction scores from four algorithms (SIFT, Polyphen2,LRT, and 
MutationTaster), along with a conservation score (PhyloP) and other related information, for 
every potential non synonymous variant in the human genome. 
7. Conclusion 
Despite the progress in knowledge of the mechanisms, risk factors, and management of 
SCD, it remains being a major public-health problem. One of the challenges is the accurate 
identification of the person at risk, especially in younger people where the sudden death is 
most of the times the first manifestation of the disease. Multimarker SCD risk scores 
including demographic, clinical and genetic variables should improve the identification of 
persons at risk (Adabag et al., 2010). 
Although there are other processes affecting the electrical cardiac systole, pathologies 
considered in this chapter are the familiar diseases with a clear genetic inheritance in which 
genetic diagnosis has a great relevance.  
Capturing strategies followed by NGS allowed us to accurately detect arrhythmogenic 
disease causing mutations in a fast and cost-efficient manner that will be suitable for daily 
clinical practice of genetic testing. Nevertheless, we cannot forget the need to use additional 
strategies proving their disease causality. 
Additional benefits of great value in these  genetically and phenotypically heterogeneous 
disease are: 1) the ability to detect both, known mutations and novel mutations, 2) the 
possibility of screening only selected gene exons or all exons in the human genome, and 
finally 3) the ability to detect individuals with multiple mutations. 
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1. Introduction 
Much progress has been made in identifying genetic loci linked to hereditary arrhythmia 
syndromes over the past decade and a half. Linkage analyses for Mendelian diseases have 
been powerful in the discovery phases. Considerable challenges remain however, for the 
clinician faced with individual patients and families when the clinical symptoms are 
atypical or intermediate and when novel mutations or polymorphisms are reported in the 
course of genetic testing. To unambiguously define the deleterious nature of any given 
mutation, additional functional analyses are required. Such studies should not only detect the 
functional consequence of mutations but also the degree of severity and mechanisms that bring 
about the deleterious behavior. These principles apply not only to cardiac arrhythmia 
syndromes but also to any hereditary genetic disease. In practice, this is not always feasible or 
possible with current technology. This is particularly problematic when standard genetically 
manipulable animals (mouse) differ considerably from human, as they do in cardiac 
electrophysiology. An additional obstacle occurs when the target organ is not amenable to 
biopsy without considerable risk (e.g. heart, brain, etc.). For evaluation of genetic mutations in 
cardiac arrhythmia syndromes, heterologous expression of affected genes has helped 
tremendously. 
Hereditary arrhythmia syndromes include: the long QT syndrome, the Brugada syndrome, 
catecholaminergic polymorphic ventricular tachycardia, the short QT syndrome, and 
arrhythmogenic right ventricular dysplasia. We will restrict our discussion to the long QT 
syndrome; however, the basic principles of verifying functional consequences of mutations 
also applies to the other syndromes. In this chapter we will review the progress in 
characterizing arrhythmia-linked genetic mutations. Several areas of recent technical 
advancement have been achieved which we will discuss in detail. We will also highlight 
how biophysical, biochemical and cell-biological studies may be used to help inform 
clinicians in managing the more subtle and varied aspects of patients with specific 
mutations. Lastly, we will discuss how such studies may eventually point to therapeutic 
modalities that will lead to gene-specific, or personalized medicine. 
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characterizing arrhythmia-linked genetic mutations. Several areas of recent technical 
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2. Overview of the long QT syndrome 
Congenital long QT syndrome (LQTS) was first described by Jervell and Lange-Nielsen in 
1957, who presented a family in which four of six children were born deaf, had episodes of 
syncope, prolonged QT interval and early sudden death (Jervell & Lange-Nielsen, 1957). In 
1963 and 1964, independent reports of a similar constellation of findings in patients, but 
without hearing loss, were made (Romano et al., 1963; Ward, 1964). Subsequently, these 
were classified as autosomal-recessive (Jervell-Lange-Nielsen syndrome, with hearing loss) 
and autosomal dominant (Romano-Ward syndrome) forms of LQTS. The incidence of 
hereditary LQTS has been estimated to be as high as 1 in 2500 (Crotti et al., 2008). Notably, 
disease severity varies widely—from patients who are mostly asymptomatic, to ones who 
suffer multiple episodes of syncope and/or sudden cardiac death at a young age. 
The common pathophysiological feature of LQTS is delayed repolarization, manifest on 
electrocardiogram (ECG) as a prolonged QT interval corresponding to a prolonged action 
potential duration (APD). Delayed repolarization occurs either due to an excess of sodium (Na+) 
or calcium (Ca2+) influx, or to deficient potassium (K+) efflux. This disruption in the normal ionic 
currents across the cell membrane undermines the highly regulated electrical activity in the heart 
required for normal, rhythmic beating, and leaves patients at risk for potentially lethal 
arrhythmias. Abnormal currents can result from congenital mutations in the ion channels, or 
from pharmacological agents and acquired disease that can alter cardiac ion channel function. 
When a ventricular myocyte action potential is prolonged, abnormal depolarizations may 
develop, known as early afterdepolarizations (EAD) that occur during the plateau or 
repolarization phases of the action potential (i.e. a type of depolarization that occurs before 
an action potential has completed repolarization). An EAD can then trigger an action 
potential that is self-perpetuating, leading to a particularly deadly type of arrhythmia 
known as polymorphic ventricular tachycardia or “torsade de pointes” which may degenerate 
into ventricular fibrillation. Furthermore, intracardiac imbalances of ion currents may lead 
to disperson of refractoriness that may play a role in susceptibility to micro-reentry. 
Symptoms include syncope (fainting), palpitations and sudden cardiac death. 
2.1 Linkage studies 
The hereditary long QT syndrome (LQTS) is now recognized as a genetically heterogeneous 
disorder with at least 13 different proposed loci (Table 1). Most of the loci contain genes of 
cardiac ion channels, accessory subunits, or channel-associated scaffolding proteins. The 
approaches taken by researchers in the 1990s to initially characterize hereditary LQTS relied on 
classical genetics with pedigree analysis of large families using microsatellite markers and 
logarithm of odds (LOD) score calculation. LOD scores indicate the likelihood of linkage of two 
loci by comparing the calculated recombination frequency against chance. A positive LOD score 
signifies linkage, whereas a negative score signifies the absence of linkage. The major goal of the 
early studies was to connect symptomatic LQTS patients with a common genetic feature. 
Originally, LQTS was thought to be a single-gene disorder linked to chromosome 11 
(Keating et al., 1991a; Keating et al., 1991b). Subsequent refinement revealed that 
heterogeneity and multiple loci were involved (Worley et al., 1992; Benhorin et al., 1993). In 
1994, analysis of multiple LQTS families using LOD scores showed that some had linkage to 
chromosome 7, others linked to chromosome 3, and both excluded chromosome 11 linkage 
(Jiang et al., 1994). Other of the families in the study did not show linkage to any of the three 
known loci, suggesting the existence of additional loci. Once the first three LQTS loci were 
identified, several groups worked to identify the genes responsible for the phenotypes. In 
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1995, Wang et al. used linkage analysis to show that locus LQT3 contained SCN5A, a Na+ 
channel that was previously cloned and characterized in 1992 (Gellens et al., 1992; Wang et 
al., 1995a; Wang et al., 1995b).  
 
Locus Gene  Protein Function Chromosome Other Diseases 
LQT1 KCNQ1 KvLQT1 K
+ channel  
 subunit 11p15.5 
Short QT Syndrome (SQTS1) 
Familial Atrial Fibrillation (FAF) 
LQT2 KCNH2 HERG K
+ channel 
 subunit 7q35-q36 SQT1 
LQT3 SCN5A Na
+ Channel 
 subunit 3p21 
Brugada Syndrome (BrS1) 
Conduction & Sinus node 
disease 
LQT4 ANK2 Ankyrin B adaptor protein 4q25-q27 LQTS 
LQT5 KCNE1 minK  subunit 21q22.1-2 Atrial Fibrillation, Deafness 
LQT6 KCNE2 MiRP1 
 subunit 21q22.1-22.2 
Hypothyroidism, Periodic 
paralysis 
LQT7 KCNJ2 Kir2.1 K+ Channel 17q23.1-q24.2 Andersen’s Syndrome, myotonia 
LQT8 CACNA1c Ca
2+ channel 
 subunit 12p13.3 Timothy Syndrome, BrS3 
LQT9 CAV3 Caveolin 3 membrane scaffold 3p25 Cardiomyopathy 
LQT10 SCN4B Na
+ Channel 
 subunit 11q23 Conduction Disease 
LQT11 AKAP9 Yotiao PKA scaffold 7q21-q22 LQTS 
LQT12 SNTA1 Syntrophin  1 scaffold protein 20q11.2 LQTS 
LQT13 KCNJ5 Kir3.4 K+ Channel 11q24 Neonatal hyper-insulinemia 
Table 1. The Hereditary Long QT Syndrome Loci  
In 1995 Curran et al. analyzed LQTS families using markers linked to locus LQT2 on 
chromosome 7q35-36 (Curran et al., 1995). Physical mapping using yeast artificial 
chromosomes (YACs) and fluorescent in situ hybridization (FISH) indicated that a candidate 
gene with homology to potassium ion channels (K+ channels) resided in that position. This 
gene had been previously identified as the human ether-à-go-go related gene (HERG or 
KCNH2) (Warmke & Ganetzky, 1994). Patient sample analysis for mutations in HERG with 
single-strand conformation polymorphisms (SSCP) detected the presence of genetic variants 
and functional expression of the cDNA in Xenopus oocytes showed that HERG encoded a 
channel that carried the rapidly activating delayed rectifier K+ current (IKr) and confirmed 
the deleterious nature of the mutations. Further positional cloning showed that LQT1 on 
chromosome 11 encoded KvLQT1/KCNQ1, another K+ channel (Wang et al., 1996). 
Concurrently, Schott et al. used similar linkage techniques to map the LQT4 locus to 
chromosome 4q25-27 (Schott et al., 1995). The gene responsible for LQT4 was identified in 
2003 by the Mohler group as ankyrin-B, a scaffolding protein which when mutated causes 
aberrant targeting of essential cardiac channel proteins (Mohler et al., 2004). 
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Identification of other LQTS loci was done through a variety of techniques ranging from 
classical genetics to modern genomic methods (Chevillard et al., 1993; Duggal et al., 1998; 
Abbott et al., 1999; Fodstad et al., 2004; Vatta et al., 2006; Ueda et al., 2008). The loci include 
other channel proteins such as the Kir2.1 channel encoded by KCNJ2 and the voltage-gated 
Cav1.2 calcium channel encoded by CACNA1c, K+  channel accessory subunits (KCNE1 and 
KCNE2), as well as scaffolding proteins such as AKAP9 and syntrophin. While the genes are 
numerous and diverse, the overall themes of cardiac ion channel function/dysfunction and 
alterations in regulation unify the genetic causes of LQTS. 
3. Heterologous expression of arrhythmia-linked genes 
The ideal system for studying behavior of cardiac ion channels would be isolated cardiac 
myocytes that survive in culture for a long time period. Such primary cells however, entail 
significant risk to patients and are extremely difficult to maintain long term in culture. The 
next option is to express the channel proteins in a cell type that can be maintained and 
manipulated as necessary. 
3.1 Xenopus oocytes 
Xenopus laevis oocytes are an established system for studying ion channels using 
electrophysiological techniques. The procedure consists of creating cRNAs of the gene of 
interest followed by injection into oocytes, which contain all the necessary cellular 
machinery for protein expression (Gurdon et al., 1971; Barnard et al., 1982). Two-electrode 
voltage clamp is a relatively easy method to use with oocytes given their large size and 
provides a rapid way to functionally characterize many of the genes involved in LQTS, and 
many of the first studies utilized this method. Xenopus oocytes however, contain an 
endogenous K+ channel similar to KCNQ1, thus confounding some of the early studies on 
KCNE1 and KCNQ1. Moreover, oocytes are maintained at 16-19ºC, a temperature that may 
permit mutant proteins to properly fold and traffic to the cell surface thereby masking a 
misfolding phenotype that would normally occur at human physiological temperatures. 
Such an occurrence was noted in the initial analysis of the cystic fibrosis transmembrane 
conductance regulator protein (CFTR)(Cheng et al., 1990; Denning et al., 1992). 
3.2 Mammalian cultured cell systems 
Another approach is to use immortalized mammalian cell lines such as human embryonic 
kidney (HEK 293), Chinese hamster ovary (CHO), or COS-7 cells. Unlike primary cell 
lines, immortalized cell lines can be propagated many times and maintain baseline 
characteristics. The cells are incubated at 37°C and contain all the necessary components 
for protein transcription, translation, trafficking and degradation. They are more 
amenable than oocytes for immunoblotting, immuno-precipitation, high-resolution 
immuno-fluorescence, trafficking assays, cell-surface expression assays, and patch clamp 
electrophysiology. The cells may also have endogenous K+ current; however, the 
magnitude is small and does not usually interfere with measurements of over-expressed 
channels currents. Mammalian cell lines more closely mimic native systems than oocytes 
and are useful for analyzing biological consequences of LQTS mutations. A caveat to this 
system is that the LQT-linked channels may exist in macromolecular complexes in vivo. 
Such complexes may comprise accessory subunits and regulatory proteins, which may not 
be recapitulated by heterologous expression system. 
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3.3 Purified proteins for biochemistry and structural analysis 
Functional expression in oocytes and cells allows the study of many aspects of mutations but 
the fundamental mechanism of mutational effects ultimately relies on structural analysis. The 
primary challenge is finding conditions under which a large quantity of protein can be 
expressed and purified. This process can be relatively straightforward for soluble, cytosolic 
proteins, but is more difficult for membrane proteins such as ion channels. Because of the large 
amount of protein needed for purification, transfection of mammalian cells, or even the use of 
stably transfected mammalian cells lines, may not be feasible. Alternative systems of 
expression have been developed for bacteria, yeast, and insect cells, but determining the best 
host for producing a particular protein is usually an empirical process. 
One of the most commonly used expression systems is the bacteria Escherichia coli. There are 
several technical and economic advantages: the ease of introducing DNA via transformation 
with a plasmid expression vector, rapid growth, and simple growth media. Problems do exist, 
though, in expressing mammalian membrane proteins in bacteria. These include alternative 
translation, posttranslational modification and trafficking mechanisms. Certain limitations can 
be overcome by changing growth conditions, co-expressing necessary chaperones, or creating 
fusions with prokaryotic partners such as maltose-binding protein (MBP) or glutathione  
S-transferase (GST) to improve their solubility and stability. Even with these modifications, it 
can still be difficult to express the full length of a protein (for example, the full length of 
KCNQ1 is nearly 700 amino acids, and Nav1.5 is around 2000 amino acids). An alternative 
expression host is the yeast Pichia pastoris, which has a eukaryotic protein synthesis pathway 
and is capable of post-translational modifications, though it is not entirely equivalent to a 
mammalian system. The first (and thus far, only) mammalian K+  channel to be crystallized 
was expressed in P. pastoris, whereas several previously crystallized bacterial channels were 
expressed in E. coli (Doyle et al., 1998; Jiang et al., 2002; Jiang et al., 2003; Long et al., 2005).  
A higher eukaryotic system that may be used is insect cells, with baculovirus as the vector for 
protein expression. Insect cells are even better equipped with the machinery needed for proper 
protein folding and for post-translational modifications. While they provide high expression 
levels and can be grown to high density, a disadvantage is that the growth media is more 
expensive than for bacteria or yeast. 
If a system for high-yield expression and purification of a protein can be achieved, the 
protein can then be used in a multitude of biochemical and structural experiments. The 
highest resolution is crystal structure; however, this is a difficult and time consuming task. 
The difficulty of this task is evident in the small fraction of membrane proteins that have 
been crystallized, compared to soluble proteins. An alternative that has been used 
successfully is solution nuclear magnetic resonance (NMR) structure. Besides the obvious 
advantage of not needing crystals, NMR may yield structure that is closer to native form, 
since formation of crystals may impose non-native constraints on the protein. 
4. Animal models of inherited human arrhythmias 
Ideally, it is desirable to create an animal model of a disease—acquired or hereditary—in order 
to study pathophysiological mechanisms, and to design and test therapeutic options. To 
accomplish this it is important that the model recapitulate the human condition as closely as 
possible. For hereditary diseases it is necessary that the animal be genetically manipulable and 
that homologues of the genes of interest exist and be expressed in the same tissues as humans. 
Here we will discuss animal models that have been proposed and used for LQTS. 
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Mice and rats are valuable systems for modeling a variety of human diseases, especially in 
terms of organ system pathophysiology and immune diseases. Since they can be easily 
genetically manipulated, they are good surrogates and provide clues to the hierarchy of 
genetic pathways and regulation that occur in the healthy and disease states. 
Once the genetic loci were identified, investigators created knock-out (null) and knock-in 
mice to model the LQTS phenotype. The knock-out is done by creating an exogenous 
construct based on the sequence of the mouse gene, but where the relevant allele has been 
inactivated or nullified by inserting a stop codon or deletion/insertion to inhibit expression 
of the native protein. This construct is then injected into mouse embryos where homologous 
recombination occurs and the endogenous mouse gene is replaced by the null construct, 
which contains a marker so that recombinant mice may be distinguished. The recombinant 
mouse must then be bred to create heterozygous and homozygous null mice in subsequent 
generations. A knock-in mouse is created by a similar method, where the construct is a 
human gene (or mouse ortholog) that contains a known functional mutation. The 
engineered heterozygous mice will express one copy of endogenous mouse gene and one of 
the transgenic mutated gene.  
There are at least 40 mouse models of LQTS genes. Two mouse models were created that 
disrupted exons 1 and 2 in KCNQ1 (Lee et al., 2000; Casimiro et al., 2001). Interestingly, the 
mouse with mutation in exon 1 did not show any ECG abnormalities. However, this mouse 
did have auditory-vestibular aspects of the Jervell and Lange-Nielsen syndrome. The mouse 
with KCNQ1 exon 2 disruption showed abnormal T-wave morphology on in vivo ECGs and 
inner ear abnormalities. In a third study, mice were created that expressed a dominant 
negative isoform of KCNQ1; these mice had QT prolongation on ECG as well as torsade de 
pointes arrhythmias (Demolombe et al., 2001). For KCNE1 null mice, the models exhibit 
deafness, but no baseline QT prolongation (Schulze-Bahr et al., 1997). One KCNE1 null 
mouse showed abnormal rate adaptation, which is similar to the phenotype seen in humans 
with KCNQ1/KCNE1 mutations upon exercise challenge (Charpentier et al., 1998; Warth & 
Barhanin, 2002). Mice express the HERG ortholog Merg1 in the heart. The Merg1 
homozygous knock-out mouse is embryonic lethal as it dies early in development (London, 
1998). A mouse model that expresses the dominant-negative HERG-G628S mutation showed 
a normal ECG phenotype (Babij et al., 1998). 
While these studies yielded valuable information about pathogenesis of LQTS, they also 
highlighted how mice have limited value in studying inherited cardiac arrhythmias 
resulting from mutations in delayed rectifier K+ current channels. Mice have a baseline heart 
rate of ~600 beats per minute. As such, they have a short action potential and repolarization 
phase that is largely dependent on the transient outward K+  current (Ito) and have little to 
no IKs or IKr (Nerbonne, 2004; Milan & MacRae, 2005). So while they are genetically tractable, 
they may not be electrophysiologically similar enough to humans to provide a good model 
system. In contrast to the limitations of modeling human repolarization in the mouse, more 
success has been achieved for the depolarizing currents, which are more akin to those in the 
human. A LQTS mouse model generated by knock-in of an LQT3 mutation (KPQ deletion in 
SCN5A) (Nuyens et al., 2001). The transgenic mice had prolonged APD and polymorphic 
ventricular tachycardia.  
Early studies of guinea pig ventricular myocytes revealed that two components making up 
the repolarization current IKr and IKs (Sanguinetti, 1990). This work was the original 
characterization of two repolarizing K+  currents and forms the basis for many of the 
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subsequent studies. Considering that isolated guinea pig ventricular myocytes was the in 
vitro system that launched a whole field of study, some groups have used an interesting 
approach by injecting adenoviral vectors containing wild-type or mutant KCNE1 or HERG 
into guinea pig myocardium (Hoppe et al., 2001). This group found that myocytes 
expressing the HERG G628S mutant, IKr was reduced, but action potential duration was not 
shortened however, beat-to-beat variability increased as did EADs. They also expressed the 
KCNE1-D76N mutant which suppressed IKs, significantly slowing repolarization, leading to 
frequent EADs and QT prolongation on ECG. 
4.2 Rabbit 
Given the limitations of rodent models, larger animals with cardiac electrophysiology more 
similar to humans might be considered. These included study of dogs, ferrets and rabbits. 
The Koren group has developed transgenic rabbits expressing human LQT mutations 
(Brunner et al., 2008). To create the transgenic rabbits the investigators injected embryos 
with a cDNA construct that contained either mutant HERG or KCNQ1 under a cardiac 
specific promoter, so that the transgene will only be active in the heart. These animals have 
enabled the investigators to gain significant insights by ECG analysis in awake freely 
moving animals, optical mapping of repolarization waves using voltage-sensitive dyes, and 
at the cellular level by recording from isolated rabbit myocytes. To date, this may be the 
most accurate model system that exists for hereditary LQTS. 
4.3 Zebrafish 
The newest model system to be explored is the zebrafish, Danio rerio. These are genetically 
tractable animals that expresses an endogenous ortholog of HERG (zERG) (Langheinrich et 
al., 2003). zERG is expressed specifically in both heart chambers of zebrafish embryos, is 
similarly composed of six transmembrane domains, and displays a particularly high degree 
of amino acid conservation in the S6 helix and pore domain. One specific mutant that was 
characterized named breakdance displayed prolonged ventricular APD, spontaneous EADs, 
and 2:1 atrio-ventricular block in the embryonic stages of development. The group of Scholz 
et al. expressed cloned zERG in Xenopus oocytes and showed current characteristics similar 
to the human channel however the details of its kinetics and gating were distinctly different 
(Scholz et al., 2009). Arnaout et al. recently performed a forward genetic screen and 
identified two zebrafish HERG mutants s213 and s290. They showed that homozygous 
animals had virtually no ventricular contraction and impaired calcium handling in the 
ventricles. Heterozygous animals showed increased APD and prolonged QT-interval on 
ECG (Arnaout et al., 2007). These studies show that given the conserved channel function, 
zebrafish does represent a valuable genetic model system to investigate HERG channel 
mutations. 
4.4 Primary isolated myocytes 
To find a more native system to study ion channels, researchers have sought methods to 
isolate and maintain primary cardiac myocytes. Primary isolated myocytes are best suited 
for short-term culture (approximately four days) and electrophysiological or 
immunofluorescence experiments that require only a low yield of viable cells (10s 
compared to 10,000s needed for biochemistry experiments) (Nuss & Marban, 1994). Some 
of the technical challenges involved include obtaining fresh healthy heart samples, 
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appropriate and not over-digestion of the tissue by enzymes, purification of myocytes 
from fibroblasts and matrix, calcium tolerance of the freshly isolated myocytes, and 
finding the correct conditions for culture. Most adult myocytes have been isolated from 
mouse, rat, guinea pig, and rabbit since the animals are readily available and economical. 
Fresh human heart samples for cardiomyocyte isolation are difficult to obtain routinely 
for ethical reasons. Rat neonatal cardiomyocytes have provided a fairly easy-to-obtain and 
widely applicable system in recent years (Chlopcikova et al., 2001). Since the rat neonatal 
cardiomyocytes may only transiently express the relevant channel, another approach is to 
use adenoviral or lentiviral vectors containing the cDNA of interest to infect the cells and 
allow adequate expression for study in a more native system. Comparing the behavior of 
wild type HERG and KCNQ1 channels with previously characterized deleterious mutants 
in rat neonatal myocytes has confirmed initial phenotypic characterization (Li et al., 2001; 
Lin et al., 2010). These groups found that the wild-type and mutant channel behaved 
generally the same as in cultured cells with some slight differences. Additionally some 
groups used the neonatal cardiomyocyte system to understand localization and 
interaction of the HERG, KCNQ1 and  accessory subunits (Rasmussen et al., 2004; Wu et 
al., 2006).  
5. Human phenotypic studies 
5.1 Locus-specific triggers 
While QT interval prolongation puts patients at risk for abnormal heart rhythms, most 
patients are asymptomatic on a daily basis, with arrhythmias triggered by certain conditions 
or stimuli. In a 2001 study of 670 patients with known symptomatic LQT1, LQT2, or LQT3, a 
correlation between genotype and one of three specific triggers: exercise, emotion, or sleep 
was found. LQT1 patients had most events (syncope, cardiac arrest, or sudden death) 
triggered by exercise (62% of cases), while LQT2 patients had most events triggered by 
emotion (43% of cases), and LQT3 patients had most events during sleep (39% of cases) 
(Schwartz et al., 2001). In another study exercise induced significant further prolongation of 
QTc in LQT1 patients compared to LQT2 (Takenaka et al., 2003). In mice with an LQT3 
knock-in mutation, bradycardia induced by cholinergic stimulation provoked torsade de 
pointes, while physical stress, mental stress, isoproterenol, and atropine did not (Fabritz et 
al., 2010). In female LQT2 patients, the post-partum period is a time of increased risk for 
arrhythmia (Khositseth et al., 2004). These efforts to categorize locus-specific triggers help 
clinicians in initial diagnostic phases and to better advise patients diagnosed with a specific 
LQTS genotype. There are some overlaps in triggers; for example, a certain percentage of 
LQT2 patients have cardiac events triggered by exercise. One study found a correlation of 
mutation location within HERG and the type of trigger causing symptoms: pore-loop 
mutations correlated with arousal-triggered events, non-pore mutations more often 
associated with exercise-triggered events (Kim et al., 2010). 
5.2 Therapeutic approaches 
Currently, there are five main avenues for treatment for adult patients with LQTS: (1) -
blockers, (2) gene-specific therapy, (3) pacemakers, (4) left cervico-thoracic sympathetic 
ganglionectomy, and (5) implanted cardio-verter defibrillators (ICDs). The primary goal of 
these therapies is to prevent life-threatening ventricular tachyarrhythmias and sudden 
cardiac death. 
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Given the correlation of LQTS locus and specific arrhythmia triggers, an important part of 
LQTS management is avoidance of triggers. LQT1 patients are advised to avoid competitive 
and endurance athletics, especially swimming. LQT2 patients are advised to reduce 
exposure to startle-stimuli, such as loud alarm clocks. LQT3 patients may have a pacemaker 
implanted to prevent bradycardia during sleep. For all patients with a LQTS diagnosis, the 
first line treatments demand avoidance of all potentially QT-prolonging drugs and the 
correction of electrolyte imbalances or other precipitating metabolic conditions. 
Pharmacological treatment may used in combination with trigger avoidance. β-blocker 
therapy is widely used for treatment of LQT1 and LQT2, having been associated with 
significant risk-reduction in adult and pediatric cases and is considered a treatment with 
very low risk of adverse effects (Goldenberg et al., 2010). Mortality of patients on -blockers 
is around 0.5% (Schwartz, Priori et al., 2001; Priori et al., 2004). Channel blockers or openers 
may also be used, though they can be pro-arrhythmic if not properly monitored. A study 
examining the effects of the K+  channel opener nicorandil on canine models of LQT1, 2 and 
3 showed that the drug may be effective in shortening the QT interval and preventing 
torsade de pointes in LQT1 and LQT2, but not LQT3 (Shimizu & Antzelevitch, 2000). For 
LQT3 patients where cardiac events are more likely to happen at low heart rates, -blocker 
therapy is generally less helpful. LQT3 who have mutations in SCN5A where the defect is a 
persistent late current, channel blockers such as mexilitene, or flecainide are potentially 
helpful (Rosero et al., 1997). 
Novel approaches include potassium supplementation for LQT2 patients. In vitro 
experiments have showed that proper intracellular K+ concentration is a requirement for 
normal HERG channel trafficking to the membrane, and that extracellular potassium 
modulates HERG current (Guo et al., 2009; Wang et al., 2009). These findings correlate with 
earlier studies that focused on HERG current density, showing that IKr current paradoxically 
increased when extracellular K+ concentration was increased (Sanguinetti & Jurkiewicz, 
1992). One group administered spironolactone to eight LQT2 patients for four weeks, and 
observed a decrease in QT interval, (Etheridge et al., 2003) while another treated seven 
subjects with potassium supplementation and had similar findings (Compton et al., 1996). 
Such approaches may be considered in LQT2 patients. 
Invasive therapies include left cardiac sympathetic denervation (LCSD), stellate 
ganglionectomy, and implantable cardioverter defibrillators (ICDs). LCSD involves the 
removal or ablation of the first four thoracic ganglia (which includes the stellate ganglion). 
In a 2004 study that included 174 high-risk, symptomatic LQTS patients who underwent 
LCSD, post-surgical QT intervals were shortened, and there was a 91% reduction in cardiac 
events over eight years of follow-up (Schwartz et al., 2004). These types of surgical 
interventions decrease sympathetic stimulation to the heart and may be recommended for 
patients who have not experienced cardiac arrest, but still experience syncope while on -
blocker therapy. ICD placement in such patients may be problematic because they may 
receive an intolerably high number of shocks. ICDs are most appropriate for patients who 
have already had an episode of cardiac arrest and are at higher risk for recurrence. 
5.3 Male / female differences 
To date, all LQTS loci are autosomal and not sex-linked. There are however, interesting 
differences between male and female LQTS patients. The QTc for women during the 
reproductive years (age 16-45) is longer than that for men of the same age (Bazett, 1920). 
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Women also have a higher resting heart rate than men (Ashman, 1942; Jose & Collison, 
1970). The QTc intervals for males and females under age 16 are comparable as are those of 
post-menopausal women and men of the same age (Locati et al., 1998). There is also an 
increased risk for women of reproductive age with LQT1 and LQT2 mutations to have 
arrhythmic events (Zareba et al., 1995); (Lehmann et al., 1997). These findings implicate 
differential affects of the sex hormone pathways on cardiac electrophysiology. 
Interestingly, there is an increased risk of having a cardiac event for female LQT1 and LQT2 
patients in the immediate post-partum period (Seth et al., 2007). Another recent report 
described a patient with KCNE1 mutation who experienced aborted sudden cardiac death 
in the post-partum period (Nakajima et al., 2010). The current recommendation is to 
continue -blocker therapy throughout the pregnancy and post-partum period to avoid 
cardiac events. While LQT1 and LQT2 mutations seem to adversely affect women more, the 
LQT3 (and Brugada syndrome mutations) event rate is greater in men (Priori et al., 2003). 
Among LQT3 genotyped individuals, men have a longer QTc than women. Another 
important condition where there are significant male/female differences is in acquired 
LQTS that may occur with drugs that block K+  channels, mainly HERG. Multiple studies 
found that women are more likely to have adverse events when taking a QT-prolonging 
medication (Woosley & Sale, 1993; Drici et al., 1996; Reinoehl et al., 1996). This should be a 
key consideration when prescribing medications to patients with LQTS and in the general 
population. 
6. New model systems: Induced patient-specific stem cells (iPSCs) 
A novel model that has been under recent investigation to better understand the 
pathophysiology of LQTS is induced patient-specific stem cells. This process consists of 
obtaining skin cells (dermal fibroblasts) from patients with known LQTS mutations as well 
as unaffected control subjects, culturing them, de-differentiating them into pluripotent stem 
cells, and re-differentiating them into cardiomyocytes in vitro. The dermal fibroblasts are 
infected with retroviruses or lentiviruses containing specific transcription factors that 
convert and reprogram the dermal cell to a pluripotent stem cell without affecting the other 
genomic DNA containing the LQTS mutation. The pluripotent stem cells are then given 
specific growth factors in a precise order and grown on feeder cells until they form 
embryoid bodies: aggregates of cells that can differentiate into cardiomyocytes of three 
distinct types: “nodal”, “atrial” and “ventricular” (Zhang et al., 2009). The cells were also 
shown to have cardiomyocyte architecture including sarcomeric organization of actin, 
myosin and other components, albeit immature. 
In 2010, Moretti et al. characterized cells derived from a LQT1 patient who had the mutation 
R190Q in KCNQ1. They showed that these cells exhibited a prolonged APD due to reduced 
IKs current density (Moretti et al., 2010). Itzhaki et al. derived cardiomyocytes from a patient 
with an LQT2 mutation in HERG (A614V); these cells also showed a prolonged APD and 
reduction in IKr (Itzhaki et al., 2011). They used microelectrode arrays to record from groups 
of mutant cells and showed an increased incidence of EADs. To study mutations in the 
calcium channel, the group of Yazawa and colleagues were able to derive iPSCs from 
patients with LQT8 (Timothy syndrome) (Yazawa et al., 2011). They found that the 
mutation-carrying cells contracted slowly and irregularly, had exaggerated calcium influx 
with prolonged APD in ventricular type cells. These studies were able to confirm previous 
findings of channel dysfunction in a more native setting. 
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Two notable caveats with the iPSC approach are that the differentiated cells are immature 
and may not express the full complement of ion channels and accessory or regulatory 
proteins and cellular architecture as does an adult cardiomyocyte and that the differentiated 
cells may be heterogeneous. A challenge is to develop a selection method or purification 
scheme to isolate the induced cardiomyocytes in larger and more uniform quantities. 
The iPSC system holds particular promise in determining the effect of potentially 
deleterious mutations in proteins other than ion channels such as regulatory or scaffolding 
proteins. This system may also be of particular utility in analysis of mutations non-coding 
areas (introns promoters, splice-sites and untranslated mRNA sequences). For therapeutics, 
iPSCs may provide a platform to test new potential pharmacologic approaches in a more 
native and genotype-specific setting prior to testing in animals and humans. 
7. Mechanisms of deleterious mutations 
LQTS mutations cause alterations in cardiac ionic currents that result in delayed action 
potential repolarization. The delay can be caused by sustained inward sodium or calcium 
currents, or impaired outward K+ current. Mutations to ion channels or their regulatory 
proteins alter channel function such that an increase or decrease in current occurs; the 
mechanism by which the mutation causes these functional changes can be categorized into 
several classes: (1) changes in biophysical properties, (2) changes in channel synthesis and 
processing, and (3) changes channel regulation. 
7.1 Biophysical 
Biophysical defects are caused by mutation to channel subunits that result in channel gain or 
loss of function. Several biophysical parameters affect how much current a channel carries: 
the structure of the channel pore, channel gating, and the stability of the channel in the open 
versus closed states. 
To discuss the effects on channel structure, we will focus on voltage-gated K+ channels as an 
example (see Figure 1). The pore of a K+ channel subunit is composed of two 
transmembrane helices (S5 and S6) and an intervening loop; when tetramerized, the loops 
form the K+  selectivity filter that extends into the ion conduction pathway, while the helices 
line the remainder of the pore (Doyle, Morais Cabral et al., 1998; Jiang, Lee et al., 2002; Jiang, 
Lee et al., 2003; Long, Campbell et al., 2005). The structure of the selectivity filter is rigid as 
ion selectivity is based on size; it holds the same conformation regardless of whether the 
channel is open or closed. The pore-lining transmembrane helices though, move in response 
to changes in membrane voltage; when the channel is closed, the intracellular end of the 
helices prevent ions from accessing the selectivity filter, and when the channel is open, the 
helices are positioned such that ions can enter the pore. Deleterious mutations have been 
identified in the pore region. They presumably alter the structure of this sensitive region 
such that ions cannot access the selectivity filter, or cannot pass through the selectivity filter. 
A second region that may be affected is the voltage sensor. The S4 transmembrane domain 
of a K+ channel is lined with positively charged amino acids. A change in the membrane 
potential causes movement in the voltage-sensor, and subsequently the pore region to 
which it is linked. Mutation to the voltage-sensing domain can result in delayed or impaired 
channel opening. Analysis of several LQT1 mutations in the S4 domain revealed a 
depolarizing shift in voltage-dependent activation of the channel, which indicates that a 
larger driving force was required to open the mutant channels (Henrion et al., 2009). Though 
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Women also have a higher resting heart rate than men (Ashman, 1942; Jose & Collison, 
1970). The QTc intervals for males and females under age 16 are comparable as are those of 
post-menopausal women and men of the same age (Locati et al., 1998). There is also an 
increased risk for women of reproductive age with LQT1 and LQT2 mutations to have 
arrhythmic events (Zareba et al., 1995); (Lehmann et al., 1997). These findings implicate 
differential affects of the sex hormone pathways on cardiac electrophysiology. 
Interestingly, there is an increased risk of having a cardiac event for female LQT1 and LQT2 
patients in the immediate post-partum period (Seth et al., 2007). Another recent report 
described a patient with KCNE1 mutation who experienced aborted sudden cardiac death 
in the post-partum period (Nakajima et al., 2010). The current recommendation is to 
continue -blocker therapy throughout the pregnancy and post-partum period to avoid 
cardiac events. While LQT1 and LQT2 mutations seem to adversely affect women more, the 
LQT3 (and Brugada syndrome mutations) event rate is greater in men (Priori et al., 2003). 
Among LQT3 genotyped individuals, men have a longer QTc than women. Another 
important condition where there are significant male/female differences is in acquired 
LQTS that may occur with drugs that block K+  channels, mainly HERG. Multiple studies 
found that women are more likely to have adverse events when taking a QT-prolonging 
medication (Woosley & Sale, 1993; Drici et al., 1996; Reinoehl et al., 1996). This should be a 
key consideration when prescribing medications to patients with LQTS and in the general 
population. 
6. New model systems: Induced patient-specific stem cells (iPSCs) 
A novel model that has been under recent investigation to better understand the 
pathophysiology of LQTS is induced patient-specific stem cells. This process consists of 
obtaining skin cells (dermal fibroblasts) from patients with known LQTS mutations as well 
as unaffected control subjects, culturing them, de-differentiating them into pluripotent stem 
cells, and re-differentiating them into cardiomyocytes in vitro. The dermal fibroblasts are 
infected with retroviruses or lentiviruses containing specific transcription factors that 
convert and reprogram the dermal cell to a pluripotent stem cell without affecting the other 
genomic DNA containing the LQTS mutation. The pluripotent stem cells are then given 
specific growth factors in a precise order and grown on feeder cells until they form 
embryoid bodies: aggregates of cells that can differentiate into cardiomyocytes of three 
distinct types: “nodal”, “atrial” and “ventricular” (Zhang et al., 2009). The cells were also 
shown to have cardiomyocyte architecture including sarcomeric organization of actin, 
myosin and other components, albeit immature. 
In 2010, Moretti et al. characterized cells derived from a LQT1 patient who had the mutation 
R190Q in KCNQ1. They showed that these cells exhibited a prolonged APD due to reduced 
IKs current density (Moretti et al., 2010). Itzhaki et al. derived cardiomyocytes from a patient 
with an LQT2 mutation in HERG (A614V); these cells also showed a prolonged APD and 
reduction in IKr (Itzhaki et al., 2011). They used microelectrode arrays to record from groups 
of mutant cells and showed an increased incidence of EADs. To study mutations in the 
calcium channel, the group of Yazawa and colleagues were able to derive iPSCs from 
patients with LQT8 (Timothy syndrome) (Yazawa et al., 2011). They found that the 
mutation-carrying cells contracted slowly and irregularly, had exaggerated calcium influx 
with prolonged APD in ventricular type cells. These studies were able to confirm previous 
findings of channel dysfunction in a more native setting. 
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Two notable caveats with the iPSC approach are that the differentiated cells are immature 
and may not express the full complement of ion channels and accessory or regulatory 
proteins and cellular architecture as does an adult cardiomyocyte and that the differentiated 
cells may be heterogeneous. A challenge is to develop a selection method or purification 
scheme to isolate the induced cardiomyocytes in larger and more uniform quantities. 
The iPSC system holds particular promise in determining the effect of potentially 
deleterious mutations in proteins other than ion channels such as regulatory or scaffolding 
proteins. This system may also be of particular utility in analysis of mutations non-coding 
areas (introns promoters, splice-sites and untranslated mRNA sequences). For therapeutics, 
iPSCs may provide a platform to test new potential pharmacologic approaches in a more 
native and genotype-specific setting prior to testing in animals and humans. 
7. Mechanisms of deleterious mutations 
LQTS mutations cause alterations in cardiac ionic currents that result in delayed action 
potential repolarization. The delay can be caused by sustained inward sodium or calcium 
currents, or impaired outward K+ current. Mutations to ion channels or their regulatory 
proteins alter channel function such that an increase or decrease in current occurs; the 
mechanism by which the mutation causes these functional changes can be categorized into 
several classes: (1) changes in biophysical properties, (2) changes in channel synthesis and 
processing, and (3) changes channel regulation. 
7.1 Biophysical 
Biophysical defects are caused by mutation to channel subunits that result in channel gain or 
loss of function. Several biophysical parameters affect how much current a channel carries: 
the structure of the channel pore, channel gating, and the stability of the channel in the open 
versus closed states. 
To discuss the effects on channel structure, we will focus on voltage-gated K+ channels as an 
example (see Figure 1). The pore of a K+ channel subunit is composed of two 
transmembrane helices (S5 and S6) and an intervening loop; when tetramerized, the loops 
form the K+  selectivity filter that extends into the ion conduction pathway, while the helices 
line the remainder of the pore (Doyle, Morais Cabral et al., 1998; Jiang, Lee et al., 2002; Jiang, 
Lee et al., 2003; Long, Campbell et al., 2005). The structure of the selectivity filter is rigid as 
ion selectivity is based on size; it holds the same conformation regardless of whether the 
channel is open or closed. The pore-lining transmembrane helices though, move in response 
to changes in membrane voltage; when the channel is closed, the intracellular end of the 
helices prevent ions from accessing the selectivity filter, and when the channel is open, the 
helices are positioned such that ions can enter the pore. Deleterious mutations have been 
identified in the pore region. They presumably alter the structure of this sensitive region 
such that ions cannot access the selectivity filter, or cannot pass through the selectivity filter. 
A second region that may be affected is the voltage sensor. The S4 transmembrane domain 
of a K+ channel is lined with positively charged amino acids. A change in the membrane 
potential causes movement in the voltage-sensor, and subsequently the pore region to 
which it is linked. Mutation to the voltage-sensing domain can result in delayed or impaired 
channel opening. Analysis of several LQT1 mutations in the S4 domain revealed a 
depolarizing shift in voltage-dependent activation of the channel, which indicates that a 
larger driving force was required to open the mutant channels (Henrion et al., 2009). Though 
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S4 contains the voltage-sensing residues, transmembrane domains S1 to S4 are structurally 
clustered together as the voltage-sensing domain; thus, mutations to residues in S1, S2, and 
S3 have also been associated with LQTS.  
Unlike in K+ channels, where loss-of-function mutations are the pathophysiologial defect, in 
Na+ channels, gain-of-function mutations lead to an increased Na+ current that maintain the 
cell in a depolarized state. Na+ channels are responsible for the rapid influx of Na+ ions in 
phase 0 of the action potential; this phase is extremely short-lived (milliseconds) as Na+ 
channels normally rapidly inactivate. Mutations that alter Na+ channel inactivation (rather 
than activation or deactivation) account for the majority of LQT3 . A defect in inactivation 
leads to a persistent Na+ current throughout the action potential duration, which delays 
repolarization. Several cytoplasmic regions of the Na+ channel are responsible for 
inactivation, and mutations in these regions lead to persistent current (Jones & Ruben, 2008). 
Biophysical mutations can act in a dominant-negative manner in patients with one wild-
type allele and one mutant allele. Because K+ channels are composed of four separate, 
identical channel subunits, wild-type and mutant subunits randomly combine together. 
Mutations that act in a dominant-negative manner may affect the function of channels that 
contain even one mutant subunit; less severe mutations may result in heteromeric channels 
with normal function or a partial defect. Sodium and calcium channels, however, are 
encoded such that the entire pore-forming channel is translated into a single polypeptide. 
Therefore, a patient who inherits a single mutant allele will have roughly 50% normal and 
50% mutant channels. The mechanisms for dominant phenotype in these cases resides in the 
fact that LQTS mutations in sodium and calcium channels are “gain-of-function” which 
cannot be overcome by expression of the normal allele. 
 
 
Fig. 1. Schematic representation of K+ (top) and sodium or calcium (bottom) channel 
proteins. Note that four identical subunits combine to form a single unit for K+ channels. 
Sodium and calcium channels are encoded as a singe polypeptide that is compised of four 
domains that are homologous the single subunit of a K+ channel. S1 through S6 signify the 
transmembrane helices 
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7.2 Cell biological processes 
7.2.1 Errors in synthesis 
The first steps in channel synthesis include transcription of RNA in the nucleus and post-
transcriptional modifications (capping, addition of a poly-A tail, splicing, and editing). The 
mature mRNA is then targeted to ribosomes on the endoplasmic reticulum to begin protein 
translation. Several classes of mutations can change mRNA stability and negatively affect 
abundance of functional protein. These include frame-shift and premature termination 
codons. These types of mutations may cause mRNA instability and subsequent degradation, 
a process called nonsense-mediated decay (NMD). NMD has been shown to be an 
underlying mechanism in other diseases. This phenomenon has been implicated as a cause 
recurrent intrauterine fetal death or LQTS in mutations of HERG (Bhuiyan et al., 2008) 
(Zarraga et al., 2011). Similarly NMD has been implicated to play a role in LQT3 mutation of 
the Na+ channel SCN5A (Teng et al., 2009). It is certainly conceivable that mutations, yet to 
be described, may also introduce new binding motifs for micro-RNAs that would alter 
stability and the mRNA and hence, protein synthesis.  
7.2.2 Errors in trafficking 
In general, defective protein trafficking is emerging as an important disease mechanism that 
concerns a variety of cell types. A newly synthesized channel goes through numerous 
processing steps before it ultimately reaches the membrane and is functional. At the earliest 
stage, some signaling systems may affect channel synthesis itself (Chen et al., 2009; Chen et 
al., 2010; Sroubek & McDonald, 2011). After the channel is synthesized at the endoplasmic 
reticulum (ER) it must fold to attain its tertiary structure and then assemble with other 
subunits to form the functional macromolecular complex. Folding is a complex process 
involving helper proteins called chaperones, which work in iterations to achieve the final 
proper conformation. Once the protein is properly folded it may be glycosylated and it 
leaves the ER through vesicle transport to arrive at the Golgi. At the Golgi the glycoslyations 
may be further modified and finally the channel leaves the Golgi in vesicles bound for the 
plasma membrane. 
Mutations may cause channel proteins to fold improperly; these mis-folded proteins may be 
recognized by the quality-control system and marked for degradation by the proteasome. 
This causes a trafficking error, and mis-folded protein may accumulate in the ER or Golgi 
membrane. Though severe mis-folding results in a non-functional channel (for example, 
mutations that prevent tetramerization of channel subunits), milder mutations may allow 
for a functional channel to fold, yet still be retained intracellularly. This is in theory possible, 
but under most circumstances it is difficult to test because functional experiments such as 
electrophysiology require proper trafficking. Mutations in HERG and KCNQ1 that affect 
trafficking can be loss-of-function and many of them can act in a dominant-negative fashion 
interfering with associated normal allele subunits. While tetramerization has been studied 
for these channels, the mechanisms are incompletely understood. Given a situation where 
wild-type and mutant subunits are co-expressed, the heterogeneous pool of tetrameric 
channels may express a range of current density from zero to the full wild-type amount. 
This could explain why some trafficking mutations have a more severe phenotype than 
others. 
It is worth considering LQTS mutation-associated trafficking errors in HERG. A trafficking 
defect is the most common cellular phenotype for LQT2 mutants (Anderson et al., 2006). 
Particular attention has been paid to the HERG cytoplasmic C-terminal portion where 
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S4 contains the voltage-sensing residues, transmembrane domains S1 to S4 are structurally 
clustered together as the voltage-sensing domain; thus, mutations to residues in S1, S2, and 
S3 have also been associated with LQTS.  
Unlike in K+ channels, where loss-of-function mutations are the pathophysiologial defect, in 
Na+ channels, gain-of-function mutations lead to an increased Na+ current that maintain the 
cell in a depolarized state. Na+ channels are responsible for the rapid influx of Na+ ions in 
phase 0 of the action potential; this phase is extremely short-lived (milliseconds) as Na+ 
channels normally rapidly inactivate. Mutations that alter Na+ channel inactivation (rather 
than activation or deactivation) account for the majority of LQT3 . A defect in inactivation 
leads to a persistent Na+ current throughout the action potential duration, which delays 
repolarization. Several cytoplasmic regions of the Na+ channel are responsible for 
inactivation, and mutations in these regions lead to persistent current (Jones & Ruben, 2008). 
Biophysical mutations can act in a dominant-negative manner in patients with one wild-
type allele and one mutant allele. Because K+ channels are composed of four separate, 
identical channel subunits, wild-type and mutant subunits randomly combine together. 
Mutations that act in a dominant-negative manner may affect the function of channels that 
contain even one mutant subunit; less severe mutations may result in heteromeric channels 
with normal function or a partial defect. Sodium and calcium channels, however, are 
encoded such that the entire pore-forming channel is translated into a single polypeptide. 
Therefore, a patient who inherits a single mutant allele will have roughly 50% normal and 
50% mutant channels. The mechanisms for dominant phenotype in these cases resides in the 
fact that LQTS mutations in sodium and calcium channels are “gain-of-function” which 
cannot be overcome by expression of the normal allele. 
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proteins. Note that four identical subunits combine to form a single unit for K+ channels. 
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domains that are homologous the single subunit of a K+ channel. S1 through S6 signify the 
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7.2 Cell biological processes 
7.2.1 Errors in synthesis 
The first steps in channel synthesis include transcription of RNA in the nucleus and post-
transcriptional modifications (capping, addition of a poly-A tail, splicing, and editing). The 
mature mRNA is then targeted to ribosomes on the endoplasmic reticulum to begin protein 
translation. Several classes of mutations can change mRNA stability and negatively affect 
abundance of functional protein. These include frame-shift and premature termination 
codons. These types of mutations may cause mRNA instability and subsequent degradation, 
a process called nonsense-mediated decay (NMD). NMD has been shown to be an 
underlying mechanism in other diseases. This phenomenon has been implicated as a cause 
recurrent intrauterine fetal death or LQTS in mutations of HERG (Bhuiyan et al., 2008) 
(Zarraga et al., 2011). Similarly NMD has been implicated to play a role in LQT3 mutation of 
the Na+ channel SCN5A (Teng et al., 2009). It is certainly conceivable that mutations, yet to 
be described, may also introduce new binding motifs for micro-RNAs that would alter 
stability and the mRNA and hence, protein synthesis.  
7.2.2 Errors in trafficking 
In general, defective protein trafficking is emerging as an important disease mechanism that 
concerns a variety of cell types. A newly synthesized channel goes through numerous 
processing steps before it ultimately reaches the membrane and is functional. At the earliest 
stage, some signaling systems may affect channel synthesis itself (Chen et al., 2009; Chen et 
al., 2010; Sroubek & McDonald, 2011). After the channel is synthesized at the endoplasmic 
reticulum (ER) it must fold to attain its tertiary structure and then assemble with other 
subunits to form the functional macromolecular complex. Folding is a complex process 
involving helper proteins called chaperones, which work in iterations to achieve the final 
proper conformation. Once the protein is properly folded it may be glycosylated and it 
leaves the ER through vesicle transport to arrive at the Golgi. At the Golgi the glycoslyations 
may be further modified and finally the channel leaves the Golgi in vesicles bound for the 
plasma membrane. 
Mutations may cause channel proteins to fold improperly; these mis-folded proteins may be 
recognized by the quality-control system and marked for degradation by the proteasome. 
This causes a trafficking error, and mis-folded protein may accumulate in the ER or Golgi 
membrane. Though severe mis-folding results in a non-functional channel (for example, 
mutations that prevent tetramerization of channel subunits), milder mutations may allow 
for a functional channel to fold, yet still be retained intracellularly. This is in theory possible, 
but under most circumstances it is difficult to test because functional experiments such as 
electrophysiology require proper trafficking. Mutations in HERG and KCNQ1 that affect 
trafficking can be loss-of-function and many of them can act in a dominant-negative fashion 
interfering with associated normal allele subunits. While tetramerization has been studied 
for these channels, the mechanisms are incompletely understood. Given a situation where 
wild-type and mutant subunits are co-expressed, the heterogeneous pool of tetrameric 
channels may express a range of current density from zero to the full wild-type amount. 
This could explain why some trafficking mutations have a more severe phenotype than 
others. 
It is worth considering LQTS mutation-associated trafficking errors in HERG. A trafficking 
defect is the most common cellular phenotype for LQT2 mutants (Anderson et al., 2006). 
Particular attention has been paid to the HERG cytoplasmic C-terminal portion where 
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analysis of various LQT2 mutations has revealed that this segment is critical for tetrameric 
assembly and proper trafficking. While many of these studies have focused on the C-
terminus of HERG, it is important to note that trafficking defective mutants have also been 
found throughout the N-terminus as well as the transmembrane domains (Balijepalli et al., 
2010). Complex mechanisms for the forward trafficking (from ER to Golgi) of HERG have 
been suggested. Recently, Delisle et al. showed that HEK cell expressed HERG undergoes 
COPII-dependent ER export and also endosomal trafficking which determine its plasma 
membrane expression (Delisle et al., 2009). They also showed that this atypical trafficking 
route is mediated by small GTPases such as Sar1 and Rab11b. More recent trafficking 
studies show that LQT2 mutants may be subjected to quality-control in the ER-Golgi 
intermediate compartment (ERGIC) (Smith et al., 2011). It has also been shown that 
trafficking defective LQT2 mutants are subsequently degraded by the ER-associated 
degradation pathway (ERAD) and the ubiquitin proteasome pathway (Kagan et al., 2000; 
Gong et al., 2005). While this picture is incomplete (studies rely on heterologous expression), 
it does give us insight into the points during synthesis where HERG is particularly 
susceptible and how mutations affect its maturation. 
Recent studies have examined the role of extracellular potassium in the endocytosis and 
degradation of HERG. Recently, the work of Guo and colleagues has provided a biochemical 
basis and mechanistic approach to study the behavior of HERG in low-potassium 
conditions. The 155 kDa form of HERG undergoes endocytic internalization from the 
plasma membrane and proteasomal degradation through a mechanism involving caveolin 
(Massaeli et al., 2010). Further work was done by Massaeli and colleagues who studied the 
behavior of pore-lining mutations in HERG under zero-potassium conditions. They found 
that alanine mutants at certain positions in the pore helix and selectivity filters abolished the 
low-potassium induced degradation. This is an interesting mechanism since arrhythmias are 
often precipitated by electrolyte disturbances such as hypokalemia (Berthet et al., 1999). 
7.3 Regulation 
In addition to intrinsic channel defects, there are many regulatory proteins that interact with 
channels to modulate their activity. Since LQT1 and LQT2 patients often have arrhythmias 
precipitated by physical or emotional stress, it is important to consider the human stress 
response affect these channels. The - and -adrenergic systems are activated during stress. 
The -adrenergic system involves the -adrenergic receptor, a hetero-trimeric G-protein, and 
cyclic adenosine monophosphate (cAMP), a second messenger that ultimately activates 
protein kinase A (PKA). HERG current is acutely reduced by PKA signaling due to direct 
phosphorylation of the channel. Furthermore, cAMP can interact with the HERG channel 
directly in a manner that partially abrogates the suppressive effects of phosphorylation. An 
added complexity to this signaling pathway is the interaction between 14-3-3, a scaffolding 
protein, and HERG (Kagan et al., 2002; Kagan & McDonald, 2005)). 14-3-3 dynamically 
binds proteins (including HERG) upon phosphorylation, primarily by PKA. When this 
occurs with HERG, channel activation is accelerated and current augmented. An LQT2 
mutation has been described in which the deleterious effect is disruption of 14-3-3 binding 
(Choe et al., 2006). An A-kinase anchoring protein (AKAP) is likely involved in targeting 
PKA to HERG in a macromolecular complex, which may intensify current modulation (Li et 
al., 2008). The Kass group showed S27 in the KCNQ1 N-terminus is phosphorylated by PKA 
and this causes an increase in current. They also showed that a AKAP Yotiao targets PKA to 
the channel complex (Marx et al., 2002). These studies demonstrate an important, specific, 
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and tightly controlled form of regulation by the components of the -adrenergic pathway in 
relation to the two K+ channels. 
In contrast to the -adrenergic system, the -adrenergic system involves phospholipase C, 
which hydrolyzes the membrane lipid phosphatidyl inositol-4,5-bisphosphate (PIP2) into the 
signaling molecules inositol 1,4,5-trisphosphate (IP3) and the second messenger 
diacylglycerol (DAG). DAG and calcium go on to activate protein kinase C (PKC) isoforms. 
An acute decrease in the PIP2 concentration, which occurs upon -adrenergic stimulation, 
reduces HERG currents (Bian et al., 2001). This effect is dependent on consumption of PIP2 
at the membrane and direct binding of PIP2 to HERG but occurs independently of calcium 
signaling or PKC activity (Bian et al., 2004; Bian & McDonald, 2007)). PKC regulation of 
HERG remains an active area of investigation where conclusive results await (Thomas, 2003)  
(Cockerill et al., 2007). For KCNQ1/KCNE1 and IKs, Varnum et al. showed that PKC 
stimulation decreased in IKs due to KCNE1 phosphorylation at serine-102 (Varnum et al., 
1993). The mechanism of this IKs downregulation remained unclear until the Abbott group 
showed that PKC downregulates IKs current through inducing endocytosis (Kanda et al., 
2011). Another group studied the regulation of IKs by PIP2 and showed that application of 
PIP2 delayed rundown of IKs in excised patch recordings (Loussouarn et al., 2003). 
7.4 Correlation of mutational mechanisms with clinical phenotype and the approach 
to genetic testing results 
Different channel mutations cause a range of clinical phenotypes, from very mild 
(asymptomatic) to severe (sudden cardiac death at a young age). Though some generalizations 
can be made correlating the mechanism by which a mutation acts and severity of clinical 
phenotype, the task is made difficult by the extensive list of implicated residues and their 
broad distribution across each gene. As one may expect, mutations to channel pore loops are 
generally severe, since they directly impact on channel conductance. A study of 858 LQT2 
patients in 2009 revealed that patients with mutation to the pore region of HERG (S5 – pore 
loop – S6) had significantly higher rates of cardiac events than patients with mutations in the 
S1 – S4 transmembrane domains or the N- or C-termini, with the difference increasing with 
increasing age. The study also explored possible differences between types of mutations and 
found that in the C-terminus, patients with non-missense mutations were at significantly 
higher risk than those with missense mutations (Shimizu et al., 2009). 
It is still difficult, though, to predict what type of cellular defect a certain mutation may case. 
Mutations that affect trafficking are not clustered in any particular region, and mutations 
that cause biophysical defects can also affect trafficking. K+ channel mutations are 
complicated by the ability to form wild-type/mutant heteromultimeric channels that exhibit 
different levels of defect depending on the number of mutant subunits. Functional analysis 
by in vitro expression of mutant channels is the only way to fully assess the cellular 
phenotype of a mutation. Additional genetic and environmental influences exist such that 
two patients with the same mutation may differ in clinical presentation. We do not yet know 
all the different factors that may affect the relative expression of mutant versus wild-type 
channels in a heterozygous patient, such that the distribution is not a 50/50 mix. One patient 
may express significantly differing amounts of normal or mutant allele subunits, and 
therefore have a variable clinical phenotype. For K+ channels, there is an overlap between 
the IKr and IKs currents in their role during repolarization (known as “repolarization 
reserve”), so the clinical presentation of a patient may be mild unless the unaffected current 
is also compromised by environmental factors. 
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analysis of various LQT2 mutations has revealed that this segment is critical for tetrameric 
assembly and proper trafficking. While many of these studies have focused on the C-
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found throughout the N-terminus as well as the transmembrane domains (Balijepalli et al., 
2010). Complex mechanisms for the forward trafficking (from ER to Golgi) of HERG have 
been suggested. Recently, Delisle et al. showed that HEK cell expressed HERG undergoes 
COPII-dependent ER export and also endosomal trafficking which determine its plasma 
membrane expression (Delisle et al., 2009). They also showed that this atypical trafficking 
route is mediated by small GTPases such as Sar1 and Rab11b. More recent trafficking 
studies show that LQT2 mutants may be subjected to quality-control in the ER-Golgi 
intermediate compartment (ERGIC) (Smith et al., 2011). It has also been shown that 
trafficking defective LQT2 mutants are subsequently degraded by the ER-associated 
degradation pathway (ERAD) and the ubiquitin proteasome pathway (Kagan et al., 2000; 
Gong et al., 2005). While this picture is incomplete (studies rely on heterologous expression), 
it does give us insight into the points during synthesis where HERG is particularly 
susceptible and how mutations affect its maturation. 
Recent studies have examined the role of extracellular potassium in the endocytosis and 
degradation of HERG. Recently, the work of Guo and colleagues has provided a biochemical 
basis and mechanistic approach to study the behavior of HERG in low-potassium 
conditions. The 155 kDa form of HERG undergoes endocytic internalization from the 
plasma membrane and proteasomal degradation through a mechanism involving caveolin 
(Massaeli et al., 2010). Further work was done by Massaeli and colleagues who studied the 
behavior of pore-lining mutations in HERG under zero-potassium conditions. They found 
that alanine mutants at certain positions in the pore helix and selectivity filters abolished the 
low-potassium induced degradation. This is an interesting mechanism since arrhythmias are 
often precipitated by electrolyte disturbances such as hypokalemia (Berthet et al., 1999). 
7.3 Regulation 
In addition to intrinsic channel defects, there are many regulatory proteins that interact with 
channels to modulate their activity. Since LQT1 and LQT2 patients often have arrhythmias 
precipitated by physical or emotional stress, it is important to consider the human stress 
response affect these channels. The - and -adrenergic systems are activated during stress. 
The -adrenergic system involves the -adrenergic receptor, a hetero-trimeric G-protein, and 
cyclic adenosine monophosphate (cAMP), a second messenger that ultimately activates 
protein kinase A (PKA). HERG current is acutely reduced by PKA signaling due to direct 
phosphorylation of the channel. Furthermore, cAMP can interact with the HERG channel 
directly in a manner that partially abrogates the suppressive effects of phosphorylation. An 
added complexity to this signaling pathway is the interaction between 14-3-3, a scaffolding 
protein, and HERG (Kagan et al., 2002; Kagan & McDonald, 2005)). 14-3-3 dynamically 
binds proteins (including HERG) upon phosphorylation, primarily by PKA. When this 
occurs with HERG, channel activation is accelerated and current augmented. An LQT2 
mutation has been described in which the deleterious effect is disruption of 14-3-3 binding 
(Choe et al., 2006). An A-kinase anchoring protein (AKAP) is likely involved in targeting 
PKA to HERG in a macromolecular complex, which may intensify current modulation (Li et 
al., 2008). The Kass group showed S27 in the KCNQ1 N-terminus is phosphorylated by PKA 
and this causes an increase in current. They also showed that a AKAP Yotiao targets PKA to 
the channel complex (Marx et al., 2002). These studies demonstrate an important, specific, 
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and tightly controlled form of regulation by the components of the -adrenergic pathway in 
relation to the two K+ channels. 
In contrast to the -adrenergic system, the -adrenergic system involves phospholipase C, 
which hydrolyzes the membrane lipid phosphatidyl inositol-4,5-bisphosphate (PIP2) into the 
signaling molecules inositol 1,4,5-trisphosphate (IP3) and the second messenger 
diacylglycerol (DAG). DAG and calcium go on to activate protein kinase C (PKC) isoforms. 
An acute decrease in the PIP2 concentration, which occurs upon -adrenergic stimulation, 
reduces HERG currents (Bian et al., 2001). This effect is dependent on consumption of PIP2 
at the membrane and direct binding of PIP2 to HERG but occurs independently of calcium 
signaling or PKC activity (Bian et al., 2004; Bian & McDonald, 2007)). PKC regulation of 
HERG remains an active area of investigation where conclusive results await (Thomas, 2003)  
(Cockerill et al., 2007). For KCNQ1/KCNE1 and IKs, Varnum et al. showed that PKC 
stimulation decreased in IKs due to KCNE1 phosphorylation at serine-102 (Varnum et al., 
1993). The mechanism of this IKs downregulation remained unclear until the Abbott group 
showed that PKC downregulates IKs current through inducing endocytosis (Kanda et al., 
2011). Another group studied the regulation of IKs by PIP2 and showed that application of 
PIP2 delayed rundown of IKs in excised patch recordings (Loussouarn et al., 2003). 
7.4 Correlation of mutational mechanisms with clinical phenotype and the approach 
to genetic testing results 
Different channel mutations cause a range of clinical phenotypes, from very mild 
(asymptomatic) to severe (sudden cardiac death at a young age). Though some generalizations 
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A computational prediction tool called KvSNP for voltage-gated K+ channel genes to predict 
the severity of possible disease-causing mutations has been published (Stead et al., 2011). 
Two recent case studies illustrate the complexity of patient presentation and how prediction 
databases, although initially valuable, have limitations. Each case involved patients with QT 
prolongation noted on ECG, yet mild clinical history until presentation with sudden cardiac 
death in early adulthood. One patient had the LQT1 mutation KCNQ1-S277L, located in the 
S5 pore helix just proximal to the pore loop, predicted by KvSNP to be a severe mutation. 
The location suggests a biophysical defect, but thorough analysis revealed a combination of 
trafficking defect with a partially dominant-negative biophysical effect on heteromultimeric 
channels that managed to traffic properly to the membrane. The second patient had the 
LQT2 mutation HERG-G816V, located in the C-terminal region adjacent to a cyclic-
nucleotide binding domain important for HERG regulation. This mutation was not 
predicted to be severe, yet functional analysis showed abnormal trafficking and significantly 
reduced current. Given the severe cellular defects, one would not predict a generally mild 
clinical phenotype. Both patients presented with sudden death when they experienced a 
second exogenous insult such as drug-induced blockade or electrolyte disturbance that 
reduced their remaining repolarizing current (Chen et al., 2011; Krishnan et al., 2011). 
 
 
Fig. 2. A general approach to managing families with suspected hereditary arrhythmia 
syndromes after receiving genetic testing results. 
These reports highlight the challenge that clinicians face upon receiving genetic testing 
results for patients suspected of having a hereditary cause of cardiac arrhythmia. The results 
from clinical laboratories may be given as clear-cut pathogenic deleterious mutations that 
have been reported in the literature. Such cases are relatively straightforward and further 
testing of at-risk family members is indicated with treatment and management dictated by 
the clinical presentation and recommendations for the documented mutation. Alternatively, 
the testing result may be read as a known non-pathogenic polymorphism that has been 
documented in normal populations. In this instance the clinician must guide therapy to the 
clinical diagnosis and consider whether the patient warrants further investigation such as 
analysis of copy number variance or various "omics" studies (whole exome or genome 
sequencing), which presently comprise investigative research studies. The third possibility 
is that genetic testing results are given as possible deleterious mutation or variants of 
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unknown significance. This is a difficult puzzle for the clinician to solve. An initial step 
might be to search mutational or polymorphism genetic databases for reports of the given 
variant, but the commercial laboratories usually perform this task. Another is to submit the 
reported variant to in silico analysis as described above (KvSNP), but remaining aware of 
the potential inaccuracies. More desirable is to perform one or more of the several functional 
analyses outlined above. Although this will entail collaboration with an academic 
laboratory, it will provide more solid evidence for, or against the variant being deleterious. 
Figure 2 illustrates a suggested algorithm for the approach of genetic testing results.  
7.5 Exploring novel therapeutic modalities 
One of the greatest challenges in LQTS is developing new therapeutic modalities aimed at 
the root cause of the defect instead of managing or preventing arrhythmias. One example is 
designing methods that correct the trafficking defective phenotype in many LQT2 cases. 
Work by January and colleagues have sought to use pharmacological methods to rescue 
trafficking deficient HERG mutants (Gong, 2006). In some LQT2 mutations trafficking can 
be partially rescued in heterologous systems by lower temperature, glycerol or DMSO, 
which act as non-specific chaperones. HERG channel blocking drugs E-4031, astemizole and 
cisapride have also been shown to rescue some mutant-related trafficking defects, but 
functionality was abolished since the channel pore was blocked. As is the case for many in-
vitro studies, the results are hard to translate into clinical therapies at present. Similar 
therapeutic models are in development for cystic fibrosis and rescue of CFTR trafficking 
mutants, but the same difficulties prevail (Becq et al., 2011). The ideal goal is to achieve a 
trafficking rescue without pore blockage. Encouraging results have been reported by 
Rajamani et al. who showed that the antihistamine fexofenadine was able to rescue some 
trafficking-deficient HERG mutants without channel block (Rajamani et al., 2002).  
Other efforts have utilized functional screens to discover small molecules that would 
suppress the long-QT phenotype irrespective of mechanism. An interesting approach has 
been reported using the breakdance (see section 4.3) mutant to screen for molecules that 
would rescue the phenotype (Peal et al., 2010). The investigators isolated 2 compounds that 
shortened the APD. The mechanisms by which these drugs work remain unclear as does the 
application of these drugs to mammals or later to humans. Nevertheless, this provides a 
good starting point and shows the utility of zebrafish as a genetic model in a high-
throughput screen.  
8. Conclusion 
Modern medical genetics has advanced the diagnosis and treatment of hereditary 
arrhythmia syndromes greatly in the past 15 years. Future advances will include recognition 
of modifying genetic and environmental factors that influence penetrance and severity. 
There is also hope for novel gene- and mutation-specific therapies. An achievable goal in the 
sort-term will be clear delineation of genetic mutations and variants that presently reported 
to clinicians that patients and families with possible hereditary arrhythmias. 
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1. Introduction 
Action potentials are mediated by transient changes in ion conductance across the cell 
surface membrane. These changes in conductance are primarily mediated by ion channels. 
Ion channels are membrane-embedded proteins that selectively pass specific ions upon 
opening. Some ion channels are constitutively open; however, most channels open following 
stimulation, such as through voltage changes, intracellular messengers, neurotransmitters, 
or shear stress. In the heart, voltage gated ion channels, conducting sodium, calcium and 
potassium ions, are primarily important in generating and shaping the action potential as 
well as exchangers and pumps that contribute to ion fluxes. 
The most prominent features of the cardiac action potential is the synchronised 
depolarisation of all the cardiomyocytes and the very long lasting depolarisation period, 
which in humans lasts 200-450 ms, depending on the beating frequency. The electrical 
impulse is generated in the pacemaker cells in the sinoatrial node located at the junction 
of the superior vena cava and right atrium. The electrical signal spreads to the right and 
left atria, thereby initiating muscular contraction and resulting in additional filling of the 
ventricles. When the depolarisation reaches the atrioventricular node, conduction is 
slowed before the depolarisation progresses to the ventricular cardiomyocytes. The 
electrical impulse is spread to the ventricles through a specialised conduction system 
formed by the His bundle branches and the Purkinje fibres, resulting in the depolarisation 
of the ventricular cardiomyocytes within a relatively short time span. The very long 
cardiac action potential mediates a long lasting increase in cytosolic calcium and, thereby, 
a long lasting contraction. Furthermore, the long action potential duration makes the 
myocardium refractory, whereby under normal physiological conditions no new action 
potentials will disturb the ongoing contraction. After the depolarisation phase and the 
plateau phase, the myocardium repolarises such that the contraction cesses and the 
ventricular chambers can be refilled. Disturbances in this highly fine-tuned electrical-
contraction pattern - termed arrhythmia - can be detrimental since unorganised electrical 
impulse propagation in the musculature will lead to uncoordinated muscle contraction 
and therefore a loss of pumping function (Jespersen, 2011). 
The cardiac action potential is the summarised output of several different types of ion 
channels. The functional significance of the different ion channels depends on both the 
subcardial location and the biophysical configuration of the channels, as well as the 
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physiological demands to be fulfilled. This is illustrated by the fact that the action potential 
morphology differs whether it is recorded in nodal tissue, in atria or else in either the 





Fig. 1. Ionic currents shape the cardiac action potential. Illustration of a ventricular action 
potential and the underlying currents. 
Ion channels consist of a central protein, named the α-subunit, where ions pass through a 
pore. Cardiac sodium and calcium channel α-subunits are composed of a single protein 
constituting a functional channel, while the potassium channels are tetrameric complexes of 
either homomeric or heteromeric composition. The pore contains a selectivity filter which 
ensures, for most channels, a high selectivity of one ion over the others (Hille, 2001). The 
opening, closing and inactivation of the channels are managed in a number of different 
ways. The voltage-gated channels contain a voltage sensor - primarily located in 
transmembrane segment 4 - which detects voltage changes, thereby initiating a 
conformational change in the protein leading to the opening and closing of the channel 
(Gouaux & Mackinnon, 2005). The inactivation of channel conductance - which is important 
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for the physiological functions of a number of the cardiac channels - can be induced either 
by fast intramolecular changes or by slower extramolecular regulation, such as through the 
binding of calcium ions to calmodulin, which interacts with the channel. A number of 
different classes of proteins interact with the cardiac ion channels. Closely associated 
proteins which are believed to be specific to the ion channels are termed β-subunits. β-
subunits can regulate both surface expression and opening and inactivation kinetics (Isom et 
al., 1992). Many of these β-subunits have been suggested as being promiscuous since they 
can interact with several different α-subunits (Panaghie & Abbott, 2006). In addition to the 
β-subunits, a growing number of regulatory and scaffolding proteins have been found to 
interact with the different cardiac ion channel complexes. 
This chapter will provide an overview of the major cardiac currents, the protein complexes 
constituting the ion channels and the regulatory mechanisms of these channels which are of 
crucial importance for controlling the progression, synchronisation and rhythmicity of the 
cardiac action potentials. 
1.1 Impulse generation 
The sinoatrial node, the atrioventricular node and the purkinje fibres all show spontaneous 
beating activity, but because the sinoatrial node normally has the highest frequency this is 
considered the primary pacemaker of the heart. The automaticity of the sinoatrial node is 
thus the basis for the rhythm and rate of the heart. The nodal action potential is initiated by 
a slow increase in depolarisation - driven by a sodium influx - followed by a faster 
depolarisation due to a calcium influx and terminated by a potassium ion efflux (reviewed 
by Mangoni & Nargeot, 2008a).  
One of the important ion currents participating in generating the spontaneous impulse is the 
hyperpolarisation activated current If (f for ‘funny’), which is conducted through the 
hyperpolarisation-activated cyclic nucleotide-gated channels (HCN) of which four members 
are known (HCN1-4). HCN4 is the primary expressed pacemaker channel, but HCN1 and 
HCN2 are also present in the sinoatrial node (Marionneau et al., 2005; Moosmang et al., 1999; 
Moroni et al., 2001; Shi et al., 1999; Sizarov et al., 2011). HCN channels are permeable to both 
sodium and potassium (Xue et al., 2002). However, as the channels deactivate at 
depolarising potentials, the predominant conductance is an inward sodium current. These 
channels are activated by cyclic nucleotides and hyperpolarisation potentials negative to ~-
55 mV (Gauss et al., 1998; Ludwig et al., 1998; Santoro et al., 1998). The one transmembrane 
spanning β-subunit, KCNE2 (MiRP1), has been reported to increase the surface expression 
and accelerate the kinetics of the HCN channels and has, therefore, been proposed as 
playing a role in generating the pacemaker signal (Macri et al., 2002; Qu et al., 2004; Yu et al., 
2001). 
In the sinoatrial and atrioventricular nodes, the activation of the HCN channels leads to a 
gradual depolarisation. This depolarisation is counteracted by an acetylcholine-activated 
potassium current (IK,Ach) conducted through the G-protein coupled inward rectifier (GIRK) 
(Noma & Trautwein, 1978). The cardiac IK,Ach channels are heteromeric complexes consisting 
of Kir3.1 (GIRK1) and Kir3.4 (GIRK4) subunits (Wickman et al., 1999). The Kir3 channels are 
activated by various heptahelical receptors coupled to G proteins of the pertussis toxin class 
(Gi/Go). Upon receptor activation, the heterotrimeric G protein complex is dissociated in its 
α and ßγ subunits, where the latter interacts with Kir3 subunits inducing an increased open 
probability of the channel complex (Logothetis et al., 1987). The activation of cardiac GIRK 
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channels by acetylcholine, adenosine and ATP mediates a negative chronotropic effect (Friel 
& Bean, 1990; Kurachi et al., 1986a; Kurachi et al., 1986b; Medina et al., 2000; Ravens & 
Dobrev, 2003). Vagal stimulation activates cardiac muscarinic M2 receptors whereby IK,Ach 
increases. This results in a slowing of the depolarising phase of the sinoatrial action 
potential and thereby provides a reduced action potential frequency. In contrast, the 
sympathetic stimulation of β-adrenergic receptors in the sinoatrial node mediates a positive 
chronotropic effect by increasing the cAMP levels, which reduces the GIRK-mediated 
current and - at the same time - increases the activity of the HCN and Ca2+ channels (see 
below), whereby the diastolic depolarisation phase is shortened and the spike frequency is 
increased (Baruscotti et al., 2005; Bucchi et al., 2003; DiFrancesco & Tromba, 1988; 
DiFrancesco, 1993; Noma et al., 1980; Zaza et al., 1996). Although HCN and GIRK channel 
regulation is considered central to setting the firing frequency of the sinoatrial node, other 
ion channels, including the ryanodine receptors (calcium-activated calcium channels located 
in the sarcoplasmic reticulum), IST channels with unknown molecular correlates and voltage-
gated sodium channels (probably of the neuronal type) have also been found to play a role 
(Lakatta & DiFrancesco, 2009; Mangoni & Nargeot, 2008b). 
The increasing depolarisation triggers the activation of T-type and L-type calcium channels 
(Fermini & Nathan, 1991; Hagiwara et al., 1988; Vuill & Hancox, 2002), whereby an action 
potential is generated. The repolarisation of the nodal cells is controlled by voltage-gated 
potassium channels. Both the rapid and slow inward rectifying current (IKr and IKs) as well 
as the transient outward current (ITo) are present, but further investigation is necessary to 
establish the relative and spatial importance of these currents (Mangoni & Nargeot, 2008b). 
As both the calcium and potassium currents play prominent roles in shaping the atrial and 




Fig. 2. The major ion channels responsible for the ventricular and atrial action potentials.  
An illustration of the different depolarising (red) and repolarising (blue) currents underlying 
the action potential in the ventricle and the atria. The current names, together with the major 
proteins constituting the channels conducting these currents, are listed to the right. 
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1.2 The atrial and ventricular action potentials 
The majority of the ion channels responsible for determining the action potential in atrial 
and ventricular myocytes are the same (Nerbonne & Kass, 2005). However, the relative 
expression level and means of being regulated differ for several of them (Gaborit et al., 
2007). The action potential can be divided into 5 phases (Fig. 1). Propagation and the rapid 
depolarisation (phase 0) of the cardiac action potential is mediated by a voltage-gated 
sodium current. Nav1.5 is the predominant α-subunit responsible for conducting the sodium 
current, but recently several reports have suggested other channels within the same voltage-
gated sodium channel family to be important. The fast activation of the sodium channels 
drives the membrane potential towards the equilibrium potential of sodium - which is quite 
positive - depolarising the membrane. Partial repolarisation (phase 1), after a few 
milliseconds, happens due to inactivation of the sodium channels together with the 
somewhat slower activation of L-type calcium channels (Striessnig, 1999). The depolarising 
sodium and calcium currents are countered by a repolarising potassium flux. In the 
ventricular subepicardium, the transient outward potassium current (ITo) - conducted 
through a multimeric complex with Kv4.x α-subunits - induces a notch in the beginning of 
the plateau phase (phase 2). In the atria, the ultra-rapid potassium current (IKur) - conducted 
through the Kv1.5 channels, potentially together with ITo - induces a partial repolarisation 
early in the action potential. The L-type calcium channels undergo a slow calcium and 
voltage-dependent inactivation and, at the same time, an increase in the rapid and slow 
delayed rectifier potassium currents, IKr and IKs, respectively, is observed. This moves the 
action potential into phase 3. The inward rectifier current IK1 participates in the latter part of 
phase 3, together with IKr and IKs, in driving the membrane potential towards the 
equilibrium potential of potassium and thereby terminating the action potential. IKr is 
conducted through human the ether-a-go-go-related gene channel 1 (hERG1, also called 
Kv11.1), while IKs is conducted through the Kv7.1/KCNE1 channels and IK1 through the 
Kir2.x channels. Together with the sodium potassium exchanger 1 (NCX1), IK1 is the current 
that is primarily responsible for setting the resting membrane potential (phase 4). Several 
other ion channels, including the KATP channels, the T-type calcium channels, the GIRK 
channels and the small conductance potassium channels, have been reported to be present 
in atrial and ventricular myocytes, but a thorough review these channels is beyond the 
scope of this chapter . 
2. Sodium channels 
The primary determinant in depolarising the surface membrane in the atrial and ventricular 
myocytes is the sodium current. the activation of the sodium channels leads to a very fast 
depolarisation of the myocytes, changing the membrane potential from approximately –85 
mV to approximately +25 mV within 10th of milliseconds (Petitprez et al., 2008) (phase 0, Fig. 
1). The sodium channels inactivate equally fast and only a small fraction of the channels are 
open during what remains of the action potential (Fig. 3).  
2.1 Nav1.5 voltage-gated sodium channels 
The voltage-gated sodium channel Nav1.5 is the primary component in generating the cardiac 
sodium current. This is proved by the fact that several cardiac syndromes, including long QT 
syndrome and Brugada Syndrome, have been linked to mutations in SCN5A, which is the 
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The voltage-gated sodium channel Nav1.5 is the primary component in generating the cardiac 
sodium current. This is proved by the fact that several cardiac syndromes, including long QT 
syndrome and Brugada Syndrome, have been linked to mutations in SCN5A, which is the 
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gene encoding Nav1.5 (Jespersen, 2011; Tfelt-Hansen et al., 2009). The Nav1.5 protein is a 
relatively large glycosylated membrane protein consisting of 2015 or 2016 residues (depending 
on the splice variant) with a molecular weight of ~220 kilo Dalton (Makielski et al., 2003). The 
Nav1.5 protein comprises 4 homologue domains (I to IV), each consisting of 6 transmembrane 
segments (TM1 to TM6) forming a functional channel (Fig. 3). The channel can be found in 
three confirmations: closed, open and inactivated. Around the resting membrane potential, the 
majority of channels are in the closed state. When a depolarising pulse reaches the Nav1.5 
channels - which are embedded in the cardiomyocyte plasma membrane - the channels 




Fig. 3. The cardiac Nav1.5 sodium channel. A) The SCN5A gene is transcribed into the large 
Nav1.5 protein containing 24 transmembrane domains. B) This protein can fold up into a 
functional channel, but it is believed to be modulated by the Navβ one-transmembrane 
spanning β-subunits in vivo. When an action potential (AP) induces a depolarisation of the 
membrane, Nav1.5 is activated and a transient influx of sodium begins. C) Illustration of the 
current conducted through Nav1.5 channels following a depolarising pulse. The channels 
will activate very quickly, but as soon as the action potential has commenced a fast 
inactivation is also initiated. After approximately 10 milliseconds, only a small fraction of 
the channels will be open. 
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This opening is, however, only transient as the inactivation of the channels is also a fast 
process, beginning immediately after depolarisation and making almost all of the channel 
complexes non-conducting after a few milliseconds. Although the vast majority of sodium 
conductance is within the first few milliseconds of the action potential sustained - or late - 
the inward sodium current is also observed. This sustained current, which is in the range of 
5 ‰ of the peak current, participates in determining the action potential duration, which is 
illustrated in long QT syndrome 3 patients who have mutations in SCN5A resulting in an 
increased sustained sodium current (~1-3 % of peak current) (Bennett et al., 1995). In 
cardiomyocytes with an increased sustained sodium current, the depolarising power of this 
current will lead to a longer depolarisation time and as the QT interval reflects the 
ventricular action potential duration, a prolonged QT interval is observed. This sodium ion 
selectivity is due to peptide sequences located in the pore between TM5 and TM6, while 
TM4 is involved in the activation of the channel. Furthermore, an intracellular sequence 
between domain 3 and 4 is important for the inactivation (West et al., 1992).  
2.2 Navβ1-β4 subunits interact with Nav1.5 
Four sodium channel β-subunits, Navβ1-β4, are encoded by SCN1-4B and have been 
identified (Meadows & Isom, 2005). SCN1-4B all comprise large extracellular 
immunoglobulin-like domains, a single transmembrane spanning segment and intracellular 
C-terminal domains. The β-subunits have been found implicated in sodium channel 
expression at the cell surface, the modulation of channel gating and the voltage dependency 
of the sodium current. All SCNB transcripts are present in the heart, but thorough 
investigations of protein expression have not been performed (Gaborit et al., 2007; Olesen et 
al., 2011). In vivo investigations of the cardiac role of Navβs are restricted to knock-out mice, 
and the reported in vitro effects inflicted by these β-subunits often depend on the cellular 
expression system applied; further studies in native settings are needed. However, the fact 
that mutations in the genes underlying the β-subunits have been linked to a number of 
arrhythmic disorders (reviewed in detail by Abriel, 2010) underlines the importance of these 
proteins in the heart. 
SCN1B is spliced into two variants, β1 (Isom et al., 1992) and β1A in rats (Kazen-Gillespie et 
al., 2000), and β1B in humans (Qin et al., 2003). While the rat and human β1 proteins have a 
high degree of similarity, the alternatively spliced part of rβ1A and hβ1B only shows a 33% 
sequence homology. In heterologous expression systems, the two most consistent findings 
with Navβ1 co-expressed with Nav1.5 are a positive voltage shift in the steady-state 
inactivation and an increase in peak current (Dhar et al., 2001; Herfst et al., 2003; Qu et al., 
1995). SCN1B mutations have been associated with atrial fibrillation and Brugada syndrome, 
both of which can be caused by a reduced sodium conductance, indicating that the in vitro 
observations can - at least to some extent - be translated into a functional myocyte context 
(Watanabe et al., 2008; Watanabe et al., 2009).  
In most studies, the expression of Navβ2 in various cell systems does not promote changes 
in the electrophysiological properties of Nav1.5, but it has been suggested that Navβ2 is 
involved in linking sialic acids to Nav1.5, which alters the activation properties (Johnson & 
Bennett, 2006). SCN2B mutations have been found in patients with atrial fibrillation 
(Watanabe et al., 2009). The Navβ3 subunit is reported to modify a number of biophysical 
properties - depending on expression system - including both activation and inactivation 
voltage dependence, as well as reducing the sustained current of Nav1.5 (Fahmi et al., 2001; 
Ko et al., 2005). SCN3B knock-down mice show a reduced sodium current and a negative 
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This opening is, however, only transient as the inactivation of the channels is also a fast 
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identified (Meadows & Isom, 2005). SCN1-4B all comprise large extracellular 
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C-terminal domains. The β-subunits have been found implicated in sodium channel 
expression at the cell surface, the modulation of channel gating and the voltage dependency 
of the sodium current. All SCNB transcripts are present in the heart, but thorough 
investigations of protein expression have not been performed (Gaborit et al., 2007; Olesen et 
al., 2011). In vivo investigations of the cardiac role of Navβs are restricted to knock-out mice, 
and the reported in vitro effects inflicted by these β-subunits often depend on the cellular 
expression system applied; further studies in native settings are needed. However, the fact 
that mutations in the genes underlying the β-subunits have been linked to a number of 
arrhythmic disorders (reviewed in detail by Abriel, 2010) underlines the importance of these 
proteins in the heart. 
SCN1B is spliced into two variants, β1 (Isom et al., 1992) and β1A in rats (Kazen-Gillespie et 
al., 2000), and β1B in humans (Qin et al., 2003). While the rat and human β1 proteins have a 
high degree of similarity, the alternatively spliced part of rβ1A and hβ1B only shows a 33% 
sequence homology. In heterologous expression systems, the two most consistent findings 
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both of which can be caused by a reduced sodium conductance, indicating that the in vitro 
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In most studies, the expression of Navβ2 in various cell systems does not promote changes 
in the electrophysiological properties of Nav1.5, but it has been suggested that Navβ2 is 
involved in linking sialic acids to Nav1.5, which alters the activation properties (Johnson & 
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voltage shift in steady-state inactivation, indicating that this subunit augments sodium 
conductance in the heart. The observations are supported by the fact that mutations in 
SCN3B have been associated with both Brugada Syndrome and atrial fibrillation (Hu et al., 
2009; Olesen et al., 2011). 
The studies performed with heterologous expression systems and transgenic mice have so 
far been inconclusive in determining the role of Navβ4 in the heart. However, SCN4B 
mutations have been linked to both long QT syndrome and sudden infant death syndrome, 
as in vitro electrophysiological investigations revealed an increased sustained current of 
Nav1.5 when these Navβ4 mutant proteins were co-expressed (Medeiros-Domingo et al., 
2007; Tan et al., 2010). 
2.3 Phosphorylation of Nav1.5  
Phosphorylation is a well-known regulatory mechanism of ion channels, often resulting in 
altered biophysical properties. Protein kinase C (PKC) activation provokes a drastic 
reduction in Nav1.5 current amplitude as well as a negative shift in steady-state inactivation 
(Qu et al., 1994). This effect is believed to be primarily mediated through the 
phosphorylation of serine residue 1503 (Murray et al., 1997; Qu et al., 1996). The function of 
glycerol 3-phosphate dehydrogenase 1-like (GPD1L) has recently been linked to the PKC 
phosphorylation of Nav1.5 (Valdivia et al., 2009). GPD1L catalyses the conversion of 
glycerol-3-phosphate to dihydroxyacetone phosphate. Glycerol-3-phosphate stimulates - 
through several intermediate proteins - PKC and thereby feeds the PKC-mediated 
phosphorylation of Nav1.5. Mutations in GPD1L have been associated to Brugada (London 
et al., 2007; Weiss et al., 2002) and sudden infant death syndromes (Van Norstrand et al., 
2007), and Valdivia and colleagues have shown this to be related to the decreased activity of 
GPD1L, inducing higher PKC activity and a reduced sodium current (Valdivia et al., 2009). 
The tyrosine phosphorylation of Nav1.5 has also been found to promote changes in the 
channel kinetics. The cardiac-expressed protein kinase Fyn induces a depolarising shift in 
steady-state inactivation (Ahern et al., 2005). By mutating tyrosine residue 1495, located in 
the linker between domains 3 and 4 and in close proximity to residues involved in 
inactivation (Patton et al., 1992), the authors found the effect of Fyn to be abolished. In 
contrast, the expression of the protein tyrosine phosphatase PTPH1 - which is also expressed 
in the heart - induced a hyperpolarisation shift in steady-state inactivation (Jespersen et al., 
2006). PTPH1 interacts with the 14-3-3β regulatory protein suggest that 14-3-3β functions as 
a regulator or adapter protein of the phosphatase (Zhang et al., 1997). Another member of 
the 14-3-3 family, namely 14-3-3η, has been found to interact with the Nav1.5 cytoplasmic I 
inter-domain, modifying the biophysical properties of the channel (Allouis et al., 2006). 
Whether or not this interaction modulates the level of Nav1.5 phosphorylation is unknown. 
2.4 Plasma membrane stability of Nav1.5 
Nav1.5 holds a C-terminal PDZ domain-binding motif. This domain binds syntrophin, 
which again interacts with dystrophin (Gavillet et al., 2006). The most prominent role of 
dystrophin is to provide a structural link between the cytoskeleton and the extracellular 
matrix in order to maintain muscle integrity. However, experiments performed by Abriel 
and co-workers on dystrophin-deficient mdx mice indicated the cardiac sodium channel to 
be regulated through a syntrophin/dystrophin complex (Gavillet et al., 2006). A significant 
reduction in Nav1.5 protein and current levels - together with ECG alterations - was found 
when the hearts from these mdx mice were analysed. The functional importance of this 
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interaction has been confirmed in humans, where mutations in α1-syntrophin have been 
associated with long QT syndrome and sudden infant death syndrome (Cheng et al., 2009; 
Ueda et al., 2008; Wu et al., 2008). 
For an increasing number of ion channels, Nedd4/Nedd4-like ubiquitin-protein ligase 
mediated internalisation has been found to be important (review by Abriel & Staub, 2005). 
This class of protein ligases - counting 9 members - interacts with membrane proteins 
holding a PY-motif (Staub et al., 1996). Ubiquitin is a 76 amino acid protein which can be 
covalently linked to lysine residues on target proteins, marking them for internalisation, 
followed by either degradation or intracellular storage (Hershko & Ciechanover, 1998; 
Hicke, 1999). Nav1.5 is regulated by Nedd4/Nedd4-like mediated ubiquitylation (Rougier et 
al., 2005; van Bemmelen et al., 2004). In vitro electrophysiological experiments revealed that a 
down-regulation in current density - without altering the biophysical properties - to be was 
induced by Nedd4-2 through a PY-motif located in the C-terminal tail of Nav1.5. Nedd4-2 
induces an increase in the ubiquitylation of Nav1.5, which leads to a drastic redistribution, 
where Nav1.5 proteins are almost absent from the surface membrane but are instead found 
in intracellular compartments. 
2.5 Other sodium channels in the heart 
Although Nav1.5 is the most important sodium channel in the heart, other voltage-gated 
sodium channels may also play a role in generating the cardiac INa. Neuronal sodium 
channels do, in contrast to Nav1.5, have a very high sensitivity to tetrodotoxin. This has been 
used to investigate the potential function of neuronal voltage-gated sodium channels in the 
heart. Although present at a relatively low mRNA level (Gaborit et al., 2007) neuronal 
sodium channels have been suggested to play a role in electrical-chemical coupling, as low 
tetrodotoxin concentrations lead to a reduction in sercoplasmic reticulum calcium release 
(Torres et al., 2010) and thereby reduce left ventricular functioning (Maier et al., 2002). Brette 
& Orchad found that TTX-sensitive INa makes up approximately 15% of the total INa in 
isolated rat ventricular cells, which decreased the rate of the depolarisation of the action 
potential by 10% (Brette & Orchard, 2006). Further, the sodium current in Purkinje fibres has 
been shown to be sensitive to low concentrations of tetrodotoxin (Carmeliet, 1987), 
indicating that the neuronal sodium channels participate in the propagation of the cardiac 
action potential. 
Recently, genome-wide association studies have revealed that SCN10A - encoding the 
Nav1.8 sodium channel - seems to participate in determining the conduction velocity in both 
atria (PR interval) and the ventricles (QRS duration) (Chambers et al., 2010; Holm et al., 2010; 
Pfeufer et al., 2010). Nav1.8 has a low sensitivity to tetrodotoxin, as with Nav1.5, and it can 
therefore be speculated that this channel has been overlooked up until now.  
3. L-type calcium channels 
The fast depolarisation (phase 0) driven by the influx of sodium through the voltage-gated 
sodium channels triggers the activation of voltage-gated calcium channels. Both voltage-
gated T-type and L-type calcium channels have been reported to be expressed in the heart. 
The T-type channels are low voltage-activated transient Ca2+ channels which are 
functionally expressed during development, while they are drastically down-regulated in 
adult myocytes (Ono & Iijima, 2010). However, these T-type calcium channels may still play 
a role in impulse generation in the sinoatrial node (Hagiwara et al., 1988). The long lasting, 
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voltage shift in steady-state inactivation, indicating that this subunit augments sodium 
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high voltage-activated L-type Ca2+ channels are both abundant and ubiquitously expressed 
in the heart (Bodi et al., 2005). These voltage-dependent calcium channels (VDCC) bind 
dihydropyridine and have, therefore, also been named dihydropyridine receptors (Taira et 
al., 1987; Tanabe et al., 1987). The L-type Ca2+ channels are the primary source of 
extracellular calcium influx. The opening of L-type Ca2+ channels is delayed when compared 
with Na+ channels and in contrast to the voltage-gated sodium channels, the L-type Ca2+ 
channels inactivate slowly (<100 ms) in a voltage- and calcium-dependent manner (Bean, 
1985). This slowly inactivated calcium current is - together with the fine-tuned regulation of 
sodium and potassium conductance - the basis for the action potential plateau observed in 
ventricular myocytes (phase 2). The ryanodine receptor calcium channels (RYR2) - which are 
located in the sarcoplasmic reticulum in close proximity to the L-type Ca2+ channels - is 
activated by the calcium influx (Bers, 2004). This RYR2-mediated sarcoplasmic calcium 
release is the major contributor in the activation of the contractile machinery (Bers, 2002). 
The cardiac L-type calcium channel consists of a pore-forming α-subunit, the Cav1.2 protein, 
which is encoded by Cacna1c. Cav1.2 has a similar topology to Nav1.5 (Fig. 3). A functional 
cardiac channel complex is composed of four polyproteins which, apart from Cav1.2, form 
the β and α2/δ auxiliary subunits (Bodi et al., 2005). The α2 and δ subunits are encoded by 
the same gene and are separated by proteolytic cleavage (De Jongh et al., 1990). Several 
different isoforms of this protein are known. The α2/δ subunits are linked together by a 
disulphide bridge and are closely associated with the Cav1.2 α-subunit by surface 
interaction. The α2 subunit is entirely extracellular, and the δ subunit has a single 
transmembrane region with a very short intracellular part. The α2/δ subunits have been 
suggested to increase the membrane density of the channel complex, and mice lacking this 
gene have a tendency to have bradycardia (Ivanov et al., 2004). All four calcium channel β-
subunits (CACNB1-4) are known to modify the currents; however, it has been suggested 
that β2 is the primary subunit in the heart (Colecraft et al., 2002). The β-subunits play a 
prominent role in the trafficking of the channel complexes to the cell surface membrane 
(Bichet et al., 2000; Chen et al., 2004; Van et al., 2004). Furthermore, the absence of β-subunits 
renders the channel insensitive to β-adrenergic stimulation (Mikala et al., 1998). 
One of the important regulatory mechanisms of L-type calcium channels is cAMP-
dependent phosphorylation, which increases the amplitude of the calcium current 
(McDonald et al., 1994). An increase in cAMP is induced by the β-adrenergic control of 
cardiac functions. β-adrenergic stimulation thereby leads to an increased calcium influx 
through the L-type channels, which facilitates an increased calcium release from the 
ryanodine receptors. Other important regulators of L-type calcium channels are calmodulin-
dependent protein kinase II (CaMKII) (Maier & Bers, 2007) and calcium-induced 
inactivation through binding to calmodulin (Bodi et al., 2005). 
4. Potassium channels 
In the heart, potassium conductance is conducted through a number of different potassium 
channels. All of the potassium channels described below consist of six transmembrane 
domains - except for Kir2.x which has two - and assembles into tetrameric complexes, which 
can either be homo- or heteromeric (Nerbonne & Kass, 2005) (Fig. 4). In the early phase of 
the action potential, the transient outward potassium current (ITo) is important in the atria 
and in subepicardial ventricular myocytes. The ultra-rapid potassium current (IKur) - which 
is also a fast activating current present early on in the action potential - is predominantly 
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expressed in the atria. The rapid and slow delayed rectifier potassium currents, IKr and IKs, 
respectively, are, together with the inward rectifier current IK1, the primary currents 
responsible for repolarising the myocyte membranes in the final part of the action potential 
and thereby terminating it (phase 3). All three of these currents are important in both atria 
and the ventricles. 
 
 
Fig. 4. Topology of the major repolarising potassium channels and their β-subunits. 
4.1 The transient outward (Kv4.x/ITo) potassium channels 
The transient outward current ITo is composed of two different components, namely a 
calcium-dependent chloride current and a calcium-independent potassium current. While 
the molecular components underlying the chloride current are unknown, several recently 
published reports have revealed a detailed picture of the proteins involved in forming the 
potassium transient outward current (reviewed by Patel & Campbell, 2005). This current can 
be divided into a rapidly activating and inactivating current - named ITo,f - and a current 
with slow recovery kinetics - named ITo,s. ITo,s, conducted through Kv1.4 channels - which 
are regulated by Kvβ cytosolic proteins (Morales et al., 1995). Kv1.4 channels are expressed 
throughout the ventricular wall as well as in the atria, where it is suggested that they 
participate to a minor extent with ITo (Calloe et al., 2010; Calloe et al., 2011). The ITo,f channels 
activate rapidly (in the order of milliseconds) in a voltage-dependent manner and are 
inactivated through a somewhat slower process (in the order of tens of milliseconds). The 
pore-forming subunit in ITo,f which is predominantly present in larger mammals is Kv4.3, 
which when co-expressed with the Kv channel interacting protein 2 (KChiP2) recapitulates 
most of the features of the native current (An et al., 2000; Deschenes et al., 2002). Kv4.3 is 
homogenously expressed in the ventricle. The KChiP2 auxiliary protein potentiates the 
current conducted through the Kv4.3 channels by promoting cell surface expression. In fact, 
in human and canine ventricles, a transmural expression gradient of KChiP2 has been found 
to correlate with a much higher ITo,f in the subepicardial layer than in the subendocardial 
layer (Calloe et al., 2010; Deschenes et al., 2002; Gaborit et al., 2007; Soltysinska et al., 2009; 
Zicha et al., 2004). This large expression of ITo,f is responsible for the characteristic notch 
(phase 1 repolarisation) observed in subepicardial cardiomyocytes (Calloe et al., 2009; Di 
Diego et al., 2002). ITo,f is also prominently expressed in the atria, where it likewise 
participates in early repolarisation (Calloe et al., 2010; Calloe et al., 2011; Gaborit et al., 2007). 
While KChIP2 has the most prominent effect on Kv4.3 channels, with altered current levels 
as well as inactivation and recovery parameters (Patel & Campbell, 2005), other auxiliary 
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high voltage-activated L-type Ca2+ channels are both abundant and ubiquitously expressed 
in the heart (Bodi et al., 2005). These voltage-dependent calcium channels (VDCC) bind 
dihydropyridine and have, therefore, also been named dihydropyridine receptors (Taira et 
al., 1987; Tanabe et al., 1987). The L-type Ca2+ channels are the primary source of 
extracellular calcium influx. The opening of L-type Ca2+ channels is delayed when compared 
with Na+ channels and in contrast to the voltage-gated sodium channels, the L-type Ca2+ 
channels inactivate slowly (<100 ms) in a voltage- and calcium-dependent manner (Bean, 
1985). This slowly inactivated calcium current is - together with the fine-tuned regulation of 
sodium and potassium conductance - the basis for the action potential plateau observed in 
ventricular myocytes (phase 2). The ryanodine receptor calcium channels (RYR2) - which are 
located in the sarcoplasmic reticulum in close proximity to the L-type Ca2+ channels - is 
activated by the calcium influx (Bers, 2004). This RYR2-mediated sarcoplasmic calcium 
release is the major contributor in the activation of the contractile machinery (Bers, 2002). 
The cardiac L-type calcium channel consists of a pore-forming α-subunit, the Cav1.2 protein, 
which is encoded by Cacna1c. Cav1.2 has a similar topology to Nav1.5 (Fig. 3). A functional 
cardiac channel complex is composed of four polyproteins which, apart from Cav1.2, form 
the β and α2/δ auxiliary subunits (Bodi et al., 2005). The α2 and δ subunits are encoded by 
the same gene and are separated by proteolytic cleavage (De Jongh et al., 1990). Several 
different isoforms of this protein are known. The α2/δ subunits are linked together by a 
disulphide bridge and are closely associated with the Cav1.2 α-subunit by surface 
interaction. The α2 subunit is entirely extracellular, and the δ subunit has a single 
transmembrane region with a very short intracellular part. The α2/δ subunits have been 
suggested to increase the membrane density of the channel complex, and mice lacking this 
gene have a tendency to have bradycardia (Ivanov et al., 2004). All four calcium channel β-
subunits (CACNB1-4) are known to modify the currents; however, it has been suggested 
that β2 is the primary subunit in the heart (Colecraft et al., 2002). The β-subunits play a 
prominent role in the trafficking of the channel complexes to the cell surface membrane 
(Bichet et al., 2000; Chen et al., 2004; Van et al., 2004). Furthermore, the absence of β-subunits 
renders the channel insensitive to β-adrenergic stimulation (Mikala et al., 1998). 
One of the important regulatory mechanisms of L-type calcium channels is cAMP-
dependent phosphorylation, which increases the amplitude of the calcium current 
(McDonald et al., 1994). An increase in cAMP is induced by the β-adrenergic control of 
cardiac functions. β-adrenergic stimulation thereby leads to an increased calcium influx 
through the L-type channels, which facilitates an increased calcium release from the 
ryanodine receptors. Other important regulators of L-type calcium channels are calmodulin-
dependent protein kinase II (CaMKII) (Maier & Bers, 2007) and calcium-induced 
inactivation through binding to calmodulin (Bodi et al., 2005). 
4. Potassium channels 
In the heart, potassium conductance is conducted through a number of different potassium 
channels. All of the potassium channels described below consist of six transmembrane 
domains - except for Kir2.x which has two - and assembles into tetrameric complexes, which 
can either be homo- or heteromeric (Nerbonne & Kass, 2005) (Fig. 4). In the early phase of 
the action potential, the transient outward potassium current (ITo) is important in the atria 
and in subepicardial ventricular myocytes. The ultra-rapid potassium current (IKur) - which 
is also a fast activating current present early on in the action potential - is predominantly 
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expressed in the atria. The rapid and slow delayed rectifier potassium currents, IKr and IKs, 
respectively, are, together with the inward rectifier current IK1, the primary currents 
responsible for repolarising the myocyte membranes in the final part of the action potential 
and thereby terminating it (phase 3). All three of these currents are important in both atria 
and the ventricles. 
 
 
Fig. 4. Topology of the major repolarising potassium channels and their β-subunits. 
4.1 The transient outward (Kv4.x/ITo) potassium channels 
The transient outward current ITo is composed of two different components, namely a 
calcium-dependent chloride current and a calcium-independent potassium current. While 
the molecular components underlying the chloride current are unknown, several recently 
published reports have revealed a detailed picture of the proteins involved in forming the 
potassium transient outward current (reviewed by Patel & Campbell, 2005). This current can 
be divided into a rapidly activating and inactivating current - named ITo,f - and a current 
with slow recovery kinetics - named ITo,s. ITo,s, conducted through Kv1.4 channels - which 
are regulated by Kvβ cytosolic proteins (Morales et al., 1995). Kv1.4 channels are expressed 
throughout the ventricular wall as well as in the atria, where it is suggested that they 
participate to a minor extent with ITo (Calloe et al., 2010; Calloe et al., 2011). The ITo,f channels 
activate rapidly (in the order of milliseconds) in a voltage-dependent manner and are 
inactivated through a somewhat slower process (in the order of tens of milliseconds). The 
pore-forming subunit in ITo,f which is predominantly present in larger mammals is Kv4.3, 
which when co-expressed with the Kv channel interacting protein 2 (KChiP2) recapitulates 
most of the features of the native current (An et al., 2000; Deschenes et al., 2002). Kv4.3 is 
homogenously expressed in the ventricle. The KChiP2 auxiliary protein potentiates the 
current conducted through the Kv4.3 channels by promoting cell surface expression. In fact, 
in human and canine ventricles, a transmural expression gradient of KChiP2 has been found 
to correlate with a much higher ITo,f in the subepicardial layer than in the subendocardial 
layer (Calloe et al., 2010; Deschenes et al., 2002; Gaborit et al., 2007; Soltysinska et al., 2009; 
Zicha et al., 2004). This large expression of ITo,f is responsible for the characteristic notch 
(phase 1 repolarisation) observed in subepicardial cardiomyocytes (Calloe et al., 2009; Di 
Diego et al., 2002). ITo,f is also prominently expressed in the atria, where it likewise 
participates in early repolarisation (Calloe et al., 2010; Calloe et al., 2011; Gaborit et al., 2007). 
While KChIP2 has the most prominent effect on Kv4.3 channels, with altered current levels 
as well as inactivation and recovery parameters (Patel & Campbell, 2005), other auxiliary 
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subunits have also been shown to be important for ITo,f. Dipeptidyl aminopeptidase-related 
proteins (DPPs) affect the biophysical properties of the Kv4.3 channels in a manner very 
similar to KCHiP2 proteins, with the important difference that they also accelerate 
activation, thereby providing current properties resembling native ITo,f (Cotella et al., 2010; 
Nadal et al., 2003; Radicke et al., 2005). Kvβ cytosolic proteins, which increase the expression 
of Kv4.3, have been suggested to regulate this transient outward potassium current (Yang et 
al., 2001). KCNE β-subunits, of which 5 different subtypes exit, have also been suggested to 
interact with Kv4.3/KCHiP2 channels as they modify the channel kinetics in in vitro studies 
(Radicke et al., 2006; Radicke et al., 2008). Recently, mutations in KCNE3 and KCNE5 have 
been linked to Brugada syndrome, which is a syndrome associated with an increased risk of 
ventricular fibrillation (Brugada & Brugada, 1992; Delpon et al., 2008; Ohno et al., 2011). Both 
KCNE3 and KCNE5 decrease the ITo current level when co-expressed, and as the mutations 
found in Brugada Syndrome patients provide an increase in current level compared to 
controls, it is suggested that this inhibitory effect of ITo is important in maintaining the 
current balance between the sodium and potassium currents in the early part of the 
ventricular action potential. 
4.2 The ultra-rapid (Kv1.5/IKur) potassium channels 
The ultra rapid potassium current IKur is well-expressed in the atria, where it contributes to 
repolarisation (Amos et al., 1996). This current activates early during an action potential and 
inactivates slowly. Hence, IKur is an important repolarising current throughout most of the 
atrial action potential. The molecular constituent of IKur is the Kv1.5 potassium channel 
(Wang et al., 1993). Although, IKur has predominantly been reported in atria, this current has 
also been suggested to play a role in canine and human ventricles (Calloe et al., 2010; Nielsen 
et al., 2007; Sridhar et al., 2007). 
4.3 The fast delayed rectifier (hERG1/IKr) potassium channels 
The rapid delayed rectifier current IKr is present in nodal tissue, atria, purkinje fibres and 
ventricles. The molecular correlate of IKr is the ether-a-go-go-related gene 1 product ERG1, 
also termed Kv11.1 (Sanguinetti et al., 1995; Trudeau et al., 1995). It is the unique biophysical 
features - with fast inactivation followed by slow deactivation - of the ERG1 potassium 
channel which makes it pivotal in cardiac repolarisation (Grunnet, 2010; Spector et al., 1996). 
Upon depolarisation, the ERG1 channels open but inactivate very quickly and at the same 
time display marked inward rectification (Grunnet et al., 2008b). This means that the ERG1 
channel complexes conduct a minor potassium current during the initial depolarisation and 
the plateau phase of the cardiac action potential. However, when the membrane potential 
moves slightly towards the repolarisation potential - partly due to L-type calcium channel 
inactivation and partly due to IKs activation - then ERG1 channels are released from 
inactivation. As ERG1 channels only slowly progress into a closed state (deactivation) – and, 
therefore, are kept in an open state (Piper et al., 2005) - a relatively large potassium current is 
conducted and the membrane potential is accelerated towards the resting membrane 
potential. The inactivation of ERG1 channels is called C-type inactivation, which involves a 
change at the extracellular mouth of the pore modulated by the extracellular potassium 
concentration (Baukrowitz & Yellen, 1995). A low concentration of potassium will lead to a 
pore collapse. Hence, the external potassium concentration is an important regulator of 
potassium conductance, where low concentrations will reduce activity and high 
concentrations will increase activity. Loss-of-function mutations in hERG1 are associated 
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with long QT syndrome type 2 (Sanguinetti et al., 1996a), while gain-of-function mutations 
have been found in short QT syndrome type 1 (Brugada et al., 2004; Cordeiro et al., 2005; 
Grunnet et al., 2008a).  
Two splice variants of ERG1 have been reported. The originally identified ERG1 protein is 
termed ERG1a while an alternatively spliced variant, termed ERG1b, has a much shorter 
intracellular N-terminal with a unique 36 residue sequence (Lees-Miller et al., 1997; London et 
al., 1997). ERG1b displays different deactivation kinetics to ERG1a (Lees-Miller et al., 1997; 
London et al., 1997). The co-expression of mRNA levels corresponding to the levels found in 
the human ventricles of the two variants alter several of the kinetic parameters (Larsen et al., 
2008), and this may explain a reported dispersion of IKr deactivation kinetics observed between 
myocytes isolated from the subepicardium and the mid-myocardium (Szabo et al., 2005). 
The membrane-spanning KCNE2 β-subunits have been found to modify the kinetics of the 
hERG1 channel (Abbott et al., 1999; McDonald et al., 1997). KCNE2/hERG1 expression in 
heterologous expression systems has been found to provide currents partly resembling 
native IKr, and as KCNE2 mutations found in long QT syndrome patients alter the channel 
properties it has been suggested that KCNE2 interacts with ERG1 in the heart (Abbott et al., 
1999). However, another report has not found KCNE2 to act as an essential constituent of 
the ERG1 channel complex carrying native IKr (Weerapura et al., 2002).  
4.4 The slow delayed rectifier (Kv7.1/IKs) potassium channels  
The KCNQ1 gene, encoding Kv7.1 proteins, was cloned by Wang and co-workers using 
linkage analyses on genomic material from Long QT syndrome patients (Wang et al., 1996), 
and was, therefore, originally named KvLQT1. The voltage-gated Kv7.1 channel is 
progressively opened by increasing membrane depolarisations. The channel gives rise to 
slowly activating and deactivating potassium currents. Upon longer depolarising steps, a 
fraction of the KCNQ1 channels inactivate (Pusch, 1998). KCNQ1 potassium channels are 
expressed in several tissues throughout the body and regulate key physiological functions. 
The two most important roles of KCNQ1 channels are: i) the repolarisation of the cardiac 
tissue following an action potential, and ii) water and salt transport across epithelial tissues 
(reviewed by Jespersen et al., 2005).  
The five relatively small one-transmembrane spanning KCNE proteins - KCNE1-5 - have 
been found to be highly promiscuous with respect to modulating the biophysical properties 
of Kv potassium channels as well as HCN pacemaker channels (McCrossan & Abbott, 2004). 
All five members of the KCNE family modify the properties of Kv7.1 channels (Jespersen et 
al., 2005). The co-expression of Kv7.1 with KCNE1 - formerly known as minK - recapitulates 
native IKs (Barhanin et al., 1996; Sanguinetti et al., 1996b), which not only plays a pivotal role 
in repolarising the myocardium but which is also important in transporting potassium 
across the strial marginal cells in the inner ear (Sunose et al., 1997). The co-assembly of Kv7.1 
and KCNE1 results in an increase in single channel conductance, a positive shift in the 
voltage activation threshold, the slowing of activation and deactivation, and an almost 
complete absence of inactivation (Splawski et al., 1997). In long QT syndromes 1 and 5, 
which are caused by mutations in Kv7.1 and KCNE1, a reduced IKs current is observed 
(Wang et al., 1996; Wang et al., 1999). 
IKs is the only potassium current which is upregulated with increased beating frequency. 
The upregulation of IKs is orchestrated by sympathetic mediated β-adrenergic receptor 
activation. The β-adrenergic receptor activation results in an increased level of cAMP and 
PKA stimulation, which interacts with the IKs channel complex through an A-kinase 
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subunits have also been shown to be important for ITo,f. Dipeptidyl aminopeptidase-related 
proteins (DPPs) affect the biophysical properties of the Kv4.3 channels in a manner very 
similar to KCHiP2 proteins, with the important difference that they also accelerate 
activation, thereby providing current properties resembling native ITo,f (Cotella et al., 2010; 
Nadal et al., 2003; Radicke et al., 2005). Kvβ cytosolic proteins, which increase the expression 
of Kv4.3, have been suggested to regulate this transient outward potassium current (Yang et 
al., 2001). KCNE β-subunits, of which 5 different subtypes exit, have also been suggested to 
interact with Kv4.3/KCHiP2 channels as they modify the channel kinetics in in vitro studies 
(Radicke et al., 2006; Radicke et al., 2008). Recently, mutations in KCNE3 and KCNE5 have 
been linked to Brugada syndrome, which is a syndrome associated with an increased risk of 
ventricular fibrillation (Brugada & Brugada, 1992; Delpon et al., 2008; Ohno et al., 2011). Both 
KCNE3 and KCNE5 decrease the ITo current level when co-expressed, and as the mutations 
found in Brugada Syndrome patients provide an increase in current level compared to 
controls, it is suggested that this inhibitory effect of ITo is important in maintaining the 
current balance between the sodium and potassium currents in the early part of the 
ventricular action potential. 
4.2 The ultra-rapid (Kv1.5/IKur) potassium channels 
The ultra rapid potassium current IKur is well-expressed in the atria, where it contributes to 
repolarisation (Amos et al., 1996). This current activates early during an action potential and 
inactivates slowly. Hence, IKur is an important repolarising current throughout most of the 
atrial action potential. The molecular constituent of IKur is the Kv1.5 potassium channel 
(Wang et al., 1993). Although, IKur has predominantly been reported in atria, this current has 
also been suggested to play a role in canine and human ventricles (Calloe et al., 2010; Nielsen 
et al., 2007; Sridhar et al., 2007). 
4.3 The fast delayed rectifier (hERG1/IKr) potassium channels 
The rapid delayed rectifier current IKr is present in nodal tissue, atria, purkinje fibres and 
ventricles. The molecular correlate of IKr is the ether-a-go-go-related gene 1 product ERG1, 
also termed Kv11.1 (Sanguinetti et al., 1995; Trudeau et al., 1995). It is the unique biophysical 
features - with fast inactivation followed by slow deactivation - of the ERG1 potassium 
channel which makes it pivotal in cardiac repolarisation (Grunnet, 2010; Spector et al., 1996). 
Upon depolarisation, the ERG1 channels open but inactivate very quickly and at the same 
time display marked inward rectification (Grunnet et al., 2008b). This means that the ERG1 
channel complexes conduct a minor potassium current during the initial depolarisation and 
the plateau phase of the cardiac action potential. However, when the membrane potential 
moves slightly towards the repolarisation potential - partly due to L-type calcium channel 
inactivation and partly due to IKs activation - then ERG1 channels are released from 
inactivation. As ERG1 channels only slowly progress into a closed state (deactivation) – and, 
therefore, are kept in an open state (Piper et al., 2005) - a relatively large potassium current is 
conducted and the membrane potential is accelerated towards the resting membrane 
potential. The inactivation of ERG1 channels is called C-type inactivation, which involves a 
change at the extracellular mouth of the pore modulated by the extracellular potassium 
concentration (Baukrowitz & Yellen, 1995). A low concentration of potassium will lead to a 
pore collapse. Hence, the external potassium concentration is an important regulator of 
potassium conductance, where low concentrations will reduce activity and high 
concentrations will increase activity. Loss-of-function mutations in hERG1 are associated 
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with long QT syndrome type 2 (Sanguinetti et al., 1996a), while gain-of-function mutations 
have been found in short QT syndrome type 1 (Brugada et al., 2004; Cordeiro et al., 2005; 
Grunnet et al., 2008a).  
Two splice variants of ERG1 have been reported. The originally identified ERG1 protein is 
termed ERG1a while an alternatively spliced variant, termed ERG1b, has a much shorter 
intracellular N-terminal with a unique 36 residue sequence (Lees-Miller et al., 1997; London et 
al., 1997). ERG1b displays different deactivation kinetics to ERG1a (Lees-Miller et al., 1997; 
London et al., 1997). The co-expression of mRNA levels corresponding to the levels found in 
the human ventricles of the two variants alter several of the kinetic parameters (Larsen et al., 
2008), and this may explain a reported dispersion of IKr deactivation kinetics observed between 
myocytes isolated from the subepicardium and the mid-myocardium (Szabo et al., 2005). 
The membrane-spanning KCNE2 β-subunits have been found to modify the kinetics of the 
hERG1 channel (Abbott et al., 1999; McDonald et al., 1997). KCNE2/hERG1 expression in 
heterologous expression systems has been found to provide currents partly resembling 
native IKr, and as KCNE2 mutations found in long QT syndrome patients alter the channel 
properties it has been suggested that KCNE2 interacts with ERG1 in the heart (Abbott et al., 
1999). However, another report has not found KCNE2 to act as an essential constituent of 
the ERG1 channel complex carrying native IKr (Weerapura et al., 2002).  
4.4 The slow delayed rectifier (Kv7.1/IKs) potassium channels  
The KCNQ1 gene, encoding Kv7.1 proteins, was cloned by Wang and co-workers using 
linkage analyses on genomic material from Long QT syndrome patients (Wang et al., 1996), 
and was, therefore, originally named KvLQT1. The voltage-gated Kv7.1 channel is 
progressively opened by increasing membrane depolarisations. The channel gives rise to 
slowly activating and deactivating potassium currents. Upon longer depolarising steps, a 
fraction of the KCNQ1 channels inactivate (Pusch, 1998). KCNQ1 potassium channels are 
expressed in several tissues throughout the body and regulate key physiological functions. 
The two most important roles of KCNQ1 channels are: i) the repolarisation of the cardiac 
tissue following an action potential, and ii) water and salt transport across epithelial tissues 
(reviewed by Jespersen et al., 2005).  
The five relatively small one-transmembrane spanning KCNE proteins - KCNE1-5 - have 
been found to be highly promiscuous with respect to modulating the biophysical properties 
of Kv potassium channels as well as HCN pacemaker channels (McCrossan & Abbott, 2004). 
All five members of the KCNE family modify the properties of Kv7.1 channels (Jespersen et 
al., 2005). The co-expression of Kv7.1 with KCNE1 - formerly known as minK - recapitulates 
native IKs (Barhanin et al., 1996; Sanguinetti et al., 1996b), which not only plays a pivotal role 
in repolarising the myocardium but which is also important in transporting potassium 
across the strial marginal cells in the inner ear (Sunose et al., 1997). The co-assembly of Kv7.1 
and KCNE1 results in an increase in single channel conductance, a positive shift in the 
voltage activation threshold, the slowing of activation and deactivation, and an almost 
complete absence of inactivation (Splawski et al., 1997). In long QT syndromes 1 and 5, 
which are caused by mutations in Kv7.1 and KCNE1, a reduced IKs current is observed 
(Wang et al., 1996; Wang et al., 1999). 
IKs is the only potassium current which is upregulated with increased beating frequency. 
The upregulation of IKs is orchestrated by sympathetic mediated β-adrenergic receptor 
activation. The β-adrenergic receptor activation results in an increased level of cAMP and 
PKA stimulation, which interacts with the IKs channel complex through an A-kinase 
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anchoring protein (AKAP) called ‘yotiao’ (Marx et al., 2002; Potet et al., 2001). PKA and 
protein phosphatase 1 interact with the C-terminal tail of KCNQ1 through yotiao, which 
leads to a phosphorylation of serine 27 in the N-terminus. cAMP-induced regulation of 
Kv7.1 is dependent on KCNE1 and Long QT mutations in both KCNQ1 and KCNE1 have 
been shown to disrupt this regulation (Kurokawa et al., 2004; Marx et al., 2002). The β-
adrenergic activation increases the activation and slows the deactivation kinetics of IKs, and 
these features - together with the increased beating frequencies - have been suggested to 
underlie the profoundly augmented cardiac IKs current (Marx et al., 2002; Terrenoire et al., 
2005). IKs is therefore essential for action potential shortening at increased beating 
frequencies. The importance of β-adrenergic stimulation is underlined by the fact that in 
humans IKs is almost absent without sympathetic stimulation (Jost et al., 2005). 
KCNE2-5 β-subunits also interact with Kv7.1 channels, modifying the biophysical 
parameters (Angelo et al., 2002; Bendahhou et al., 2005; Grunnet et al., 2002; Jespersen et al., 
2004; Mazhari et al., 2002; Tinel et al., 2000). Although KCNE2 is primarily believed to be of 
importance in the stomach, it has also been suggested as modifying IKs properties in the 
heart (Jiang et al., 2009; Wu et al., 2006). A polymorphism in KCNE4 has been associated 
with atrial fibrillation through a proposed gain-of-function mechanism (Ma et al., 2007), but 
solid evidence is still missing concerning a potential physiological function of the 
Kv7.1/KCNE4 interaction in the heart. KCNE5 expression drastically reduces the IKs current 
amplitude (Angelo et al., 2002). A KCNE5 mutation found in a patient with atrial fibrillation 
has been shown to increase IKs and it has therefore been suggested that KCNE5 β-subunits 
regulate the current conducted through Kv7.1/KCNE1 channels (Ravn et al., 2005; Ravn et 
al., 2008).  
Under pathophysiological conditions, such as during ischemia, cell volume and pH may 
undergo considerable alterations. KCNQ1 channels have been found to be activated by a 
drastic increase in extracellular hyperosmolarity in cardiomyocytes (Sasaki et al., 1994; 
Vandenberg et al., 1996). In heterologous expression systems, it has been shown that 
hyperosmolar-induced swelling increases the Kv7.1 current while hyperosmolar shrinkage 
decreases the current (Grunnet et al., 2003). The ability of Kv7.1 to sense volume changes 
depends on an intact cytoskeleton which interacts with the N-terminal part of Kv7.1. As 
with volume changes, internal and external acidification also modifies the Kv7.1 current 
density. Homomeric KCNQ1 channels are inhibited by both intracellular and extracellular 
acidic pH (Freeman et al., 2000; Peretz et al., 2002; Unsold et al., 2000). KCNE β-subunits 
enforce differential effects on the Kv7.1 channel complex following acidification. While 
KCNE3 renders Kv7.1 insensitive to external acidification, KCNE2 induces an increase in the 
current level following such acidification, which seems to be determined by the extracellular 
and transmembrane domains of KCNE2 (Heitzmann et al., 2007). The pH-dependent 
regulation induced by KCNE1 has been disputed, as both a small decrease (Peretz et al., 
2002) and an increase (Heitzmann et al., 2007) in current amplitude has been found; 
however, both external and internal acidification seem to modify the Kv7.1/KCNE1 current 
kinetics by changing the slow activation kinetics to an instantaneous onset (Heitzmann et al., 
2007; Unsold et al., 2000). 
4.5 The inward rectifier (Kir2.X/IK1) potassium channels 
The resting membrane potential of cardiomyocytes - being between -80 and -90 mV - is close 
to the equilibrium potential of potassium, partly due to relatively large resting K+ 
conductance through inward rectifier potassium channels (IKir) (phase 4) (Dhamoon & Jalife, 
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2005). IKir channels are composed of four pore-forming subunits, being either homomeric or 
heteromeric and characterised by a preferentially conducting current at potentials below –50 
mV (Lu, 2004). IKir is not, in contrast to the above described currents, voltage gated. The 
inward rectification profile, where much less current is passing when the membrane is 
depolarised than when it is repolarised, is not an inherent property of the channel protein 
itself, but reflects strong voltage dependence of channel block by intracellular cations, such 
as Mg2+ and polyamines (Ficker et al., 1994; Lopatin et al., 1994; Matsuda et al., 1987; 
Vandenberg, 1987). The primary inward rectifying current responsible for terminating the 
action potential - as well as for setting the resting membrane potential - is IK1, constituted by 
Kir2.1 and, to a lesser extent, the Kir2.2 and Kir2.3 proteins (Preisig-Muller et al., 2002; 
Zaritsky et al., 2001). Regional differences in the expression of IK1 have been described 
(Dhamoon et al., 2004; Samie et al., 2001) (Samie et al., 2001; Dhamoon et al., 2004) and the 
modulation of this current affects cardiac excitability and arrhythmogenesis (Nakamura et 
al., 1998; Plaster et al., 2001; Poelzing & Veeraraghavan, 2007; Warren et al., 2003). 
IK1 channels, such as ERG1 (IKr) channels, are regulated by extracellular potassium 
(Dhamoon et al., 2004; Hume & Uehara, 1985; Knot et al., 1996). Increased extracellular 
potassium augments potassium conductance - even though the potassium driving force is 
decreased - while a decreased concentration reduces the current. This biophysical property 
of IK1 and IKr channels is important in a clinical setting, as a patient with hypokalaemia will 
have a reduction in two of the three major repolarising cardiac currents which will lead to 
action potential prolongation as potentially being the trigger of arrhythmia. Another 
important regulator of the IK1 function is phosphatidylinositol 4,5-bisphosphate (PIP2) 
(Soom et al., 2001; Takano & Kuratomi, 2003). PIP2 is a quantitatively minor membrane 
component, although its local concentration may be relatively high. PIP is a key signalling 
phospholipid, whereby its hydrolysis by phospholipase C as well as its phosphorylation by 
PI3 kinases generates important second messengers. PIP2 binds directly to Kir channels, 
where it stabilises the open state. PIP2 has a high affinity with Kir2.X channels, which 
probably underlies the almost constitutive active IK1 (Lopes et al., 2002).  
5. Summary 
The length and morphology of cardiac action potential are shaped by the expression and 
fine-tuning of a number of ion channels. Sodium channels are responsible for the rapid 
depolarisation of the myocardium. The influx of sodium is followed by an influx of calcium 
through L-type calcium channels, contributing to keeping the depolarisation for several 
hundred milliseconds. The cardiac action potential is terminated by an increased efflux of 
potassium driving the membrane potential towards repolarisation. The dynamic properties 
of the action potential are obtained through a number of regulatory mechanisms 
maintaining the delicate balance between the different depolarising and repolarising ionic 
currents. Many of the primary regulatory mechanisms - such as β-subunits and 
phosphorylation sites - have been established. However, below the direct channel 
interacting proteins there is a whole network of modulatory mechanisms, and we are only 
just on the brink of discovering their role in regulating the cardiac action potential. 
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anchoring protein (AKAP) called ‘yotiao’ (Marx et al., 2002; Potet et al., 2001). PKA and 
protein phosphatase 1 interact with the C-terminal tail of KCNQ1 through yotiao, which 
leads to a phosphorylation of serine 27 in the N-terminus. cAMP-induced regulation of 
Kv7.1 is dependent on KCNE1 and Long QT mutations in both KCNQ1 and KCNE1 have 
been shown to disrupt this regulation (Kurokawa et al., 2004; Marx et al., 2002). The β-
adrenergic activation increases the activation and slows the deactivation kinetics of IKs, and 
these features - together with the increased beating frequencies - have been suggested to 
underlie the profoundly augmented cardiac IKs current (Marx et al., 2002; Terrenoire et al., 
2005). IKs is therefore essential for action potential shortening at increased beating 
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importance in the stomach, it has also been suggested as modifying IKs properties in the 
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al., 2008).  
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drastic increase in extracellular hyperosmolarity in cardiomyocytes (Sasaki et al., 1994; 
Vandenberg et al., 1996). In heterologous expression systems, it has been shown that 
hyperosmolar-induced swelling increases the Kv7.1 current while hyperosmolar shrinkage 
decreases the current (Grunnet et al., 2003). The ability of Kv7.1 to sense volume changes 
depends on an intact cytoskeleton which interacts with the N-terminal part of Kv7.1. As 
with volume changes, internal and external acidification also modifies the Kv7.1 current 
density. Homomeric KCNQ1 channels are inhibited by both intracellular and extracellular 
acidic pH (Freeman et al., 2000; Peretz et al., 2002; Unsold et al., 2000). KCNE β-subunits 
enforce differential effects on the Kv7.1 channel complex following acidification. While 
KCNE3 renders Kv7.1 insensitive to external acidification, KCNE2 induces an increase in the 
current level following such acidification, which seems to be determined by the extracellular 
and transmembrane domains of KCNE2 (Heitzmann et al., 2007). The pH-dependent 
regulation induced by KCNE1 has been disputed, as both a small decrease (Peretz et al., 
2002) and an increase (Heitzmann et al., 2007) in current amplitude has been found; 
however, both external and internal acidification seem to modify the Kv7.1/KCNE1 current 
kinetics by changing the slow activation kinetics to an instantaneous onset (Heitzmann et al., 
2007; Unsold et al., 2000). 
4.5 The inward rectifier (Kir2.X/IK1) potassium channels 
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as Mg2+ and polyamines (Ficker et al., 1994; Lopatin et al., 1994; Matsuda et al., 1987; 
Vandenberg, 1987). The primary inward rectifying current responsible for terminating the 
action potential - as well as for setting the resting membrane potential - is IK1, constituted by 
Kir2.1 and, to a lesser extent, the Kir2.2 and Kir2.3 proteins (Preisig-Muller et al., 2002; 
Zaritsky et al., 2001). Regional differences in the expression of IK1 have been described 
(Dhamoon et al., 2004; Samie et al., 2001) (Samie et al., 2001; Dhamoon et al., 2004) and the 
modulation of this current affects cardiac excitability and arrhythmogenesis (Nakamura et 
al., 1998; Plaster et al., 2001; Poelzing & Veeraraghavan, 2007; Warren et al., 2003). 
IK1 channels, such as ERG1 (IKr) channels, are regulated by extracellular potassium 
(Dhamoon et al., 2004; Hume & Uehara, 1985; Knot et al., 1996). Increased extracellular 
potassium augments potassium conductance - even though the potassium driving force is 
decreased - while a decreased concentration reduces the current. This biophysical property 
of IK1 and IKr channels is important in a clinical setting, as a patient with hypokalaemia will 
have a reduction in two of the three major repolarising cardiac currents which will lead to 
action potential prolongation as potentially being the trigger of arrhythmia. Another 
important regulator of the IK1 function is phosphatidylinositol 4,5-bisphosphate (PIP2) 
(Soom et al., 2001; Takano & Kuratomi, 2003). PIP2 is a quantitatively minor membrane 
component, although its local concentration may be relatively high. PIP is a key signalling 
phospholipid, whereby its hydrolysis by phospholipase C as well as its phosphorylation by 
PI3 kinases generates important second messengers. PIP2 binds directly to Kir channels, 
where it stabilises the open state. PIP2 has a high affinity with Kir2.X channels, which 
probably underlies the almost constitutive active IK1 (Lopes et al., 2002).  
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fine-tuning of a number of ion channels. Sodium channels are responsible for the rapid 
depolarisation of the myocardium. The influx of sodium is followed by an influx of calcium 
through L-type calcium channels, contributing to keeping the depolarisation for several 
hundred milliseconds. The cardiac action potential is terminated by an increased efflux of 
potassium driving the membrane potential towards repolarisation. The dynamic properties 
of the action potential are obtained through a number of regulatory mechanisms 
maintaining the delicate balance between the different depolarising and repolarising ionic 
currents. Many of the primary regulatory mechanisms - such as β-subunits and 
phosphorylation sites - have been established. However, below the direct channel 
interacting proteins there is a whole network of modulatory mechanisms, and we are only 
just on the brink of discovering their role in regulating the cardiac action potential. 
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1. Introduction  
The cardiac arrhythmia is a common cause of morbidity and mortality in the present 
world, especially in developed countries. The etiology of cardiac arrhythmia is quite 
broad involving both hereditary and secondary backgrounds. An increasing number of 
rare but lethal arrhythmogenic mutations have been identified by genome-wide 
association assays in genes associated with cardiac excitation, conduction and 
morphogenesis. Such well-characterized examples include causative mutations in voltage-
dependent Na+, Ca2+ or K+ channel (Nav, Cav, Kv) genes for the prolongation of QT 
interval which sometimes result in premature sudden death and may act as predisposing 
factors to drug-induced arrhythmia (Chen et al., 1998; Roden, 2004; Saenen & Vrints, 2008; 
Towbin & Vatta, 2001; Zareba et al., 2004). Furthermore, some of heart malformations (e.g. 
atrial septal defect) and idiopathic cardiomyopathy (e.g. dilated cardiomyopathy) with 
symptoms of arrhythmias have also proved to have some genetic linkage to impaired 
impulse conduction (Benson et al., 1999; Bonne, et al.,2001; Schott et al., 1998). However, 
much more prevalent are rhythm disturbances and conduction failures occurring in 
‘remodeling’ hearts which progressively undergo structural and electrical changes in 
prolonged metabolically and mechanically stressed states, e.g. chronic heart failure and 
myocardial infarction (Nattel, 2007; Olson, 2005). The well-known consequences of 
cardiac remodeling are; altered expression and gating properties of ion channels shaping 
the action potential and generating pace-making activities; reduced electrical coupling 
which leads to aberrant conduction of excitation. These changes are thought to work as 
the ‘substrates’ increasing the risk of lethal cardiac arrhythmia (Janse, 2004; Nattel, 2007). 
It has also been known that abnormal handling of intracellular Ca2+ occurring in the 
remodeled heart may cause spontaneous membrane depolarizations triggering ectopic 
excitations (Dobrev, 2010; Janse, 2004; Nattel, 2007). However, the available knowledge is 
still limited largely to ion channels/transporters/pumps whose roles in the cardiac 
excitation-contraction cycle have relatively been well established.  
The transient receptor potential (TRP) channels constitute a newly-emerging non-selective 
cation channel (NSCC) superfamily activated by a plethora of physico-chemical stimuli 
other than voltage change. Because of this unique activation profile as well as the ability to 
permeate Ca2+ (except for TRPM4/TRPM5), TRP channels have attracted great attention as 
promising candidate molecules elucidating a variety of biological functions and disorders 
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associated with slow sustained Ca2+ influx initiated by neurohormonal factors, pheromones, 
mechanical (membrane stretch/bending, osmotic change, shear force etc.) and thermal 
(from cold through cool and warm to heat) stresses, noxious stimuli (acid, respiratory 
irritants and toxicants) and many gustatory and pungent/cooling agents (camphor, citral, 
capsaicin, eucalyptol, icilin, menthol, allicin, mustard oil, sweet, umami and bitter tastants 
etc.) (Holzer, 2011; Vay et al., 2011; Wu et al., 2010). In the cardiovascular system, recent 
investigations have revealed pathophysiological implications of TRP channels in vasospasm, 
hypertension, occlusive vascular diseases, cardiac hypertrophy, cardiomyopathy and 
cardiac arrhythmia (Dietrich et al., 2010; Inoue et al, 2009b; Watanabe et al., 2008). 
Especially, as will be described below, involvement of some TRP channels in abnormal 
intracellular Ca2+ handling and increased responses to mechanical and noxious stresses may 
make them particularly relevant to the pathogenesis of acquired cardiac arrhythmias tightly 
associated with cardiac hypertrophy and failure, myocardial infarction and atrial fibrillation 
(Nattel, 2007; Ter Keurs & Boyden, 2007).  
This chapter will deal with the arrhythmogenic potential of several TRP isoforms identified 
in the cardiovascular system, with brief introduction to the general concepts of cardiac 
arrhythmia and its connection to cardiac diseases and with several examples in which the 
roles of TRP channels have been established or suggested.  
2. Factors contributing to cardiac arrhythmia 
 Cardiac arrhythmia is the abnormality of cardiac rhythm, the highly coordinated and 
integrated electrophysiological behavior of multiple ion channels/transporters/exchangers 
residing in tens of billions of myocytes and non-myoctes consisting of the heart. Clinically, 
cardiac arrhythmia can be defined as any anomalous excitations out of normal sinus control, 
and is conventionally classified into bradyarrhythmia (<50 beats per minute) and 
tachyarrhythmia (>100). Faulty or abnormal excitation of sinus node and various extents of 
conduction blocks mainly explain the former. In contrast, ectopic excitations occurring 
outside the sinus node (triggered activity, ectopic automaticity) and perpetuation of 
spiral/scroll waves rotating around a central core/filament (reentry) are thought to 
contribute to the latter. Although the mechanism remains still incompletely understood, 
shortened refractoriness, slowed and anisotropic conduction facilitate the occurrence of 
reentry (Jalife, 2000). Thus, altered expression or activities of ion channels contributing to 
the upstroke (Nav) and repolarization of action potential (Kv) as well as those determining 
the conduction velocity and cell-to-cell coupling [Nav and connexins (Cx), respectively] are 
involved in the reentrant mechanism.  
Ectopic excitations result from premature depolarizations before the next normal 
excitation arrives. Early afterdepolarization (EAD) occurs before the repolarization of 
action potential completely terminates, thereby prolonging it and evoking premature 
action potentials due to re-opening of Nav and/or Cav channels. This is a mechanistic 
background for the initiation of a specific form of polymorphic ventricular arrhythmias 
(Torsades de pointes) observed in both congenital and drug-induced Long QT syndromes; 
the function of ‘repolarization reserve’, i.e. Kv channels, is compromised, or residual 
activity of Nav channel sustains because of its incomplete inactivation (Roberts & Gollob, 
2010).  
Delayed afterdepolarization (DAD) is thought to reflect the generation of transient inward 
currents (Iti) activated by diastolic Ca2+ release from the sarcoplasmic reticulum (SR) of 
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myocytes (Venetucci et al., 2008). If the magnitude of DAD exceeds the threshold of Nav 
channel activation, an extrasystolic discharge of action potentials occurs. Sustained 
discharges from one or more foci may propagate around to cause tachyarrhythmias (focal 
excitation). In ventricular myocytes from rabbit failing heart which shows spontaneous 
ventricular tachyarrhythima, Iti has been ascribed exclusively to enhanced forward-mode 
Na+/Ca2+ exchanger type 1 (NCX1) current (Pogwizd et al., 2001; Pogwizd & Bers, 2004). 
However, there is evidence that implicates Ca2+-dependent Cl- and nonselective cationic 
conductances in the genesis of DAD (Han & Ferrier, 1992; Hill et al., 1988; Kass et a., 1978; 
Laflamme & Becker, 1996; Wu & Anderson, 2000). The mechanism underlying the 
diastolic Ca2+ release is likely to reflect Ca2+ overload into the sarcoplasmic reticulum (SR) 
caused by a net increase in Ca2+ uptake into the SR (increased Ca2+ influx and SRECA2a 
Ca2+-ATPase activity), or the dysfunction of ryanodine type 2 receptor (RyR2) which may, 
especially when intensively phosphorylated by protein kinase A (Wehrens et al., 2003) or 
Ca2+/calmodulin-dependent kinase II (Ai et al, 2005), causes a diastolic Ca2+ leak from the 
SR (Bers, 2006). Thus, under excessive sympathetic activities (hard exercise, mental stress, 
chronic heart diseases) or upon the application of drugs increasing the cAMP level 
(caffeine, catecholamines, phosphodiesterase inhibitors) or [Na+]i (digitalis) in 
cardiomyocytes which increase Ca2+ loading into the SR, the occurrence of DAD and 
resultant tachyarrhythmias may be greatly enhanced (Pogwizd, 2003; Sipido, 2007; 
Venetucci, 2008). In addition, in some pathological settings such as unphysiologically 
decreased extracellular K+ level and excessive sympathetic activity, ectopic automaticity, 
particularly in the Purkinje fiber, can also be abnormally increased to cause 
tachyarrhythmias (Osadchii, 2010).  
Clinical significance of mechanical loading in inducing arrhythmia has been well recognized 
(Dean & Lab, 1989). It is widely accepted that both acute and chronic stretch of myocardial 
tissue significantly affects its electrophysiological properties to increase the propensity for 
arrhythmia (Janse, 2003; Ravens, 2003). Experimentally, a transient diastolic stretch of 
isolated left ventricle was shown to induce ventricular arrhythmia which was inhibited by 
micromolar Gd3+ (Hansen et al. 1991; Stancy et al, 1992). Atrial fibrillation elicited by an acute 
increase in intra-atrial pressure in isolated rabbit hearts was also found effectively blocked 
by MSCC blockers, Gd3+ and a Tarantula toxin GsMTx-4 (Franz and Bode, 2003; Suchyna, 
2000). At the single cell level, Kamkin et al. (2000a) demonstrated that direct stretch of a 
ventricular myocyte could cause membrane depolarization and prolongation of action 
potential resembling EAD, which, at extensive stretch, led to an extrasystolic depolarization. 
This stretch-induced depolarization was attributed to the activation of Gd3+-sensitive 
mechanosensitive NSCCs (MSCCs) (Hamill & Martinac, 2001; Inoue et al., 2009b). The 
stretch sensitivity of MSCCs was significantly enhanced in hypertrophied cardiomyocytes 
with increased susceptibility to stretch-induced arrhythmia (Kamkin et al., 2000a). 
Considering that the heart is continuously subjected to hemodynamic stresses and 
deformation due to contraction, mechanical stresses may play a significant role in the 
causality and severity of arrhythmia, particularly under pressure- and volume-overloaded 
conditions. 
3. Connection of cardiac diseases to cardiac remodeling and arrhythmia 
The cardiac remodeling can be defined as the restructuring and reactivation of differentiated 
cardiac tissues comprised of myocytic and non-myocytic populations, and is initiated and 
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progressed by a complex interplay of genetic, environmental and aging factors (Cohn, et al., 
2000; Fedak, et al., 2005; Swynghedauw, 1999). Chronic heart failure, myocardial infarction 
and atrial fibrillation (AF) are three common pathological states accompanying the 
remodeling process with arrhythmic changes; in which excessively activated sympathetic 
nervous and renin-angiotensin-aldosterone systems, increased generation of inflammatory 
cytokines and reactive oxygen/nitrogen species, and sustained mechanical stresses likely 
play active roles. The remodeling process is initially ‘adaptive’ to compensate the impaired 
pumping function, but gradually becomes ‘maladaptive’ with disturbances in rhythm 
formation and conduction as common clinical complications.  
The key consequences of cardiac remodeling associated with the appearance of arrhythmia 
include both structural and electrical alterations. Enhanced collagen synthesis promotes the 
fibrotic replacement of damaged myocardial tissues thereby increasing the electrical 
heterogeneity. Altered expression and activities of ion channels, transporters and 
exchangers also bring about significant changes in the shape of action potential and its 
conduction properties as well as induce the susceptibility to premature excitations (Nattel, 
et al., 2007; Janse, 2004).  
In chronic heart failure, the major electrophysiological changes are pronounced 
prolongation of action potential which often accompanies EAD-like membrane oscillations. 
These changes likely occur through decreased expression or activity of transient outward 
current (Ito; Kv4,3) and voltage-dependent K+ channels forming the repolarization phase of 
action potential (IKr, IKs) (Bers, 2006; Janse, 2004; Nattel, et al.,2007; Ravens, 2010). The 
reduced inward rectifying K+ current (IK1) may also destabilize the membrane (i.e. increases 
the diastolic membrane resistance) and thereby enhance extrasystolic depolarizing 
responses (DAD) (Nattel, et al., 2007; Pogwitz et al, 2001). Furthermore, upregulation of 
hyperpolarization-activated current (If) and its mRNA (HCN2/4) (Cerbai, 1994; Fernandez-
Velasco et al., 2003) and reduced expression of gap junction channel (Cx43; Dupont et al, 
2001) have been reported to contribute to abnormally enhanced automaticity and impaired 
conduction, respectively. However, more notable changes observed in failing heart are 
abnormalities in intracellular Ca2+ handling (Bers, 2006; Janse, 2004). Despite a reduction in 
the SR Ca2+ content due to decreased expression of SERCA2a, the propensity for triggered 
activity based on DAD is enhanced. This likely reflects the other two major changes in Ca2+ 
handling, i.e. (1) the increased Ca2+ sensitivity of RyR2 under intensive phosphorylation by 
protein kinase A (however controversial now; Wehrens et al, 2003) or Ca2+/calmodulin 
kinase II (Ai et al, 2005) which causes diastolic Ca2+ leak from the SR, and (2) upregulation of 
Na+/Ca2+ exchanger (NCX1) protein which can carry depolarizing inward currents in the 
diastole. It has been suggested that increased β-adrenergic drive, which is prominent in 
chronic heart failure, may greatly facilitate the occurrence of DAD by increasing the Ca2+ 
content in the SR above the threshold of spontaneous Ca2+ release (Bers, 2006; Pogwizd, 
2003).   
Myocardial infarction is initiated by a sudden cessation of blood supply to heart tissues 
(i.e. myocardial ischemia), most frequently by thrombotic obstruction of coronary arteries. 
The time course of ischemic changes in the heart is variable and complex, and can 
mechanistically be distinguished between early and late acute phases, and subsequent 
postinfarction period vulnerable to structural and electrical remodeling (Clements-Jewery 
et al., 2005; Janse & Wit, 1989; Nattel et al., 2007). In acute phases, rapid depletion of 
intracellular ATP and accumulation of intracellular ADP, extracellular K+ and lactate 
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occur because of anaerobic glycolysis, and loss of intracellular K+ and intracellular 
acidosis follows. The extracellular accumulation of K+ leads to the depolarization of 
myocyte membrane that attenuates the amplitude and upstroke velocity of action 
potential (facilitated Nav inactivation) and the shortening of action potential duration 
(due to enhanced Kv activities) or refractoriness. Simultaneously, intercellular 
accumulation and release of many biochemical substances occurs including 
catecholamines, ATP, lysophosphatidylcholine, cytokines (e.g., TNFα), reactive oxygen 
species (ROS), and platelet-activating factors (Clements-Jewery et al., 2005; de Jong & 
Dekker, 2010). All these possess arrhythmogenic potential to induce ventricular 
premature excitations (DAD, EAD) and reentry. In postinfarction period, down-regulation 
of K+ channels (Ito, IKs, IKr, IK1) occurs in border-zones adjacent to infarct areas which 
impairs the repolarization of action potential leading to EAD, and altered intracellular 
Ca2+ handling facilitates spontaneous subcellular Ca2+ release events that can trigger 
arrhythmic episodes (Nattel, et al., 2007). 
Atrial fibrillation (AF) is a common supraventicular tachyarrhythmia with rapid and highly 
irregular firing, being closely associated with aging and cardiovascular diseases such as 
heart failure, myocardial infarction, valvular diseases and hypertension (Nattel et al, 2007; 
Ravens, 2010). AF per se is thought to serve as an arrhythmogenic remodeling process, 
because the occurrence of AF itself progressively aggravates electrophysiological features 
and facilitates fibrotic changes of atrial tissues in favor of more frequent and sustained 
occurrences. This clinical feature is described “AF begets AF” and experimentally confirmed 
by the finding that rapid atrial pacing causes significant shortening of atrial refractoriness 
and persistent AF (Wijffels, et al. 1995). The major arrhythmogenic changes found for AF are 
marked shortening of action potential duration which reduces the refractoriness and 
increases the susceptibility to reentry (Nattel et al, 2007; Ravens, 2010). In AF, this change is 
combined with abnormal Ca2+ handling with increased Ca2+ release from the SR and 
augmented NCX1 expression which facilitates ectopic premature depolarizations (i.e. DAD) 
that serve as a trigger to initiate the reentry (Dobrev, 2010). Both reduced/increased or 
unchanged expression of gap-junction channels have been reported, but their increased 
regional heterogeneity may contribute to various extents of conduction failure and reentry 
(Nattel, et al., 2007). 
4. TRP channels and cardiac arrhythmia  
The above considerations strongly suggest that, although alterations in the genesis and 
conduction properties of action potential are undoubtedly of central importance, other 
factors, e.g. Ca2+ overload, increased stretch sensitivity and noxious stimuli generated in 
ischemia/reperfusion, may also play a vital role in arrhythmogenicity. It is also possible that 
structural remodeling (necrotic/apoptotic and fibrotic changes) may contribute to the 
electrical heterogeneity of the myocardium which may act as the pro-arrhythmic substrates 
for altered conduction and reentry. As described above, Ca2+- and stretch-sensitivities, 
nociception as well as association to remodeling are the hallmark features of TRP channel 
members (Inoue et al., 2009b; Nishida & Kurose, 2008; Watanabe et al., 2008; Wu et al, 2010; 
Vay et al., 2011). Therefore, in the following, we would like to discuss about the 
pathophysiological relevance of several TRP isoforms particularly in these aspects of 
acquired arrhythmogenicity (see Table 1). 
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Table 1. Arrhythmogenic TRP channels 
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Abbreviations; CaM, calmodulin: GPCR, G-protein-coupled receptor (Gq-coupled): const-act, 
constitutively active: BDNF, brain-derived neurotrophic factor: DAG, diacylglycerol: PKC, 
protein kinase C: PKG, protein kinase G: LPC, lysophosphatidylcholine: S1P, sphingosin 1-
phosphate: EGF, epidermal growth factor: PGE2, prostaglandin E2: 20-HETE, 20-
hydroxytetraenoic acid: PIP3, phosphatidylinositol 3,4,5-trisphospate: PIP2, phosphatidylinositol 
4,5-trisphospate: CaMKII, calmodulin-dependent kinase II: ADPR, ADP ribose: cADPR, cyclic 
ADP ribose: NAADP, nicotinic acid adenine dinucleotide phosphate: PKA, protein kinase A: 12-
HETE, 12-hydroxy-5,8,10,14-eicosatetraenoic acid: LOX, lipooxygenase: PAR2, Proteinase-
activated receptor 2: NGF, nerve growth factor: GDNF, glial cell-line derived neurotrophic factor: 
MAPK, mitogen-activated protein kinase: SCF, stem cell factor: SKF, SK&F96365: BTP-2, 4-
methyl-4 -[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide: Pyr-2, 
Ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoroluoromethyl)-1H-pyrazole-4-
carboxylate: 2-APB, 2-aminoethoxydiphenyly boroate, 9-PA, 9-phenanthrol. 
4.1 Stretch-induced arrhythmia in pathological settings 
As described above, acute stretch of cardiac muscle can induce arrhythmic responses in both 
atrium and ventricle, which are inhibited by widely used MSCC blockers Gd3+ and GsMTx-
4. This has led to the speculation that activation of nonselective cationic MSCCs causes 
premature depolarizations. There are at least three candidates for these MSCCs in TRPs 
expressed in the heart, i.e. TRPC1, TRPC6 and TRPM4.  
In both heterologous and native overexpression systems, TRPC1 and TRPC6 have been 
found to activate in response to mechanical stimuli (Maroto et al.,2005; Spassova et al., 2006). 
Albeit controversial (e.g. Inoue et al., 2009a), the so-called MSCC-selective peptide blocker 
GsMTx-4 has been found to inhibit the mechanical activation of both TRPC1- and TRPC6-
mediated MSCC activities (Maroto et al.,2005; Spassova et al., 2006). TRPC1 and TRPC6 are 
ubiquitously expressed in whole myocardial tissues (Huang et al, 2009; Ward et al., 2008), 
and GsMTx-4 suppresses stretch-induced force development and concomitant [Ca2+]i 
increase in mouse left ventricular trabecular muscle (Ward et al., 2008) and pressure-
induced atrial fibrillation (Franz and Bode, 2003). Moreover, the expression of TRPC1 and 
TRPC6 is greatly increased in hypertrophied heart under prolonged pressure overload 
(Kuwahara, et al; 2006; Ohba, et al., 2007), where the susceptibility to mechanically-induced 
arrhythmia is also enhanced (Kamkin et al., 2000a). All these observations favor the view 
that TRPC1 and TRPC6 contribute to stretch-induced arrhythmias as MSCCs in some 
pathological settings. However, there is controversy over the mechanosensitivity of these 
two TRPC channels. In knock-out mice deficient in TRPC1 or TRPC6 expression, pressure-
induced vasoconstriction (myogenic response), which is believed to reflect the depolarizing 
effects of MSCC activation, was found intact (Dietrich et al., 2005; Gottlieb et al., 2007). 
Although this fact could not totally negate the roles of these TRP channels in the heart, it is 
essential to test whether mechanical activation of myocardial MSCCs and mechanical 
arrhythmogenicity are indeed impaired in these knock-out mice or vice versa in TRPC1- or 
TRPC6-overexpressing mice. Alternatively, it may also deserve to test the possible 
involvement of a recently identified GsMTx-4-sensitive MSCC, Piezo1/Piezo2, in stretch-
induced arrhythmia in the heart (Bae et al., 2011). 
In cerebral arterial myocytes, TRPM4 has been proposed as a MSCC responsible for 
myogenic response (Earley et al., 2004). However, again, the results from TRPM4-deficient 
mice do not support this role (for more detail, see below) (Mathar et al., 2010). Nevertheless, 
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hydroxytetraenoic acid: PIP3, phosphatidylinositol 3,4,5-trisphospate: PIP2, phosphatidylinositol 
4,5-trisphospate: CaMKII, calmodulin-dependent kinase II: ADPR, ADP ribose: cADPR, cyclic 
ADP ribose: NAADP, nicotinic acid adenine dinucleotide phosphate: PKA, protein kinase A: 12-
HETE, 12-hydroxy-5,8,10,14-eicosatetraenoic acid: LOX, lipooxygenase: PAR2, Proteinase-
activated receptor 2: NGF, nerve growth factor: GDNF, glial cell-line derived neurotrophic factor: 
MAPK, mitogen-activated protein kinase: SCF, stem cell factor: SKF, SK&F96365: BTP-2, 4-
methyl-4 -[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide: Pyr-2, 
Ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoroluoromethyl)-1H-pyrazole-4-
carboxylate: 2-APB, 2-aminoethoxydiphenyly boroate, 9-PA, 9-phenanthrol. 
4.1 Stretch-induced arrhythmia in pathological settings 
As described above, acute stretch of cardiac muscle can induce arrhythmic responses in both 
atrium and ventricle, which are inhibited by widely used MSCC blockers Gd3+ and GsMTx-
4. This has led to the speculation that activation of nonselective cationic MSCCs causes 
premature depolarizations. There are at least three candidates for these MSCCs in TRPs 
expressed in the heart, i.e. TRPC1, TRPC6 and TRPM4.  
In both heterologous and native overexpression systems, TRPC1 and TRPC6 have been 
found to activate in response to mechanical stimuli (Maroto et al.,2005; Spassova et al., 2006). 
Albeit controversial (e.g. Inoue et al., 2009a), the so-called MSCC-selective peptide blocker 
GsMTx-4 has been found to inhibit the mechanical activation of both TRPC1- and TRPC6-
mediated MSCC activities (Maroto et al.,2005; Spassova et al., 2006). TRPC1 and TRPC6 are 
ubiquitously expressed in whole myocardial tissues (Huang et al, 2009; Ward et al., 2008), 
and GsMTx-4 suppresses stretch-induced force development and concomitant [Ca2+]i 
increase in mouse left ventricular trabecular muscle (Ward et al., 2008) and pressure-
induced atrial fibrillation (Franz and Bode, 2003). Moreover, the expression of TRPC1 and 
TRPC6 is greatly increased in hypertrophied heart under prolonged pressure overload 
(Kuwahara, et al; 2006; Ohba, et al., 2007), where the susceptibility to mechanically-induced 
arrhythmia is also enhanced (Kamkin et al., 2000a). All these observations favor the view 
that TRPC1 and TRPC6 contribute to stretch-induced arrhythmias as MSCCs in some 
pathological settings. However, there is controversy over the mechanosensitivity of these 
two TRPC channels. In knock-out mice deficient in TRPC1 or TRPC6 expression, pressure-
induced vasoconstriction (myogenic response), which is believed to reflect the depolarizing 
effects of MSCC activation, was found intact (Dietrich et al., 2005; Gottlieb et al., 2007). 
Although this fact could not totally negate the roles of these TRP channels in the heart, it is 
essential to test whether mechanical activation of myocardial MSCCs and mechanical 
arrhythmogenicity are indeed impaired in these knock-out mice or vice versa in TRPC1- or 
TRPC6-overexpressing mice. Alternatively, it may also deserve to test the possible 
involvement of a recently identified GsMTx-4-sensitive MSCC, Piezo1/Piezo2, in stretch-
induced arrhythmia in the heart (Bae et al., 2011). 
In cerebral arterial myocytes, TRPM4 has been proposed as a MSCC responsible for 
myogenic response (Earley et al., 2004). However, again, the results from TRPM4-deficient 
mice do not support this role (for more detail, see below) (Mathar et al., 2010). Nevertheless, 
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it is noteworthy that TRPM4 can be secondarily activated by mechanical stretch through 
stretch-induced Ca2+ release from ryanodine-sensitive stores in arterial myocytes (Morita et 
al., 2007), since similar axial stretch-induced Ca2+ release from the SR has been demonstrated 
in cardiomyocytes (Iribe, et al., 2009). Considering that heart wall is periodically distended 
by diastolic filling pressure, this mechanosensitive mechanism may have considerable 
pathophysiological significance for the genesis of DAD in remodeled heart in which the 
expression of TRPM4 and Ca2+ loading into SR are prominently enhanced (see below).  
It has been shown that repeated cyclic stretch induces hypertrophic responses of cardiac 
myocytes, which are significantly attenuated by antagonists for a PLC-linked G-protein 
coupled receptor (GPCR), angiotensin type 1 (AT1) receptor (Komuro and Yazaki, 1993). 
This is explained by direct mechanical activation of unoccupied AT1 receptor as 
demonstrated by the substituted cysteine accessibility mapping technique (Yasuda et al., 
2008). Similar mechanical activation also appears to occur for many other PLC-linked 
GPCRs including endothelin ETA, vasopressin V1A and muscarinic M5 receptors (Mederos y 
Schnitzler et al., 2008). TRPC6 and its homologue TRPC3 are activated by stimulation of 
PLC-coupled GPCRs via generation of diacylglycerol (DAG) (Hofmann, et al., 1999) and 
Ca2+ influx through activated TRPC3 and TRPC6 channels has been shown to be essential 
for hypertrophic responses of caridomyocyte via calcineurin/NFAT pathway (Kuwahra et 
al., 2006; Bush et al., 2006; Onohara et al., 2006). In failing hearts where pressure overload is 
sustained, the release of catecholamines from sympathetic nerves and adrenal gland is 
increased (see above), and the production of angiotensin II (AngII) and expression of AT1 
receptor and angiotensin converting enzyme are greatly enhanced (Goette, A et al., 2000; 
Ihara M et al, 2000; Kaprielian RR et al., 1997). Moreover, the mechanosensitivity of TRPC6 
channel is remarkably enhanced by the simultaneous stimulation of PLC-linked GPCRs via 
concerted actions of two lipid messengers DAG and 20-HETE (Inoue et al., 2009a). Thus, 
taken together, it is highly conceivable that sustained mechanical loads promote the 
hypertrophic remodeling of cardiomyocytes through synergistic interplay between 
excessive activation of GPCR-PLC pathways and enhanced receptor/mechanical activation 
of TRPC6 (and TRPC3) channels. This would in turn exacerbate Ca2+ overload into the 
myocyte SR to increase the propensity for pro-arrhythmic depolarizations. Consistent with 
this scenario, cardiac-specific TRPC6 transgenic mice have been found to exhibit much 
increased susceptibility to mechanical stress with increased incidence of sudden death 
accompanied by severe macroscopic and histological signs of cardiomyopathy (Kuwahara et 
al., 2006). The same study also found that expression of TRPC6 was several-fold upregulated 
in human failing heart. Obviously, detailed electrophysiological analyses are required to 
corroborate whether the above changes could indeed induce the arrhythmogenicity. 
4.2 Ca2+-dependent arrhythmia 
Abnormal Ca2+ handling or cycling in cardiac tissues is the main cause for arrhythmia (Ter 
Keurs & Boyden, 2007). As briefly introduced above, diastolic Ca2+ release (or leak) from the 
SR is a key event to initiate arrhythmogenic premature depolarizations DAD. Presently, the 
mechanism whereby DAD is generated by the Ca2+ release can be accounted for by the 
activation of three ionic conductances which can generate Iti near the resting membrane 
potential; an electrogenic forward-mode NCX1 current which allows the influx of three Na+ 
ions in exchange of one Ca2+ efflux after the repolarization has completed; and Ca2+-
activated Cl- and nonselective cation channel (CAN) currents. Although the most accepted 
hypothesis suggests that Iti is carried exclusively by enhanced forward-mode NCX1 inward 
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current in failing ventricle (Pogwizd, et al. 2001; Pogwizd, 2003; Wu and Anderson, 1999), 
there is also experimental evidence suggesting the involvement of Ca2+-activated Cl- current 
(Han et al., 1996; Laflamme et al., 1996) and CAN (Hill et al., 1988; Kass et a., 1978; Wu & 
Anderson, 2000) in the genesis of Iti.  
CAN constitutes a large heterogenous family of cation channels with varying unitary 
conductances, Ca2+-sensitivities, voltage dependence and regulations, and distributes 
broadly in neurons, smooth muscle, heart, exocrine and endocrine glands, and other 
epithelial tissues (Siemen, 1993). The most frequently recorded CAN from cardiac tissues, 
first identified in a cultured rat neonatal ventricular myocyte (Colquhoun, 1981), is a 20-
40pS channel with almost equal selectivity over monovalent cations and poor permeability 
to divalent cations (Guinamard et al, 2006). Albeit rather great variations, these cardiac 
CANs are activated by the micro- to mili-molar range of Ca2+ and voltage-dependent. The 
molecular identification that best fits this type of CAN is now thought to be TRPM4 protein 
(Launay et al., 2002). Expressed TRPM4 channel shows a ~25pS conductance (in near-
physiological ionic milieu), is monovalent cation-selective, and, in cell-free conditions, 
undergoes Ca2+-dependent activation and depolarization-dependent enhancement of open 
probability only in their unphysiologically high ranges. However, it has been found that the 
Ca2+- and voltage-sensitivities of TRPM4 rapidly shift to their much higher ranges 
immediately after the excision of patch membrane (‘desensitization’ or ‘rundown’), and this 
is substantially prevented by pretreatment with MgATP, protein kinase C activators, 
maneuvers replenishing phosphatidylinositol 4,5-bisphosphate and increased temperature 
(Nilius, 2006). These findings suggest that, in vivo, TRPM4 may be more effectively 
regulated by physiological ranges of [Ca2+]i and membrane potential. Expressed TRPM4 
channel also undergoes negative regulation of free adenosine nucleotide phosphates 
(efficacy; ADP > ATP = AMP), and is subject to spermine block, so that severe ischemic 
conditions might affect this channel activity (Nilius et al., 2004).  
In human, cardiac expression of TRPM4 is ubiquitous in the order of abundance; Purkinje 
fibers, septum, atrium, left and right ventricles (Kruse et al., 2009). Guinamard et al (2002) 
found that expression of TRPM4-like CAN, which was virtually absent at the time of cell 
isolation, was progressively enhanced in rat dedifferentiating ventricular myocytes with the 
time of culture. Studies from the same group also found that purinergic receptor activation by 
ATPγS, PKC activators and DAG, all of which act as interventions to facilitate cardiac 
remodeling, enhanced the occurrence of TRPM4-like channel in cultured ventricular myocytes. 
This led to the postulation that remodeling of ventricular myocytes in response to excessive 
hypertrophic signals may enhance the activity of TRPM4 thereby increasing arrhythmogenic 
propensity mostly likely by increasing DAD. Consistent with this, in the hypertrophic heart of 
spontaneously hypertensive rat, the elongation of Q-T interval in electrocardiogram has been 
reported together with increased expression of TRPM4 protein and density of CAN 
(Guinamard et al., 2006). Recent reports indicate that TRPM4 is more abundantly expressed in 
atrium and sinoatrial node (Demion et al, 2007; Guinamard, 2004; Kruse et al., 2009), where 
DAD-based tachyarrhythmias have been well established (Dobrev, 2010; Guinamard 2006; 
Nattel 2007; Raves, 2010). However, TRPM4-deficient mice showed no obvious abnormalities 
in heart rate, cardiac output, ejection fraction and cardiac contractility at basal conditions 
questioning a vital role of TRPM4 in physiological regulation of cardiac functions (Mathar et 
al., 2009). Rather unexpectedly, the genetic deletion of TRPM4 caused postnatal development 
of high blood pressure due to increased sympathetic catecholamine secretion. These seemingly 
paradoxical observations might point to the pathological contribution of TRPM4 to 
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it is noteworthy that TRPM4 can be secondarily activated by mechanical stretch through 
stretch-induced Ca2+ release from ryanodine-sensitive stores in arterial myocytes (Morita et 
al., 2007), since similar axial stretch-induced Ca2+ release from the SR has been demonstrated 
in cardiomyocytes (Iribe, et al., 2009). Considering that heart wall is periodically distended 
by diastolic filling pressure, this mechanosensitive mechanism may have considerable 
pathophysiological significance for the genesis of DAD in remodeled heart in which the 
expression of TRPM4 and Ca2+ loading into SR are prominently enhanced (see below).  
It has been shown that repeated cyclic stretch induces hypertrophic responses of cardiac 
myocytes, which are significantly attenuated by antagonists for a PLC-linked G-protein 
coupled receptor (GPCR), angiotensin type 1 (AT1) receptor (Komuro and Yazaki, 1993). 
This is explained by direct mechanical activation of unoccupied AT1 receptor as 
demonstrated by the substituted cysteine accessibility mapping technique (Yasuda et al., 
2008). Similar mechanical activation also appears to occur for many other PLC-linked 
GPCRs including endothelin ETA, vasopressin V1A and muscarinic M5 receptors (Mederos y 
Schnitzler et al., 2008). TRPC6 and its homologue TRPC3 are activated by stimulation of 
PLC-coupled GPCRs via generation of diacylglycerol (DAG) (Hofmann, et al., 1999) and 
Ca2+ influx through activated TRPC3 and TRPC6 channels has been shown to be essential 
for hypertrophic responses of caridomyocyte via calcineurin/NFAT pathway (Kuwahra et 
al., 2006; Bush et al., 2006; Onohara et al., 2006). In failing hearts where pressure overload is 
sustained, the release of catecholamines from sympathetic nerves and adrenal gland is 
increased (see above), and the production of angiotensin II (AngII) and expression of AT1 
receptor and angiotensin converting enzyme are greatly enhanced (Goette, A et al., 2000; 
Ihara M et al, 2000; Kaprielian RR et al., 1997). Moreover, the mechanosensitivity of TRPC6 
channel is remarkably enhanced by the simultaneous stimulation of PLC-linked GPCRs via 
concerted actions of two lipid messengers DAG and 20-HETE (Inoue et al., 2009a). Thus, 
taken together, it is highly conceivable that sustained mechanical loads promote the 
hypertrophic remodeling of cardiomyocytes through synergistic interplay between 
excessive activation of GPCR-PLC pathways and enhanced receptor/mechanical activation 
of TRPC6 (and TRPC3) channels. This would in turn exacerbate Ca2+ overload into the 
myocyte SR to increase the propensity for pro-arrhythmic depolarizations. Consistent with 
this scenario, cardiac-specific TRPC6 transgenic mice have been found to exhibit much 
increased susceptibility to mechanical stress with increased incidence of sudden death 
accompanied by severe macroscopic and histological signs of cardiomyopathy (Kuwahara et 
al., 2006). The same study also found that expression of TRPC6 was several-fold upregulated 
in human failing heart. Obviously, detailed electrophysiological analyses are required to 
corroborate whether the above changes could indeed induce the arrhythmogenicity. 
4.2 Ca2+-dependent arrhythmia 
Abnormal Ca2+ handling or cycling in cardiac tissues is the main cause for arrhythmia (Ter 
Keurs & Boyden, 2007). As briefly introduced above, diastolic Ca2+ release (or leak) from the 
SR is a key event to initiate arrhythmogenic premature depolarizations DAD. Presently, the 
mechanism whereby DAD is generated by the Ca2+ release can be accounted for by the 
activation of three ionic conductances which can generate Iti near the resting membrane 
potential; an electrogenic forward-mode NCX1 current which allows the influx of three Na+ 
ions in exchange of one Ca2+ efflux after the repolarization has completed; and Ca2+-
activated Cl- and nonselective cation channel (CAN) currents. Although the most accepted 
hypothesis suggests that Iti is carried exclusively by enhanced forward-mode NCX1 inward 
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current in failing ventricle (Pogwizd, et al. 2001; Pogwizd, 2003; Wu and Anderson, 1999), 
there is also experimental evidence suggesting the involvement of Ca2+-activated Cl- current 
(Han et al., 1996; Laflamme et al., 1996) and CAN (Hill et al., 1988; Kass et a., 1978; Wu & 
Anderson, 2000) in the genesis of Iti.  
CAN constitutes a large heterogenous family of cation channels with varying unitary 
conductances, Ca2+-sensitivities, voltage dependence and regulations, and distributes 
broadly in neurons, smooth muscle, heart, exocrine and endocrine glands, and other 
epithelial tissues (Siemen, 1993). The most frequently recorded CAN from cardiac tissues, 
first identified in a cultured rat neonatal ventricular myocyte (Colquhoun, 1981), is a 20-
40pS channel with almost equal selectivity over monovalent cations and poor permeability 
to divalent cations (Guinamard et al, 2006). Albeit rather great variations, these cardiac 
CANs are activated by the micro- to mili-molar range of Ca2+ and voltage-dependent. The 
molecular identification that best fits this type of CAN is now thought to be TRPM4 protein 
(Launay et al., 2002). Expressed TRPM4 channel shows a ~25pS conductance (in near-
physiological ionic milieu), is monovalent cation-selective, and, in cell-free conditions, 
undergoes Ca2+-dependent activation and depolarization-dependent enhancement of open 
probability only in their unphysiologically high ranges. However, it has been found that the 
Ca2+- and voltage-sensitivities of TRPM4 rapidly shift to their much higher ranges 
immediately after the excision of patch membrane (‘desensitization’ or ‘rundown’), and this 
is substantially prevented by pretreatment with MgATP, protein kinase C activators, 
maneuvers replenishing phosphatidylinositol 4,5-bisphosphate and increased temperature 
(Nilius, 2006). These findings suggest that, in vivo, TRPM4 may be more effectively 
regulated by physiological ranges of [Ca2+]i and membrane potential. Expressed TRPM4 
channel also undergoes negative regulation of free adenosine nucleotide phosphates 
(efficacy; ADP > ATP = AMP), and is subject to spermine block, so that severe ischemic 
conditions might affect this channel activity (Nilius et al., 2004).  
In human, cardiac expression of TRPM4 is ubiquitous in the order of abundance; Purkinje 
fibers, septum, atrium, left and right ventricles (Kruse et al., 2009). Guinamard et al (2002) 
found that expression of TRPM4-like CAN, which was virtually absent at the time of cell 
isolation, was progressively enhanced in rat dedifferentiating ventricular myocytes with the 
time of culture. Studies from the same group also found that purinergic receptor activation by 
ATPγS, PKC activators and DAG, all of which act as interventions to facilitate cardiac 
remodeling, enhanced the occurrence of TRPM4-like channel in cultured ventricular myocytes. 
This led to the postulation that remodeling of ventricular myocytes in response to excessive 
hypertrophic signals may enhance the activity of TRPM4 thereby increasing arrhythmogenic 
propensity mostly likely by increasing DAD. Consistent with this, in the hypertrophic heart of 
spontaneously hypertensive rat, the elongation of Q-T interval in electrocardiogram has been 
reported together with increased expression of TRPM4 protein and density of CAN 
(Guinamard et al., 2006). Recent reports indicate that TRPM4 is more abundantly expressed in 
atrium and sinoatrial node (Demion et al, 2007; Guinamard, 2004; Kruse et al., 2009), where 
DAD-based tachyarrhythmias have been well established (Dobrev, 2010; Guinamard 2006; 
Nattel 2007; Raves, 2010). However, TRPM4-deficient mice showed no obvious abnormalities 
in heart rate, cardiac output, ejection fraction and cardiac contractility at basal conditions 
questioning a vital role of TRPM4 in physiological regulation of cardiac functions (Mathar et 
al., 2009). Rather unexpectedly, the genetic deletion of TRPM4 caused postnatal development 
of high blood pressure due to increased sympathetic catecholamine secretion. These seemingly 
paradoxical observations might point to the pathological contribution of TRPM4 to 
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arrhythmogenicity in diseased remodeling heart rather than to normal rhythm formation, in 
which the expression and activity of TRPM4 are enhanced.  
A recent genetic analysis of human families with lethal conduction failure has found a gain-
of-function mutation (c.19G→A in exon 1 or p.E7K) in the N-terminal domain of TRPM4 
channel (PFHBI; progressive familial heart block type I) (Kruse et al., 2009). More recently, 
other TRPM4 mutations with very similar biological impacts (p.R164W, p.A432T, p.G844D) 
have also been assigned to autosomal dominant isolated cardiac conduction block (ICCD) of 
Lebanese and French families (Liu et al., 2010). Biochemical and immunocytochemical data 
suggested that these mutations increase the cell surface expression of TRPM4 protein due to 
desregulated SUMOylation/deSUMOylation process which results in impaired endocytotic 
protein degradation. The accompanying electrophysiological changes for these mutations 
are consistent with the biochemical/immunicytochemical data; the density of whole-cell 
CAN current was increased with little noticeable changes in macroscopic Ca2+ sensitivity 
and voltage dependence or in unitary conductance and open probability at single channel 
level. These results suggest that the number of functional channels were increased without 
altered biophysical properties. The precise pathogenic mechanism for these mutations to 
cause conduction block remains unclear. However, RT-PCR analysis indicated the highest 
expression of TRPM4 in Purkinje fiber, and detailed immunohistochemical examination 
showed strongly TRPM4-positive subendocardial bundles of Purkinje fibers branching and 
penetrating toward subepithelial layer (Kruse et al., 2009; Liu et al., 2010). These 
morphological findings, combined with a broadened QRS complex in ECG in both PFHBI 
and ICCD patients, led the authors to speculate that elevated TRPM4 expression may 
increase the membrane leak conductance thereby disabling action potential propagation 
along the Purkinje fibers. There are several previous studies showing that Ca2+ overload 
causes membrane oscillations in Purkinje fibers due to increased spontaneous Ca2+ release 
when Na+ extrusion via Na+/K+-ATPase was pharmacologically inhibited (Kass et al., 1978; 
Kass & Tsien, 1982; Lederer & Tsien, 1976). Considering that TRPM4 may also act as a Na+ 
entry pathway in response to GPCR stimulation (Launay, et al., 2002), the resultant increase 
in [Na+]i might then elevate [Ca2+]i via the reversed mode operation of NCX1 in Purkinje 
fiber cells (Bers, 2006; Pogwizd, 2003). This would not only facilitate Ca2+ overload and DAD 
generation due to increased TRPM4 channel activation, but could also induce cell death 
leading to cardiac injury/remodeling if the elevation of [Ca2+] would persist. Fibrotic 
replacement observed in the His-Purkinje fiber system of a PFHBI patient (Kruse et al., 2009) 
may support the latter possibility. Thus, the depolarizing and Na+-permeating properties of 
TRPM4 channel could bring about both acute (induction of DAD) and chronic (conduction 
block due to remodeling) pro-arrhythmic effects. 
4.3 Arrhythmia associated with ischemia and oxidative stress  
In the acute phases of myocardial infarction, many arrhythmogenic substances are released 
(see above). ATP and UTP are amongst these, being released from cardiomycytes during 
ischemia and may promote the occurrence of ventricular tachyarrhythmias (Dutta et al., 
2004; Kuzmin et al., 1998). In vitro, ATP can induce DAD-based arrhythmic depolarizations 
in single cadiomyocytes when combined with Ca2+ increasing agents such as catecholamines 
(Song & Belardinelli, 1994). In voltage-clamped adult ventricular myocytes, ATP/UTP can 
activate a sustained inward current via P2Y2 receptor and enhance the opening of 14 and 
23pS single channel activities in a PLC-dependent manner. TRPC3 and TRPC7 proteins from 
rat ventricular myocytes immunocoprecipitated, and the macroscopic current induced by 
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ATP was suppressed by intracellular application of anti-TRPC3 antibody from the patch 
pipette (Alvarez et al., 2008). These findings are collectively interpreted as indicating that 
ATP/UTP may cause arrhythmia by activating TRPC3/TRPC7 heterotetrameric Ca2+ and 
Na+ entry channels whereby to facilitate intracellular Ca2+ overloading and trigger electrical 
activities. Consistent with this scenario, the same researchers’ group has recently shown that 
flash photolysis of caged ATP can evoke one or even a train of extrasystolic contractions. 
Further, intraperitoneal injection of creatine, which is capable of buffering a sudden 
ATP/UTP release and clinically exhibits anti-arrhythmic effects, markedly reduced 
ventricular tachyarrhythmias and early death events in a rat coronary-ligature myocardial 
infarction model. These ameliorating effects of creatine were defective in an inactive creatine 
analogue β-guanidinopropionate (Vassort et al., 2010). Cell surface expression of TRPC3 was 
found tightly controlled by vesicular trafficking, cytoskeletal actin dynamics and interaction 
with caveolar or subsarcolemmal proteins and molecules (Groschner K, et al., 2005). And 
PLC stimulation by AngII in cardiomycytes was reported to facilitate the recruitment of 
TRPC3 complexed with NCX1 to cell membrane, resulting in the reverse mode Ca2+ entry 
through NCX1 (Eder et al., 2007). Thus, although the precise connection between TRPC3 
(and possibly TRPC7) channel activation by ATP and arrhythmogenicty is unclear, the 
above mechanism may have particular pathophysiological significance in Ca2+-dependent 
arrhythmogenesis during postinfaction remodeling period or sudden ischemic insult of 
hypertrophied heart, where enhanced expression of TRPC3 and sympathetic nerve activity 
play pivotal roles. Seemingly in line with these results, a recent independent study has 
reported that cardiomyocytes from TRPC3-overexressing mice show an increased 
susceptibility to apoptotic death due to Ca2+ overload when subjected to 
hypoxia/reoxgenation (Shan et al., 2007).  
Oxidative stress causes tissue damage in a variety of pathological states including aging, 
cancer, neurogenerative disorders, autoimmune diseases, atherosclerosis and 
ischemia/reperfusion injury of myocardium (Chandra et al., 2000; Langley et al., 2004; Misra 
et al., 2009). Many reactive oxygen spices (ROS; O2-·,·OH, H2O2, NO, ·ONOO-) are generated 
as the result of ischemia and reoxygenation and may confer the susceptibility to arrhythmia 
in direct and indirect ways (via modifying autonomic nerve activity (Danson et al., 2006; 
Misra et al., 2009). Several TRP members including TRPM2, TRPM7, TRPC5 and a 
TRPC3/TRPC4 heterooligomer are known to be activated by oxidative stresses (Miller & 
Zhang, 2011; Naylor et al., 2011; Poteser et al., 2006). TRPM2 is the first reported ROS-
sensitive Ca2+-permeable nonselective cation channel activated by H2O2, ADP-ribose, TNFα, 
and β-amyloid peptide, and is implicated in both physiological functions and 
pathophysiology including oxidant (H2O2)-induced cell damage/death in pancreatic β-cells 
and neurons. TRPM2 is positively regulated by intracellular Ca2+, and its cell damaging 
action appears to be mediated at least in part by sustained [Ca2+]i elevation (Takahashi et al., 
2011). In myocardial infarction, reperfusion injury and congestive heart failure, elevated 
plasma levels of TNFα have been reported (Sack et al., 2000). TNFα can activate both 
cytotoxic and cytoprotective signaling pathways in many cell types including mitochondrial 
ROS production through the recruitment of caspase-8 into the death-inducing signaling 
complex (Kroemer et al., 2007; Zhu et al., 2006). Further, altered redox state changes the 
activity of cardiac ion channels and transporters regulating Ca2+ dynamics in the 
cardiomyocyte, i.e. L-type Cav, RyR2, NCX1 and SERCA2a (Zima & Blatter, 2006). In 
keeping with these observations, activation of TRPM2 by oxidative stress (H2O2) has been 
found to cause apoptotic/necrotic changes in single cardiomyocytes with ultrastructural 
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arrhythmogenicity in diseased remodeling heart rather than to normal rhythm formation, in 
which the expression and activity of TRPM4 are enhanced.  
A recent genetic analysis of human families with lethal conduction failure has found a gain-
of-function mutation (c.19G→A in exon 1 or p.E7K) in the N-terminal domain of TRPM4 
channel (PFHBI; progressive familial heart block type I) (Kruse et al., 2009). More recently, 
other TRPM4 mutations with very similar biological impacts (p.R164W, p.A432T, p.G844D) 
have also been assigned to autosomal dominant isolated cardiac conduction block (ICCD) of 
Lebanese and French families (Liu et al., 2010). Biochemical and immunocytochemical data 
suggested that these mutations increase the cell surface expression of TRPM4 protein due to 
desregulated SUMOylation/deSUMOylation process which results in impaired endocytotic 
protein degradation. The accompanying electrophysiological changes for these mutations 
are consistent with the biochemical/immunicytochemical data; the density of whole-cell 
CAN current was increased with little noticeable changes in macroscopic Ca2+ sensitivity 
and voltage dependence or in unitary conductance and open probability at single channel 
level. These results suggest that the number of functional channels were increased without 
altered biophysical properties. The precise pathogenic mechanism for these mutations to 
cause conduction block remains unclear. However, RT-PCR analysis indicated the highest 
expression of TRPM4 in Purkinje fiber, and detailed immunohistochemical examination 
showed strongly TRPM4-positive subendocardial bundles of Purkinje fibers branching and 
penetrating toward subepithelial layer (Kruse et al., 2009; Liu et al., 2010). These 
morphological findings, combined with a broadened QRS complex in ECG in both PFHBI 
and ICCD patients, led the authors to speculate that elevated TRPM4 expression may 
increase the membrane leak conductance thereby disabling action potential propagation 
along the Purkinje fibers. There are several previous studies showing that Ca2+ overload 
causes membrane oscillations in Purkinje fibers due to increased spontaneous Ca2+ release 
when Na+ extrusion via Na+/K+-ATPase was pharmacologically inhibited (Kass et al., 1978; 
Kass & Tsien, 1982; Lederer & Tsien, 1976). Considering that TRPM4 may also act as a Na+ 
entry pathway in response to GPCR stimulation (Launay, et al., 2002), the resultant increase 
in [Na+]i might then elevate [Ca2+]i via the reversed mode operation of NCX1 in Purkinje 
fiber cells (Bers, 2006; Pogwizd, 2003). This would not only facilitate Ca2+ overload and DAD 
generation due to increased TRPM4 channel activation, but could also induce cell death 
leading to cardiac injury/remodeling if the elevation of [Ca2+] would persist. Fibrotic 
replacement observed in the His-Purkinje fiber system of a PFHBI patient (Kruse et al., 2009) 
may support the latter possibility. Thus, the depolarizing and Na+-permeating properties of 
TRPM4 channel could bring about both acute (induction of DAD) and chronic (conduction 
block due to remodeling) pro-arrhythmic effects. 
4.3 Arrhythmia associated with ischemia and oxidative stress  
In the acute phases of myocardial infarction, many arrhythmogenic substances are released 
(see above). ATP and UTP are amongst these, being released from cardiomycytes during 
ischemia and may promote the occurrence of ventricular tachyarrhythmias (Dutta et al., 
2004; Kuzmin et al., 1998). In vitro, ATP can induce DAD-based arrhythmic depolarizations 
in single cadiomyocytes when combined with Ca2+ increasing agents such as catecholamines 
(Song & Belardinelli, 1994). In voltage-clamped adult ventricular myocytes, ATP/UTP can 
activate a sustained inward current via P2Y2 receptor and enhance the opening of 14 and 
23pS single channel activities in a PLC-dependent manner. TRPC3 and TRPC7 proteins from 
rat ventricular myocytes immunocoprecipitated, and the macroscopic current induced by 
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ATP was suppressed by intracellular application of anti-TRPC3 antibody from the patch 
pipette (Alvarez et al., 2008). These findings are collectively interpreted as indicating that 
ATP/UTP may cause arrhythmia by activating TRPC3/TRPC7 heterotetrameric Ca2+ and 
Na+ entry channels whereby to facilitate intracellular Ca2+ overloading and trigger electrical 
activities. Consistent with this scenario, the same researchers’ group has recently shown that 
flash photolysis of caged ATP can evoke one or even a train of extrasystolic contractions. 
Further, intraperitoneal injection of creatine, which is capable of buffering a sudden 
ATP/UTP release and clinically exhibits anti-arrhythmic effects, markedly reduced 
ventricular tachyarrhythmias and early death events in a rat coronary-ligature myocardial 
infarction model. These ameliorating effects of creatine were defective in an inactive creatine 
analogue β-guanidinopropionate (Vassort et al., 2010). Cell surface expression of TRPC3 was 
found tightly controlled by vesicular trafficking, cytoskeletal actin dynamics and interaction 
with caveolar or subsarcolemmal proteins and molecules (Groschner K, et al., 2005). And 
PLC stimulation by AngII in cardiomycytes was reported to facilitate the recruitment of 
TRPC3 complexed with NCX1 to cell membrane, resulting in the reverse mode Ca2+ entry 
through NCX1 (Eder et al., 2007). Thus, although the precise connection between TRPC3 
(and possibly TRPC7) channel activation by ATP and arrhythmogenicty is unclear, the 
above mechanism may have particular pathophysiological significance in Ca2+-dependent 
arrhythmogenesis during postinfaction remodeling period or sudden ischemic insult of 
hypertrophied heart, where enhanced expression of TRPC3 and sympathetic nerve activity 
play pivotal roles. Seemingly in line with these results, a recent independent study has 
reported that cardiomyocytes from TRPC3-overexressing mice show an increased 
susceptibility to apoptotic death due to Ca2+ overload when subjected to 
hypoxia/reoxgenation (Shan et al., 2007).  
Oxidative stress causes tissue damage in a variety of pathological states including aging, 
cancer, neurogenerative disorders, autoimmune diseases, atherosclerosis and 
ischemia/reperfusion injury of myocardium (Chandra et al., 2000; Langley et al., 2004; Misra 
et al., 2009). Many reactive oxygen spices (ROS; O2-·,·OH, H2O2, NO, ·ONOO-) are generated 
as the result of ischemia and reoxygenation and may confer the susceptibility to arrhythmia 
in direct and indirect ways (via modifying autonomic nerve activity (Danson et al., 2006; 
Misra et al., 2009). Several TRP members including TRPM2, TRPM7, TRPC5 and a 
TRPC3/TRPC4 heterooligomer are known to be activated by oxidative stresses (Miller & 
Zhang, 2011; Naylor et al., 2011; Poteser et al., 2006). TRPM2 is the first reported ROS-
sensitive Ca2+-permeable nonselective cation channel activated by H2O2, ADP-ribose, TNFα, 
and β-amyloid peptide, and is implicated in both physiological functions and 
pathophysiology including oxidant (H2O2)-induced cell damage/death in pancreatic β-cells 
and neurons. TRPM2 is positively regulated by intracellular Ca2+, and its cell damaging 
action appears to be mediated at least in part by sustained [Ca2+]i elevation (Takahashi et al., 
2011). In myocardial infarction, reperfusion injury and congestive heart failure, elevated 
plasma levels of TNFα have been reported (Sack et al., 2000). TNFα can activate both 
cytotoxic and cytoprotective signaling pathways in many cell types including mitochondrial 
ROS production through the recruitment of caspase-8 into the death-inducing signaling 
complex (Kroemer et al., 2007; Zhu et al., 2006). Further, altered redox state changes the 
activity of cardiac ion channels and transporters regulating Ca2+ dynamics in the 
cardiomyocyte, i.e. L-type Cav, RyR2, NCX1 and SERCA2a (Zima & Blatter, 2006). In 
keeping with these observations, activation of TRPM2 by oxidative stress (H2O2) has been 
found to cause apoptotic/necrotic changes in single cardiomyocytes with ultrastructural 
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changes characteristic of cardiac ischemia/reperfusion injury (Yang et al, 2006). Although 
whether these changes are pro-arrhythmic remains to be explored, it is possible that 
sustained [Ca2+]i elevation through activated TRPM2 channel would disturb basal Ca2+ 
homeostasis underlying rhythmic excitations in cardiomyocytes thereby inducing Ca2+-
dependent arrhythmogenicity. The arrhythmogenic effect of TRPM2 may not necessarily be 
restricted to direct cell-damaging actions via sustained [Ca2+]i elevation. It could occur 
indirectly through the production of inflammatory cytokines from ambient immune cells, as 
was demonstrated in an animal model of inflammatory bowel syndrome (Yamamoto et al., 
2008).  
In addition, expression of TRPC4 and TRPC5 was found to increase 2-3-fold in cultured rat 
cardiomyocytes subjected to downregulation of SERCA by siRNA technology which mimics 
the remodeling process of diseased heart (Seth et al., 2004). TRPC5 is known to be activated 
by many noxious stimuli such as H2O2 and LPC (Flemming et al., 2006; Naylor et al., 2011), 
and thus could act as a pro-arrhythmic mediator in ischemic remodeling heart. This 
possibility will be an intriguing subject of future investigation, together with other TRP 
isoforms implicated in the pathogenesis of cardiomyopathy (TRPV2, TRPC7; Iwata et al., 
2003; Satoh et al., 2007). 
4.4 Arrhythmia related to fibrosis 
Cardiac fibroblasts occupy about 70% of whole cardiac cell populations, and, once placed in 
pathological states such as myocardial injury, oxidative stress and excessive mechanical 
stretch, start to proliferate and differentiate into the active phenotype ‘myofibroblast’. 
Activated myofibroblasts secrete extracellular matrix proteins (e.g. collagen), matrix 
metaloproteinases, cytokines and growth factors thereby promoting the pathological 
restructuring of diseased heart with fibrotic replacement of damaged myocardial tissue 
(Souders, et al., 2009). Cardiac fibroblasts have a shallow resting membrane potential (-30 - -
10mV) and are non-excitable themselves, but show mechanically-induced depolarizations 
well synchronized with spontaneous contractions of myocardium (Kamkin et al, 2000b; 
Kamkin et al, 2003). These electrophysiological properties allow them, by coupling 
electrically to myocytes as a leaky capacitor, to modify the electrical properties of myocyte 
action potential and its propagation (Yue et al., 2011). In contrast, fibrotic tissues generated 
by myofibroblasts act as a physical barrier insulating the spread of electrical currents 
between the bundles of cardiomyocytes. Thus, disturbances in the myocyte-fibroblast 
coupling and alterations in myocardial architecture due to spatially inhomogenous fibrosis 
can lead to cardiac arrhythmias associated with reentry or conduction block.  
It has been known that fibrotic remodeling is a fundamental process underlying the 
perpetuation of AF. Atrial fibrosis is dependent on Ca2+, but what source of Ca2+ is involved 
therein had been elusive. A recent study of Du et al. (2010) demonstrated that upregulation 
of TRPM7, a constitutively active Ca2+/Mg2+ entry channel (Wu et al, 2010), and resultant 
Ca2+ influx was crucial for the progression of atrial fibrosis in AF patients. This was 
supported by the following evidence; (1) human atrial fibroblasts express TRPM7 protein 
abundantly, and show basal Ca2+ influx and spontaneously active Ca2+-permeable inward 
currents with the fingerprint features of heterologously expressed TRPM7 channels 
[potentiation by low pH and inhibition/potentiation by low/high concentrations of 2-
aminoethoxydiphenyly boroate (2-APB) respectively: Li et al., 2006, 2007]; (2) TRPM7-like 
current and accompanying Ca2+ influx were strikingly increased in parallel with the 
upregulation of TRPM7 expression in differentiated fibroblasts from AF patients; (3) all 
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these changes were largely eliminated by knockdown of TRPM7 expression with small 
hairpin RNA; and (4) in vitro promotion of myofibroblastic differentiation by TGF-β1, a 
major stimulator of atrial fibrosis, was correlated with the upregulation of TRPM7. 
Although in this study a direct linkage between Ca2+ influx through TRPM7 channel, the 
fibrogenesis and arrhythmogenesis in AF have not been explored, the above results may 
provide a new therapeutic target against the progression of AF, by disclosing an essential 
role of TRPM7-asscociated Ca2+ influx in fibroblast proliferation and differentiation.     
In rat neonatal cardiac fibroblasts, endothelin-1 (ET-1) or AngII can induce myofibroblastic 
differentiation and collagen synthesis via the Gα12/13 signaling. ET-1 (via ETA receptor) and 
AngII can also selectively enhance the expression of TRPC6, thereby increasing basal Ca2+ 
influx in the fibroblasts. Importantly, increased TRPC6 expression is causally correlated 
with anti-fibrotic effects via calcineurin/NFAT pathway (Nishida et al., 2007). The 
upregulation of TRPC6 likely occurs through the G12/13- (Rac/NOX)-ROS-JNK signaling, 
which is reminiscent of TRPC6-mediated abnormal proliferation of pulmonary artery 
smooth muscle cells induced by platelet-derived growth factor, a pathogenic model of 
pulmonary artery hypertension (Yu et al., 2003). The concentrations of ET-1 or AngII 
required to upregulate TRPC6 are significantly higher than those for the differentiation of 
fibroblasts (Nishida et al., 2007). Thus, in an intriguing contrast to the pro-fibrotic role of 
TRPM7, the anti-fibrotic effects of enhanced TRPC6 channel activity may serve as a negative 
feedback mechanism to limit excessive fibrogenesis via ET-1/AngII signaling during cardiac 
remodeling. It remains to be determined whether this mechanism works beneficially in 
human AF patients or other fibrosis-associated arrhythmias. 
4.5 Arrhythmia related to autonomic imbalance 
The cardiac rhythm is under tight control of the autonomic nervous system. For instance, 
baroreceptors monitor blood pressure fluctuations and transmit the information to the 
brainstem vasomotor center via parasympathetic afferents, which then modulates the 
cardiac pumping force and rate via sympathetic efferents. The renin-angiotensin-
aldosterone system is another well-established system centrally controlled via sympathetic 
nerves (via β1-adrenoceptor). It fulfills a long-term control of body fluid and electrolyte 
balance, thereby effectively regulating the cardiac output (Guyenet, 2006). Any disturbances 
in these centrally-mediated autonomic regulations could therefore become the substrates for 
cardiac arrhythmias (Danson, et al., 2006; Janse 2004; Nattel, et al., 2007). Accumulating 
evidence however suggests that nociceptive reflexes via respiratory sensory neurons (e.g. C-
fibers in nose and lung) have also some pathophysiological impact on cardiac functions 
through centrally-mediated autonomic mechanisms, as exemplified by air pollutant–
induced changes in ‘repolarization’ parameters of ECG (Henneberger et al., 2005). The 
sensory nerve endings in respiratory airways contain two TRP members sensing noxious 
stimuli, i.e. TRPV1 and TRPA1 which likely participate in airway chemosensation and 
inflammation (Bessac & Jordt, 2008). It has thus been postulated that these TRP isoforms 
may be involved in nociceptive signaling in the respiratory system (Vay et al., 2011).  
Two recent studies have revealed intriguing associations between respiratory sensory TRP 
channels and arrhythmogenicity. In one experimental model, activation of respiratory 
sensory neurons by inhalation of concentrated ambient particles significantly affected the 
cardiac rhythm with decreased heart rate, and shortened QT interval and P wave duration. 
Abrogation of these cardiac effects by a selective TRPV1 antagonist capsazepine suggested 
that TRPV1-mediated autonomic reflexes play a central role therein (Ghelfi et al., 2008). In 
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changes characteristic of cardiac ischemia/reperfusion injury (Yang et al, 2006). Although 
whether these changes are pro-arrhythmic remains to be explored, it is possible that 
sustained [Ca2+]i elevation through activated TRPM2 channel would disturb basal Ca2+ 
homeostasis underlying rhythmic excitations in cardiomyocytes thereby inducing Ca2+-
dependent arrhythmogenicity. The arrhythmogenic effect of TRPM2 may not necessarily be 
restricted to direct cell-damaging actions via sustained [Ca2+]i elevation. It could occur 
indirectly through the production of inflammatory cytokines from ambient immune cells, as 
was demonstrated in an animal model of inflammatory bowel syndrome (Yamamoto et al., 
2008).  
In addition, expression of TRPC4 and TRPC5 was found to increase 2-3-fold in cultured rat 
cardiomyocytes subjected to downregulation of SERCA by siRNA technology which mimics 
the remodeling process of diseased heart (Seth et al., 2004). TRPC5 is known to be activated 
by many noxious stimuli such as H2O2 and LPC (Flemming et al., 2006; Naylor et al., 2011), 
and thus could act as a pro-arrhythmic mediator in ischemic remodeling heart. This 
possibility will be an intriguing subject of future investigation, together with other TRP 
isoforms implicated in the pathogenesis of cardiomyopathy (TRPV2, TRPC7; Iwata et al., 
2003; Satoh et al., 2007). 
4.4 Arrhythmia related to fibrosis 
Cardiac fibroblasts occupy about 70% of whole cardiac cell populations, and, once placed in 
pathological states such as myocardial injury, oxidative stress and excessive mechanical 
stretch, start to proliferate and differentiate into the active phenotype ‘myofibroblast’. 
Activated myofibroblasts secrete extracellular matrix proteins (e.g. collagen), matrix 
metaloproteinases, cytokines and growth factors thereby promoting the pathological 
restructuring of diseased heart with fibrotic replacement of damaged myocardial tissue 
(Souders, et al., 2009). Cardiac fibroblasts have a shallow resting membrane potential (-30 - -
10mV) and are non-excitable themselves, but show mechanically-induced depolarizations 
well synchronized with spontaneous contractions of myocardium (Kamkin et al, 2000b; 
Kamkin et al, 2003). These electrophysiological properties allow them, by coupling 
electrically to myocytes as a leaky capacitor, to modify the electrical properties of myocyte 
action potential and its propagation (Yue et al., 2011). In contrast, fibrotic tissues generated 
by myofibroblasts act as a physical barrier insulating the spread of electrical currents 
between the bundles of cardiomyocytes. Thus, disturbances in the myocyte-fibroblast 
coupling and alterations in myocardial architecture due to spatially inhomogenous fibrosis 
can lead to cardiac arrhythmias associated with reentry or conduction block.  
It has been known that fibrotic remodeling is a fundamental process underlying the 
perpetuation of AF. Atrial fibrosis is dependent on Ca2+, but what source of Ca2+ is involved 
therein had been elusive. A recent study of Du et al. (2010) demonstrated that upregulation 
of TRPM7, a constitutively active Ca2+/Mg2+ entry channel (Wu et al, 2010), and resultant 
Ca2+ influx was crucial for the progression of atrial fibrosis in AF patients. This was 
supported by the following evidence; (1) human atrial fibroblasts express TRPM7 protein 
abundantly, and show basal Ca2+ influx and spontaneously active Ca2+-permeable inward 
currents with the fingerprint features of heterologously expressed TRPM7 channels 
[potentiation by low pH and inhibition/potentiation by low/high concentrations of 2-
aminoethoxydiphenyly boroate (2-APB) respectively: Li et al., 2006, 2007]; (2) TRPM7-like 
current and accompanying Ca2+ influx were strikingly increased in parallel with the 
upregulation of TRPM7 expression in differentiated fibroblasts from AF patients; (3) all 
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these changes were largely eliminated by knockdown of TRPM7 expression with small 
hairpin RNA; and (4) in vitro promotion of myofibroblastic differentiation by TGF-β1, a 
major stimulator of atrial fibrosis, was correlated with the upregulation of TRPM7. 
Although in this study a direct linkage between Ca2+ influx through TRPM7 channel, the 
fibrogenesis and arrhythmogenesis in AF have not been explored, the above results may 
provide a new therapeutic target against the progression of AF, by disclosing an essential 
role of TRPM7-asscociated Ca2+ influx in fibroblast proliferation and differentiation.     
In rat neonatal cardiac fibroblasts, endothelin-1 (ET-1) or AngII can induce myofibroblastic 
differentiation and collagen synthesis via the Gα12/13 signaling. ET-1 (via ETA receptor) and 
AngII can also selectively enhance the expression of TRPC6, thereby increasing basal Ca2+ 
influx in the fibroblasts. Importantly, increased TRPC6 expression is causally correlated 
with anti-fibrotic effects via calcineurin/NFAT pathway (Nishida et al., 2007). The 
upregulation of TRPC6 likely occurs through the G12/13- (Rac/NOX)-ROS-JNK signaling, 
which is reminiscent of TRPC6-mediated abnormal proliferation of pulmonary artery 
smooth muscle cells induced by platelet-derived growth factor, a pathogenic model of 
pulmonary artery hypertension (Yu et al., 2003). The concentrations of ET-1 or AngII 
required to upregulate TRPC6 are significantly higher than those for the differentiation of 
fibroblasts (Nishida et al., 2007). Thus, in an intriguing contrast to the pro-fibrotic role of 
TRPM7, the anti-fibrotic effects of enhanced TRPC6 channel activity may serve as a negative 
feedback mechanism to limit excessive fibrogenesis via ET-1/AngII signaling during cardiac 
remodeling. It remains to be determined whether this mechanism works beneficially in 
human AF patients or other fibrosis-associated arrhythmias. 
4.5 Arrhythmia related to autonomic imbalance 
The cardiac rhythm is under tight control of the autonomic nervous system. For instance, 
baroreceptors monitor blood pressure fluctuations and transmit the information to the 
brainstem vasomotor center via parasympathetic afferents, which then modulates the 
cardiac pumping force and rate via sympathetic efferents. The renin-angiotensin-
aldosterone system is another well-established system centrally controlled via sympathetic 
nerves (via β1-adrenoceptor). It fulfills a long-term control of body fluid and electrolyte 
balance, thereby effectively regulating the cardiac output (Guyenet, 2006). Any disturbances 
in these centrally-mediated autonomic regulations could therefore become the substrates for 
cardiac arrhythmias (Danson, et al., 2006; Janse 2004; Nattel, et al., 2007). Accumulating 
evidence however suggests that nociceptive reflexes via respiratory sensory neurons (e.g. C-
fibers in nose and lung) have also some pathophysiological impact on cardiac functions 
through centrally-mediated autonomic mechanisms, as exemplified by air pollutant–
induced changes in ‘repolarization’ parameters of ECG (Henneberger et al., 2005). The 
sensory nerve endings in respiratory airways contain two TRP members sensing noxious 
stimuli, i.e. TRPV1 and TRPA1 which likely participate in airway chemosensation and 
inflammation (Bessac & Jordt, 2008). It has thus been postulated that these TRP isoforms 
may be involved in nociceptive signaling in the respiratory system (Vay et al., 2011).  
Two recent studies have revealed intriguing associations between respiratory sensory TRP 
channels and arrhythmogenicity. In one experimental model, activation of respiratory 
sensory neurons by inhalation of concentrated ambient particles significantly affected the 
cardiac rhythm with decreased heart rate, and shortened QT interval and P wave duration. 
Abrogation of these cardiac effects by a selective TRPV1 antagonist capsazepine suggested 
that TRPV1-mediated autonomic reflexes play a central role therein (Ghelfi et al., 2008). In 
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another study employing a gaseous pollutant (Hazari et al., 2011), one-day exposure of rats 
to diesel exhaust gas resulted in increased heart rate with pro-arrhythmic ECG changes of 
prolonged action potential and shorted repolarization. Notably, these rats showed much 
heightened sensitivity to aconitine challenge that can induce moderate to lethal ventricular 
tachyarrhythmias dose-dependently. This pro-arrhythmic change was prevented by 
pretreatment with a TRPA1 antagonist HC-030031 or by sympathetic blockade with 
guanethidine, suggesting the involvement of increased sympathetic drive. In addition, 
partial involvement of TRPV1 in moderate aconitine-induced tachyarrhythmias was also 
suggested by pharmacological inhibition with a selective TRPV1 antagonist SB-366791. 
Although detailed mechanisms underlying remain unclear, these results clearly point to the 
pro-arrhythmic risk of environmentally-induced autonomic imbalance in which sensory 
chemosensing channels TRPA1 and TRPV1 may play a pivotal role. 
5. Conclusions and therapeutic implications 
The evidence presented above has disclosed that the unique activation profile (e.g. stretch- 
and Ca2+-sensitivities, neurohormonal activation, sensitivity to noxious stimuli) and 
permeability to Ca2+ and Na+ (TRPM4/TRPM5 are however virtually Ca2+-impermeable) 
render several TRP channels contribute to the acquired arrhythmogenesis during cardiac 
remodeling and other pathological processes. The examples so far available implicates, at 
least, TRPC1 and TRPC6 (and possibly their homologues) in stretch-induced arrhythmias in 
both acute and chronic manners, TRPM4 in Ca2+-dependent arrhythmia and familial 
conduction block, TRPC3 and TRPM2 in ischemia-induced arrhythmia, TRPA1 and TRPV1 
in autonomic imbalance-induced arrhythmia, and TRPM7 and TRPC6 in fibrosis-related 
arrhythmogenicity, especially in AF, as pro-fibrotic and anti-fibrotic factors respectively. 
Although the mechanism of the actions of each TRP isoform appears variable in different 
pathophysiological settings, these new lines of evidence have certainly put forward our 
essential understanding about the pathogenesis of commonly observed arrhythmias 
associated with cardiac diseases accompanying structural and electrical remodeling. 
Simultaneously it may open an avenue toward exploiting an entirely new generation of anti-
arrhythmic drugs for increased mechanosensitivity, abnormal Ca2+ handling, oxidative 
stress, or nociception.  
When considering the actual strategy for developing such drugs, however, there are at least 
two not easily tractable problems. The serious lack of structure-based chemical knowledge 
about the selectivity and efficacy for most TRP members is the first obvious one, although 
substantial progress is going on for analgesic therapy based on TRPV1 pharmacology 
(Szallasi et al., 2007). Virtually all drugs so far shown to be effective for cardiovascular TRP 
isoforms appear to be non-specific or have only narrow ranges of concentrations for their 
relatively selective actions, as exemplified by a pyrazole compound Pyr-3 for TRPC3 which 
reportedly inhibits experimentally-induced cardiac hypertrophy (Kiyonaka et al., 2009). The 
second type of difficulty for exploiting TRP-selective drugs is that connecting one TRP 
isoform to one end-function is almost always irrelevant oversimplification. This is because 
signaling pathways linked to TRPs appear to form a complex interwoven network with high 
degrees of divergence and convergence and with numerous feed-back and -forward 
regulations. In addition to this, activation of TRP channels depends intimately on local lipid 
dynamics in the cell membrane, which dramatically changes by lipid composition, voltage, 
temperature, membrane stretch, and enzyme-assisted catalysis (Hardie, 2007; Inoue et al., 
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2009b). In the current absence of good knowledge about lipid physiology/pathophysiology 
for membrane proteins, these disadvantages would make it difficult to pharmacologically 
manipulate the gating of TRP channels. In this context, recent observations that activation of 
the cGMP-PKG signaling by nitric oxide, atrial natriuretic peptides and their structural and 
functional mimetics attenuate hypertrophic cardiac remodeling partly via inhibition of TRP 
channels (Inoue et al., 2010; Tsai & Kass, 2009) may provide a promising alternative 
maneuver to ameliorate the acquired arrhythmogenicity. Activation of this pathway is also 
known to improve myocardial damage after myocardial infarction (Burley et al., 2007; 
Garcia-Dorado et al., 2009). Obviously, there is much to be learned about the pathogenic 
roles and therapeutic potential of cardiovascular TRP channels for cardiac arrhythmias. 
6. Acknowledgment  
Part of this work is supported by Grants-in-aid for Scientific Research on Innovative Areas 
(No.22136008) and Scientific Research (C) (No. 21590246), and a grant from Seizon Kagaku 
Institute to R.I.  
7. References  
Ai, X., Curran, J. W., Shannon, T. R., Bers, D. M., & Pogwizd, S. M. (2005). Ca2+/calmodulin-
dependent protein kinase modulates cardiac ryanodine receptor phosphorylation 
and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res, 97(12), pp. 1314-
1322. 
Alvarez, J., Coulombe, A., Cazorla, O., Ugur, M., Rauzier, J. M., Magyar, J., et al. (2008). 
ATP/UTP activate cation-permeable channels with TRPC3/7 properties in rat 
cardiomyocytes. Am J Physiol Heart Circ Physiol, 295(1), pp. H21-28. 
Bae, C.,  Sachs, F.,& Gottlieb, P.A.(2011). The Mechanosensitive ion channel Piezo1 is 
inhibited by the peptide GsMTx4. Biochemistry,50, pp. 6295–6300. 
Benson, D. W., Silberbach, G. M., Kavanaugh-McHugh, A., Cottrill, C., Zhang, Y., Riggs, S., 
et al. (1999). Mutations in the cardiac transcription factor NKX2.5 affect diverse 
cardiac developmental pathways. J Clin Invest, 104(11), pp. 1567-1573. 
Bers, D. M. (2006). Altered cardiac myocyte Ca regulation in heart failure. Physiology 
(Bethesda), 21, pp. 380-387. 
Bessac, B. F., & Jordt, S. E. (2008). Breathtaking TRP channels: TRPA1 and TRPV1 in airway 
chemosensation and reflex control. Physiology (Bethesda), 23, pp. 360-370. 
Bonne, G., Di Barletta, M. R., Varnous, S., Becane, H. M., Hammouda, E. H., Merlini, L., et al. 
(1999). Mutations in the gene encoding lamin A/C cause autosomal dominant 
Emery-Dreifuss muscular dystrophy. Nat Genet, 21(3), pp. 285-288. 
Burley, D. S., Ferdinandy, P., & Baxter, G. F. (2007). Cyclic GMP and protein kinase-G in 
myocardial ischaemia-reperfusion: opportunities and obstacles for survival 
signaling. Br J Pharmacol, 152(6), pp. 855-869. 
Bush, E.W., Ho, D.B., Papst, P.J. et al. (2006). Canonical transient receptor potential channels 
promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J 
Biol Chem, 281, pp.33487-96. 
 
Cardiac Arrhythmias – New Considerations 
 
86
another study employing a gaseous pollutant (Hazari et al., 2011), one-day exposure of rats 
to diesel exhaust gas resulted in increased heart rate with pro-arrhythmic ECG changes of 
prolonged action potential and shorted repolarization. Notably, these rats showed much 
heightened sensitivity to aconitine challenge that can induce moderate to lethal ventricular 
tachyarrhythmias dose-dependently. This pro-arrhythmic change was prevented by 
pretreatment with a TRPA1 antagonist HC-030031 or by sympathetic blockade with 
guanethidine, suggesting the involvement of increased sympathetic drive. In addition, 
partial involvement of TRPV1 in moderate aconitine-induced tachyarrhythmias was also 
suggested by pharmacological inhibition with a selective TRPV1 antagonist SB-366791. 
Although detailed mechanisms underlying remain unclear, these results clearly point to the 
pro-arrhythmic risk of environmentally-induced autonomic imbalance in which sensory 
chemosensing channels TRPA1 and TRPV1 may play a pivotal role. 
5. Conclusions and therapeutic implications 
The evidence presented above has disclosed that the unique activation profile (e.g. stretch- 
and Ca2+-sensitivities, neurohormonal activation, sensitivity to noxious stimuli) and 
permeability to Ca2+ and Na+ (TRPM4/TRPM5 are however virtually Ca2+-impermeable) 
render several TRP channels contribute to the acquired arrhythmogenesis during cardiac 
remodeling and other pathological processes. The examples so far available implicates, at 
least, TRPC1 and TRPC6 (and possibly their homologues) in stretch-induced arrhythmias in 
both acute and chronic manners, TRPM4 in Ca2+-dependent arrhythmia and familial 
conduction block, TRPC3 and TRPM2 in ischemia-induced arrhythmia, TRPA1 and TRPV1 
in autonomic imbalance-induced arrhythmia, and TRPM7 and TRPC6 in fibrosis-related 
arrhythmogenicity, especially in AF, as pro-fibrotic and anti-fibrotic factors respectively. 
Although the mechanism of the actions of each TRP isoform appears variable in different 
pathophysiological settings, these new lines of evidence have certainly put forward our 
essential understanding about the pathogenesis of commonly observed arrhythmias 
associated with cardiac diseases accompanying structural and electrical remodeling. 
Simultaneously it may open an avenue toward exploiting an entirely new generation of anti-
arrhythmic drugs for increased mechanosensitivity, abnormal Ca2+ handling, oxidative 
stress, or nociception.  
When considering the actual strategy for developing such drugs, however, there are at least 
two not easily tractable problems. The serious lack of structure-based chemical knowledge 
about the selectivity and efficacy for most TRP members is the first obvious one, although 
substantial progress is going on for analgesic therapy based on TRPV1 pharmacology 
(Szallasi et al., 2007). Virtually all drugs so far shown to be effective for cardiovascular TRP 
isoforms appear to be non-specific or have only narrow ranges of concentrations for their 
relatively selective actions, as exemplified by a pyrazole compound Pyr-3 for TRPC3 which 
reportedly inhibits experimentally-induced cardiac hypertrophy (Kiyonaka et al., 2009). The 
second type of difficulty for exploiting TRP-selective drugs is that connecting one TRP 
isoform to one end-function is almost always irrelevant oversimplification. This is because 
signaling pathways linked to TRPs appear to form a complex interwoven network with high 
degrees of divergence and convergence and with numerous feed-back and -forward 
regulations. In addition to this, activation of TRP channels depends intimately on local lipid 
dynamics in the cell membrane, which dramatically changes by lipid composition, voltage, 
temperature, membrane stretch, and enzyme-assisted catalysis (Hardie, 2007; Inoue et al., 
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2009b). In the current absence of good knowledge about lipid physiology/pathophysiology 
for membrane proteins, these disadvantages would make it difficult to pharmacologically 
manipulate the gating of TRP channels. In this context, recent observations that activation of 
the cGMP-PKG signaling by nitric oxide, atrial natriuretic peptides and their structural and 
functional mimetics attenuate hypertrophic cardiac remodeling partly via inhibition of TRP 
channels (Inoue et al., 2010; Tsai & Kass, 2009) may provide a promising alternative 
maneuver to ameliorate the acquired arrhythmogenicity. Activation of this pathway is also 
known to improve myocardial damage after myocardial infarction (Burley et al., 2007; 
Garcia-Dorado et al., 2009). Obviously, there is much to be learned about the pathogenic 
roles and therapeutic potential of cardiovascular TRP channels for cardiac arrhythmias. 
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1. Introduction 
The cardiac action potential is arised by the highly orchestrated activity of dozens of ion 
channel proteins. These transmembrane proteins govern the influx of ion across the 
sarcolemma of cardiomyocytes generating the ionic currents responsible for excitation. In 
order to myocardium contract and ensure rhythmic pump function, the long-lasting action 
potential of the working myocardium maintains a refractory state. Because some channels 
must recover from inactivation after-repolarization before they have ability of re-opening, 
and during this time, the myocardial cells remain refractory for re-excitation. 
Typical normal action potentials consist of five distinct phases (Figure 1). Na+ influx triggers 
a rapid depolarization (phase 0) followed by an early fast repolarization phase (phase 1) and  
 
 
Fig. 1. (cited from The Sicilian gambit, 2008). Currents of sodium, calcium and potassium 
channels underlie the atrial and ventricular action potential. 
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a plateau phase (phase 2), in which repolarization is slowed due to the activation of inward 
Ca2+ current. During the final rapid repolarization phase (phase 3), membrane potential 
returns to the resting level (phase 4). Therefore, normal action potentials attributed to the 
normal function of ion channel participated to formation of action potentials.  
1.1 Ion channels in human heart disease 
Regular excitation is formed by normal AP which generated in the sino-atrial node and 
spreads throughout the heart in an orderly manner. Oppositely, disorganization of electrical 
activity is the basis of cardiac arrhythmias. Arrhythmias are caused by the perturbation of 
physiological impulse formation, impaired impulse conduction, or disturbed electrical 
recovery. Abnormal excitability of myocardial cells may give rise to kinds of cardiac 
diseases.  
The most ordinary cardiac arrhythmia diseases was inherited long QT syndrome (LQTS) 
which was recognized 40 years ago as 2 distinct clinical phenotypes, such as the Romano-
Ward and the Jervell and Lange-Nielsen syndromes. Interestingly, while LQTS was initially 
thought to be a pure cardiac channelopathy, it is now clear that non-ion-channel encoding 
genes may also cause the desease. Nevertheless, LQTs attributed to dysfunctions of ionic 
currents, either directly (ion channel) or indirectly (chaperones and/or other modulators). 
To date, 12 forms of inherited LQTS described because LQTS arise from polygenic causes 
and 9 of them directly combine with ion channels (Table 1). LQT1, 2, 5, and 6 are referred to 
prolong the plateau of cardiac APs (phase 2) by reducing K+ channel currents activated 
during depolarization. LQT1 and 5 are caused by mutations in KCNQ1 (KvLQT1) and 
KCNE1 (MinK), which encode the  and ancillary  subunits, respectively and together 
form the slowly activating delayed rectifier K+ current (IKs). LQT2 and 6 are caused by 
mutations in KCNH2 (human-ether a-go-go-related gene; HERG) and KCNE2 (MiRP1), 
which encode the  and putative  subunits, respectively and together form the rapidly 
activating delayed rectifier K+ current (IKr). LQT7 is characterized by mutations in KCNJ2 
(Kir2.1), which reduces the inward rectifier K+ channel current (IK1) to slow the return of the 
membrane to the resting potential. These cause failure of normal inactivation to decrease of 
K+ current (loss of function) and abbreviate action potentials. Besides potassium channel, 
LQT3, 10 attributed to mutations in hNaV1.5 (SCN5a), and SCNb4, which encode  and 
ancillary  subunits of Na+ channel. LQT8 are determined by mutation in CACNA1c, which 
encode alpha subunit of calcium channel. LOT3,10 and LQT8 arise from the increase of Na+ 
currents and Ca2+ currents, respectively, for prolong action potential. Therefore, “loss of 
function” or “gain of function” mutations in the affected ion channels are often formed 
different phenotypes of cardiac arrhythmia desease.  
Except the mentioned above, LQT4,9,11,12 are determined by mutation in ANK2, Cav3, 
AKAP9 and SNTA1, which encode ankyrin B, caveolin, A-kinase-anchoring protein and 
alphal1-syntrophin, respectively. All proteins increase or decrease the ironic currents (loss of 
function or gain of function). Although the remarkable genetic heterogeneity in LQT, three 
genes, such as KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3), are dominant and 
cover more than 90 percentage of LQTS patients with identified mutations. 
With exception of LQTS, some of these involve gain of function mutations in K+ channels 
(short QT syndrome) and loss of function mutations in and Ca channel and Na+ channels 
(Brugada syndrome, cardiac conduction disease, etc). Additional congenital arrhythmia 
syndromes continue to be described, and these are summarized in Table 1. 
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functional 
effect inheritance 



































 SQT3 KCNJ2 17q23.2-q24.2 IK1 potassium channel (Kir2.1) 
gain of 
function AD 
 AF4 KCNJ2 17q23.2-q24.2 IK1 potassium channel (Kir2.1) 
gain of 
function AD 
Table 1. Mutations of ion channels 
1.2 Mechanism of ion channels dysfunction 
Based on the discussion mentioned above we can easy to understand the mutation how 
reduce or increase the currents and lead the kinds of cardiac arrhythmia. The change of the 
magnitude of currents in cardiac is based on the below three factors. For instance, the total 
number of channels on the membrane (N), the open probability of the channel (P0) and the 
conductance of single channel (i). Gain of function or loss of function mutations of ion 
channel through changing of N, Po and I alone or all contribute to kinds of congenital 
cardiac arrhythmia.  
1.2.1 Change of the channel number 
There are two distinct process in which can change the number of channel in the plasma 
membrane, one is in the synthesis channel process and another is during the channel 
trafficking.  
About defective synthesis of mutations contained the premature termination codons is 
maybe the most mutations of ion channel. For example, there are one fourths of all 
mutations of hERG channel (http: //www. fsm. it/cardmoc). The protein encoded by the 
mutation with premature termination codon is a truncated one which can be eliminated by 
nonsense-mediated mRNA decay. And the hERG truncation mutation is proved to be clear 
by the nonsense-mediated mRNA decay in recently.  
Exception of the nonsense-mediated mRNA decay, another important clear mechanism is at 
mRNA level by microRNA (miRNA) mediated mRNA silencing. The degradation of the target 
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mRNA is through partial complementary combination with the miRNA followed binding 
with kinds of protein or nucleotide to form a huge ribosome. To date, many miRNA are 
detected in heart and decrease of ion channel protein at translaton or/and transcript levels.   
There are three steps during the process of ion channel synthesis: i) the formation of core-
glycoslyted monomer in ER  followed the correct to the tetramer ii), iii) then complex 
glycaslytaton to form the mature subunit  in Gorgi. Accordingly, Western blot check can be 
utend to detect weather composition of the channel protein is complete. The primarychannel 
protein is common synthesized in ER.  
In order to export completely from the synthesis location (ER), each channel subunit protein 
contained more than one of the ER exit signal (D/E-X-D/E) motif which can guide the protein 
correctly from ER to Golgi, where X represens any kinds of amino acid. To ensure the channel 
deviated from ER, channel form a tetramer in ER by masking or shielding the ER retention 
signal. Therefore, mutations in ER exit signal or with correlation of the assembly of channel 
maybe lead to the retention in ER then decrease the number of channel in the membrane.  
1.2.2 Change of channel open probability 
Change of activation and inactivation maybe are two ways of altering of channel open 
probability. In Xenopus laevis oocytes system, to date many mutations have been detected to 
alter the channel gated. But there are much difference between the oocytes system and the 
mammalian system. In addition, there are many mutations that have been expressed in 
mammalian and shown to result in gating defects.  
1.2.3 Change of single channel conductance 
To alter the conductance of single channel, the mutation sites of ion channel exits in the 
vicinity of the selective filter. Owing to the selective filter of ion channel is determined the 
kinds of ions across the channel. Accordingly, the single channel conductance change may 
be attributed to the conformation altering of the selective filter.  
2. Sodium channel 
Cardiac voltage-gated sodium channel has critical role in excitability of myocardial cells and 
proper conduction of the electrical impulse within the heart. Infux of Na+ across sodium 
channel is responsible for the initial fast upstroke of the cardiac action potential. Therefore, this 
inward sodium channel triggers the initiation and propagation of action potential throughout 
the myocardium. The gene of SCN5A encodes the major sodium channel in heart. 
2.1 Structure of sodium channel  
The voltage-gated sodium channel is composed by a pore-forming  subunit and an 
ancillary  subunit. Nav1.5 encoded by SCN5A consists of four homologous domains (DⅠ-
DⅡ) and each domain has six transmembrane segments (S1-S6). Similar to other voltage-
gated ion channel, the S4 contained many positive residues in each domain forms the 
voltage sensor and the S4 and S5 in all domains together make up ion-conductance pore 
including the selectivity filter. When sodium channel is activated, influx of Na+ begin, 
thereby the depolarizing of the membrane until the activation of L-calcium channel, at last 
forming the upstroke of action potential. Continue to depolarization, the fast and low 
inactivation happen causing the sodium channel close. Sodium channel gating properties 
and current kinetics may be altered when channel is dysfunction. 
 
Cardiac Arrhythmias – New Considerations 
 
100 
current  disease  gene name  chromosomal locus Protein 
functional 
effect inheritance 



































 SQT3 KCNJ2 17q23.2-q24.2 IK1 potassium channel (Kir2.1) 
gain of 
function AD 
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gain of 
function AD 
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Cardiac sodium channel function can be regulated by a vast number of proteins. The single 
tansmembrane β-subunit consists of a small C-terminal cytoplasmic domain and a large 
glycosylated N-terminal extracellular domain. The ancillary subunit alters the currents 
density and kinetics by physical interaction with the  subunit. Other proteins regulating 
Nav1.5 by directly binding include ankyrins, fibroblast growth factor homologous factor 1B, 
calmodulin, caveolin-3, Nedd4-like ubiquitin-protein ligases, dystrophin, and syntrophin, as 
well as glycerol-3-phosphate dehydrogenase 1-like protein and MOG1. In addition, sodium 
channel density and kinetics are furthermore also regulated by phosporylation and 
glycosylation, even by changes in temperature.  
2.2 Functions of sodium channel in heart 
During myocardial ischemia, the mechanisms involved in arrhythmogenesis are complex, 
but excitability and conduction are considered as the major determinants. During ischemia, 
local metabolic changes within the myocardium lead to inactivation of the sodium current 
and consequent repression of cardiac excitability and slowing of conduction. In clinical, 
slowing conduction produced by sodium channel blockers application has been shown to be 
proarrhythmic. Some papers have reported an association between SCN5A loss-of-function 
mutations and the occurrence of ischemia-induced severe episodes of ventricular 
tachyarrhythmias. It is as yet unknown whether SCN5A mutations and/or polymorphisms 
play a substantial role in the prevalence of sudden arrhythmic death in the setting of 
myocardial infarction, 
2.3 Cardiac sodium channelopathies 
To date, more than 150 mutations in SCN5A have been reported, the vast majority of them 
caused either LQTS3 and Brugada syndrome. Some patients with LQTS can be healing 
well whereas most of them may increase risk for sudden death due to ventricular 
tachyarrhythmias, in particular torsades de pointes. The character of LQTS3 is that 
display arrhythmias predominantly during rest or sleep videlicet at slow heart rate. 
Therefore, the first clinical event of the patient with LQTS3 often is cardiac arrest rather 
than syncope. About the molecualr mechanism of LQTS, vast majority of mutations in 
SCN5A produced the disruption of the fast inactivation but not the slow inactivation. The 
disruption allows the sodium channel reopen and produces the persistent inward current 
during the action potential plateau phase. Gain of function mutations in sodium channel 
delays the depolarization of the action potential and causes the prolongation of the action 
potential.  
Brugada syndrome, a familial disease which charactered by ventricular arrhythmia and 
sudden cardia death even occuring in healthy person at relatively young age (mainly 
between 30 to 40) and more in male, is first raised by brothers of Brugada in 1992. the 
features on ECG show the elevation of ST segments in the precordial line. Mutation in 
SCN5A is acquired as original of the SQTS3 in a familial disorder in 1998. More than 100 
mutations in SCN5A is related the Brugada syndrome. Besides the mutation in SCN5A, 
mutations in the β-subunits SCN1B and SCN3B, and the regulatory protein GPD1-L have 
been described in some Brugada syndrome patients. In a word, mutations in SCN5A or 
ancillary subunit caused to Brugada syndrome becausing of the reduction of sodium 
channel availabality, loss of function. Some factors cause loss of function in ion channel. 
For example the decreased trafficking will degrade the number of sodium channel (N) in 
membrane surface, or disruption of activation, accelerated inactivation, and impaired 
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recovery from inactivation will alter channel gating properties (the open probability and 
the single channel conductance).  
Loss of mutations in SCN5A underlies the mechanism of progressive cardiac conduntance 
defect (PCCD) due to reduction the sodium channel availability. PCCD is charactered by 
progressive conduction slowing through the His-Purkinje system, leading to the complete 
AV block, syncope and sudden death. Same to PCCD, Sick Sinus Syndrome is also caused 
by the mutations in SCN5A by decreasing the current of inward sodium currents. Sodium 
channel contribute to the cardiac automaticity owe to the inward sodium currents in 
depolarizing progress. Therefore, automaticity of sinoatrial pacemake can also be regulated 
by the sodium channel. Atrial fibrillation is often happened in elderly person with the 
abnormal heart and younger person with normal structure. In recent, both loss of function 
and gain of function mutations in SCN5A have been identified as atrial fibrillation due to 
decrease atrial conductance velocity attributed to the degrade of sodium inward currents 
and increase atrial action potential duration and excitability owe to the raise of sodium 
channel avaibality, respectively. In addition, the patients with dilated cardiomyopathy are 
evoked by the mutations in SCN5A. 
In recent years, “overlap syndrome” of cardiac sodium channel deseases have known  
to exit. The term of “overlap syndrome” is refered to extensive clinical and biophysical 
overlap. For example, the patients with the mutation SCN5A-1795insD+/- shows extensive 
variability in type and severity of symptoms of sodium channel disease. Otherwise,  
the single mutation in SCN5A alone but express pleiotropic effects make further verified 
through a transgenic mice SCN5A-1798insD+/- (equal to human SCN5A-1795insD+/-).  
It is further confirmed that a single SCN5A-1795insD+/- mutation is sufficient to express 
the overlap syndrome of the sodium channel. Heterogenous biophysical properties  
of ion channel mutations causing the mixed disease expressively are now increasing 
recognized. Therefore, it is necessary that improve diagnosis for the sodium 
channelopathies. 
3. Calcium channel 
Voltage gated calcium channel is the main channel across by Ca2+ into the intracellular in 
many excited cell. L-type Cav1.2 channel is an important voltage gated calcium channel 
and have been detected in many organs. Notwithstanding the widespread important 
function of the L-type calcium channel, the mutations have been identified is very rare. 
Mutations of deletion of the pore forming part in Cav1.2 channel change significantly the 
properties of the channel leading to the embryonically lethal. On the contrary, mutations 
associated with mold effects on ICa,L kinetics is well adapted and the patients with no 
obvious symptoms. 
3.1 Structure of L-type CaV1.2 channel 
Similar to the voltage-gated sodium channel, structure of L-type CaV1.2 channel is formed 
by a pore-forming subunit divided for four dormains (from I to II). Each domain consists of 
six transmembrane segments (S1 to S6). As the common to other voltage gated channel, the 
S4 of each domain is the voltage sensor moving across the membrane corresponding to the 
depolarization of the membrane potential. The part of S5, S6 and the linker S5-6 in each 
domain are composed to the ion conduction pathway.  
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Fig. 2. a (cited from Liao and Soong, 2010). Location of the mutations identified in CaV1.2 
pore-forming α1 subunit. Red circles (G402S and G406R) reprents spliced cardiac exon. 
Blue circle (G406R) is located in smooth muscle exon. Purple circles (A39V and G490R) 
represents constitutive exons. b Computer modeling revealed cardiac action potential when 
the mutation in smooth muscle exon and in cardiac exon. 
3.2 Ancillary subunits 
To date, four β subunits of calcium channel genes are expressed in the heart. The ancillary 
subunits can in theory bind to the Cav1.2 subunit at the α1 interaction domain (AID). The 
domain is highly conserved binding motif of 18 amino acid residues present in the 
cytoplasmic linker between repeat I and II of α1 subunits. The β2 subunit is generally 
believed to constitute the intracellular, accessory subunit of the Cav1.2 channel in adult 
mammalian myocardium.  
There are two distinct function of  subunit binding with the pore-forming subunit: before 
binding as a chaperone helping  subunit correct location at the membrane, after binding as 
an allosteric modulator to regulate the kinetic of the currents. Otherwise, different  subunit 
increase the currents of ICa,L at different levels by increasing the the channel opening 
probability, produce distinctive effects on channel inactivation kinetics and induce 
hyperpolarizing shifts in the voltage-dependence of channel activation.  
Recent studies have shown that the ancillary subunits are members of the membrane-
associated guanylate kinase (MAGUK) family of proteins by crystallographic information. 
Therefore, the ancillary subunits, as a ideal targets, interact with other protein such as ahnak 
or various members of the Gem/kir family of small Ras-like GTPase. 
3.3 Functions of L-type Cav1.2 in heart 
The L-type Cav1.2 channel plays a critical and dominant role in triggering excitation-
contraction coupling in cardiomycytes through the influx of the calcium ions to form the 
plateau of the ventricular action potential. Otherwise, the L-type Cav1.2 channel contribute 
to the trigger of the contraction when initiate the Ca2+ from the sarcoplasmic reticulum.  
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LQTS8 (also called Timothy syndrome) is first reported in 1990s with the symptoms of 
syndactyly.  The molecular basis of Timothy Sydrome is the mutations in L-type Cav1.2 at 
IS6 segment encoded by the two mutually exclusive exons 8/8a. Timothy syndrome is 
several features. Firstly, mutations are common caused by the deamination of a methylated 
cytosine to a thymine at de nove. Secondly, gain of function of L-type Cav1.2 lead to the 
increase of current density of ICa,L through slowing the inactivation of the channel. The net 
effects of the mutations increase of intracellular calcium ion. Thirdly, mutations are common 
in the mutually exclusive exons. The mutation of exons alters dramatically channel 
properties and the unaffected exon function normally. Lastly, mutation in Cav1.2 is also 
related to normal function of immune system.  
Different Cav1.2.variants are formed by the extensive alternative splicing by changing the 
pattern of splicing causing a series of disease. Among of them, only a few major splicing site 
can be divided to the cardiac and smooth muscle subfamily. In human heart, Cav1.2 channel 
contained cardiac exon may be 77 percent of all Cav1.2 channel. The first Timothy 
Syndrome mutation G406R is at the smooth muscle exon whereas other mutation G406R 
and F402s is at the cardiac exon. The latter can be named as TS2 and the cardiac arrhythmia 
of what is more serous than TS. 
TS2 mutant Cav1.2 belong to gain of function mutation leading to more calcium ion into the 
cytoplasm. Therefore, the action potential duration are be prolonged and a longer QT 
interval on ECG is shown. Comparision with TS (mutaions at smooth muscle exon), TS2 
(mutations at cardiac exon) produces more effects on action potential duration and 
excitability. For example, the prolongation of action potential duration by mutation at 
cardiac exon and smooth muscle exon is 30% and 8% by computer analysis, respectively. 
Therefore, symptom of patient with TS is molder than one with TS2.  
Otherwise, loss of function mutation in Cav1.2 or ancillary subunit cause to Brugada 
syndrome charactered by the elevating QT segments and shortening QT interval on ECG. 
The ages of the patients with Brugada syndrome is ranging from 21 to 44 years old which is 
elder than TS patients. Besides the dysfunction in cardiac tissues, other organs are nearly 
normal in patient with Brugada syndrome.  
4. Potassium channel 
Potassium channel is the largest family of ion channel protein and divided into voltage- and 
ligand- potassium channel owing to activating by voltage and ligand, respectively. Most of 
potassium channel are determined and depended by membrane potential. The ion-
conducting pore of a K+ channel is formed by four α-subunits that co-assemble as homo- or 
hetero-tetramers with different biophysical properties. Their gating characteristics can also 
be modulated by ancillary subunits or all kinds of blocker or activator.  
4.1 Classification of the cardiac potassium channel 
On the basis of their function, cardiac K+ channels are further classified into the transient 
outward channels, the delayed rectifier channels and the inward rectifier channels (Figure 1). 
Firstly, the transient outward current (Ito) formed by Kv4.3 manifests rapid activation and 
subsequent inactivation during the early repolarization phase (at phase 1). (ii) The delayed 
rectifier channels consist of at least three members Kv1.5, Kv11.1 and Kv7.1, for three 
different currents IKur, IKr, and IKs, respectively. All three channels activate at positive 
potentials but with distinct time courses, for example ultrarapid, rapid, and slow, 
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respectively. Inactivation of IKur and IKs is slow, on the contrary that of IKr is extremely fast. 
(iii) The cardiac inward rectifier potassium channels have more than three components. The 
major classical of one is Kir2,1-2.3 which form IK1 currents. This channel is always open and 
conducts K+ better into than out of the cell. Another channel expressed in atrial myocytes is 
an acetylcholine-dependent channel whicn conducts IK,Ach corresponding with the 
stimulation of G-protein-coupled muscarinic (M2) and adenosine (A1) receptors. The 
activation of IK,ACh shortens the active potential duration (APD). The third one in 
cardiomyocytes is ordinary closed under physiological metabolic conditions and is activated 
when the cells are deprived of intra-cellular adenosine triphosphate (ATP). Similar to IK,ACh, 
IK,ATP causes profound APD shortening.  
Notwithstanding general similarity in the mechanism of action potential arised, the 
distribution of potassium channel in cardiac ventricular myocardium and cardiac atrium is the 
most striking difference. For example, IKur and IK,Ach currents are both detected just in atrial but 
not in ventricular. Under the positive potential IKur is activated rapidly followed by ICa,L 
activation and therefore lead to less positive plateau phase in atrial than ventricular cells. 
4.2 Structure of potassium channel 
Remarkable advances about the structure-function relationship in ion channel have great 
progress in over past 30 years. Especially the progress in two experimental techniques, one 
is the single channel conductance recorded limpidly and plainly by patch clamp and 
another is the first determination at atomic-resolution of the structure of potassium channel 
protein. By means of these techniques, we can monitor real-time behaviour of single 
macromolecule in cell membrane and associate the behaviour with the molecular 
architecture of the protein 
4.2.1 Structures of voltage gated potassium channel 
Voltage-gated potassium channel is a homotetramer formed by each subunit containing six 
transmembrane domains (S1-S6). The pore domain comprise of the S5, the pore helix and S6 
segment. The S1-S4 segments of each subunit form the voltage sensor domains (VSD). The 
part of VCD regulates the open and close of the pore domain through moving across 
membrane in response to change of membrane potential. The channel pore is anisomerous 
and its dimensions change when the transition of channel gates from a closed to an open 
state. The K+-selectivity filter, a narrow cylinder, exists in the extracellular end of the pore 
that optimally utilize for conduction of K+ ions. The difference of the selectivity filter of Kv 
channels with other channel is charactered by the highly conserved sequence Thr-Val-Gly-
Tyr-Gly (the K+ signature sequence), located at the carboxy-terminal end of the pore helix. In 
hERG channel, the Thr and Tyr residues are substituted with Ser and Phe. The hydroxyl 
group of Thr in side-chain and the carbonyl oxygen atoms of the other four residues in each 
subunit all expose to the narrow K+ selectivity filter. These atoms mentioned above (OH- and 
O) encircle several octahedral binding sites that compete with the single water molecule of  
hydrated K+ ions and make a single water molecule alone arranged in a single line pass 
across the filter.  
The central cavity under the selectivity filter is much more widen and is a filled water region 
boundary by the S6 α-helices. In the closed state, the four S6 domains criss-cross near the 
cytoplasmic interface to form a narrow aperture that is too small to permit entry of ions 
from the cytoplasm. In response to membrane depolarization, the S6 α-helices splay 
outwards and increase the diameter of the aperture to allow passage of ions.  
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4.2.2 Structures of Kir channel 
Inward rectifier K+ channels (Kirs) consist of two transmembrane domains (M1 and M2). M1 
and M2, equal to the S5 and S6 part of voltage-gated potassium channel, is connected by a 
pore containing the G(Y/F)G sequence. In addition, the Kirs channels comprise of 
intracellular N- and C-termini. This architecture is typical structure of KATP and Kirchannels. 
They conduct K+ currents more in the inward direction than the outward and play an 
important role in setting the resting potential close to the equilibrium potential for K+ (EK, 
approximately -90 mV for [K+]o = 5 mM) and in repolarization. Kir channels form either 
homo- or heterotetramers. 
About the essential properties of rectification which attributed to blocking of Kir2 channels 
by intracellular organic cations called polyamines response to potent and strongly voltage-
dependent. Of the polyamines, free spermine in cell is the most potent inducer of inward 
rectification, followed by spermidine, putrescine, and then Mg2+. Accordingly, the 
“activation” of inward rectifiers upon membrane hyperpolarization is essentially 
uncoupling of polyamines or Mg2+ from the Kir channel pore.  
The general architecture of the Kir channels and the key structures involved in permeation 
and block is well established. Similar to bacterial homologs, the Kir channel in mammalian 
has a selective filter at the extracellular of the membrane with a signature sequence GYG. 
Under the filter there are a widen water cavity towards the intracellular of the membrane. 
There are a number of residues in Kir2 critical for inward rectification. For example, 
Mutations of D172 located at the level of the water cavity is firstly identified, a ‘rectification 
controller’. Spermine has high affinity with D172 in the vincity of the filter and unbinding 
from the residues highly voltage-dependent. Another important residue in rectification is 
E224 and E299 in the cytoplasmic region which form a ring of acidic. Contrast to D172, 
spermine has a low-affinity binding with E224 and E299 and low voltage-dependent. 
Spermine, as the largest (∼16–18 Å) polyamine, the pore of the Kir2 is long enough to easily 
accommodate two or more spermine.  
In native IK,ACh channels, spermine can also induce strong inward rectification. There are 
half of the residues in underlying Kir3.1/Kir3.4 channels equal to D172 and E224 in Kir2.1. 
The negative residues in Kir3.1/Kir3.4 channels have important role causing strong inward 
rectification. Although Kir2 and Kir3 have many common similarities there are lots of 
differences in the kinetical properties between both of them (Anumonwo and Lopatin, 
2011). 
5. Kv11.1 
Kv11.1 formed a kind of the delayed rectifier currents IKr encoded by KCNH2 which is 
identified as the molecular basis of LQT2 in 1995. To date, nearly 300 different mutations of 
Kv11.1 is the direct reason of congenital LQTs (http://www.fsm.it/cardmoc/; see Table 1) 
and almost all drugs induced acquired LQTS do so through interaction with the hERG 
channel. Besides that, dysfunction of Kv11.1 may cause short QT syndrome and artrial 
fibrillation. Therefore, Kv11.1 has vital role in excitability and action potential conductance 
in heart  
5.1 The features of the structure 
Differences from other Kv potassium channel, hERG channel has a unique extracellular part 
between S5 and the “pore”, so called “S5P linker” that contained an amphipathic helix. With 
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exception of transmembrane segment, hERG has intracellular N-terminal and C-terminal. 
The N-terminal has a Per-Arnt-Sim (PAS) domain which is unique to hERG channe in 
mammalian ion channel and play a role in deactivation of the channel. The C-terminal has a 
cyclic nucleotide binding domain (CNBD) which has relatively little effect on gating by 
binding with cAMP. However, mutation of the domain cause trafficking defects followed by 
loss of function of hERG channel and the last lead to cardiac arrhythmia. 
5.2 Kinetic characters of Kv11.1 
Similar to other Kv potassium channel, hERG channel exits at least three distinct 
conformational states: closed, open and inactivated. Transition from closed to open states or 
from open to inactivated state of channel attributed to the activation or inactivation which 
evokes the constrain of the conduction pathway and disrupted ion translocation. hERG 
channel have significant homology to other Kv family members by sequence analysis. 
However, kinetics characters of hERG channel activation and inactivation is distinct with 
other Kv channel. Contrast with other Kv channel, activation of hERG channel is much 
slower (on ranging from 100s of ms to many second) and inactivation is more rapid (off 
ranging from 1 to 10 ms) and voltage-dependent. Because of the slow activation of hERG at 
depolarized potentials, little outward currents produced by the channel flows through the 
phase 1 and 2 of cardiac action potential. Reduced outward currents conduce to the 
maintenance of the plateau of cardiac action potential by allowing Ca2+ entry and avoid the 
cell refractory to premature excitation. In addition, the increase outward currents, due to the 
much faster recovering from inactivation, is the most important determination  of the 
plateau of cardiac action potential. Besides that the distinct gating kinetics of hERG channel 
leads to form the character IKur currents which is help for suppression of propagation of 
premature beats. Therefore, hERG channel has crucial role in normal or abnormal cardiac 
action potential.  
5.2.1 Activation  
The gate of potassium channel is the bundle crossing formed by four the intracellular 
parts of S6 transmembrane helices of each subunit. The gate at closed state is too narrow 
to allow transverse of K+ ions. Transition to open state attribute to these helices which 
kink at a gate hinge revoking to enlargement of the pore and allow potassium ion pass it. 
In the bacterial KcsA, MthK and KvAP channels, a conserved Gly residue in S6 is 
proposed to serve as the hinge for the activation gate. Mutation of the putative Gly hinge 
in hERG alters gating but does not prevent channel opening. Although Kv1–Kv4 channels 
also have a Gly in the same location, a different molecular hinge may mediate channel 
activation. Therefore, the gating hinge, common formed by PVP motif in Kv1-Kv4, has 
vital roles in change of channel gate whereas the second proline of PVP motif was 
replaced by glycine in hERG channel.  
The S1-S4 VSDs also have important role in regulating the transition from closed to open 
state in voltage-gated potassium channel. The voltage sensor in hERG channel which is the 
six basic positive amino acid every 3 residues localized in the position between 525 and 538 
of the S4 domain Especially, the most important amino acid is the K525, R528 and K538 
conducing to voltage sensing for slow activation. With exception of the positive residues, 
the acidic amino acid in S1-S4 stablize the VSD at open and closed conformation through 
forming salt bridge with S4 residues.  
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It is well known that the voltage sensing regulating the channel open or closed by voltage 
sensor domain (VSDs) up or down across the transmembranes. However, to date the exact 
rearrangement of the structure between up or down and the exact magnitude of movement 
of VSD is still debated. For instance, although the structure of mammalian Kv1.2 channel at 
open state, especially the location of VSD up relative to the membrane have revealed. But 
crystal structure of the channel at closed state scilicet the down relative to the membrane do 
not still detected. Another meaning thing is about the distinct kinetics of the hERG channel 
because the overall of SVD is high homology with other members of Kv channel family by 
analysis sequence and hydropathy plots.  
To find the reason that the kinetics of hERG is so different, many scientists are attracted in 
the field and find several key pieces of evidence. When the gating currents corresponding to 
the movement of voltage sensor domain are measured at the same time the results show 
that a slow time course corresponding with the slow the activation. From the results we can 
conclude that the slow activation of hERG attribute to the slow movements of VSDs 
5.2.2 Inactivation 
About the hERG channel, the mechanism of the inactivation is the C-type at original stage. 
However, hERG inactivation is orders of magnitude faster than C-type inactivation and its 
intrinsically voltage-dependent. Many papers pay attention to the molecular basis of the 
voltage-sensitive of channel inactivation and the relationship between activation and 
inactivation gating, whether the process are couple or completely separate. Some data 
indicate that other part but not the S4 contribute to regulate the hERG inactivation. Ser620 
and Ser 631 in the P-domain are vital for inactivation. In addition, the charge change of S5P 
can markedly alter the inactivation of hERG. Therefore, Perrin conclude that different parts 
of voltage sensor domain participate in regulate the channel activation and inactivation. The 
amphipathic -helix of S5P contain in the regulation of hERG inactivaon, due to the relative 
movements between the -helix of S5P and the pore domain.  
5.2.3 The regulation of KCNE2 
It is well known that KCNE2 (Mirp1) was described as a modulator of the ether-à-go-go-
related gene 1 (ERG1) potassium current. The protein of KCNE2 is a single transmembrane 
peptide with an intracellular C-terminal and an extracellular N-terminal. Coexpression with 
Kv11.1 increase the currents of IKr owing to increasing the single conductance, altering the 
kinetic characters of inactivation and inactivation. Later KCNE2 was found to also change 
the KCNQ1 potassium current by drastically changing the gating properties. Mutations in 
KCNE2 are associated with long QT syndrome (LQT6) (http://www.fsm.it/cardmoc/) 
because of a decreasing influence on both ERG1 and KCNQ1 currents by KCNE2 mutation. 
Accordingly, both types of complexes KCNQ1/KCNE1 and KCNH2/KCNE2 could play a 
functional role in the heart. 
5.3 Functions of Kv11.1 in heart   
Loss of function and gain of function mutations in Kv11.1 produce to the formation and 
conductance of action potential in cardiac tissues. Loss of function mutations decreases the 
currents of IKr due to decrease of channel number, channel open probability and single 
channel conductance as mentioned above. 
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Fig. 3. (adapted from Perrin et al, 2008) Topological map of position of nearly 300 different 
mutations in hERG in LQTS2.  
5.3.1 Congenital cardiac arrhythmia 
LQTs is charactered by the prolongation of QT interval on ECG of the patients. Loss of 
function in Kv11.1 caused LQT2. Defective synthesis of mutations contained the premature 
termination codons is maybe the one fourths of all mutations of hERG channel  
(http: //www. fsm. it/cardmoc). Otherwise, hERG mutation of R534C display an increased 
open probability expressed in Xenopus laevis oocytes whereas in clinically the mutant 
induces the gain of function. Therefore, it is importance of detecting the mutations in 
mammalian system. 
Gain of function mutation in KCNH2 cause increasing of currents amplitude IKr which lead 
to shorten the action potential duration and in final to decurtate the QT interval on ECG. 
Some patients with SQT will be healing well in the future through the regulation of 
themselves. However, if the cardiac action potential is persistent shorten and produce 
diminishing of refractory period between the continual bisaction potential. At last, SQT may 
be get worse the atrial fibrillation and sudden death or syncop. 
5.3.2 Acquired LQTS 
Comparision with congenital LQTS, acquired LQTS is more common cause of TdP. Lots of 
factors can induce to form acquired LQTS, such as myocardial ischemia, electrolyte 
disturbances, bradycardia and so on. Of the most important factors is drug. Accordingly, the 
drug-induced  LQTS is equal to the acquired LQTS in most case. However, acquired LQTS 
and drug-induced LQTS is essential two different concepts.  
Many kinds of drug can induce the acquired LQTS, for instance antiarrhythmia drug, 
antibiotic, antihistamine and so on. Atiarrhythmia drug quinidine is a relatively frequent 
side effects, caused 2-9% of treated patient induced RdP. Other drugs induced TdP is less 
 
Contributions of Ion Channels in Cardiac Arrhythmias 
 
111 
than antiarrhythmia drugs. The compounds (dofetilide, sotalol and ibutilide), predictable 
designed to block cardiac repolarizing currents, can induce the prolongation of the OT 
interval which unfortunately arises as a side effect of the compound treated for non-cardiac 
diseases. Therefore, the compound in already marketed drugs will be withdrawal or 
restriction. In order to the expenses of the pharmaceutical companies, it is now common 
practice to screen for compound for hERG-channel activity early during preclinical safety 
assessment. However, in clinical the blockage of hERG can counteract by blocking of L-type 
of calcium channel.  
Most of drugs which can induce acquired LQTS can also block of hERG channel. Contrast to 
other Kv channel, the hERG is unusually susceptible to blockage by drugs is unknown, 
suggesting that it has a unique binding site. In order to find the interact sites hERG with the 
blockers, an ala-scanning mutagenesis approach is used. Mutations of two polar residues 
(Thr 623 and Ser 624) located at the base of the pore helix and mutations two aromatic 
residues Tyr652 and Phe656 located in the S6 domain of hERG has vital roles in combination 
with the compounds. The side chains of all four residues are oriented toward the large 
central cavity of the channel and can block the transmembrane pass of potassium ions by 
combining with the blocker. 
5.4 Future perspectives 
Over the past 16 years a great deal of discovery of hERG channel has been detected but 
there is still much to explore about the channel.  
6. Kv7.1  
Kv7.1 (also known as KCNQ1, KvLQT1) is the -subunit of a voltage-gated potassium 
channel cloned in 1996 by Wang and co-workers using linkage analyses of LQTS1 patients 
and expressed in several tissues including cardiac myocytes and epithelial cells. The most 
important roles of KCNQ1 channels are repolarization of the cardiac tissue following an 
action potential. In cardiac myocytes, the KCNQ1 subunit assembles with the KCNE1 -
subunit (minK) to form a channel complex. The channel complex of KCNQ1/KCNE1 
produce the delayed rectifier current IKs, which is partly responsible for terminating the 
cardiac action potential during phase 2. Up to now, there are nearly three hundred mutation 
of KCNQ1 have been detected. Most of the mutations produce the loss of function of 
KCNQ1, lead to the LQTS (http://www.fsm.it/cardmoc/), a most kind of cardiac 
arrhythmia characterized by prolongation of QT interval in electrocardiogram, syncope and 
sudden death. Only a few gain-of function mutations have been verified and have correlate 
with the atrial fibrillation or the short QT syndrome (SQTs). 
Based on the molecular mechanism of altering of KCNQ1 currents, mutations of the channel 
are divided into impaired trafficking, impaired voltage dependence, impaired selectivity 
and impaired tetramerization. For the majority of these three hundred KCNQ1 mutations, 
little is known about the molecular mechanism producing to the pathologies or limited to 
which of the categories. Therefore, there are many unknown knowledge about the three 
hundred KCNQ1 mutaions and make further progress in the future with the application of 
new technology of structure prediction in study. 
6.1 Structure and electrophysiological characters of KCNQ1 
As a member of Kv potassium channel, KCNQ1 channel show a high similarity to voltage-
gated potassium channels of the Kv type which assemble a tetramer, with each subunit of 
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KCNQ1 contained S1-S6 trans-membrane. Different from other Kv members, KCNQ1 often 
form heterotetramer with auxiliary subunits contained one-transmembrane in vivo. To date, 
there are five member of KCNE family have been detected and in Xenopus laevis oocytes or 
mammalian system the  subunit of KCNQ1 channel can combinate with any one of them to 
form miscellaneous kinds heterotetramer with distinct kinetic characters of channel such as 
activation, inactivation or deactivation and so on. Accordingly,  subunit of KCNQ1 
channel has been check in lots of tissues in the body and with different physiological 
characters. 
In the full-length human KCNQ1 gene, 16 exons constitute of KCNQ1 with the very GC-rich 
5’-end. The translated protein is composed of 676 residues and has six transmembrane 
domains S1-S6, a pore loop with a typical potassium-channel pore signature sequence 
(GYGD), and intracellular NH2 and COOH terminals covering 122 and 322 residues, 
respectively. To date, with the exception of KCNQ1, there are other four members in the 
KCNQ family have been detected, such as KCNQ2-5. Comparision with other members of 
KCNQ family, KCNQ can not assemble a hetertetramer with other members and just 
forming a homotetramer only with themselves.  
As a voltage-gated potassium channel, KCNQ1 was activated by decreasing of 
depolarization. And similar the other voltage-gated potassium channel, the voltage sensor is 
located in the S4. However, mutations in the linker of between S4 and S5 still have effect on 
activation of the KCNQ1 channel. When KCNQ1 channel are fully open at the positive 
potential followed by a strikingly repolarization produces a hook currents which represent a 
fraction of KCNQ1 channel inactivation. Because the channel will be open again from the 
closed state. Researches show that the five transmembrane and the pore part of each subunit 
have vital roles in the inactivation of KCNQ1 channel.  
6.2 Regulation of KCNQ1 channel activation and inactivation 
As mentioned above, the KCNQ1 subunit and the ancillary subunit KCNE1 collect together 
to form the currents of IKs in cardiac tissues. The KCNE1 subunit has important roles in 
regulation of kinetical properties of KCNQ1 channel. For example, the currents formed by 
KCNQ1 subunit alone is activated rapidly whereas ones formed by coexpressed of KCNQ1 
and KCNE1 is activated very slowly. In addition, the presence of KCNE1 produce a large 
increase in the macroscopic KCNQ1 currents, a positive shift of voltage-dependence curves, 
slowing of the activation and deactivation and almost of absent of inactivation. Some 
researches have shown that the distinguished increase of the magnitude of currents of 
KCNQ1/KCNQ1 complex is owing to increase the single channel conductance for four to 
sevenfold and almost eliminate the inactivation the channel by KCNE1 subunit. As for the 
exact combination of KCNQ1 and KCNE1 subunit, there are distinct views about it. Some 
results display that KCNE1 lines to the conductance pathway. On the contrary other results 
show the combination site is out of the conductance pathway. Van Horn proposes a Q1/E1-
TMD model, a new model to elucidate the interaction of protein-protein about KCNQ1 and 
KCNE1 in recent researches. The emphasis of the new model is on the KCNE1 
transmembrane domain (also called TMD). It is generally accepted that in closed state the 
S4-S5 linker interact with the C-end of S6 from another subunit to lock it in the closed 
configuration. In response to depolarization, the change of conformation of S4 voltage 
sensor, the S4-S5 linker pull off and deviate from the S6 inducing the channel open. The 
Q1/E1-TMD model consider that the C-terminal end of KCNE sits on the end of the S4–S5 
linker while simultaneously N-terminal end makes extensive (and presumably adhesive) 
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contacts in the cleft between the voltage sensor and pore domains of the channel. Therefore, 
during the transition of the channel from closed to open state, the presence of KCNE1 TMD 
will interfere with the S4-S5 linker deviating from the S6. Uniformly, because of the KCNE1 
presence, transition state open to close become very slow and is help for maintenance of the 
open state of the channel.   
Besides the ancillary subunit of KCNE1, there are other members (KCNE2-5) in the family. It 
is interesting that all ancillary subunits can co-assemble with KCNQ1 channel in different 
tissue and alter the kinetic characters of KCNQ1 channel. In cardiac tissue, besides of 
KCNE2, KCNE2 is another important ancillary subunit. KCNE2 (also named Mirp1), 
originally described as a ancillary of the ether-à-go-go-related gene 1 (ERG1) potassium 
current, was later found to change the KCNQ1 potassium current though drastically 
changing the gating properties. Otherwise, in organs such as stomach and intestine, 
Moreover, the mRNA of KCNE4 and KCNE5 has been detected in the heart. They may be 
has vital roles in maintaneine of the ordinary function of the heart. However, there is no 
relative report about it.  
6.3 Functions of KCNQ1 channel in heart 
Currents of IKs formed by KCNQ1/KCNE1 have slow activation, whereas IKur and IK1 
constituted by ERG1 and Kir2.x, respectively, have rapide activation kinetics. The three 
repolarizing potassium currents together have been called the repolarization reserve 
because to some extent they can substitute for each other. However, in the fast heart beat, 
only IKs currents are upregulated by phosphorylation and by current accumulation due to 
slow deactivation. In addition, In heart tissue, distribution of KCNQ1 through the cardiac 
wall is also inhomogeneous and the expression of KCNQ1 is less in medmyocardium than 
epi- and endomyocardium.  
The cardiac function of KCNQ1 and its accessory subunits is emphasized by the functional 
impact of numerous mutations in these proteins (http://www.fsm.it/cardmoc/). Mutations 
in KCNQ1 causing loss of function by trafficking defective, assembly defective, or single 
channel conductance lead to prolonged action potentials and LQTS. A domain located near 
the COOH terminal (residues 589–620) is responsible for this assembly specificity, and 
deletion of a part of this domain leads to an impaired assembly of the channel complexes 
followed by mistrafficking. Mutations in ancillary subunits such as KCNE1 and KCNE1 also 
cause LQTS4 and LQTS5, respectively.  
KCNQ1 mutation (S140G), as a gain of function mutation, is detected in a family with 
arterial fibrillation inherited as an autosomal dominant way through four generations. The 
mutation shortens the action potential through increasing the currents of IKs. Similarly, a 
gain-of-function mutation in KCNE2 (R27C) increasing the activity of the KCNQ1/KCNE2 
channel has also been implicated in atrial fibrillation. 
Acquired LQTS is predominantly found when the patients take the blocker of hERG channel 
as medicine. Because the currents of IKr are blocked, the repolarization reserve is decreased 
and the disperation of repolarization is leaded to a further increase due to the 
inhomogeneous distribution of KCNQ1 in heart wall.  
7. Kv4.3  
Kv4.3 is formed the rapid activated currents Ito (encoded by KCND3) which is a voltage-
dependent, 4-aminopyridine (4-AP) sensitive, calcium-independent K+ current (Ito). Ito have 
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been detected in human artial and ventricular myocytes and is responsible for the early 
rapid depolarization (at phase 1) so determining the height of plateau. Therefore, Ito will 
influence of other ion channel activation such as the L-type calcium channel and the delayed 
rectifier channel (KCNQ1). Distribution of Kv4.3 is heterogeneous through the cardiac 
tissue. For example, Ito density in atrial tissue, Purkinje fibers, epicardial and midmyocardial 
(M) cells is higher than in the endocardial cells. The prominent epicardial Ito conduce to the 
depression of epicardial in ischemia and to the progress of a significant dispersion of 
repolarization between normal and ischemic epicardium, between epicardium and 
endocardium.  
7.1 Regulation of Kv4.3  
Kv4.3 can be blocked by many compounds but which bind with the channel either at open 
state or at close state. It has been raised that blocker of Ito prolong the action potential duration 
in atria or in ischemic ventricular tissues. However, blockage of Ito subsequently changes the 
other potassium channel underlying during repolariztion of cardiac action potential. 
Reduction of Ito magnitude can shorten the duration of ventricular action potential. Therefore, 
it is still unclear that the exact role in control human cardiac action potential. 
Channel properties of Kv4.3 is modified by the phosphorylation, mediated by protein kinase 
A (PKA) and C (PKC) through altering the channel kinetic (activation, inactivation or single 
channel conductance) and the expression of active channel in the membrane. Decrease in Ito 
by PKC attributed to enhance the inactivation and step down the time of deactivate of the 
channel Kv4.3. a-adrenergic agonists reduce Ito magnitude in rat ventricular myocytes and 
oppositely the -adrenergic agonists has no effect on Ito currents. 
7.2 Functions of Kv4,3 in heart 
Heart failure, cardiac hypertrophy and myocardial ischemia and infarction decrease the 
magnitude of Ito resulting in the prolongation of action potential. The degrade in Ito in heart 
failure may be adaptive in the short-term because increased depolarization during the 
cardiac cycle means that more time is available for excitation–contraction coupling, which 
moderate the decrease in cardiac output, however it becomes maladaptive in the long-term, 
because a prolongation of the APD may contribute to arrhythmogenesis, either by causing 
inhomogeneous repolarization or by increasing the likelihood of early afterdepolarizations. 
On the contrary, it is proved that up-regulation of Ito in cardiac hypertrophy and in cardiac 
myocytes after induced myocardial infarction. Increase in Ito presents as a protector 
moderating the excessive prolongation of action potential duration and Ca2+ inflow to 
minimize the incidence of ventricular arrhythmia. In addition, the patients with chronic 
atrial fibrillation decrease the currents of Ito and downregulate the mRNA.  
8. Kv1.5 
Ikur currents in human atrium are formed by the  subunit (Kv1.5) and  ancillary subunit 
(Kv1.2). The features of IKur, as outward rectifired currents, are activated rapidly in the 
plateau range and inactivation slowly. Interestingly, currents of IKur just have been detected 
in human atria rather than cardiac ventricle. Therefore, currents of IKur have vital roles 
during the atrial repolarization. There is a huge difference of Kv1.5 from other ion cardiac 
channel. Distribution of Kv1.5 is homogeneous across the atrial wall.  
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8.1 Regulations of Kv1.5 
hKv1.5 can be regulated by both PKA and PKC. One consensus site in Kv1.5 for 
phphosphorylation by PKC is located on the extracellular S4–S5 linker and 4 consensus 
sites for PKA is located in the N- and C-terminal domains. Isoproterenol and adenylate 
cyclase both increase the magnitude of IKur and the increase can be counteract by PKA 
inhibitor. Otherwise, propranolol and phenylephrine decrease the amplitude of IKur 
moderating by the PKC inhibitor. Accordingly, -adrenergic stimulation enhances the 
currents of IKur by PKA. Oppositely, -adrenergic stimulation inhibits IKur currents by 
PKC. Human thrombin or rat 5-HT1c receptors inhibits the currents of IKur by increasing 
phospholipase C (PLC). Moreover, the Scr tyrosing kinase inhibits the hKv1.5 by 
phosphorylation of the N-terminus proline-rich sequences mediated by SH3 domain of 
the tyrosine kinase.  
8.2 Functions of IKur in heart 
IKur is relatively insensitive to TEA, Ba2+ and class III antiarrhythmics of the 
methanesulfonanilide group. Antiarrhythmia drug is often weak bases that predominant 
cationic ion at pH7. At the channel open state, the cationic ion can bind with the pore 
and/or selective filter domain of the channel leading to the blockage of the channel. The 
binding site for some drugs is existed at the external mouth of the channel pore formed by 
the P loop and adjacent S5–S6 segments.  
Because of the Kv1.5 just located in atria, the channel is a promising target for the 
development of new safe antiarrhythmic drugs to prevent atrial fibrillation and without a 
risk of ventricular proarrhythmia. However, In patients in chronic artrial fibrillation, the 
action potential duration in atria is significantly prolongated due to both blockage of Ica,L 
and IKur. Accordingly, it is not expected what will be happened by use of IKur blocker to treat 
the patient with chronic AF. In a rat, rapid atrial pacing just immediately and transiently 
increases the mRNA of Kv1.5 rather than the ones of KCNQ1 and hERG. It shows that Kv4.3 
at least in part contribute to the rapid shortening of the atrial refractoriness at the onset of 
AF. Therefore, the selective blockers of IKur counteract the shortening of atrial action 
potential duration at rapid rate state. From mentioned above, application of IKur selective 
blocker in clinical is a challege job in the future.  
9. Kir2.1 and Kir3 
Inward rectifiers (Kir) is composed of a large family of potassium channel. Among them, 
only two subfamilies (Kir2 and Kir3) share great structural similarity and underlie classical 
‘strong inwardly rectifying currents’ originally observed in skeletal and cardiac muscle. In 
cardiac tissue, there are only two similar types of these currents: (1) IK1, as a constitutively 
active Kir current, is more prominent in ventricular tissue, and (2) IK,Ach, as a receptor-
activated Kir current, is more prominent in atrial tissue, as well as in SA node and AV node. 
There are two common features of the kir2 and Kir3. one is a strongly voltage-dependent 
decline of potassium conductance upon membrane depolarization producing a 
characteristic region of so-called ｀negative slope’ conductance. Another unique property of 
Kir currents is the unusual dependence of rectification on extracellular K+. In order to 
comprehend the two characters of Kir channel, firstly to fully the molecular basis of the 
channels.  
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activated Kir current, is more prominent in atrial tissue, as well as in SA node and AV node. 
There are two common features of the kir2 and Kir3. one is a strongly voltage-dependent 
decline of potassium conductance upon membrane depolarization producing a 
characteristic region of so-called ｀negative slope’ conductance. Another unique property of 
Kir currents is the unusual dependence of rectification on extracellular K+. In order to 
comprehend the two characters of Kir channel, firstly to fully the molecular basis of the 
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Fig. 4. (cited from Anumonwo et al, 2009). The family of inward rectifier potassium 
channels. All members of this family share significant structural similarity, but only Kir2 
and Kir3 subfamilies represent channels carrying classical strongly rectifying currents.  
In human heart, the distribution of IK1 and IK,Ach has distinct region. IK1 is more prominent in 
the ventricles, including Purkinje myocytes. IK,Ach has generally an opposite distribution to 
that of IK1. It is more prominent in the atria than in ventricles. Similarity, the current density 
of IK1 and IK,Ach may vary across the ventricular or atrial tissues, distinctively. About the 
subunit composition of IK,Ach, under normal conditions native IK,Ach channels are heteromers 
of Kir3.1/ Kir3.4 subunits. However, recent data suggest that Kir3.4 subunit alone has 
similar function with the native IK,Ach. Comparision with IK,Ach, IK1 is formed by coassembly 
of the Kir2.1.x subfamily of proteins (Kir 2.1, 2.2, and 2.3) with Kir2.1 the most abundant 
subtype in ventricular tissue.  
9.1 Functions of Kir2 and Kir3 in heart 
To date, IK1, formed by coassembly of the Kir2.1.x subfamily of proteins (Kir 2.1, 2.2, and 2.3) 
In cardiac tissue, is the major component of inward rectifier potassium current and have a 
vital role in determinant of the resting membrane potential and conduces to the terminal 
phase of repolarization (phase 3). Loss of function of Kir2 channel ≥ 90%, the heart of 
transgene (TG) mice led to prolongation of QRS and QT intervals as well as expected 
prolongation of action potential. Surprisingly, resting membrane potential in TG ventricular 
myocytes was nearly unaffected. It is unexpectedly that upregulation of IK1 in TG mice 
expressing Kir2.1 subunits, gain of function, cause to multiple abnormalities of cardiac 
excitability contained significant AP shortening and various types of atrial and ventricular 
arrhythmias. 
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In heart, another contribution of IK1 to excitability is through an unusual and strong 
dependence on extracellular K+. During repetitive firing, cardiac activity is followed by 
markedly changes in the concentration of K+ in the restricted (0.01–5 μM) intercellular space, 
even more accumulation in the t-tubules. Increase of extracellular K+ should be 
accompanied by the increase of IK1 conductance with results on electrical activity, e.g., AP 
duration and propagation  
 
 
Fig. 5. (cited from Anumonwo et al, 2009). Mutations on Kir2.1 protein associated with 
channelopathies of the classical inward rectifier channel. Mutant residues are color coded to 
represent the long QT7 (LQT7; black), catecholaminergic polymorphic ventricular 
tachycardia (CPVT; red), familial atrial fibrillation (FAF; green), and short QT3 (SQT3; blue). 
To date, four channelopathies related with inward rectifier currents have been detected, all 
due to loss of function or gain of function of IK1 currents (encoded by KCNJ2), LQT7, 
catecholaminergic polymorphic ventricular tachycardia (CPVT), familial atrial fibrillation 
(FAF), and short QT3. LQT7 at early is also called Andersen syndrome (AS) or Andersen–
Tawil syndrome (ATS). Symptoms of the disease are characterized by a triad of clinical 
phenotypes affecting morphogenesis as well as the functioning of skeletal and cardiac 
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muscles. ATS patients are often companied by features that include scoliosis, cleft palate, 
and short stature and display skeletal muscle weakness. Besides that, cardiac electrical 
abnormalities include prolongation of the QT interval, short runs of ventricular tachycardia, 
ventricular bigeminy and multi-focal ventricular ectopy mediated by adrenergic 
stimulation. However, recent works suggest that classification of ATS into LQTS is incorrect 
because of the former largely related to the abnormalities of the T–U complex. Because more 
than half of ATS is the mutations in KCNJ2 the term AST1 is reffered to the disease of IKir2. 
To date, more than 33 mutation in KCNJ2 is related to AST1 and the mutations have been 
identified as the autosomal-dominant. Some of mutations, such as D71V in AST1 patients, 
can decrease by ∼94% of  the magnitude of wild type currents IKir2. Several of ATS1 
mutations, such as R21Q/W mutations, result in a loss-of function in the Kir2.1 channels due 
to reduced interaction with membrane PIP2.  
Short QT syndrome (SQTS) is charactered by the shorten of QT interval on ECG. SQTS is an 
inherited abnormality that predisposes afflicted individuals to a high risk of having 
fibrillation (atrial/ventricular) and sudden death. Three forms of SQTS have been identified 
and SQTS3 is caused by the gain of function of mutations in inward rectifier channel gene, 
KCNJ2. SQTS3, charactered by electrocardiographic phenotype with asymmetrical T waves, 
is distinguished with other two kinds of SQTS. The molecular basis of SQTS3 is the mutation 
D172N at a position critical for inward rectification of Kir2.1 channel. Heterologous 
coexpression of wild type and mutant Kir2.1 subunits showed increased outward currents 
in mutant channels which account for the tall, asymmetrical T waves on the ECG of LQTS3 
patients. Researches by computer simulations suggest that mutations in SQT3 might 
predispose patients to a higher risk of reentrant arrhythmias. 
Mutation of V93I in Kir2.1 is associated with familial atrial fibrillation, thereby implicating 
IK1 in this disease. In addition, the mutant channels have larger outward currents by whole-
cell patch-clamp studies, however the underlying mechanism(s) responsible for the increase 
remains unknown.  
In a recent study, three novel (R67Q, R85W, and T305A) mutations belonged to CPVT3 and 
one previously described (T75M) mutations in KCNJ2 are identified. ECG analysis reveals 
prominent U-waves, ventricular ectopy, and polymorphic ventricular tachycardia. It is 
interestingly that there were no dysmorphic features or skeletal muscle abnormalities in the 
patients. Whole-cell patch-clamp experiments revealed that mutant channels had 
significantly reduced by ≥ 95 % amplitude of wild type outward current and that T75M and 
R67Q mutations had dominant negative effects when co-expressed with wild type channels. 
Importantly, the study showed that the T305A mutation selectively affected channel 
rectification properties.  
Cardiac strong inward rectifier potassium channels continue to surprise researchers with 
their novel roles in cardiac excitability, complex structure, function, and regulation. While 
significant progress has been made in recent years, clearly, many questions still remain to be 
answered and we certainly will soon witness new, and likely unexpected, discoveries in this 
field. 
10. Kir6.2 
ATP-sensitive potassium (KATP) channels (encoded by KCNJ11) are evolutionarily conserved 
and are first discovered in the cardiac sarcolemma where they are expressed in high density. 
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IKATP is formed by the complex protein composed by the pore-forming subunit and the 
regulatory sulfonylurea receptor which is an ATPase-harboring ATP-binding cassette 
protein. To date, members of the inwardly rectifying K+ channel family (Kir6.1 and Kir6.2) 
and the sulfonylurea receptor isoforms (SUR1, SUR2A and SUR2B) have been identified. In 
cardiac tissue, KATP channel is a hetero-octameric complex composed of four pairs of these 
two distinct subunits Kir6.2 and SUR2A. The structure of KATP channel is very similar to 
Kir3 and Kir2. Therefore, there is no redundant description in this part.  
10.1 Functions of KATP channels in heart 
KATP channels, as a cardio-protective role, were recognized early in ischemia heart. The 
channel can mediate shortening of the cardiac action potential by increase of the IKATP 
currents then control calcium influx into the cytosol. Moreover, when the heart expose to a 
brief periods of ischemia causing a sustained ischemic insult KATP channel activity can 
depress significantly the injury produced by ischemia such as infarct size, coined ischemic 
preconditioning. Therefore, in ischemia heart, KATP channel can degrade markedly heart 
injure caused by ischemia.  
Another important function of KATP channel is during the process of stress without 
distress in heart. The concept of “stress without distress” is referred to describe the ability 
of an organism to confront and/or escape imposed threat. The concept is very likewise to 
the “flight-or-fight” response, through the general adaptation syndrome. For example, 
acute exercise-stress causes a systemic sympathetic stimulation that raises cardiac 
contractility, heart rate and thereby provides the necessary higher cardiac output. How 
huge change of the heart excitability has happened after acute exercise. Many researches 
suggest that stress without distress is dependent in the KATP channel in heart. The change 
of this enhanced cardiac output imposes a significant metabolic in large part of the heart 
due to the highly energy consuming calcium handling machinery. A compensatory 
increase in outward potassium current formed by KATP channel is normally activated to 
offset the resulting calcium influx in order to reducing energy-demanding myocardial 
calcium overload.  
KATP channel also has important roles in heart failure. Heart failure has no effect on the 
intrinsic biophysical properties of the cardiac KATP channel whereas the structural 
remodeling disrupts communication of energetic signal and channel.  Then the disruption 
leads to interfere markedly the metabolic regulation of the channel at last. Accordingly, 
metabolic dysregulation of KATP channels created by the disease-induced structural 
remodeling appears to contribute to the dysfunction of heart failure. 
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Cardiac arrhythmias result from the confluence of structural and functional changes in the 
heart and genetic predisposition, reflecting an interaction between a susceptible substrate 
(e.g. an anatomically defined circuit, a myocardial scar, fibrosis or a monogenic arrhythmia 
syndrome) and a specific electrophysiological triggering event. Such triggered activities 
arises from delayed afterdepolarizations (DADs) or early afterdepolarizations (EADs), in 
which action potential prolongation and aberrant Ca2+ fluxes are a recurrent theme. 
Ca2+ channels in cardiomyocytes provide the main influx pathway for Ca2+. Three types of 
high threshold Ca2+ channels are expressed in heart: two L-type channels, Cav1.2 and Cav1.3 
and a P-type channel, Cav2.1. The Cav2.1 channel protein is expressed at a very low level the 
in heart (Starr et al., 1991) while Cav1.3 is mainly expressed in fetal hearts and only in adult 
sinoatrial and atrioventricular nodes and atrial tissues of adult (Lipscombe et al., 2004; Qu et 
al., 2005). We will focus attention on the Cav1.2 L-type Ca2+ channel (LTCC) which is the 
main player in electrical activity and excitation-contraction coupling (EC coupling) in the 
ventricular cardiomyocyte. 
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Cardiac arrhythmias result from the confluence of structural and functional changes in the 
heart and genetic predisposition, reflecting an interaction between a susceptible substrate 
(e.g. an anatomically defined circuit, a myocardial scar, fibrosis or a monogenic arrhythmia 
syndrome) and a specific electrophysiological triggering event. Such triggered activities 
arises from delayed afterdepolarizations (DADs) or early afterdepolarizations (EADs), in 
which action potential prolongation and aberrant Ca2+ fluxes are a recurrent theme. 
Ca2+ channels in cardiomyocytes provide the main influx pathway for Ca2+. Three types of 
high threshold Ca2+ channels are expressed in heart: two L-type channels, Cav1.2 and Cav1.3 
and a P-type channel, Cav2.1. The Cav2.1 channel protein is expressed at a very low level the 
in heart (Starr et al., 1991) while Cav1.3 is mainly expressed in fetal hearts and only in adult 
sinoatrial and atrioventricular nodes and atrial tissues of adult (Lipscombe et al., 2004; Qu et 
al., 2005). We will focus attention on the Cav1.2 L-type Ca2+ channel (LTCC) which is the 
main player in electrical activity and excitation-contraction coupling (EC coupling) in the 
ventricular cardiomyocyte. 
The LTCC of cardiomyocytes is a complex multimeric molecular sarcolemmal ensemble that 
during an action potential (AP) allows Ca2+ to flow down its electrochemical gradient into 
the cardiac cell. LTCCs are mostly localized in the transverse tubular system of 
cardiomyocytes (Wibo et al., 1991; Kawai et al., 1999; Brette et al., 2004). Activation of LTCC 
generates a Ca2+ current (ICaL) through the sarcolemma large enough to be involved in AP 
overshoot and in the control of AP duration (APD) in different cardiac cells types (Bers, 
2001). ICaL serves as a trigger for Ca2+ release from the sarcoplasmic reticulum (SR) during 
the excitation-contraction coupling by a mechanism known as calcium-induced calcium 
release (CICR, Fabiato & Fabiato, 1975; Bers, 2001). LTCC activation can also play a role in 
transcription mechanisms in cardiomyocytes (Atar et al., 1995; Brette et al., 2006). Several 
hormones and neuromediators modulate the activity of LTCC via complex intracellular 
signaling pathways and, as well, several intracellular molecules and the cytoskeleton can 
influence LTCC activity (Benitah et al., 2010). However, intracellular Ca2+ concentration is 
strictly controlled in normal cells by different mechanisms (Bers, 2001) since a Ca2+ overload 
can have deleterious effects including arrhythmias and myocardial remodeling via a genetic 
reprogramming of the cardiac cell (Benitah et al., 2003). 
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2. Macromolecular structure 
The typical structure of LTCC in ventricular cardiomyocytes is a macromolecular 
multimeric complex consisting of a ~240 kDa pore-forming unit α1C (encoded by the 
CACNA1C gene) and two auxiliary (modulator) subunits: an intracellular β subunit (mainly 
β2A, encoded by the CACNB2A gene) and the dimer α2δ subunit (mainly α2δ-1, encoded by 
the CACNA2D1 gene) in a 1:1:1 ratio (Catterall et al., 2005). The α1C subunit consists of four 
homologous repeating motifs (I–IV), each one composed of six membrane-spanning α-
helices (S1 to S6) linked by variable extracellular and cytoplasmic loops (linkers). This 
subunit contains all the necessary structures to allow the channel to gate (activation and 
inactivation) and confers the Ca2+ selectivity as well as the electrophysiological and 
pharmacological properties of the LTCC (Takahashi & Catterall, 1987; Catterall, 2000; 
Carafoli et al., 2001; Lacinová & Hoffmann, 2001; Bodi et al., 2005; Lacinova & Hofmann, 
2005; Brette et al., 2006; Benitah et al., 2010). However, more native LTCC properties can be 
achieved when all three subunits are present (Lacinová & Hoffmann, 2001; Lacinova & 
Hofmann, 2005; Benitah et al., 2010). The β2A subunit seems to be involved in membrane 
targeting of α1C and influence LTCC inactivation (Bodi et al., 2005; Lacinova & Hofmann, 
2005; Brette et al., 2006). Its structure reveals a module of two interacting domains, a Src 
homology 3 (SH3) domain and a Guanylate Kinase (GK) domain (Chen et al., 2004; Bodi et 
al., 2005). It was initially believed that its conserved sequence, BID (Beta Interaction 
Domain), interacted directly with the Alpha Interaction Domain (AID) within the 
intracellular loop between domains I and II of the α1C subunit (De Waard et al., 1996; 
Arikkath & Campbell, 2003). However, recent data indicate that BID is largely buried in the 
Cavβ core and is unavailable for protein-protein interactions (Chen et al., 2004; Van Petegem 
et al., 2004). The AID is bound in a hydrophobic groove (α-binding pocket, ABP) in the GK 
domain and positions the β-subunit near the intracellular pore-lining segment I6 (which is 
important in Ca2+ channel inactivation) thus providing evidence that Cavβ influence Ca2+ 
channel gating by direct modulation of this segment (Van Petegem et al., 2004). Although 
the BID does not participate directly in binding the α1C subunit, structural integrity and 
bridging of the SH3 and GK domains are greatly influenced by BID. The α2δ-1 subunit 
seems to be involved in targeting (or stabilization) of the α1C to the sarcolemma (Lacinová & 
Hoffmann, 2001; Lacinova & Hofmann, 2005; Brette et al., 2006; Benitah et al., 2010) and 
could confer more native LTCC properties. The δ subunit is composed of a single 
transmembrane segment with a very short intracellular C-term and links by disulphide 
bonds the α2 subunit that is entirely extracellular (Davies et al., 2007). The α2 subunit 
contains a Von Willebrand factor A domain (VWA) that has a metal-ion-dependent 
adhesion site that seems to be key in trafficking the α1C subunit to the membrane (Canti et 
al., 2005). 
3. Biophysics of the cardiac L-type Ca2+ channel 
3.1 Selectivity and permeation 
The cardiac LTCC is a multi-ion pore in which a Ca2+ ion bound to a high affinity site can be 
repelled by a second Ca2+ ion entering the pore thus allowing selectivity with high ionic flux 
(Hess & Tsien, 1984). The LTCC pore exhibits two different affinities for Ca2+: a KD ~ 1 μM 
for Ca2+ block of monovalent current through the channel and a KD ~ 10-14 mM for 
saturation of divalent current (which can be lower if surface charge screening is taken into 
account at high divalent concentrations), suggesting the existence of two Ca2+ binding sites 
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within the channel’s pore (Almers & McCleskey, 1984; Hess & Tsien, 1984). In the absence of 
Ca2+ other ions can pass the channel and unitary conductance measurements gave the 
following sequence Ca2+ < Ba2+ < Li+ < Na+ < K+ < Cs+ (Hess et al., 1986). Four glutamate 
residues, one in each of the four P-loops of the LTCC (the EEEE locus), are important for 
channel selectivity (Tang et al., 1993; Yang et al., 1993). The current view of the selectivity 
filter considers that the EEEE locus is physically flexible (Sather & McCleskey, 2003). Some 
recent results suggest that an EEEE locus is not enough to explain selectivity and 
permeation in LTCC and other high voltage activated Ca2+ channels. A set of non conserved 
(channel specific) charged residues (Divalent Cation Selection or DCS locus) located in the 
upper half of the channel (pointing toward the pore) could form a second Ca2+ binding site 
important in defining a Ca2+ permeability profile. It was proposed that the number of 
charged residues in the DCS locus is critical for Ca2+ binding. In the cardiac LTCC the DCS 
locus contains three negative charges (DSED) that seem to be important for the high Ba2+ 
conductance (Cens et al., 2007). 
3.2 Activation, inactivation and reactivation of LTCC 
In a ventricular cardiomyocyte at rest (resting potential ~ -80 mV) there is a transmembrane 
Ca2+ concentration gradient (~ 2 mM outside, ~ 100 nM inside) that generates a huge driving 
force (electrochemical gradient) for Ca2+ that tends to move it into the cell. Activation of 
LTCC allows Ca2+ to enter the cardiomyocyte during the AP and constitutes the major Ca2+ 
entry pathway. With a threshold at  -40 mV (or slightly positive to), activation of ICaL is fast 
with a time constant of 2-3 ms and time-to peak inward current ranging around 4-5 ms or 
less at the membrane potentials at which maximal inward current occurs (0 to +10 mV), and 
even faster at higher depolarizations (McDonald et al., 1994; Bers, 2001). Similar to Na+ 
channels, LTCC inactivate but with a much slower inactivation time course. With Ca2+ as 
charge carrier, ICaL inactivation is usually a biexponential process with an “U-shaped” 
voltage-dependence. Minimal values for time constants of 4 to 10 ms (τfast) and 40 to 60 ms 
(τslow) occur at around 0 and +10 mV depending on cardiomyocyte type (McDonald et al., 
1994; Bers, 2001). Deactivation of peak ICaL after a short depolarizing pulse and 
repolarization to a negative holding potential is fast with a time constant ranging between 
0.2 and 0.5 ms (Josephson et al., 1984; Cohen et al., 1992). However, it can be slower in rat 
cardiomyocytes (~1 ms) (Richard et al., 1993). 
3.2.1 Current-to-Voltage relationship 
Current-to-voltage relationship for ICaL is bell-shaped with a threshold around -40 or -30 mV 
and a peak inward current at 0 (or +10 mV); it is almost linear at positive potentials and 
reverses around +60 to +70 mV at normal Ca2+ concentrations. At potentials beyond its 
reversal, ICaL exhibits some inward going rectification (McDonald et al., 1994; Bers, 2001). 
Whole cell ICaL can be roughly described by a Hodgkin-Huxley formalism considering that 
ICaL = GCaL⋅d∞ f∞ (Vm − VCa) 
where GCaL is the maximal Ca2+ conductance, d∞ is the activation gate variable, f∞ the 
inactivation gate variable, Vm is the membrane potential and VCa is the Ca2+ reversal 
potential (Luo & Rudy, 1994). Since ICaL inactivation is both voltage- and Ca2+-dependent 
(see below), the formalism can be more complex and could include a variable related to the 
Ca2+-dependent inactivation (CDI) process (Hirano & Hiraoka, 2003; Findlay et al., 2008). 
However, since the Hodgkin-Huxley formalism does not represent kinetic states of the ion 
 
Cardiac Arrhythmias – New Considerations 
 
122 
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The typical structure of LTCC in ventricular cardiomyocytes is a macromolecular 
multimeric complex consisting of a ~240 kDa pore-forming unit α1C (encoded by the 
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seems to be involved in targeting (or stabilization) of the α1C to the sarcolemma (Lacinová & 
Hoffmann, 2001; Lacinova & Hofmann, 2005; Brette et al., 2006; Benitah et al., 2010) and 
could confer more native LTCC properties. The δ subunit is composed of a single 
transmembrane segment with a very short intracellular C-term and links by disulphide 
bonds the α2 subunit that is entirely extracellular (Davies et al., 2007). The α2 subunit 
contains a Von Willebrand factor A domain (VWA) that has a metal-ion-dependent 
adhesion site that seems to be key in trafficking the α1C subunit to the membrane (Canti et 
al., 2005). 
3. Biophysics of the cardiac L-type Ca2+ channel 
3.1 Selectivity and permeation 
The cardiac LTCC is a multi-ion pore in which a Ca2+ ion bound to a high affinity site can be 
repelled by a second Ca2+ ion entering the pore thus allowing selectivity with high ionic flux 
(Hess & Tsien, 1984). The LTCC pore exhibits two different affinities for Ca2+: a KD ~ 1 μM 
for Ca2+ block of monovalent current through the channel and a KD ~ 10-14 mM for 
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within the channel’s pore (Almers & McCleskey, 1984; Hess & Tsien, 1984). In the absence of 
Ca2+ other ions can pass the channel and unitary conductance measurements gave the 
following sequence Ca2+ < Ba2+ < Li+ < Na+ < K+ < Cs+ (Hess et al., 1986). Four glutamate 
residues, one in each of the four P-loops of the LTCC (the EEEE locus), are important for 
channel selectivity (Tang et al., 1993; Yang et al., 1993). The current view of the selectivity 
filter considers that the EEEE locus is physically flexible (Sather & McCleskey, 2003). Some 
recent results suggest that an EEEE locus is not enough to explain selectivity and 
permeation in LTCC and other high voltage activated Ca2+ channels. A set of non conserved 
(channel specific) charged residues (Divalent Cation Selection or DCS locus) located in the 
upper half of the channel (pointing toward the pore) could form a second Ca2+ binding site 
important in defining a Ca2+ permeability profile. It was proposed that the number of 
charged residues in the DCS locus is critical for Ca2+ binding. In the cardiac LTCC the DCS 
locus contains three negative charges (DSED) that seem to be important for the high Ba2+ 
conductance (Cens et al., 2007). 
3.2 Activation, inactivation and reactivation of LTCC 
In a ventricular cardiomyocyte at rest (resting potential ~ -80 mV) there is a transmembrane 
Ca2+ concentration gradient (~ 2 mM outside, ~ 100 nM inside) that generates a huge driving 
force (electrochemical gradient) for Ca2+ that tends to move it into the cell. Activation of 
LTCC allows Ca2+ to enter the cardiomyocyte during the AP and constitutes the major Ca2+ 
entry pathway. With a threshold at  -40 mV (or slightly positive to), activation of ICaL is fast 
with a time constant of 2-3 ms and time-to peak inward current ranging around 4-5 ms or 
less at the membrane potentials at which maximal inward current occurs (0 to +10 mV), and 
even faster at higher depolarizations (McDonald et al., 1994; Bers, 2001). Similar to Na+ 
channels, LTCC inactivate but with a much slower inactivation time course. With Ca2+ as 
charge carrier, ICaL inactivation is usually a biexponential process with an “U-shaped” 
voltage-dependence. Minimal values for time constants of 4 to 10 ms (τfast) and 40 to 60 ms 
(τslow) occur at around 0 and +10 mV depending on cardiomyocyte type (McDonald et al., 
1994; Bers, 2001). Deactivation of peak ICaL after a short depolarizing pulse and 
repolarization to a negative holding potential is fast with a time constant ranging between 
0.2 and 0.5 ms (Josephson et al., 1984; Cohen et al., 1992). However, it can be slower in rat 
cardiomyocytes (~1 ms) (Richard et al., 1993). 
3.2.1 Current-to-Voltage relationship 
Current-to-voltage relationship for ICaL is bell-shaped with a threshold around -40 or -30 mV 
and a peak inward current at 0 (or +10 mV); it is almost linear at positive potentials and 
reverses around +60 to +70 mV at normal Ca2+ concentrations. At potentials beyond its 
reversal, ICaL exhibits some inward going rectification (McDonald et al., 1994; Bers, 2001). 
Whole cell ICaL can be roughly described by a Hodgkin-Huxley formalism considering that 
ICaL = GCaL⋅d∞ f∞ (Vm − VCa) 
where GCaL is the maximal Ca2+ conductance, d∞ is the activation gate variable, f∞ the 
inactivation gate variable, Vm is the membrane potential and VCa is the Ca2+ reversal 
potential (Luo & Rudy, 1994). Since ICaL inactivation is both voltage- and Ca2+-dependent 
(see below), the formalism can be more complex and could include a variable related to the 
Ca2+-dependent inactivation (CDI) process (Hirano & Hiraoka, 2003; Findlay et al., 2008). 
However, since the Hodgkin-Huxley formalism does not represent kinetic states of the ion 
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channel, single channel-based Markov models could be more useful to fully describe 
coupling between kinetic gating transitions and molecular interactions in LTCC (Faber et al., 
2007). At the single channel level, current-to-voltage relationship for LTCC is essentially 
ohmic over the whole potential range with some inward rectification near the reversal 
potential (McDonald et al., 1994). Since the single channel current iCaL can be described as 
iCaL = γCa (Vm − VCa) 
where γCa is the unitary conductance, the relationship between whole cell ICaL and iCaL is 
ICaL = NPo iCaL = NPo γCa (Vm − VCa) 
where N is the total number of functional channels and Po the probability that a channel is 
open. 
Unitary conductance of LTCC is 3-5 pS when Ca2+ is the charge carrier and 15 - 25 pS with 
Ba2+ as charge carrier (McDonald et al., 1994; Bers, 2001; Guia et al., 2001). However, 
subconductance levels of 50% to 70% of the major conductance have been also demonstrated 
(McDonald et al., 1994). On depolarization LTCC activity can vary between different modes: 
gating mode 0 (or “null mode”) in which the channel is not available to open; gating mode 1 
(or “normal”) consisting of short bursts of brief openings and closings and gating mode 2 
(with high Po) in which the channel show long openings interrupted by short closings. This 
gating mode 2 is induced by phosphorylation, “Ca2+ channel agonists” (such as BAY K 8644) 
or strong depolarizations (Pietrobon & Hess, 1990; McDonald et al., 1994). 
3.2.2 Voltage-dependence of activation and inactivation 
Steady-state activation of ICaL (d∞) has a sigmoidal relationship with the membrane potential 
with a half-activation potential around -15 mV. The relationship for the inactivation variable 
(f∞; availability) is more complex since for potentials from -80 to 0 mV it is sigmoidal with a 
half-inactivation potential around -35 mV; however an “overshoot” can often be seen at 
potentials negative to -50 mV in cells clamped at negative holding potentials (> -80 mV). 
Other singularities of the availability curve of ICaL are that f∞ rarely attains a zero value but a 
minimum between 0 and +10 mV and that the curve bends up at potentials positive to +10 
mV, a phenomenon that is related to the CDI of ICaL (Mentrard et al., 1984). These 
characteristics d∞ and f∞ are consistently seen in cardiomyocytes from different species 
including humans (McDonald et al., 1994; Bers, 2001; Treinys & Jurevicius, 2008; Benitah et 
al., 2010). 
3.2.3 Voltage- and Ca2+-dependent inactivation of LTCC 
Time-dependent inactivation of ICaL during depolarization is both voltage- and Ca2+-
dependent (Kass & Sanguinetti, 1984; Mentrard et al., 1984; Lee et al., 1985; Hadley & Hume, 
1987). A very slow inactivation has also been described in the heart including human 
ventricular myocytes (Schouten & Morad, 1989; Benitah et al., 1992). CDI can be considered 
as the result of a two-component process, one due to Ca2+ ions passing through the channel 
and another due to Ca2+ release from the SR in the vicinity of the LTCC (Imredy & Yue, 
1992; Richard et al., 2006; Faber et al., 2007). CDI can be easily shown up by using Ba2+ 
instead of Ca2+ as charge carrier which markedly prolonged LTCC inactivation time course. 
An increase in current amplitude is also seen since the LTCC has less affinity for Ba2+ than 
for Ca2+ (Hess et al., 1986). It is generally believed that under this condition, LTCC 
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inactivation is essentially controlled by a voltage-dependent inactivation mechanism (VDI). 
However, this paradigm has been called into question since it has been well demonstrated 
that Ba2+ can induce ion (or current) -dependent inactivation (Markwardt & Nilius, 1988; 
Ferreira et al., 1997; Ferreira et al., 2003) and thus the “apparent VDI” with Ba2+ as charge 
carrier also shows fast and slow components. Evidences exist that VDI can also have fast 
and slow components (Hering et al., 2000; Ferreira et al., 2003; Findlay, 2004). The situation 
could be even more complicated since, at least for N-type Ca2+ channels, the permeant ion 
could interact in a complex way with the voltage sensor (Shirokov, 1999). 
The relative contribution of CDI to total inactivation of ICaL is still under dispute. It is 
commonly accepted that the fast inactivation phase of ICaL represents the CDI component 
(Findlay, 2004). However, it has been shown that the fast inactivation time constant of ICaL of 
rat ventricular cardiomyocytes was “unexpectedly” slowed down after ICaL was increased by 
β-adrenergic stimulation, as well as after manipulations not involving CDI (Alvarez et al., 
2004; Haase et al., 2005; Alvarez et al., 2010). This makes difficult to ascertain which one of CDI 
or fast VDI predominates in the fast inactivation phase of ICaL with Ca2+ as charge carrier. 
Nevertheless, it has been suggested that VDI could be more important under control 
conditions and that after β-adrenergic stimulation, CDI becomes the main inactivation 
mechanism due to a slow down of VDI (Findlay, 2004). It should be noted that CDI could be 
visualized as a “Ca2+-dependent brake for a pre-existing voltage-dependent inactivation” 
based on the conserved regulation of both VDI and CDI by the auxiliary β-subunit, and that 
the I-II intracellular loop, essential for VDI, could also play a role in CDI (Cens et al., 1999; 
Cens et al., 2006). The precise mechanisms underlying CDI are not completely well defined. 
However, a general picture emerged in which in the presence of Ca2+ (entering through the 
LTCC or released from the SR) a calmodulin (CaM) molecule binds to the C-terminal tail of the 
α1C subunit to promote CDI. CaM binds to two segments (LA and IQ), in a Ca2+-dependent 
manner (Xiong et al., 2005) and it has been shown that the amino acid sequence of the IQ 
region in the α1C subunit is critical for CaM binding and CDI (Ohrtman et al., 2008). Several 
other structures seem to be involved in CDI such as an EF-hand locus in the C-terminus of α1C 
subunit (Peterson et al., 2000), the Cavβ subunit (Zhang et al., 2005), the N-terminus of the α1C 
subunit, the I-II intracellular linker (Pitt et al., 2001; Erickson et al., 2003; Kobrinsky et al., 2005) 
and the pore region involved in slow inactivation (Shi & Soldatov, 2002). 
3.2.4 Reactivation 
Reactivation (removal of inactivation) of LTCC has been described as a mono or 
biexponential process, however, the time for half reactivation (t50) can be considered as a 
reliable parameter and has been reported to be in the range of 70-100 ms in cardiomyocytes 
clamped at negative holding potentials (-80 mV or more negative) and an overshoot at short 
coupling intervals is often seen. At more depolarized holding potentials, t50 can be notably 
increased and the overshoot disappears (Argibay et al., 1988; Tseng, 1988; Schouten & 
Morad, 1989; Alvarez & Vassort, 1992). A voltage-dependent transition into a closed 
available state and/or reopenings from the inactivated state could explain in part the 
reactivation of LTCC (Jones, 1991; Slesinger & Lansman, 1991). However, reactivation of 
LTCC is a more complex phenomenon since it is Ca2+-dependent (Argibay et al., 1988; 
Tseng, 1988) and thus related to CDI. The overshoot in ICaL reactivation could be of 
physiological relevance since it is, at least in part, related to the well-known increase in 
premature (extrasystolic) APD in well polarized cardiomyocytes but not in partially 
depolarized ones (Hiraoka & Sano, 1976). 
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channel, single channel-based Markov models could be more useful to fully describe 
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half-inactivation potential around -35 mV; however an “overshoot” can often be seen at 
potentials negative to -50 mV in cells clamped at negative holding potentials (> -80 mV). 
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inactivation is essentially controlled by a voltage-dependent inactivation mechanism (VDI). 
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carrier also shows fast and slow components. Evidences exist that VDI can also have fast 
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subunit, the I-II intracellular linker (Pitt et al., 2001; Erickson et al., 2003; Kobrinsky et al., 2005) 
and the pore region involved in slow inactivation (Shi & Soldatov, 2002). 
3.2.4 Reactivation 
Reactivation (removal of inactivation) of LTCC has been described as a mono or 
biexponential process, however, the time for half reactivation (t50) can be considered as a 
reliable parameter and has been reported to be in the range of 70-100 ms in cardiomyocytes 
clamped at negative holding potentials (-80 mV or more negative) and an overshoot at short 
coupling intervals is often seen. At more depolarized holding potentials, t50 can be notably 
increased and the overshoot disappears (Argibay et al., 1988; Tseng, 1988; Schouten & 
Morad, 1989; Alvarez & Vassort, 1992). A voltage-dependent transition into a closed 
available state and/or reopenings from the inactivated state could explain in part the 
reactivation of LTCC (Jones, 1991; Slesinger & Lansman, 1991). However, reactivation of 
LTCC is a more complex phenomenon since it is Ca2+-dependent (Argibay et al., 1988; 
Tseng, 1988) and thus related to CDI. The overshoot in ICaL reactivation could be of 
physiological relevance since it is, at least in part, related to the well-known increase in 
premature (extrasystolic) APD in well polarized cardiomyocytes but not in partially 
depolarized ones (Hiraoka & Sano, 1976). 
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3.3 Facilitation of LTCC 
The overshoots seen in the availability and reactivation curves of ICaL are both a 
manifestation of a “facilitation” phenomenon of LTCC. In both cases an increase in τfast is 
commonly observed and both seem to be related to the pacing-dependent (staircase) 
facilitation of ICaL (Lee, 1987). However, the “overshoots” and the staircase phenomena 
could be dependent on the basal ICaL density disappearing at higher current densities 
(Argibay et al., 1988; Alvarez & Vassort, 1992; Piot et al., 1996). Facilitation of LTCC has been 
more extensively studied by stimulating cardiomyocytes at high rates after a rest period or 
by applying prepulses of moderate and high amplitude (Richard et al., 2006). At negative 
holding potentials (> -80 mV) the frequency-dependent changes in ICaL amplitude upon 
stimulation can be variable: significant (Lee, 1987), modest or absent (Piot et al., 1996; 
Delgado et al., 1999) and even modestly decrease (Argibay et al., 1988; Alvarez & Vassort, 
1992; Alvarez et al., 2004). However, an increase in τfast has been consistently reported in 
these conditions, resulting, independently of what happens with ICaL amplitude, in a 
significant increase in Ca2+ influx (Delgado et al., 1999). The mechanism of this “Ca2+-
dependent facilitation” (CDF) or potentiation seems to be related to a negative feedback 
involving less CDI at frequencies at which Ca2+ load and release from the SR are decreased 
(Delgado et al., 1999). This phenomenon has often been related to phosphorylation by cyclic 
AMP-dependent protein kinase (Tiaho et al., 1994; Piot et al., 1996) although there are also 
reports that β-adrenergic stimulation significantly diminished ICaL facilitation (Zygmunt & 
Maylie, 1990; Delgado et al., 1999; Alvarez et al., 2004). Disruption of the interaction between 
α1C and β2A subunits also abolished CDF (Alvarez et al., 2004). In this sense, this 
phenomenon is still far to be completely understood. CDF also involves CaM and the 
Ca2+/CaM kinase II (CaMKII). Similar to CDI, the CDF requires the binding of CaM to the 
IQ motif located in the α1C C-terminus but to a structural frame different to that involved in 
CDI (Zuhlke et al., 1999). Activation of CaMKII by Ca2+ entry or release from the SR is also 
involved in ICaL facilitation (Anderson et al., 1994; Yuan & Bers, 1994; Anderson, 2004). More 
recently phosphorylation of β2A has been reported to be critical for CaMKII-dependent ICaL 
facilitation (Grueter et al., 2006). 
Similar to frequency-dependent facilitation, prepulse-induced facilitation of ICaL is 
characterized by an increase in τfast (Barrere-Lemaire et al., 2000) and its underlying 
mechanism seems to involve a negative feedback on LTCC related to CDI as discussed 
above (Guo & Duff, 2003) and a positive feedback on LTCC following CaMKII activation by 
membrane potential and Ca2+ entry (Xiao et al., 1994). 
3.4 LTCC “window” current 
Activation and inactivation (availability) curves overlap at membrane potentials between 
the threshold for ICaL at -40 to potentials of 0 or +10 mV thus defining a “window” Ca2+ 
current (d∞.f∞ > 0) in the plateau range of the cardiac AP. The peak window current (which 
is proportional to d∞.f∞) is between -25 and -20 mV and could be as large as 10% of maximal 
ICaL (McDonald et al., 1994). Its existence has been verified in whole cell recordings (Hirano 
et al., 1992; McDonald et al., 1994). Within this window LTCC channels can cycle between 
closed, open and inactivated states but a transition again to the closed state and reopenings 
are possible before inactivating again (Shorofsky & January, 1992). Such reopenings have 
been clearly demonstrated in single channel recordings (Shorofsky & January, 1992; 
McDonald et al., 1994) and constitute the underlying mechanism for the EAD (January et al., 
1988). EADs are more frequently observed at low rates when the APD is increased and 
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during interventions that increase ICaL (e.g. after activation of β-adrenergic receptors). They 
are supposed to underlie the cellular mechanism of “Torsades de Pointes” (TdP) in long QT 
syndromes (Napolitano & Antzelevitch, 2011). Transient K+ outward current (Ito) 
reactivation at low rates could contribute to generation of EADs since it drives the 
membrane (plateau) potential to more negative “take off” potentials and warrants higher 
peak amplitude of EADs (January et al., 1988). β-adrenergic stimulation increases ICaL and 
shifts the window current to more negative potentials due to an increase in channel’s Po at 
more negative potentials (hyperpolarizing shifts in d∞) and a shift of f∞ to more 
hyperpolarized potentials (McDonald et al., 1994) thus favoring the appearance of EADs. It 
is to be noted that, at these membrane potentials, the fast Na+ current (INa) and Ito are 
inactivated, the inward rectifier current IK1 is decreased and outward rectifier currents are 
just activating. As a result the total membrane resistance is increased (Weidmann, 1951) thus 
making the membrane space constant high enough to guarantee a rather high safety margin 
for the slow response to be conducted for a given ICaL density. 
3.4.1 A note on “EADs” recorded in multicellular cardiac preparations 
It is possible that in some cases EADs recorded in multicellular cardiac preparations represent 
a reentry from a distant site rather than a true EAD arising from the recording site. In any case, 
the mechanism underlying this activity is the same as the previously described for EAD. This 
reentry mechanism, at these short coupling intervals (during the AP plateau) is due to “slow 
response” APs that can be conducted with a large enough safety margin and are due to the 
activation of LTCC (Cranefield, 1975). The biophysical properties of LTCC described above, 
can fully account for the conducted slow response APs in partially depolarized cells. Under 
several pathological conditions these slow responses can be conducted and are at the origin of 
reentry, for example in depressed fibres in ischemia (Cranefield, 1975) since the slow response 
APs are rather resistant to hypoxia (Alvarez et al., 1981), in TdP associated to long QT 
syndromes (Antzelevitch & Burashnikov, 2001) (see below) or during the verapamil-sensitive 
reentrant intranodal tachycardia involving the AV node (Wellens et al., 1977). 
3.4.2 A role for a second window current? 
The characteristics of the activation and inactivation curves of ICaL could predict the 
existence of a “second window” current at potentials positive to +10 mV since at these 
values, the product d∞.f∞ is > 0. Whether the overlap between d∞ (=1) and the increasing f∞ at 
positive prepulse potentials could represent a true “secondary” window current or not is 
debatable, but it is clear that after these prepulse potentials LTCCs recover from inactivation 
and reopen in a sort of “facilitation” (Pietrobon & Hess, 1990). Nonetheless, the 
physiological (or physiopathological) relevance of this window current is uncertain since at 
these membrane potentials the fast INa is the main depolarizing current and physiologically 
membrane potentials over +40 mV never exist. This property, however, has been important 
for the characterization of the CDI of LTCC in cardiac cells (Mentrard et al., 1984). 
4. Role of ICaL in the cardiac arrythmogenesis associated to acquired 
pathophysiological states 
4.1 Myocardial ischemia and ventricular fibrillation 
Ventricular fibrillation (VF) and myocardial ischemia are inseparable. In general terms, 
myocardial ischemia is defined as disequilibrium between myocardial oxygen demand 
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3.3 Facilitation of LTCC 
The overshoots seen in the availability and reactivation curves of ICaL are both a 
manifestation of a “facilitation” phenomenon of LTCC. In both cases an increase in τfast is 
commonly observed and both seem to be related to the pacing-dependent (staircase) 
facilitation of ICaL (Lee, 1987). However, the “overshoots” and the staircase phenomena 
could be dependent on the basal ICaL density disappearing at higher current densities 
(Argibay et al., 1988; Alvarez & Vassort, 1992; Piot et al., 1996). Facilitation of LTCC has been 
more extensively studied by stimulating cardiomyocytes at high rates after a rest period or 
by applying prepulses of moderate and high amplitude (Richard et al., 2006). At negative 
holding potentials (> -80 mV) the frequency-dependent changes in ICaL amplitude upon 
stimulation can be variable: significant (Lee, 1987), modest or absent (Piot et al., 1996; 
Delgado et al., 1999) and even modestly decrease (Argibay et al., 1988; Alvarez & Vassort, 
1992; Alvarez et al., 2004). However, an increase in τfast has been consistently reported in 
these conditions, resulting, independently of what happens with ICaL amplitude, in a 
significant increase in Ca2+ influx (Delgado et al., 1999). The mechanism of this “Ca2+-
dependent facilitation” (CDF) or potentiation seems to be related to a negative feedback 
involving less CDI at frequencies at which Ca2+ load and release from the SR are decreased 
(Delgado et al., 1999). This phenomenon has often been related to phosphorylation by cyclic 
AMP-dependent protein kinase (Tiaho et al., 1994; Piot et al., 1996) although there are also 
reports that β-adrenergic stimulation significantly diminished ICaL facilitation (Zygmunt & 
Maylie, 1990; Delgado et al., 1999; Alvarez et al., 2004). Disruption of the interaction between 
α1C and β2A subunits also abolished CDF (Alvarez et al., 2004). In this sense, this 
phenomenon is still far to be completely understood. CDF also involves CaM and the 
Ca2+/CaM kinase II (CaMKII). Similar to CDI, the CDF requires the binding of CaM to the 
IQ motif located in the α1C C-terminus but to a structural frame different to that involved in 
CDI (Zuhlke et al., 1999). Activation of CaMKII by Ca2+ entry or release from the SR is also 
involved in ICaL facilitation (Anderson et al., 1994; Yuan & Bers, 1994; Anderson, 2004). More 
recently phosphorylation of β2A has been reported to be critical for CaMKII-dependent ICaL 
facilitation (Grueter et al., 2006). 
Similar to frequency-dependent facilitation, prepulse-induced facilitation of ICaL is 
characterized by an increase in τfast (Barrere-Lemaire et al., 2000) and its underlying 
mechanism seems to involve a negative feedback on LTCC related to CDI as discussed 
above (Guo & Duff, 2003) and a positive feedback on LTCC following CaMKII activation by 
membrane potential and Ca2+ entry (Xiao et al., 1994). 
3.4 LTCC “window” current 
Activation and inactivation (availability) curves overlap at membrane potentials between 
the threshold for ICaL at -40 to potentials of 0 or +10 mV thus defining a “window” Ca2+ 
current (d∞.f∞ > 0) in the plateau range of the cardiac AP. The peak window current (which 
is proportional to d∞.f∞) is between -25 and -20 mV and could be as large as 10% of maximal 
ICaL (McDonald et al., 1994). Its existence has been verified in whole cell recordings (Hirano 
et al., 1992; McDonald et al., 1994). Within this window LTCC channels can cycle between 
closed, open and inactivated states but a transition again to the closed state and reopenings 
are possible before inactivating again (Shorofsky & January, 1992). Such reopenings have 
been clearly demonstrated in single channel recordings (Shorofsky & January, 1992; 
McDonald et al., 1994) and constitute the underlying mechanism for the EAD (January et al., 
1988). EADs are more frequently observed at low rates when the APD is increased and 
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during interventions that increase ICaL (e.g. after activation of β-adrenergic receptors). They 
are supposed to underlie the cellular mechanism of “Torsades de Pointes” (TdP) in long QT 
syndromes (Napolitano & Antzelevitch, 2011). Transient K+ outward current (Ito) 
reactivation at low rates could contribute to generation of EADs since it drives the 
membrane (plateau) potential to more negative “take off” potentials and warrants higher 
peak amplitude of EADs (January et al., 1988). β-adrenergic stimulation increases ICaL and 
shifts the window current to more negative potentials due to an increase in channel’s Po at 
more negative potentials (hyperpolarizing shifts in d∞) and a shift of f∞ to more 
hyperpolarized potentials (McDonald et al., 1994) thus favoring the appearance of EADs. It 
is to be noted that, at these membrane potentials, the fast Na+ current (INa) and Ito are 
inactivated, the inward rectifier current IK1 is decreased and outward rectifier currents are 
just activating. As a result the total membrane resistance is increased (Weidmann, 1951) thus 
making the membrane space constant high enough to guarantee a rather high safety margin 
for the slow response to be conducted for a given ICaL density. 
3.4.1 A note on “EADs” recorded in multicellular cardiac preparations 
It is possible that in some cases EADs recorded in multicellular cardiac preparations represent 
a reentry from a distant site rather than a true EAD arising from the recording site. In any case, 
the mechanism underlying this activity is the same as the previously described for EAD. This 
reentry mechanism, at these short coupling intervals (during the AP plateau) is due to “slow 
response” APs that can be conducted with a large enough safety margin and are due to the 
activation of LTCC (Cranefield, 1975). The biophysical properties of LTCC described above, 
can fully account for the conducted slow response APs in partially depolarized cells. Under 
several pathological conditions these slow responses can be conducted and are at the origin of 
reentry, for example in depressed fibres in ischemia (Cranefield, 1975) since the slow response 
APs are rather resistant to hypoxia (Alvarez et al., 1981), in TdP associated to long QT 
syndromes (Antzelevitch & Burashnikov, 2001) (see below) or during the verapamil-sensitive 
reentrant intranodal tachycardia involving the AV node (Wellens et al., 1977). 
3.4.2 A role for a second window current? 
The characteristics of the activation and inactivation curves of ICaL could predict the 
existence of a “second window” current at potentials positive to +10 mV since at these 
values, the product d∞.f∞ is > 0. Whether the overlap between d∞ (=1) and the increasing f∞ at 
positive prepulse potentials could represent a true “secondary” window current or not is 
debatable, but it is clear that after these prepulse potentials LTCCs recover from inactivation 
and reopen in a sort of “facilitation” (Pietrobon & Hess, 1990). Nonetheless, the 
physiological (or physiopathological) relevance of this window current is uncertain since at 
these membrane potentials the fast INa is the main depolarizing current and physiologically 
membrane potentials over +40 mV never exist. This property, however, has been important 
for the characterization of the CDI of LTCC in cardiac cells (Mentrard et al., 1984). 
4. Role of ICaL in the cardiac arrythmogenesis associated to acquired 
pathophysiological states 
4.1 Myocardial ischemia and ventricular fibrillation 
Ventricular fibrillation (VF) and myocardial ischemia are inseparable. In general terms, 
myocardial ischemia is defined as disequilibrium between myocardial oxygen demand 
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versus supply, which episodes can trigger serious and fatal arrhythmic events. Thus, in the 
clinical setting around 80% of all sudden cardiac deaths (SCD) are due to myocardial 
ischemia. The most common sequence of events leading SCD appears to be the degeneration 
of ventricular tachycardia (VT) into ventricular fibrillation (VF) (Rubart & Zipes, 2005). VF is 
thought as a disorganized cardiac activation in which electrical waves propagate through 
the ventricles haphazardly and unpredictably (Jalife, 2000). The last consequence of this 
disorganized process is strong alteration in the adequate contractions of the ventricles that 
fail to eject blood effectively as a consequence of a strong electrical dysfunction, which is 
detected in the heart even during the first minutes after acute myocardial ischemia (usually 
lasting for 30 min) where abundant arrhythmogenesis is detected. During acute ischemia, in 
the border zone between the ischemic and normal tissue the excitability is increased 
resulting in spontaneous activation of Purkinje fibers initiating VT. During reperfusion the 
rapid inhomogeneous improvement in tissue excitability contributes to arrhythmogenesis 
again (Opthof et al., 1993; Luqman et al., 2007). 
At intracellular level, an important ionic imbalance occurs during myocardial ischemia. This 
electrophysiological imbalance is characterized by the opening of ATP-sensitive potassium 
channels (IKATP) and causes acidosis and hypoxia of myocardial cells together with an 
aberrant intracellular Ca2+ handling that is determinant to trigger arrhythmias. Because ICaL 
constitutes the first trigger for the EC coupling necessary for each beat in the heart, a lot of 
attention has been focused in the involvement of ICaL in the conversion of VT to VF. With 
myocardial ischemia, the abrupt cessation of blood flow provokes a new distribution of a 
number of ions. The abnormal increase in the intracellular Na+ concentration ([Na+]i) 
consequently results in an increase in the intracellular Ca2+ concentration ([Ca2+]i) due to an 
increase in the Ca2+ influx via the Na+/Ca2+ exchanger (NCX) working in the reverse 
manner and also via depolarization-activated LTCCs. These events induce cellular Ca2+ 
overload (as a consequence of cellular Na+ overload) favoring the presence of spontaneous 
(non-voltage dependent) diastolic Ca2+ release as Ca2+ waves that induce depolarization of 
myocyte membrane triggering DAD and finally DAD-related arrhythmias (Schlotthauer & 
Bers, 2000). The presence of DADs also can trigger abnormal electrical activity with the 
wavebreak causing VF (Koretsune & Marban, 1989; Lakatta & Guarnieri, 1993). 
It is important to point out that cardiac ischemia is also characterized by a significant 
increase in circulating and tissue cathecholamine levels, which increase the probability of 
VT and SCD (Dorian, 2005). In the presence of β-adrenergic receptor (β-AR) stimulation and 
hypoxic conditions, a significant increase in Ca2+ influx through ICaL is able to prolong APD 
and also triggers EADs (Gaur et al., 2009), which in ventricular myocytes appear not to be 
due to spontaneous regional increase in [Ca2+]i or propagating Ca2+ waves. These results can 
be explained by the increase in the sensitivity of LTCC due to changes in gating properties 
by the modification of the phosphorylated state or by the modification of thiol groups of the 
channel, since the presence of dithiothreitol or catalase mimics the effect of acute hypoxia on 
ICaL (Hool, 2000; Hool & Arthur, 2002; Tanskanen et al., 2005). Alterations in ICaL have been 
also detected in simulated experimental ischemic-like conditions in single pacemaker cells 
isolated from the rabbit sinoatrial node (SAN). In contrast to ventricular myocytes, ICaL is 
declined under metabolic inhibition or ischemic conditions in SAN cells (Vinogradova et al., 
2000; Ju & Allen, 2003). However, it has been reported that in vitro ischemic conditions 
enhanced ICaL significantly at potentials between -30 and +30 mV suggesting that the greater 
ICaL could account for a 6 mV increase in the AP overshoot (Du & Nathan, 2007a). This is 
related to an increase in the GCaL and a positive shift of the f∞ curve and reduction of 
inactivation, likely due to a H+- increased of ICaL (Du & Nathan, 2007b). 
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Torsades de Pointes (TdP) is a polymorphic type of VT also associated to acquired QT 
prolongation and maintained bradycardia that potentially leads to SCD (Jackman et al., 
1988). Several studies carried out in rabbits and dogs prone to spontaneous TdP as a 
consequence of the chronic atrioventricular block (AVB) showed important alterations in the 
control of Ca2+ (Sipido et al., 2000; Antoons et al., 2007; Qi et al., 2009). For example, AVB in 
dogs resulted in an increase in the SR Ca2+ content which improved Ca2+ release from SR as 
Ca2+ transients (Sipido et al., 2000). Although, the overall density-voltage relationship of ICaL 
is unchanged, a depolarizing shift in the f∞ curve resulted in an increased window current 
(Antoons et al., 2007). The CaM activation of CaMKII has been proposed to underlie this 
effect, as well the induced EADs (Qi et al., 2009).  
4.2 Atrial fibrillation 
Among supraventricular tachyarrhythmias, atrial fibrillation (AF) is the most common. Its 
prevalence is considerably increased with age, and thus AF is now classified as an epidemic 
(Lip et al., 2007). The cellular and molecular bases of AF electrophysiology and the 
underlying mechanisms have been extensively investigated (Hatem et al., 2010). The 
definition of the latest report of the American College of Cardiology/American Heart 
Association/European Society of Cardiology (ACC/AHA/ESC) guidelines for AF is limited 
to a description of the pattern of irregular atrial waveforms on the electrocardiogram (ECG) 
as a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with 
a replacement of consistent P waves by rapid oscillations or fibrillatory waves (Fuster et al., 
2011). At the cellular level, AF is characterized by strong alterations in the cardiac 
electrophysiology. The repolarizing currents such as Ito is almost suppressed and the 
voltage-gated K+ current (IKur) is decreased by around 50% (Le Grand et al., 1994; Van 
Wagoner et al., 1997). While upon the onset of AF, an increase in the intracellular Ca2+ load 
is observed, in persistent AF the intracellular Ca2+ load is restored to normal levels. There is 
a consensus in the drastic reduction in ICaL (around 70%) that is observed during 
experimental and clinical AF. Because this current is the main depolarizing current that 
activates during plateau phase of the AP, its reduction contributes greatly to the shortening 
of the AP, reducing atrial effective refractory period with a loss of physiological rate 
adaptation and finally favouring the formation of re-entrant circuits during AF (Le Grand et 
al., 1994; Van Wagoner et al., 1997; Yue et al., 1997). Several authors have postulated a 
significant decrease in the number of Ca2+ channels subunits Cav1.2 associated with AF 
(Brundel et al., 2001; Shinagawa et al., 2003). In fact, experiments carried out in cultured 
adult canine atrial myocytes subjected to in vitro model of atrial tachycardia by continuous 
tachypacing have demonstrated that during the first hours of pacing exist a Ca2+ overload 
involved in the activation of the phosphatase (PP) calcineurin (Cn) that allows the 
translocation of the transcriptor factor NFAT into the nucleus. This rapid Ca2+ overload 
induces the activation of the Ca2+-dependent CaM-Cn-NFAT system to cause the 
transcriptional downregulation of α1C subunit mRNA expression and also in the levels of 
Cav1.2 protein expression that is observed from 8 hours of pacing (Qi et al., 2008). These 
results are in conflict with others demonstrating no changes in mRNA and protein levels of 
the pore-forming α1C and the regulatory β2A subunits in atrial myocardium from patients 
with chronic AF (Schotten et al., 2003). Nevertheless, the reduction of ICaL can also be the 
result of changes in gating properties of the channel (Bodi et al., 2005), due to alterations in 
the phosphorylation state of the LTCC. Indeed, it has been observed that the maximum of 
the current-voltage relationship of ICaL is rightward shifted to more positive potentials in AF, 
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versus supply, which episodes can trigger serious and fatal arrhythmic events. Thus, in the 
clinical setting around 80% of all sudden cardiac deaths (SCD) are due to myocardial 
ischemia. The most common sequence of events leading SCD appears to be the degeneration 
of ventricular tachycardia (VT) into ventricular fibrillation (VF) (Rubart & Zipes, 2005). VF is 
thought as a disorganized cardiac activation in which electrical waves propagate through 
the ventricles haphazardly and unpredictably (Jalife, 2000). The last consequence of this 
disorganized process is strong alteration in the adequate contractions of the ventricles that 
fail to eject blood effectively as a consequence of a strong electrical dysfunction, which is 
detected in the heart even during the first minutes after acute myocardial ischemia (usually 
lasting for 30 min) where abundant arrhythmogenesis is detected. During acute ischemia, in 
the border zone between the ischemic and normal tissue the excitability is increased 
resulting in spontaneous activation of Purkinje fibers initiating VT. During reperfusion the 
rapid inhomogeneous improvement in tissue excitability contributes to arrhythmogenesis 
again (Opthof et al., 1993; Luqman et al., 2007). 
At intracellular level, an important ionic imbalance occurs during myocardial ischemia. This 
electrophysiological imbalance is characterized by the opening of ATP-sensitive potassium 
channels (IKATP) and causes acidosis and hypoxia of myocardial cells together with an 
aberrant intracellular Ca2+ handling that is determinant to trigger arrhythmias. Because ICaL 
constitutes the first trigger for the EC coupling necessary for each beat in the heart, a lot of 
attention has been focused in the involvement of ICaL in the conversion of VT to VF. With 
myocardial ischemia, the abrupt cessation of blood flow provokes a new distribution of a 
number of ions. The abnormal increase in the intracellular Na+ concentration ([Na+]i) 
consequently results in an increase in the intracellular Ca2+ concentration ([Ca2+]i) due to an 
increase in the Ca2+ influx via the Na+/Ca2+ exchanger (NCX) working in the reverse 
manner and also via depolarization-activated LTCCs. These events induce cellular Ca2+ 
overload (as a consequence of cellular Na+ overload) favoring the presence of spontaneous 
(non-voltage dependent) diastolic Ca2+ release as Ca2+ waves that induce depolarization of 
myocyte membrane triggering DAD and finally DAD-related arrhythmias (Schlotthauer & 
Bers, 2000). The presence of DADs also can trigger abnormal electrical activity with the 
wavebreak causing VF (Koretsune & Marban, 1989; Lakatta & Guarnieri, 1993). 
It is important to point out that cardiac ischemia is also characterized by a significant 
increase in circulating and tissue cathecholamine levels, which increase the probability of 
VT and SCD (Dorian, 2005). In the presence of β-adrenergic receptor (β-AR) stimulation and 
hypoxic conditions, a significant increase in Ca2+ influx through ICaL is able to prolong APD 
and also triggers EADs (Gaur et al., 2009), which in ventricular myocytes appear not to be 
due to spontaneous regional increase in [Ca2+]i or propagating Ca2+ waves. These results can 
be explained by the increase in the sensitivity of LTCC due to changes in gating properties 
by the modification of the phosphorylated state or by the modification of thiol groups of the 
channel, since the presence of dithiothreitol or catalase mimics the effect of acute hypoxia on 
ICaL (Hool, 2000; Hool & Arthur, 2002; Tanskanen et al., 2005). Alterations in ICaL have been 
also detected in simulated experimental ischemic-like conditions in single pacemaker cells 
isolated from the rabbit sinoatrial node (SAN). In contrast to ventricular myocytes, ICaL is 
declined under metabolic inhibition or ischemic conditions in SAN cells (Vinogradova et al., 
2000; Ju & Allen, 2003). However, it has been reported that in vitro ischemic conditions 
enhanced ICaL significantly at potentials between -30 and +30 mV suggesting that the greater 
ICaL could account for a 6 mV increase in the AP overshoot (Du & Nathan, 2007a). This is 
related to an increase in the GCaL and a positive shift of the f∞ curve and reduction of 
inactivation, likely due to a H+- increased of ICaL (Du & Nathan, 2007b). 
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Torsades de Pointes (TdP) is a polymorphic type of VT also associated to acquired QT 
prolongation and maintained bradycardia that potentially leads to SCD (Jackman et al., 
1988). Several studies carried out in rabbits and dogs prone to spontaneous TdP as a 
consequence of the chronic atrioventricular block (AVB) showed important alterations in the 
control of Ca2+ (Sipido et al., 2000; Antoons et al., 2007; Qi et al., 2009). For example, AVB in 
dogs resulted in an increase in the SR Ca2+ content which improved Ca2+ release from SR as 
Ca2+ transients (Sipido et al., 2000). Although, the overall density-voltage relationship of ICaL 
is unchanged, a depolarizing shift in the f∞ curve resulted in an increased window current 
(Antoons et al., 2007). The CaM activation of CaMKII has been proposed to underlie this 
effect, as well the induced EADs (Qi et al., 2009).  
4.2 Atrial fibrillation 
Among supraventricular tachyarrhythmias, atrial fibrillation (AF) is the most common. Its 
prevalence is considerably increased with age, and thus AF is now classified as an epidemic 
(Lip et al., 2007). The cellular and molecular bases of AF electrophysiology and the 
underlying mechanisms have been extensively investigated (Hatem et al., 2010). The 
definition of the latest report of the American College of Cardiology/American Heart 
Association/European Society of Cardiology (ACC/AHA/ESC) guidelines for AF is limited 
to a description of the pattern of irregular atrial waveforms on the electrocardiogram (ECG) 
as a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with 
a replacement of consistent P waves by rapid oscillations or fibrillatory waves (Fuster et al., 
2011). At the cellular level, AF is characterized by strong alterations in the cardiac 
electrophysiology. The repolarizing currents such as Ito is almost suppressed and the 
voltage-gated K+ current (IKur) is decreased by around 50% (Le Grand et al., 1994; Van 
Wagoner et al., 1997). While upon the onset of AF, an increase in the intracellular Ca2+ load 
is observed, in persistent AF the intracellular Ca2+ load is restored to normal levels. There is 
a consensus in the drastic reduction in ICaL (around 70%) that is observed during 
experimental and clinical AF. Because this current is the main depolarizing current that 
activates during plateau phase of the AP, its reduction contributes greatly to the shortening 
of the AP, reducing atrial effective refractory period with a loss of physiological rate 
adaptation and finally favouring the formation of re-entrant circuits during AF (Le Grand et 
al., 1994; Van Wagoner et al., 1997; Yue et al., 1997). Several authors have postulated a 
significant decrease in the number of Ca2+ channels subunits Cav1.2 associated with AF 
(Brundel et al., 2001; Shinagawa et al., 2003). In fact, experiments carried out in cultured 
adult canine atrial myocytes subjected to in vitro model of atrial tachycardia by continuous 
tachypacing have demonstrated that during the first hours of pacing exist a Ca2+ overload 
involved in the activation of the phosphatase (PP) calcineurin (Cn) that allows the 
translocation of the transcriptor factor NFAT into the nucleus. This rapid Ca2+ overload 
induces the activation of the Ca2+-dependent CaM-Cn-NFAT system to cause the 
transcriptional downregulation of α1C subunit mRNA expression and also in the levels of 
Cav1.2 protein expression that is observed from 8 hours of pacing (Qi et al., 2008). These 
results are in conflict with others demonstrating no changes in mRNA and protein levels of 
the pore-forming α1C and the regulatory β2A subunits in atrial myocardium from patients 
with chronic AF (Schotten et al., 2003). Nevertheless, the reduction of ICaL can also be the 
result of changes in gating properties of the channel (Bodi et al., 2005), due to alterations in 
the phosphorylation state of the LTCC. Indeed, it has been observed that the maximum of 
the current-voltage relationship of ICaL is rightward shifted to more positive potentials in AF, 
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suggesting phosphorylation-dependent changes in the channel regulation more than 
changes in its expression (Christ et al., 2004). In addition, it has been also described a high 
sensitivity of ICaL to β-adrenergic agonists during AF, suggesting that LTCCs are in a 
dephosphorylated and silent state (Boixel et al., 2001; Schotten et al., 2003; Dinanian et al., 
2008; Hatem et al., 2010). Moreover, the activity of CaMKII is increased in AF (Neef et al., 
2010). However, increased CaMKII activity in AF seems to be offset by an increased PP 
activity, because CaMKII inhibitor KN-93 reduce ICaL in control cells, while it did not affect 
ICaL in AF cells (Greiser et al., 2007; Greiser et al., 2011). Moreover, the PP inhibitor, okadaic 
acid, increased ICaL to almost normal levels in human atrial myocytes from AF patients 
(Christ et al., 2004; Greiser et al., 2011). In conclusion, in AF the ratio between protein 
kinase/phosphatase is altered in favor of increased PP activity, suggesting that the basal 
phosphorylation of the Ca2+ channel is reduced which induces lower basal ICaL activity.  
It seems clear that the abnormal atrial electrical remodeling associated to AF contributes to 
perpetuation of the arrhythmia and has profound effects on intracellular Ca2+ handling 
(Greiser et al., 2011). Contractile force of atrial tissue strips from patients with AF is also 
reduced around 75% and exposure to high extracellular Ca2+ concentration is able to restore 
atrial functions (Schotten et al., 2001; Schotten et al., 2004). In a sheep model of persistent 
AF, even with only a slight reduction in ICaL (around 24%), its efficiency to highly reduced 
CICR (Lenaerts et al., 2009). In the presence of Ca2+ chelators, ICaL was unchanged in AF 
conditions while it is increased in control cells. These results are well-matched with a 
possible reduction in the CDI of ICaL. 
4.3 Cardiac hypertrophy and heart failure 
Following a pathological stress, the heart can adapt by developing cardiac hypertrophy, 
which improves contractile force as an adaptative mechanism to meet the new body 
demands. In this case, the cardiac hypertrophy is “compensated”, as in physiologic cardiac 
hypertrophy by exercise or during the pregnancy. When the stimulus is prolonged, cardiac 
hypertrophy can “decompensate” toward heart failure (HF) with compromised pump 
function (Benitah et al., 2010). One of the best documented changes in hypertrophy and HF, 
both in animal models and in humans, is the prolongation of the AP, which is highly 
significant in the production of ventricular arrhythmias. Important abnormalities of 
intracellular Ca2+ handling has been showed in the hypertrophic and failing myocytes: 
reduced SERCA function, enhanced NCX function and enhanced SR Ca2+ leak contributing 
to the reduced SR Ca2+ load (Bers et al., 2003). It is also well known that changes in ICaL in the 
hypertrophic and failing heart can also contribute to the electrical instability. Although the 
different degrees in the severity of pathological stresses as well as the variability among 
different models appear to influence the regulation of ICaL, the amplitude of ICaL is increased 
in hypertrophied and failing myocytes while its density (normalized to cell capacitance, as 
an indirect measure of cell surface) is unchanged (Benitah et al., 2002a; Benitah et al., 2003; 
Song et al., 2005; Loyer et al., 2008). In an early analysis of a pressure-overloaded cardiac 
hypertrophy model, ICaL was augmented in non-hypertrophic cells (Keung, 1989). It was 
thus suggested that ICaL could be increased before the cellular hypertrophy and then, as the 
cell grows, ICaL density would regain control values and even decrease in models of overt 
HF (Aimond et al., 1999; Benitah et al., 2002b). This process involves, at least partly, the 
cardiac mineralocorticoid pathway (Perrier et al., 2004; Benitah et al., 2010). Although most 
reports agree with the idea that ICaL density is normal in failing hearts, its kinetic seems to be 
significantly altered (Ryder et al., 1993; Bito et al., 2008). Thus, the decay of the whole-cell 
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ICaL and its CDI have been found to be slowed, causing a reduction in the peak of the [Ca2+]i 
transients producing less Ca2+-induced inactivation of ICaL. Thus, the maintained ICaL density 
together with a slowing of its inactivation would at the end increase the total account of Ca2+ 
entry through the channel (Aimond et al., 1999; Benitah et al., 2010). Such slowing of the 
decay of the current has a direct effect on the EC-coupling and is involved in the 
prolongation of APD favoring EADs observed in failing conditions (Tomaselli & Rose, 2000). 
An increase in Po and availability of LTCCs in human failing myocardium have been 
reported (Schröder et al., 1998), suggesting that the failing myocytes has fewer but more 
active channels. Hence, the response of ICaL to cAMP is reduced in ventricular myocytes 
from failing hearts (Chen et al., 2002). The attenuated increase of ICaL by β-adrenergic 
stimulation is consistent with a reduction in the maximal number of channels, which have a 
higher activity (Bito et al., 2008). This is related to the concept of “defective EC coupling” in 
HF (Gómez et al., 1997): The failing myocytes had a significant reduction in triggered Ca2+ 
release from the SR despite unaltered ICaL, which could be due to structural alteration in the 
relation between LTCCs and ryanodine receptors, related to important structural changes as 
a loss of T-tubules density in human and experimental HF (He et al., 2001; Balijepalli et al., 
2003; Louch et al., 2004; Lyon et al., 2009; Horiuchi-Hirose et al., 2011). The increased basal 
activity at the single Ca2+ channel levels is also consistent with changes in the 
phosphorylation state of the channel. Thus, both increases in PKA and CaMKII-dependent 
phosphorylation of LTCC have been described in failing myocytes (Schröder et al., 1998; 
Chen et al., 2008; Wang et al., 2008). PKA activation through β-adrenergic stimulation leads 
to increase ICaL, as well as the CaMKII-dependent phosphorylation of both pore-forming α1C 
and β2 subunits, which also increased ICaL CDF (Yuan & Bers, 1994; Hudmon et al., 2005; 
Grueter et al., 2006). In cardiac hypertrophy with prolongation of APD, these features are 
important since ICaL can be inappropriately reactivated and contribute to EADs triggered 
arrhythmia (Wu et al., 2002; Anderson et al., 2011). Moreover, Cavβ2 expression is 
downregulated in the compensated phase of cardiac hypertrophy, while an upregulation is 
observed in failing states, which could explain the increase in the activity of LTCCs 
observed in single channel studies (Hullin et al., 2007).  
5. Inherited channelopathies or genetically determined ion-channel disorder 
The critical role of LTCCs in cardiac cells has led many to suggest that inherited defects of 
LTCCs could be incompatible with life. This view dramatically changed in the 2004 when 
the CaCNA1C gene was found to show genetic linkage to life-threatening arrhythmias 
associated with Timothy syndrome (Splawski et al., 2004). Since, we witnessed an explosion 
of information linking LTCC genes mutations (more than 25 mutations identified in the past 
decade) with a wide variety of inherited arrhythmia syndromes (Napolitano & Antzelevitch, 
2011). 
5.1 LQT8 or Timothy syndrome 
Identified in the 1990s (Marks et al., 1995), Timothy syndrome, or syndactyly-associated 
LQTS or LQT8, is a dominantly inherited genetic condition characterized by multisystem 
dysfunction, with severe arrhythmic disorders including: QT prolongation; 2:1 
atrioventricular block (due to delayed ventricular repolarisation); T-wave alternans, 
polymorphic VT, and TdP; and abnormal changes in multiple organs (heart, skin, eyes, 
teeth, immune system, brain, and dysmorphism, such as syndactyly). Patients with LQT8 
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suggesting phosphorylation-dependent changes in the channel regulation more than 
changes in its expression (Christ et al., 2004). In addition, it has been also described a high 
sensitivity of ICaL to β-adrenergic agonists during AF, suggesting that LTCCs are in a 
dephosphorylated and silent state (Boixel et al., 2001; Schotten et al., 2003; Dinanian et al., 
2008; Hatem et al., 2010). Moreover, the activity of CaMKII is increased in AF (Neef et al., 
2010). However, increased CaMKII activity in AF seems to be offset by an increased PP 
activity, because CaMKII inhibitor KN-93 reduce ICaL in control cells, while it did not affect 
ICaL in AF cells (Greiser et al., 2007; Greiser et al., 2011). Moreover, the PP inhibitor, okadaic 
acid, increased ICaL to almost normal levels in human atrial myocytes from AF patients 
(Christ et al., 2004; Greiser et al., 2011). In conclusion, in AF the ratio between protein 
kinase/phosphatase is altered in favor of increased PP activity, suggesting that the basal 
phosphorylation of the Ca2+ channel is reduced which induces lower basal ICaL activity.  
It seems clear that the abnormal atrial electrical remodeling associated to AF contributes to 
perpetuation of the arrhythmia and has profound effects on intracellular Ca2+ handling 
(Greiser et al., 2011). Contractile force of atrial tissue strips from patients with AF is also 
reduced around 75% and exposure to high extracellular Ca2+ concentration is able to restore 
atrial functions (Schotten et al., 2001; Schotten et al., 2004). In a sheep model of persistent 
AF, even with only a slight reduction in ICaL (around 24%), its efficiency to highly reduced 
CICR (Lenaerts et al., 2009). In the presence of Ca2+ chelators, ICaL was unchanged in AF 
conditions while it is increased in control cells. These results are well-matched with a 
possible reduction in the CDI of ICaL. 
4.3 Cardiac hypertrophy and heart failure 
Following a pathological stress, the heart can adapt by developing cardiac hypertrophy, 
which improves contractile force as an adaptative mechanism to meet the new body 
demands. In this case, the cardiac hypertrophy is “compensated”, as in physiologic cardiac 
hypertrophy by exercise or during the pregnancy. When the stimulus is prolonged, cardiac 
hypertrophy can “decompensate” toward heart failure (HF) with compromised pump 
function (Benitah et al., 2010). One of the best documented changes in hypertrophy and HF, 
both in animal models and in humans, is the prolongation of the AP, which is highly 
significant in the production of ventricular arrhythmias. Important abnormalities of 
intracellular Ca2+ handling has been showed in the hypertrophic and failing myocytes: 
reduced SERCA function, enhanced NCX function and enhanced SR Ca2+ leak contributing 
to the reduced SR Ca2+ load (Bers et al., 2003). It is also well known that changes in ICaL in the 
hypertrophic and failing heart can also contribute to the electrical instability. Although the 
different degrees in the severity of pathological stresses as well as the variability among 
different models appear to influence the regulation of ICaL, the amplitude of ICaL is increased 
in hypertrophied and failing myocytes while its density (normalized to cell capacitance, as 
an indirect measure of cell surface) is unchanged (Benitah et al., 2002a; Benitah et al., 2003; 
Song et al., 2005; Loyer et al., 2008). In an early analysis of a pressure-overloaded cardiac 
hypertrophy model, ICaL was augmented in non-hypertrophic cells (Keung, 1989). It was 
thus suggested that ICaL could be increased before the cellular hypertrophy and then, as the 
cell grows, ICaL density would regain control values and even decrease in models of overt 
HF (Aimond et al., 1999; Benitah et al., 2002b). This process involves, at least partly, the 
cardiac mineralocorticoid pathway (Perrier et al., 2004; Benitah et al., 2010). Although most 
reports agree with the idea that ICaL density is normal in failing hearts, its kinetic seems to be 
significantly altered (Ryder et al., 1993; Bito et al., 2008). Thus, the decay of the whole-cell 
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ICaL and its CDI have been found to be slowed, causing a reduction in the peak of the [Ca2+]i 
transients producing less Ca2+-induced inactivation of ICaL. Thus, the maintained ICaL density 
together with a slowing of its inactivation would at the end increase the total account of Ca2+ 
entry through the channel (Aimond et al., 1999; Benitah et al., 2010). Such slowing of the 
decay of the current has a direct effect on the EC-coupling and is involved in the 
prolongation of APD favoring EADs observed in failing conditions (Tomaselli & Rose, 2000). 
An increase in Po and availability of LTCCs in human failing myocardium have been 
reported (Schröder et al., 1998), suggesting that the failing myocytes has fewer but more 
active channels. Hence, the response of ICaL to cAMP is reduced in ventricular myocytes 
from failing hearts (Chen et al., 2002). The attenuated increase of ICaL by β-adrenergic 
stimulation is consistent with a reduction in the maximal number of channels, which have a 
higher activity (Bito et al., 2008). This is related to the concept of “defective EC coupling” in 
HF (Gómez et al., 1997): The failing myocytes had a significant reduction in triggered Ca2+ 
release from the SR despite unaltered ICaL, which could be due to structural alteration in the 
relation between LTCCs and ryanodine receptors, related to important structural changes as 
a loss of T-tubules density in human and experimental HF (He et al., 2001; Balijepalli et al., 
2003; Louch et al., 2004; Lyon et al., 2009; Horiuchi-Hirose et al., 2011). The increased basal 
activity at the single Ca2+ channel levels is also consistent with changes in the 
phosphorylation state of the channel. Thus, both increases in PKA and CaMKII-dependent 
phosphorylation of LTCC have been described in failing myocytes (Schröder et al., 1998; 
Chen et al., 2008; Wang et al., 2008). PKA activation through β-adrenergic stimulation leads 
to increase ICaL, as well as the CaMKII-dependent phosphorylation of both pore-forming α1C 
and β2 subunits, which also increased ICaL CDF (Yuan & Bers, 1994; Hudmon et al., 2005; 
Grueter et al., 2006). In cardiac hypertrophy with prolongation of APD, these features are 
important since ICaL can be inappropriately reactivated and contribute to EADs triggered 
arrhythmia (Wu et al., 2002; Anderson et al., 2011). Moreover, Cavβ2 expression is 
downregulated in the compensated phase of cardiac hypertrophy, while an upregulation is 
observed in failing states, which could explain the increase in the activity of LTCCs 
observed in single channel studies (Hullin et al., 2007).  
5. Inherited channelopathies or genetically determined ion-channel disorder 
The critical role of LTCCs in cardiac cells has led many to suggest that inherited defects of 
LTCCs could be incompatible with life. This view dramatically changed in the 2004 when 
the CaCNA1C gene was found to show genetic linkage to life-threatening arrhythmias 
associated with Timothy syndrome (Splawski et al., 2004). Since, we witnessed an explosion 
of information linking LTCC genes mutations (more than 25 mutations identified in the past 
decade) with a wide variety of inherited arrhythmia syndromes (Napolitano & Antzelevitch, 
2011). 
5.1 LQT8 or Timothy syndrome 
Identified in the 1990s (Marks et al., 1995), Timothy syndrome, or syndactyly-associated 
LQTS or LQT8, is a dominantly inherited genetic condition characterized by multisystem 
dysfunction, with severe arrhythmic disorders including: QT prolongation; 2:1 
atrioventricular block (due to delayed ventricular repolarisation); T-wave alternans, 
polymorphic VT, and TdP; and abnormal changes in multiple organs (heart, skin, eyes, 
teeth, immune system, brain, and dysmorphism, such as syndactyly). Patients with LQT8 
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may also have episodic hypoglycaemia, which can trigger arrhythmias, and structural heart 
anomalies, including patent ductus arteriosus, patent foramen ovale, ventricular septum 
defect, and tetralogy of Fallot. Prognosis is very poor and SCD often occurs during 
childhood. 
Gain-of-function mutations in CACNA1C, localized at the end of IS6 segment that is 
important for the regulation of channel inactivation and the binding of the Cavβ subunit, 
have been associated with Timothy syndrome (Splawski et al., 2004; Splawski et al., 2005). A 
missense mutation G406R in the minor alternatively splice exon 8 of CACNA1C gene, as 
been first identified in all probands analysed (Splawski et al., 2004). Later, two other Gly 
mutations in the mutually exclusive major spliced exon 8a (G402S and G406R) were shown 
to cause a very similar syndrome but without the syndactyly (Splawski et al., 2005). These 
mutations exert powerful effect on inactivation, slowing the VDI irrespective of auxiliary β 
subunits, while through a proposed low-Po gating shift speeding the kinetics of CDI (Barrett 
& Tsien, 2008), which was previously reported unchanged (Splawski et al., 2005). Moreover, 
the mutation did not affect closed-state VDI, which might explain absence of hypertension 
associated with LQT8, and along with impaired open-state VDI, slowed activation and 
deactivation (Yarotskyy et al., 2009). The later is in part consistent with spontaneous 
increased occurrence of mode 2 gating at single channel level, which has been associated 
with the generation of a consensus phosphorylation site for CaMKII (Erxleben et al., 2006). 
Indeed, on isolated rat cardiomyocytes infected with dihydropyridine-resistant G406R 
Cav1.2 channel, CaMKII autophosphorylation is increased, which mediated enhanced ICaL 
facilitation, AP prolongation, increased Ca2+ spark frequency and afterdepolarizations (Thiel 
et al., 2008). The impaired inactivation of LTCC leads to sustained Ca2+ influx, AP 
prolongation, and Ca2+ overload, which promotes EADs and DADs (Jacobs et al., 2006; 
Sicouri et al., 2007). Roscovitine, a compound that increases the VDI, rescues the 
electrophysiological and Ca2+ homeostasis properties of Timothy syndrome cardiomyocytes 
(Yazawa et al.). Ca2+ channel blockade (eg, by verapamil and diltiazem) can control 
arrhythmias without affecting the QT interval, and is a possible treatment (Napolitano et al., 
2006). 
5.2 ICaL and LQT syndrome 
The QT interval is an electrocardiographic index of ventricular repolarization and a measure 
of the duration of the ventricular AP. Ca2+ influx through LTCC plays a significant role in 
maintaining the plateau phase of AP and hence contributes importantly to APD and QT 
interval. Therefore, administration of CCB is a logical strategy in all types of LQTS. In the 
clinical study involving recording of monophasic AP (MAP) in eight patients with LQTS, 
verapamil effectively abbreviated MAP duration and suppressed epinephrine-induced 
EADs (Shimizu et al., 1995). At the bench side, verapamil effectively abbreviates QT interval 
and suppresses TdP in models of congenital and acquired LQTS (LQT1+ LQT2) (Aiba et al., 
2005). In a rabbit model of drug-induced LQT2, the  increased ICaL at the base of hearts, 
attributable to gender and regional difference in Cav1.2 expression, is an important 
determinant of the arrhythmia phenotype (Sims et al., 2008). This echoes clinical reports 
suggesting that Ca2+ channel antagonists might be appropriate as adjunctive therapy for 
arrhythmia suppression in LQT1, LQT2 and even LQT3 (Shimizu et al., 2005). Hence, an 
anti-arrhythmic effect of the specific LTCC antagonist nifedipine has been reported in mice 
with targeted disruption of the Na+ channel gene (Thomas et al., 2007), as well as in intact 
hearts from LQT5 mice model (Balasubramaniam et al., 2003). 
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5.3 J wave syndromes 
Because they share a common arrhythmic platform and similarities in ECG characteristics, 
clinical outcomes and risk factors, congenital and acquired forms of Brugada (BrS) and early 
repolarization (ERS) syndromes have been grouped together under the heading of J wave 
syndromes (Antzelevitch & Yan, 2010). Recent studies have implicated loss of function 
mutations in all 3 subunits of the cardiac LTCC in the generation and accentuation of 
electrocardiographic J waves associated with these syndromes (Antzelevitch et al., 2007; 
Cordeiro et al., 2009); (Burashnikov et al.). 
5.3.1 Short QT syndrome 
Although QT prolongation has long been known to increase the risk of SCD and overall 
cardiac mortality among patients with a variety of underlying etiologies, a shorter than 
normal QT interval could also be detrimental leading to the concept of a new clinical entity, 
the short QT syndrome, associated with AF and SCD (Gussak et al., 2000). Since more than 
30 patients with SQTS have been reported (Schulze-Bahr et al., 1997; Gaita et al., 2003; 
Schimpf et al., 2005; Giustetto et al., 2006). 
SQT4 and SQT5 are associated with mutations in CACNA1C and CACNB2B (Antzelevitch 
et al., 2007). These mutations reduce ICaL, shorten QT, and are associated with asymmetrical 
T waves, attenuated QT-heart rate relations, and AF. More recently, a new variant of SQTS 
at a heterozygous state caused by a mutation in the CACNA2D1 gene has been reported 
(Templin et al., 2011). This mutation leads also to a decreased ICaL, without modification in 
the Cav1.2 expression suggesting alteration of some of the biophysical single channel 
properties of channel. 
5.3.2 Brugada syndrome 
Brugada syndrome (BrS), an inherited cardiac arrhythmia syndrome associated with a 
relatively high risk of VF, was first described as a new clinical entity in 1992 (Brugada & 
Brugada, 1992). The ECG features of the Brugada patient includes an accentuated J wave 
displaying a real or apparent right branch bundle block and ST segment elevation in the 
right precordial leads. Although the BrS has thus far been linked to mutations that impede 
Na+ channel expression or function, alterations in ICaL current with CCBs have been 
implicated in the development of BrS both clinically (Shimizu, 2005) and experimentally 
(Fish & Antzelevitch, 2004). 
Recently, novel mutations of the cardiac LTCC genes responsible for shortening of the QT 
interval in families characterized by SCD, AF and a BrS type I ECG pattern have been 
reported (Antzelevitch et al., 2007). Functional analyses revealed loss-of-function missense 
mutations of the CACNA1C (A39V in the N-terminus and G490R in the I-II domain linker) 
and CACNB2 (S481L). These mutations reduce ICaL amplitude (due to trafficking defect for 
A39V), shorten QT, and are associated with asymmetrical T waves, attenuated QT-heart rate 
relations, and AF. Some patients also have tall, peaked T waves. These patients can also 
have BrS-type ST elevation in the right precordial leads with or without drug provocation, 
suggesting that the same reduction in ICaL underlies both SQTs and BrS. More recently, a 
novel missense mutation (T11L) in CACNB2B has been associated with BrS (Cordeiro et al., 
2009). Characterized in heterologous expression system, this mutation induced faster 
inactivation kinetics and hyperpolarized shift in the steady-state inactivation without any 
other alteration in ICaL, resulting in a reduced depolarizing current in response to epicardial 
AP waveform. 
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anomalies, including patent ductus arteriosus, patent foramen ovale, ventricular septum 
defect, and tetralogy of Fallot. Prognosis is very poor and SCD often occurs during 
childhood. 
Gain-of-function mutations in CACNA1C, localized at the end of IS6 segment that is 
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anti-arrhythmic effect of the specific LTCC antagonist nifedipine has been reported in mice 
with targeted disruption of the Na+ channel gene (Thomas et al., 2007), as well as in intact 
hearts from LQT5 mice model (Balasubramaniam et al., 2003). 
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5.3 J wave syndromes 
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6. Current antiarrhythmic strategies and ICaL 
Current therapy to prevent cardiac arrhythmia is multidimensional and complicated. The 
conventional antiarrhythmic drugs have limited efficacy and safety. In the case of the most 
common cardiac arrhythmia, AF, treatment strategies can be pharmacological or 
interventional (e.g. catheter ablation techniques) but are also complicated by the presence of 
co-morbidities such as hypertension, diabetes, and/or pre-existing cardiovascular diseases 
(HF or coronary artery disease) (Prystowsky et al., 2010). Within the pharmacological 
strategies there are several groups of drugs including β-blockers, angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), lipid-lowering and 
antithrombotic agents, spironolactone, among others, which have also demonstrated its 
efficacy in the prevention of SDC (Alberte & Zipes, 2003). From among all of them, the 
greatest reduction in cardiovascular mortality has been demonstrated with the treatment of 
β-blockers (Dorian, 2005). However, these drugs most likely exert their antiarrhythmic 
potential indirectly by affecting “upstream events” that contribute to the development of 
electrophysiological instability (Rubart & Zipes, 2005). 
It has been demonstrated that the direct blockade of ICaL with dihydropyridine Ca2+ channel 
blockers (CCBs) produces a strong shortening in the APD. So, blocking ICaL is a potent 
means of suppressing VF. In Langendorff-perfused rabbit hearts, verapamil decreased the 
frequency of arrhythmia and changed it from disorganized VF into more organized VT 
(Samie et al., 2000). Similar results were also obtained using nifedipine (Choi et al., 2002). 
Therefore, CCBs could be considered promising antiarrhythmic drugs. However, the effects 
of these drugs have not emerged as unequivocally favorable in all clinical studies. Thus, 
verapamil and diltiazem can, in some cases, prevent episodes of acute ischemia VF in 
human, but they do not demonstrated to have as much of a beneficial effect on overall 
mortality as β-blockers or angiotensin-converting enzyme (ACE) inhibitors (Bodi et al., 
2005). The problem observed with the direct blockade of ICaL using CBBs is that, at the same 
time that VT is prevented, the contractility could be suppressed, precluding their clinical 
usefulness as antifibrillatory drugs. Therefore, in the last years it has been proposed that 
only modifying ICaL kinetic properties, instead of blocking ICaL, could produce equivalent 
anti-fibrillatory effects without impairing EC coupling (Mahajan et al., 2008). 
In the clinical setting it is well established that the improvement in the current approach to 
treat AF is completely necessary. Amiodarone is the most effective antiarrhythmic drug for 
maintaining sinus rhythm in patients with AF. However, the extra-cardiac side effects have 
been a limiting factor, especially during chronic use, and may offset its benefits. 
Dronedarone is a new antiarrhythmic drug similar to amidarone that has been developed to 
provide rhythm and rate control in AF patients with fewer side effects. Dronedarone is 
considered as a potent blocker of multiple ion currents, including ICaL, and also exhibits 
antiadrenergic effects. In myocytes from several experimental animals, it has been 
demonstrated that the effect of dronedarone on ICaL consists in 76% block at dose of 10 µM 
with IC50=0.18 µM (Varró et al., 2001; Gautier et al., 2003). Dronedarone has also important 
antiarrhythmic effects. Intravenous administration of dronedarone shortened ventricular 
APD, suppressed EADs, ectopic beats and also TdP (Verduyn et al., 1999). Moreover, 
intravenous dronedarone was able to prevent VF in a rat model of ischemia and 
reperfusion-induced arrhythmias (Manning et al., 1995). Similarly, several clinical trials 
have demonstrated that dronedarone is able to maintain sinus rhythm and control 
ventricular rate in AF, reducing the number of cardiovascular hospitalizations and mortality 
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in patients with high-risk of AF (Singh et al., 2007; Davy et al., 2008; Hohnloser et al., 2009). 
The current DIONYSOS clinical trial has demonstrated that in a short-term, dronedarone 
was less effective than amiodarone in decreasing AF recurrence and maintaining normal 
sinus rhythm, but had a better safety profile, specifically with regard to thyroid and 
neurologic events and a lack of interaction with oral anticoagulants (Le Heuzey et al., 2010). 
However, the ANDROMEDA clinical trial has showed that dronedarone is also 
contraindicated in severe or deteriorating HF (Køber et al., 2008). The reason of that is 
because of a negative inotropic effect of dronedarone resulting from inhibition of ICaL that 
could have contributed to worsening of severe HF, increasing its mortality (Gautier et al., 
2003; Zimetbaum, 2009). Therefore, dronedarone is still under clinical studies and has to 
demonstrate its real antiarrhythmic potency and effectiveness over other antiarrhythmic as 
well as its possible effects in the management of additional arrhythmias, e.g. VT. 
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1. Introduction 
Hibernation is a physiological adaptation to periods of seasonal resource limitation (Carey 
et al., 2003a; Drew et al., 2007). Hibernators undergo several bouts of torpor during a 
hibernation season. Torpor in hibernation is a period of profound bradycardia, tachycardia, 
metabolic suppression and decreased core body temperature (Drew et al. 2007). Hibernation 
is characterized by alternating phases of torpor and euthermy that begins in the fall and 
continues until the hibernation season ceases in spring (Lyman, 1958; Geiser and Ruf, 1995; 
Boyer and Barnes, 1999). Based on whole-body metabolic rate and core body temperature 
each torpor bout consists of an entrance, steady-state, and arousal phases (Boyer and Barnes, 
1999; Carey et al., 2003a; Heldmaier et al., 2004; Drew et al., 2007) (Fig.1). Successive torpor 
bouts are interrupted by a brief period (12-24h) of interbout euthermy.  
Cardiac arrhythmia is described as any deviation from the normal sequence of electrical 
impulses resulting in slow (bradycardia), fast (tachycardia) or erratic hearbeats such as atrial 
and ventricle fibrillations and conduction disorders (Keating and Sanguinetti, 2001).  
Cardiac arrhythmias are observed during hibernation (Chatfield and Lyman, 1950; Eagles et 
al., 1988; Milsom et al., 1993; Milsom et al., 1999; Toien et al., 2011). In spite of that no 
untoward effects such as ventricular fibrillation or heart failure are noticed in hibernators 
and the hearts remain functional even at a body temperature of 0oC (Johansson, 1996). 
Moreover, hibernators can rewarm to euthermic body temperature of about 36oC in a span 
of few hours (Lyman, 1958)(Fig1&2) without any cardiac or nervous system complications 
(Drew et al., 2007). In contrast, similar conditions in non-hibernators including humans lead 
to fatal cardiac complications and death (Nardone, 1955; Johansson, 1996; Drew et al., 2007). 
Unresolved intrinsic mechanisms protect the hibernating species against lethal cardiac 
arrhythmias at reduced body temperatures. Understanding the intrinsic functional 
mechanisms existing in hibernators can lead to novel therapies in treating several conditions 
such as cardiac arrest and stroke (Drew et al., 2007).  
Patients with cardiac arrest are subjected to hypothermia in a clinical setting (Polderman, 
2004; Polderman and Herold, 2009). However, inducing hypothermia beyond a certain level 
is not without complications. Patients subjected to temperatures colder than 30oC suffer 
cardiac arrhythmias (Polderman and Herold, 2009). Cooling more slowly should mimic 
similar drop in body temperature seen during torpor in hibernators and may thus avoid 
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arrhythmias. The question is how to achieve this state where the temperature can be 
dropped below 30oC without any cardiac complications.  
Difference exists between hibernators and nonhibernators in resisting ventricular fibrillation 
induced by hypothermia. Several factors are responsible including heart size (Surawicz, 
1971).Hibernating animals vary in size (Geiser, 2004). Large hearts tend to develop 
ventricular fibrillations (Surawicz, 1971). Although bears are regarded as hibernators their 
body temperature does not fall below 30oC which is above the critical body temperature 
where ventricular fibrillations are noticed (Johansson, 1984; Eagles et al., 1988; Toien et al., 
2011). This chapter discusses about small hibernators in general focusing on the role of 
nervous system regulation of cardiac function in the light of recent research findings and the 
importance of adenosine (Miyazawa et al., 2008; Jinka et al., 2011). This chapter gives an 
overview of hibernation physiology, various mechanisms regulating hibernation, cardiac 
arrhythmias observed during hibernation, functional difference between hibernator and a 
non-hibernator, especially in regard to heart function, and finally discusses novel findings 
and hypothesis that may be translated to treat certain medical conditions such as cardiac 
arrest and stroke to improve the outcome in such patients.  
2. Phases of hibernation and cardiac arrhythmias  
2.1 The entrance phase  
A decrease in heart rate and metabolism prior to decrease in core body temperature is a 
characteristic phenomenon observed during entrance into hibernation (Lyman, 1958). Heart 
rate, metabolism and core body temperature gradually decline during the entrance phase 
until the core body temperature drops down to the lowest limit where the core body 
temperature is just above the ambient temperature (Boyer and Barnes, 1999; Tamura et al., 
2005). Heart rate declines to 2-7 beats per minute (Dawe and Morrison, 1955) , metabolism 
drops  to 2% of  resting metabolic rate (Geiser, 1988; Buck and Barnes, 2000) and core body 
temperature drops to as low as -2.9o C (Barnes, 1989)(Fig.1&2). 
2.1.1 Cardiac arrhythmias during entrance into hibernation  
Evidence supports the central nervous system regulation during entrance into hibernation. 
Administration of adenosine agonist into the brain induces torpor in arctic ground squirrels 
(Jinka et al., 2011). By lowering the set-point (Tset) threshold below the actual hypothalamic 
temperature (Thy) during entrance into hibernation a smooth entrance is facilitated. An 
occasional burst of body temperature paralleled by an increase in metabolism is observed 
when Thy below Tset. (Heller et al., 1977; Heldmaier et al., 2004). The changes in heart rate 
parallel the change in metabolic rate suggesting that entrance into hibernation is a highly 
regulated, orchestrated event of several physiological processes rather than a consequence 
of a drop in body temperature (Milsom et al., 1999).  
A comparison between heart rate and temperature in hedgehogs during entrance into 
hibernation indicates a shift towards parasympathetic influence (Dawe and Morrison, 1955). 
Atropine is a parasympatholytic and increases heart rate by slowing of parasympathetic 
output. Administration of atropine during entrance into hibernation increased heart rate in 
hamsters (Lyman and O'Brien, 1963). Cardiac arrhythmias during entrance into hibernation 
are abolished by administration of atropine in marmots (Lyman, 1982). All these studies 
suggest that a well coordinated activation of parasympathetic system, preparatory initial 
changes in the heart rate, skipped beats and asystoles altogether are necessary for decline in 
heart rate and for a smooth entrance into hibernation (Milsom et al., 1999; Zimmer et al., 2000). 
 




Fig. 1. Core body temperature was measured in an Arctic ground squirrel after  
arousal from torpor induced by gentle handling and until the animal entered another  
bout of torpor. 
Core body temperature and heart rate were measured with an ip transmitter as described 
previously (Jinka et al., 2011). Torpor in hibernation is broadly divided into three phases-
entrance, steady-state, and arousal (Boyer and Barnes, 1999; Carey et al., 2003a; Heldmaier et 
al., 2004; Drew et al., 2007). Entrance phase is followed by steady-state phase which lasts for 
1-3 weeks before the arousal phase is initiated. Core body temperature in an Arctic ground 
squirrel can drop to as low as -2.9oC (Barnes, 1989) before it reaches steady-state phase.  
A fully aroused animal stays at euthermic body temperature of 35-37oC for about a day 
before another torpor bout ensues. Changes in heart rate reflect changes in core body 
temperature during a hibernation bout.  
Several unique behavioral patterns of heart beats are noticed during entrance into 
hibernation. It is interesting to know how a hibernator can drastically reduce its heart rate 
during entrance into hibernation without any adverse effects. Heart rate drops prior to any 
changes in body temperature indicating that a decreased heart rate during entrance into 
hibernation is independent of body temperature. (Landau and Dawe, 1958; Lyman, 1958; 
Elvert and Heldmaier, 2005). Appearance of skipped beats is a characteristic feature 
exhibited by several species of hibernators during entrance into hibernation (Dawe and 
Morrison, 1955; Lyman, 1958; Twente and Twente, 1978; Lyman, 1982) (Fig.3). A drastic 50% 
fall in heart rate while a drop in body temperature by 0.6oC  observed during initial stages of 
entrance into hibernation occurs around 33-34oC (Strumwasser, 1959).  
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arrhythmias. The question is how to achieve this state where the temperature can be 
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Fig. 2. Changes in core body temperature and whole animal oxygen consumption as 
measured in an Arctic ground squirrel after arousal from torpor was iniated by gentle 
handling and until the animal entered another bout of torpor.  
Core body temperature was measured with an ip transmitter and oxygen consumption was 
measured using open flow respirometry as described previously (Jinka et al., 2011). The 
inset illustrates how oxygen consumption precedes a decline in core body temperature 
during entrance into torpor as shown on a smaller scale. Entrance into hibernation is 
characterized by a characteristic decline in whole animal oxygen consumption (metabolism) 
that precedes a decrease in core Tb (Lyman, 1958). [source: (Drew et al., 2009)] 
2.2 The steady-state phase 
Animal enters into a steady-state phase of hibernation after a few hours of initiation of 
torpor. Steady-state phase represents the nadir of mammalian heart rate, metabolism, and 
core body temperature (Drew et al., 2007) where the animal maintains its lowest heart rate, 
metabolism, and core body temperature for about 1-3 weeks (Boyer and Barnes, 1999; Buck 
and Barnes, 2000; Carey et al., 2003a). An occasional burst of activity paralleled with an 
increase in heart rate, metabolism and heat production is observed during this phase and is 
hypothesized as a measure to avoid decreases in body temperature beyond a certain point 
(Heldmaier et al., 2004). 
2.2.1 Cardiac arrhythmias during steady state hibernation 
Diastolic arrhythmias are noticed in deep hibernation (Twente and Twente, 1978; Milsom et 
al., 1999). Different opinions exist on the influence of sympathetic and parasympathetic 
systems on deep hibernation with no definitive conclusion (Milsom et al., 1999).  
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2.3 The arousal phase  
Periodic arousals from hibernation are noticed in true hibernators (Lyman, 1958; Geiser 
and Ruf, 1995; Boyer and Barnes, 1999; Karpovich et al., 2009). A characteristic gradual 
increase in heart rate, metabolism and respiration followed by a gradual increase in core 
body temperature is observed during arousal from hibernation (Lyman, 1958). It is 
interesting to note that the rewarming from hibernation without any external source of 
heat suggests that hibernation is not a state of energy deficiency (Carey et al., 2003a). 
Animals attain a core body temperature of 35-37oC, then maintain euthermic body 
temperature for about a day before another hibernation bout starts (Boyer and Barnes, 
1999; Carey et al., 2003b). 
2.3.1 Cardiac arrhythmias during arousal from hibernation 
Cardiac arrhythmias appear throughout arousal (Twente and Twente, 1978). Heart rate 
gradually increases in frequency as the body temperature increases (Lyman, 1958). The 
initial rapid increase in heart rate during arousal from hibernation is due to sympathetic 
activation (Milsom et al., 1993) and as such the increase in endogenous catecholamines are 
arrhythmogenic (Burn, 1961; Trautwein, 1963). Asystoles are followed by bradycardia 
during arousal from hibernation. Asystoles appear between 11-18oC during which period 
the heart rate falls below what it was before the appearance of asystolic episodes, and 
attains a regular rhythm and a higher rate as soon as the asystoles disappear at about 18oC 
(Eagles et al., 1988). This waxing and waning appearance of heart rate during arousal may 
be due to alternating sympathetic and parasympathetic dominance on the way to euthermia 
(Milsom et al., 1999). A ventricular bigeminy with a repetitive premature ventricular heart 
beats alternating with supraventricular beats is also demonstrated on ECG (Eagles et al., 
1988). During mid to late arousal the heart rate, metabolism and respiratory frequency 
gradually reach a peak followed by body temperature under the influence of sympathetic 
tone until the animal reaches  euthermia during which period the autonomic balance is 
restored (Lyman, 1958; Lyman and O'Brien, 1963; Twente and Twente, 1965; Lyman and 
O'Brien, 1969; Twente and Twente, 1978; Milsom et al., 1993).  
3. Cardiac arrhythmias in hibernation vs hypothermia in hibernators 
A study on ground squirrels revealed several differences in the ECG during hibernation 
and hypothermia (Dawe and Morrison, 1955; Nardone, 1955). A slow heart rate in 
hibernation is facilitated by a 40-70 fold increase in the duration of T-P segment 
suggesting a slowed SA node during hibernation. A 4-5 fold increase in duration of QRS 
complex is observed. About a 7 fold increase in the duration of P-R segment of an ECG 
indicates an increase in conduction time. On the other hand, a gradual decline in heart 
beats, appearance of right bundle branch block, and a notched QRS complex suggests a 
possibility of aberration in myocardial conduction. A reduced time span of QRS complex 
and a faster appearance of T wave soon after QRS complex were also noticed in 
hypothermia. Forced induction of hypothermia in Syrian hamsters induced J-waves and 
atrioventricular block while spontaneous hibernation had no adverse effect (Miyazawa et 
al., 2008). A study in ground squirrel has shown that decreased body temperature during 
spontaneous hibernation slows ventricular conduction velocity and increases excitation 
threshold thus avoiding arrhythmias at extreme low body temperatures (Fedorov et al., 
2005).   
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Fig. 3. Electrocardiogram of an arctic ground squirrel at different core body temperatures 
during different phases of hibernation. 
Steady-state phase of hibernation is characterized by bradycardia with even beats as shown 
here at a body temperature of 4oC (a). An increase in heart rate occurs as soon as arousal is 
initiated as indicated in ECG at a body temperature of 5oC (b). A gradual progressive 
increase in heart rate is noticed through arousal phase at a body temperature of 20oC (c) 
until the animal reaches a euthermic body temperature of 37oC (d). Skipped beats and 
bradycardia follows as the animal prepares to enter into another torpor bout as represented 
by ECG at a body temperature of 36oC (e) and mid-entrance phase at 15oC (f). A brief pause 
in heart beats is a characteristic finding during the last stage of entrance phase (g) at a body 
temperature of 8oC. 
4. Anatomical peculiarity of hibernator’s heart  
An insight into the anatomy of a hibernator’s heart may provide clues as to how a 
hibernator can overcome heart failure under extreme hypothermia. The peculiar anatomy 
of the heart  of a hibernator has been described by Walls in a hamster (Walls, 1942). 
Several interesting features of the conducting tissue have been identified in this study. 
Purkinje fibers are identified in the sino-atrial node, the pacemaker of the heart, and not in 
the atria suggesting that Purkinje fibers may have a function other than a simple 
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conduction of the cardiac contraction impulse. The atrio-ventricular node has a compound 
nature of fibers which are similar to Purkinje type. Purkinje tissue is absent in the right 
ventricle and a limited amount of Purkinje tissue is present in the left ventricle whose wall 
is six times thicker than the right ventricle. In spite of limited Purkinje tissue distribution 
to the ventricles it is interesting to note that the heart is capable of about 450 beats per 
minute.  
Gap junctions are specialized intercellular connections in the heart and are needed for 
conduction in the heart. Gap junctions ensure the propagation of action potentials between 
the myocytes and provide low resistance intercellular channels facilitating coordinated 
contraction of myocardium (Saitongdee et al., 2000). Connexins are gap junction proteins 
with four-membrane spanning domains. Among several types of connexins, connexin43 
(Cx43) is the major connexin found in the mammalian heart (Beyer et al., 1987). Cx43 and 
Cx45 are upregulated in the hearts of hibernators (Gros and Jongsma, 1996; Fedorov et al., 
2005; Van Der Heyden et al., 2007). Increased density of Cx43 has been identified in 
ventricular cardiomyocytes of hibernators during hibernation (Saitongdee et al., 2000). Cx43 
density returned to normal control levels within 2 hours of arousal from torpor suggesting 
the importance of Cx43 and Cx45 in overcoming ventricular fibrillation during hibernation. 
(Saitongdee et al., 2000; Fedorov et al., 2005).  
5. Adenosine in hibernation 
A growing body of evidence supports the significance of adenosine in hibernation (Drew et 
al., 2007). Adenosine is a widely distributed inhibitory neuromodulator throughout the 
central nervous system including the brainstem, the principle cardiovascular control center 
(Mosqueda-Garcia et al., 1989; Barraco and Phillis, 1991). Adenosine decreases neuronal 
excitability and modulates the actions of other neurotransmitters (Dunwiddie and Masino, 
2001). Adenosine acts through A1, A2a, A2b, and A3 receptors (Fredholm et al., 1994; Olah 
and Stiles, 1995; Dunwiddie and Masino, 2001). Endogenous adenosine is produced from 
multiple sources in the central nervous system, some sources associated to energy levels and 
functions as a homeostatic regulator in the CNS (White, 1977; Fredholm et al., 1994; 
Dunwiddie and Masino, 2001). Dephosphorylation of adenosine triphosphate (ATP) is one 
of the major sources of endogenous adenosine production where ATP released into synapse 
is metabolized to adenosine and mediates its effect through adenosine receptors (Fredholm 
et al., 1994; Dunwiddie and Masino, 2001).  
5.1 Adenosine in induction of torpor during hibernation 
Central nervous system regulation of hibernation is implicated by several studies (Drew et 
al., 2007; Jinka et al., 2011). Recent study has shown that administration of the adenosine A1 
receptor agonist N6-cyclohexyladenosine (CHA) into the lateral ventricle of arctic ground 
squirrel induces hibernation. CHA-induced hibernation is similar to natural spontaneous 
entrance into hibernation. Results indicate that onset of hibernation is regulated within the 
central nervous system through activation of A1AR (Jinka et al., 2011). Studies focusing on 
specific sites in the brain including the hypothalamus and hippocampus indicate a 
prominent influence of CNS on hibernation (Heller and Colliver, 1974; Popov et al., 1992). 
Studies on central nervous system also direct towards involvement of adenosine, a 
neuromodulator in hibernation regulation (Shintani et al., 2005; Tamura et al., 2005; Jinka et 
al., 2011).  
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Successful translation of hibernation to non-hibernating species will open possibilities of 
applying the concept of metabolic suppression and low body temperature to humans in 
treating conditions such as stroke, hemorrhagic shock, cardiac arrest, cerebral ischemia, and 
multiorgan failure (Drew et al., 2007).  
5.2 Significance of adenosine on dietary restriction induced hypothermia and 
cardiovascular regulation 
Adenosine-induced hypothermia is mediated through A1AR (Dunwiddie and Masino, 2001; 
Shintani et al., 2005). Adenosine modulates the cardiovascular system through numerous 
A1AR in nucleus tractus solitarius (NTS) (Badman and Flier, 2005; Scislo et al., 2008) located 
in the brainstem which receives projections from hypothalamus, the thermoregulatory 
center in the brain (Scislo and O'Leary, 2006). Cardiovascular centers of the medulla are 
innervated by projections from the hypothalamus which alleviates cardiac arrhythmias by 
modulating the blood pressure (Willette et al., 1984; Lumb and Lovick, 1993; Kiely and 
Gordon, 1994; Hirasawa et al., 1996; Krukoff et al., 1997; Yang and Coote, 1998; Hardy, 
2001). NTS influences cardiovascular system. Hypotensive responses in the cardiovascular 
system are mediated through A1AR in NTS (White et al., 1996). Adenosine microinjections 
into the NTS result in a slow and regulated decrease in heart rate (Tseng et al., 1995; Phillis 
et al., 1997; Ho et al., 2008). Thus NTS and A1AR contribute significantly towards induction 
of hypothermia and modulation of cardiovascular responses.  
Dietary restriction is a dietary regimen defined by a decrease in food intake unassociated with 
malnutrition which lowers core body temperature, improves longevity, protects heart and 
attenuates progression of neurodegenerative diseases in animal models (Contestabile, 2009; 
Katare et al., 2009). These effects have been suggested to be through a reduction in metabolic 
demand (Ungvari et al., 2008) associated with a decrease in body temperature (Tb)(Conti et al., 
2006). Mechanisms involved in induction of hypothermia are under investigation. Results 
from our studies have shown that DR-induced hypothermia is due to adenosine sensitization 
(Jinka et al., 2010). Our results have demonstrated that intraperitoneal administration of CHA 
(0.5mg/kg) in DR-sensitized rats induced a significant cooling undetected in ad libitum (AL) 
rats. However, it is not clear as to how the heart responds to this induced cooling in DR rats 
because hypothermia beyond a certain level is not without complications like cardiac 
arrhythmias (Polderman and Herold, 2009). It was shown that DR has certain beneficial effects 
on heart (Lee et al., 1999) including protection from arrhythmias (Johnson et al., 2006) although 
it is yet to be investigated whether these beneficial effects on heart are applicable under 
hypothermic conditions induced by the A1AR agonists. 
Central administration of A1AR agonist-induced hypothermia in Syrian hamsters is free of 
cardiac arrhythmias while forced induction of hypothermia through intraperitoneal 
pentobarbital sodium causes J-waves and atrioventricular block (Miyazawa et al., 2008). 
Syrian hamsters undergo periods of food restriction, a process comparatively similar to 
dietary restriction, which prepares them to hibernate (Stamper et al., 1999). Dietary 
restriction influences NTS (Badman and Flier, 2005). Thus it can be hypothesized that 
centrally administered A1AR agonist-induced hypothermia in dietary restricted rats may 
avoid cardiac arrhythmias.  
5.3 Previous studies and results 
In our previous studies we have shown that prolonged DR sensitizes A1AR agonist-induced 
cooling. Sprague-Dawley rats were implanted with subcutaneous IPTT-300 transponders for 
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monitoring body temperature. Rats were fed every other day for 27 days and then 
administered the A1AR agonist, N6-cyclohexyladenosine (CHA; 0.5mg/kg, ip). Respiratory 
rate (RR) and subcutaneous body temperature were monitored every day and after drug 
administration. A lower RR on day 20 and lower body temperature on day 22 were 
displayed by DR rats when compared to rats fed ad libitum and displayed a larger response 
to CHA. RR, a metabolic indicator, declined before body temperature in all cases suggesting 
that a decrease in oxidative metabolism associated with thermogenesis caused animals to 
cool. This is comparable to torpor because of prior changes in metabolism than body 
temperature as observed during hibernation (Lyman, 1958). An increased surface expression 
of A1AR is demonstrated within the hypothalamus in DR rats. These results suggest that 
sensitization of thermoregulatory effects of endogenous adenosine through increased 
surface expression of A1AR may play a role in enhanced hypothermia associated with DR. 
These results also suggest that a torpid like effect is seen with CHA-induced hypothermia in 
DR rats. However, it is not known from these studies as to how the heart responds to this 
CHA- induced hypothermia in DR rats (Jinka et al., 2010).  
5.4 Hypothermia in hibernation vs hypothermia in A1AR stimulated DR rats 
Hypothermia is seen in hibernators during torpor where their core body temperature (Tb) 
can reach to as low as -2.9C (Barnes, 1989) without any complications. A sudden drop in 
metabolism followed by a decrease in core body temperature is the hallmark of hibernation 
(Lyman, 1958). CHA-induced hypothermia in DR rats resembled torpor in hibernators as 
there is a sudden decrease in respiration, an indicator of metabolism, followed by a slow 
decrease in body temperature (Jinka et al., 2010). Central administration of CHA in 
hibernators results in hypothermia without any untoward effects on heart while cardiac 
arrhythmias were seen with anesthetic-induced hypothermia (Miyazawa et al., 2008). 
Atrioventricular blocks and J-waves are observed in nonhibernators during induced 
hypothermia (Osborn, 1953; Brunson et al., 2005). Appearance of J-waves, also known as 
Osborne waves, indicates injury, delayed ventricular conduction, tissue anoxia or acidosis 
(Miyazawa et al., 2008). These studies suggest that an unidentified intrinsic mechanism in 
the heart of hibernators may be responsible for circumventing heart failure under extreme 
hypothermia.  
5.5 Neuroprotection by induction of hypothermia and circumventing cardiac 
arrhythmias 
Neuronal cell death is one of the major aftermaths of cardiopulmonary arrest and stroke. 
Under clinical setting, regulated hypothermia induced in the stroke patient in order to 
mitigate neuronal injury has proven to be helpful. Neuroprotection is evident in hibernators 
which experience extreme hypothermia. Thus inducing a hibernation-like state would be 
more beneficial in cardiac arrest patients. DR-induced cooling is well established in various 
rodents (Conti et al., 2006; Ungvari et al., 2008; Contestabile, 2009). What is novel in the 
recent research is that adenosine A1 receptor (A1AR) agonist; CHA administration induces 
increased hypothermic response in DR rats (Jinka et al., 2010), although the response of the 
cardiovascular system is not measured. This CHA-induced hypothermia in DR rats is 
similar to the torpor seen in hibernation and this is achieved through sensitization of A1AR 
in the brain’s hypothalamus, the principle thermoregulatory center in the CNS. Recent study 
in hibernators also has shown that central administration of CHA induces cooling without 
cardiac arrhythmias (Miyazawa et al., 2008). Hence there is a possibility of circumventing 
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cardiac arrhythmias (Miyazawa et al., 2008). Hence there is a possibility of circumventing 
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cardiac arrhythmias in DR rats when hypothermia is achieved through central 
administration of CHA. Thus it can be hypothesized that A1AR agonist-induced 
hypothermia in dietary restricted rats may avoid cardiac arrhythmias.  
5.6 Hypothesized model 
Sensitized adenosinergic system in DR rats acts through nucleus of the solitary tract (NTS), a 
primary integrative center for cardiovascular reflex. Adenosine in NTS modulates 
sympathetic, parasympathetic, and cardiovascular systems which in turn modulate arterial 
pressure, heart rate and vascular conductance by acting on and tuning the activity of the 
sympathetic and parasympathetic systems. The effect of adenosine may be one of the 
mechanisms behind cardioprotective effect (Fig.4) leading to generation of normal cardiac 
rhythms circumventing cardiac arrhythmias.  
 
 
Fig. 4. Hypothesized model of dietary restriction induced cardioprotection. 
6. Conclusion 
Hibernators undergo a variety of complex morphological, behavioral, and physiological 
adaptive changes during hibernation period. Profound metabolic suppression, hypothermia, 
and bradycardia observed at the organismal level during the hibernation period have no 
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harmful effects (Geiser, 1988; Barnes, 1989; Buck and Barnes, 2000; Drew et al., 2001; Zhou et 
al., 2001; Carey et al., 2003a; Heldmaier et al., 2004; Tamura et al., 2005; Ross et al., 2006; 
Drew et al., 2007). The hearts of hibernating mammals remain functional even at 0°C  while 
the hearts of non-hibernating mammals becomes arrhythmic and stop functioning between 
10°C and 15°C (Lyman, 1982; Caprette and Senturia, 1984; Burlington and Darvish, 1988). 
This implies that an intrinsic difference in functional mechanism may exist between the 
hearts of a hibernator and a non-hibernator enabling the hibernator to survive despite low 
body temperatures. Understanding the mechanisms regulating hibernation has the potential 
to develop therapies for conditions such as cardiac arrhythmias, hemorrhagic shock, stroke, 
cardiac arrest and cerebral ischemia (Drew et al., 2007).  
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1. Introduction 
It is well known that the heart generates and conducts electrical impulses, leading to a 
rhythmical contraction of the cardiac muscle. In normal situations, the atria contract about 
one sixth of a second ahead of ventricular contraction, allowing the filling of the ventricles 
before they pump the blood through the lungs and peripheral circulation. Additionally, all 
portions of the ventricles contract almost simultaneously, which is essential for a most 
effective pressure generation in the ventricular chambers. This rhythmical and conductive 
system is susceptible to damage by heart disease, especially by ischemia of the cardiac 
tissues. The result is often an abnormal heart rhythm and sequence of contraction of the 
heart chambers, leading to a reduction in pumping effectiveness, even to the extent of 
causing death (Hall, 2011). 
Heart rate (HR) is not a static hemodynamic parameter but instead changes over time in 
response to physical and mental demands. HR is normally determined by spontaneous and 
periodic depolarizations of the sinoatrial node, the frequency of which is modulated by the 
sympathetic and parasympathetic divisions of the autonomic nervous system, the intrinsic 
cardiac nervous system, reflexes, and respiration. These neural systems also partially control 
cardiac contractility and conduction of electrical activity through the heart. As a result, HR 
(chronotropism), contractility (inotropism), and conduction (dromotropism) are adjusted to 
meet the changing needs of the body (Feldman et al, 2010).  
2. Electrical activity of the heart 
The properties of automaticity and rhythmicity are intrinsic to the cardiac tissue and 
considered a very complex phenomenon and, besides cellular mechanisms, integrative 
different factors are involved in cardiac pacemaking. The cardiac electrical events are 
initiated with changes in the permeability of the cell membrane, mainly to Na+, K+ and Ca2+ 
ions. Changes in cell membrane permeability alter the rate of ion passage across the 
membrane with the opening and closing of ion channels. Two main types of action 
potentials are observed in the heart: (A) fast action potentials, that occur in the normal 
myocardial fibers in the atria and ventricles and in the specialized conducting fibers 
(Purkinje´s fibers) and (B) slow action potentials, which are found in the sinoatrial (SA) 
node, the natural pacemaker of the heart, and in the atrioventricular (AV) node, the 
specialized tissue involved in conducting the cardiac impulse from atria to ventricles 
(Bouman and Jongsma, 1986). 
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In mammalian, the region of the heart that ordinarily generates impulses at the greatest 
frequency is the SA node. In humans, it lies in the groove where the superior vena cava joins 
the right atrium. It is a small, roughly rectangular region at the edge of the right atrium, 
bounded on two sides by the superior and inferior vena cava and on the other two by the 
interatrial septum and the crista terminalis, a part of the right atrial muscle over whose 
endocardial surface the pacemaking tissue of the SA node extends (Brown, 1982). The intact 
sinoatrial node is a heterogeneous structure and contains 2 principal types of cells: 1) small, 
round cells, which have few organelles and myofibrils; and 2) slender, elongated cells, 
which are intermediate in appearance between the round and the ordinary atrial myocardial 
cells. The round cells are probably the pacemaker cells, whereas the transitional cells 
probably conduct the impulses within the node and to the nodal margins (Verheijck et al., 
2011; Verheijck et al., 2004; Tellez et al, 2006).  
In the SA node cells, the upstroke of action potential is less steep, the plateau is not 
sustained and the depolarization is more gradual. However, the principal distinguish 
feature of a pacemaker resides in resting phase. In nonautonomic cells,  the resting potential 
is constant, whereas in a pacemaker fiber there is as low depolarization that proceeds at 
steady rate until a threshold is attained, and then an action potential is triggered (Brown, 
1982; Berne and Levy, 2009). In the pacemaker cells of the SA node the diastolic 
depolarization is attributed to at least 3 ionic currents: (1) an inward current (If), induced by 
hyperpolarization; (2) an inward Ca+2 current, (ICa); and (3) an outward K+ current, IK . The 
inward current (If) is carried mainly by Na+  and the current is conducted through specific 
channels that differ from the fast Na+ channels. This current becomes activated during the 
repolarization phase of the action potential, as the membrane potential becomes more 
negative than about -50mV. The more negative the membrane potential becomes at the end 
of repolarization, the greater is the activation of the If current. The second current 
responsible for diastolic depolarization is the slow inward current. This current is composed 
mainly of Ca+2 and therefore it is referred to as the Ca+2 current, (ICa). This Ca+2 current is 
carried mainly by T-type Ca+2 channels. Once the Ca+2 channels become activated, the influx 
of Ca+2 into the cell increases and accelerates the rate of diastolic depolarization, which then 
leads to upstroke of the action potential. The progressive diastolic depolarization mediated 
by the 2 inward currents, If and ICa, is opposed by a third current, an outward K+ current, IK . 
This efflux of K+ tends to repolarize the cell after upstroke of the action potential. The 
outward K+ current continues well beyond the time of maximum repolarization, but it 
diminishes throughout the end repolarization. Hence the opposition of IK to the 
depolarizing effects of the 2 inward currents (ICa and If) gradually decreases (Brown, 1982; 
Berne and Levy, 2009). 
From the SA node the cardiac impulse spreads radially throughout the right atrium along 
ordinary atrial myocardial fibers, at a conduction velocity of approximately 1m/sec. A special 
pathway, the anterior interatrial myocardial band, conducts the impulse from the SA node 
directly to the left atrium. Tree tracts, the anterior, middle, and posterior internodal pathways, 
constitute the principal routes to the conduction of the cardiac impulse from the SA to AV 
node. The AV node contains the same two cell types as the SA node, however the round cells 
are sparser and elongated cells preponderate. The AV node has been divided into three 
functional regions: 1) the AN region, the transitional zone between the atrium and the remnant 
node; 2) the N region, the midportion of the AV node; and 3) the NH region, the upper portion 
of the specialized conducting system for the ventricles. Usually, the AV node and the bundle 
of His constitute the only pathways to action potential conduction from atria to ventricles. The 
 
Neurohumoral Control of Heart Rate 
 
169 
conductive system passes subendocardially down the right side of the interventricular septum 
for about 1cm and divides into the right and left bundle branches. The right bundle branch is a 
direct continuation of the bundle of His and it proceeds down the right side of the 
interventricular septum. The left bundle branch, which is considerably thicker than the right, 
arises almost perpendicularly from the bundle of His and cross the interventricular septum. 
The right bundle branch and the two divisions of the left bundle branch ultimately subdivide 
into a complex network of conducting fibers called Purkinje´s fibers, which ramify over the 
subendocardial surfaces of both ventricles (Brown, 1982). 
In the myocardium, the action potential generation includes 5 distinct phases:  1) Phase 0: the 
chemical and electrostatic forces both favor the entry of Na+ into the cell through fast Na+ 
voltage-gated channels to generate the upstroke; 2) Phase 1: the chemical and electrostatic 
forces both favor the efflux of K+ through transient outward current (Ito) channels to generate 
early, partial repolarization; 3) Phase 2: during the plateau, the net influx de Ca2+ through L-
type Ca2+ voltage-gated channels is balanced by the efflux of K+ through rectifier (Ik), inwardly 
rectifying (Ik1) and Ito channels;  4) Phase 3: the chemical forces that favor the efflux of K+ 
through  Ik, Ik1,Ito channels predominate over the electrostatic forces that favor the efflux of K+ 
through these same channels; 5) Phase 4: the chemical forces that favor the efflux of K+ through  
Ik and Ik1 channels exceed very slightly the electrostatic forces that favor the influx of K+ 
through these same channels (Berne and Levy, 2009).  
3. Neural control of HR 
The peripheral circulation distributes the cardiac output to the various organs and tissues 
according to their individual metabolic or functional needs while maintaining arterial blood 
pressure within a relatively narrow range. Regional blood flows can be efficiently regulated 
at the local level by the intrinsic ability of vessels to respond to various mechanical forces 
(e.g., wall tension and shear stress) as well as chemical stimuli (e.g., tissue metabolites and 
O2). However, a perfect regulation of the peripheral circulation cannot be achieved only by 
the local vascular control mechanisms, but require the coordinating activity of central neural 
outflow to the heart and blood vessels (Thomas, 2011). In this field, the autonomic nervous 
system plays an important role to normal cardiovascular control and changes in autonomic 
balance has been related to several cardiovascular disorders, such as cardiac arrhythmias 
and hypertension (Workman, 2010; Pagani and Lucini, 2001). 
3.1 The autonomic nervous system and cardiovascular control  
The autonomic nervous system is responsible for the involuntary control of most visceral 
organs, including the heart and the interactions between the sympathetic and 
parasympathetic limbs play a critical role in cardiac electrical stability and arrhythmias 
generation. In general, sympathetic activation has a profound arrythmogenic potential 
(Schwartz et al., 1978, Schwartz 1984). Experimental stimulation of sympathetic nerves or 
stellate ganglia induces ECG repolarization changes and reduces the brillation threshold, 
facilitating ventricular fibrillation (Yanowitz et al, 1966; Podrid et al, 1990), while the use of 
β-adrenergic blocking agents can improve survival in patients following myocardial 
infarction (Gottlieb et al, 1998). On the other hand, vagal activation has a powerful 
antifibrillatory effect (Vanoli et al., 1991; De Ferrari et al., 1994).  Therefore, autonomic 
imbalance could become either proarrythmic or anti-arrythmic based on which of the two 
components is going to prevail (Schwartz and De Ferrari, 2011).  
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In mammalian, the region of the heart that ordinarily generates impulses at the greatest 
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Preganglionic fibers of autonomic nervous system are originated from central nervous 
system (CNS) at the level of the brainstem or sacral spinal cord (parasympathetic fibers) and 
the thoracic or lumbar spinal cord (sympathetic fibers). Both parasympathetic and 
sympathetic preganglionic fibers release acetylcholine which binds to nicotinic receptors 
located in the cell bodies of postganglionic neurons, leading to action potential generation. 
This synapse occurs in autonomic ganglia located outside of the CNS (Thomas, 2011). 
The axons of postganglionic neurons innervate the effector tissues, including cardiovascular 
tissues. Parasympathetic neurons are distributed much more heterogeneously throughout 
the heart than sympathetic neurons. The density of parasympathetic innervation in the 
sinoatrial (SA) and AV nodes is considerably higher than in the surrounding atrial or 
ventricular tissue (Vaseghi and Shivkumar, 2008). Cardiac sympathetic innervation of the 
heart includes innervation of the SA node and myocardial cells. Based on norepinephrine 
content studies, a gradient exists in sympathetic innervation from atria to ventricles and 
from base to apex of the heart, indicating that the atria are most densely innervated, but the 
ventricles are also supplied with a sympathetic network, most densely at the base (Vaseghi 
and Shivkumar, 2008). Regarding the neurotransmitters, postganglionic parasympathetic 
fibers release acetylcholine, which binds to muscarinic receptors on the target tissue, while 
postganglionic sympathetic fibers release norepinephrine, which binds to either α or β 
adrenergic receptors (Thomas, 2011). 
The effects of sympathetic and parasympathetic neurons on HR will be based on changes in 
the ion currents of SA node action potential generation. Norepinephrine release from post 
ganglionic sympathetic neurons will increase the slope of diastolic depolarization in SA 
node by the enhancement of the resting potential, while acetylcholine release from 
parasympathetic postganglionic neurons will decrease the slope of diastolic depolarization 
by hyperpolarization of the resting potential (Verrier and Tan, 2009). Additionally, 
sympathetic stimulation increases the rate of conduction as well as the level of excitability in 
all portions of the heart and augments greatly the force of contraction of all the cardiac 
musculature. Maximal stimulation can almost triple the frequency of heartbeat and can 
increase the strength of heart contraction as much as twofold. On the other hand, 
parasympathetic stimulation to the heart decreases the excitability of the A-V junctional 
fibers between the atrial musculature and the A-V node, thereby slowing the transmission of 
the cardiac impulse into the ventricles (Guyton and Hall, 2006). 
Given the ability to modulate both HR and stroke volume, the autonomic nerves provide an 
important mechanism to rapidly adjust cardiac output to meet short-term changes in the 
body’s needs (cardiovascular reflexes). In humans, there is a good deal of tonic vagal 
discharge and a moderate amount of tonic sympathetic discharge, showing a 
parasympathetic prevalence on the heart. Additional vagal discharge can further reduce HR, 
consequently cardiac output, whereas additional sympathetic discharge can increase HR 
and stroke volume and augment cardiac output. Conversely, withdrawal of tonic vagal or 
sympathetic discharge has opposing effects to increase or decrease cardiac output, 
respectively (Thomas, 2011). 
4. Cardiovascular reflexes 
It is well known that the maintenance of arterial pressure at adequate levels to perfuse the 
tissues is a basic requirement for survival. In cardiovascular system, among the mechanisms 
that act buffering arterial pressure fluctuations we can highlight the role of the neural 
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reflexes. Such control is an important pathway to effect rapid changes in blood pressure and 
in the distribution of cardiac output that are essential to maintain a sufficient perfusion to 
vital organs, such as heart, brain and the kidney in face of physiological and environmental 
challenges. This rapid control of cardiovascular function is achieved through arterial and 
non-arterial reflexes that detect and correct changes in arterial blood pressure (baroreflex), 
blood volume (cardiopulmonary reflex) or chemical composition (chemoreflex) of the blood 
(Vasquez et al., 1997). It is important to notice that the effectiveness of these systems may be 
modulated by hormonal systems, such as angiotensin II and nitric oxide. The understanding 
of the key concepts about these reflexes under physiological conditions and the effects of 
hormonal substances on its functioning is an important step to clarify the development of 
arrhythmias. 
4.1 Baroreflex 
The baroreflex feedback loop is one of the most important mechanisms controlling arterial 
pressure. The main purpose of the baroreflex function is to provide a rapid and efficient 
stabilization of arterial blood pressure on a beat-to-beat basis by means of strategically 
located arterial sensors which are sensitive to high blood pressure and known as arterial 
baroreceptors. The baroreceptors endings are located in adventitia layer of carotid sinus and 
aortic arch with their soma located in the petrosal and nodose ganglia respectively. These 
receptors are mechano-sensitive and the distension of the vessels that occurs at each heart 
beat leads to action potential generation on these terminals which are transmitted to CNS, 
buffering arterial pressure fluctuations through changes in sympathetic and 
parasympathetic activity (Vasquez et al., 1997). 
To achieve this precise control, the generated action potentials in each systole travel 
centrally to synapse onto neurons in the nucleus tractus solitarii (NTS) in the dorsal 
medulla. NTS neurons project to “higher” brain nuclei, as well as other nuclei in  
the brainstem that are critical for efferent sympathetic and parasympathetic activity 
(Loewy and Spyer, 1990). Projections from NTS are connected to the inhibitory neurons of 
caudal ventrolateral medulla (CVLM) that subsequently synapse to excitatory neurons  
in the rostral ventrolateral medulla (RVLM). RVLM exerts a tonic discharge upon  
the preganglionic sympathetic neurons, located in the intermediolateral column (IML) of 
the spinal cord (Kirkman and Sawdon, 2004). Therefore, activation of the baroreceptor 
afferents innervating the NTS causes excitation of neurons projecting to the CVLM,  
which in turn inhibits RVLM. These events lead to less activity from the RVLM to IML, 
reducing sympathetic efferent activity (Figure 1A). Several studies have demonstrated 
that disturbances in the normal functioning of these nuclei can be related to the 
development of arrhythmias. In example, Issa et al. (2005) showed that the central 
inhibition of the sympathetic drive using clonidine reduces the occurrence of ventricular 
tachycardia/ventricular fibrilation in a canine heart failure model. 
In parallel, NTS neurons also synapse onto preganglionic vagal neurons localized within 
nucleus ambiguus (NA) and in the dorsal motor nucleus of the vagus (DMNX, Figure 1A). 
These neurons dominate the neural control of HR under normal conditions and also influence 
the prognosis of many cardiovascular disorders, such as sudden cardiac death, ventricular 
fibrillation, and myocardial ischemia (Wand et al, 2001). The axons from preganglionic cardiac 
vagal neurons travel down the vagus nerve and synapse onto postganglionic cardiac vagal 
neurons in cardiac ganglia. The synaptic innervation of cardiac vagal neurons is therefore 
critical for the tonic and reflex evoked changes in cardiac vagal activity that control HR. 
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Fig. 1. Schematic diagram showing the baroreflex functioning during normal (A), increased (B) 
and decreased blood pressure (C). NTS: nucleus tractus solitarii, NA: nucleus ambiguus, 
DMNX: dorsal motor nucleus of the vagus, CVLM: caudal ventrolateral medulla,  
RVLM: rostral ventrolateral medulla, IML: intermediolateral column, PSNS: parasympathetic 
nervous system, SNS: sympathetic nervous system, BP: blood pressure. The continuous arrow 
and the dashed arrows indicate a stimulatory and an inhibitory synapse, respectively. 
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Therefore, when blood pressure rises, the baroreceptor afferent activity augments, leading to 
increased vagal activity and diminished sympathetic outflow. These effects will reduce HR 
and cardiac contractility, causing a decrease in cardiac output. Additionally, the fall the 
sympathetic activity to blood vessels also leads to vasodilation, diminishing the vascular 
resistance (Figure 1B). The reduced cardiac output and vascular resistance return blood 
pressure to its original level.  On the other hand, a fall in blood pressure results in reduced 
baroreceptor afferent activity, causing a decrease in vagal activity and augmented 
sympathetic outflow (Figure 1C). These events increase cardiac output and vascular 
resistance, normalizing arterial blood pressure. 
Experimentally, the baroreflex function can be evaluated through changes in arterial 
pressure. In bolus phenylephrine injections elicits increases in arterial pressure leading  
to reflex bradycardia and sodium nitroprusside injections reduces arterial pressure 
causing reflex tachycardia. Typical recordings of baroreflex evaluation are displayed in 
Figure 2. 
4.2 Cardiopulmonary reflex 
Despite the great importance of baroreflex in controlling arterial pressure, several 
investigations have demonstrated that the neural reflex of circulation also depends on 
cardiopulmonary reflex. 
Cardiopulmonary receptors are found in low pressure portions of the circulation, such as 
walls of the atria and pulmonary arteries. These mechano-sensitive receptors are activated 
by the distension of the vessels walls, responding to changes in central blood volume 
(Thomas, 2011). The impulses arising from these receptors exert a tonic restraint on 
cardiac function and contribute to the physiological control of circulation. 
Cardiopulmonary reflexes are stimulated not only by changes in cardiac filling pressure 
but also by chemical agents, such as prostaglandins and serotonin (Vasquez et al., 1997). 
The cardiopulmonary fibers converge to the same pool of central neurons as the 
baroreceptors and act in a similar way (Spyer, 1990). Therefore, increased discharge of 
cardiopulmonary vagal afferent C fibers results in reflex enhancement of parasympathetic 
activity and decreased sympathetic outflow, leading to bradycardia, hypotension and 
apnea, also known as the Bezold-Jarisch reflex (BJR) (Kashihara, 2009). In addition, 
increased discharge of the cardiopulmonary receptors diminishes renal sympathetic 
outow and pituitary release of vasopressin, thereby decreasing Na+ and water 
reabsorption by the kidneys, increasing urine volume, and reducing blood volume. As 
changes in blood volume affect cardiac output and arterial pressure, this provides an 
additional mechanism by which the cardiopulmonary reex contributes to blood pressure 
regulation (Thomas, 2011). 
Interestingly, cardiopulmonary reflex may exert a tonic inhibitory influence in the arterial 
baroreflex sensitivity (Abboud and Thames, 1983). In pathological conditions, such as acute 
myocardial infarction, the reduction in baroreflex sensitivity could be explained by an 
increase in cardiopulmonary reflex sensitivity (Lacerda et al., 2007). Furthermore, the BJR 
activation might cause sudden cardiac death during ischemic injury (Robertson et al., 1985), 
since the overactivation of cardiopulmonary reflex together with baroreflex blunting might 
cause severe bradycardia and hypotension, placing the patient's life at risk due to the 
magnitude of sympathetic inhibition and vagal activation. These data demonstrate that the 
interplay between baroreflex and cardiopulmonary reflex may exert an important role in the 
progression of cardiovascular diseases and arrhythmias generation. 
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Fig. 2. Typical recordings of baroreflex evaluation in anesthetized rats. The phenylephrine-
induced increase in arterial pressure leads to reflex bradycardia (upper panel) and the 
sodium nitroprusside-induced decrease in arterial pressure results in reflex tachycardia 
(lower panel). The images were generously provided by Professor Helder Mauad from 
Federal University of Espirito Santo, Brazil. Data from Pedrosa et al., 2009. PAP: pulsatile 
arterial pressure, MAP: mean arterial pressure, HR: heart rate, PHE: phenylephrine, SNP: 
sodium nitroprusside. 
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Experimentally, the cardiopulmonary reflex function can be evaluated through 
phenylbiguanide injections. Figure 3 shows typical recordings of changes in arterial 
pressure and HR during cardiopulmonary reflex test. 
 
 
Fig. 3. Typical recordings of cardiopulmonary reflex evaluation in anesthetized rats.  
The activation of cardiopulmonary receptors is achieved by intravenous phenilbiguanide 
injections. The images were generously provided by Professor Helder Mauad from Federal 
University of Espirito Santo, Brazil. Data from Pedrosa et al., 2009. PAP: pulsatile arterial 
pressure, MAP: mean arterial pressure, HR: heart rate, PBG: phenybiguanide. 
4.3 Arterial chemoreflex 
The peripheral chemoreflex is considered one of the main mechanisms of control of the 
ventilatory responses to the changes in arterial O2 and CO2 concentrations. The peripheral 
chemoreceptors located in the carotid and aortic bodies, with afferents to the respiratory 
center in the medulla oblongata and the NTS, respond primarily to hypoxia (Guimarães et 
al., 2009). These chemo-sensitive receptors constantly receive information of arterial pO2, 
pCO2 e pH through a thin artery originated in the middle of the bifurcation of the common 
carotid artery that maintains these cells in close contact with blood gases (Vasquez et al., 
1997). Increases in the firing rate of these neurons lead to a simultaneously activation of 
sympathetic outflow to blood vessels and increased vagal activity to the heart (Kara et al., 
2003). Therefore, the excitation of the peripheral chemoreceptors produces an increased 
minute ventilation, systemic vasoconstriction and hypertension. The primary HR response 
to chemoreceptor stimulation is a parasympathetic mediated-bradycardia, but this 
mechanism is usually apparent only in the absence of ventilation. In the presence of the 
normal ventilatory response to hypoxia, tachycardia is generated by a lung inflation reflex 
that inhibits vagal outflow to the heart (Marshall, 1994). It is interesting to notice that, if 
blood pressure is within its normal range, the chemoreex does not evoke a powerful 
cardiovascular response because of the predominant effect of the arterial baroreex. 
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However, if blood pressure is low, generally below 80 mmHg, activation of the chemoreex 
potentiates the vasoconstriction evoked by the baroreex and helps to restore blood 
pressure to normal (Thomas et al., 2011).  
The role of chemoreflex in cardiac arrhythmias have been already demonstrated. Patients 
with survived ventricular arrhythmias show signicantly decreased chemoreex sensitivity 
(Hennersdorf et al., 1997). The chemoreflex sensitivity is also considered as a marker of 
increased risk for ventricular tachyarrhythmias, since it shows a high positive predictive 
power in patients with prior myocardial infarction and who previously survived ventricular 
tachyarrhythmias (Hennersdorf et al., 2002). Central sleep apnea, which is associated with 
absent respiratory effort and results from instability in the chemoreflex control of breathing, 
is thought to predispose to cardiac arrhythmias generation (Leung et al., 2009). 
Experimentally, the chemoreflex function can be evaluated through potassium cyanide 




Fig. 4. Typical recordings of chemoreflex evaluation. The activation of chemoreflex  is 
achieved by intravenous potassium cyanide injections. The images were generously 
provided by Professor Helder Mauad from Federal University of Espirito Santo, Brazil. Data 
from Pedrosa et al., 2009. PAP: pulsatile arterial pressure, MAP: mean arterial pressure, HR: 
heart rate, KCN: potassium cyanide. 
5. Humoral control of HR 
Several investigations have demonstrated that humoral systems can play a pivotal role in 
maintaining cardiac electric activity homeostasis and changes in their production and/or 
action pathways may contribute to various disorders in cardiac excitability. Additionally, 
the humoral systems can also modulate the autonomic nervous system and cardiovascular 
reflexes, demonstrating the importance of these substances in cardiovascular functioning.  
 




The sexual hormones are related mainly with the control of reproductive function, however 
they can also modulate the cardiovascular function. Estrogen is the main female sex 
hormone in both humans and animal models. It is produced in the granulosa cells of the 
ovarian cortex through the conversion of androgen precursors by the aromatase enzyme, 
which in turn is modulated by the hormonal hypothalamic-pituitary axis (Filicori, 1986). The 
protective effects of estrogen on cardiovascular function have been already demonstrated by 
several investigations. Indeed, estrogen replacement therapy reduces the incidence of 
coronary artery disease (Rowland & Fregly, 1992; Farhat et al., 1996). Corroborating these 
data, Moyses et al. (2001) showed that estrogen treatment in ovariectomized female rats 
restored coronary vasodilation produced by serotonin in isolated hearts, and a bolus 
injection of 17ß-estradiol elicited a transient vasodilatory response in male and female 
normotensive (Santos et al., 2004) and spontaneously hypertensive rats (Santos et al., 2010). 
It has been already demonstrated that estrogen levels are also related with the development 
of cardiac arrhythmias. During the menstrual cycle, estrogen levels rise and fall in women 
and these fluctuations are related with more frequent episodes with a longer duration of 
supraventricular tachycardia (Rosano et al., 1996). During perimenopause there is a marked 
decrease in ovarian estrogen production that is associated with an increase in HR (sinus 
tachycardia) and an enhancement in the frequency of palpitations and non-threatening 
arrhythmias, such as premature ventricular contractions (Rosano et al., 1996; Asplund and 
Aberg, 2003). During menopause a further decline in estrogen occurs and this event is 
associated with irregular heartbeats, palpitations, spasmodic chest pain and nightmares in 
women from 40 to 64 years old (Asplund and Aberg, 2003). Corroborating this data, 
hormonal replacement therapy (HRT) may decrease palpitations and other symptoms such 
as hot flashes, insomnia, and sweating (Grady et al., 2002). On the other hand, the Heart and 
Estrogen/Progestin Replacement Study (HERS) found no benefit to reduce cardiovascular 
events in women on HRT, which may even increase risk of thromboembolism during the 
first year (Grady et al., 2002). HRT has also being associated with lengthening the QT 
interval, although the relevance of this finding is not known (Gokce et al., 2005). Therefore, 
more investigations are necessary to better elucidate the benefits of HRT in preventing 
cardiac arrhythmias generations.   
The mechanisms by which estrogen may affect the development of cardiac arrhythmias 
include changes ion channels expression and/or activity. Most of the studies demonstrate 
that estrogen exerts antiarrhythmic effects, possibly by acting the L-type Ca2+ channels, 
contributing to its cardioprotective actions (Nakajima et al., 1999). Ulrich et al (2007) 
demonstrated that estrogen inhibits ICaL through direct interactions of the steroid with the 
channel protein in a rate dependent way, leading to a decreased contraction.  However, 
estrogen can also upregulates the sodium-calcium exchanger (NCX1) through a genomic 
mechanism mediated by estrogen receptors (ER), contributing to the enhanced propensity to 
early after depolarizations in female hearts (Cheng et al 2011). 
It is well established that estrogen can cross the blood brain barrier and be accumulated in 
regions of the brain to bring about changes in neural activity, including in autonomic 
functions (Lee and McEwen, 2001). This modulation may occur via activation of ERs, since 
ER mRNAs expression have been identified in central areas controlling cardiovascular 
function such as, NTS, CVLM, RVLM and IML (Spary et al, 2009).  
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Several studies have demonstrated the effects of estrogen on cardiovascular reflexes. In 
ovariectomized female rats, intravenous estrogen supplementation significantly reduced 
sympathetic tone within 30 minutes and significantly increased parasympathetic tone 
within 5 minutes of administration (Saleh and Connel, 2000). Corroborating these 
findings, Flues et al (2010) demonstrated that ovariectomized rats supplemented with 17β 
estradiol presented an exacerbated vagal tonus when compared to ovariectomized rats. 
This study also showed that ovarian hormones deprivation induced a higher sympathetic 
activity to the heart. Additionally, Minson et al (2000) reported an increase of baroreflex 
sensitivity (BRS) in phases of menstrual cycle with estrogen preponderance. An enhanced 
BRS is associated with an increase in parasympathetic and/or a decrease in sympathetic 
tone (Rovere et al, 2000), and the degree of BRS depression is significantly correlated to an 
increased likelihood of cardiac arrhythmogenesis (Saleh et al, 2003). Taken together, those 
data indicate a beneficial effect of estrogen in autonomic balance and in arrhythmias 
prevention. 
5.2 Testosterone 
Testosterone, the major androgenic hormone is synthetized and released by the Leydig cells in 
the testis. It also gives rise to two other potent androgens: dihydrotestosterone and 5-alfa-
androstenediol. Epidemiological and clinical studies indicate that testosterone status influence 
cardiovascular physiology and pathophysiology (Golden et al., 2002; Er et al., 2007). 
The effects of testosterone on cardiac electric activity have been poorly investigated. Sanchez 
et al. (2009) showed that the acute administration of 5-alpha-dihydrotestosterone elicited a 
negative chronotropism effect and increased SA node recovery time, which could improve 
cardiac performance. The authors also suggested that this effect might be due to an 
interaction with the underlying mechanisms involved in the pacemaker activity (Mangoni 
and Nargeot, 2008) such as T-type Ca2+ channel and inward rectier currents and a 
functional interaction with ionic pumps of plasma membranes. On the other hand, the acute 
treatment with testosterone enhanced the spontaneous beating frequency of cultured 
neonatal cardiomyocytes, which was associated with an increase in the level of expression of 
T-type Ca2+ channels (Michels et al., 2006).  It has also been reported that androgens produce 
changes in the male heart phenotype and on electrophysiological properties, such as 
shortening of the QT interval in males after puberty (Rautaharju, 1992; Lehmann, 1997; 
Locati et al., 1998). These contradictory data may be related to different basal HR values 
among various mammalian species, and more studies are necessary to better elucidate the 
role of testosterone on cardiac electric activity. 
Most of the research concerning the effects of gonadal hormones on the cardiovascular 
reflexes has focused on 17β-estradiol. However, other studies have provided evidence 
that androgens (including testosterone) play an important role in the control of 
cardiovascular function by modulation of cardiovascular reflexes (Caminiti et al., 2009). 
Steroids can cross the blood–brain barrier and act on the central nervous system, where 
androgen receptors in the central cardiovascular regulatory regions, such as NA and 
DMNX (Peuler et al., 1990; Pouliot et al., 1996) have been demonstrated. Therefore it is 
possible that androgens may act on brainstem vagal preganglionic neurons to modulate 
cardiomotor vagal activity. In accordance with this data, El-Mass et al. (2001) have shown 
that in male rats, castration caused a significant attenuation of baroreceptor control of 
reflex bradycardia versus no effect on reflex tachycardia. Testosterone replacement 
increased BRS to phenylephrine in castrated rats and restored reflex bradycardic 
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responses to levels similar to those of sham-operated rats. The muscarinic blockade by 
atropine in sham-operated rats caused a substantial reduction in BRS to phenylephrine, an 
effect that was significantly attenuated by castration and restored to sham-operated levels 
after testosterone replacement, suggesting that testosterone facilitates baroreceptor 
control of reflex bradycardia. Moreover, the modulatory role of testosterone on baroreflex 
responsiveness appears to involve, at least partly, enhancement of cardiac vagal efferent 
activity. Corroborating these data, a long-term testosterone therapy (6 weeks) improves 
the baroreflex sensitivity in men with chronic heart failure (Caminiti et al., 2009). The 
blockade of androgen receptor with flutamide attenuates the enhancement of baroreflex 
bradycardia in sexually mature male rats, indicating that the effects of testosterone on 
BRS depend on the involvement of the androgen receptor (Ward and Abdel-Rahman, 
2006). 
Besides the testosterone-induced effects on baroreflex, this sexual hormone may also 
modulate the cardiopulmonary reflex and the chemoreflex. Bissoli et al (2009) demonstrated 
that long-term treatment (8 weeks) with supraphysiological doses of nandrolone decanoate 
reduces the sensitivity of BJR control of HR in male rats. The effects of testosterone on BJR 
seem to be time-dependent, since the same treatment for 4 weeks had no effects on BJR nor 
the basal HR (Andrade et al., 2008). Pereira-Junior et al. (2006) showed that 10 weeks of 
high-dose nandrolone decanoate treatment leads to dysfunction in tonic cardiac autonomic 
regulation, with marked impairment of parasympathetic cardiac modulation and 
sympathetic hyperactivity. Regarding the chemoreflex, data from castrated male cats 
suggest that testosterone increases the hypoxic and hypercapnic ventilatory responses and 
augmented carotid body sensitivity to hypoxia (Behan et al., 2003). In adult rats, however, 
castration had no effect on the ventilatory response measured at the end of hypoxia (Joseph 
et al., 2002). On the other hand, Bairam et al. (2009) demonstrated that gonadectomy 
increased the acute breathing frequency response to hypoxia in neonatal rats. Because the 
rapid increase in breathing frequency is attributed to peripheral chemoreceptor activation, 
these data suggest that testosterone attenuates carotid body function. Although several 
studies demonstrated contradictory results about the benefic or malefic effects of 
testosterone on the modulation of cardiovascular reflexes, the characterization of the 
mechanisms could lead to a better understanding of the effects of testosterone in 
cardiovascular system and to the development of new therapies. 
5.3 Nitric oxide (NO) 
Since the discovery of the signaling properties of nitric oxide (NO) (Ignarro et al. 1987), it 
has been suggested that this important molecule may be involved in many physiological 
processes, such as the control of cardiovascular function. NO is a free radical synthesized 
from L-arginine by three isoforms of nitric oxide synthase (NOS): NOS1 (neural), NOS2 
(inducible), and NOS3 (endothelial) and all three isoforms have been shown to influence 
autonomic neural function in some manner (Schultz, 2009).  NO generated at nerve synapses 
diffuses in an autocrine and paracrine way to influence both presynaptic and postsynaptic 
events on excitatory and inhibitory synapses. NO exerts its cellular actions by binding to  
guanylyl cyclase to activate cGMP production, which remains the only fully recognized 
physiological signal transduction mechanism for NO. In central neurons, cGMP then can 
have diverse effects on neuronal excitability. Cyclic GMP can directly bind to and modulate 
cyclic nucleotide-gated ion channels, bind to phosphodiesterases to impair cAMP 
hydrolysis, or most prominently, activate cGMP-dependent protein kinase which can 
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guanylyl cyclase to activate cGMP production, which remains the only fully recognized 
physiological signal transduction mechanism for NO. In central neurons, cGMP then can 
have diverse effects on neuronal excitability. Cyclic GMP can directly bind to and modulate 
cyclic nucleotide-gated ion channels, bind to phosphodiesterases to impair cAMP 
hydrolysis, or most prominently, activate cGMP-dependent protein kinase which can 
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directly or indirectly leads to phosphorylation of effector proteins or ion channels (Schultz, 
2009). 
The effects of NO on baroreflex have been already demonstrated by several investigations. 
Meyrelles et al (2003) have shown that adenovirus-mediated eNOS delivery to carotid sinus 
adventitia leads to a diminished baroreceptor activity. NO seems to have an inhibitory effect 
on sodium currents in baroceptor neurons (Li et al., 1999) and activates calcium dependent 
potassium channels, leading to membrane hyperpolarization (Bolotina et al., 1994). 
Besides NO effects on baroreceptor afferents, NO also exerts effects on central nuclei 
regulating baroreflex function.  
Intracerebroventricular injections of L-NAME (an inhibitor of NO synthases) caused an 
enhancement in baroreflex sensitivity, indicating that NO may exert an inhibitory effect upon 
baroreflex (Matsumura et al, 1998). This inhibition appears to occur in both sympathetic and 
parasympathetic component of baroreflex. Liu et al (1996) demonstrated that NO synthase 
blockade with L-NNA causes an increase in the baroreflex gain, which is prevented by L-
arginine injections. This augmented sensitivity is blocked by the use of atropine, indicating an 
inhibitory effect of NO on the parasympathetic component of the reflex. NO also seems to 
exert sympatoinhibitory effects, as demonstrated by Zanzinger et al (1995) who show that L-
NNA administration leads to an increased basal sympathetic tonus. On the other hand, Dias et 
al. (2005) demonstrated a stimulatory effect of NO in the central nuclei controlling 
cardiovascular function. In this study, the renal sympathoinhibition induced by activation of 
baroreceptors and cardiopulmonary receptors is attenuated by the microinjection of L-NAME 
in the NTS.  The same investigators also demonstrated that NO increases the number of 
discharges evoked by excitatory amino acids in NTS neurons that receive vagal afferent inputs, 
and action potentials induced by iontophoretic application of AMPA in the NTS was reduced 
by L-NAME, indicating a excitatory effect of NO in this nucleus (Dias et al., 2003). Some 
studies also showed no effects of NO on baroreflex function. eNOS gene therapy did not alter 
baroreflex sensitivity and autonomic balance in C57 mice and was not able to prevent the 
increase in sympathetic tonus and the decrease parasympathetic activity to the heart in 
hypertensive mice (Gava et al., 2008). 
In addition to the brain, emerging evidence suggests that NO can also inuence 
sympathovagal function at the site of the end-organ itself, acting in sympathetic ganglia or 
vagal neurons. Neuronal nitric oxide synthase is localized in both intrinsic cardiac vagal 
neurons and stellate sympathetic ganglia innervating the SA node, indicating an important 
role NO in modulating of peripheral neuronal function (Herring and Paterson, 2009). In 
cholinergic neurons, NO seems to act increasing acetylcholine release through stimulation of 
soluble guanylate cyclase. The resultant generation of cGMP causes phosphodiesterase-3 
inhibition, increasing cAMP-PKA dependent phosphorylation of N-type calcium channel and 
calcium-induced exocytotic release of acethycholine (Herring & Paterson, 2001). However, in 
the AV nodal cells, NO regulates AV excitabilility by muscarinic cholinergic attenuation of 
ICa-L (L-type calcium current), the mechanism likely involves the cGMP-stimulated 
phosphodiesterase (Han et al., 1997). In sympathetic ganglia, NO reduces the release of 
noradrenaline through a soluble guanylate cyclase–cGMP dependent pathway that reduces 
calcium inux (Schwartz et al. 1995; Wang et al. 2007), probably via stimulation of PDE2 
and/or protein kinase G (Herring and Paterson, 2009). Despite some contradictory results, the 
role of NO in the modulating HR it is well established and the implication of changes in the 
NO production and/or activity for cardiovascular disease development remains an intriguing 
possibility of new targets for treating arrhythmias.  
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5.4 Renin-angiotensin-aldosterone system (RAAS) 
The RAAS is a peptidergic cascade with endocrine characteristics and is considered one of 
the most important systems that participate of cardiovascular control. In the classical view 
of RAAS, angiotensinogen, an alfa-glycoprotein, is released from the liver and is cleaved in 
the circulation by the enzyme renin that is secreted from the juxtaglomerular apparatus of 
the kidney to form the decapeptide angiotensin I (Ang I). Ang I is then transformed into to 
the octapeptide angiotensin II (Ang II) by angiotensin converting enzyme (ACE), a 
membrane-bound metalloproteinase, which is predominantly expressed in high 
concentrations on the surface of endothelial cells in the pulmonary circulation. Ang II, 
considered the main effector peptide of the RAAS, acts on specific receptors (AT1 and AT2), 
for example, to induce vasoconstriction on vascular smooth muscle cells or to stimulate the 
release of aldosterone from the adrenal cortex (Paul et al., 2006). 
Several lines of evidence suggest that Ang II may exert a direct modulation on cardiac 
ionic channels. Experiments have shown that stimulation of AT1 receptor result in the 
inhibition of transient outward potassium channel in myocytes from rat or canine 
ventricle (Shimoni and Liu, 2003; Yu et al., 2000). Ang II also increases cardiac L-type Ca2+ 
current (ICaL) in isolated cat myocytes (Aiello and Cingolani, 2001). In this view, the 
RAAS activation may therefore significantly contribute to the pathogenesis of cardiac 
arrhythmias. On the other hand, Ang II decreased the current density of L-type Ca2+ 
current in SA node cells and reduces the auto rhythm of SA node cells via enhancing 
slowly activated delayed rectifier K+ currents and reducing ICaL. Therefore, the elevated 
levels of Ang II may be involved in the occurrence of SA node dysfunction in cardiac 
pathophysiology (Sheng et al., 2011). 
Numerous studies already demonstrated that Ang II plays a pivotal role in the neural 
regulation of cardiovascular system. High concentrations of AT1 receptor and bers with 
Ang II immunoreactivity have been described in the dorsomedial and ventrolateral areas 
of the medulla (Allen et al., 1998; Averill and Diz, 2000). It is well known that Ang II 
causes an increased sympathetic drive, particularly by means of central mechanisms. In 
dogs, acute (21 h) and chronic (5 days) infusion of Ang II caused a two- to threefold 
increase in Fos-Li immunoreactivity in the NTS and CVLM, leading to a baroreceptor 
suppression of sympathoexcitatory cells in the RVLM (Lohmeier et al, 2002). Lesions at 
either the area postrema or the subfornical organ attenuate angiotensin II-based 
hypertension, indicating a direct central sympathoexcitatory action of Ang II (Collister 
and Hendel, 2003; Collister and Hendel, 2005). Corroborating these data, experimental 
models of angiotensin II-dependent hypertension present an augmented sympathetic 
drive (Peotta et al., 2007) and patients with chronic angiotensin-dependent renovascular 
hypertension have generally demonstrated higher sympathetic levels, correlated with 
circulating angiotensin II concentrations (Grassi e Esler, 2002). Besides Ang II effects on 
sympathetic drive, this peptide also exerts effects on the parasympathetic component of 
the reflexes. Borges et al. (2008) demonstrated that mice with renovascular hypertension 
presented diminished cardiac vagal activity, and together with an enhanced cardiac 
sympathetic activity, contributed to a reduced baroreflex sensitivity in this animal model 
of hypertension. Moyses et al. (1994) also demonstrated a reduced cardiac vagal activity in 
renovascular hypertensive rats.  
Although Ang II is considered the major effector of RAAS system, growing evidence have 
demonstrated an important role of angiotensin-(1-7) in cardiovascular regulation. This 
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In addition to the brain, emerging evidence suggests that NO can also inuence 
sympathovagal function at the site of the end-organ itself, acting in sympathetic ganglia or 
vagal neurons. Neuronal nitric oxide synthase is localized in both intrinsic cardiac vagal 
neurons and stellate sympathetic ganglia innervating the SA node, indicating an important 
role NO in modulating of peripheral neuronal function (Herring and Paterson, 2009). In 
cholinergic neurons, NO seems to act increasing acetylcholine release through stimulation of 
soluble guanylate cyclase. The resultant generation of cGMP causes phosphodiesterase-3 
inhibition, increasing cAMP-PKA dependent phosphorylation of N-type calcium channel and 
calcium-induced exocytotic release of acethycholine (Herring & Paterson, 2001). However, in 
the AV nodal cells, NO regulates AV excitabilility by muscarinic cholinergic attenuation of 
ICa-L (L-type calcium current), the mechanism likely involves the cGMP-stimulated 
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possibility of new targets for treating arrhythmias.  
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molecule can be formed from Ang I and Ang II fragments through an angiotensin-
converting enzyme (ACE) independent pathway (Santos et al., 2007). It has been 
demonstrated that Ang-(1-7) actions are often contrary to those described for Ang II 
(Benter et al., 1993). In fact, regarding the neural control of circulation, several studies 
have provided evidence that endogenous Ang-(1-7) enhances the baroreceptor reex 
bradycardia, while Ang II attenuates it (Campagnole-Santos, 1992; Sakima et al., 2007). 
The beneficial effect of Ang-(1-7) on cardiovascular reflexes was also demonstrated by 
Oliveira et al (1996) who showed that the central infusion of a selective Ang-(1-7) 
antagonist attenuates baroreflex and blocks the improvement in the reflex bradycardia 
produced by Ang-(1-7). The specific binding of Ang-(1-7) to its receptor (Mas receptor) 
seems to be a basic requirement for the maintenance of normal arterial blood pressure and 
cardiovascular reex control, since Mas-knockout mice presented hypertension and 
altered cardiovascular reflexes (Moura et al., 2010). 
5.5 Natriuretic peptides (NPs) 
The NPs play an important role in the regulation of cardiovascular homeostasis 
maintaining blood pressure and extracellular fluid volume. There are four major 
natriuretic peptides (NPs) that have been isolated: atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and Dendroaspis-type 
natriuretic peptide (DNP).  NPs exert their biological effects by binding to three distinct 
cell surface receptors denoted NP receptors A, B and C (NPR-A, NPR-B and NPR-C) (Rose 
and Giles, 2008).  
Several studies demonstrated that NPs affect the electrophysiology of the heart (Rose et al., 
2004) and central nervous system (Trachte et al., 2003; Rose et al., 2005). Voltage-clamp 
studies demonstrated that CNP can inhibit L-type Ca2+ current (ICa-L) through NPR-C 
binding. This inhibition involves a decrease in adenylyl cyclase activity, which leads to 
reduced intracellular levels of cAMP (Rose et al., 2003). These results were also 
demonstrated in isolated myocytes from mouse  SA node, that express several cAMP-
sensitive currents, including ICa-L (DiFrancesco, 1993). Corroborating these data, inhibition 
of adenylyl cyclase decreases HR and increases the P–R interval, suggesting that the 
atrioventricular conduction system is slowed following the activation of NPR-C. These data 
are consistent with other studies demonstrating a key role for L-type Ca2+ channels in the 
intrinsic regulation of SA node function and the determination of HR (Zhang et al., 2002; 
Mangoni et al., 2003). The molecular mechanism(s) by which CNP–NPR-C effects are 
compartmentalized in animal models SA node myocytes is not clear and will require further 
investigation. 
In addition to their effects on cardiac electric activity, NPs also exert effects on 
cardiovascular reflexes.  Thomas et al. (2001) showed that ANP, BNP and CNP enhance 
bradycardic responses to cardiopulmonary chemoreceptor activation in conscious sheep. 
On the other hand, Tallarida et al. (1991) demonstrated that intravenous infusion of ANP 
did not substantially change the baroreflex cardiocirculatory responses to loading and 
unloading carotid and aortic baroreceptors. Some of the reported discrepancies may be 
attributed to the dose of ANP, preparation (e.g., synthetic peptide vs. atrial extract) or to 
experimental conditions (e.g., anaesthetized vs. conscious). The target site(s) for the NPs 
action on cardio-cardiac vagal reflexes is not clear and more studies are necessary to 
better elucidate the mechanisms involved in NP-induced changes in cardiovascular 
reflexes.   
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5.6 Thyroid hormones (TH) 
Variations from euthyroid status affect virtually all physiological systems and the  effects on 
the cardiovascular system are particularly pronounced (Levey and Klein, 1990). 
Hyperthyroidism causes tachycardia and cardiac arrhythmias whereas bradycardia, 
reduced cardiac output, and slowed relaxation result from hypothyroidism (Klein and 
Ojamaa, 2001). The actions of TH are mediated by two nuclear TH receptors (TRs)- α and- β, 
encoded by two separate genes (Yen, 2001). TR-α1 isoform represents 70% of the TRs and 
serves an important role in cardiac development (Mai et al., 2004) and the regulation of 
heart rate and contractility (Dilmann, 2010; Macchia et al., 2001). Corroborating these data, 
Wikström et al. (1998) demonstrated that TR-α1 knockout mice presented a 20% reduction in 
HR and a prolonged relaxation time. The molecular explanation for these results includes a 
diminished expression of the hyperpolarization activated cyclic nucleotide-gated potassium 
channel 2, which plays a pivotal role for pacemaking (Macchia et al., 2001). 
Changes in thyroid status are associated with changes not only in cardiac and vascular 
function but also in autonomic regulation of the cardiovascular system (Levey and Klein, 
1990). In example, Foley et al. (2001) evaluated the effect of thyroid status on arterial baroreex 
control of lumbar sympathetic nerve activity (LSNA) and HR in conscious rats. The authors 
report that rats with hypothyroidism exhibit blunted baroreex mediated increases in LSNA 
and HR and a downward shift in baroreex control of HR compared with euthyroid rats. On 
the other hand, rats with hyperthyroidism presented normal baroreflex function and 
sympathetic tone to the vasculature. Although hypothyroidism has been associated with 
sympathovagal imbalance, current literature shows conicting results with either increased 
sympathetic activity  (Cacciatori et al., 2000), decreased sympathetic modulation (Gallet et al., 
2008) or an increased vagal tone (Xing et al., 2001).  
As observed, there is a complex relationship between humoral factors, neural systems (CNS 
and autonomic nervous system) and cardiac electric activity (Figure 5) and disturbances in 
these interactions may be related with the development of arrhythmias. 
 
 
Fig. 5. Schematic diagram showing the interactions between humoral factors, cardiac electric 
activity, autonomic balance and central nervous system and their role in arrhythmias 
generation. 
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Fig. 5. Schematic diagram showing the interactions between humoral factors, cardiac electric 
activity, autonomic balance and central nervous system and their role in arrhythmias 
generation. 
 




As observed, the normal control of HR depends on a complex interaction between neural 
and humoral factors and disturbances on these systems are strongly related with 
arrhythmias generation.  The formation of an action potential in the SA node and its 
propagation throughout the heart involves several ion channels, mainly Na+, K+ and Ca+2, 
and can be modulated by sympathetic and parasympathetic activation. The central outflow 
of autonomic nervous system is generated mainly in the brainstem and it involves the 
participation of diverse nuclei, such as NTS, CVLM and RVLM. The neuronal activity of 
these structures can be modulated by several hormones, including estrogen, testosterone, 
nitric oxide, angiotensin II, angiotensin (1-7), natriuretic peptides and thyroid hormones. 
Besides its effects on CNS, hormones can also regulate the release of neurotransmitters, the 
expression of ion channels and the activity of membrane transporters. Taken together, these 
data demonstrate the importance of neural and humoral systems in controlling 
cardiovascular function and brings out the possibility of new drug targets to treat 
arrhythmias. 
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As observed, the normal control of HR depends on a complex interaction between neural 
and humoral factors and disturbances on these systems are strongly related with 
arrhythmias generation.  The formation of an action potential in the SA node and its 
propagation throughout the heart involves several ion channels, mainly Na+, K+ and Ca+2, 
and can be modulated by sympathetic and parasympathetic activation. The central outflow 
of autonomic nervous system is generated mainly in the brainstem and it involves the 
participation of diverse nuclei, such as NTS, CVLM and RVLM. The neuronal activity of 
these structures can be modulated by several hormones, including estrogen, testosterone, 
nitric oxide, angiotensin II, angiotensin (1-7), natriuretic peptides and thyroid hormones. 
Besides its effects on CNS, hormones can also regulate the release of neurotransmitters, the 
expression of ion channels and the activity of membrane transporters. Taken together, these 
data demonstrate the importance of neural and humoral systems in controlling 
cardiovascular function and brings out the possibility of new drug targets to treat 
arrhythmias. 
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1. Introduction 
Presently is well established, that most physiological functions of living organisms fluctuate 
with a circadian dependence. Many experimental and clinical studies have demonstrated 
that cardiovascular functions show a marked circadian rhythmicity (Smith et al., 1987; 
Henry et al., 1990). Circadian fluctuations occur both in blood pressure and heart rate, but 
also in the ocurrence of ventricular dysrhythmias, the onset of cardiovascular symptoms, 
and the manifestations of cardiovascular diseases.  
Ventricular fibrillation is the most dangerous type of arrhythmia in humans and belongs 
to the group of the most frequent causes of sudden death after myocardial infarction. The 
development of ventricular fibrillation is strengthened by the difference between the 
duration of the refractory period and irregular electrical activity in the various parts of the 
heart. The probability of the development of such irregular activity is increased by an 
increased resting excitability, a decreased conduction velocity, and an increase in 
automaticity (Fisch, 1973; Opie et al., 1979; Carmeliet, 1988). The resistance of the heart to 
these disorders is dependent on its electrical stability, which can be measured by several 
parameters such as the duration of the vulnerable period (Wegria et al., 1941; Axelrod et 
al., 1975), ventricular flutter threshold (Szekeres & Papp, 1967), excitability threshold 
(Jones & Klein, 1982), or ventricular fibrillation threshold (Wegria et al., 1941; Gerst et al., 
1966). 
Factors that contribute to the development of various cardiac disorders not only include 
local myocardial ischemia (Ferrier et al., 1985; Saint et al., 1992), but also hypoxia 
(Nishimura et al., 1989) and respiratory and metabolic acidosis (Gerst et al., 1966; Rogers et 
al., 1973; Kujanik et al., 1984; 1985). It is generally accepted that some disorders of 
pulmonary ventilation belong to the group of proarrhythmogenic factors. The effect of 
systemic hypoxia, hypercapnia and acidosis (consequences of hypoventilation or an apneic 
episode) were investigated not only in experimental studies (Kujaník et al., 1984; 1985, 
Tomori et al., 1997; 2000) but also in clinical ones (Guilleminault et al., 1983; Peter, 1990; 
Kujanik et al., 2000a; 2000b). 
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Surprisingly, only a few studies have described the time of day that experiments were 
conducted or the synchronization of animals to external environmental periodicity such 
as the light-dark (LD) cycle. This can be a problem because the LD cycle represents one of 
the strongest circadian synchronizers of endogenous animal rhythms. For this reason, 
circadian variability should be considered an important factor especially in cardiovascular 
studies.  
2. Circadian rhythms of the electrical stability of the heart at the changes of 
the pulmonary ventilation 
2.1 Circadian rhythm of the electrical stability of the heart during normal ventilation 
In the cardiovascular system, most physiological phenomena (such as heart rate, blood 
pressure, atrioventricular conduction, etc), pathological events (cardiac ischemia, infarction, 
sudden cardiac death, etc.) as well as non-invasive cardiac electrophysiological phenomena 
(heart rate variability, T-wave alternans, QT dispersion, etc.) have circadian rhythms (Guo & 
Stein, 2002). Data regarding circadian patterns in arrhythmias reported in the medical 
literature are unclear because the data derived from almost all of the studies were 
confounded by a variety of factors extraneous to intrinsic arrhythmogenic activity 
(Portaluppi & Hermida, 2007).  
Knowledge regarding circadian variations in the electrophysiological properties of the heart 
is needed for more precise estimation of the risk of occurrence of ventricular arrhythmia. QT 
dispersion is considered to be an index of spatial inhomogenity of repolarization duration; 
increased dispersion of ventricular repolarization is believed to increase the risk of 
ventricular arrhythmia. Circadian variation of QT dispersion was detected in healthy 
subjects and in patients with uncomplicated coronary artery disease, with a peak value in 
the morning hours shortly after awakening (Bissinger et al., 2008; Hansen et al., 2008). In 
patients with heart failure or previous myocardial infarction (Hansen et al., 2008), or in 
patients with diabetes mellitus and coronary artery disease (Bissinger et al., 2008), circadian 
variation of QT dispersion was not detected. Gunez et al. (2008) found that P-wave 
dispersion (a new parameter for assessing the risk of atrial fibrillation) and QT dispersion 
do not show diurnal variation in patients with either ischemic or nonischemic heart failure 
treated with optimal drug therapy.  
The dependence of the electrophysiological parameters of ECG on the changing of LD cycles 
was also confirmed in experimental studies. The circadian fluctuation of the electrical 
stability of the heart, measured by ventricular arrhythmia threshold (VAT), was followed 
during normal ventilation, hypoventilation and hyperventilation in pentobarbital-
anesthetized rats after adaptation to a daily LD cycle of 12h:12h, with the dark period from 
18:00h to 6:00h for 4 weeks. The VAT was estimated as the minimal amount of electrical 
current (in mA) needed for elicitation of ventricular arrhythmias and was measured directly 
by electrical stimulation of the heart (in open-chest experiments). The stimulating electrodes 
(diameter 1 mm and 5 mm inter-electrode distance) were fixed at the base of the right 
ventricle of rats positioned supine. Cardiac stimulation (rectangular pulses with a frequency 
of 30 Hz, impulse lenght of 10 ms, stimulation duration of 400 ms) was triggered by the 
initial pulse of the R wave. Current intensity was increased progressively by steps of 0,2 mA 
until ventricular arrhythmias were obtained. The parameters of stimulation were chosen to 
apply at least one of the impulses during the vulnerable period provided that the duration 
of the stimulation covered a minimum of 2 to 3 heart cycles. The ventricular arrhythmias 
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were of a mixed type with spontaneous mutual transitions between ventricular fibrillation, 
ventricular tachycardia and flutter which were comparable among the groups.  
The 24h course of the VAT showed the highest susceptibility of the rat ventricular 
myocardium to arrhythmias between 12:00h and 15:00h and highest resistance between 
24:00h and 03:00h under normoxic conditions (Svorc et al., 1994). Acrophase with confidence 
intervals were on -3380 (-2880; -70), in time at 22:53h (19:20; 00:28h) with mesor 2,59 ± 0,53 
mA and amplitude 0,33 ± 0,11 mA (Figure 1). 
 
 
Fig. 1. Circadian rhythms of ventricular arrhythmia threshold during normal ventilation 
(gray columns), hypoventilation (empty columns) and hyperventilation (black columns); 
cosinor presentation of these rhythms during normoventilation (A), hypoventilation (B) and 
hyperventilation (C). Data are presented as mean ± SD. The dark bar indicates the dark cycle 
of the rat regime day.  
Mechanisms responsible for the circadian changes in the vulnerability of the heart are 
probably multifactorial and are associated mainly with changes in electrophysiological 
properties of the myocardium. These are recognized as essential for the triggering and 
maintenance of arrhythmias. Portaluppi & Hermida (2007) summarized circadian 
rhythms of arrhythmia occurrence in humans, with peaks between 06:00h and 12:00h (ie. 
during the active part of the day). Similarly, during the day, when sympathetic output is 
enhanced and heart rate increased, P wave duration and its area, P-R interval, QRS 
duration and Q-T interval have been found to decrease. Estimated trough values usually 
occurred between 10:00h and 14:00h. During the night, following sympathetic withdrawal 
and parasympathetic dominance, the values of these electrical parameters increase, 
reaching their peak values between 12:00h and 06:00h. These changes are regulated 
mainly by the autonomic nervous system, which enables the heart to adapt to circadian 
fluctuations in demand by adjusting both its electrical activities and mechanical function 
(Guo & Stein, 2002).  
In rats, the opposite tendency was observed. The highest vulnerability of the rat ventricular 
myocardium to arrhythmias occurred between 12:00h and 15:00h (non-active part of the day) 
and the highest resistance between 24:00h and 03:00h (active part). The possible mechanisms 
controlling the circadian rhythm of the VAT under normoxic conditions in rats can mainly be 
seen in the circadian alternations of the electrophysiological properties of the myocardium, 
which are determined to a large extent by a K+ gradient (Fisch, 1973). Dispersion of duration of 
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were of a mixed type with spontaneous mutual transitions between ventricular fibrillation, 
ventricular tachycardia and flutter which were comparable among the groups.  
The 24h course of the VAT showed the highest susceptibility of the rat ventricular 
myocardium to arrhythmias between 12:00h and 15:00h and highest resistance between 
24:00h and 03:00h under normoxic conditions (Svorc et al., 1994). Acrophase with confidence 
intervals were on -3380 (-2880; -70), in time at 22:53h (19:20; 00:28h) with mesor 2,59 ± 0,53 
mA and amplitude 0,33 ± 0,11 mA (Figure 1). 
 
 
Fig. 1. Circadian rhythms of ventricular arrhythmia threshold during normal ventilation 
(gray columns), hypoventilation (empty columns) and hyperventilation (black columns); 
cosinor presentation of these rhythms during normoventilation (A), hypoventilation (B) and 
hyperventilation (C). Data are presented as mean ± SD. The dark bar indicates the dark cycle 
of the rat regime day.  
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the refractory period (QT interval) is the result of the action of more ion currents (Ca2+, Na+, Cl- 
and inward rectifying K+ current) (Amitzur et al., 2000), which depends mainly on 
intracellular K+ concentration (Froldi et al., 1994). The incidence of ventricular arrhythmias 
directly correlates with serum K+ decreasing with a higher K+ concentration (Curtis et al., 1985; 
Winslow et al., 1989). In circadian dependence, the peak of minimal myocardial vulnerability 
to ventricular arrhythmias coincides with the peak of the maximal K+ serum concentration in 
rats (Stoynev et al., 1986; Poulis et al., 1989; Granda et al., 1996). The speed of impulse 
conduction from atria to ventricles (PQ interval duration) depends on action potential 
amplitude, reflecting the active role of Na+ channels (Carmeliet , 1988; Amitzur et al., 2000). 
Statistically significant sodium circadian rhythm occurs in the dark part of the rat regime day 
(Granda et al., 1996), which can increase vulnerability of the heart mainly to the arrhythmias 
originating from disorders of impulse production and conduction. Thus, the circadian 
pacemaker controlling the rhythm of serum K+ likely plays a key role in the circadian control 
of the VAT in rats under normal ventilatory conditions. 
The next mechanism directly controlling the circadian rhythm of the electrical stability of 
the heart, involves the autonomic nervous system. Circadian rhythms in the autonomic 
nervous system activity are well known and constitute major triggers of cardiac 
arrhythmias. Increased sympathetic activity accelerates heart rate, favors spontaneous 
depolarization, shortens the effective ventricular refractory period, and decreases the 
threshold for ventricular fibrillation. In contrast, increased parasympathetic activity slows 
heart rate, decreases atrioventricular (AV) nodal conduction and in the presence of 
baseline sympathetic neural activity, increases both the ventricular refractory period and 
the ventricular fibrillation threshold (VFT) (reviewed in Portaluppi & Hermida, 2007). 
This direct and clear dependence, described in humans and in larger experimental 
animals, was not confirmed in rats (Svorc et al., 1994). The course and acrophase of the 
circadian rhythm of heart rate did not correspond either to the course or to the acrophase 
of the circadian rhythm of the VAT. Loss of heart rate dependence on the LD cycle refers 
to the fact that pentobarbital anesthesia probably minimizes or disturbs the effect of the 
LD cycle on heart rate under conditions of normal pulmonary ventilation. These results 
are consistent with results of Bruguerolle's group, who demonstrated the pertubations of 
daily rhythm of heart rate, locomotor activity and body temperature in rats but under 
ketamine anaesthesia.  Total anaesthesia can probably modify the acrophase, mesor and 
amplitude of some rhythms but without the loss of the total rhythmicity (Prudian et al., 
1997; Pelissier et al., 1998). 
2.2 Circadian rhythm of the electrical stability of the heart during hypoventilation 
Hypoxic states of the heart result from disproportionate amounts of oxygen supplied to 
cardiac cells and the amount actually required by the cell. The degree of hypoxic injury does 
not only depend on the intensity and duration of the hypoxic stimulus, but also on the level 
of cardiac tolerance to oxygen deprivation. Such oxygen deprivation can result from 
systemic hypoxia or local ischemia with consequences of two different mechanisms of action 
at the cellular level. Systemic hypoxia is usually a generalized phenomenon diffusely 
involving the whole myocardium, whereas ischemia is confined to the area supplied by the 
affected coronary artery. In ischemia, there is not only a drop in the supply of oxygen and 
other substrates, but also a significant reduction in the clearance of metabolites. In contrast, 
in ischemic hypoxia (often described as „cardiac hypoxia“) there is a combined action of 
both ischemia and hypoxia, while perfusion results in partial elimination of metabolites. 
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Ischemic hypoxia is clinically manifested primarily in ischemic heart disease (coronary 
artery disease) and its acute form, myocardial infarction, whereas systemic hypoxia is 
associated with chronic cor pulmonale of various origin, cyanosis due to a hypoxemic 
congenital heart disease, exposure to low barometric pressure (e.g. at high altitudes and 
ventilatory disorders) (Ostadal et al., 1999).   
The effects of ventilatory disorders on the heart were broadly investigated in more 
experimental animal studies and under various experimental conditions. Failure of, or 
decrease in pulmonary ventilation is associated with systemic hypoxia, hypercapnia and 
acidosis resulting in various disorders of cardiovascular system activity.  
There are some clinical trials describing the circadian rhythmicity of the cardiovascular 
events associated with changes in pulmonary ventilation. We cite the study by Kujanik et al. 
(2010) who referred to the incidence of the supraventricular and ventricular extrasystoles in 
healthy elderly men at low (200 m) and moderate altitude (1350 m) in the circadian 
dependence. The moderate altitude with the lower pO2 shifted the highest occurrence of 
supraventricular and vetricular extrasystoles to the other times of day and increased the 
incidence of extrasystoles compared to low altitude by 2-fold. The authors concluded that 
the increase in extrasystole occurrence at high altitudes is probably caused by higher 
hypobaric hypoxia and resulting sympathetic drive. Healthy men at elevated altitudes show 
circadian and several ultradian rhythms of single ventricular extrasystoles dependent on the 
level of hypoxia.  
Sleep, ventilatory disorders, especially obstructive or central sleep apnea (OSA or CSA), 
are associated with neurohormonal and electrophysiological abnormalities that may 
increase the risk of sudden death from cardiac causes, especially during sleep. Gami et al. 
(2005) followed this dependence in 112 subjects who died suddenly from cardiac causes. 
They found that from midnight to 06:00h, sudden death from cardiac causes occurred in 
46% of patients with OSA compared with 21% of individuals without OSA. Patients who 
experienced sudden death from cardiac causes from midnight to 06:00h, had a 
significantly higher apnea-hypopnea index than those with sudden death from cardiac 
causes during other intervals, and the apnea-hyponea index correlated directly with the 
relative risk of sudden death from cardiac causes from midnight to 06:00h. Thus, 
individuals with OSA experience a peak in sudden death from cardiac causes during the 
hours of sleep, which contrasts strikingly with the nadir of sudden death from cardiac 
causes during this period in people without OSA. Variation in the onset of myocardial 
infarction was found in patients with and without OSA. Myocardial infarction occurred 
between midnight and 06:00h in 32% of OSA patients and 7% of non-OSA patients. Of all 
patients who experienced a myocardial infarction between midnight and 06:00h, 91% had 
OSA (Kuniyoshi  et al., 2008). These findings suggest that OSA may be a trigger for 
myocardial infarction in patients who experience nocturnal onset of myocardial infarction 
should be evaluated for OSA. Future research should address the effects of OSA therapy 
for prevention of nocturnal cardiac events. These studies refer to the fact that circadian 
rhythmicity may have practical relevance in screening for patients with OSA and may 
have prognostic clinical value in predicting future cardiovascular events (Gami et al., 
2005; Kuniyoshi et al., 2008). 
In experimental animal models, the link between disorders of pulmonary ventilation and 
the incidence of ventricular arrhythmias was also demonstrated in the circadian 
dependence. Otsuka & Watanabe (1990) followed the circadian rhythms of three types of 
bradyarrhythmia incidence in rats. The 24h chronogram of bradyarrhythmia incidence 
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showed 2 peaks: the higher peak between 05:00h and 09:00h (immediately after the start of 
the light cycle) and the second one between 11:00h and 18:00h.  The hourly distribution of 
the apnea index coincided with the highest peak of the 24h chronogram of bradyarrhythmia 
incidence in rats. In ketamine/xylazine-anesthetized rats from experiments performed by 
Bacova et al. (2010), RR and PQ interval duration showed the significant LD differences, 
except in the QT and QTc interval in spontaneously breathing animals. The initial significant 
LD differences in PQ interval and loss of dependence on LD cycle in the QT interval were 
preserved during short-term asphyxia induced by apneic episode (30 s to 60 s). In contrast, 
long-term asphyxia (90 s to 120 s) eliminated LD dependence in the PQ interval; however, 
significant LD differences were shown in the QT interval. It was concluded that myocardial 
vulnerability was dependent not only on changes in pulmonary ventilation but also on the 
LD cycle.   
In our hypoventilatory rat model, hypoventilation-induced systemic hypoxia, hypercapnia 
and acidosis decreased the VAT and heart rate values in all measured intervals during a 24h 
period. The mesor (1, 33 mA), amplitude (0,14 mA) was decreased, and the circadian 
rhythm of the VAT was changed to biphasic with a smaller peak between 15:00h and 18:00h 
and higher peak between 24:00h and 03:00h. The hypoventilatory circadian rhythm of the 
VAT was not significant as revealed by the population mean cosinor (Svorc et al., 1997, 
2000a) (Figure  1).    
The decreased electrical stability of the heart during the course of the entire 24h period 
confirmed results from other electrophysiological studies investigating the effect of 
hypoxia on myocardium. The duration of the action potential was significantly decreased 
at the start of hypoxia in isolated hearts of rats (Perchenet and Kreher, 1995), rabbits 
(Baker et al., 2001), cats (Vleugels et al., 1980), guinea pigs (Sanguinetti et al., 1988) and 
dogs (Ferrier et al. 1985). The phase plateau of action potential shortened, and ATP 
content decreased (Noma, 1983). In isolated rabbit AV preparations, hypoxia impaired AV 
nodal conduction and depressed automaticity (Nishimura et al., 1989). In in vivo rabbit 
models, the sinus interval was gradually increased with duration of hypoxia. Atrio-His 
interval and His-ventricular intervals were prolonged (Sawanobori et al., 1995). The 
membrane potential was decreased, excitability and impulse conduction between Purkinje 
fibres and muscle tissue were depressed in isolated Purkinje fibres of papillary muscle 
from dogs (Ferrier et al. 1985).   
In experiments using cats, hypercapnic hypoxemia produced N2 inhalation and evoked all 
types of conduction blockades, supraventricular extrasystoles, peaked T waves, elevated ST 
segments and decreases in R waves (Tomori et al., 1997; 2000).  In experiments conducted by 
Gerst et al. (1966) using dogs, pH changes owing to respiratory acidosis and alkalosis did 
not affect the electrical stability of the heart, measured by VFT. Neither respiratory acidosis 
nor hypoxia alone significantly changed the VFT, but together they increased the followed 
parameter in the canine ventricle (Rogers et al., 1973). Kujanik et al. (1985) described 
dynamic changes of the VFT in rats with various types of ventilation, but not its circadian 
dependence. The VFT was decreased during mild hypoxia and acidosis and increased 
during serious hypoxia and acidosis. The vulnerable duration period was prolonged during 
hypoventilation.   
These disorders can be explained by a sudden increase in extracellular K+ concentration, 
which plays a crucial role in the changes in resting membrane potential, and can produce 
ectopic activity as well as inhibition of the rapid reaction (Opie et al., 1979). The rapid 
increase in extracellular K+ concentration is the result of KATP channel  activation. It is 
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inactivated in normoxic conditions, but it is activated in hypoxic or anoxic conditions 
(Noma & Shibasaki, 1985; Sanguinetti et al., 1988; Daut et al., 1990; Billman et al., 1993). 
During ischemia, activation of  KATP channels limits Ca2+ input into metabolically stressed 
cells. In ischemic regions, it can lead to the dispersion of refractory periods between normal 
and ischemic myocardium; thus, the blockade of KATP channels acts as an antiarrhythmic 
(Wolleben et al., 1989). On the other hand, no correlation between total ATP concentration 
and the electrical activity of the heart was found during relative hypoxia or ischemia of the 
myocardium (Kreher & Wedetti, 1986). We can suppose that the mechanism of K+ current 
activation by hypoxia can also be responsible for changes in the electrical stability of the 
heart in circadian dependence, although the biphasic course of VAT is not specifically 
explained by this mechanism.  
The control mechanisms responsible for the biphasic circadian course in the electrical 
stability of the heart during hypoventilation are not known, they are probably multifactorial 
and are mainly associatedwith changes in the electrophysiological properties of 
myocardium in hypoxic conditions. The biphasic course can be partly explained by the 
effect of histamine on rat ventricular arrhythmias under hypoxic conditions. Dai (1989) 
demonstrated that hypoxia and histamine can increase susceptibility to arrhythmias. If 
hypoxia does not alter the circadian rhythm of blood histamine levels, then increased 
myocardial susceptibility to arrhythmias can be in the certain range influenced by histamine 
under the hypoxic conditions. Our results from a hypoventilatory rat model support this 
hypothesis. The very close relationship is between rhythm of the electrical stability of the 
heart and the rhythm of histamine concentration in the blood. In a rat model, Catini & 
Legnaioli (1992) showed (upon synchronization to a natural lighted regime) that circadian 
oscillations in histamine concentration in the blood and in the thyroid gland are biphasic, 
with peaks at 07:50h and at 19:50h, in time the lowest VAT.    
2.3 Circadian rhythm of the electrical stability of the heart during hyperventilation 
In our experiments, hyperventilation increased the VAT at each measurement interval, but 
did not change the characteristic of its circadian rhythm. The 24h hyperventilatory rhythm 
of the VAT was non-significant, acrophase was shifted to –400 (02:40h), mesor was increased 
(2,91 mA) and amplitude was decreased (0,13 mA) (Figure 1) (Svorc et al., 2002). Although 
the results are not unequivocal, these ventilatory changes probably have a causal 
relationship with disorders of ion kinetics and/or ion distributions inside and outside of 
myocardial cells, and also with  circadian dependence.  From what is currently known, if the 
electrical stability of the heart is dependent on ion concentration changes, it follows that 
circadian rhythm of the VAT most probably behaves similarly to the circadian rhythms of 
the single ions. The unanswered question is how does light and dark act on ion kinetics 
ventilatory disorders and on return to normal ventilatory conditions, after synchronization 
to a 12h:12h LD regime?  
3. The electrical stability of the heart in a hypoventilation/reoxygenation 
model 
The onset and development of ventricular arrhythmias depends on many factors to which 
some disorders of pulmonary ventilation also belong. However, not all consider the effect of 
the recovery of oxygen delivery (reoxygenation) after hypoxic episodes to be the onset or 
development of ventricular arrhythmias. Reoxygenation after hypoxic episodes does not 
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automatically normalize myocardial properties (electrophysiological and mechanical), but 
can increase the risk of onset of reoxygenation arrhythmias (Winslow et al., 1983; Perchenet 
& Kreher, 1995; Bilinska et al., 1996; Bernauer, 1997; Mubagwa et al., 1997; Shinmura et al., 
1997; Guo et al. 2005).  
Tissue hypoxia, for example in patients with sleep apnea, is an important factor in heart 
disease (Yokoe et al., 2003). Hypoxia and reoxygenation expose the myocardium to extremes 
in redox stress, which can result in the initiation of a series of cellular pathways leading to 
tissue injury and death. Myocardial hypoxia reduces left ventricular contractile performance 
(Tanonaka et al., 1989; Draper & Shah, 1997; Jeroudi et al., 1994; Kang et al., 2000); however, 
recovery of the contractile force was less than 10% and recovery of the myocardial high-energy 
phosphates during reoxygenation was approximately 40% (Tanonaka et al., 1989). 
The study by Pahor et al. (1989) demostrated the antiarrhythmic effect of verapamil on 
spontaneous ventricular arrhythmias during reoxygenation after 15 min of glucose-free 
hypoxia and on programmed electrical stimulation-induced ventricular fibrillation in 
isolated Langendorff-perfused guinea pig hearts. Verapamil added during reoxygenation 
reduced the incidence of reoxygenation arrhythmias and ventricular fibrillation, but it had 
no effect on programmed stimulation-induced ventricular fibrillation. It is likely that 
verapamil exerts its antiarrhythmic effect by preventing cellular calcium overload during 
hypoxia and reoxygenation.  
Hypoxia and mild acidosis progressively diminished the amplitude and duration of these 
slow-response action potentials, whereas reperfusion/reoxygenation progressively 
increased their amplitude even more than that in the control (prehypoxic value). Action 
potential duration increased (at all levels) during reperfusion compared with that in 
hypoxia and mild acidosis; however, action potential duration remained shorter than the 
control (prehypoxic level). The effects of hypoxia (and mild acidosis) and subsequent 
reoxygenation seem similar to the effects of elevating extracellular kalcium levels (increased 
inward current). From these experiments, one cannot, however, distinguish the effects of 
hypoxia on the inward currents from those on the outward currents (Bhattacharyya & 
Acharya, 1988). The response of hypoxic and acidotic ventricular muscle tissue to 
subsequent reoxygenation was studied by Bhattacharyya et al. (1991). Ventricular muscle 
tissue exhibited the different response to reoxygenation after hypoxia and acidosis: (1) 
arrhythmias, without much depolarization of the membrane potential; (2) oscillatory 
afterpotentials during the late diastole, which lessened in amplitude as the time of 
reoxygenation increased, but no arrhythmias; or (3) a pronounced slowed phase of 
repolarization (hump), but no arrhythmias. These different effects of reoxygenation did not 
occur if the concentration of K+ in hypoxic and acidotic ventricular muscle tissue was much 
higher than 4.6 mM. Common to these three different responses was the prolongation of the 
action potential duration during reoxygenation at the 50% and 90% levels of repolarization 
(APD50 and APD90) and a slight increase in the resting tension after 30 to 40 min. of 
reoxygenation.  
Membrane potential changes of atrial fibroblasts in response to mechanical stress have 
been considered to modulate the rhythmic electrical activity of healthy hearts. It is 
suggested that cardiac arrhythmia after infarction is related to enhanced susceptibility of 
fibroblasts to physical stretch. It indicates that transmembrane currents in atrial 
fibroblasts are sensitive to changes in tissue oxygenation and altered electro-mechanical 
function of the ischemic heart may involve changes in the membrane potential of cardiac 
fibroblasts (Kamkin et al., 2003). 
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The proarrhythmogenic effect of reoxygenation was confirmed by several studies using 
various agents. For example, in the papillary muscles of guinea pigs, Ca2+ entry through 
Ca2+ channels apparently synchronized Ca2+ release from the sarcoplasmic reticulum, and 
a high concentration of D-600  apparently decreased the incidence of arrhythmias. 
Tetrodoxin and nicorandil decreased arrhythmias, probably by decreasing the Na+ current 
or by increasing the ATP-sensitive K+ current, respectively (Hayashida et al., 1996). Thus 
nicorandil antagonizes the cellular mechanisms that underlie the reoxygenation 
arrhythmias and prevent reoxygenation-induced arrhythmias (Xu et al., 1993). The effects 
of a selective blocker of Ca2+ influx by Na+/Ca2+ exchange, KB-R7943, on the 
reoxygenation-induced arrhythmias and the recovery of developed tension after 
reoxygenation, were investigated in guinea pig papillary muscles. This blocker selectively 
inhibited the reverse mode of Na+/Ca2+ exchange, attenuated reoxygenation-induced 
arrhythmic activity and prevented contractile dysfunction in guinea pig papillary 
muscles. These results suggest that Ca2+ influx by Na+/Ca2+ exchange may play a key role 
in reoxygenation injury (Mukai et al., 2000).  
It is well established that hypoxia followed by reperfusion may be fatal and result in 
generation of reactive oxygen species (ROS) and subsequent tissue damage (Danielsson et 
al., 2007) and is associated with additional damage to the myocardium by oxidation of 
cellular components and activation of the inflammatory cascade (Cerniway et al., 2002). 
Some of isoflurane's cellular actions, such as interference with intracellular Ca2+ handling, 
inhibition of the respiratory chain, and the capability to produce oxygen radicals, could 
result in impaired cellular function during ischemia/reoxygenation. When isoflurane was 
applied during ischemia/reperfusion, intracellular Ca2+, oxygen radical formation, 
arrhythmic events, and contractile function were increased in rat cardiomyocytes. 
Furthermore, increased oxygen radical generation was detected in isoflurane-treated 
myocytes during reoxygenation. Isoflurane given during ischemia/reperfusion in a study 
by Dworschak et al. (2004) induced intracellular Ca2+ accumulation and impaired cell 
function. These potentially harmful effects were associated with diminished Ca2+ clearance 
and accelerated oxygen radical production. In clinical practice, reperfusion of ischemic 
myocardium usually occurs under high arterial oxygen levels. However, this might 
aggravate cardiac ischemia/reperfusion injury caused by excessive oxidative stress. In an 
experimental in vivo study, the cardioprotective role of hypoxic reoxygenation during initial 
reperfusion was assessed. Hypoxic reoxygenation at the onset of reperfusion attenuated 
myocardial ischemia/reperfusion injury and helped to preserve cardiac performance after 
myocardial ischemia in a pig model (Abdel-Rahman et al., 2009). 
The mitochondrial KATP channel (mitoKATP) opening which can be triggered by activation 
of the angiotensin II (Ang II) type 1 receptor on ischemia/reperfusion causes ROS-
induced ROS release. The electrophysiological actions of Ang II linked with the genesis of 
reperfusion arrhythmias were elucidated by clarifying the roles of Ang II and mitoKATP on 
cardiac impulse propagation. MitoKATP blocker and AT1 receptor blocker abolished 
conduction block and conduction delay induced by Ang II. This result demonstrated that 
a mitoKATP channnel blocker protectively associated with arrhythmogenesis properties 
during reoxygenation (Wakatsuki et al., 2009). The inhibition of inducible nitric oxide 
(NO) synthese (NOS) raises the peroxidative and apoptotic level in the hypoxic heart 
indicating that this isoform may have a protective effect on this organ against 
hypoxia/reoxygenation injuries, and challenges the conventional wisdom that isoforms of 
NOS are deleterious under these conditions. These findings could help in the design of 
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new treatments based on NO pharmacology against hypoxia/reoxygenation dysfunctions 
(Rus et al., 2011).  
In contrast to previous evidence about the harmful effect of reoxygenation on 
myocardium, Milano et al. (2010) refer to the protective effect of chronic hypoxia against 
ischemia/reperfusion damage. In rat experiments, exposure to chronic hypoxia results in 
impairment of myocardial tolerance to ischemia/reperfusion, greater injury and reduced 
recovery of performance. Daily reoxygenation markedly reduced hypoxia-induced 
derangements by accelerating intrinsic adaptive changes in the myocardium. These 
findings correlate with enhanced NO signalling via up-regulation of the endothelial 
isoform of NOS.   
Studies investigating the effect of ischemia/reperfusion or hypoxia/reoxygenation on the 
onset and development of ventricular arrhythmias concentrate mainly on the temporally 
current mechanical and metabolic changes in myocardial cells, often without respect to 
circadian dependence. The question remains whether vulnerability of the ventricles to 
arrhythmias is primarily changed only by the factors resulting from altered ventilation, or 
are there also natural factors (eg, environmental periodicities) that can influence the 
parameter being studied?   
 
 
Fig. 2. Circadian rhythms of the ventricular arrhythmia threshold during normoventilation 
(empty columns) and reoxygenation after hypoventilation (black columns); cosinor 
presentation of these rhythms during normoventilation (A) and reoxygenation (B). Data 
presented as mean ± SD. The dark bar indicates the dark cycle of the rat regime day.  
The analysis of VAT circadian rhythms was performed in a hypoventilation/reoxygenation 
group, in which pentobarbital anaesthetized animals were subjected to 20 min. of 
hypoventilation followed by 20 min. of reoxygenation. Reoxygenation expressively altered 
the VAT circadian rhythms inversely compared to the control group. Biphasic character was 
kept only after 5 min. of reoxygenation. 10, 15 and 20 min. of reoxygenation gradually 
changed the VAT circadian courses to inverse ones with the highest values between 12:00h 
and 15:00h and lowest values between 24:00h and 03:00h. The mesor was decreased (1,41 
mA), amplitude was increased (0,57 mA) and acrophases was on -1650 (Figure 2).  
A more detailed analysis of the circadian VAT changes after 5., 10., 15. and 20. min. 
hypoventilation showed that the acrophases from 10., 15. and 20 min, of hypoventilation 
were nonsignificantly shifted  compared to 5 min. of hypoventilation (Table 1). The 
characteristic biphasic course of the circadian rhythms of VAT was seen only after 10 min. of 
hypoventilation (Figure 3) (Svorc et al., 2000b, 2002).  
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Fig. 3. Circadian rhythms of the ventricular arrhythmia threshold from 
hypoventilation/reoxygenation model after 5 min. (circles), 10  min. (squares), 15 min. 
(rhombus) and 20 min. (triangles) of the respective ventilation. A – initial hypoventilation,  
B – subsequent reoxygenation. The dark bar indicates the dark cycle.  
 
 Initial hypoventilation Subsequent reoxygenation 
 5 min. 10 min. 15 min. 20 min. 5 min. 10 min. 15 min. 20 min. 
Mesor 1.32±0.1 1.17±0.2 0.15±0.2 0.12±0.1 1.41±0.1 1.41±0.1 1.29±0.1 1.42±0.1 
Amplitude 0.33±0.2 0.33±0.2 0.35±0.2 0.20±0.2 0.41±0.2 0.48±0.1 0.37±0.2 0.53±0.1 
Acrophase         
in degrees -356±25 -11±37 -36±30 -30±58 -166±24 -165±17 -172±29 -156±10 
in hours 23:50±1.40 00:44±2.28 02:24±2.00 02:50±2.32 11:04±1.36 11:00±1.08 11:28±1.56 10:24±0.4 
Table 1. Parameters of the circadian rhythms of the ventricular arrythmia threshold (VAT) in 
a rat model of  hypoventilation/reoxygenation.   
Results from an experimental study involving ketamine/xylazine-anaesthetized rats (Svorc 
et al., 2005) indicated that although the electrical stability of the rat heart did not demostrate 
a  dependence on LD cycle during normal pulmonary ventilation (probably an effect of 
ketamine/xylazine anaesthesia), hypoventilation/reoxygenation changed myocardial 
vulnerability by a manner dependent on LD cycle. It appears that rat myocardium is 
probably more sensitive to systemic asphyxia induced by hypoventilation and 
reoxygenation during the light (non-active) part of the day (Figure 4).  
Hypoventilation and recovery of pulmonary ventilation produce different myocardial 
responses to electrical stimulation of the heart in individual animals. The reactions of 
animals to electrical stimulation under different ventilation conditions in both light parts of 
the day are shown in Table 2. A Χ2-test was performed on the basis of these individual 
responses in the aspect of previous threshold values for evaluating the effect on the LD 
cycle. The significant effect of the LD cycle on the VAT changes was conformed for the 
period of hypoventilation (p < 0,05) as well as reoxygenation (p < 0,01), respectively. 
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Fig. 4. The changes of the VAT in the hypoventilation (Hypo)/reoxygenation (Reoxy) rat 
model in the light and dark part of the regime day. Control – VAT value after the surgical 
interventions (tracheotomy, thoracotomy) and 5 min. stabilization at the parameters of 
normal artificial pulmonary ventilation (empty column – light and dark group). Hypo – the 
average VAT value from measurement after 5, 10, 15 and 20 min. of hypoventilation (gray 
columns). Reoxy – the average VAT value from measurement after 5, 10, 15 and 20 min. of 
reoxygenation (black columns).  
 
 Hypoventilation vs. control Reoxygenation vs. hypoventilation 
 Light Dark Light Dark 
VAT decrease 10/11 (90,9 %) 7/19 (36,8 %) 2/12 (18,2 %) 13/19 (68,4 %) 
VAT increase 1/11 (9,1 %) 12/19 (63,2 %) 9/11 (81,8 %) 6/19 (31,6 %) 
Table 2. Individual responses of animals to electrical stimulation of the heart. Numerator - 
number of animals with VAT changes against the previous VAT measurement, denominator 
- number of animals in experimental group. 
As  mentioned above, alterations in myocardial vulnerability depend mainly on changes in 
ion concentrations. LD differences in the electrical stability of the heart might reflect the LD 
differences in ion concentrations. In hypoxia/reoxygenation or ischemia/reperfusion 
models, more authors describe myocardial Ca2+ accumulation. Ca2+ overload in myocytes is 
one of the many causes of the reperfusion injury (Kamiyama et al., 1996; Mubagwa et al., 
1997; Shinmura et al., 1997; Sharikabad et al., 2000). It was hypothetized that the delayed 
afterdepolarizations producing the substrate for arrhythmogenesis of the serious ventricular 
dysrhythmias (Ca-mediated, non re-entry arrhythmias) are the result of such Ca2+ overload 
(Whalley et al., 1995). Sharikabad et al. (2000) describe unchanged intracellular 
concentration of Ca2+ ions during hypoxia, but concentrations were 3 to 4 times higher 
during reoxygenation in isolated rat hearts. During reoxygenation of hypoxic rat 
cardiomyocytes there is a correlation between extracellular Ca2+ and ROS (the second factor 
involved in ischemia/reperfusion-induced cardiomyocyte damage), whereas the correlation 
between cell Ca2+ and ROS levels is less consistent. These results indicate that ROS levels 
during oxidative stress are at least partly dependent on extracellular Ca2+ concentration, but 
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ROS (H2O2) can increase or decrease cardiomyocyte Ca2+ accumulation during 
reoxygenation in a concentration-dependent manner (Sharikabad et al., 2004). Decrease of 
intracellular pH can also participate in the mechanism of myocardial reoxygenation 
damage. This decrease is mediated, at least in part, by anion exchange stimulation (Cl-
/HCO3- exchange) through protein kinase C activation. This exchange takes part in the 
reoxygenation-induced Ca2+ overload and in contractile dysfunction (Kawasaki et al., 2001).   
The decrease in electrical stability of the heart can also be the result of cellular K+ loss during 
hypoxia (Shivkumar et al., 1997). Hypoxia (Perchenet & Kreher, 1995) significantly decreases 
action potential duration probably through the activation of the KATP channels and increased 
K+ ion efflux. The inhibition of the outward K+ currents showed the cardioprotective effect 
during reperfusion (Liu et al., 1993; Tosaki et al., 1996). The increase of intracellular 
concentration of Na+ ions in myocardial cells, and Ca2+ overload, can contribute to the rise of 
reoxygenation arrhythmias (Takeo et al., 1995; Kamiyama et al., 1996; Shinmura et al., 1997).  
Systemic hypoxia induced by hypoventilation changed the electrical stability of the rat heart 
in dependence on the LD cycle. Although the VAT decreased parallelly in both light parts of 
day during 20 min. hypoventilation, it was demonstrated that 1. The significant higher 
average VAT values were in the dark part of the day (active phase) versus the light part 
(non-active phase); 2. Rat hearts are more resistant to systemic hypoxia in the dark part of 
the day; and 3. The significant decrease of the VAT refer to the proarrhythmogenic effect of 
the systemic hypoxia only in the light part of day. These differences are probablya result of 
the changed myocardial reactivity to electrical stimulation dependent on the LD cycle.  
Although reoxygenation returned VAT level to that of control values in both light (non-
active) and dark (active) parts of the day, the problem remains that the VAT was 
significantly increased versus hypoventilatory value only in the light part of the day. The 
contrary tendency was found in the dark part of the day. The decrease in the dark part of 
the day probably signals the larger extent of the reoxygenation injury or increased 
sensitivity of the myocardium to the ventricular arrhythmias in the dark part of the day. 
This fact is supported by our previous results in rats under pentobarbital anaesthesia, where 
the nadir of the VAT circadian rhythm was found between 24:00h and 03:00h during 
reoxygenation (Svorc et al., 2000a).    
The significant hypoventilatory LD differences in the thresholds show the different LD 
effects of hypoventilation–induced systemic asphyxia on the electrical stability of the rat 
heart. The higher values in the dark part of the day are probably the result of varying 
myocardial sensitivity to systemic asphyxia in the LD dependence, although there are more 
reports referring to the depressive effect of hypoxia on the circadian rhythms in rats (Bishop 
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Stephenson, 2000), and in humans (Bosco et al., 2003).  An important and still unanswered 
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are mobilized mainly by hypoventilation-induced systemic asphyxia and reoxygenation 
with the additive effect of the LD cycle, or are they mobilized by the factors oscillating in the 
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Fig. 4. The changes of the VAT in the hypoventilation (Hypo)/reoxygenation (Reoxy) rat 
model in the light and dark part of the regime day. Control – VAT value after the surgical 
interventions (tracheotomy, thoracotomy) and 5 min. stabilization at the parameters of 
normal artificial pulmonary ventilation (empty column – light and dark group). Hypo – the 
average VAT value from measurement after 5, 10, 15 and 20 min. of hypoventilation (gray 
columns). Reoxy – the average VAT value from measurement after 5, 10, 15 and 20 min. of 
reoxygenation (black columns).  
 
 Hypoventilation vs. control Reoxygenation vs. hypoventilation 
 Light Dark Light Dark 
VAT decrease 10/11 (90,9 %) 7/19 (36,8 %) 2/12 (18,2 %) 13/19 (68,4 %) 
VAT increase 1/11 (9,1 %) 12/19 (63,2 %) 9/11 (81,8 %) 6/19 (31,6 %) 
Table 2. Individual responses of animals to electrical stimulation of the heart. Numerator - 
number of animals with VAT changes against the previous VAT measurement, denominator 
- number of animals in experimental group. 
As  mentioned above, alterations in myocardial vulnerability depend mainly on changes in 
ion concentrations. LD differences in the electrical stability of the heart might reflect the LD 
differences in ion concentrations. In hypoxia/reoxygenation or ischemia/reperfusion 
models, more authors describe myocardial Ca2+ accumulation. Ca2+ overload in myocytes is 
one of the many causes of the reperfusion injury (Kamiyama et al., 1996; Mubagwa et al., 
1997; Shinmura et al., 1997; Sharikabad et al., 2000). It was hypothetized that the delayed 
afterdepolarizations producing the substrate for arrhythmogenesis of the serious ventricular 
dysrhythmias (Ca-mediated, non re-entry arrhythmias) are the result of such Ca2+ overload 
(Whalley et al., 1995). Sharikabad et al. (2000) describe unchanged intracellular 
concentration of Ca2+ ions during hypoxia, but concentrations were 3 to 4 times higher 
during reoxygenation in isolated rat hearts. During reoxygenation of hypoxic rat 
cardiomyocytes there is a correlation between extracellular Ca2+ and ROS (the second factor 
involved in ischemia/reperfusion-induced cardiomyocyte damage), whereas the correlation 
between cell Ca2+ and ROS levels is less consistent. These results indicate that ROS levels 
during oxidative stress are at least partly dependent on extracellular Ca2+ concentration, but 
Chronobiological Aspects of the Heart  
Rhythm Disorders at the Change of Pulmonary Ventilation in Rat Model 
 
205 
ROS (H2O2) can increase or decrease cardiomyocyte Ca2+ accumulation during 
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ischemia/reperfusion injury. This mechanism, known as ischemic preconditioning (IPC), 
was first suggested by Reimer et al. (1981) and later elaborated on by Murry et al. (1986).  
Similar cardioprotective effects, albeit of variable intensity, have been obtained after pre-
treatment with repetitive episodes of hypoxia, which may provide clinical benefit over 
ischemia in that systemic blood flow into critical organs remains stable (Shizukuda et al., 
1993). Most of the available information regarding hypoxic preconditioning (HPC) has come 
from in vitro studies on isolated perfused hearts using transient local hypoxia.  
Therefore, it is important to know whether HPC with hypoventilation can also reduce 
experimentally induced ventricular arrhythmias or increase the electrical stability of the 
heart against the effect of a prolonged subsequent period of hypoventilation and 
reoxygenation. We hypothesized that 1. If hypoventilation, similar to ischemia, decreases 
the electrical stability of the heart, HPC with hypoventilation could have an effect 
comparable to IPC. Moreover, we focused on whether there were differences in the 
conditions and dynamics of the developing protective effects of myocardial PC applied 
during the light (nonactive) and dark (active) parts of the rat regime day and aimed to 
obtain an understanding of the chronophysiological aspects of this phenomenon in in vivo 
rat experiments; 2. If the autonomic nervous system participates in IPC-induced 
cardioprotection, it would also participate in the process of HPC. If the autonomic nervous 
system plays a role in HPC,  the effect would depend on external periodicity because 
cardiovascular and autonomic nervous functions show dependence on 24h periodicity. 
Thus, the design was aimed to examine the effect of the LD cycle adaptation on the VAT, 
marker of the electrical stability of the heart, and on heart rate responses, as a marker of 
autonomic drive, during the post-anaesthetic state, hypoventilatory hypoxia and cardiac 
preconditioning induced by repeated  asphyxias in vivo (Svorc & Bracokova, 2003; Svorc & 
Benacka, 2008; Svorc et al, 2011).   
The main aim of these studies was to gain information about the chronophysiological aspect 
of cardioprotection by hypoventilation-induced asphyxia preconditioning in in vivo rat 
experiments. The experiments were performed in anaesthetized (ketamine/xylazine 
anaesthesia, ketamine 100 mg/kg [Narkamon, Prague] + xylazine 15 mg/kg [Rometar, 
Prague] i.m) rats (weight, 300 ± 15 g; 3 to 4 months of age). The rats were adaptated to a LD 
cycle of 12h:12h, with the dark part of day from 06:00h to 18:00h for 4 weeks and they were 
divided into 4 groups. During the experiments, all animals were subjected to 20 min of 
artificial hypoventilation-induced asphyxia, followed by a 20 min recovery period 
(reoxygenation). The first group of animals was not preconditioned (n = 19) and the other 
three experimental groups were preconditioned by one (1PC group; n = 9), two (2PC group; 
n = 15), and three (3PC group n = 11) 5 min cycles of hypoventilation (5 min), each separated 
by 5 min cycles of reoxygenation (Scheme 1).   
The chest was opened by parasternal thoracotomy and after gentle mediastinal preparation, 
the heart was exposed. The VAT was estimated as the minimal amount of electrical current 
(mA) needed for elicitation of ventricular arrhythmias by direct electrical stimulation of the 
heart (400 ms series of rectangular pulses; frequency, 30 Hz; and 10 ms impulse lengths). 
Stimuli were triggered by the onset of the R wave in lead II of the ECG and the current 
intensity was increased progressively by steps of 0.2 mA until ventricular arrhythmias were 
obtained. Recovery of the sinus rhythm was spontaneous. Control recordings of VAT were 
performed after surgical interventions and a 5 min period of artificial ventilation with the 
parameters of the normal pulmonary ventilation. Values of VAT were measured in the 5th, 10th, 
15th, and 20th min of hypoventilation and in the same intervals during ventilatory recovery.  
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Scheme 1. Protocol of experiments using preconditioning (PC) by systemic asphyxia. The 
black-white columns refer to the initial phase of experiments with heating of the animals to 
the rectal temperature measured before the application of the anaesthetic agent, 
tracheotomy, thoracotomy, 5 min. period of stabilization (normal artificial ventilation at the 
parameters of the artificial ventilation VT 1 ml/100 g of body weight and respiratory rate 50 
breaths/min.). The hatched columns represent 5 min. cycles of PC by systemic asphyxia. 
The empty bars represent 5 min. cycles of reoxygenation, while the black columns represent 
20 min. cycles of hypoventilation.  
The measurement of heart rate (the mean value of the last 4 cycles) was performed in intact 
animals (before the surgical interventions in the supine position, spontaneous breathing), 
after tracheotomy and thoracotomy, after each minute of 5 min. stabilization (the parameters 
of the normal artificial ventilation), after each minute of PC cycles by systemic asphyxia and 
after each minute of 20 min. hypoventilation. Because the animals from each group passed 
through the same conditions from the start of the experiment, heart ratee were summed and 
one average value was calculated for intact animals (Ini), after the tracheotomy (Tr), 
thoracotomy (To), during the period of stabilization (Stabil) and during the single cycles of 
asphyxic PC.  
Animals were artificially ventilated by humidified room air at the parameters of the initial 
ventilation and reoxygenation: respiratory rate 40 breaths/min. and tidal volume 1 ml/100g 
body weight. During experimental hypoventilatory asphyxia, the respiratory rate and tidal 
volume were reduced to 20 breaths/min and 0.5 ml/100g b.w., respectively. The respiratory 
effect of the ventilation was monitored by the analysis of the pH, pO2, pCO2, and O2 
saturation from blood samples taken from the femoral artery.  
The control values of VATs in the experimental groups did not show any significant 
difference, although systematically higher values were found during the dark part of the day 
compared to the light part of the day (control light, 1,87 ± 0,80 mA vs. control dark, 2,12 ± 0,93 
mA; 1PC light, 1,96 ± 0,73 mA vs. 1PC dark, 2,44 ± 0,68 mA; 2PC light, 2,19 ± 1,21 mA vs. 2PC 
dark, 2,48 ± 1,20 mA; and 3PC light, 2,32 ± 0,69 mA vs. 3PC dark, 1,85 ± 0,69 mA) (Figure 5).  
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Fig. 5. Mean ± SD values of the ventricular arrhythmia threshold immediately before 
preconditioning (C), during 20 min. hypoventilatory asphyxia (H) following 20 min. 
reoxygenation (R) in the control animals (control group) and groups preconditioned by 1 
(1PC group), 2 (2PC group) and 3 (3PC group) short cycles of hypoventilation-induced 
systemic hypoxia, hypercapnia and acidosis.  Empty and black columns refer to light and 
dark parts of the day, respectively. Embedded scheme shows the timing of trials (arrows) in 
animals adapted to the light-dark cycle. *** p < 0,001, ** p < 0,01.  
During the dark part of the day, hypoventilation non-significantly decreased the VAT in the 
group without PC (2,12 ± 0,93 mA [control] vs. 2,05 ± 0,85 mA [hypo]); in 1 PC (2,44 ± 0,68 
mA [control] vs. 1,68 ± 0,87 mA [hypo]); and in 2 PC (2,48 ± 1,2 mA [control] vs. 1,87 ± 0,60 
mA [hypo]). In the 3 PC group, the VAT was not changed and remained at the level of the 
pre-hypoventilatory value (1,85 ± 0,69 mA [control] vs. 1,87 ± 0,76 mA [hypo]). During the 
light part of the day, similar but significant VAT decreases were found in the group without 
PC and in the 1 PC group and non-significant decreases were found in the 2 PC group. In 
the 3 PC group, where the VAT was markedly increased (p < 0,001) above the control value. 
Significant LD differences were seen in all groups, with higher values in the dark part of the 
day, except the 3 PC group which had a higher VAT in the light part of the day. In the dark 
part of the day, reoxygenation after one and two cycles of  HPC did not change and 
recovery of the VAT to control values and values from the period of hypoventilation (1 PC 
group, 2,44  0,68 mA [control] vs. 1,68 ± 0,87 mA [hypo] vs. 1,53  0,58 mA [reoxy]), (2 PC 
group, 2,48  1,2 mA [control] vs. 1,87 ± 0,60 mA [hypo] vs. 1,93  0,57 mA [reoxy]). In the 
group without preconditioning (2,12 ± 0,93 mA [control] vs. 2,05 ± 0,85 mA [hypo] vs. 2,00 ± 
0,86 mA [reoxy]) and in the 3 PC group (1,85 ± 0,69 mA [control] vs. 1,87 ± 0,76 mA [hypo] 
vs. 1,91 ± 0,69 mA [reoxy]) the VAT was not changed and remained on the pre- and 
hypoventilatory levels. In the light part of the day, similar VAT changes were seen in all 
groups, except the 3 PC group, where the VAT was markedly (p < 0,001) increased versus 
control and hypoventilatory values. The higher VAT values were found in all groups, with 
higher values in the dark part of the day, except the 3 PC group, in which a higher VAT 
occurred in the light part of the day. A significant effect of the PC by the HPC was not 
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confirmed by the 2 test nor for hypoventilation (p < 0,09) or for reoxygenation (p < 0,64) in 
the dark part of the day. In the light part, such significance was confirmed only for a 
prolonged period of hypoventilation (p < 0,001), but not during reoxygenation (p < 0,39).  
A considerable intraindividual variability of results is a problem concerning mainly in vivo 
studies, which was also confirmed in our experimental groups. Such variability can be 
explained by production of spontaneous unpredictible alterations in the electrical stability of 
the heart induced by anaesthesia or hormonal and homeostatic reflexes operating only in 
intact animals (Lubbe et al., 1975).  
LD differences in the VATs are probably a reflection of the changes in electrophysiological 
properties of the myocardium. These changes after HPC were also evident in the background 
of our observations. Possible mechanisms of protection might involve a faster shortening of 
the action potential (Tan et al., 1993; Ravingerova et al., 1998), also reflected as a shortening of 
refractoriness (Grover et al., 1994) during hypoxia after PC. Moreover, the duration of 
arrhythmic activity was significantly shorter in papillary muscles from the hearts of guinea 
pigs after HPD (Kamasaki et al., 1997), which refers to the fact that HPC can significantly 
attenuate arrhythmic activity. Unfortunately, these experiments were performed without LD 
dependence; therefore no information regarding the effect of HPC could be gained. Thus, the 
question remains whether the effects of these electrophysiological changes protecting the 
myocardium also depends on the LD cycle. Our results indirectly confirm the fact that the 
above described electrophysiological changes resulting from PC are probably more effective 
mainly during the light (nonactive) part of the rat regime day (Svorc et al., 2003).   
The effect of PC also depends on the balance between the intensity of the first stimulus and the 
duration and severity of the prolonged stress. Following the changes in VAT during 
hypoventilation/reoxygenation, one cycle of HPC had an identical proarrhythmogenic effect 
in both light parts of the day, but with significantly higher values in the dark part of the day. 
However, the LD discrepancies in the VAT changes occurred during reoxygenation. In the 
light part of the day, reoxygenation partly recovered the VAT (antiarrhythmogenic effect), but 
in the dark part of the day, it was followed by a further decrease in VAT (proarrhythmogenic 
effect). In both light parts of the day, although hypoventilation/reoxygenation still decreased 
the VATs in the 2PC group, the decrease was not significant, values were higher than in the 
1PC group, but with the preservation of LD differences. Reoxygenation was without effect. 
The three cycles of HPC stabilized the VAT in the dark part of the day, but a marked and 
significant cardioprotection against the hypoventilation/reoxygenation decrease of the 
electrical stability of the heart was detected in the light part,  meaning that there are different 
reactions of the rat myocardium for theHPC  in the dependence on the LD cycle. 
Although the average hypoventilatory VAT value was lower in the 1PC group compared 
with the hypoventilatory VAT value from the control group (without HPC) in both light 
parts of the day, the VAT increased gradually in the dependence on the number of cycles of 
HPC. It appears that 1) one cycle of HPC is too weak of a stimulus for the production of 
cardioprotection in both light parts of the day; 2) the cardioprotection probably starts after 
two cycles of HPC in both light parts; and 3) the effect of HPC depends on the numbers of 
HPC cycles and the LD cycle - it is highlighted by three cycles of HPC.  
The dependence of cardioprotection on the number of HPC cycles has been confirmed by 
others. In isolated rat hearts Testoni et al. (2000) and later Cerruti et al. (2002), showed that 
as long as the animals were exposed only to hypoxia (60 min.) and reoxygenation (60 min.), 
without HPC, the more severe atrial and right ventricle contractile disorders and less 
posthypoxic recovery (other endpoints of PC) were found. Whereas HPC by one 5 min. 
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confirmed by the 2 test nor for hypoventilation (p < 0,09) or for reoxygenation (p < 0,64) in 
the dark part of the day. In the light part, such significance was confirmed only for a 
prolonged period of hypoventilation (p < 0,001), but not during reoxygenation (p < 0,39).  
A considerable intraindividual variability of results is a problem concerning mainly in vivo 
studies, which was also confirmed in our experimental groups. Such variability can be 
explained by production of spontaneous unpredictible alterations in the electrical stability of 
the heart induced by anaesthesia or hormonal and homeostatic reflexes operating only in 
intact animals (Lubbe et al., 1975).  
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The dependence of cardioprotection on the number of HPC cycles has been confirmed by 
others. In isolated rat hearts Testoni et al. (2000) and later Cerruti et al. (2002), showed that 
as long as the animals were exposed only to hypoxia (60 min.) and reoxygenation (60 min.), 
without HPC, the more severe atrial and right ventricle contractile disorders and less 
posthypoxic recovery (other endpoints of PC) were found. Whereas HPC by one 5 min. 
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cycle of hypoxia and subsequent 10 min. reoxygenation had a small effect, PC with two 
cycles of hypoxia exacerbated the contractile changes. O’Connor & Merrill (1995) referred to 
the fact that initial exposure to hypoxia can protect myocardium in in vivo conditions against 
arrhythmias during the second hypoxic period (significant percentage decrease of ectopy 
incidence). Blockade of cardiac β-adrenoceptors attenuated the incidence of arrhythmia in 
the second hypoxic period, demonstrating the possible role of catecholamines in the course 
of HPC. Myocardial ischemia, as well as non-ischemic hypoxia, stimulate efferent 
adrenergic nervous endings (Daly & Scott, 1963, 1964; Herrmann & Feigl, 1992), the  
assumption being that the ventricular arrhythmias induced by systemic hypoxia depend on 
intact adrenergic innervation (O’Connor & Merrill, 1993), which was also shown in our 
experiments. These interventions deliver possible protection by PC against electrogenic and 
mechanical effects of the prolonged ischemic period of the myocardium (Lasely et al., 1993). 
The differences in the number of cycles of hypoxia necessary for the mobilization of the 
cardioprotective mechanism in the prezent study and previous studies performed in vitro 
and in vivo, could be explained by different experimental procedures. Low-oxygen perfusion 
of isolated hearts in vitro (Testoni et al., 2000; Cerruti et al., 2002) may facilitate 
cardioprotection much sooner compared to an in vivo condition. The anaesthesia in in vivo 
experiments is an important variable, as is the animal species in use, e.g., ketamine 
anaesthesia inhibits PC with anoxia in rats (Ko et al., 1997), in rabbits (Han et al., 2002), and 
in our results, or α-chloralose in beagles (O’Connor & Merrill, 1993). 
4.2 Heart rate – A measure of autonomic nervous system activity 
Cyclic fluctuations based on subdiurnal, circadian or supradian cardiovascular responses 
are also influenced by the short- and long-term variability of the autonomic nervous system. 
Previous data showed that daily rhythmicity in sympathetic and parasympathetic nerve 
tone in healthy organisms is paralleled by corresponding changes in the electrophysiological 
properties of the myocardium (Cinca et al., 1986). Circadian variability in the autonomic 
nervous system might also represent a substantial influence on the electrical stability of the 
myocardium under pathological conditions including systemic hypoxia, pulmonary 
hypoventilation, asphyxia and acidosis (Meurling et al., 2001; Simantirakis et al., 2001; 
Watanabe et al., 2002).   
It is known that both the hypoxic changes in the phasic and tonic drive od the autonomic 
nervous system and the alterations in the sensitivity of the myocardium to autonomic 
nervous drive, may also be involved in the effect of PC. It is now apparent that protection 
from IPC spreads from distant organs to the heart (Pell et al., 1998; Wolfrum et al., 2002) 
possibly via activation of the autonomic nervous system (Gho et al., 1996; Schoemaker & 
Van Heijningen, 2000; Liem et al., 2002; Wolfrum et al., 2002). It is possible that the release of 
local triggers of IPC activates the autonomic nervous system either directly (Schoemaker & 
Van Heijningen, 2000; Liem et al., 2002) or via sensory nerves (Tang et al., 1999; Xiao et al., 
2001; Hu et al., 2002), and transfers the signal to the myocardium or other remote tissues.  
Evidence exists that sympathovagal regulation might be related to the protective mechanism 
of IPC (Loukogeorgakis et al., 2005; Wu et al., 2005). IPC is mediated by sympathetic 
neurotransmitter release and α1-adrenergic receptor stimulation (Banerjee et al., 1993; Cohen et 
al., 2001). Acetylcholine, the parasympathetic mediator, is also involved in the IPC triggering 
process (Cohen et al., 2001). The anti-arrhythmic protection afforded by IPC may be mediated 
by preservation of autonomic function (Miyazaki & Zipes, 1989). Other evidence implies that 
IPC may affect sympathovagal activity from the initial to the target effect (Airaksinen et al., 
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1995; Pasceri et al., 1996). Brief coronary occlusion may result in severe autonomic reaction as 
measured by reduced heart-rate variability; however, the autonomic reaction after further 
coronary occlusion has been significantly smaller (Woo et al., 1994; Airaksinen al., 1995; 
Huikuri & Makikallio, 2001). These phenomena highlight the importance of cardiac autonomic 
regulation in the IPC protective process. 
The above mentioned results clearly refer to probable autonomic nervous system 
participation in cardioprotection induced by IPC. Although HPC is less studied, it is known 
that pre-treatment with repetitive episodes of systemic hypoxia or hypoventilation-induced 
asphyxia under in vivo conditions evoked not only the similar cardioprotective effects 
(Shizukuda et al., 1993) but also showed marked LD dependence (Svorc et al., 2003). In the 
present, the date about the autonomic nervous system participation in HPC are absent and 
especially, in the dependence on the environment periodicities. 
Results of a study with HPC show that the initial heart rate data measured in the intact 
spontaneously breathing ketamine/xylazine-anaesthetized animals (Ini) treated during the 
light part of the day (LP) were significantly lower compared to those from the dark part of 
the day (DP) (M ± SD, 231 ± 28 vs. 264 ± 31 beats/min. p < 0,001). Similar LD-dependent 
differences in the averaged heart rate values were maintained after tracheotomy, 
thoracotomy (To; LP 168 ± 39 vs. DP 218 ± 57 beats/min. p< 0.001) and after the onset of the 
artificial pulmonary ventilation (5 min after the onset, LP vs. DP, 202 ± 34 vs. 262 ± 44 
beats/min p < 0,001). Interestingly, while the heart rate values in DP-treated animals 
usually returned to  close to initial values within 1-5 min. of artificial ventilation (5 min, 262 
± 44 vs. Ini, 264 ± 31 beats/min,) similar recovery was not seen in LP-treated animals (5. 





Fig. 6. The average heart rate (HR) values (mean ± SD) before, during and after the surgical 
interventions in the light (empty rhombus) and the dark (black square) part of the rat regime 
day. Ini – animals before the surgical interventions in ketamine/xylazine anaesthesia, 
spontaneous breathing), Tch – immediately after tracheotomy, To – immediately after 
thoracotomy and after 1., 2., 3., 4. and 5. min. of artificial ventilation (period of stabilization). 
*** p < 0,001 statistically significant differences between heart rates measured during the 
light and dark part of the rat regime day.  
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Fig. 6. The average heart rate (HR) values (mean ± SD) before, during and after the surgical 
interventions in the light (empty rhombus) and the dark (black square) part of the rat regime 
day. Ini – animals before the surgical interventions in ketamine/xylazine anaesthesia, 
spontaneous breathing), Tch – immediately after tracheotomy, To – immediately after 
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*** p < 0,001 statistically significant differences between heart rates measured during the 
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Statistically significant LD differences were found in each cycle of PC using hypoventilation-
induced systemic asphyxia (Figure 7). HR changes in each cycle of asphyxic PC showed LD 
dependence. In the light period of the rat regime day, HR was significantly increased in the 
5. min. vs. 1. min. in each cycle (1. cycle 203 ± 36 vs. 191 ± 35 beats/min., p < 0,05; 2. cycle 
208 ± 36 vs. 190 ± 32 beats/min., p < 0,01; and 3. cycle 202 ± 34 vs. 189 ± 35 beats/min., p < 
0,01). In the dark period, the significant differences between 1. min. and the 5. min. of each 
cycle were not detected (Figure 7).   
 
 
Fig. 7. Average values (mean ± SD) of heart rate during hypoventilation-induced asphyxia 
preconditioned cycles in the light (empty rhombus) and in the dark (black square) part of 
the rat regime day. Ini – average heart rate value from the anaesthetized rats before the 
surgical interventions and at the spontaneous breathing, Stabil – average heart rate value 
from the 5. min. of artificial ventilation. *** p < 0,001; ** p < 0,01 statistically significant 
differences between heart rates measured during the light and dark part of the rat regime 
day. ^ p < 0,05; ^^ p < 0,01 statistically significant heart rate difference between the 1. and 5. 
min. of the preconditioned hypoventilation-induced systemic asphyxia cycles.  
In the light part of the day, the heart rate increased gradually with the duration of 
hypoventilation until the 10. to 11. min. mark in all experimental groups and with the 
followed stabilization in the control, 1PC and 2PC groups to the end of the asphyxic period. 
The next heart rate increase was seen only in the 3PC group with the significantly higher 
values in the 20. min. of hypoventilation against control, 1PC and 2PC groups (3PC vs. 
control, 235 ± 36 beats/min. vs. 215 ± 36 beats/min., p < 0,05; 3PC vs. 1PC, 235 ± 36 
beats/min. vs. 196 ± 26 beats/min., p < 0,01 and 3PC vs. 2PC 235 ± 36 beats/min. vs. 209 ± 
29 beats/min., p < 0,002). In the dark part of the day, the heart rate was stabilized in the 
course of the whole period of asphyxia in all experimental groups (Figure 8).  
The spontaneously breathing rats under the ketamine/xylazine anaesthesia are in asphyxic 
conditions from the start of the experiment in vivo, independent of the LD cycle (Svorc et al., 
2009). Thus, the disruptive effect of hypoxia on the LD-dependent differences in heart rate 
response curve was not demostrated, as suggested by the previously mentioned authors. 
One of the main conclusions from the present study was that heart rates were significantly 
and systematically higher in the dark part of the regime day than in the light part of the day, 
and  also in asphyxic conditions even if the heart rate response curves in either condition 
practically paralleled one another. 
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Fig. 8. Mean ± SD values of heart rate during hypoventilation-induced systemic asphyxia in 
the control group and in the groups pre-treated with a number of different preconditioning-
cycles in the light (empty symbols) and the dark (filled symbols) parts of the rat regime day, 
respectively. Control group – rhombus, 1PC group – square, 2PC group – triangle and 3PC 
group – circle. 
Interestingly, we found that this type of anaesthesia in rats expressively increases 
parasympathetic tone and decreases sympathetic drive, respectively. The results of heart-rate 
variability analysis show that in intact spontaneously breathing rats, power HF was 
significantly higher (light 19,387 ms2; dark 3,129 ms2) than power LF (light 0,974 ms2; dark 
0,432 ms2) and there was also significant LD difference  in both parameters (p < 0.01 for HF; p 
< 0.02 for LF) (Svorc, Jr. unpublished results). Although heart rates were on the level of 
bradycardia, the onset of asphyxia was regularly accompanied by a decrease in heart rate, 
which increased in intensity within a 5 min period in both light and dark parts of the day and 
persisted for the next 20 min. Atropine-resistant hypoxic bradycardia in rats was also reported 
by Kaplan et al. (2003) and in isolated ischemic rat hearts by Chanine et al. (1993) who 
explained that the response was due to a reduction of tissue noradrenaline in the ischemic rat 
myocardium. In contrast, in rats under moderate hypoxia, Ohkuwa et al. (2005) observed 
increased plasmatic noradrenaline levels as an indicator of increased sympathetic stimulation. 
The increase in heart rate was observed only after the first hour in the process of 
acclimatization the decrease was found with the amplitude reduction of the diurnal variation 
of heart rate (Kawaguchi et al., 2005). The relative contribution of afferent feedback, autonomic 
nervous drive and direct hypoxic effect on circulatory responses was examined by Hayashida 
et al. (1996) in conscious rats with or without chemoreceptor/baroreceptor input. In intact 
animals, they found that hypoxia facilitated sympathetic activity, while in chemodenervated 
animals hypoxia induced a decrease in blood pressure, heart rate and renal sympathetic 
activity. Nevertheless, their data from hypercapnic hypoxia suggest that CO2–dependent 
chemical drive may contribute to larger parasympathetic influence to the heart, similar to 
asphyxia used in present work.  In addition to differences in the hypoxic protocols, afferent 
inputs and behavioural state, sex-dependent differences may play an additional role. 
Hinojosa-Laborde & Mifflin (2005) reported increases in heart rate after exposure to 
intermittent hypoxia in males but not in females, in whom the response could even be 
opposite.  
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Adaptation in the light part of the day has an important effect on the efficiency of the PC 
mechanism in vivo as shown in our previous studies (Svorc et al., 2003). This later finding 
increases the practical value for pharmacological interventions, since the majority of the 
current data on the myocardial IPC or HPC come almost exclusively from in vitro studies. 
Significant LD cycle effects on heart rate responses, as a marker of autonomic nervous drive, 
were not reported previously during defined stages of open-surgery preparation.  
In conclusion, the study showed that the effect of HPC depends on the LD cycle as well as 
on the number of PC cycles in in vivo conditions in rats. Cardioprotection against the 
hypoventilation/reoxygenation-induced decrease in the electrical stability of the heart likely 
begins to occur after two cycles of PC with asphyxia in both light parts of the rat regime day. 
If stabilization of the electrical stability of the heart is also considered to be a possible means 
of cardioprotection, then hypoventilation/reoxygenation myocardial injury is minimized 
only after 3 cycles of PC with asphyxia in the dark (active) part of the day, and the 
cardioprotection proved to be effective only after 3 cycles of PC by asphyxia in the light 
(nonactive) part.  
This may suggest that while PC with 1-2 short asphyxias does not obviously alter LD-
dependent differences in autonomic drive to the heart, several more cycles may eliminate 
the circadian effects. As to the variability and effects of PC by asphyxias, heart rate 
responses during the light part of the regime day obviously showed less pronounced 
dependence on the number of PC cycles and exhibited less interindividual variability than 
in the dark part of the day particularly during the first half of 20 min hypoventilatory 
challenge. In the group adapted to the light part of the regime day with 3 PC cycles, heart 
rate responses after 10 min of recovery lost obvious LD-dependence. Whether observed LD-
dependent effects upon asphyxia merely reflect the variations in the autonomic nervous 
inputs, or represent more complex effects including remodelling of the PC mechanism, 
alterations in the sensitivity of cardiac conductive system, local effects of hypoxia and 
acidosis on myocardium remain unclear and require further study.   
5. Conclusions 
Cardiovascular responses show circadian fluctuations and significant dependence on the LD 
cycle in  pentobarbital- and ketamine/xylazine-paralyzed rats, confirming that LD-related 
differences are not merely transient or procedure dependent. It is a systematic response 
assured by distinct neuro-humoral regulation during the light and dark parts of the day, 
and also under  both types of anaesthesia.  
This suggests that synchronization to local time may be an important factor in the 
evaluation of cardiovascular risks in patients also suffering from various respiratory 
disorders. Analyses of myocardial reactions to acute systemic asphyxia, and to 
reoxygenation are very important in cardiology because the myocardium reacts differently 
depending on  synchronization to external environmental periodicity.  
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differences are not merely transient or procedure dependent. It is a systematic response 
assured by distinct neuro-humoral regulation during the light and dark parts of the day, 
and also under  both types of anaesthesia.  
This suggests that synchronization to local time may be an important factor in the 
evaluation of cardiovascular risks in patients also suffering from various respiratory 
disorders. Analyses of myocardial reactions to acute systemic asphyxia, and to 
reoxygenation are very important in cardiology because the myocardium reacts differently 
depending on  synchronization to external environmental periodicity.  
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1. Introduction  
Late ventricular potentials (LVPs) are low amplitude, high frequency waveforms, appearing 
in the terminal part of the QRS complex of the electrocardiogram (Barbosa et al, 2002; Olinic 
& Zdrenghea, 1998), generated by diseased myocardium. They may extend in the ST 
segment (Zimmermann et al, 1983). Late ventricular potentials may be also defined as 
fragmented electrical activity, appearing in heterogeneous tissue areas, located at the border 
zone of a myocardial infarction (Fetsch, 1999). They are markers of an electrophysiological 
substrate for reentry ventricular tachycardia (VT) and sudden cardiac death (SCD) (Zipes et 
al, 2006).  
Most of the clinical research in this field is focused on risk stratification of patients with a 
history of myocardial infarction (MI), but the role of LVPs in other cardiac and extracardiac 
diseases is also discussed. At present, there is considerable interest on improved tests for 
risk stratification of sudden cardiac death and appropriate selection of prophylactic 
implantable cardioverter defibrillator recipients.   
2. History  
Late ventricular potentials were first reported by Berberi and Simson in dogs (Engel et al, 
2004). Berbari et al. (Berbari et al., 1978) first demonstrated that, using high-gain 
amplification, filtering and signal averaging, late potentials could be recorded. Initially, 
LVPs were obtained directly from the endocardium or epicardium, but they can be recorded 
from the body surface, as well. The amplitude of LVPs is too low to be detected on the 
standard surface ECG, requiring an amplified high-resolution ECG recording. Simson and 
Breithardt et al. first showed the clinical value of ventricular signal averaged 
electrocardiography (SAECG) for identification of patients with sustained VT (Breithardt et 
al., 1981; Simson, 1981).   
By the end of the 1980s, LVPs were helpful for the diagnosis, risk stratification and therapy 
of patients with ventricular arrhythmias. The initial enthusiasm diminished over time due to 
variability in the sensitivity, but lately, its predictive value for VT and fibrillation (VF) has 
been re-evaluated (Frances, 2010).  
SAECG was originally developed for use in patients with coronary artery disease and VT, 
but it has been subsequently applied to other groups of patients (Goldberger et al., 1994). 
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3. Recording of LVPs  
The amplitude of LVPs is in the order of microvolts and can not be detected on the standard 
surface ECG, requiring an amplified high-resolution ECG recording for their identification 
(Santangeli et al, 2008). Thus, LVPs are recorded using SAECG (Olinic & Zdrenghea, 1998).  
The leads are different from those used in standard 12-lead ECG. Most investigators use an 
XYZ lead system, made of three orthogonal bipolar electrode combinations (Engel et al, 
2004) and high-pass filtering. The leads are combined into a vector magnitude, a measure 
that sums up the high frequency information contained in all these leads. This vector 
magnitude is called filtered QRS complex (Santangeli et al, 2008). 
Considering the low intensity of LVPs, averaging of aproximately 300 ECG cycles is needed, 
in order to minimize the level of noise (Santangeli et al, 2008). The signal-to-noise ratio 
increases with the number of averaged beats (Gottfridsson et al, 2011). 
Recording of LVPs using body surface mapping is, also, possible (Linnenbank et al, 2001).  
3.1 Diagnosis criteria  
LVPs are present, if, according to an international convention (Goldberger et al, 2008), 2 of 
the following criteria (variables of the filtered QRS) (Fig. 1) are positive: 
 SAECG-QRS duration (SA-QRS)>120 ms. Other authors consider SA-QRS>114 ms 
(Breithardt et al, 1991; Lander et al, 1993) 
 LAS40: low amplitude signal (duration of the terminal part of the QRS complex with an 
amplitude below 40 μV) >38 ms 
 RMS40: root mean square signal amplitude of the last 40 ms of the signal < 20 μV. 
Each laboratory should define its own normal values (Breithardt et al, 1991). Other authors 
(Askenazi et al, 1978) use two sets of criteria to classify SAECG results. SAECG-I criteria are 
positive if one or more variables are abnormal, and SAECG-II criteria are positive if two or 
more variables are abnormal.   
 
 
Fig. 1. Late ventricular potentials in a patient with an old inferior myocardial infarction. 
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Besides temporal domain analysis, frequency domain analysis allows identification of 
arrhythmia risk considering changes of ECG frequency components. Frequency domain 
analysis was not validated in clinical practice. 
3.2 Limits  
The amplitude of the signals is low, and averaging the electrocardiogram, amplifying it and 
filtering out the low frequencies is needed (Mehta & Camm, 1989; Santangeli et al, 2008). 
Several noise sources may appear in highly amplified recordings: artifacts from respiratory 
muscles, electronic noise arising from the electrodes, electrical power lines and other nearby 
electronic equipment (Engel et al, 2004). Despite technical improvement of the devices, 
electrical interferences and preexistent electrophysiological changes may cause false negative 
results. High-pass filters may attenuate or abolish LVPs (Santangeli et al, 2008).   
Noise level was considered an important technical aspect influencing the results of the test. 
Steinberg and Bigger stated that the 0.3 μV level improves detection of late potentials 
(Steinberg & Bigger, 1989). The sensitivity of SAECG may be increased, by using a very low 
noise level (0.1 μV) (Frances, 2010). On the other hand, Engel et al. suggested that noise does 
not influence the SAECG variables and Christiansen et al. concluded that LVPs appear in 
healthy subjects at low noise levels (Christiansen et al, 1995; Engel et al, 1993). 
The weakness of LVPs is the low positive predictive value. However, their negative 
predictive value for arrhythmic events is very high (Santangeli et al, 2008).  
Difficulties may appear in detecting LVPs in patients with an anterior MI. Because of the 
early activation of the anterior regions during the normal sequence of electrical activation of 
the ventricles, delayed depolarization potentials of these regions after an anterior MI may 
not outlast the QRS complex, and therefore may be hidden within the QRS complex and not 
detected by SAECG (Santangeli et al, 2008).   
Patients with a prolonged QRS complex duration, due to a bundle-branch block (BBB) or 
intraventricular conduction defect, have late-occurring depolarization potentials caused by 
these conduction disorders (Galinier et al, 1996). Separate LVPs criteria were used for 
patients with BBB:   SA-QRS ≥145 ms, LAS40 ≥55 ms and RMS40≤17 μV (Galinier et al, 1996). 
Assessment of LVPs using multiple channel electrocardiographs, allows the use of the 
method in patients with wide QRS complexes, identifying the origin of LVPs . 
4. Predictive value of LVPs  
LVPs characterize ventricular depolarisation and its signal is more stable and easy 
reproducible compared to the repolarisation process (Askenazi et al, 1978).  
The positive predictive accuracy for malignant ventricular arrhythmias, in patients 
recovering from MI, of LVPs, ranges only from 8% to 29% (Santangeli et al, 2008). A high 
negative predictive value (90%) is mentioned for LVPs.  
5. Pathophysiology of LVPs 
LVPs represent delayed conduction through a diseased myocardium and indicate the 
presence of a potential anatomical substrate for macroreentry ventricular arrhythmias 
(Olinic & Zdrenghea 1998, Santangeli et al, 2008).    
LVPs appear as a consequence of late ventricular depolarisation due to delayed impulse 
conduction in certain myocardial regions (Olinic & Zdrenghea 1998; Engel et al, 2004). 
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Besides temporal domain analysis, frequency domain analysis allows identification of 
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Decremental conduction appears in coronary heart disease due to decreased conduction 
speed in ischemic myocardium or due to a prolonged impulse propagation path (Breithardt 
et al, 1991).  
Certain conditions must be met by the area that provides LVPs. First, conduction must be 
slow enough to enable reentry in the healthy tissue. Second, a 1/1 conduction should be 
mentained at high frequencies; otherwise a bidirectional block appears and reentry is 
imposible. Third, an unidirectional block is needed, to allow depolarisation of the 
decremental zone in a single direction (Olinic & Zdrenghea, 1998).  
If the lenght of the reentry circuit is not long enough, the amplitude of the potentials can not 
be detected on the surface ECG and LVPs are absent despite arrhythmia favorable 
conditions. This explains the reduced positive predictive value of LVPs for ventricular 
arrhythmia (Olinic & Zdrenghea, 1998). 
In old MI, disorganised and asynchronous electrical activity arises from areas of surviving 
muscle at the border of a MI (Breithardt et. al, 1991; Savard et. al, 1997). Such areas are 
separated from each other by fibrous tissue, creating a disorganized, disconnected, 
heterogeneous network (Cain et al, 1996; Clayton, 2003).  Considering other opinions, LVPs 
arise in the viable cells inside the necrotic and fibrotic mass, or in the injured myocardial 
fibers, with slow conduction (Cain et al, 1996; La Vecchia et al, 1998; Turrini et al, 1999).  
An anatomical substrate, able to cause delayed conduction and produce LVPs, was reported 
in several other clinical conditions: dilated cardiomyopathy (Mancini et al, 1993), 
hypertrophic cardiomyopathy (Cripps et al, 1990), myocarditis, and infiltrative heart disease 
(Santangeli et al, 2008).   
LVPs are favored by modified tissue architecture due to: necrosis, fibrosis or dystrophy, 
causing a delayed and fragmented depolarization. Fibrosis disturbs ventricular activity, 
separates myocardial bundles and prolongs conduction pathways (Cain et al, 1996). 
Anisotropic reentry is the result of fibrosis in addition to the density and distribution of gap 
junctions, which are responsible for variations in the conduction velocity (Kitamura et al, 
2003; Peters et al, 1997). Some authors have demonstrated a close link between the 
distribution of the gap junctions, the specialized intercellular connections, and the 
development of reentrant arrhythmia in patients with healed MI and nonischemic dilated 
cardiomyopathy (Kitamura et al, 2003; Peters et al, 1997). The slow and discontinuous 
conduction caused by abnormalities in gap junction distribution and function form a 
functional, rather than anatomical, substrate for reentry (Santangeli et al, 2008).   
To generate an arrhythmia needs a substrate (LVPs), but also a trigger and maintenance 
(Santangeli et al, 2008).   
Arrhythmia triggers, such as acute ischemia, imbalance in autonomic tone, or the onset of 
clinical heart failure, may provide the link between the presence of LVPs and occurrence of 
spontaneous VT (Santangeli et al, 2008).   
When sympathetic tone to the heart is augmented, vagal activation exerts a protective effect 
on ventricular vulnerability. Sympathetic stimulation unopposed by vagal activity induces 
ventricular electrical instability, increases susceptibility to ventricular fibrillation, resulting 
in a high risk of arrhythmia and SCD (Gussak & Antzelevitch, 2008). Myocardial infarction 
may damage nerve pathways, thereby limiting the potential of the vagus nerve to be 
activated (Gussak & Antzelevitch, 2008). 
QRS prolongation may be explained by: intraventricular conduction disturbances and 
ventricular dilation, known to prolong ventricular conduction; and ventricular remodeling, 
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which increases tissue mass and slows conduction velocity. A correlation was found 
between QRS duration and end-diastolic volume after a few weeks after a MI. Some authors 
suggest that arrythmias are due to left ventricular dysfunction and do not depend on its 
etiology, considering that no differences were found in patients with myocardial ischemia or 
idiopathic cardiomyopathy (Kondo et al, 2001). 
Reentry explains the appearance of LVPs mainly in old myocardial infarctions, due to 
scarring. An abormal automatism due to a recurrent acute MI can also cause LVPs. A 
significant proportion of deaths occuring after discharge are caused by an arrythmia focus 
due to acute ischemia, hence the lack of sensitivity of LVPs in predicting SCD (Savard et al, 
1997). A prolonged QRS duration was suggested to be predictive for arrythmia SCD, 
regardless of arrythmia mechanism. 
LVPs extend beyond the normal QRS complex due to the low velocity, and may be detected 
in the ST segment, as well (Barbosa et al, 2002; Cain et al, 1996). Abnormal intra-QRS 
potentials, as markers of reentry, may also appear (Lander et al, 1993).  
6. Analysis of SAECG variables  
Positivity criteria for LVPs (SA-QRS, LAS40 and RMS40) are significantly influenced by 
several factors: age, gender and myocardial infarction location (Barbosa et al, 2002; Savard et 
al, 1997). Criteria adjusted for sex, age and myocardial infarction location were developed 
only for SA-QRS, due to its higher predictive value for arrhythmic events (Lander et al, 
1993).  
SA-QRS measured by SAECG is higher in men than in women. This can be attributed to the 
greater myocardial mass. The significant increase of SA-QRS in aging MI patients was 
attributed to degenerative processes afecting conduction (Mozos, 2007). 
All three SAECG variables showed significant predictive power for ventricular arryhthmic 
events. Several authors consider SA-QRS to have higher accuracy for arrhythmic events than 
any other combination of SAECG parameters (Ammann et al, 2004; Lander et al, 1993). 
Other authors concluded that RMS40 has the highest predictive value for ventricular 
arrhythmia (Nakai et al, 1988).  
In patients with inferior myocardial infarction and documented episodes of sustained VT, 
all variables were significantly different (lower voltages, longer durations) compared to 
patients with anterior infarction (Barbosa et al,  2002). LVPs can be better identified at higher 
frequencies, confirming the high frequency of these signals. 
7. The role of SAECG 
The predictive value of SAECG for arrhythmic events after a MI (Savard et al, 1997) exceeds 
that of other tests such as left ventricular ejection fraction (LVEF) or ambulatory ECG. The 
existence of LVPs increases 6 to 8 times the risk of arrhythmic events after a MI and it is 
considered the best non-invasive method to identify postinfarction VT risk (Ho et al, 1993). 
The widespread use of thrombolytic therapy, beta-blockers, antiplatelet therapy and 
revascularisation, lifetime changes and risk factor management, improved post-infarction 
survival. In this context and considering the proarrhythmic effects of antiarrhythmic drugs, 
it is important to identify patients with low risk. Due to its high negative predictive value, 
LVPs can play an important role in selecting patients for interventional studies. The role of 
SAECG as a screening test is limited due to the low positive predictive accuracy. 
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The behavior of LVPs on the body surface during programmed stimulation was evaluated 
by Ho et al (Ho et al, 1996), concluding that LVPs detected during sinus rhythm but lost 
after ventricular extrastimuli are often clinically irrelevant and may explain the false 
positive results and the reduced specificity of SAECG. LVPs revealed by ventricular 
extrastimuli but concealed during sinus rhythm may be clinically relevant and may explain 
some of the false negative results and the reduced sensitivity of SAECG.  
8. Myocardial infarction (MI) 
SAECG is still a very usefull method to identify MI patients at risk for lethal arrhythmic 
events (Huebner, 2010). In patients with acute MI, the electrophysiological substrate for 
LVPs gradually develop in the first 2 weeks of the acute event. LVPs were found in the first 
3 hours after MI onset and their prevalence increased in the next 7-10 days. LVPs recorded 
in the first week were associated with subsequent ventricular dilation and may be due to 
cell slides (Zaman et al, 1993).  
Once established, LVPs seem to remain indefinitely in most patients (Santangeli et al, 2008). 
LVPs can also disappear in the first year after an acute MI. Yang et al. consider that the 
prevalence of LVPs in the first week of a MI increases from 32% in the firs day to 52% in the 
days 7-10 (Yang et al, 1990).  
Time-dependend changes have been also attributed to cell death in the border zone of the 
MI or resolution of myocardial ischemia (Goldberger et al, 1994).  
In the second week and in old myocardial infarction, prevalence stabilizes at 25-35%. 
Savard et al. (Savard et al, 1997) consider that LVPs recorded after 5-15 days from an acute 
MI, are the best predictors of ventricular arrhythmia appearing in the first year. If LVPs are 
missing at hospital discharge, their subsequent appearance is unlikely (Kuchar et al, 1986). 
LVPs may disappear later due to reshuffle of the myocardial scar.  
In the first year after a transmural infarction, the predictive value of LVPs is low for SCD, 
because factors like: unidirectional block, heart rate and autonomic imbalance are triggering 
repetitive arrythmias. 
Patients with two MI (inferior and right ventricle) have a high prevalence of LVPs, 
independent of LVEF, and a high arrhythmia risk should be considered in those patients 
(Iltumur et al, 2001).  
Prevalence of LVP is 7-10% in coronary heart disease without myocardial infarction.  
Most studies on LVPs in MI patients were performed before the reperfusion era (Steinberg& 
Berbari, 1996). Studies investigating the effects of thrombolysis on LVPs reported 
controversial results. Bauer et al. (Bauer et al, 2005) suggested that LVP are of limited use for 
risk stratification in post infarction patients who received reperfusion/revascularization 
therapy. Zipes et al. considered that repermeabilisation of infarct related artery modifies the 
arrhythmogenic substrate and reduces the predictive power of LVPs (Zipes et al, 2006). The 
evidence for a benefit of thrombolysis on LVPs prevalence depended on the success of 
thrombolysis in achieving early and full coronary blood flow restoration (Hohnloser et al, 
1994). LVPs were found in 25% to 65% of patients with an occluded infarct-related artery 
despite thrombolysis, but in only 6% to 34% of those with a patent infarct-related artery 
after thrombolytic therapy (Chew et al, 1990). Malik et al. showed that the usefulness of 
LVPs to predict subsequent arrhythmic events was significantly worse in patients who 
received thrombolytic therapy than in those who did not receive thrombolytic therapy 
(Malik et al, 1992). The controversial results may be due to the differences in therapy, lack of 
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adequate randomization and controlled studies, different techniques of recording SA-ECG 
and criteria to define LVPs. Savard et al. demonstrated that the prevalence of arrhythmic 
events declined from 9.6% to 5.8% after trombolysis. Both the low positive predictive value 
(about 20%) and the high negative predictive value (97%) remained unchanged (Savard et 
al, 1997). 
Percutaneous coronary interventions (PCIs) are associated with a significant reduction of the 
prevalence of LVPs (Santangeli et al, 2008). Bauer et al. showed that LVPs were significantly 
associated with SCD (Bauer et al, 2005). Ikeda et al. reported no significant prognostic role of 
LVPs for SCD/resuscitated cardiac arrest at a short-term follow-up of 3 to 6 months, but 
LVPs were independent predictors of sustained VT (Ikeda et al, 2002). 
Reperfusion of severely ischemic myocardium may also lead to hemorrhages in the infarct 
core by extravasations of red blood cells through the damaged endothelium (Mather et al, 
2010). The presence of hemorrhage was associated with a prolonged SA-QRS in patients 
with first ST-elevation acute MI, treated successfully with PCIs.  
LVPs persist in patients not undergoing reperfusion, and may be caused by ventricular 
remodeling, involving fibrosis, redistribution of the fibers in the damaged region and one 
side left ventricular hypertrophy (LVH).  
9. Cardiomyopathies 
Cardiomyopathies are an important cause of SCD in young people.  
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) is an inherited 
myocardial disease, characterized by fibro-fatty substitution of the right ventricle (Corrado 
& Thiene, 2006). The fibro-fatty areas can create reentry circuits, the substrate for repetitive 
ventricular arrhythmias and a delayed, fragmented activation font (Folino et al, 2006). The 
typical clinical manifestations are ventricular arrhythmias with left BBB pattern. LVPs were 
observed in more than 50% of patients with ARVC, and are minor diagnostic criteria in this 
setting (Santangeli et al, 2008). SAECG has shown particular reliability in ARVC, 
considering the classical location of the myocardial alterations in the right ventricle, which 
induce a delayed potential only in the terminal portion of QRS (Folino et al, 2006). Folino et 
al. (Folino et al, 2006) detected a progressive increase in delayed ventricular conduction, not 
associated with significant echocardiographic changes in patients with ARVC, and 
concluded that the baseline SAECG and echocardiographic parameters are useful in 
identifying patients with sustained VT. It was, also, hypothesized that the progression of the 
disease with an extension of fibro-fatty degeneration could completely isolate some 
infiltrated areas, with appearance of different preferential pathways of activation and 
reduction in late potentials (Folino et al, 2006).  
A close correlation was found between SAECG and extent of disease (Nava et al, 2000).  
Turrini et al, found an increased percentage of fibrous tissue and a high risk for sustained 
ventricular arrhythmias in patients with LVPs and ARVC (Turrini et al, 1999). The 
sensitivity of SAECG for diagnosis of ARVC increased by using only 1 of 3 criteria (Kamath 
et al, 2011).  
Santangeli et al (Santangeli et al, 2010) tested the association between noninvasive 
diagnostic criteria for ARVC and low voltage areas, detected at electroanatomic voltage 
mapping. SAECG abnormalities correlated with the presence of low voltage areas 
selectively in the right ventricular outflow tract, supporting the appropriateness of its 
inclusion among ARVC diagnostic criteria. 
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reduction in late potentials (Folino et al, 2006).  
A close correlation was found between SAECG and extent of disease (Nava et al, 2000).  
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ventricular arrhythmias in patients with LVPs and ARVC (Turrini et al, 1999). The 
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The prediction of sudden cardiac death is a major goal in the management of patients with 
hypertrophic cardiomyopathy (Cripps et al, 1990). Abnormal SAECGs were more prevalent 
in patients with hypertrophic cardiomyopathy compared to healthy controls, and were 
significantly associated with nonsustained VT on 48 h ECG Holter monitoring, but not with 
a family history of premature sudden cardiac death or a history of syncope (Cripps et al, 
1990).  
Fauchier et al. found a significantly higher incidence of severe ventricular premature beats 
in patients with idiopathic dilated cardiomyopathy (IDCM) and late ventricular potentials 
(Fauchier et al, 1991). Ohnishi et al. (Ohnishi et al, 1990 ) and Mancini et al. (Mancini et al, 
1993) mentioned a high incidence of prospective arrhythmias and SCD in patients with a 
IDCM and abnormal SAECG. Kitamura et al (Kitamura et al, 2003) concluded that the 
heterogeneous expression of connexin 43 protein may contribute to impaired ventricular 
conduction and LVPs detected on SAECG in patients with IDCM. Patchy interstitial fibrosis 
adjacent to viable myocardium is commonly seen in dilated cardiomyopathy. Fibrosis 
decreases electrical coupling, slows the propagation of impulses between myocytes and can 
become the anatomical substrate for reentrant VT. Alterations of the gap junctions are 
accompanied by discontinuity of tissue structure, which includes the naturally occurring 
myocardial cell orientation and the collagen matrix formed by the fibrosis (Kitamura et al, 
2003). The expression of connexin 43 was more decreased in patients with late ventricular 
potentials than in those without LVPs (Kitamura et al, 2003), but the degree of fibrosis seem 
not to influence the results. 
10. Congenital heart defects 
The predictive value of LVPs after repair of tetralogy of Fallot has been controversial. Al 
Balkhi et al. reported LVPs only 1 month after surgery in patients with tetralogy of Fallot, 
probably as a result of scarring (Al Balkhi et al, 2004). Zimmermann et al. found a 
correlation between inducibility of VT and LVPs (Zimmermann et al, 1991), but Giroud et al 
(Giroud et al, 1994) and Daliento et al. (Daliento et al, 1995) could not demonstrate a 
predictive value of LVPs alone in their studies. Janousek et al. found LVPs, and especially 
RMS40, to be predictive of spontaneous or induced VT in patients who underwent surgical 
correction of congenital cardiac disease (Janousek et al, 1995). 
11. Heart failure (HF) 
Patients with HF have a high SCD risk, despite therapeutic advances. Ventricular 
arrhythmias and SCD result from an interaction between a trigger and a substrate with 
neurohumoral factors (Bounhoure et al, 2010). The identification of the mechanisms of SCD 
in patients with HF is complicated by the different causes of HF. SCD risk correlates with 
the severity of congestive HF (Wilson et al, 1983). The high electrical instability in patients 
with post-infarction HF is due to structural inhomogeneities: patchy areas of fibrous tissue 
interdigitating with viable myocardium and scars. Interstitial fibrosis and hypertrophy are 
frequently seen on endomyocardial biopsies in patients with congestive HF. This can result 
in complex electrophysiological changes: abnormal impulse conduction with slow 
ventricular activation, changes in the refractory period responsible for ventricular 
arrhythmias (Bounhoure et al, 2010; Galinier et al, 1996).  
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There are conflicting results regarding the predictive value of LVPs for ventricular 
arrhythmias in HF patients. Small patient population studies (Meinertz et al, 1985; 
Middlekauff et al, 1990; Silverman et al, 1995) did not find SAECG to be predictive for SCD 
or ventricular arrhythmias in chronic HF. The studies by Mancini et al. and Galinier et al. 
found that the SAECG identified patients with congestive HF at high risk for death and/or 
ventricular tachycardia (Manicini et al, 1993; Galinier et al, 1996). 
According to current guidelines, most patients with left ventricular dysfunction and 
symptomatic HF may benefit from implanted devices and resynchronization therapy. It is 
important but difficult to identify patients at risk, and LVPs , combined with other 
electrocardiographic stratification methods, etiologic and clinical information, may help to 
select the candidates (Bounhoure et al, 2010). 
12. Brugada syndrome 
Brugada syndrome is characterized by abnormal repolarization in the right ventricle, 
detected as ST elevation in the right precordial leads, and depolarization abnormality, 
detected as right bundle branch block and LVPs (Morita et al, 2008). Repolarization 
heterogeneity within the epicardium of the right ventricular outflow tract seems to be the 
origin of reentry arrhythmia (Morita et al, 2007). A reduced sodium current, due to 
mutations of the sodium channel gene SCN5A, slows the conduction velocity and causes 
conduction abnormalities. Conduction abnormalities provide a substrate for the 
degeneration of polymorphic VT into VF (Meregalli et al, 2005).  
LVPs have been found in patients with the Brugada syndrome and might be helpful to 
identify patients at a higher risk of life-threatening arrhythmic events (Ikeda et al, 2001; 
Santangeli et al, 2008).  
Kutsuzawa et al. (Kutsuzawa et al, 2011) reported two patients with Brugada syndrome and 
hypokalemia induced lethal events. Normalization of serum potassium concealed the 
typical ECG pattern, but LVPs persisted even at 18-month follow-up. 
SAECG can detect not only LVPs, but also conduction abnormalities within the QRS 
complex: fragmented QRS (multiple spikes within the QRS complex) (Morita et al, 2008). It 
is considered that delayed activation within a small mass of ventricular tissue could 
produce LVPs and delayed activation in a larger ventricular mass can cause multiple spikes 
within the QRS complex. Fragmented QRS predicts syncope and VF in patients with 
Brugada syndrome (Morita et al, 2008). 
13. Syncope 
In patients with syncope of unknown cause, SAECG, combined with patient history and 
other diagnostic tests, can help identify or exclude a mechanism of VT as a cause of the 
syncope (Gang, et al, 1986; Santangeli et al, 2008).  
14. Atrial fibrillation and flutter 
It was hypothesized that the chaotic atrial activation in atrial fibrillation causes false-positive 
LVPs, making the analysis of SAECG very difficult (Buckingham et al, 1993; Halimi et al, 
1994). But, atrial fibrillation rarely creates problems with time-domain analysis of the 
SAECG (Fitzgerald et al, 1996; Halimi et al, 1994). LVPs analysis provides similar results in 
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atrial fibrillation and sinus rhythm, was concluded by Gottfridsson et al. (Gottfridsson et al, 
2011) in a study including 82 patients with atrial fibrillation, undergoing electrical 
cardioversion, despite decrease of heart rate and prolongation of SA-QRS. Conflicting 
results were obtained by different authors, analyzing SAECG variables after cardioversion. 
Halimi et al (Halimi et al, 1994) mentioned significant changes of LAS40 and RMS40 after 
cardioversion. Buckingham et al (Buckingham et al, 1993) found no significant changes of 
SA-ECG parameters. 
Atrial flutter waves occur during ventricular systole and mimic LVPs (Gatzoulis et al, 1993). 
In conclusion, atrial flutter can create significant errors in the automated time-domain 
analysis of the SAECG, and patients with atrial flutter should not undergo SAECG for 
postinfarction risk assessment (Fitzgerald et al, 1996).   
15. Bundle branch block (BBB) 
Increased QRS duration has been previously associated with increased mortality in patients 
with coronary heart disease and hypertensive patients (Brembilla-Perrot et al, 2001; Liew, 
2011). Syncope and dizziness may be related either to atrio-ventricular conduction 
disturbances or to ventricular arrhythmias. On the other hand, the presence of 
intraventricular conduction defects interferes with the detection of LVPs (Brembilla-Perrot 
et al, 2001; Englund et al, 1995), and, thus, patients with BBB are often excluded from the 
SAECG studies. Therefore, the management of these patients needs special attention.  
BBB decreased the specificity of the SAECG to predict VT risk in patients with dilated 
cardiomyopathy (Brembilla-Perrot et al, 1997). Among noninvasive parameters, only a 
prolonged SA-QRS (>165 ms) was a significant predictor of cardiac mortality (Brembilla-
Perrot et al, 2001). 
Delayed terminal conduction observed in incomplete right BBB may cause false positive 
LVPs (Manolis et al, 1997). In order to prevent false positive results, separate LVPs criteria 
were used for patients with BBB (Galinier et al, 1996). 
16. Hypertension (HT) 
A significant association has been demonstrated between hypertension and SCD (Yildirir et 
al, 2002). The risk of SCD due to ventricular arrhythmias was demonstrated by a prolonged 
QT interval or LVPs. The most important mechanisms by which HT predisposes to SCD are: 
the degree of left ventricular hypertrophy (LVH), interstitial fibrosis, myocardial or 
subendocardial scars, silent myocardial ischemia, diastolic dysfunction and disturbances in 
cardiac autonomic balance (Galinier et al, 1997; Kaftan AH & Kaftan O, 2000; Palatini et al, 
1995; Yildirir et al, 2002). Coronary artery disease may interact with LVH in the genesis of 
ventricular arrhythmias and SCD (Galinier et al, 1997). 
LVPs wer found by several authors in HT (Brune et al, 1991; Vester et al, 1992). Galinier et 
al. (Galinier et al, 1992) and Franchi et al. (Franchi et al, 1992) found a greater prevalence of 
LVPs in subjects with eccentric LVH than in those with concentric hypertrophy. Non-
sustained VT has been found to have a prognostic value in HT patients (Galinier et al, 1997). 
Vardas et al. (Vardas et al, 1994) and Palatini et al (Palatini et al, 1995) confirmed that a high 
prevalence of ventricular arrhythmias was associated with LVPs in HT patients. Only the 
E/A ratios were related to the presence of either LVPs or VT, and they were far lower in 
patients with LVPs (Palatini et al, 1995).  
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The initial reports of the Framingham Heart Study demonstrated the deleterious effect on 
survival of LVH (Kannel & Abbot, 1986; Levy et al, 1990). A downward trend in the 
prevalence of LVH was noticed in the last decades, which coincided with improved HT  
control (Priori et al, 2001). A lack of a relation between left ventricular mass and the 
occurrence of LVPs has been also reported by some authors (Panagides et al, 1990; Prisant et 
al, 1993; Rizzo et al, 2000). 
Experimentally, LVH delays ventricular conduction and prolongs action potential duration. 
Electrocardiographic QRS duration and QT interval measures reflect these changes 
(Oikarinen et al, 2004). The increased QRS duration may be attributed to the increased 
thickness of the left ventricle wall and to intramural fibrosis, which distorts and prolongs 
transmural impulse propagation, or it could be a manifestation of intraventricular or 
interventricular conduction delay or block (Hancock et al, 2009). Alterations in ion channels 
due to hypertrophy were also mentioned as possible causes of QT interval prolongation in 
LVH (Hancock et al, 2009).  
LVPs were present in both dippers and nondippers, and the values were significantly lower 
in dippers for SA-QRS and LAS40, and nondipper pattern was not linked to a worse 
arrhythmogenic substrate (Rizzo et al, 2000).  
There is no study with power to show prognostic significance of LVPs in HT patients. All 
studies on LVPs in hypertensive patients have all been small scale, with short follow up.  
17. Dyslipidemia and metabolic syndrome 
The epidemiological association between elevated LDL cholesterol and risk of all 
manifestations of coronary artery disease including SCD is well established (Priori et al, 
2001). A relation between dyslipidemia and electrical instability has been hypothesized. 
Gimaev et al. (Gimaev et al, 2009) evaluated the effect of disturbed lipid metabolism on 
SAECG characteristics and found LVPs in patients with high, moderately elevated, low and 
normal serum cholesterol. Hypercholesterolemia has been reported to induce proarrhythmic 
sympathetic neural sprouting and ventricular electrophysiologic remodeling, and an 
increased vulnerability to VF in a high-fat-fed animal model (Liu et al, 2003). 
A significant correlation was found between serum cholesterol and SAQRS, LAS40 and 
RMS40 in patients with an old MI (Mozos & Hancu, 2010). 
Clinical trials of lipid lowering in the primary prevention of coronary artery disease have 
not evaluated SCD risk, and have not sufficient statistical power to identify a significant 
reduction (Priori et al, 2001).  Statins seem to have antiarrhythmic properties in addition to 
their lipid-lowering effects (Chu et al 2007; Abuissa et al, 2009). 
Isolated metabolic syndrome is associated with an increase in left ventricular mass index 
and diastolic dysfunction, increasing the risk of cardiovascular disease (Aijaz et al, 2008). 
The prevalence of increased QT interval duration has been investigated with respect to 
single components of the metabolic syndrome (Strohmer et al, 2007).  
18. Obesity 
Patients with morbid obesity have high rates of sudden, unexpected cardiac death (Duflou 
et al, 1995). An increased prevalence of abnormal SAECG results has been found in obese 
patients without known clinical heart disease, and body mass index (BMI) can be considered 
as an independent predictor of abnormal SAECG results (Lalani et al, 2000). Mizia-Stec et al . 
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(Mizia-Stec et al, 2000) found an increased QT dispersion (QTd) in obese women, associated 
with LVH and significantly higher QTd in patients with late ventricular potentials. 
The mechanism of death in these patients remains uncertain. Parasympathetic withdrawal, 
occuring with increasing obesity, conduction abnormalities, cardiomyopathy of obesity, the 
lipotoxicity of the myocardium induced by free fatty acids, released from hypertrophied 
adipocytes in obese persons with myocardial steatosis, structural heterogeneity due to fatty 
infiltration of the heart, myocyte hypertrophy, focal myocardial disarray, fibrosis and 
mononuclear cell infiltration could be involved (Alexander, 1985; Bharati & Lev, 1995; 
Duflou et al, 1995; Lalani et al, 2000). Particularly, with a concentric pattern of LVH, the 
prevalence of ventricular ectopic beats is substantially elevated in obese patients (Schunkert, 
2002). The cardiomyopathy of morbid obesity, the most common cause of SCD in these 
patients, is characterized by cardiomegaly, left ventricular dilatation, and myocyte 
hypertrophy in the absence of interstitial fibrosis.  
A BMI associated increase in chronic MI patients’ SCD risk was mentioned by Mozos et al. 
and SAECG-QRS and LAS40 correlated with BMI in patients with an old MI (Mozos et al, 
2007).  
19. Diabetes mellitus and hyperglycemia 
There is controversy in the literature as to whether glucose intolerance or diabetes mellitus 
are independent risk factors for SCD (Priori et al, 2001). Streptozocin experimentally 
induced diabetes impairs both depolarization and repolarization (Pacher et al, 1999). QT 
interval prolongation in diabetic patients has been attributed to autonomic neuropathy and 
insulin resistance, and in healthy non-diabetic subjects with high plasma glucose, to 
increased cytosolic calcium content, oxidative stress and enhanced sympathetic activity 
(Muntean et al, 2009).  
Kowalewski et al. (Kowalewski et al, 2002) included 72 children with type 1 diabetes 
mellitus in his study and found an increased prevalence of abnormal SAECGs and LVPs. 
Diabetic children with LVPs had thicker left ventricular posterior wall and longer diabetes 
duration time than children without LVPs. Nonlinear regression model showed that 
duration of diabetes, cardiac autonomic neuropathy, and left ventricular posterior wall were 
the strongest independent parameters of LVPs occurrence. 
An association between hyperglycemia on admission in patients with acute ST elevation MI 
and arrhythmias during hospitalization has been observed (Sanjuan et al, 2011). Stress 
hyperglycemia on admission was found to be a predictor of mortality and arrhythmias in 
patients with acute ST elevation MI and could be used in the stratification of risk in these 
patients (Pinto et al, 2008; Sanjuan et al, 2011).  
20. End-stage renal failure and hemodialysis 
Cardiac disease is the major cause of death in dialysis patients (Herzog et al, 2008). LVH 
with interstitial fibrosis, deposition of calcium and aluminum salts in the heart tissue often 
occur in patients with end-stage renal disease (ESRD) (Morales et al, 1998). Autonomic 
neuropathy and impairment of left ventricular functions have been frequently encountered 
in chronic renal failure and depend on the disease duration (Karayaylali et al, 2003). SCD 
risk due to ventricular arrhythmias is high in ESRD patients on hemodialysis (HD) 
(Dubrava et al, 2003; Sakhuja et al, 2009). SAECG parameters are abnormal in a significant 
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proportion of patients with chronic renal failure (Girgis et al, 1999). The mentioned 
histological changes could represent a potential substrate for LVPs. LVH was already 
considered as SA-QRS prolonging factor in hypertensive patients (Vester et al, 1992) and 
associated with a high prevalence of LVPs in post-infarction HF patients (Mozos et al, 2009). 
This explanation appears unlikely in renal failure. Morales et al. did not detect significant 
differences in left ventricular mass between end-stage renal failure patients with and 
without late ventricular potentials before HD (Morales et al, 1998). Roithinger et al. did not 
find a significant association between mortality and LVPs or structural myocardial changes 
in HD patients, but a tendency towards an excess mortality of patients with coronary artery 
disease and compromised left ventricular function (Roithinger et al, 1992). On the other 
hand, Girgis et al. concluded that SAECG parameters improve with HD, and, decreased left 
ventricular dimensions, because of fluid removal during HD, (Girgis et al, 1999).  
Volume, electrolyte, acid-base balance, heart rate and blood pressure changes appearing 
during HD, can trigger supraventricular and ventricular arrhythmias (Dubrava et al, 2003; 
Morales et al, 1998). Most of the studies performed in HD patients have focused on QRS 
amplitude and T wave (Morales et al, 1998). Abnormalities in SAECG were also mentioned 
in patients undergoing HD and peritoneal dialysis (Girgis et al, 1999; Ichikawa et al, 1997; 
Morales et al, 1998; Roithinger et al, 1992).  
The prevalence of late ventricular potentials was 25% in the study of Morales et. al (Morales 
et al, 1998), including patients with a known history of myocardial infarction, and only 14% 
in another study including younger patients, with a lower prevalence of coronary heart 
disease (Roithinger et al, 1992). Ichikawa et al reported no LVPs before HD and abnormal 
SAECGs in only 2.4% of the patients (Ichikawa et al, 1997). Late ventricular potentials were 
attributed to underlying coronary heart disease with left ventricular dysfunction (Morales et 
al, 1998). Most of the studies reported improved SAECGs after HD. 
Morales et al and Ichikawa et al reported a prolongation of SA-QRS duration after dialysis 
(Ichikawa et al, 1997; Morales et al, 1998), probably due to widening of the initial portion of 
the QRS, related to the acute reduction in serum potassium (Morales et al, 1998). Girgis et al. 
showed that only LAS40 and RMS40 change significantly after hemodialysis (Girgis et al, 
1999). LAS40 was also significantly increased postdialysis in a study of Ichikawa et al, and 
the changes in LAS40 correlated with the changes in potassium in the high-K group 
(Ichikawa et al, 1997). Larger studies are needed to verify the effect of HD on time-domain 
SAECG parameters.  
Animal studies demonstrated that hypokalemia-induced arrhythmogenicity is due to 
slowed conduction, prolonged ventricular repolarisation (caused by inhibition of outward 
potassium currents) and abnormal pacemaker activity (Osadchii, 2010). Hypokalemia effect 
on repolarisation is not uniform, causing amplified spatial repolarisation gradients and an 
unidirectional conduction block (Osadchii, 2010). Prolongation of action potential may be 
associated with shortening of the effective refractory period, facilitating reentry. Serum 
potassium between 4.6 and 5.3 mEq/l was associated with best survival in HD patients, and 
potassium <4 or ≥5.6 mEq/l was associated with increased mortality (Kovesdy et al, 2007). 
An insufficient decrease of serum potassium by hemodialysis was suggested to be an 
arrhythmogenic factor (Ichikawa et al, 1997). 
21. Alcoholism 
Acute alcoholic states, binge drinking, the “holiday heart syndrome” and liver cirrhosis are 
associated with prolonged QT intervals and an increased prevalence of cardiac arrhythmias 
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(Mizia-Stec et al, 2000) found an increased QT dispersion (QTd) in obese women, associated 
with LVH and significantly higher QTd in patients with late ventricular potentials. 
The mechanism of death in these patients remains uncertain. Parasympathetic withdrawal, 
occuring with increasing obesity, conduction abnormalities, cardiomyopathy of obesity, the 
lipotoxicity of the myocardium induced by free fatty acids, released from hypertrophied 
adipocytes in obese persons with myocardial steatosis, structural heterogeneity due to fatty 
infiltration of the heart, myocyte hypertrophy, focal myocardial disarray, fibrosis and 
mononuclear cell infiltration could be involved (Alexander, 1985; Bharati & Lev, 1995; 
Duflou et al, 1995; Lalani et al, 2000). Particularly, with a concentric pattern of LVH, the 
prevalence of ventricular ectopic beats is substantially elevated in obese patients (Schunkert, 
2002). The cardiomyopathy of morbid obesity, the most common cause of SCD in these 
patients, is characterized by cardiomegaly, left ventricular dilatation, and myocyte 
hypertrophy in the absence of interstitial fibrosis.  
A BMI associated increase in chronic MI patients’ SCD risk was mentioned by Mozos et al. 
and SAECG-QRS and LAS40 correlated with BMI in patients with an old MI (Mozos et al, 
2007).  
19. Diabetes mellitus and hyperglycemia 
There is controversy in the literature as to whether glucose intolerance or diabetes mellitus 
are independent risk factors for SCD (Priori et al, 2001). Streptozocin experimentally 
induced diabetes impairs both depolarization and repolarization (Pacher et al, 1999). QT 
interval prolongation in diabetic patients has been attributed to autonomic neuropathy and 
insulin resistance, and in healthy non-diabetic subjects with high plasma glucose, to 
increased cytosolic calcium content, oxidative stress and enhanced sympathetic activity 
(Muntean et al, 2009).  
Kowalewski et al. (Kowalewski et al, 2002) included 72 children with type 1 diabetes 
mellitus in his study and found an increased prevalence of abnormal SAECGs and LVPs. 
Diabetic children with LVPs had thicker left ventricular posterior wall and longer diabetes 
duration time than children without LVPs. Nonlinear regression model showed that 
duration of diabetes, cardiac autonomic neuropathy, and left ventricular posterior wall were 
the strongest independent parameters of LVPs occurrence. 
An association between hyperglycemia on admission in patients with acute ST elevation MI 
and arrhythmias during hospitalization has been observed (Sanjuan et al, 2011). Stress 
hyperglycemia on admission was found to be a predictor of mortality and arrhythmias in 
patients with acute ST elevation MI and could be used in the stratification of risk in these 
patients (Pinto et al, 2008; Sanjuan et al, 2011).  
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with interstitial fibrosis, deposition of calcium and aluminum salts in the heart tissue often 
occur in patients with end-stage renal disease (ESRD) (Morales et al, 1998). Autonomic 
neuropathy and impairment of left ventricular functions have been frequently encountered 
in chronic renal failure and depend on the disease duration (Karayaylali et al, 2003). SCD 
risk due to ventricular arrhythmias is high in ESRD patients on hemodialysis (HD) 
(Dubrava et al, 2003; Sakhuja et al, 2009). SAECG parameters are abnormal in a significant 
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proportion of patients with chronic renal failure (Girgis et al, 1999). The mentioned 
histological changes could represent a potential substrate for LVPs. LVH was already 
considered as SA-QRS prolonging factor in hypertensive patients (Vester et al, 1992) and 
associated with a high prevalence of LVPs in post-infarction HF patients (Mozos et al, 2009). 
This explanation appears unlikely in renal failure. Morales et al. did not detect significant 
differences in left ventricular mass between end-stage renal failure patients with and 
without late ventricular potentials before HD (Morales et al, 1998). Roithinger et al. did not 
find a significant association between mortality and LVPs or structural myocardial changes 
in HD patients, but a tendency towards an excess mortality of patients with coronary artery 
disease and compromised left ventricular function (Roithinger et al, 1992). On the other 
hand, Girgis et al. concluded that SAECG parameters improve with HD, and, decreased left 
ventricular dimensions, because of fluid removal during HD, (Girgis et al, 1999).  
Volume, electrolyte, acid-base balance, heart rate and blood pressure changes appearing 
during HD, can trigger supraventricular and ventricular arrhythmias (Dubrava et al, 2003; 
Morales et al, 1998). Most of the studies performed in HD patients have focused on QRS 
amplitude and T wave (Morales et al, 1998). Abnormalities in SAECG were also mentioned 
in patients undergoing HD and peritoneal dialysis (Girgis et al, 1999; Ichikawa et al, 1997; 
Morales et al, 1998; Roithinger et al, 1992).  
The prevalence of late ventricular potentials was 25% in the study of Morales et. al (Morales 
et al, 1998), including patients with a known history of myocardial infarction, and only 14% 
in another study including younger patients, with a lower prevalence of coronary heart 
disease (Roithinger et al, 1992). Ichikawa et al reported no LVPs before HD and abnormal 
SAECGs in only 2.4% of the patients (Ichikawa et al, 1997). Late ventricular potentials were 
attributed to underlying coronary heart disease with left ventricular dysfunction (Morales et 
al, 1998). Most of the studies reported improved SAECGs after HD. 
Morales et al and Ichikawa et al reported a prolongation of SA-QRS duration after dialysis 
(Ichikawa et al, 1997; Morales et al, 1998), probably due to widening of the initial portion of 
the QRS, related to the acute reduction in serum potassium (Morales et al, 1998). Girgis et al. 
showed that only LAS40 and RMS40 change significantly after hemodialysis (Girgis et al, 
1999). LAS40 was also significantly increased postdialysis in a study of Ichikawa et al, and 
the changes in LAS40 correlated with the changes in potassium in the high-K group 
(Ichikawa et al, 1997). Larger studies are needed to verify the effect of HD on time-domain 
SAECG parameters.  
Animal studies demonstrated that hypokalemia-induced arrhythmogenicity is due to 
slowed conduction, prolonged ventricular repolarisation (caused by inhibition of outward 
potassium currents) and abnormal pacemaker activity (Osadchii, 2010). Hypokalemia effect 
on repolarisation is not uniform, causing amplified spatial repolarisation gradients and an 
unidirectional conduction block (Osadchii, 2010). Prolongation of action potential may be 
associated with shortening of the effective refractory period, facilitating reentry. Serum 
potassium between 4.6 and 5.3 mEq/l was associated with best survival in HD patients, and 
potassium <4 or ≥5.6 mEq/l was associated with increased mortality (Kovesdy et al, 2007). 
An insufficient decrease of serum potassium by hemodialysis was suggested to be an 
arrhythmogenic factor (Ichikawa et al, 1997). 
21. Alcoholism 
Acute alcoholic states, binge drinking, the “holiday heart syndrome” and liver cirrhosis are 
associated with prolonged QT intervals and an increased prevalence of cardiac arrhythmias 
 
Cardiac Arrhythmias – New Considerations 
 
240 
and SCD (Day et al, 1993; Genovesi et al, 2008; Wever & Robles de Medina, 2004;). In 
contrast, case-control studies have demonstrated a protective effect of moderate alcohol 
consumption against sudden cardiac death (Priori et al, 2001; Vreede-Swagemakers et al, 
1999). Alcohol inhibits the Na-K-ATPase, which alters the resting membrane potential, 
delays calcium binding and transport by the cardiac sarcoplasmic reticulum and impairs 
calcium channels (Lorsheyd & de Lange, 2005). 
Life-threatening ventricular arrhythmias are found in alcoholics without heart disease 
(Moushmoush et al, 1991). Alcoholic cardiomyopathy is associated with localized delays in 
intraventricular conduction and nonuniform myocardial involvement (Luca, 1979). 
Koskinen & Kupari did not find LVPs in chronic alcoholics without detectable heart disease 
(Koskinen & Kupari, 1993). The absence of LVPs does not exclude nonuniformity of alcohol 
induced myocardial changes.  
Chronic heavy alcohol consumption increases left ventricular mass and may cause 
subclinical impairment in left ventricular function (Luca, 1979).    
Pochmalicki et al. found LVPs in chronic alcoholics (Pochmalicki et al, 1997) and concluded 
that cronic alcohol intake, sufficient to cause histologically significant fatty liver, is ssociated 
with LVPs. LVPs could reveal early, preclinical myocardial lesions, and help to identify 
alcoholic patients at high risk of lethal arrhythmias. 
22. Chronic obstructive pulmonary disease (COPD) 
COPD is an independent risk factor for cardiovascular morbidity and mortality (Celli et al, 
2010). Potential explanations for this association include: smoking, negative cardiac 
consequences of dynamic hyperinflation, exercise limitations and hypoxemia (Celli et al, 
2010; Priori et al, 2001). 
Carjea (Carjea, 2003) studied the prevalence and characteristics of late ventricular potentials 
in 90 patients with COPD compared to healthy subjects and found significant differences. 
The highest prevalence was noticed in moderate to severe cases. 
23. Acromegaly 
The heart is an end-organ of growth hormone action. A high prevalence of complex 
ventricular arrhythmias has been mentioned in patients with acromegaly, possible as a 
result of disordered left ventricular architecture and ventricular remodeling (Clayton, 
2003).  
The frequency of premature ventricular complexes increased with duration of acromegaly, 
and the severity of arrhythmia correlated with left ventricular mass but not with growth 
hormone levels (Kahaly et al, 1992). Structural heterogeneity in acromegalic heart is due to 
areas of hypertrophied myocytes, separated by fibrosis and cellular infiltrations (Clayton, 
2003). Late ventricular potentials are frequently seen in active acromegaly, are associated 
with disease activity and may represent an early and sensitive parameter to detect 
myocardial injury (Herrmann et al, 2001). No association was found between presence of 
late ventricular potentials and left ventricular mass index. Longitudinal studies are needed 
to determine whether therapy changes the electrophysiological abnormalities.  
Earlier studies showed that arrhythmias were as frequent before and after treatment of 
acromegaly, implying that fibrous tissue infiltration caused irreversible scarring (Hayward 
et al, 1987; Rodrigues et al, 1989). 
 




Beta–thalassemia, the impaired production of the beta hemoglobin chain, is associated with 
significant changes in heterogeneity of cardiac ventricular repolarization and SCD (Russo et 
al, 2011). In the late stages, frequent premature ventricular contractions and sustained 
ventricular tachycardia have been mentioned, related to cardiac death. Thalassemia patients 
require intensive blood transfusions due to severe anemia, and an increase in body iron 
burden occurs both in patients who are or are not receiving transfusions (Lekawanvijit & 
Chattipakorn, 2009). 
The role of iron overload in causing conduction delays in the thalassemic heart is well 
documented and iron overload thalassemic cardiomyopathy may explain the occurrence of 
LVPs (Isma'eel et al, 2007), as well as changes in QRS duration and RMS40 voltage. The 
patchy nature of cardiac iron deposition may provide substrates for re-entry and risk of fatal 
arrhythmias (Lekawanvijit & Chattipakorn, 2009). Iron-overloaded cardiomyocytes have a 
smaller overshoot potential and shorter action potential duration than iron-free 
cardiomyocytes in the same heart and reduced Na+ currents may be an underlying 
mechanism (Lekawanvijit & Chattipakorn, 2009). Further mechanisms related to 
tachyarrhythmias and SCD are changes in calcium homeostasis, elevated prostaglandin E2 
to prostacyclin ratio, increased interleukin 1 level and lipid peroxidation. 
Future large populations, long-term follow-up studies are needed to demonstrate further 
clinical consequences in iron overload cardiomyopathy. 
25. Connective tissue and systemic diseases 
Cardiovascular involvement is common in connective tissue diseases (Lazzerini et al, 2006), 
but myocardial involvement is seldom recognized clinically (Stanescu & Dan, 1992). 
Ventricular arrhythmias represent a major cause of SCD in autoimmune rheumatic diseases 
(Sefarovic et al, 2006). The mechanisms are probably multiple and myocardial fibrosis seems 
to play a pivotal role (Lazzerini et al, 2006). Lazzerini et al (Lazzerini et al, 2007) concluded 
that anti-Ro/SSA positive patients have a particularly high risk of developing ventricular 
arrhythmias.  
The heart is one of the major organs involved in scleroderma. Ventricular arrhythmias are 
common among asymptomatic patients with systemic sclerosis, especially: premature 
ventricular contractions and non-sustained VT (Sefarovic et al, 2006). Patchy myocardial 
fibrosis represents an ideal substrate for reentry tachyarrhythmias. LVPs occurred in 
patients with diffuse progressive systemic sclerosis; a lower myocardial involvement was 
noticed in the CREST syndrome (Paradiso et al, 1996). Diffuse abnormalities of the cardiac 
tissue detected by SAECG may be present in patients with systemic sclerosis without 
cardiac symptoms and higher skin scores correlated with the presence of LVPs (Paradiso et 
al, 2002). Pignone et al (Pignone et al, 1994) found no correlation between LVPs and 
immunologic patterns, cutaneous and pulmonary involvement in 26 patients with systemic 
sclerosis. 
Myocardial lesions in systemic lupus erythematosus are characterized by an increase in 
interstitial connective tissue and myocardial scarring (Paradiso et al, 2001).  The most 
important cardiac manifestations of systemic lupus erythematosus are: pericarditis, lesions 
of valves, myocardium and coronary artery disease (Gomez-Leon Manduiano & Amezcua-
Guerra, 2008). Sinus and atrial arrhythmias are more prevalent, but QT interval 
 
Cardiac Arrhythmias – New Considerations 
 
240 
and SCD (Day et al, 1993; Genovesi et al, 2008; Wever & Robles de Medina, 2004;). In 
contrast, case-control studies have demonstrated a protective effect of moderate alcohol 
consumption against sudden cardiac death (Priori et al, 2001; Vreede-Swagemakers et al, 
1999). Alcohol inhibits the Na-K-ATPase, which alters the resting membrane potential, 
delays calcium binding and transport by the cardiac sarcoplasmic reticulum and impairs 
calcium channels (Lorsheyd & de Lange, 2005). 
Life-threatening ventricular arrhythmias are found in alcoholics without heart disease 
(Moushmoush et al, 1991). Alcoholic cardiomyopathy is associated with localized delays in 
intraventricular conduction and nonuniform myocardial involvement (Luca, 1979). 
Koskinen & Kupari did not find LVPs in chronic alcoholics without detectable heart disease 
(Koskinen & Kupari, 1993). The absence of LVPs does not exclude nonuniformity of alcohol 
induced myocardial changes.  
Chronic heavy alcohol consumption increases left ventricular mass and may cause 
subclinical impairment in left ventricular function (Luca, 1979).    
Pochmalicki et al. found LVPs in chronic alcoholics (Pochmalicki et al, 1997) and concluded 
that cronic alcohol intake, sufficient to cause histologically significant fatty liver, is ssociated 
with LVPs. LVPs could reveal early, preclinical myocardial lesions, and help to identify 
alcoholic patients at high risk of lethal arrhythmias. 
22. Chronic obstructive pulmonary disease (COPD) 
COPD is an independent risk factor for cardiovascular morbidity and mortality (Celli et al, 
2010). Potential explanations for this association include: smoking, negative cardiac 
consequences of dynamic hyperinflation, exercise limitations and hypoxemia (Celli et al, 
2010; Priori et al, 2001). 
Carjea (Carjea, 2003) studied the prevalence and characteristics of late ventricular potentials 
in 90 patients with COPD compared to healthy subjects and found significant differences. 
The highest prevalence was noticed in moderate to severe cases. 
23. Acromegaly 
The heart is an end-organ of growth hormone action. A high prevalence of complex 
ventricular arrhythmias has been mentioned in patients with acromegaly, possible as a 
result of disordered left ventricular architecture and ventricular remodeling (Clayton, 
2003).  
The frequency of premature ventricular complexes increased with duration of acromegaly, 
and the severity of arrhythmia correlated with left ventricular mass but not with growth 
hormone levels (Kahaly et al, 1992). Structural heterogeneity in acromegalic heart is due to 
areas of hypertrophied myocytes, separated by fibrosis and cellular infiltrations (Clayton, 
2003). Late ventricular potentials are frequently seen in active acromegaly, are associated 
with disease activity and may represent an early and sensitive parameter to detect 
myocardial injury (Herrmann et al, 2001). No association was found between presence of 
late ventricular potentials and left ventricular mass index. Longitudinal studies are needed 
to determine whether therapy changes the electrophysiological abnormalities.  
Earlier studies showed that arrhythmias were as frequent before and after treatment of 
acromegaly, implying that fibrous tissue infiltration caused irreversible scarring (Hayward 
et al, 1987; Rodrigues et al, 1989). 
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significant changes in heterogeneity of cardiac ventricular repolarization and SCD (Russo et 
al, 2011). In the late stages, frequent premature ventricular contractions and sustained 
ventricular tachycardia have been mentioned, related to cardiac death. Thalassemia patients 
require intensive blood transfusions due to severe anemia, and an increase in body iron 
burden occurs both in patients who are or are not receiving transfusions (Lekawanvijit & 
Chattipakorn, 2009). 
The role of iron overload in causing conduction delays in the thalassemic heart is well 
documented and iron overload thalassemic cardiomyopathy may explain the occurrence of 
LVPs (Isma'eel et al, 2007), as well as changes in QRS duration and RMS40 voltage. The 
patchy nature of cardiac iron deposition may provide substrates for re-entry and risk of fatal 
arrhythmias (Lekawanvijit & Chattipakorn, 2009). Iron-overloaded cardiomyocytes have a 
smaller overshoot potential and shorter action potential duration than iron-free 
cardiomyocytes in the same heart and reduced Na+ currents may be an underlying 
mechanism (Lekawanvijit & Chattipakorn, 2009). Further mechanisms related to 
tachyarrhythmias and SCD are changes in calcium homeostasis, elevated prostaglandin E2 
to prostacyclin ratio, increased interleukin 1 level and lipid peroxidation. 
Future large populations, long-term follow-up studies are needed to demonstrate further 
clinical consequences in iron overload cardiomyopathy. 
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Cardiovascular involvement is common in connective tissue diseases (Lazzerini et al, 2006), 
but myocardial involvement is seldom recognized clinically (Stanescu & Dan, 1992). 
Ventricular arrhythmias represent a major cause of SCD in autoimmune rheumatic diseases 
(Sefarovic et al, 2006). The mechanisms are probably multiple and myocardial fibrosis seems 
to play a pivotal role (Lazzerini et al, 2006). Lazzerini et al (Lazzerini et al, 2007) concluded 
that anti-Ro/SSA positive patients have a particularly high risk of developing ventricular 
arrhythmias.  
The heart is one of the major organs involved in scleroderma. Ventricular arrhythmias are 
common among asymptomatic patients with systemic sclerosis, especially: premature 
ventricular contractions and non-sustained VT (Sefarovic et al, 2006). Patchy myocardial 
fibrosis represents an ideal substrate for reentry tachyarrhythmias. LVPs occurred in 
patients with diffuse progressive systemic sclerosis; a lower myocardial involvement was 
noticed in the CREST syndrome (Paradiso et al, 1996). Diffuse abnormalities of the cardiac 
tissue detected by SAECG may be present in patients with systemic sclerosis without 
cardiac symptoms and higher skin scores correlated with the presence of LVPs (Paradiso et 
al, 2002). Pignone et al (Pignone et al, 1994) found no correlation between LVPs and 
immunologic patterns, cutaneous and pulmonary involvement in 26 patients with systemic 
sclerosis. 
Myocardial lesions in systemic lupus erythematosus are characterized by an increase in 
interstitial connective tissue and myocardial scarring (Paradiso et al, 2001).  The most 
important cardiac manifestations of systemic lupus erythematosus are: pericarditis, lesions 
of valves, myocardium and coronary artery disease (Gomez-Leon Manduiano & Amezcua-
Guerra, 2008). Sinus and atrial arrhythmias are more prevalent, but QT interval 
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prolongation, abnormalities in the autonomic tone and LVPs indicate high risk of 
developing life-threatening ventricular arrhythmias (Sefarovic et al, 2006). LVPs were 
recorded in patients with systemic lupus (Paradiso et al, 2001; Wranicz et al, 2001), and the 
depolarization abnormalities revealed by SAECG reflect a longer extent of myocardial 
fibrosis and echocardiography and SAECG alterations are markers of subclinical myocardial 
involvement. Increasing evidence suggest that anti-Ro/SSA antibodies may trigger rhythm 
disturbances due to an inhibiting cross-reaction with several cardiac calcium and potassium 
ionic channels (Lazzerini et al, 2010).  
So far, the evidence related to electrocardiographic disturbances in this setting is restricted 
to studies with small number of patients (Teixeira, et al, 2010). The mechanisms of 
arrhythmias are related to the inflammatory process of pericarditis and myocarditis, 
atherosclerotic myocardial ischemia, increased sympathetic activity, vasculitis of small 
vessels with collagen deposits and anti-Ro/SSA antibodies (Lazzerini et al, 2010; Teixeira, et 
al, 2010). 
Cardiac sarcoidosis affects the myocardium, pericardium and endocardium, and the disease 
may present with: atrioventricular and intraventricular conduction disturbances, ventricular 
arrhythmias and HF. Ventricular arrhythmias are among the main causes of SCD in cardiac 
sarcoidosis. LVPs on SAECG were mentioned and they were abolished after steroid therapy 
(Yodogawa et al, 2011). 
26. Schizophrenia 
Schizophrenia patients were also found to be positive for LVPs. Cardiac autonomic 
dysregulation in schizophrenia patients and use of psychiatric and/or non-psychiatric 
medications that affect conduction, may account for LVPs (Nashoni et al, 2010). 
27. Influence of therapy on LVPs 
LVPs are influenced by antiarrhythmic therapy, trombolytic drugs, anevrismectomy, 
percutaneous coronary interventions, coronary artery bypass surgery, statins, steroids. 
The effect on the prevalence of LVPs of modern pharmacologic therapy in patients with 
acute MI has been assessed in several studies (Santangeli et al, 2008). Class I, II and III 
antiarrhythmics may reduce the prevalence of LVPs.  Class IV antiarrhythmics (Verapamil) 
do not influence LVPs. Some class III antiarrhythmic drugs are able to prolong SA-QRS and 
LAS40, and may be associated with the occurence of LVPs.  
Freedman and Steinberg showed that sodium channel blockers (quinidine, procainamide, 
imipramide) have preferential effects on slowly conducting tissue in patients with a history 
of VT, causing an important prolongation of LVPs (Freedman & Steinberg, 1991).  
Santarelli et al, reported that LVPs were less frequent in acute MI patients treated with 
betablockers compared with those not treated with betablockers during hospitalization. This 
effect was found only in patients with a preserved LVEF (Santarelli et al, 1993).  
No significant SAECG changes have been observed after Sotalol. 
Adrenergic stimulation with adrenaline and isoprenaline, and parasympatholytic agents 
such as atropine, lead to significant changes in the signal averaged electrocardiogram in 
healthy subjects (Goldberger et al, 1994). Beta-adrenergic stimulation with isoproterenol led 
to a significant shortening of SA-QRS, and epinephrine prolonged the QRS duration. 
Increased alfa-adrenergic stimulation with phenylephrine and parasympathetic stimulation 
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did not affect the SAECG. Parasympathetic blockade caused a mild decrease in the QRS 
duration. Changes in the RMS40 and LAS40 paralleled those of the QRS duration 
(Goldberger et al, 1994). 
Junker et al, found in a substudy of the CONSENSUS II trial, a reduced prevalence of LVPs 
after the angiotensin converting enzyme inhibitor enalapril (Junker et al, 1995). 
Lipid-lowering interventions reduce coronary events, VT/VF episodes, SCD and all-cause 
mortality (Liu et al, 2009). Recent studies have demonstrated that statins have 
antiarrhythmic properties in addition to their lipid-lowering effects (Abuissa et al, 2009; Chu 
et al 2007; Liu et al, 2009).  Kayikcioglu et al. found a significant decrease of the prevalence 
of LVPs and ventricular arrhythmias in acute MI patients receiving pravastatin, irrespective 
of lipid level (Kayikcioglu et al, 2003). Pre-treatment with statin could reduce the 
reperfusion arrhythmias after acute myocardial infarction (Zhao et al, 2008). Most of the 
antiarrhythmic benefits after statin therapy observed in high cardiovascular risk patients 
might be explained by statins’ pleiotropic effects: anti-ischemia, anti-inflammation, 
antihypertrophy, angiogenic and sympathetic effects (Chu et al, 2007). Statins achieve their 
antiarrhythmic drug action in part by preventing or reversing electrophysiologic 
remodeling induced by hypercholesterolemia, but they also have an independent 
antiarrhythmic effect (Liu et al, 2009).  
The ratio between QTc and QRS changes caused by several antiarrhythmic drugs identifies 
patients with sustained VT risk, which appear despite therapy (Cain et al, 1996). 
LVPs may disappear after coronary artery bypass surgery in acute MI patients (Bigger et al, 
1997). Anevrisectomy is also known to reduce the prevalence of LVPs.   
Corticosteroid therapy may be effective for ventricular arrhythmias in the early stage of 
cardiac sarcoidosis (Yodogawa et al, 2011). 
28. Correlation and combination with other ECG methods 
Several studies have mentioned correlations between surface standard 12-lead ECG and 
SAECG parameters. The relation between LVP and QT dispersion (QTd) (Ducceschi et al, 
1996; Mozos, 2006), suggested that the existence of some slow conducting myocardial areas, 
related to positive LVPs, is associated with a higher inhomogeneity of ventricular 
repolarisation, expressed as a higher QTd. LAS40 and SA-QRS correlated with QT 
dispersion (Ducceschi et al, 1998).  
QT intervals and Tpeak-Tend intervals were prolonged in post-infarction HF patients with 
LVPs. LVPs and SAECG parameters can be predicted using 12-lead ECG: QT intervals, QRS 
duration, T wave variables (Mozos et al, 2011). The significant association between SA-QRS 
and Tpeak-Tend interval and T wave amplitude was attributed to the extension of LVP into 
the ST segment.   
Breithardt et al. (Breithardt et al, 1990) showed that the presence of LVPs was positively 
correlated with an ECG score based on R and Q wave duration and R/S ratio in MI patients 
with or without a history of sustained VT.  
LVPs were not related to the frequency of ventricular ectopic activity and malignant 
premature ventricular contractions because each test assesses different components of 
arrhythmia susceptibility. The combination of the two abnormalities may identify a high-
risk group for SCD (Middelkauff et al, 1990; Fauchier et al, 1991).  
The combination of T wave alternans and SAECG, increases sensitivity, specificity, positive 
and negative predictive value for VT risk (Kondo et al, 2001).   
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prolongation, abnormalities in the autonomic tone and LVPs indicate high risk of 
developing life-threatening ventricular arrhythmias (Sefarovic et al, 2006). LVPs were 
recorded in patients with systemic lupus (Paradiso et al, 2001; Wranicz et al, 2001), and the 
depolarization abnormalities revealed by SAECG reflect a longer extent of myocardial 
fibrosis and echocardiography and SAECG alterations are markers of subclinical myocardial 
involvement. Increasing evidence suggest that anti-Ro/SSA antibodies may trigger rhythm 
disturbances due to an inhibiting cross-reaction with several cardiac calcium and potassium 
ionic channels (Lazzerini et al, 2010).  
So far, the evidence related to electrocardiographic disturbances in this setting is restricted 
to studies with small number of patients (Teixeira, et al, 2010). The mechanisms of 
arrhythmias are related to the inflammatory process of pericarditis and myocarditis, 
atherosclerotic myocardial ischemia, increased sympathetic activity, vasculitis of small 
vessels with collagen deposits and anti-Ro/SSA antibodies (Lazzerini et al, 2010; Teixeira, et 
al, 2010). 
Cardiac sarcoidosis affects the myocardium, pericardium and endocardium, and the disease 
may present with: atrioventricular and intraventricular conduction disturbances, ventricular 
arrhythmias and HF. Ventricular arrhythmias are among the main causes of SCD in cardiac 
sarcoidosis. LVPs on SAECG were mentioned and they were abolished after steroid therapy 
(Yodogawa et al, 2011). 
26. Schizophrenia 
Schizophrenia patients were also found to be positive for LVPs. Cardiac autonomic 
dysregulation in schizophrenia patients and use of psychiatric and/or non-psychiatric 
medications that affect conduction, may account for LVPs (Nashoni et al, 2010). 
27. Influence of therapy on LVPs 
LVPs are influenced by antiarrhythmic therapy, trombolytic drugs, anevrismectomy, 
percutaneous coronary interventions, coronary artery bypass surgery, statins, steroids. 
The effect on the prevalence of LVPs of modern pharmacologic therapy in patients with 
acute MI has been assessed in several studies (Santangeli et al, 2008). Class I, II and III 
antiarrhythmics may reduce the prevalence of LVPs.  Class IV antiarrhythmics (Verapamil) 
do not influence LVPs. Some class III antiarrhythmic drugs are able to prolong SA-QRS and 
LAS40, and may be associated with the occurence of LVPs.  
Freedman and Steinberg showed that sodium channel blockers (quinidine, procainamide, 
imipramide) have preferential effects on slowly conducting tissue in patients with a history 
of VT, causing an important prolongation of LVPs (Freedman & Steinberg, 1991).  
Santarelli et al, reported that LVPs were less frequent in acute MI patients treated with 
betablockers compared with those not treated with betablockers during hospitalization. This 
effect was found only in patients with a preserved LVEF (Santarelli et al, 1993).  
No significant SAECG changes have been observed after Sotalol. 
Adrenergic stimulation with adrenaline and isoprenaline, and parasympatholytic agents 
such as atropine, lead to significant changes in the signal averaged electrocardiogram in 
healthy subjects (Goldberger et al, 1994). Beta-adrenergic stimulation with isoproterenol led 
to a significant shortening of SA-QRS, and epinephrine prolonged the QRS duration. 
Increased alfa-adrenergic stimulation with phenylephrine and parasympathetic stimulation 
 
Late Ventricular Potentials in Cardiac and Extracardiac Diseases 
 
243 
did not affect the SAECG. Parasympathetic blockade caused a mild decrease in the QRS 
duration. Changes in the RMS40 and LAS40 paralleled those of the QRS duration 
(Goldberger et al, 1994). 
Junker et al, found in a substudy of the CONSENSUS II trial, a reduced prevalence of LVPs 
after the angiotensin converting enzyme inhibitor enalapril (Junker et al, 1995). 
Lipid-lowering interventions reduce coronary events, VT/VF episodes, SCD and all-cause 
mortality (Liu et al, 2009). Recent studies have demonstrated that statins have 
antiarrhythmic properties in addition to their lipid-lowering effects (Abuissa et al, 2009; Chu 
et al 2007; Liu et al, 2009).  Kayikcioglu et al. found a significant decrease of the prevalence 
of LVPs and ventricular arrhythmias in acute MI patients receiving pravastatin, irrespective 
of lipid level (Kayikcioglu et al, 2003). Pre-treatment with statin could reduce the 
reperfusion arrhythmias after acute myocardial infarction (Zhao et al, 2008). Most of the 
antiarrhythmic benefits after statin therapy observed in high cardiovascular risk patients 
might be explained by statins’ pleiotropic effects: anti-ischemia, anti-inflammation, 
antihypertrophy, angiogenic and sympathetic effects (Chu et al, 2007). Statins achieve their 
antiarrhythmic drug action in part by preventing or reversing electrophysiologic 
remodeling induced by hypercholesterolemia, but they also have an independent 
antiarrhythmic effect (Liu et al, 2009).  
The ratio between QTc and QRS changes caused by several antiarrhythmic drugs identifies 
patients with sustained VT risk, which appear despite therapy (Cain et al, 1996). 
LVPs may disappear after coronary artery bypass surgery in acute MI patients (Bigger et al, 
1997). Anevrisectomy is also known to reduce the prevalence of LVPs.   
Corticosteroid therapy may be effective for ventricular arrhythmias in the early stage of 
cardiac sarcoidosis (Yodogawa et al, 2011). 
28. Correlation and combination with other ECG methods 
Several studies have mentioned correlations between surface standard 12-lead ECG and 
SAECG parameters. The relation between LVP and QT dispersion (QTd) (Ducceschi et al, 
1996; Mozos, 2006), suggested that the existence of some slow conducting myocardial areas, 
related to positive LVPs, is associated with a higher inhomogeneity of ventricular 
repolarisation, expressed as a higher QTd. LAS40 and SA-QRS correlated with QT 
dispersion (Ducceschi et al, 1998).  
QT intervals and Tpeak-Tend intervals were prolonged in post-infarction HF patients with 
LVPs. LVPs and SAECG parameters can be predicted using 12-lead ECG: QT intervals, QRS 
duration, T wave variables (Mozos et al, 2011). The significant association between SA-QRS 
and Tpeak-Tend interval and T wave amplitude was attributed to the extension of LVP into 
the ST segment.   
Breithardt et al. (Breithardt et al, 1990) showed that the presence of LVPs was positively 
correlated with an ECG score based on R and Q wave duration and R/S ratio in MI patients 
with or without a history of sustained VT.  
LVPs were not related to the frequency of ventricular ectopic activity and malignant 
premature ventricular contractions because each test assesses different components of 
arrhythmia susceptibility. The combination of the two abnormalities may identify a high-
risk group for SCD (Middelkauff et al, 1990; Fauchier et al, 1991).  
The combination of T wave alternans and SAECG, increases sensitivity, specificity, positive 
and negative predictive value for VT risk (Kondo et al, 2001).   
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SAECG and body surface mapping (BSM) provide complementary information in patients 
with an old MI, and an important, significant correlation was found between isointegral 
QRST maximum and LAS40 and RMS40 (Mozos et al, 2008). SAECG may be assessed using 
BSM, increasing its sensitivity in anterior and inferior MI (Ho, 1993). BSM may detect LVPs, 
undetected by SAECG, even if the underlying substrate is relative small or the electrodes are 
placed outside that area (Linnenbank et al, 2001). Analysis of isopotential maps of the 
terminal part of the QRS complex may provide additional information regarding LVPs 
distribution, slow conducting areas and VT origin (Faugere et al, 1986). 
29. LVPs and other ventricular arrhythmia predictors 
Despite the significant predictive value for arrhythmic events, LVPs show a low positive 
predictive accuracy, thus resulting in limited usefulness as a single variable to identify 
patients at high risk (Santangeli et al, 2008). Significantly impaired LVEF is an established 
predictor of SCD and is included in the current guidelines for primary prevention of SCD. 
But patients with a preserved LVEF are not included in the current guidelines (Liew, 
2011). 
Combination of LVPs with LVEF (Jain & Avasthi, 1992; Konta et al, Kudaiberdieva et al, 
2003), ventricular volumes (Pollak et al, 1985), heart rate variability (Gomes et al, 2001), 
ventricular diskinezia (Olinic & Zdrenghea, 1998), programmed ventricular stimulation 
(Ho et al, 1996), atrial pacing (Steinbigler et al, 1999), a high Killip class (3 or 4) in a 
patient with a history of a MI, may improve the predictive value of LVPs for ventricular 
arrhythmias.  
Kudaiberdieva et al (Kudaiberdieva et al, 2003) investigated incidence of ventricular 
tachycardia/ventricular fibrillation in relation with noninvasive arrhythmia risk markers in 
54 patients with an old myocardial infarction. Logistic regression analysis revealed that the 
highest association with ventricular tachyarrhythmia had combination of LVPs and 
increased QT variability index, followed by combination of LVPs and left ventricular 
ejection fraction. 
Standard methods fail to reveal late potentials in 20 to 30% of patients with ventricular 
arrhythmias after myocardial infarction (Steinbigler et al, 1999). Increase in heart rate may 
unmask late potentials in patients prone to malignant ventricular arrhythmias, because 
conduction in the arrhythmogenic area is critically slowed by an increased heart rate. 
Functional late potential analysis, with non-invasive clinical stress tests, should be 
performed in order to identify patients at risk of malignant ventricular arrhythmias, not 
identified with conventional late potential analysis (Steinbigler et al, 1999). 
Epicardial mapping has demonstrated that during sinus rhythm, activation of the tissue 
critical to ventricular tachycardia is completed before the end of the QRS complex and is not 
detectable within the ST segment (Steinbigler et al, 1999). A shift of septal mid-QRS 
potentials toward the terminal QRS complex by critical slowing of conduction during 
increased heart rate, could explain the appearance of new late ventricular potentials. 
Different findings may be due to myocardial infarction location: an increase of QRS duration 
in patients with anterior infarction and an increase of magnitude and LAS40 in patients after 
inferior infarctions (Steinbigler et al, 1999). 
Combining electrocardiography methods with other methods may help to select the 
candidates for pharmacological therapy, defibrillator implantation and resynchronization, 
in order to reduce overall mortality and SCD. 
 




Sudden cardiac death, caused mainly by fatal ventricular arrhythmias, can be predicted 
using a practical and low-cost tool: SAECG. LVPs represent slowed conduction through a 
diseased myocardium and may form the substrate for life-threatening ventricular 
arrhythmias in patients with cardiac and extracardiac pathology. SAECG is altered due to a 
variety of physiological and pharmacologic conditions. Antiarrhythmic therapy, trombolytic 
drugs, anevrismectomy, percutaneous coronary interventions, coronary artery bypass 
surgery, statins and steroid therapy are able to influence LVPs. Late ventricular potentials 
have a high negative predictive value. When positive, LVPs help better stratify the 
arrhythmic risk of patients, alone or in combination with other methods, in several clinical 
settings.  
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predictor of SCD and is included in the current guidelines for primary prevention of SCD. 
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in patients with anterior infarction and an increase of magnitude and LAS40 in patients after 
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Combining electrocardiography methods with other methods may help to select the 
candidates for pharmacological therapy, defibrillator implantation and resynchronization, 
in order to reduce overall mortality and SCD. 
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1.1 Ventricular arrhythmias 
A large number of clinical and epidemiological studies [1,2] have reported a correlation 
between the mass increase of the left ventricle (LV) and the risk of disease or death. The 
prevalence of left ventricular hypertrophy (LVH) in patients with essential hypertension 
may be as high as 40% (12%-70%) [3]. It has been suggested [4] that in patients with LVH 
sudden death may be associated with an increased number of ventricular extrasystoles 
(VPB), which is frequently observed in this population. In effect, a review by Lombardi et al. 
[5] indicated that nonsustained ventricular arrhythmias are an independent predictor of 
cardiac death in hypertensive patients.  
Most frequently it concerns concentric hypertrophy with no enlargement of ventricular 
cavities, interpreted by multiplication of sarcomeras in a parallel arrangement. This type of 
hypertrophy is characterised by increased mass and increased relative wall thickness. In a 
smaller number of hypertensives LVH is initially eccentric, with a multiplication of 
sarcomeras in sequence in the process of which enlargement of the ventricular cavity is 
prevalent and thickening of the wall is only proportional or less marked. Although many 
hypertensive patients develop isolated septum hypertrophy, data on the structure and 
function of the myocardium and arrhythmias in hypertensive patients with this type of LVH 
are limited [6]. It would appear that concentric hypertrophy carries the greatest and 
eccentric hypertrophy a moderate risk of cardiovascular (CV) events [7]. Published data 
regarding arrhythmias are still conflicting and unconvincing [6,8]. It is unclear whether the 
greatest risk of CV events in the concentric type is due to arrhythmias or something else 
(ishaemia for inst.). According to some authors [9] the correlation between left ventricular 
mass (LVM) and ventricular arrhythmias is graded and permanent. Arrhythmias described 
in hypertensive patients with LVH are usually single premature ventricular contractions, 
frequently bigeminal or multiform, and more rarely ventricular tachycardia. [10]. 
1.2 Supraventricular arrhythmias 
Risk of AF (and other supraventricular arrhythmias) is also increased in patients with left 
ventricular hypertrophy (LVH) [11]. Concentric hypertrophy appears to hold the highest 
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risk [12]. Earlier investigations reported that LVH leads to diastolic dysfunction, decreased 
coronary blood flow reserve and the occurrence of ventricular and atrial arrhythmias. It 
appears that in the development of atrial arrhythmias, atrial volume overloading and the 
distension and dilatation of the myofibrils have a greater impact. This results from 
ventricular diastolic dysfunction (particularly of the left ventricle), due to hypertrophy 
and subsequent decreased compliance [13]. From the pathophysiological point of view, 
this is caused by the hypertrophy of cardiac myocytes, interstitial fibrosis and media 
hypertrophy of the arterioles. Microangiopathy can be diagnosed as the earliest sign of 
hypertensive heart disease, with diastolic dysfunction also being found as an early 
change. [14]. More recently, an increasing number of investigations conducted on 
supraventricular premature beats (SVPB) have documented enlarged atria in hypertrophic 
hypertensive hearts.  
1.3 QT interval and QT dispersion 
Marked left ventricular hypertrophy (LVH) is associated with potentially arrhythmogenic 
ventricular repolarization abnormalities and may generate conditions for QT interval (QTi) 
prolongation and increase QT dispersion (QTd)) [15,16]. Prolongation of QTc interval and 
QTd are risk markers for malignant ventricular arrhythmias (VA) and sudden cardiac death 
[17,18]. QT prolongation and dispersion are indicators for abnormalities in ventricular 
repolarization. This could suggest the presence of functional reentrant proarrhythmic 
circuits [19]. Defined as the difference between the longest and shortest QTi measured in 
any lead of the 12-lead electrocardiogram (ECG), QTd reflects the inhomogeneity in 
ventricular repolarisation. Both parameters include also depolarisation. Increased QTd has 
been shown to correlate positively to complex VA in many clinical conditions [17,20]. QTd 
and QTi correlate with the left ventricular mass index (LVMI) determined 
echocardiographically in a group of selected patients with essential hypertension [19,21,22]. 
Normal QTd values vary extensively from 10 to 71 ms. QTd is higher in cardiac patients in 
comparison to normal subjects. The probability is that only explicitly abnormal values (i.e., 
those >100 ms) outside error margins may potentially have a practical value, suggesting a 
markedly abnormal repolarisation [23]. Scarce data was published regarding QTc interval 
prolongation/QTd and complex ventricular arrhythmias in hypertensive patients with LVH 
[24,25], but which type of LVH has the greatest influence has been understudied (especially 
for the asymmetric type). 
1.4 Discussion  
Examined patients included in such studies should have essential hypertension and LVH 
confirmed by echocardiography. For that reason one must exclude congestive heart 
failure, known coronary disease (angina pectoris, previous myocardial infarction, 
percutaneous coronary interventions), heart surgery, valvular diseases, other cardiac 
diseases (previous myocarditis and hypertrophic obstructive cardiomyopathy in the 
absance of systemic hypertension), diabetes mellitus, alcoholics, mental disorders, 
overuse of non-antihypertensive drugs (psychiatric drugs: sedatives, psychopharmacs etc; 
antiparkinsonics, antirheumatics, analgesics and hormones), malignant or accelerated 
hypertension, stroke in the previous six months, patients with cancer, abnormal 
electrolytes, anemia, cardiopulmonary diseases, serum creatinine >140 µmol/L and 
abnormal thyroid function. 
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Study subjects usualy have long-term hypertension (average duration of 17 years in our 
sample) and excessive body weight. The majority subjects are physically inactive with 
elevated values of lipids and urea in serum [26].  
Echocardiographic measurements confirme anthropological differences between genders [27]. 
Men have larger cardiac cavities and LVM. By indexing left ventricular mass according to 
the body surface (LVMI) this difference between genders is lost. Ejection fraction (EF) is 
most often very good (>60%). The values of mean LVMI, and in both genders are much 
higher than normal values (>170 g/m2) Concentric LVH is the most frequent (63% in [26]), 
which is not in agreement with some earlier investigations [28]. Eccentric LVH, usually of a 
mild degree, is more frequently observed in male patients. This could be explained by the 
larger diameter of the cardiac cavity in men. Mild LVH, according to some authors [29], 
does not carry increased risk either of complex neither of simple ventricular arrhythmias. 
Complex ventricular arrhythmias on ECG are usualy found in small number (4%) of patients. 
During Holter monitoring this percentage increased to over 40% of patients, and during the 
stress test it increased by additional 7,4% (in proportion to heart rate and blood pressure). 
Ventricular tachycardia can be found in 7-18% [26]. Some authors [24] found that concentric 
hypertrophy carries the greatest risk, and the eccentric a moderate risk of death and of CV 
complications. Nunez et al. [6] found equal prevalence and complexity of ventricular 
arrhythmias in hypertensive patients with concentric and asymmetric LVH. Some earlier 
investigations [8] reported an equal incidence of ventricular arrhythmias with regard to the 
morphological type of LVH and LVMI, similar to our results. Devereux et al. [30] also 
obtained a negative correlation. Only a small number of studies in the literature (not written 
in the English language) have monitored this correlation and obtained a statistical 
significance. 
Atrial fibrillation associated with atrial dilatation is often observed in patients with 
hypertension [31]. About 40% of patients have paroxysmal atrial fibrillation or paroxysmal 
supraventricular tachycardia during Holter monitoring and additional 4% during the 
exercise test [32]. Until now it is unable to conclude whether any of the LVH types had a 
greater effect on the appearance of these arrhythmias. 
The left atrial size significantly positively correlates with left ventricular hypertrophy 
degree, and it seems that a larger number of supraventricular premature beats for moderate 
and severe concentric LVH compared to mild concentric LVH, can bee found [32]. 
Schannwell et al. [13] also found greater prevalence of supraventricular arrhythmias 
proportional to the degree of LVH.  
The largest left atrial diameters can bee found in patients with eccentric LVH and the higher 
prevalence of supraventricular premature beats in the concentric and eccentric type [32]. 
Some outhors [6,33] found significantly greater prevalence and complexity of 
supraventricular arrhythmias in patients with asymmetric LVH. The relationship between 
arrhythmias and concentric geometry appears more coherent if we consider that a recent 
study [34] reported an independent association of impaired left ventricular relaxation with 
concentric LV geometry. The abnormal diastolic function of LV and the stretch in LA may be 
less expressed in the asymmetric tipe of hypertrophy. In the context of epidemiology, this 
means that in patients with asymmetric left ventricular hypertrophy (about 9% of subjects) a 
lower incidence of arrhythmias should be expected. Concentric LVH is most frequently 
found in hypertensive patients, and it appears to cause the most severe diastolic left 
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ventricular disfunction. Patients with eccentric LVH possibly have the largest LA 
dimension, and can have a slightly lower incidence of supraventricular premature beats 
then those with concentric LVH, meaning that the LA size is not the only factor that affecs 
the prevalence of supraventricular arrhythmias. Apart from mechanical remodeling, 
electrical remodeling that occures earlier should also be considered (change in the 
structure/function of ion channels and compounds, catecholamines, free oxygen radicals, 
angiotensin-converting enzyme, angiotensin II, cytokins and nitrogenous oxid), 
hypertrophy of media arteriola, dicrease in the coronary blood flow reserve and genetic 
factors (repeted expression of fetal genome isoforms, heme oxygenase-1[35]). These factors 
may differ in individual LVH forms.  
Measurement of left atrial size from the parasternal long axis view using the 2-dimensional 
“M-mode” method is limited in accuracy for LA size quantification because of the irregular 
geometry of the LA and the angulations of the ultrasound beam [36]. Methods for 
measuring the LA volume are more appropriate for the assessment of the asymmetric 
remodelling of the LA chamber [37].  
In patients with severe concentric and eccentric LVH higher values of the QTc interval can be 
find. Regarding the degree of LVH, a positive correlation with QTc length can be observed 
[38]. Not many articles investigating this correlation have been published in the literature 
[39,40]. In some [41] only 38 patients with essential hypertension and LVH were analyzed, 
and an attempt to classify them into groups with regard to LVH type was made. Their 
conclusion was that the QTc interval length correlates positively with LVMI and LVIDd. The 
longest QTc intervals were found in patients with LVH and complex arrhythmias. They also 
found that the incidence of complex ventricular arrhythmias was greater in patients with 
LVH, and that the prolonged QTc interval in these patients may be a good indicator for 
higher risk of arrhythmias. The mentioned authors also obtained the highest QTc interval 
values in patients with dilated (eccentric) LVH but the LVH type was not defined by 
calculating RWT, than by a simple addition of IVS and LVPW thickness. Patients with 
myocardial dilatation (with and without LVH) had the most severe arrhythmias. Measuring 
QTi only from the second lead represented a limitation to the study recognized by the 
authors. Other researchers also obtained the correlation between QTi and LVMI lengths 
[39,41]. QTc interval in patients with ventricular septal hypertrophy was significantly longer 
than in the normal group [42].  
Higher values of the QTdispersion in severe concentric and eccentric LVH can also be find 
[38]. Manual assessment of the T-wave end is extremely unreliable. Regrettably, the existing 
automated methods have not proven to be advantageous. The main source of mistakes for 
readers and computers are the low amplitudes of T waves [43] and the border between the T 
and U wave or the P wave [44]. Increased QTc dispersion was associated with LVH, 
especially with its concentric variant in some studies [20,45]. In the LIFE study both 
concentric and eccentric LVH were associated with prolonged QTi and increased QTd [15]. 
In another study [46] QTd >60 ms and QTi >440 ms were associated with greater probability 
of LVH.  
In our patients, the QTi length correlates with the VA incidence. QTc interval was also 
longer in patients having complex arrhythmias but the difference in relation to simple 
arrhythmias was not significant [38]. 
Several factors may influence the increased LV ectopic activity in patients with LVH. 
Increased stimulation of hypertrophic myocytes, fibrosis in hypertrophic myocardium that 
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leads to electrophysiological inhomogeneity, distention of certain myocytes, increased 
oxygen requirement of the myocardium, damaged membrane porosity for various ions, and 
increased sympatic activity are possible pathophysiological factors for the increased 
incidence of ventricular arrhythmias [47,48]. 
In subjects without heart disease, during a 15-20 years follow-up period, prospective studies 
found significant correlation between prolonged QTc interval and increased risk for 
coronary events [49], cardiovascular (CV) mortality and all-cause mortality (mean follow-up 
of 4.9 years) [50], as well as for sudden cardiac death or CV death [51]. The Zutphen study 
[51] concluded that men with QTc interval 420 ms were at greater risk for CV death than 
men with shorter QTc interval. Increased QTd in patients with LVH and higher incidence of 
ventricular premature beats (VPB) or complex VA was also described by other authors 
[22,24,52]. Ichkhan et al. [22] found a significant correlation between QTd and LVM in 
hypertensive patients. They concluded that LVH and not hypertension per se leads to 
increased QTd, because hypertensive patients without LVH did not have an increased QTd. 
Ozdemir et al. [53] studing 80 patients with concentric LVH have found strong correlation 
between increased QTd and the incidence of VA. Other authors [33] obtained the highest 
influence of asymmetric LVH on QTd, but without correlation between VPB and QTd, 
neither between VPB and LVMI. 
According to some investigations patients with increased QTd should be treated with 
angiotensin receptor blockers and nebivolol [54,55]. 
It is very important to exclude the possible effect of the extent of antihypertensive therapy and the 
types of antihypertensive drugs on the result. Discontinuation of all drugs seven days prior 
to ergometric examination and Holter monitoring is optimal. It is sometimes not possible to 
keep patients 7 days without antihypertensive and anti-arrhythmic drugs because a longer 
suspension of treatment could have threatened the patient or lead to reduced cooperation.. 
Shorter discontinuation can bee applied but the duration and the type of drugs should not 
differ between the examined groups. 
2. Conclusion 
In conclusion, The degree of LVH contributes more to the greater prevalence of VA then 
the LVH pattern. Given that this correlation (between the degree and VA) is most 
expressed in the concentric type (which is at the same time the most frequent pattern of 
LVH in hypertensive patients), the combination of severe degree and concentric type 
carries the greatest risk. Asymmetric LVH does not necessarily represent an increased 
risk. Concentric and eccentric types have a greater impact on the frequency of atrial 
arrhythmias. The prevalence of supraventricular premature beats correlates with the 
degree of left ventricular hypertrophy in the concentric type. QTc interval and QT 
dispersion tend to increase proportionally to the left ventricular mass probably only in the 
concentric and eccentric LVH type.  
In clinical practice this means that patients with moderate and severe LVH (concentric in 
particular) should be tested by Holter monitoring and bicycle ergometry and treated with 
maximally tolerable doses of antihypertensives, particularly with angiotensin converting 
enzyme inhibitors/ angiotensin receptor blockers and also with outpatient training 
program.  
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values in patients with dilated (eccentric) LVH but the LVH type was not defined by 
calculating RWT, than by a simple addition of IVS and LVPW thickness. Patients with 
myocardial dilatation (with and without LVH) had the most severe arrhythmias. Measuring 
QTi only from the second lead represented a limitation to the study recognized by the 
authors. Other researchers also obtained the correlation between QTi and LVMI lengths 
[39,41]. QTc interval in patients with ventricular septal hypertrophy was significantly longer 
than in the normal group [42].  
Higher values of the QTdispersion in severe concentric and eccentric LVH can also be find 
[38]. Manual assessment of the T-wave end is extremely unreliable. Regrettably, the existing 
automated methods have not proven to be advantageous. The main source of mistakes for 
readers and computers are the low amplitudes of T waves [43] and the border between the T 
and U wave or the P wave [44]. Increased QTc dispersion was associated with LVH, 
especially with its concentric variant in some studies [20,45]. In the LIFE study both 
concentric and eccentric LVH were associated with prolonged QTi and increased QTd [15]. 
In another study [46] QTd >60 ms and QTi >440 ms were associated with greater probability 
of LVH.  
In our patients, the QTi length correlates with the VA incidence. QTc interval was also 
longer in patients having complex arrhythmias but the difference in relation to simple 
arrhythmias was not significant [38]. 
Several factors may influence the increased LV ectopic activity in patients with LVH. 
Increased stimulation of hypertrophic myocytes, fibrosis in hypertrophic myocardium that 
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leads to electrophysiological inhomogeneity, distention of certain myocytes, increased 
oxygen requirement of the myocardium, damaged membrane porosity for various ions, and 
increased sympatic activity are possible pathophysiological factors for the increased 
incidence of ventricular arrhythmias [47,48]. 
In subjects without heart disease, during a 15-20 years follow-up period, prospective studies 
found significant correlation between prolonged QTc interval and increased risk for 
coronary events [49], cardiovascular (CV) mortality and all-cause mortality (mean follow-up 
of 4.9 years) [50], as well as for sudden cardiac death or CV death [51]. The Zutphen study 
[51] concluded that men with QTc interval 420 ms were at greater risk for CV death than 
men with shorter QTc interval. Increased QTd in patients with LVH and higher incidence of 
ventricular premature beats (VPB) or complex VA was also described by other authors 
[22,24,52]. Ichkhan et al. [22] found a significant correlation between QTd and LVM in 
hypertensive patients. They concluded that LVH and not hypertension per se leads to 
increased QTd, because hypertensive patients without LVH did not have an increased QTd. 
Ozdemir et al. [53] studing 80 patients with concentric LVH have found strong correlation 
between increased QTd and the incidence of VA. Other authors [33] obtained the highest 
influence of asymmetric LVH on QTd, but without correlation between VPB and QTd, 
neither between VPB and LVMI. 
According to some investigations patients with increased QTd should be treated with 
angiotensin receptor blockers and nebivolol [54,55]. 
It is very important to exclude the possible effect of the extent of antihypertensive therapy and the 
types of antihypertensive drugs on the result. Discontinuation of all drugs seven days prior 
to ergometric examination and Holter monitoring is optimal. It is sometimes not possible to 
keep patients 7 days without antihypertensive and anti-arrhythmic drugs because a longer 
suspension of treatment could have threatened the patient or lead to reduced cooperation.. 
Shorter discontinuation can bee applied but the duration and the type of drugs should not 
differ between the examined groups. 
2. Conclusion 
In conclusion, The degree of LVH contributes more to the greater prevalence of VA then 
the LVH pattern. Given that this correlation (between the degree and VA) is most 
expressed in the concentric type (which is at the same time the most frequent pattern of 
LVH in hypertensive patients), the combination of severe degree and concentric type 
carries the greatest risk. Asymmetric LVH does not necessarily represent an increased 
risk. Concentric and eccentric types have a greater impact on the frequency of atrial 
arrhythmias. The prevalence of supraventricular premature beats correlates with the 
degree of left ventricular hypertrophy in the concentric type. QTc interval and QT 
dispersion tend to increase proportionally to the left ventricular mass probably only in the 
concentric and eccentric LVH type.  
In clinical practice this means that patients with moderate and severe LVH (concentric in 
particular) should be tested by Holter monitoring and bicycle ergometry and treated with 
maximally tolerable doses of antihypertensives, particularly with angiotensin converting 
enzyme inhibitors/ angiotensin receptor blockers and also with outpatient training 
program.  
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1. Introduction 
Sleep-disordered breathing (SDB) includes a range of conditions characterized by 
abnormalities in the frequency and/or depth of breathing during sleep. Cessations in 
breathing rhythm (apneas) are momentary and often cyclical, while reductions in breath 
amplitude (hypopneas) may be momentary or sustained (Dempsey et al., 2010). Obstructive 
sleep apnea (OSA)/hypopnea syndrome (HS), obesity hypoventilation syndrome, central 
sleep apnea (CSA), upper airway resistance syndrome, and Cheyne-Stokes respiration (CSR) 
are the primary sleep-related respiratory disorders.  
Although CSA is accompanied by alterations in neural input, the obstruction characteristic 
of OSA, the most common form of SDB, is also neurally mediated (Veasey, 2009). 
Intermittent episodes of partial or complete obstruction of the upper airway during sleep 
characteristic of OSA result from collapse of the upper airway. The concomitant disruption 
of normal ventilation and sleep architecture is typically associated with snoring, repeated 
arousals from sleep, and daytime sleepiness (Bradley & Floras, 2003; Lattimore et al, 2003; 
Quan & Gersh, 2004; Shamsuzzaman et al; 2003;).  
Prevalence studies indicate that SDB, and particularly OSA, are common problems 
worldwide, affecting millions of individuals. However, OSA is also considered to be largely 
undiagnosed (Young et al, 1993; Young et al, 2002; Lavie, 2007). In the United States, for 
example, the estimated proportions of adults with OSA who are not diagnosed range from 
60% to 80%, with an even greater under diagnosis suspected for children (Carter III, 2008). 
The increasing prevalence can be intuitively associated with the global obesity epidemic; 
however, a reverse association has also been postulated based on emerging evidence that 
OSA promotes weight gain (Carter III, 2008).  
The clinical relevance of OSA was thought for years to be limited to what was considered a 
benign but often annoying manifestation as snoring, ranging to the possibly serious 
consequences of daytime sleepiness affecting cognitive function and work performance, 
mental state, and driving ability. OSA is now known to be a risk factor for other serious 
conditions, and has been associated with increased cardiovascular morbidity and mortality 
(Bradley & Floras, 2009; Devulapally et al., 2009; Lattimore et al, 2003; Lopez-Jiminez et al., 
2008). Cardiac arrhythmias are common in OSA, and the potential link between 
tachyarrhythmias and bradyarrhythmias and adverse outcomes in OSA patients continues 
to be an important area of research (Chan & Wilcox, 2010; Verrier & Josephson, 2009). 
However, the complex cascade of events triggered by OSA, the difficulty in determining 
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cause and effect from the preponderance of observational studies addressing these issues, 
lack of standardization of variable definitions, and heterogeneous patient samples allowing 
the influence of a multitude of confounders have been a constraint to producing consistent 
and definitive explanatory. Study variations complicate comparisons among reports, and 
require that sufficient individual design details are considered when evaluating the results 
of each study.  Despite these limitations, our rapidly expanding knowledge promises to 
provide guidance for the assessment and management of patients both with SDB and 
arrhythmias.   
2. Epidemiology and diagnosis of SDB  
The worldwide recognized prevalence of OSA accompanied by daytime sleepiness is 
estimated to be 3% to 7% for adult men and 2% to 5% for adult women in the general 
population, with higher risks reported for some subgroups (Punjabi, 2008).  OSA with or 
without daytime sleepiness may reach 24% in men and 9% in women by middle age (Young 
et al., 1993). 
The main risk factors for SDB include obesity, upper airway obstruction including 
abnormalities of craniofacial morphology, and male gender (Parati et al., 2007; Partinen, 
1995; Young et al., 1993; Young et al., 2002). Age also plays a role; however, the effect of age 
on SDB prevalence is not linear.  The Sleep Heart Health Study reported a plateau effect in 
age-related prevalence beginning at approximately 60 years of age (Young et al., 2002a). In 
addition, SDB in the elderly may be different from the typical SDB of middle age.  In one 
study, increased age, obesity, and snoring were significantly associated with progression of 
apnea in subjects aged 30 to 60 years at baseline; however, other studies suggest  little or no 
association among these and other common OSA correlates of middle age with OSA in the 
elderly (Young et al., 2002b). 
2.1 REM and nonREM sleep 
Sleep stages include rapid eye movement (REM) and nonREM sleep. NonREM sleep 
typically comprises 75% to 85% of the sleep time in adults, and is characterized by decreased 
metabolic demands, relative autonomic stability with dominant vagus nerve activity, high 
baroreceptor gain, and stable sympathetic nerve activity (Arias & Sanchez, 2007; Somers et 
al, 1993; Verrier & Josephson, 2009).  During stage 4 of nonREM sleep, that is, during deep 
sleep, cardiovascular system input is reduced by more than half compared with that of 
wakefulness. Parasympathetic tone increases and sympathetic tone decreases durn nonREM 
sleep.  The resultant increase in vagal nerve activity elicits bradycardia, and during the 
transition from nonREM to REM sleep bursts of vagal nerve activity can produce asystole or 
pauses in heart rhythm. REM sleep, occurring at approximately 90 minute intervals of 
increasing length during sleep, is characterized by surges in cardiac sympathetic nerve 
activity that can reach levels higher than those achieved during wakefulness, and is 
accompanied by suppression of efferent vagus nerve tone and reduced baroreceptor gain. 
During this time of increased brain excitability, breathing patterns are also irregular. The 
apneic events of SDB have been shown to occur in both REM and non-REM sleep; however, 
a recent study showed that when SDB occurred only during REM sleep, SDB was not 
associated with sleepiness, impaired quality of life, or difficulty maintaining sleep (Chami et 
al., 2010).   
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2.2 Diagnosing SDB 
The polysomnogram is considered the “gold standard” for OSA diagnosis. Measuring 
multiple physiological signals during sleep, including electroencephalography, electro-
oculography, electrocardiography, electromyography, nasal airflow, respiratory effort 
(thoracic and abdominal impedence), pulse oximetry, snoring (tracheal microphone),  
and leg and sleep position allows identification and classification of apneas and 
hypopneas.  
Obstructive, central, and mixed apneas can be distinguished based on the presence  
of a ventilatory effort during the event. Decreased upper airway muscle activation can 
result in a collapsible pharyngeal airway and produce an obstructive event, which is  
not uncommon in the unstable ventilatory control experienced by patients with CSR  
and CSA, resulting in both central and obstructive events in these patients (Somers et  
al., 2008).  
According to the American Academy of Sleep Medicine (AASM), an apnea is a complete 
cessation of airflow for ≥10 seconds (Iber et al., 2007). A hypoponea is a ≥30% decrease in 
airflow from baseline of ≥10 seconds associated with a 4% oxygen desaturation, or a ≥50% 
reduction in airflow from baseline for ≥10 seconds associated with either a 3% oxygen 
desaturation or electroencephalographic data supporting a cortical microarousal from sleep. 
The apnea-hypopnea index (AHI) quantifies the average number of apneas and hypopneas 
per hour of sleep. The AASM defines OSA categories based on AHI as well as the extent of 
daytime sleepiness, with mild OSA having an AHI of 5 to 15 (Table 1)(AASM, 2008). Some 
restrict using the term OSA to indicate an AHI ≥5, and reserve the term OSA syndrome 
(OSAS) for when symptoms are also present, especially excessive daytime sleepiness (EDS) 
(Lee et al., 2008; Young et al., 2002b).   
 
Type AHI Attention Requirements of Activities Affected by Involuntary Sleepiness  
Mild 5-15 Little (e.g., watching TV, reading) 
Moderate 15-30 
Some 
(e.g., meetings, presentations) 
Severe >30 More Active (e.g., talking, driving) 
KEY: AHI - apnea/hypopnea index 
Table 1. AASM Obstructive Sleep Apnea Classification 
EDS is typically measured by a subjective rating using questionnaires that have 3 to 5 items 
(Lee et al., 2008). The Epworth Sleepiness Scale, comprising 8 questions, is also commonly 
used. Among the physiological disturbances produced by apneic events, oxygen 
desaturation indexes more reliably predict sleepiness relative to other polysomnographic 
parameters including sleep time, AHI, or arousal index (Engleman & Douglas, 2004; 
Kingshott et al., 2000; Tihonen et al., 1998).  
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Categorization of apnea is often arbitrary, and studies frequently use different definitions of 
OSA and its severity, which seriously complicates comparisons among reports. Although 
the AHI alone is often considered adequate to define the severity of OSA, polysomnography 
results are sometimes presented as the respiratory disturbance index (RDI), which includes 
respiratory event related arousals (RERAs) that do not technically meet the definition of 
apnea or hypopnea, in addition to hypopnic and apneic events.   
3. Evidence linking SDB to arrhythymia 
The multiple physiologic and anatomic events associated with sleep apneas are conducive to 
the development of cardiac arrhythmias. Several observational studies have shown an 
association between OSA and the spectrum of arrhythmias (Table 2). Some 
tachyarrhythmias, such as persistent supraventricular tachycardia, atrial fibrillation (AF) or 
flutter, and ventricular arrhythmias, in particular sustained or nonsustained ventricular 
tachycardia, have been shown in some studies to be more likely to occur in the setting of 
preexisting structural heart disease (Grimm et al., 1996). 
3.1 Cardiac arrhythmias in community-based studies and in subjects referred for 
sleep testing 
In the seminal study by Guilleminault et al. (1983), 48% of 400 patients with OSA were 
shown by 24-h Holter monitoring to have arrhythmias, which included 18% with 
bradycardia.  There is some indication that longer monitoring may be warranted, as shown 
by the results in a small sample of 23 patients with moderate or severe OSA who underwent 
2 months of monitoring with an insertable loop recorder (Simantirikas et al., 2004). Almost 
half (47%) were shown to have severe cardiac rhythm disturbances, of whom all but 2 had 
severe bradycardia.  
In a study of 247 patients with OSAS who had been referred for polysomnography who 
were shown to have an AHI >=5 and daytime symptoms, 46 (18.6%) had rhythm 
disturbances during sleep (Olmetti et al., 2008). Tachyarrhythmias occurred in 35 (14.2%) 
and bradyarrhythmias in 11 (4.4%) patients. All bradyarrhythmias occurred during an 
episode of apnea or hypopnea, while 13 (37%) tachyarrhythmic events occurred either 
during the episode or during the subsequent phase of recovering ventilation. Premature 
ventricular complex events occurred throughout the recording interval without 
association with sleep or wakefulness. The OSA in bradyarrhythmia patients was 
significantly more severe than that in tachyarrhythmia patients. Although patients with 
bradyarrhythmia compared with those without arrhythmia had a significantly greater 
AHI (58.8 vs. 27.3; P=.02), mean desaturation amplitude (8.9 vs. 5.9; P=.03), and a lower 
oxygen saturation nadir (69% vs. 77%; P=.003), they were similar in BMI (34.5 vs. 36.1) 
and age (51.8 vs. 53.6).  The prevalence of bradyarrhythmia was, however, significantly 
higher in patients with AHI >=30 (7.8%) compared with patients with AHI <30 (1.5%; OR 
5.33; 95% CI: 1.13, 25.3; P=.03). Conversely, OSA patients with tachyarrhythmia were not 
different from those without arrhythmias with respect to AHI, mean desaturation 
amplitude, and oxygen saturation nadir, nor was the prevalence of tachyarrhythmia in 
patients with AHI >=30 (15.5%) different from that in patients with AHI <30 (13.0%). 
COPD was the only comorbidity associated with either arrhythmia, with tachyarrhythmia 
more common in patients who had both COPD and OSA than it was in patients who had 
OSA alone (OR 2.53; P=.03).  
 
Sleep-Related Breathing Disorders and Cardiac Arrhythmia 271 
Study (N) % Arrhythmia 
Tilkian et al., 1977 
(15) 
93 Marked sinus arrhythmia 
40 Extreme sinus bradycardia 
33 Asystole 
13 Second-degree AV block 
67 VA-complex premature ventricular beats 
13 VT 
Guilleminault et 
al., 1983 (400) 
18 Bradyarrhythmia 
2 Sustained VT 
11 Sinus arrest 
8 Second-degree AV block 
19 Frequent premature ventricular contractions 
Flemons et al., 
1993 
(263) 
1.3 Complex ventricular ectopy (including VT) 
2.6 Frequent premature ventricular beats 
1.3 Second-degree AV block 
5.2 Sinus arrest 
Becker et al., 1995 7 Sinus arrest and AV block 
Mooe et al., 1996 
(121) 
Incident AF in 
CABG patients 
pre-discharge 
32 AF with AHI >=5 
18 AF with AHI <5 
Javaheri et al., 1998 
(81) 22 AF (all patients with HF) 
Simantirakis et al., 
2004 (23) 48 Rhythm disturbances 
Mehra et al., 2006 
(566) 
4.8 AF 
5.3 Nonsustained VT 
25 Complex ventricular ectopy 
Mehra et al., 2009 
(3135 men ≥65 
years of age) 
4.7 AF 
36 Complex ventricular ectopy 
KEY: AF - atrial fibrillation, AHI - apnea/hypopnea index, AV - atrioventricular,  
CABG - coronary artery bypass graft, VA - ventricular arrhythmias, VT - ventricular tachycardia 
Table 2. Prevalence of Cardiac Arrhythmias in Obstructive Sleep Apnea 
The community-based Sleep Heart Health Study, which compared arrhythmia prevalence in 
228 persons with (RDI ≥30) and 338 persons without (RDI <5) SDB, provided important data 
on the risk of complex arrhythmias in persons of both genders who were at least 46 years of 
age (Mehra et al., 2006).  After adjusting for age, sex, BMI, and prevalent coronary artery 
disease (CAD), risk for arterial fibrillation (OR 4.02; 95% CI: 1.03, 15.74), nonsustained 
ventricular tachycardia (OR 3.40; 95% CI: 1.03, 11.20), and complex ventricular ectopy (OR 
1.74; 95% CI: 1.11, 2.74) remained almost 2- to 4-fold greater in persons diagnosed with OSA. 
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40 Extreme sinus bradycardia 
33 Asystole 
13 Second-degree AV block 
67 VA-complex premature ventricular beats 
13 VT 
Guilleminault et 
al., 1983 (400) 
18 Bradyarrhythmia 
2 Sustained VT 
11 Sinus arrest 
8 Second-degree AV block 
19 Frequent premature ventricular contractions 
Flemons et al., 
1993 
(263) 
1.3 Complex ventricular ectopy (including VT) 
2.6 Frequent premature ventricular beats 
1.3 Second-degree AV block 
5.2 Sinus arrest 
Becker et al., 1995 7 Sinus arrest and AV block 
Mooe et al., 1996 
(121) 
Incident AF in 
CABG patients 
pre-discharge 
32 AF with AHI >=5 
18 AF with AHI <5 
Javaheri et al., 1998 
(81) 22 AF (all patients with HF) 
Simantirakis et al., 
2004 (23) 48 Rhythm disturbances 
Mehra et al., 2006 
(566) 
4.8 AF 
5.3 Nonsustained VT 
25 Complex ventricular ectopy 
Mehra et al., 2009 
(3135 men ≥65 
years of age) 
4.7 AF 
36 Complex ventricular ectopy 
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Table 2. Prevalence of Cardiac Arrhythmias in Obstructive Sleep Apnea 
The community-based Sleep Heart Health Study, which compared arrhythmia prevalence in 
228 persons with (RDI ≥30) and 338 persons without (RDI <5) SDB, provided important data 
on the risk of complex arrhythmias in persons of both genders who were at least 46 years of 
age (Mehra et al., 2006).  After adjusting for age, sex, BMI, and prevalent coronary artery 
disease (CAD), risk for arterial fibrillation (OR 4.02; 95% CI: 1.03, 15.74), nonsustained 
ventricular tachycardia (OR 3.40; 95% CI: 1.03, 11.20), and complex ventricular ectopy (OR 
1.74; 95% CI: 1.11, 2.74) remained almost 2- to 4-fold greater in persons diagnosed with OSA. 
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Trigeminy, supraventricular tachycardia, and all conduction delay arrhythmias were not 
significantly different between subjects with and without SDB on univariate analysis. 
Other community-based studies also failed to show an increase in conduction delays in 
persons with SDB compared with those without SDB. There was also no difference in 
conduction delay arrhythmias according to SDB severity in data from the elderly men in 
U.S. MrOS Sleep Study (Mehra et al., 2009), and conduction delay prevalences in subjects 
with and without OSA in the Norwegian Akershus Sleep Apnea Project (ASAP) were 
similar (Namtvedt et al., 2011).    
The ASAP study, which included randomly recruited subjests from the general Norwegian 
population, showed similarities with other reports; for example, ventricular premature 
complexes occurred significantly more frequently both at night and during daytime in the 
presence of OSA, defined as AHI ≥5 (Namtvedt et al., 2011).  Increases in AHI were 
significantly associated with an increased prevalence of ventricular premature complexes, 
which remained after adjusting for clinically relevant confounders. In addition to 
conduction delays, supraventricular arrhythmias, including atrial fibrillation, were not 
different between subjects with and without OSA in this study.      
Diagnosis of 1456 Japanese patients suspected of having sleep apnea revealed 97.0% had at 
least mild (AHI ≥5) sleep apnea (Abe et al., 2010).  CSA, defined as having more than 50% 
central apneas, was diagnosed in 62 patients. OSA in the remaining 1412 patients was 
classified according to mild, moderate, and severe OSA, using AASM levels. The occurrence 
of paroxysmal AF (P=.051), premature atrial complex (P=.005), premature ventricular 
complex (P=.004), sinus bradycardia (P=.036), and sinus pause (P<.001) were increased with 
increasing OSA severity.  Nonsustained ventricular tachycardia and second- and third-
degree atrioventricular block were not related to OSA severity; however, prevalence was 
very low, with no cases in subjects without OSA, and prevalence ranging from 1.0% to 1.3%, 
0.3% to 1.3%, and 0% to 0.1% among OSA the 3 OSA severities for these 3 arrhythmias, 
respectively. 
This was contrasted by data from the Sleep Heart Health Study where 5.3% of subjects with 
SDB had nonsustained ventricular tachycardia compared with 1.2% of subjects without SDB 
(P=.004)(Mehra et al., 2006). Complex ventricular ectopy (25.0% vs. 14.5%; P=.002) and atrial 
fibrillation (4.8% vs. 0.9%; P=.003) were also significantly more prevalent in subjects with 
SDB.   
Other studies have failed to show a difference in atrial fibrillation prevalence between 
subjects with and without SDB, or in the prevalence of SDB in patients with and without 
atrial fibrillation (Roche et al., 2003).  Requiring an AHI of at least 15 as diagnostic for OSA, 
a case control study failed to show a difference in OSA prevalence between 59 patients with 
lone atrial fibrillation (i.e., without chronic or acute risk factors) and controls who were age, 
gender, and co-morbidity matched controls (32% vs. 29%; P=0.67)(Porthan et al., 2004).  
Another study (Leung et al., 2005) that excluded patients with a history of congestive heart 
failure (CHF), CAD, or stroke, enrolled 60 patients each without SBD, with CSA, and with 
OSA. The prevalence of atrial fibrillation was significantly higher in patients with CSA 
(27%) compared with OSA (1.7%) or no SBD (3.3%; P<.001). Patients with OSA had more 
hypertension and more extreme oxygen desaturation.  
Nocturnal bradycardia was present in 17 of 239 (7%) patients with OSA who were 
diagnosed using a validated ambulatory recording device that measured heart rate, oxygen 
saturation, snoring, and body position (Becker et al., 1995; Koehler et al., 2000). Patients with 
bradycardia were then given polysomnograms. Two-thirds of 1575 bradyarrhythmic events 
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recorded during 24-hour Holter ECG monitoring occurred during REM sleep, and all 
occurred concomitant with an apneic or hypopneic event.  Oxygen saturation was similar in 
patients with and without bradyarrhythmia at the beginning of the apnea or hypopnea; 
however, end values were significantly lower in patients with bradyarrhythmia. RDI was 
significantly higher in patients with bradyarrhythmias, who had an RDI of at least 60. 
However, 80 patients with an RDI >=60 did not have bradyarrhythmia. BMI was also 
significantly higher in patients with bradyarrhythmias, and the authors concluded that the 
obesity and high RDI associated with the bradyarrhythmias may be interrelated in their 
development. 
3.2 OSA in patients with cardiovascular disease 
Javaheri et al. (1998) recruited 81 ambulatory men with stable heart failure for 
polysomnography and nocturnal Holter monitoring. In previous studies, these authors had 
used an AHI threshold of 20 to classify sleep apnea; however, for this study the threshold 
was set at AHI ≥15 to accommodate patients with a lower AHI but with significant arterial 
oxyhemoglobin desaturation. Forty-one (51%) patients had sleep apnea, with a mean AHI of 
44 ± 19.  Compared with patients without sleep apnea, patients with sleep apnea were more 
likely to have atrial fibrillation (22% vs. 5%; P=.026), with a non-significant higher 
prevalence of nocturnal ventricular tachycardia (51% vs. 37%; P=.23). The mean numbers of 
premature ventricular depolarizations (P=.0002) and couplets (P=.0001) were significantly 
higher in sleep apnea patients, with a non-significantly higher ventricular tachycardia rate 
(P=.07). When Sin et al. (1999) compared the prevalence and characteristics of CSA and OSA 
in 450 patients with CHF, the prevalence of CSA (33%) was similar to that of OSA (38%) 
using a threshold for SDB of AHI 10; however, atrial fibrillation was significantly greater in 
CSA patients (23.0%) compared with OSA patients (11.9%) and with patients without SBD 
(7.5%; P<.05).  
Sleep apneas have been suggested to play a role in the recurrence of arrhythmias following 
successful therapy.  In a study of 44 patients with sustained ventricular tachycardia without 
heart failure or other structural heart disease who underwent catheter ablation therapy, 17 
(39%) were diagnosed with sleep apnea by polysomnography using a threshold of AHI ≥10 
(Koshino et al., 2010). Arrhythmia recurrence in successfully ablated patients with apnea 
(5/11, 45%) was significantly greater than that in patients without sleep apnea (1/17, 6%; 
P=.02). 
When sleep studies were performed in 45 patients with implantable cardioverter 
defibrillators (ICD), over half (57.87%) were diagnosed with SDB, using a threshold of AHI 
≥10 (Zeidan-Shwiri et al., 2011). The mean number of ventricular arrhythmias was 
significantly higher in patients with SDB (P=.03). A significant increase in the number of 
ventricular arrhythmias occurred with increasing AHI quartiles (0–7, 8–11, 12–33, and 34–66 
events/h; P=.003), as seen in other studies (e.g., ventricular premature complexes in the 
general population study of Namtvedt et al., 2011).  Increases in ventricular arrhythmias in 
the ICD patients were predominantly related to increased ventricular arrhythmic events 
occurring from midnight to 6 a.m.  SDB was a significant, independent predictor of 
nocturnal appropriate ICD therapy after adjusting for baseline variables including age, BMI, 
and serum creatinine (OR 3.8; 95% CI: 1.2, 12.1; P=.02). Similar results were reported by 
Serizawa et al. (2008), who enrolled 71 patients with heart failure and an ICD, of whom 47 
(66%) were diagnosed with SDB, also using an AHI threshold of 10. Appropriate ICD 
therapies occurred more frequently in SDB patients (43%) compared with those without 
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recorded during 24-hour Holter ECG monitoring occurred during REM sleep, and all 
occurred concomitant with an apneic or hypopneic event.  Oxygen saturation was similar in 
patients with and without bradyarrhythmia at the beginning of the apnea or hypopnea; 
however, end values were significantly lower in patients with bradyarrhythmia. RDI was 
significantly higher in patients with bradyarrhythmias, who had an RDI of at least 60. 
However, 80 patients with an RDI >=60 did not have bradyarrhythmia. BMI was also 
significantly higher in patients with bradyarrhythmias, and the authors concluded that the 
obesity and high RDI associated with the bradyarrhythmias may be interrelated in their 
development. 
3.2 OSA in patients with cardiovascular disease 
Javaheri et al. (1998) recruited 81 ambulatory men with stable heart failure for 
polysomnography and nocturnal Holter monitoring. In previous studies, these authors had 
used an AHI threshold of 20 to classify sleep apnea; however, for this study the threshold 
was set at AHI ≥15 to accommodate patients with a lower AHI but with significant arterial 
oxyhemoglobin desaturation. Forty-one (51%) patients had sleep apnea, with a mean AHI of 
44 ± 19.  Compared with patients without sleep apnea, patients with sleep apnea were more 
likely to have atrial fibrillation (22% vs. 5%; P=.026), with a non-significant higher 
prevalence of nocturnal ventricular tachycardia (51% vs. 37%; P=.23). The mean numbers of 
premature ventricular depolarizations (P=.0002) and couplets (P=.0001) were significantly 
higher in sleep apnea patients, with a non-significantly higher ventricular tachycardia rate 
(P=.07). When Sin et al. (1999) compared the prevalence and characteristics of CSA and OSA 
in 450 patients with CHF, the prevalence of CSA (33%) was similar to that of OSA (38%) 
using a threshold for SDB of AHI 10; however, atrial fibrillation was significantly greater in 
CSA patients (23.0%) compared with OSA patients (11.9%) and with patients without SBD 
(7.5%; P<.05).  
Sleep apneas have been suggested to play a role in the recurrence of arrhythmias following 
successful therapy.  In a study of 44 patients with sustained ventricular tachycardia without 
heart failure or other structural heart disease who underwent catheter ablation therapy, 17 
(39%) were diagnosed with sleep apnea by polysomnography using a threshold of AHI ≥10 
(Koshino et al., 2010). Arrhythmia recurrence in successfully ablated patients with apnea 
(5/11, 45%) was significantly greater than that in patients without sleep apnea (1/17, 6%; 
P=.02). 
When sleep studies were performed in 45 patients with implantable cardioverter 
defibrillators (ICD), over half (57.87%) were diagnosed with SDB, using a threshold of AHI 
≥10 (Zeidan-Shwiri et al., 2011). The mean number of ventricular arrhythmias was 
significantly higher in patients with SDB (P=.03). A significant increase in the number of 
ventricular arrhythmias occurred with increasing AHI quartiles (0–7, 8–11, 12–33, and 34–66 
events/h; P=.003), as seen in other studies (e.g., ventricular premature complexes in the 
general population study of Namtvedt et al., 2011).  Increases in ventricular arrhythmias in 
the ICD patients were predominantly related to increased ventricular arrhythmic events 
occurring from midnight to 6 a.m.  SDB was a significant, independent predictor of 
nocturnal appropriate ICD therapy after adjusting for baseline variables including age, BMI, 
and serum creatinine (OR 3.8; 95% CI: 1.2, 12.1; P=.02). Similar results were reported by 
Serizawa et al. (2008), who enrolled 71 patients with heart failure and an ICD, of whom 47 
(66%) were diagnosed with SDB, also using an AHI threshold of 10. Appropriate ICD 
therapies occurred more frequently in SDB patients (43%) compared with those without 
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SDB (17%; P=.029). In addition, ICD therapy from midnight to 6 a.m. was more frequent in 
patients with (34%) than in those without (13%) SDB (P=.046), and SDB was an independent 
predictor for appropriate ICD therapy in multivariate analysis (HR 4.05; 95% CI: 1.20 , 13.65; 
P=.015).    
The recurrence rate of atrial fibrillation during 1-year of follow-up in 39 patients who 
underwent DC cardioversion for atrial fibrillation/atrial flutter was compared with that in 
79 postcardioversion patients (controls) who did not have a previous sleep study (Kangala 
et al., 2003).  Recurrence in 27 OSA patients who received no treatment for their OSA was 
82%, compared with 42% for those with treated OSA (P=.013), and 53% in the control group 
(P=.009). Comparing nocturnal decrease in oxygen saturation in untreated OSA patients 
with recurrence of atrial fibrillation with that of untreated patients without a recurrence 
revealed a significantly greater decrease occurred in untreated OSA patients (18% vs. 8%; 
P=.034), who had a greater portion of sleep time with oxygen saturation <90% (23% vs. 4%; 
P=.063). The increased risk of recurrence of atrial fibrillation in untreated patients with OSA 
in this study prompted the authors to propose that patients with atrial fibrillation should be 
screened for OSA; and, similarly, OSA patients should be screened for atrial fibrillation. 
Gami et al. (2004) compared the prevalence of OSA, diagnosed using the Berlin questionnaire, 
in 151 patients undergoing cardioversion for atrial fibrillation with the prevalence in 312 
general cardiology practice patients.r Significantly more patients with atrial fibrillation had 
OSA compared with the general cardiology group (49% vs. 32%; P=.0004); with a multivariate 
adjusted OR for the association between atrial fibrillation and OSA of 2.19 (95% CI: 1.40, 3.42; 
P=.0006). To accommodate any misclassifications that might have occurred without using 
polysomnography for diagnosis, a separate analysis adjusted patient numbers per group using 
validation data acquired from 44 patients on whom polysomnography was performed. After 
decreasing OSA in the atrial fibrillation group by the false-positive rate and increasing it in the 
general cardiology group by the false negative rate, the difference in prevalence between the 2 
groups remained statistically significant (48% vs. 37%, P=.022). These authors also concluded 
that the presence of OSA should be considered in all patients with atrial fibrillation, 
particularly those with obesity or hypertension. This should be considered particularly sage 
advice considering the current epidemic increase in atrial fibrillation and its associated 
morbidity and mortality (Steinberg, 2004). 
The incidence of post surgical atrial fibrillation in 121 consecutive coronary artery bypass 
surgery patients was assessed by Mooe et al. (1996).  All patients underwent preoperative 
diagnosis of disordered breathing, defined as AHI ≥5 or an oxygen desaturation index (ODI) 
≥5. Atrial fibrillation was diagnosed in 25 of 78 (32%) patients with AHI ≥5 compared with 7 
of 39 (18%) of patients with AHI <5 (P=.11), and in 19 of 49 (39%) patients with ODI ≥5 
compared with 13 of 72 (18%) patients with an ODI <5 (P=.02). Using ODI ≥5, disordered 
breathing was an independent predictor of atrial fibrillation in a multiple-logistic regression 
model (RR 2.8, 95% CI: 1.2, 6.8).      
In summary, these studies revealed some differences and similarities in the manifestation of 
arrhythmias associated with SDB. For example, bradyarrhythmias, premature ventricular 
complexes, and atrial fibrillation have been shown in some studies to be increased with 
increasing severity of SDB, while no effect of SDB severity was shown for tachyarrhythmias. 
Bradyarrhythmias occur with the apneic or hypopneic event, while tachycardias also occur 
during recovery. Finally, premature ventricular complexes have been shown to occur during 
waking hours as well as during sleep in patients with SDB. These results indicate the 
importance of identifying the mechanisms associating SDB with cardiac arrhythmias. 
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4. Pathophysiological mechanisms of arrhythmia in SDB 
The exact mechanisms linking SDB and arrhythmia are not completely understood, as there 
are several complex and interrelated pathways by which arrhythmias may be produced or 
become more severe in the presence of SDB. Autonomic, hemodynamic, chemical, 
inflammatory, and metabolic mechanisms may be involved to varying degrees in relation to 
patient demographic and health characteristics (Figure 1). Research is ongoing, with the 
understanding that exploring the physiological effects of SDB should not be limited to sleep, 
as patients with sleep apnea exhibit elevated sympathetic nerve activity and blood pressure 
during wakefulness (Verrier & Josephson, 2009). 
 
 
KEY: ANS – autonomic nervous system, BP – blood pressure, BR – barorecptor gain, OSA – obstructive 
sleep apnea 
Fig. 1. Obstructive Sleep Apnea and Cardiac Arrhythmia – Possible Mechanisms 
The increased risk of arrhythmias and sudden cardiac death in obesity is well known, and 
the common occurrence of SDB in obese subjects suggests overlapping mechanisms may 
contribute to arrhythmia development in these patients. Prolonged corrected QT (QTc) 
interval, increased vasomotor tone and ventricular instability, development of dilated 
cardiomyopathy, and impairment in autonomic nervous system cardiac modulation may be 
involved (Arias & Sanchez, 2007). Intermittent hypoxemia, sympathetic hyperactivity, and 
increased left-ventricular after load that occur secondary to each apneic event in OSA 
impose an additional burden. 
The severity of OSA was shown to be independently associated with elevated inflammatory 
markers, including C-reactive protein (Shamsuzzaman et al., 2002), which is also elevated in 
atrial fibrillation (Chung et al., 2001).  Decreases in some of these markers have been 
reported when OSA was treated with continuous positive air pressure (CPAP) therapy 
(Arias & Sanchez, 2007; Svatikova et al., 2003).  
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Some generalized mechanisms that may be involved with SDB and its effect on 
arrhymogenesis have been described, which are often linked to the specific type of 
arrhythmia evoked. For example, apneas are known to induce several arrythmogenic 
dysregulations including alterations in cardiac sympathetic and parasympathetic activity, 
myocardial hypoxemia (Schafer et al., 1997), and deformation of the cardiac chambers 
resulting from intrathoracic pressure fluctuations (Condos et al., 1987). 
Mechanisms related to specific sleep stages may also impact the development of 
arrhythmias in SDB. REM-induced cardiac events may include both direct effects, such as 
alterations in electrophysiological stability, or indirect effects on heart rate and arterial blood 
pressure. Subsequent platelet aggregation or plaque disruption can be associated with the 
release of arrhythmogenic molecules. Metabolic imbalances can stimulate neural activity 
that results in myocardial ischemia or arrhythmias. Some studies have shown that 
arrhythmias were more common in SDB patients who had severe nocturnal hypoxemia 
during REM sleep (Findley et al., 1985; Shepard et al., 1985).  
4.1 Ventricular arrhythmias 
Surges in sympathetic nerve activity during REM sleep have been suggested to cause 
nocturnal ventricular arrhythmias and myocardial ischemia in patients with cardiovascular 
disease (Nowlin et al., 1965). The purported decrease in vagus nerve activity and unopposed 
cardiac sympathetic nerve activity in these patients may foster development of ventricular 
tachycardia and fibrillation (Verrier & Josephson, 2009).   
The surge in arterial blood pressure and sympathetic nerve activity that occur with apneas 
may explain the temporal association between the apnea and the onset of nonsustained 
ventricular tachycardia (Monahan et al., 2009; Somers et al., 1995; Somers et al., 2008).  In 
one sub-study from the Sleep Heart Health Study, polysomnograms from 57 patients with 
62 episodes of paroxysmal atrial fibrillation or nonsustained vetricular tachycardia (NSVT) 
were reviewed (Monahan et al., 2009). Respiratory disturbances (apneas or hypopneas) 
occurring during hazard periods defined as the 90s intervals preceding an AF event were 
compared with those occurring during referent control periods in the same subject. 
Approximately three-fourths (n=47; 76%) of the events were NSVT, and two-thirds (68%) 
occurred in nonREM sleep (atrial fibrillation: 80%; NSVT: 64%). The overall risk of 
occurrence after a respiratory disturbance was 17.5-fold greater (95% CI: 5.3, 58.4) than the 
risk of an event during normal nocturnal breathing, and was similar for each arrhythmia 
type (atrial fibrillation OR: 17.9; NSVT OR: 17.4). When each variable was considered 
independently, there was no association between EEG-defined arousal or hypoxia and 
arrhythmia risk.  Based on this data, the authors postulated that additional mechanisms may 
be involved in the link between sleep-related respiratory disturbances and arrhythmias, 
including large changes in intrathoracic pressure and stimulation of baroreflexes (Gami et 
al, 2008). However, they also suggested that the small number of respiratory disturbances in 
their study may have inhibited detection of an effect. In fact, others have suggested that the 
oxygen desaturation that occurs with apnea may be involved as an independent risk factor 
for ventricular arrhythmia (Bradley & Flores, 2003a; Bradley & Flores, 2003b).  
4.1.1 The MrOS sleep study - A model for design and analysis of community-based 
studies 
The MrOS Sleep Study, an ancillary cohort of the multicenter Osteoporotic Fractures in Men 
Study, enrolled 3135 men ≥65 years of age to explore the association of SDB with complex 
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ventricular ectopy (CVE) and nocturnal atrial fibrillation in elderly men (Mehra et al., 2009). 
This elaborate study warrants detailed discussion. The design included clearly defined 
variables across SDB severities and types, supported by rigorous, standardized data 
collection from a large, community-based sample. The study investigated the occurrence of 
nocturnal CVE and atrial fibrillation as primary endpoints, and also evaluated the 
occurrence of any atrial arrhythmias, other ventricular arrhythmias, and conduction delay 
arrhythmias. Polysomnography data were used to produce RDI data, which provided an 
overall severity of SDB by including both obstructive and central apneas per hour, 
summarized into quartiles. The upper limit of the lowest quartile was only slightly above 
the commonly used threshold for SDB (<5.9 vs 5, respectively); therefore, the lowest quartile 
was approximately equivalent to no SDB. An obstructive AHI index (OAHI), limited to 
obstructive events, was also categorized by quartile. A Central Apnea Index (CAI) was 
created from categories made from the distribution of data for central apneas/hour of sleep. 
Categories were prepared from percent of total sleep time (TST) with arterial oxygen 
saturation <90% (defining hypoxia) that accommodated the right-skewed data distribution.  
In the MrOS Sleep Study, 1048 (36%) subjects had CVE. There was a significant association 
between the fourth quartile of OAHI severity (RDI ≥23.9) and CVE (adjusted OR 1.37; 95% 
CI: 1.08, 1.75); however, the relationship between CSA and CVE was not significant after 
adjusting for confounders including cardiovascular disease. CVE was also associated with 
hypoxia, with both unadjusted and unadjusted ORs significant when at least 10% of TST 
was spent at <90% oxygen saturation (adjusted OR 1.62; 95% CI: 1.23, 2.14). The authors 
concluded that CVE is more likely to result in patients who experience intermittent hypoxia 
and collapse of the upper airway, which are triggers for intrathoracic pressure changes, 
blood pressure surges, and sympathetic nervous system activation. They compared their 
results to the study of Javaheri (2000), in which treatment of SDB resulted in reduced RDI 
and hypoxia.  
4.2 Atrial fibrillation 
Several studies in addition to those discussed in section 4.1 have explored potential 
mechanisms for atrial fibrillation to occur in the setting of SDB. Hypertension is an 
established risk factor for atrial fibrillation (Kannel et al. 1998; Chugh et al., 2001), and the 
relationship between OSA and both hypertension and left-ventricular hypertrophy has been 
documented (Arias & Sanchez, 2007; Nieto et al., 2000; Peppard et al., 2000). Data from OSA 
patients describe cardiac structural and functional changes, including right and left 
ventricular performance and left atrial enlargement (Otto et al., 2007; Romero-Corral et al., 
2007).  Shifts in transmural pressures and concomitant changes in cardiac chamber 
dimensions can occur in response to the futile ventilatory efforts during apnea (Condos et 
al., 1987; Hall et al., 1998), and may trigger stretch-activated ion channels in the atria (Franz 
& Bode, 2003) that can lead to atrial fibrillation.  The mechanical effects of negative 
intrathoracic pressure can allow cardiac stretching, whereby a mechanical-electrical 
feedback mechanism could predispose to atrial fibrillation (Franz, 2000). These data support 
a mechanistic association of OSA with the development of atrial fibrillation; however, 
causation has not yet been proven. 
Heart rate variability studies have shown that nocturnal atrial fibrillation is induced during 
periods of intense vagus nerve activity (Bettoni & Zimmerman, 2002). These vagally-
mediated episodes of atrial fibrillation are usually preceded by bradycardia (Verrier & 
Yosephson, 2009). In addition, the apnea-induced hypoxemia, sympathetic nerve activity, 
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Some generalized mechanisms that may be involved with SDB and its effect on 
arrhymogenesis have been described, which are often linked to the specific type of 
arrhythmia evoked. For example, apneas are known to induce several arrythmogenic 
dysregulations including alterations in cardiac sympathetic and parasympathetic activity, 
myocardial hypoxemia (Schafer et al., 1997), and deformation of the cardiac chambers 
resulting from intrathoracic pressure fluctuations (Condos et al., 1987). 
Mechanisms related to specific sleep stages may also impact the development of 
arrhythmias in SDB. REM-induced cardiac events may include both direct effects, such as 
alterations in electrophysiological stability, or indirect effects on heart rate and arterial blood 
pressure. Subsequent platelet aggregation or plaque disruption can be associated with the 
release of arrhythmogenic molecules. Metabolic imbalances can stimulate neural activity 
that results in myocardial ischemia or arrhythmias. Some studies have shown that 
arrhythmias were more common in SDB patients who had severe nocturnal hypoxemia 
during REM sleep (Findley et al., 1985; Shepard et al., 1985).  
4.1 Ventricular arrhythmias 
Surges in sympathetic nerve activity during REM sleep have been suggested to cause 
nocturnal ventricular arrhythmias and myocardial ischemia in patients with cardiovascular 
disease (Nowlin et al., 1965). The purported decrease in vagus nerve activity and unopposed 
cardiac sympathetic nerve activity in these patients may foster development of ventricular 
tachycardia and fibrillation (Verrier & Josephson, 2009).   
The surge in arterial blood pressure and sympathetic nerve activity that occur with apneas 
may explain the temporal association between the apnea and the onset of nonsustained 
ventricular tachycardia (Monahan et al., 2009; Somers et al., 1995; Somers et al., 2008).  In 
one sub-study from the Sleep Heart Health Study, polysomnograms from 57 patients with 
62 episodes of paroxysmal atrial fibrillation or nonsustained vetricular tachycardia (NSVT) 
were reviewed (Monahan et al., 2009). Respiratory disturbances (apneas or hypopneas) 
occurring during hazard periods defined as the 90s intervals preceding an AF event were 
compared with those occurring during referent control periods in the same subject. 
Approximately three-fourths (n=47; 76%) of the events were NSVT, and two-thirds (68%) 
occurred in nonREM sleep (atrial fibrillation: 80%; NSVT: 64%). The overall risk of 
occurrence after a respiratory disturbance was 17.5-fold greater (95% CI: 5.3, 58.4) than the 
risk of an event during normal nocturnal breathing, and was similar for each arrhythmia 
type (atrial fibrillation OR: 17.9; NSVT OR: 17.4). When each variable was considered 
independently, there was no association between EEG-defined arousal or hypoxia and 
arrhythmia risk.  Based on this data, the authors postulated that additional mechanisms may 
be involved in the link between sleep-related respiratory disturbances and arrhythmias, 
including large changes in intrathoracic pressure and stimulation of baroreflexes (Gami et 
al, 2008). However, they also suggested that the small number of respiratory disturbances in 
their study may have inhibited detection of an effect. In fact, others have suggested that the 
oxygen desaturation that occurs with apnea may be involved as an independent risk factor 
for ventricular arrhythmia (Bradley & Flores, 2003a; Bradley & Flores, 2003b).  
4.1.1 The MrOS sleep study - A model for design and analysis of community-based 
studies 
The MrOS Sleep Study, an ancillary cohort of the multicenter Osteoporotic Fractures in Men 
Study, enrolled 3135 men ≥65 years of age to explore the association of SDB with complex 
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ventricular ectopy (CVE) and nocturnal atrial fibrillation in elderly men (Mehra et al., 2009). 
This elaborate study warrants detailed discussion. The design included clearly defined 
variables across SDB severities and types, supported by rigorous, standardized data 
collection from a large, community-based sample. The study investigated the occurrence of 
nocturnal CVE and atrial fibrillation as primary endpoints, and also evaluated the 
occurrence of any atrial arrhythmias, other ventricular arrhythmias, and conduction delay 
arrhythmias. Polysomnography data were used to produce RDI data, which provided an 
overall severity of SDB by including both obstructive and central apneas per hour, 
summarized into quartiles. The upper limit of the lowest quartile was only slightly above 
the commonly used threshold for SDB (<5.9 vs 5, respectively); therefore, the lowest quartile 
was approximately equivalent to no SDB. An obstructive AHI index (OAHI), limited to 
obstructive events, was also categorized by quartile. A Central Apnea Index (CAI) was 
created from categories made from the distribution of data for central apneas/hour of sleep. 
Categories were prepared from percent of total sleep time (TST) with arterial oxygen 
saturation <90% (defining hypoxia) that accommodated the right-skewed data distribution.  
In the MrOS Sleep Study, 1048 (36%) subjects had CVE. There was a significant association 
between the fourth quartile of OAHI severity (RDI ≥23.9) and CVE (adjusted OR 1.37; 95% 
CI: 1.08, 1.75); however, the relationship between CSA and CVE was not significant after 
adjusting for confounders including cardiovascular disease. CVE was also associated with 
hypoxia, with both unadjusted and unadjusted ORs significant when at least 10% of TST 
was spent at <90% oxygen saturation (adjusted OR 1.62; 95% CI: 1.23, 2.14). The authors 
concluded that CVE is more likely to result in patients who experience intermittent hypoxia 
and collapse of the upper airway, which are triggers for intrathoracic pressure changes, 
blood pressure surges, and sympathetic nervous system activation. They compared their 
results to the study of Javaheri (2000), in which treatment of SDB resulted in reduced RDI 
and hypoxia.  
4.2 Atrial fibrillation 
Several studies in addition to those discussed in section 4.1 have explored potential 
mechanisms for atrial fibrillation to occur in the setting of SDB. Hypertension is an 
established risk factor for atrial fibrillation (Kannel et al. 1998; Chugh et al., 2001), and the 
relationship between OSA and both hypertension and left-ventricular hypertrophy has been 
documented (Arias & Sanchez, 2007; Nieto et al., 2000; Peppard et al., 2000). Data from OSA 
patients describe cardiac structural and functional changes, including right and left 
ventricular performance and left atrial enlargement (Otto et al., 2007; Romero-Corral et al., 
2007).  Shifts in transmural pressures and concomitant changes in cardiac chamber 
dimensions can occur in response to the futile ventilatory efforts during apnea (Condos et 
al., 1987; Hall et al., 1998), and may trigger stretch-activated ion channels in the atria (Franz 
& Bode, 2003) that can lead to atrial fibrillation.  The mechanical effects of negative 
intrathoracic pressure can allow cardiac stretching, whereby a mechanical-electrical 
feedback mechanism could predispose to atrial fibrillation (Franz, 2000). These data support 
a mechanistic association of OSA with the development of atrial fibrillation; however, 
causation has not yet been proven. 
Heart rate variability studies have shown that nocturnal atrial fibrillation is induced during 
periods of intense vagus nerve activity (Bettoni & Zimmerman, 2002). These vagally-
mediated episodes of atrial fibrillation are usually preceded by bradycardia (Verrier & 
Yosephson, 2009). In addition, the apnea-induced hypoxemia, sympathetic nerve activity, 
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and surges in blood pressure that can affect diastolic function by distending and remodeling 
atrial chambers may also contribute to atrial fibrillation development.  
In a study of atrial fibrillation radiofrequency ablation in 424 patients, OSA was a significant 
risk factor for conduction recurrence after multivariable adjustment (RR 2.16; 95% CI: 1.32, 
3.94; P=.01)(Sauer et al., 2006). This was postulated to be mechanistically related to left atrial 
electrical modeling, fibrosis, and chamber enlargement resulting from OSA (Gami et al., 
2008). 
In many studies of atrial fibrillation in association with OSA, oxygen saturation variables 
were independently predictive of atrial fibrillation, suggesting that hypoxemia is an 
important pathophysiological mechanism linking OSA and atrial fibrillation (Gami et al, 
2008). In addition to decreased oxygen saturation, obesity, male gender, and coronary artery 
disease in persons 65 years of age, and heart failure in older subjects, have been shown to be 
associated with the development of atrial fibrillation in patients with apnea (Wang et al., 
2004). 
In the MrOS Sleep Study, atrial fibrillation had a stronger association with CSA than OSA 
(Mehra et al., 2009). Adjusted analysis revealed increasing severity of SDB was only 
significantly related to atrial fibrillation in patients with the most severe CSA (OR 2.69; 95% 
CI: 1.61, 4.47), which remained significant after excluding subjects without heart failure from 
the analysis. The effect of hypoxia on atrial fibrillation, however, was not significant. 
Although these results were based on self-reported heart failure, the authors suggested that 
their results agree with those of Leung et al. (2005), that atrial fibrillation is more strongly 
associated with CSA than OSA, even in the absence of heart failure.  They concluded that it 
may be beneficial to screen patients with AF for CSA.      
4.3 Bradyarrhythmias 
While repeated hypoxemia and arousals enhance sympathetic nervous activity and may be 
involved with the tachyarrhymias seen in OSA, the simultaneous hypoxemia and apnea also 
induce the diving reflex, with cardiac parasympathetic vagal nerve activation and 
peripheral sympathetic activation that produces vasoconstriction in muscle, renal, and 
splanchnic, but not cerebral, vasculature (Daly et al., 1979; Madden et al., 1997; Somers et al., 
1992).  This may result in severe nocturnal bradyarrhythmia. In the study of 239 OSA 
patients by Becker et al. (1995), bradyarrhythmia occurred only during apnea and 
hypopnea. In some studies, these bradyarrhythmias occurred more frequently during REM 
sleep accompanied by at least a 4% decrease in oxygen saturation (Becker et al, 1995; 
Koehler et al., 1998; Koehler et al., 2000). Conversely, in the study by Guilleminault et al. 
(1983), in 3 patients extreme sinus bradycardia occurred during nonREM sleep, and sinus 
arrest was associated with apneas during REM sleep. These patients had both sinus arrest 
and extreme sinus bradycardia that were of similar duration.  
The lack of a difference in conduction delay arrhythmias between subjects with and without 
SDB in both the MrOS Sleep Study (Mehra et al., 2009) and Sleep Heart Health Study 
(Mehra et al., 2006) was remarked by the authors to be at variance with the opinion that SDB 
is associated with increased vagal tone.  They offered that there may be differences in the 
underlying comorbidities in these 2 studies compared with data from studies of clinic 
referral subjects that suggested an association of SDB with bradyarrhythmia and heart 
failure.     
The clinical significance of these OSA-related arrhythmias is not completely understood, 
and their association with adverse outcomes warrants further investigation in studies 
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designed to accommodate the numerous confounders influencing results. The possible 
relationship between nocturnal oxygen desaturation and arrhythmias and sudden death in 
heart failure patients was suggested 20 years ago (Davies et al., 1991). More recently, Gami 
et al. (2005) reported that sudden cardiac death in almost half of 78 heart failure patients 
with OSA occurred during sleeping hours from midnight to 6:00 a.m., significantly 
deviating from the typical time of death during early morning waking hours (6:00 a.m. to 
noon). 
In summary, despite differences among studies and gaps in understanding the mechanisms 
by which SDB impacts arrhythmias, data suggest that patients with moderate to severe OSA 
are at increased risk for arrhythmias during sleep. the majority of data support the 
importance of identifying patients with SDB and treating them appropriately.  
5. Treating OSA  
Tracheostomy was the standard treatment for SDB until CPAP was introduced in 1981. 
Although CPAP is not as invasive as tracheostomy, it can present challenges. The 
equipment and devices can be cumbersome and annoying, with treatment compliance 
commonly less than 50% due to rhinitis, nose bleeds, facial abrasions, and improper fit 
(Gami et al., 2008; Veasey, 2009). Pressure must be titrated to a level high enough to prevent 
not only apneas and hyponeas, but also to prevent snoring that can cause arousal.  
However, pressure must also be kept at a level below what would cause sleep interference.  
There have been no long-term, large, randomized controlled trials comparing OSA 
treatment with placebo on cardiovascular outcomes. Several studies, however, associated 
failing to treat OSA with increased mortality or morbidity (He et al., 1988). Data from 3 large 
observational studies that included a total of 2396 patients showed increased fatal and 
nonfatal cardiovascular outcomes in patients with severe OSA, compared with patients who 
were treated with CPAP (Buchner et al., 2007; Campos-Rodriguez et al., 2005; Marin et al., 
2005).r One of the studies (Buchner et al., 2007) enrolled 449 patients, of whom 364 received 
OSA treatment, which provided a 64% cardiovascular risk reduction after adjusting for age, 
gender, cardiovascular risk factors, and baseline comorbidities.  
In the Japanese study of the relationship between OSA and arrhythmias, 316 of 1047 patients 
with AHI ≥20 accepted treatment with CPAP therapy, and were re-evaluated an average of 
3.9 weeks after polysomnography to determine the effectiveness of CPAP therapy and 
arrhythmia status (Abe et al., 2010). AHI and arousal index were among the OSA variables 
that were significantly improved with CPAP therapy (P<.001 for both).   Premature atrial 
complex and nonsustained ventricular tachycardia were unchanged, as were the numbers of 
second- and third-degree AV block; however the latter were present in only 5 patients 
before treatment and 1 patient after treatment. The proportions of patients with premature 
ventricular complex, sinus bradycardia, pause, and paroxysmal atrial fibrillation were 
significantly decreased after treatment.  
There is no clinical basis for treating nighttime atrial fibrillation differently from that 
occurring during the day. However, patients who have nocturnal onset of atrial fibrillation 
should be monitored for SDB and provided treatment with CPAP if warranted. 
A recent study followed 47 OSA patients on CPAP for 12 months to assess changes in 
cardiac biomarkers from baseline (Colish et al., 2011). Systolic and diastolic abnormalities 
were reversed as early as 3 months after starting treatment, with additional improvements 
evident over 1-year as evidenced by transthoracic echocardiography and CMR. Levels of 
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and surges in blood pressure that can affect diastolic function by distending and remodeling 
atrial chambers may also contribute to atrial fibrillation development.  
In a study of atrial fibrillation radiofrequency ablation in 424 patients, OSA was a significant 
risk factor for conduction recurrence after multivariable adjustment (RR 2.16; 95% CI: 1.32, 
3.94; P=.01)(Sauer et al., 2006). This was postulated to be mechanistically related to left atrial 
electrical modeling, fibrosis, and chamber enlargement resulting from OSA (Gami et al., 
2008). 
In many studies of atrial fibrillation in association with OSA, oxygen saturation variables 
were independently predictive of atrial fibrillation, suggesting that hypoxemia is an 
important pathophysiological mechanism linking OSA and atrial fibrillation (Gami et al, 
2008). In addition to decreased oxygen saturation, obesity, male gender, and coronary artery 
disease in persons 65 years of age, and heart failure in older subjects, have been shown to be 
associated with the development of atrial fibrillation in patients with apnea (Wang et al., 
2004). 
In the MrOS Sleep Study, atrial fibrillation had a stronger association with CSA than OSA 
(Mehra et al., 2009). Adjusted analysis revealed increasing severity of SDB was only 
significantly related to atrial fibrillation in patients with the most severe CSA (OR 2.69; 95% 
CI: 1.61, 4.47), which remained significant after excluding subjects without heart failure from 
the analysis. The effect of hypoxia on atrial fibrillation, however, was not significant. 
Although these results were based on self-reported heart failure, the authors suggested that 
their results agree with those of Leung et al. (2005), that atrial fibrillation is more strongly 
associated with CSA than OSA, even in the absence of heart failure.  They concluded that it 
may be beneficial to screen patients with AF for CSA.      
4.3 Bradyarrhythmias 
While repeated hypoxemia and arousals enhance sympathetic nervous activity and may be 
involved with the tachyarrhymias seen in OSA, the simultaneous hypoxemia and apnea also 
induce the diving reflex, with cardiac parasympathetic vagal nerve activation and 
peripheral sympathetic activation that produces vasoconstriction in muscle, renal, and 
splanchnic, but not cerebral, vasculature (Daly et al., 1979; Madden et al., 1997; Somers et al., 
1992).  This may result in severe nocturnal bradyarrhythmia. In the study of 239 OSA 
patients by Becker et al. (1995), bradyarrhythmia occurred only during apnea and 
hypopnea. In some studies, these bradyarrhythmias occurred more frequently during REM 
sleep accompanied by at least a 4% decrease in oxygen saturation (Becker et al, 1995; 
Koehler et al., 1998; Koehler et al., 2000). Conversely, in the study by Guilleminault et al. 
(1983), in 3 patients extreme sinus bradycardia occurred during nonREM sleep, and sinus 
arrest was associated with apneas during REM sleep. These patients had both sinus arrest 
and extreme sinus bradycardia that were of similar duration.  
The lack of a difference in conduction delay arrhythmias between subjects with and without 
SDB in both the MrOS Sleep Study (Mehra et al., 2009) and Sleep Heart Health Study 
(Mehra et al., 2006) was remarked by the authors to be at variance with the opinion that SDB 
is associated with increased vagal tone.  They offered that there may be differences in the 
underlying comorbidities in these 2 studies compared with data from studies of clinic 
referral subjects that suggested an association of SDB with bradyarrhythmia and heart 
failure.     
The clinical significance of these OSA-related arrhythmias is not completely understood, 
and their association with adverse outcomes warrants further investigation in studies 
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designed to accommodate the numerous confounders influencing results. The possible 
relationship between nocturnal oxygen desaturation and arrhythmias and sudden death in 
heart failure patients was suggested 20 years ago (Davies et al., 1991). More recently, Gami 
et al. (2005) reported that sudden cardiac death in almost half of 78 heart failure patients 
with OSA occurred during sleeping hours from midnight to 6:00 a.m., significantly 
deviating from the typical time of death during early morning waking hours (6:00 a.m. to 
noon). 
In summary, despite differences among studies and gaps in understanding the mechanisms 
by which SDB impacts arrhythmias, data suggest that patients with moderate to severe OSA 
are at increased risk for arrhythmias during sleep. the majority of data support the 
importance of identifying patients with SDB and treating them appropriately.  
5. Treating OSA  
Tracheostomy was the standard treatment for SDB until CPAP was introduced in 1981. 
Although CPAP is not as invasive as tracheostomy, it can present challenges. The 
equipment and devices can be cumbersome and annoying, with treatment compliance 
commonly less than 50% due to rhinitis, nose bleeds, facial abrasions, and improper fit 
(Gami et al., 2008; Veasey, 2009). Pressure must be titrated to a level high enough to prevent 
not only apneas and hyponeas, but also to prevent snoring that can cause arousal.  
However, pressure must also be kept at a level below what would cause sleep interference.  
There have been no long-term, large, randomized controlled trials comparing OSA 
treatment with placebo on cardiovascular outcomes. Several studies, however, associated 
failing to treat OSA with increased mortality or morbidity (He et al., 1988). Data from 3 large 
observational studies that included a total of 2396 patients showed increased fatal and 
nonfatal cardiovascular outcomes in patients with severe OSA, compared with patients who 
were treated with CPAP (Buchner et al., 2007; Campos-Rodriguez et al., 2005; Marin et al., 
2005).r One of the studies (Buchner et al., 2007) enrolled 449 patients, of whom 364 received 
OSA treatment, which provided a 64% cardiovascular risk reduction after adjusting for age, 
gender, cardiovascular risk factors, and baseline comorbidities.  
In the Japanese study of the relationship between OSA and arrhythmias, 316 of 1047 patients 
with AHI ≥20 accepted treatment with CPAP therapy, and were re-evaluated an average of 
3.9 weeks after polysomnography to determine the effectiveness of CPAP therapy and 
arrhythmia status (Abe et al., 2010). AHI and arousal index were among the OSA variables 
that were significantly improved with CPAP therapy (P<.001 for both).   Premature atrial 
complex and nonsustained ventricular tachycardia were unchanged, as were the numbers of 
second- and third-degree AV block; however the latter were present in only 5 patients 
before treatment and 1 patient after treatment. The proportions of patients with premature 
ventricular complex, sinus bradycardia, pause, and paroxysmal atrial fibrillation were 
significantly decreased after treatment.  
There is no clinical basis for treating nighttime atrial fibrillation differently from that 
occurring during the day. However, patients who have nocturnal onset of atrial fibrillation 
should be monitored for SDB and provided treatment with CPAP if warranted. 
A recent study followed 47 OSA patients on CPAP for 12 months to assess changes in 
cardiac biomarkers from baseline (Colish et al., 2011). Systolic and diastolic abnormalities 
were reversed as early as 3 months after starting treatment, with additional improvements 
evident over 1-year as evidenced by transthoracic echocardiography and CMR. Levels of 
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biomarkers, including CRP, did not change significantly during 12 months of follow-up, 
however. 
Ventricular arrhythmias are assumed to be one of the major causes of sudden in heart 
failure. Screening for OSA in heart failure and treating  patients may reduce the incidence of 
these fatal arrhythmias and improve survival. 
Treating OSA has also been shown to resolve arrhythmias in many studies. Fifty OSA 
patients with arrhythmias in the study by Guilleminault et al. (1983) underwent 
tracheostomy, and after 3 to 6 months arrhythmias were no longer occurring in 46 patients. 
Arrhythmias in 4 patients with premature ventricular contractions decreased during sleep, 
and remained frequent during wakefulness.   
Several other case series have shown that  nocturnal cardiac rhythm disturbances were 
reduced following OSA treatment (Becker et al; 1995; Grimm et al., 2000; Harbison et al., 
2000; Koehler et al, 1998; Tilkian et al., 1977). It was surprising, therefore, in a recent 
retrospective cohort study of 2626 patients with OSA, that CPAP use did not affect the 
incidence of atrial fibrillation (Gami et al., 2007). The authors commented that determining 
CPAP use in the retrospective study relied on subjective reporting with subsequent 
documentation in medical records. This precluded accurately determining frequency of use, 
compliance, and treatment outcome.  In addition, in that study CPAP treatment was used by 
patients who had more severe OSA. These factors may have confounded the association 
between CPAP use and incident atrial fibrillation. 
In the study of Beckers et al. (1995), only 1 of 17 patients with bradyarrhythmia did not 
achieve resolution of their arrhythmia after CPAP therapy.  Similarly, OSA patients with 
severe cardiac rhythm disturbances reported by Simantirakis et al. (2004) experienced a 
significant reduction in bradycardias from a median of 5.5 per week in the 8-week pre-
treatment period to 0.5 per week in the first 8 weeks of CPAP therapy (P=.028). No 
bradycardias or pauses were reported beginning 5 months after starting treatment through 
14 months of follow-up. 
In response to reports noting an association between OSA and bradyarrhythmias, several 
studies were performed in the last 10 years exploring the potential for pacemakers to resolve 
OSA. As reviewed by Simantirakis & Vardas (2006), positive results were reported from a 
small study of patients with CSA but not in several studies of OSA. These authors 
postulated that in patients with predominantly OSA, the functional changes elicited by atrial 
overdrive pacing have no effect on the anatomical obstructions that cause the apnea. In CSA, 
functional and autonomic nervous system changes were able to affect the 
pathophysiological causes of respiration disturbances during sleep. The recent 
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities 
(Eptsein et al., 2008) conclude that results of randomized controlled trials (RCTs) failed to 
suggest a role for atrial overdrive pacing in OSA, and that CPAP has been shown to be 
highly effective. However,r the possible role of cardiac pacing in patients with OSA who 
continue to have persistent bradycardia episodes despite CPAP has not been confirmed. 
Data from a subsequent meta-analysis by Baranchuk et al. (2009) of 10 crossover RCTs in 
patients with AHI >=15 that enrolled 175 patients revealed that atrial overdrive pacing 
caused a significant 4.65 episode/h reduction in AHI (P=.01). However, this was 
substantially less than that achieved with CPAP treatment reported in the literature and the 
mean 42.5 episode/h reduction achieved in the 3 studies in the meta-analysis that included 
CPAP arms. The authors concluded that, although it was statistically significant, the 
reduction on atrial overdrive pacing was not clinically significant, and that patients with 
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sleep apnea should not be treated with cardiac pacing unless there is a conventional 
indication. Conversely, studies suggest that increased parasympathetic input to the heart 
may be the main mechanism for nocturnal bradycardias (reviewed by Bradley & Flores, 
2009). Therefore, treatment of OSA-induced nocturnal bradycardia may obviate the need for 
cardiac pacing; however, more studies are needed.  
6. Future directions 
Since the first suggestion was made of an association between OSA and cardiovascular 
morbidity and mortality, a rapidly expanding volume of observational data link OSA with 
the development of arrhythmias.  Much research must be done, however, to answer the 
numerous questions that remain.  In addition to larger epidemiological studies, randomized 
controlled trials must be performed that use robust designs similar to those used in 
cardiovascular intervention trials, with standardized definitions and adequate control of 
confounders.   
A major issue with properly investigating OSA and arrhythmias in both research and 
clinical settings is the expense and limited availability of sleep laboratories for the diagnosis 
of OSA. Once OSA is suspected, although other forms of diagnosis have been used, 
polysomnography remains the gold standard for diagnosis. Ambulatory in home devices 
may become a reasonable alternative, particularly in developing countries that have 
availability, access, and cost constraints (Ng et al., 2009). Many other methods are being 
investigated, and reports suggest some of these may be appropriate for initial screening in 
suspected cases, followed by full polysomnography when warranted.  
The Berlin questionnaire has been used as the diagnostic test in some studies, and has been 
validated as part of one study (Gami et al., 2004).  It has also been shown to be comparable 
to other checklists and questionnaires that have been suggested as being valid screening 
tools (Chung et al., 2008a,b).    
The high prevalence of SDB in patients on cardiac pacing prompted several investigations of 
the potential for diagnosing OSA in patients who have rate-responsive pacemakers with 
minute ventilation sensors (Simantirakis & Vardas, 2006). These devices could provide 
preliminary screening for SDB, subsequent monitoring of correlations between arrhythmias 
and apnea/hypopnea events, and evaluate therapeutic efficacy. Limitations include the 
inability to distinguish between central and obstructive apneas and to recognize specific 
sleep stages. However, its benefits can be acquired by interrogating extant devices without 
additional cost in patients with pacemakers; therefore, this may be useful in patients who 
are already on permanent pacemakers, but does not justify pacemaker placement without a 
clinical indication.  
Data have shown that OSA in the setting of cardiac arrhythmias may confer a higher risk of 
stroke and cardiovascular events (Marin et al., 2005) on affected patients,r and early 
treatment of OSA in these patients may reduce cardiovascular morbidity (Kanagala et al., 
2003; Barcena & Fang, 2007). Putting these understandings into practice is necessary. The 
importance of this is exemplified by considering the association between sleep apnea and 
heart failure, which has not resulted in increased vigilance or therapy. For example, despite 
the high prevalence (40% to 60%) of sleep apnea in heart failure, a recent study was reported 
summarizing data in U.S. Medicare files for over 30,000 incident heart failure patients, of 
whom only 4% were suspected to have sleep apnea (Javaheri et al., 2011).  Less than half of 
these received testing and treatment, and were shown to have significantly greater 2-year 
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biomarkers, including CRP, did not change significantly during 12 months of follow-up, 
however. 
Ventricular arrhythmias are assumed to be one of the major causes of sudden in heart 
failure. Screening for OSA in heart failure and treating  patients may reduce the incidence of 
these fatal arrhythmias and improve survival. 
Treating OSA has also been shown to resolve arrhythmias in many studies. Fifty OSA 
patients with arrhythmias in the study by Guilleminault et al. (1983) underwent 
tracheostomy, and after 3 to 6 months arrhythmias were no longer occurring in 46 patients. 
Arrhythmias in 4 patients with premature ventricular contractions decreased during sleep, 
and remained frequent during wakefulness.   
Several other case series have shown that  nocturnal cardiac rhythm disturbances were 
reduced following OSA treatment (Becker et al; 1995; Grimm et al., 2000; Harbison et al., 
2000; Koehler et al, 1998; Tilkian et al., 1977). It was surprising, therefore, in a recent 
retrospective cohort study of 2626 patients with OSA, that CPAP use did not affect the 
incidence of atrial fibrillation (Gami et al., 2007). The authors commented that determining 
CPAP use in the retrospective study relied on subjective reporting with subsequent 
documentation in medical records. This precluded accurately determining frequency of use, 
compliance, and treatment outcome.  In addition, in that study CPAP treatment was used by 
patients who had more severe OSA. These factors may have confounded the association 
between CPAP use and incident atrial fibrillation. 
In the study of Beckers et al. (1995), only 1 of 17 patients with bradyarrhythmia did not 
achieve resolution of their arrhythmia after CPAP therapy.  Similarly, OSA patients with 
severe cardiac rhythm disturbances reported by Simantirakis et al. (2004) experienced a 
significant reduction in bradycardias from a median of 5.5 per week in the 8-week pre-
treatment period to 0.5 per week in the first 8 weeks of CPAP therapy (P=.028). No 
bradycardias or pauses were reported beginning 5 months after starting treatment through 
14 months of follow-up. 
In response to reports noting an association between OSA and bradyarrhythmias, several 
studies were performed in the last 10 years exploring the potential for pacemakers to resolve 
OSA. As reviewed by Simantirakis & Vardas (2006), positive results were reported from a 
small study of patients with CSA but not in several studies of OSA. These authors 
postulated that in patients with predominantly OSA, the functional changes elicited by atrial 
overdrive pacing have no effect on the anatomical obstructions that cause the apnea. In CSA, 
functional and autonomic nervous system changes were able to affect the 
pathophysiological causes of respiration disturbances during sleep. The recent 
ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities 
(Eptsein et al., 2008) conclude that results of randomized controlled trials (RCTs) failed to 
suggest a role for atrial overdrive pacing in OSA, and that CPAP has been shown to be 
highly effective. However,r the possible role of cardiac pacing in patients with OSA who 
continue to have persistent bradycardia episodes despite CPAP has not been confirmed. 
Data from a subsequent meta-analysis by Baranchuk et al. (2009) of 10 crossover RCTs in 
patients with AHI >=15 that enrolled 175 patients revealed that atrial overdrive pacing 
caused a significant 4.65 episode/h reduction in AHI (P=.01). However, this was 
substantially less than that achieved with CPAP treatment reported in the literature and the 
mean 42.5 episode/h reduction achieved in the 3 studies in the meta-analysis that included 
CPAP arms. The authors concluded that, although it was statistically significant, the 
reduction on atrial overdrive pacing was not clinically significant, and that patients with 
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sleep apnea should not be treated with cardiac pacing unless there is a conventional 
indication. Conversely, studies suggest that increased parasympathetic input to the heart 
may be the main mechanism for nocturnal bradycardias (reviewed by Bradley & Flores, 
2009). Therefore, treatment of OSA-induced nocturnal bradycardia may obviate the need for 
cardiac pacing; however, more studies are needed.  
6. Future directions 
Since the first suggestion was made of an association between OSA and cardiovascular 
morbidity and mortality, a rapidly expanding volume of observational data link OSA with 
the development of arrhythmias.  Much research must be done, however, to answer the 
numerous questions that remain.  In addition to larger epidemiological studies, randomized 
controlled trials must be performed that use robust designs similar to those used in 
cardiovascular intervention trials, with standardized definitions and adequate control of 
confounders.   
A major issue with properly investigating OSA and arrhythmias in both research and 
clinical settings is the expense and limited availability of sleep laboratories for the diagnosis 
of OSA. Once OSA is suspected, although other forms of diagnosis have been used, 
polysomnography remains the gold standard for diagnosis. Ambulatory in home devices 
may become a reasonable alternative, particularly in developing countries that have 
availability, access, and cost constraints (Ng et al., 2009). Many other methods are being 
investigated, and reports suggest some of these may be appropriate for initial screening in 
suspected cases, followed by full polysomnography when warranted.  
The Berlin questionnaire has been used as the diagnostic test in some studies, and has been 
validated as part of one study (Gami et al., 2004).  It has also been shown to be comparable 
to other checklists and questionnaires that have been suggested as being valid screening 
tools (Chung et al., 2008a,b).    
The high prevalence of SDB in patients on cardiac pacing prompted several investigations of 
the potential for diagnosing OSA in patients who have rate-responsive pacemakers with 
minute ventilation sensors (Simantirakis & Vardas, 2006). These devices could provide 
preliminary screening for SDB, subsequent monitoring of correlations between arrhythmias 
and apnea/hypopnea events, and evaluate therapeutic efficacy. Limitations include the 
inability to distinguish between central and obstructive apneas and to recognize specific 
sleep stages. However, its benefits can be acquired by interrogating extant devices without 
additional cost in patients with pacemakers; therefore, this may be useful in patients who 
are already on permanent pacemakers, but does not justify pacemaker placement without a 
clinical indication.  
Data have shown that OSA in the setting of cardiac arrhythmias may confer a higher risk of 
stroke and cardiovascular events (Marin et al., 2005) on affected patients,r and early 
treatment of OSA in these patients may reduce cardiovascular morbidity (Kanagala et al., 
2003; Barcena & Fang, 2007). Putting these understandings into practice is necessary. The 
importance of this is exemplified by considering the association between sleep apnea and 
heart failure, which has not resulted in increased vigilance or therapy. For example, despite 
the high prevalence (40% to 60%) of sleep apnea in heart failure, a recent study was reported 
summarizing data in U.S. Medicare files for over 30,000 incident heart failure patients, of 
whom only 4% were suspected to have sleep apnea (Javaheri et al., 2011).  Less than half of 
these received testing and treatment, and were shown to have significantly greater 2-year 
 
Cardiac Arrhythmias – New Considerations 282 
survivals compared with patients who were not tested (P<.0001) or were tested but not 
treated (P=.009). Policies for addressing issues relating to SDB and arrhythmia should be 
developed and implemented. 
In summary, continuing research should focus on acquiring high quality, standardized data. 
As new data are acquired, policies should be developed and implement to assure screening 
for and treating SDB is available to high risk populations.   
7. Conclusions 
Many studies suggest that there is a significant association between SDB and increased 
prevalence and incidence of cardiac arrhythmias. The pathophysiological pathways between 
arrhythmias and SDB have not been clearly defined, but apnea-induced hypoxia, 
intrathoracic pressure changes, inflammation, and autonomic instability that can lead to 
adverse cardiovascular consequences are presumed to be involved. Larger epidemiological 
studies and RCTs are required to define the association and its mechanisms, which should 
control for confounding and apply standardized definitions. While studies are limited, 
initial results suggest that intervention with CPAP may be effective in reducing the 
arrhythmia burden in the OA population, however, additional RCTs are necessary. 
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1. Introduction   
Ventricular arrhythmia was once regarded uncommon in infants and children, since most 
cardiac arrests were thought to be hypoxia-induced bradycardia followed by asystole. 
Furthermore, ischemic heart disease, the basis for many of the ventricular arrhythmias in 
adults, is rare in pediatric patients. However, with the advent of pediatric critical care, 
improved techniques of extracorporeal life support, increasing awareness of genetic 
abnormalities, and a growing population of patients with congenital heart diseases, 
ventricular arrhythmia is being recognized more frequently in pediatric patients, and is 
becoming a larger management issue.  
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(3) genetic abnormalities associated with ventricular arrhythmias, including conditions such as 
long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and Brugada 
syndrome; and (4) management of ventricular arrhythmias in the PICU.  
2. Non-cardiac clinical entities associated with ventricular arrhythmias  
In a multidisplinary PICU, although it is appropriate to consider ventricular arrhythmias as 
a problem of cardiac origin, other noncardiac etiologies should not be overlooked. Table 1 
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Table 1. Systemic clinical entities associated with ventricular arrhythmia 
2.1 Electrolyte imbalance  
Serum electrolyte imbalance is very common in patients in the PICU for many non-cardiac 
reasons. Potassium is the one with the greatest chances to cause ventricular arrhythmias 
(Schaefer et al., 2005). For, example, we have previously demonstrated a case of life-
threatening ventricular arrythmias and hyperkalemia induced by tumor lysis syndrome 
during the surgical biopsy (Lee et al., 2007). Hyperkalemia causes electrocardiographic 
changes before it reaches the serum potassium levels that cause arrhythmia. With modest 
hyperkalemia, the T wave will become narrow and peaked. Pediatric patients with faster 
resting heart rates tend to have narrower T waves, and peaked T waves may not be 
immediately evident. The QRS widens with higher levels of potassium. With extremely high 
serum potassium, ventricular tachycardia and fibrillation will ultimately occur. 
Hypokalemia causes prolonged QT-U interval and prominent U waves. Although less 
common than hyperkalemia, hypokalemia may also induce polymorphic ventricular 
tachycardia or ventricular fibrillation. Different from the devastating effect of potassium, 
imbalance of serum calcium and magnesium rarely cause significant arrhythmia.  
2.2 Hypothermia 
Hypothermia can slow the rate of sinus rhythm induce ventricular arrhythmia. Mild 
hypothermia results in the development of QT interval prolongation. Deep hypothermia 
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results in AV block and subsequently ventricular arrhythmia and fibrillation (Pilichou  
et al., 2006). With the emergence of hypothermia as a critical management in the ICU, 
such as to improve the outcome especially in the survivors of out-of-hospital cardiac 
arrest and neonatal asphyxia, ventricular arrhythmia can be a growing issue to be 
concerned. Indeed, recent case reports have demonstrated occurrences of ventricular 
tachycardia, fibrillation, and Torsade de pointes during the procedure of hypothermia 
(Schaefer et al., 2005; Matsuhashi et al., 2010), suggesting that monitoring temperature 
levels is very important as the risk of life-threatening may induced by deep hypothermia 
less than 32°C.   
2.3 Infection 
Systemic infection may cause sinus tachycardia due to an increase in metabolic  
demand. Endocarditis near the normal conduction system may cause AV block by direct 
damaging conduction system. Myocarditis, one of the most common pediatric acquired 
heart diseases, is often associated with ventricular tachyarrhythmia. Myocarditis may not 
always be the primary source of infection but may complicate systemic infection, such as 
viremia or viral encephalitis For example, enteroviral infection is one of the most common 
causes of fulminant myocarditis secondary to systemic infection in the setting of pediatric 
critical care (Figure 1.). Rheumatic heart disease, a complication of group A streptococcal 
infection, may cause transient or permanent AV block and sinus node dysfunction.  
Lyme disease, transmitted by the bite of a tick infected with Borrelia burgdorferi, is  




Fig. 1. EKG of ventricular tachycardia in a child with enteroviral encephalitis complicated 
with fulminant myocarditis. 
2.4 Drugs 
Drugs commonly administered in the PICU such as exogenous catecholamines, digoxin, and 
antiarrhythmic drugs may possess potential proarrhythmic effects. Although the arrhythmic 
effects of exogenous catecholamines are usually immediately recognized and treated, 
digoxin toxicity may be more difficult to be recognized due to its insidious effect. Renal 
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function impairment in critically ill patients and administration of medications affecting 
digoxin metabolism are common in the PICU. Digitalis toxicity can result in many forms of 
arrhythmia. Treatment of digitalis toxicity has been simplified with the availability of 
digoxin-immune Fab antibody therapy. Toxicity with other antiarrhythmic drugs has 
become less frequent, such as the use of quinidine and procainamide.  
3. Cardiac entities associated with ventricular arrhythmias  
In the PICU, ventricular arrhythmias are often associated cardiac diseases. We herein 
discuss common cardiac diseases including dilated cardiomyopathy, hypertrophic 
cardiomyopathy and congenital heart diseases.  
3.1 Dilated cardiomyopathy 
Dilated cardiomyopathy (DCM) is the most common severe cardiomyopathy, accounting for 
more than 50% of pediatric cardiomyopathy (Jefferies et al., 2010). Etiology of DCM includes 
immunologic, familial, metabolic, infectious, toxic and neuromuscular causes. These 
patients are prone to ventricular arrhythmia. Treatment is targeted at symptoms, ventricular 
dysfunction and underlying rhythm disturbance. Prophylactic use of implantable cardiac 
defibrillator in the pediatric population is not well established as in adults with ischemic 
cardiomyopathies. In patients with muscular dystrophy, DCM is also common and may be a 
potential cause of mortality in these patients due to ventricular arrhythmia. Figure 3 shows 
non-sustained ventricular tachycardia and a premature ventricular contraction in a patient 




Fig. 2. A patient of Duchenne muscular dystrophy with dilated cardiomyopathy presented 
with chest pain. The Holter EKG record revealed non-sustained ventricular tachycardia and 
a premature ventricular beat. 
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3.2 Hypertrophic cardiomyopathy 
Patients with hypertrophic cardiomyopathy comprise a subgroup with myocardial 
disease that is prone to ventricular arrhythmias. Left ventricular outflow tract obstruction 
may cause coronary artery insufficiency and myocardial ischemia, thus resulting in 
ventricular arrhythmias. Microscopically, hypertrophic cardiomyopathy shows 
disorganization of the cardiac muscle cells, a substrate for arrhythmia. Indeed, this 
microscopic finding seems to put these patients at risk regardless of the degree of outflow 
tract obstruction. Non-sustained ventricular tachycardia is common in children with 
hypertrophic cardiomyopathy. Clinical risk factors of sudden death include family history 
of cardiac arrest, increased QRS duration, myocardial bridging of the left coronary artery, 
increased QT dispersion, ventricular wall thickness, exercise-induced hypotension, and 
syncope. 
3.3 Congenital heart disease post cardiac surgery 
Ventricular arrhythmia has a reported incidence of 1–5% among pediatric patients and 
adults who have had palliative surgery for congenital heart disease (CHD) (Gatzoulis et al., 
2000; Deanfield et al., 1980; Vetter et al., 1982; Kavey et al., 1982). With the advent of surgical 
technique and postoperative care, ventricular arrhythmia and sudden death have been 
reported as causes of early, intermediate and late morbidity and mortality (Garson et al., 
1979). Congenital heart diseases are associated with various types of arrhythmia, depending 
on specific lesions, as shown in Table 3. 
 
 
Congenital heart disease arrhythmia 
Tetralogy of Fallot   Atrial tachycardia  
Double outlet right ventricl Ventricular tachycardia Sinus node dysfunction 
Transposition of the great arteries Ventricular arrhythmias                                      Atrioventricular block  
Ebstein's anomaly Supraventricular tachycardia  
Ventricular septal defect repair Heart block                                        Ventricular arrhythmias  
Atrial septal defect       Atrial tachycardia 
Atrial septal defect repair   Sinus node dysfunction 
Table 2. Congenital heart disease and associated arrhythmias 
Occurrence of ventricular arrhythmia is particularly well known after the repair of tetralogy 
of Fallot (TOF). To relieve the obstruction of right ventricular outflow tract in TOF, it is 
always necessary for the surgeon to make a right ventricular outflow tract incision, to 
augment the outflow tract region, and repair the ventricular septal defect with a patch. 
Thus, the scar after surgical procedures may create a complex substrate for the development 
of arrhythmias. 
Postoperative ventricular arrhythmias have been previously found in 5-10% of patients on 
the 12-lead ECG and in 40-60% on 24-hour Holter EKG in patients undergoing surgery 
(Garson et al., 1990). The advent of surgical techniques and repair at a younger age have led 
to a significant reduction in the incidence of arrhythmias. In fact, transatrial repair has been 
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microscopic finding seems to put these patients at risk regardless of the degree of outflow 
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on specific lesions, as shown in Table 3. 
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to a significant reduction in the incidence of arrhythmias. In fact, transatrial repair has been 
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confirmed to have a beneficial effect on the incidence of ventricular arrhythmias. For 
example, a study comparing the incidence of arrhythmias in two groups of patients who 
underwent transventricular or transatrial repair showing that in the former group, 39.4% 
had significant ventricular arrhythmias, while in the latter group only 2.8% had significant 
arrhythmias (Dietl et al., 1994). 
In addition to ventricular arrhythmias, sudden cardiac death is also an important issue and 
has been reported in 1.5-5% of patients after repair of TOF. In fact, ventricular arrhythmias 
have been regarded as a controversial etiological factor of sudden cardiac death (Garson et 
al., 1980; Katz et al., 1982; Quattlebaum et al., 1975). For example, it has been reported that 
previous ventricular arrhythmias were found in 100%of patients who died suddenly, 
compared to 12%of those who did not (Garson et al., 1985). On the other hand, another 
study followed patients with TOF post surgery for 12 years and found no correlation 
between the degree of ventricular arrhythmias and sudden death (Cullen et al., 1994). 
Therefore, some studies were aimed to elucidate the relationship between ECG indices and 
the risk of ventricular tachycardia and sudden death. A QRS duration >180 ms was found to 
be a very sensitive predictor for the development of VT and sudden death (Gatzoulis et al., 
1995), so is the use of a transannular patch in combination with severe pulmonary valve 
insufficiency (Gatzoulis et al. , 2000). Furthermore, QT dispersion has also been suggested as 
risk factor of sustained ventricular tachycardia (Gatzoulis et al., 1997). Factors associated 
with the development of ventricular tachycardia in patients with TOF are summarized in 
Table 2.  
 
Older age at repair 
Earlier surgical era 
Residual ventricular septal defect  
Prior systemic-to-pulmonary artery shunt 
Trans-annular right ventricular outflow tract patch 
Right ventricular pressure overload 
Right ventricular volume overload 
Ventricular arrhythmias 
Atrial arrhythmias 
Complete heart block 
QRS duration >180 mini-seconds 
 
Table 3. Proposed risk factors for ventricular tachycardia and sudden death after repair of 
tetralogy of Fallot 
Patients with other cardiac lesions may also be at risk for ventricular arrhythmias. Patients 
with aortic stenosis seem to be the highest risk group (Wolfe et al., 1993), with an increased 
mortality risk in patients with greater outflow tract gradients. Thus, all patients with 
repaired and unrepaired congenital heart disease should be considered at increased risk for 
ventricular arrhythmias and associated morbidity, including sudden death. 
Notably, some atypical forms of supraventricular tachycardia can mimic ventricular 
tachycardia, such as supraventricular tachycardia with right bundle branch block after 
repair of TOF or double outlet of right ventricle (Figure 3). However, a wide QRS complex 
tachycardia in a patient who is hemodynamically unstable should be treated as ventricular 
tachycardia until proven otherwise. 
 










Fig. 3. Upper panel: The EKG of a patient with double outlet of right ventricle post palliative 
repair. Even with wide QRS, the inverted p wave following every QRS in aVL suggests 
supraventricular tachycardia instead of ventricular tachycardia. Lower panel: Another 
episode of ventricular tachycardia recorded in the lead II EKG strip in the same patient. 
4. Genetic abnormalities associated with ventricular arrhythmias  
Various forms of genetic abnormality-associated with ventricular arrhythmia may place a 
child at risk for sudden cardiac death. Although some diseases are clinically obvious, 
cardiovascular collapse may be the first symptom in others. Studies of sudden cardiac death 
and ventricular arrhythmia have therefore focused on identification of patients with the 
genetic abnormalities, including long QT syndrome, arrhythmogenic right ventricular 
dysplasia and Brugada syndrome. 
4.1 Long QT syndrome  
The congenital long QT syndrome (LQTS) is a rare but important clinical disorder, with the 
prevalence of 1 to 2500 live births. It includes two hereditary variants under the unifying 
name of "Long QT syndrome" (Schwartz et al., 1975). One is associated with deafness, Jervell 
and Lange-Nielsen syndrome (Jervell et al., 1957; Schwartz et al., 2006), and one is not, 
Romano-Ward syndrome (Romano et al., 1963; Ward et al., 1964). Long-QT syndrome has 
been subdivided into types based on the gene in which causative mutations occur. The most 
prevalent forms are LQT1 and LQT2 (mutations in potassium channels), and LQT3 
(mutation in a sodium channel). The clinical manifestations of the disease may be life-
threatening including syncope, cardiac arrest and sudden death. Electrocardiographic and 
genetic features of LQTS are discussed below. 
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4.1.1 Electrocardiographic features 
4.1.1.1 QT interval duration 
The Bazett's correction for heart rate remains a very useful clinical tool. Conventionally, QTc 
values in excess of 440 ms are considered prolonged; however, values up to 460 ms may still 
be normal among females (Merri et al., 1989). The longer QT values among women and 
becoming evident only after puberty suggest a role for hormonal changes (Stramba et al., 
1995). Even though syncope occurs also in patients with modest QT prolongation or even 
with a normal QT interval., however, it is believed that the longer the QT, the greater is the 
risk for malignant arrhythmias. In fact, when QTc exceeds 500–550 ms, there is a definite 
increase in risk (Priori et al., 2003; Moss et al., 1991) 
4.1.1.2 T wave morphology 
In LQTS both the duration of repolarization and its morphology are altered. The T wave is 
often biphasic or notched because of regional differences in the time course of ventricular 
repolarization, especially prominent in the precordial leads. (Figure 4) 
 
 
Fig. 4. The 12-lead EKG of a 13 year-old girl with long QT syndrome with the clinical 
presentation of recurrent syncopes. The QTc is 645 ms, with typical biphasic T waves in  
V2 and V3. 
4.1.1.3 T wave alternans 
Beat-to-beat alternation of the T wave is a marker of electrical instability suggesting the 
diagnosis of LQTS. It may be present at rest but most commonly appears during emotional 
or physical stresses and may sometimes precede torsades de pointes.   
4.1.1.4 Sinus pauses 
Sudden pauses in sinus rhythm longer than 1.2 seconds that are not related to sinus 
arrhythmia may be present in LQTS patients and may contribute to the initiation of 
ventricular arrhythmias. Their occurrence in LQT3 patients represents an important 
warning signal that warrants further life-saving management. 
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4.1.2 Genetic etiologies of LQTS 
Since 1995, following the first identification of the first three LQTS genes associated with the 
most frequently encountered LQTS variants LQT1, LQT2, and LQT3, there has been 
growing identifications of genes associated with LQTS (Wang et al., 1995; Curran et al., 1995; 
Wang et al., 1996) including the genes for LQT4 through LQT10 (Table 3)  
 
LQTS subtypes Gene Prevalence (%)  
LQT1  KCNQ1 50 
LQT1  KCNQ1 35 
LQT2 KCNH2 10 
LQT3 SCN5A <5 
LQT4 ANK2 <5 
LQT5  KCNE1 <5 
LQT6 KCNE2 <5 
LQT7  KCNJ2 <5 
LQT8  CACNA1c <5 
LQT9 CAV3 <5 
LQT10 SCN4B <5 
Table 4. Long QT syndrome (LQTS) subtypes, disease-associated genes and prevalenc 
4.1.3 Association between sudden infant death syndrome and LQTS 
Sudden infant death syndrome (SIDS) is the leading cause of sudden death during the first 
year of life. The causes of SIDS remain a mystery, even with a lot of theories focused on 
dysfunctional control of respiratory or cardiac function (Schwartz et al., 1988). However, 
there are some evidence showing the association between SIDS and LQTS. For example, a 
large cohort study measuring the QT interval during the first week of life in more than 
30,000 infants and following them for occurrence of SIDS demonstrated that infants who 
died of SIDS had a longer QTc than the survivors and the victims from other causes 
(Schwartz et al., 1998). In addition, in a study of Norway (Arnestad et al., 2007), based on 
201 SIDS victims and 187 controls, mutations in LQTS genes were identified. These data 
justify the rationale of neonatal ECG screening and the guidelines proposed by the Task 
Force of the European Society of Cardiology (Schwartz et al., 2002) Therefore, future aim is 
the prevention of those sudden deaths due to unrecognized LQTS which may result in SIDS.  
4.2 Arrhythmogenic right ventricular dysplasia 
Arrhythmogenic right ventricular dysplasia (ARVD) is a predominantly genetically 
determined and heritable form of cardiomyopathy that may lead to right ventricular failure, 
ventricular arrhythmias, and sudden cardiac death. It is uniquely characterized by the 
replacement of myocytes by adipose and fibrous tissue in histology. The estimated prevalence 
of ARVD ranges from 1 in 2,000 to 1 in 5,000, with a predominance in men than women, with 
an approximate ratio of 3:1 (Corradoet al., 2006). Twelve genes have been identified to be 
associated with ARVD (Table 4). These genes are responsible for encoding several components 
of the cardiac desmosome. Dysfunctional desmosomes cause defective cell adhesion proteins, 
such as plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP-2), and desmoglein-2 
(DSG-2) consequently cause loss of electrical coupling between cardiomyocytes, leading to 
death of cardiomyocyte, fibrous replacement of myocardium and finally arrhythmias 
(Rampazzo et al., 2002 ; McKoy et al., 2000; Gerull et al., 2004; Pilichou et al., 2006). Diagnosis is 
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based on the finding a combination of characteristic abnormalities in family history, 
electrocardiography, cardiac imaging especially MRI and biopsy.  
 
ARVD type Chromosome/locus Gene codes Mode of transmission 
ARVD type 1 14q23 – q24 TGFβ-3 Autosomal dominant 
ARVD type 2 1q42 – q43 RyR2 Autosomal dominant 
ARVD type 3 14q12 – q22  Autosomal dominant 
ARVD type 4 2q32  Autosomal dominant 
ARVD type 5 3q23 Transmembrane protein 43 Autosomal dominant 
ARVD type 6 10p12 – p14  Autosomal dominant 
ARVD type 7 10q22  Autosomal dominant 
ARVD type 8 6p24 Desmoplakin(DSP) Autosomal dominant 
ARVD type 9 12p11 Plakophilin-2(PKP2) Autosomal dominant 
ARVD type 10 18q12 Desmoglein-2(DSG2) Autosomal dominant 
ARVD type 11 18q12.1 Desmocollin-2(DSC2) Autosomal dominant 
ARVD type 12 17q21 Plakoglobin(JUP) Autosomal dominant 
Naxos Disease 17q21 Plakoglobin(JUP) Autosomal recessive 
Table 5. Genes mutations associated with arrhythmogenic right ventricular dysplasia 
Therapeutic options are limited due to the progressive course of ARVD. Competitive 
athletics should be avoided. It is generally believed that patients who meet the Task Force 
criteria for ARVD are at high risk for sudden cardiac death and should undergo ICD 
placement (Marcus et al., 2010). The role of electrophysiologic study and catheter ablation in 
ARVD is not well established, and but it is frequently used as a palliative measure in the 
setting of refractory ventricular tachycardia. Even though sotalol may be effective in 
patients with ARVD and ventricular tachycardia, heart transplantation is the choice for 
patients with refractory ventricular arrhythmias and progressive heart failure. 
4.3 Brugada syndrome 
Brugada syndrome is a genetic disease characterized by the occurrence of cardiac 
arrhythmias and sudden cardiac death in young individuals without evidence of structural 
heart disease. In fact, Brugada syndrome is associated with structural and functional 
abnormalities in the sodium channel. Because of the absence of structural heart 
abnormalities, Brugada syndrome is classified as a cardiac “channelopathy”. 
Genetic studies have determined that more than one gene is capable of causing this syndrome. 
Initially, mutations in only one gene, SCN5A, encoding the cardiac sodium channel, have been 
identified. Recently, flourishing gene mutations have been identified, such as mutations in the 
CACNA1c and CACNB2b genes, coding the calcium channels, and mutations in the KCNE3 
gene, coding a subunit of the potassium channel (Antzelevitch et al., 2007; Delpón et al., 2008). 
There is some evidence showing that the electrical disorders associated with Brugada 
syndrome are mainly located in the right ventricle, particularly in the outflow tract of right 
ventricle. These patients typically present an ECG pattern characterized by ST segment 
elevation in the right precordial leads and a RBBB (Brugada et al., 1992). 
Brugada syndrome is thought to be responsible for 4% to 12% of all sudden cardiac death 
and for up to 20% of sudden cardiac death in subjects without structural heart disease 
(Brugada et al., 2002). Sudden cardiac death associated with Brugada syndrome is caused by 
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polymorphic ventricular tachycardia or ventricular fibrillation (Antzelevitch et al., 2006). 
Unfortunately, because the ECG is often dynamic and concealed, it is difficult to estimate 
the real prevalence of this disease (Nademanee et al., 1997). However, it is believed that the 
prevalence is less frequent in western countries and higher in Southeast Asia. In fact, 
Brugada syndrome is considered to be the major cause of natural death in young 
individuals in Thailand and the Philippines (Miyasaka et al., 2001; Donohue et al., 2008). 
5. Management of ventricular arrhythmias in the PICU 
The major issue for a pediatric intensivist regarding management of ventricular arrhythmias in 
the PICU is to cope with postoperative arrhythmias in patients with congenital heart diseases 
(CHD). In these patients, ventricular arrhythmias may occur in the early postoperative stage, 
caused by surgical procedure, or in the late stage, caused by a residual structural defect or scar 
tissue. In addition to early and late postoperative management, catheter ablation and 
implantable cardioverter-defibrillators (ICD) will also be discussed in this section. 
5.1 Early postoperative ventricular arrhythmias 
Early postoperative arrhythmias are defined as occurrence within the first 10 days after 
surgery. Patients with CHD who have hemodynamically unstable early postoperative 
ventricular tachycardia or ventricular fibrillation require immediate treatment, as suggested 
by the AHA guidelines for cardiopulmonary resuscitation. After stabilizing the airway and 
breathing, cardiopulmonary resuscitation should be started immediately (Kleinman et al., 
2010). If the ventricular tachycardia persists after cardiopulmonary resuscitation, 
synchronized electrical cardioversion (0.5–1.0 J/kg) should be administered. If a second 
shock (2.0 J/kg) is unsuccessful, amiodarone or procainamide should be considered before 
administering a third shock. If the ventricular arrhythmias are successfully converted to 
sinus rhythm, potential causes for the ventricular arrhythmias must be identified. In patients 
without identifiable causes, close observation and administration of intravenous 
antiarrhythmic medications are necessary.  
Amiodarone is the antiarrhythmic treatment for pulseless ventricular tachycardia 
recommended by the AHA Committee on Resuscitation guidelines. Amiodarone dosing 
should adhere to the following regimen for pediatric patients: an intravenous bolus 
administered at 5–10 mg/kg and then maintenance infusion at 5–15 mg/kg/day. The safety 
and efficacy of amiodarone has been documented in studies performed in children with 
CHD (Drago F et al., 1998). For patients with stable ventricular tachycardia, the dosage and 
desired levels of antiarrhythmic medications are shown in Table 6. 
 
Drug Dosage Desired  level 
Propranolol 0.05 - 0.1 mg/kg/dose q6h 20 - 150 ng/ml 
Procainamide Loading: 5 - 15 mg/kg in 30 min Infusion: 20 – 80 μg/kg/min 4 – 8 μg/ml 
Lidocaine Loading: 1 - 2 mg/kg in 30 min Infusion: 10 – 50 μg/kg/min 1-5 μg/ml 
Mexiletine 3 - 5 mg/kg/dose q8h 0.5 - 2.0 μg/ml 
Amiodarone Loading: 5 - 10 mg/kg in 30 min Infusion: 5 - 15 mg/kg/day 1.5 - 2.5 μg/ml 
Table 6. Pharmacologic management of ventricular tachycardia in pediatric patients. 
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placement (Marcus et al., 2010). The role of electrophysiologic study and catheter ablation in 
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patients with refractory ventricular arrhythmias and progressive heart failure. 
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Brugada syndrome is a genetic disease characterized by the occurrence of cardiac 
arrhythmias and sudden cardiac death in young individuals without evidence of structural 
heart disease. In fact, Brugada syndrome is associated with structural and functional 
abnormalities in the sodium channel. Because of the absence of structural heart 
abnormalities, Brugada syndrome is classified as a cardiac “channelopathy”. 
Genetic studies have determined that more than one gene is capable of causing this syndrome. 
Initially, mutations in only one gene, SCN5A, encoding the cardiac sodium channel, have been 
identified. Recently, flourishing gene mutations have been identified, such as mutations in the 
CACNA1c and CACNB2b genes, coding the calcium channels, and mutations in the KCNE3 
gene, coding a subunit of the potassium channel (Antzelevitch et al., 2007; Delpón et al., 2008). 
There is some evidence showing that the electrical disorders associated with Brugada 
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polymorphic ventricular tachycardia or ventricular fibrillation (Antzelevitch et al., 2006). 
Unfortunately, because the ECG is often dynamic and concealed, it is difficult to estimate 
the real prevalence of this disease (Nademanee et al., 1997). However, it is believed that the 
prevalence is less frequent in western countries and higher in Southeast Asia. In fact, 
Brugada syndrome is considered to be the major cause of natural death in young 
individuals in Thailand and the Philippines (Miyasaka et al., 2001; Donohue et al., 2008). 
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The major issue for a pediatric intensivist regarding management of ventricular arrhythmias in 
the PICU is to cope with postoperative arrhythmias in patients with congenital heart diseases 
(CHD). In these patients, ventricular arrhythmias may occur in the early postoperative stage, 
caused by surgical procedure, or in the late stage, caused by a residual structural defect or scar 
tissue. In addition to early and late postoperative management, catheter ablation and 
implantable cardioverter-defibrillators (ICD) will also be discussed in this section. 
5.1 Early postoperative ventricular arrhythmias 
Early postoperative arrhythmias are defined as occurrence within the first 10 days after 
surgery. Patients with CHD who have hemodynamically unstable early postoperative 
ventricular tachycardia or ventricular fibrillation require immediate treatment, as suggested 
by the AHA guidelines for cardiopulmonary resuscitation. After stabilizing the airway and 
breathing, cardiopulmonary resuscitation should be started immediately (Kleinman et al., 
2010). If the ventricular tachycardia persists after cardiopulmonary resuscitation, 
synchronized electrical cardioversion (0.5–1.0 J/kg) should be administered. If a second 
shock (2.0 J/kg) is unsuccessful, amiodarone or procainamide should be considered before 
administering a third shock. If the ventricular arrhythmias are successfully converted to 
sinus rhythm, potential causes for the ventricular arrhythmias must be identified. In patients 
without identifiable causes, close observation and administration of intravenous 
antiarrhythmic medications are necessary.  
Amiodarone is the antiarrhythmic treatment for pulseless ventricular tachycardia 
recommended by the AHA Committee on Resuscitation guidelines. Amiodarone dosing 
should adhere to the following regimen for pediatric patients: an intravenous bolus 
administered at 5–10 mg/kg and then maintenance infusion at 5–15 mg/kg/day. The safety 
and efficacy of amiodarone has been documented in studies performed in children with 
CHD (Drago F et al., 1998). For patients with stable ventricular tachycardia, the dosage and 
desired levels of antiarrhythmic medications are shown in Table 6. 
 
Drug Dosage Desired  level 
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5.2 Late postoperative ventricular arrhythmias 
All patients with CHD who have undergone surgery are at risk of late postoperative 
ventricular arrhythmias. Therefore, they require follow-up for routine electrocardiography 
to evaluate the patient’s conduction system for potential bundle branch block. Evaluation of 
sinus node function, abnormalities of ST and T wave, and premature ventricular contraction 
are important, since these abnormalities can trigger the occurrence of ventricular 
tachycardia or sudden death in these patients. In addition, Holter EKG can detect 
asymptomatic ventricular arrhythmias in patients with CHD, for example in up to 9% of 
postoperative TOF (Chandar et al., 1990). Furthermore, the electrophysiologic study with 
programmed ventricular stimulation may have a role in the risk stratification because some 
investigators found that the induction of polymorphic VT could predict VT and sudden 
cardiac death (Khairy et al., 2004). The most common types of CHD associated with 
postoperative ventricular arrhythmia are listed in Table 7. 
 
Tetralogy of Fallot  
Trasposition of great arteries 
Aortic stenosis 
Ventricular septal defect  
Atrail septal defect, secundum type 




Table 7. Types of congenital heart defects commonly associated with postoperative 
ventricular arrhythmia.  
5.3 Catheter ablation 
There is some recent evidence addressing the role of catheter ablation in the treatment of 
ventricular tachycardia in CHD patients. For example, in a study of 10 patients with TOF 
who received noncontact mapping due to hemodynamically unstable ventricular 
tachycardia (Kriebelet al., 2007), ablation was achieved in eight patients and for all of them 
ventricular tachycardia was not inducible at the end of the procedure. Another study of 
electroanatomical contact mapping and catheter ablation in patients with ventricular 
tachycardia after repair of CHD demonstrated that isthmuses between patches and tricuspid 
annulus, right ventricular outflow tract, or pulmonary annulus were responsible for the 
reentrant tachycardias (Zeppenfeld et al., 2007). Ablation of these isthmuses abolished all 
ventricular tachycardias. Accordingly, there is a potential role for ventricular tachycardia 
ablation in patients after repair of CHD. 
5.4 Implantable cardioverter-defibrillators 
An implantable cardioverter-defibrillator (ICD) is recommended in CHD patients with a 
positive ventricular stimulation in the electrophysiology study. However, it is sometimes 
highly technical to implant a cardioverter-defibrillator transvenously in these patients due to 
their structural anomaly and small size of these patients. In addition, implanting a transvenous 
ICD system in patients with intracardiac shunting is not recommended, because the risk of 
thromboembolic events. The implantation of a transvenous ICD in patients younger than 8 
years of age can be a high-risk procedure because of complications such as venous occlusion, 
infection or wound dehiscence because of limited prepectoral tissue.  
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Surgical implantation is required when an ICD cannot be implanted transvenously. As such, 
the generator or device is implanted in the abdomen with the leads sewn into the 
epicardium. This surgical method is associated with some complications including 
postpericardiotomy syndrome, constrictive pericarditis, lead-induced trauma and lead 
failure (Stefanelli et al., 2002; Ketteringet al., 2004). Recent reports have described less 
invasive ways to implant an epicardial ICD in patients who are either too small or have 
mixing lesions (Cannon et al., 2006; Snyder et al., 2007). An additional problem is that 
patients may receive inappropriate shocks for sinus tachycardia due to improper 
programming. Accordingly, before programming an ICD in a patient with repaired CHD, 
patients should undergo exercise testing to determine their peak heart rate. Notably, some 
patients require adjuvant therapy with either nadolol or amiodarone, even with an ICD, to 
limit their peak heart rate and decrease chances of inappropriate shocks. 
6. Conclusions 
Ventricular tachycardias in the setting of PICU are a diverse group of rhythm disorders 
different from those seen in the adults with ischemic heart disease. They are not only 
different in ventricular substrates and etiologies, but also in the electrophysiologic 
mechanisms. Furthermore, ventricular arrhythmia after surgery for CHD requires a 
comprehensive evaluation including the clinical state of the patient, the cardiac anatomy, 
previous surgical history, and the electrophysiologic patterns of the arrhythmia. Most 
importantly, ventricular arrhythmia is an important cause of sudden death in the infants 
and children, so pediatric intensivists should be familiar with risk factors and emergent 
management of these life-threatening scenarios to ensure a better outcome.  
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5.2 Late postoperative ventricular arrhythmias 
All patients with CHD who have undergone surgery are at risk of late postoperative 
ventricular arrhythmias. Therefore, they require follow-up for routine electrocardiography 
to evaluate the patient’s conduction system for potential bundle branch block. Evaluation of 
sinus node function, abnormalities of ST and T wave, and premature ventricular contraction 
are important, since these abnormalities can trigger the occurrence of ventricular 
tachycardia or sudden death in these patients. In addition, Holter EKG can detect 
asymptomatic ventricular arrhythmias in patients with CHD, for example in up to 9% of 
postoperative TOF (Chandar et al., 1990). Furthermore, the electrophysiologic study with 
programmed ventricular stimulation may have a role in the risk stratification because some 
investigators found that the induction of polymorphic VT could predict VT and sudden 
cardiac death (Khairy et al., 2004). The most common types of CHD associated with 
postoperative ventricular arrhythmia are listed in Table 7. 
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There is some recent evidence addressing the role of catheter ablation in the treatment of 
ventricular tachycardia in CHD patients. For example, in a study of 10 patients with TOF 
who received noncontact mapping due to hemodynamically unstable ventricular 
tachycardia (Kriebelet al., 2007), ablation was achieved in eight patients and for all of them 
ventricular tachycardia was not inducible at the end of the procedure. Another study of 
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positive ventricular stimulation in the electrophysiology study. However, it is sometimes 
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their structural anomaly and small size of these patients. In addition, implanting a transvenous 
ICD system in patients with intracardiac shunting is not recommended, because the risk of 
thromboembolic events. The implantation of a transvenous ICD in patients younger than 8 
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Surgical implantation is required when an ICD cannot be implanted transvenously. As such, 
the generator or device is implanted in the abdomen with the leads sewn into the 
epicardium. This surgical method is associated with some complications including 
postpericardiotomy syndrome, constrictive pericarditis, lead-induced trauma and lead 
failure (Stefanelli et al., 2002; Ketteringet al., 2004). Recent reports have described less 
invasive ways to implant an epicardial ICD in patients who are either too small or have 
mixing lesions (Cannon et al., 2006; Snyder et al., 2007). An additional problem is that 
patients may receive inappropriate shocks for sinus tachycardia due to improper 
programming. Accordingly, before programming an ICD in a patient with repaired CHD, 
patients should undergo exercise testing to determine their peak heart rate. Notably, some 
patients require adjuvant therapy with either nadolol or amiodarone, even with an ICD, to 
limit their peak heart rate and decrease chances of inappropriate shocks. 
6. Conclusions 
Ventricular tachycardias in the setting of PICU are a diverse group of rhythm disorders 
different from those seen in the adults with ischemic heart disease. They are not only 
different in ventricular substrates and etiologies, but also in the electrophysiologic 
mechanisms. Furthermore, ventricular arrhythmia after surgery for CHD requires a 
comprehensive evaluation including the clinical state of the patient, the cardiac anatomy, 
previous surgical history, and the electrophysiologic patterns of the arrhythmia. Most 
importantly, ventricular arrhythmia is an important cause of sudden death in the infants 
and children, so pediatric intensivists should be familiar with risk factors and emergent 
management of these life-threatening scenarios to ensure a better outcome.  
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1. Introduction  
This chapter proposes a psychological approach to the cardiac arrhythmias. Initially, 
psychosocial risk factors highlighted in the specialized literature will be reviewed: 
socioeconomic status, social support, age, gender, type A behavior pattern, stress and 
depression. Following this, studies regarding the impact of negative emotions and positive 
emotions on cardiac rhythm will be reported, with emphasis on the investigation conducted 
during the Holter monitoring. Finally, prospects for future research will be outlined and the 
role of the psychologist in Cardiology will be discussed.  
2. Psychosocial risk factors 
Having the control and prevention of heart disease as their main goal, many researchers, 
both in Biomedicine and Psychology, have struggled to identify its predisposing elements. 
Risk factors can be initiators, promoters, potentiators or precipitators, according to the 
disease stage in which they operate. However, from the psychological point of view, the 
most interesting distinction is that which distinguishes them as modifiable (e.g. smoking 
and sedentary lifestyle), partially modifiable (e.g. menopause, and high waist-hip ratio) and 
non-modifiable (e.g. family history and age).  
Today, it has been established that well known organic risk factors - such as hypertension, 
hypercholesterolemia, obesity and diabetes - explain only 40% of the occurrence of cardiac 
disease (Kubzansky & Kawachi, 2000). In fact, empirical studies have demonstrated the 
relationship between cardiovascular diseases and psychosocial factors, such as the 
accumulation of stress, the type A behavior pattern, hostility and depression. That is, the 
literature indicates that psychosocial factors act synergistically with biological factors, 
increasing the predisposition to cardiac events (Frasure-Smith & Lesperance, 1998, Rozanski 
et al., 1999).  
Some of the most widely studied psychosocial factors will be addressed next. 
2.1 Socioeconomic status 
Low socioeconomic status is associated with an increase in unhealthy behavior and other 
harmful psychosocial factors, significantly contributing to an increase of risk in healthy 
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people, and with a worse prognosis in people with installed coronary artery disease 
(Rozanski et al., 1999). Linked to these conditions are the difficulties of: access to health 
services, adherence to prescribed care, nutritional diet composition and installation of an 
adequate sanitary network (Gallo & Mathews, 2003; Lotufo, 1996). 
Some studies suggest that, on one hand, the lower levels of socio-economic status precede 
the development of depressive symptoms and disorders, and of anxiety. Conversely, it is 
believed the socioeconomic status tends to diminish in individuals with impaired physical 
or emotional health. Therefore, it is increasingly accepted that these factors interact in a 
dynamic and reciprocal way (Gallo & Mathews, 2003). 
2.2 Social support 
Population surveys have found relationships between coronary artery disease and simple 
indicators of social support, such as marital status and the habit of visiting friends (Frasure-
Smith & Lesperance, 1998; Rozanski et al., 1999). The effects of the social support depend on 
both the nature of the receiver and the source of the support. Studies have shown that 
pessimistic individuals do not benefit from social support and that the support given by 
friends is more effective than that given by strangers. In general, people with a social 
support network or that feel less alone live longer and in a healthier way, regardless of 
gender, because the social support directly affects the physiological responses to stress 
(Glynn et al., 1999). 
In postmortem studies with cynomolgus monkeys, it was found that females raised in 
isolation presented more coronary atherosclerosis than isolated males and than specimens 
raised in groups. The incidence of atherosclerosis in these females was four times higher 
than in females raised in social groups and is associated with the weakening of ovarian 
function, hypercholesterolemia and exaggerated heart rate responses (Rozanski et al., 1999). 
These results suggest that females are more susceptible to social isolation.  
Berkman and Syme (1979, as cited in Eaker, 1998) found that the number of social ties is 
inversely related to total mortality among women. Regarding mortality from coronary 
diseases, it was observed that the only significantly related element was the absence of 
social groups or communities. 
High levels of perceived social support confer a lower risk for future cardiac events 
(Rozanski at al., 1999). Berkman et al. (1992, as cited in Eaker, 1998) found data suggestive, 
although limited, that social support is related to increased post-myocardial infarction 
survival. Thus, the probability of the first myocardial infarction being fatal is higher among 
unmarried men than married ones (Glynn et al., 1999).  
Social support facilitates the prognosis of coronary artery disease by predisposal to 
adherence to treatment and to modification of risk factors, as well as alleviating the 
emotional and physical responses to environmental stress (Frasure-Smith & Lesperance, 
1998). In addition, social support prevents the engagement in risk behaviors such as 
smoking, consumption of fatty foods and excessive alcohol consumption. Social support 
reduces the arterial pressure levels and the cardiac response in the face of stressor stimuli in 
humans, with an inverse relationship between levels of adrenaline in the urine, the degree of 
social support and resting heart rate (Rozanski et al., 1999). 
2.3 Age 
Age remains one of the major risk factors for coronary diseases. Hypertension, the coronary 
artery diseases and cardiac insufficiency are common in the elderly, encouraging the 
 
Psychological Approach to the Cardiac Arrhythmias: A Focus on the Emotions 
 
309 
perception that there is a general decline in cardiovascular function associated with aging. 
Age causes specific changes in the cardiovascular system, such as prolonged duration of the 
contraction and relaxation and decreased chronotropic response to catecholamines 
(Schulman, 1981). Fleg and Kennedy (1982, as cited in Carvalho-Filho, 2000) found 
ventricular arrhythmias in 80% and supraventricular arrhythmias in 88% of a sample of 
individuals of both sexes, aged between 60 and 85 years. In the sample studied by Chandra 
et al. (1988, as cited in Carvalho-Filho, 2000), the prevalence was 93.2%, both for ventricular 
arrhythmias as well as supraventricular arrhythmias.  
However, age is only a risk factor for coronary diseases when over 65 years, though not for 
idiopathic arrhythmias, as demonstrated in the study of Lane et al. (2005). These authors 
found that patients with idiopathic ventricular fibrillation were significantly younger (36.0  
11.6 years) than patients with coronary disease (57.1  8.1 years).  
It must be considered that in situations of stress, older individuals manifest less increase in 
cardiac reactivity than younger people. Despite perceiving them with the same intensity, 
older adults present less physiological reactivity to the emotions and worry less about 
inhibiting them. It is possible that the decrease in cardiac reactivity faced with emotions is 
due to physiological aging, similar to what happens in other biological systems, or that it is 
the result of changes in the emotional regulation skills, especially in relation to the 
internalization and externalization of the emotions (Labouvie-Vief et al., 2003). Uchino et al. 
(2005) found evidence of increased cardiac and vascular reactivity to stress in older 
individuals and that age predicts an increase in systolic arterial pressure related to stress.  
Although physiological aging predisposes for the emergence of cardiac diseases, maturity 
with respect to the emotions and the changes in social relationships could act as protectors 
for events or other complications, since this preserved the cognitive resources. The 
importance of the nature of social relationships also changes as a result of age. Thus, the 
Alameda County Study found that marital status was more important among the 
participants under 60 years of age at the beginning of the study, whereas among the 
participants over 65 years of age, the bonds of friendship and with other family members 
were more significant to predict mortality (Stansfeld & Fuhrer, 2002). 
2.4 Gender 
Eaker (1998) suggests that psychosocial risk factors for cardiac disease are the same for both 
genders. However, the male gender appears as a risk factor because the research has focused 
on analyzing more men than women. Studies regarding prevalence indicate that the high 
mortality rates among women were due to the high incidence in this group and not a 
reflection of a differentiated service (Lotufo, 1996). In other words, hormonal factors, genetic 
inheritance, differences in cerebral structure and function, and psychosocial factors seem to 
be associated with the prevalence of coronary disease among women. 
Among the psychosocial factors, the psychological style and mechanisms, the social and 
family role exercised by women, and social and professional changes are increasing 
highlighted (Perez et al., 2005). The climacteric stage, in turn, is related to various 
psychological symptoms and complaints, such as irritability, anxiety and depression, and 
these symptoms are exacerbated in women who have lost their social role and are unable to 
establish new existential goals (Favarato & Aldrighi, 2001). 
Studies also show that the prognosis of coronary diseases is worse in women than in men. 
Data from the American Angioplasty Registry show that the success rate of myocardial 
revascularization and coronary angioplasty surgeries are similar, however, the 
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cardiac reactivity than younger people. Despite perceiving them with the same intensity, 
older adults present less physiological reactivity to the emotions and worry less about 
inhibiting them. It is possible that the decrease in cardiac reactivity faced with emotions is 
due to physiological aging, similar to what happens in other biological systems, or that it is 
the result of changes in the emotional regulation skills, especially in relation to the 
internalization and externalization of the emotions (Labouvie-Vief et al., 2003). Uchino et al. 
(2005) found evidence of increased cardiac and vascular reactivity to stress in older 
individuals and that age predicts an increase in systolic arterial pressure related to stress.  
Although physiological aging predisposes for the emergence of cardiac diseases, maturity 
with respect to the emotions and the changes in social relationships could act as protectors 
for events or other complications, since this preserved the cognitive resources. The 
importance of the nature of social relationships also changes as a result of age. Thus, the 
Alameda County Study found that marital status was more important among the 
participants under 60 years of age at the beginning of the study, whereas among the 
participants over 65 years of age, the bonds of friendship and with other family members 
were more significant to predict mortality (Stansfeld & Fuhrer, 2002). 
2.4 Gender 
Eaker (1998) suggests that psychosocial risk factors for cardiac disease are the same for both 
genders. However, the male gender appears as a risk factor because the research has focused 
on analyzing more men than women. Studies regarding prevalence indicate that the high 
mortality rates among women were due to the high incidence in this group and not a 
reflection of a differentiated service (Lotufo, 1996). In other words, hormonal factors, genetic 
inheritance, differences in cerebral structure and function, and psychosocial factors seem to 
be associated with the prevalence of coronary disease among women. 
Among the psychosocial factors, the psychological style and mechanisms, the social and 
family role exercised by women, and social and professional changes are increasing 
highlighted (Perez et al., 2005). The climacteric stage, in turn, is related to various 
psychological symptoms and complaints, such as irritability, anxiety and depression, and 
these symptoms are exacerbated in women who have lost their social role and are unable to 
establish new existential goals (Favarato & Aldrighi, 2001). 
Studies also show that the prognosis of coronary diseases is worse in women than in men. 
Data from the American Angioplasty Registry show that the success rate of myocardial 
revascularization and coronary angioplasty surgeries are similar, however, the 
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postoperative complications are greater in women. In general, women have a greater age, 
and a higher prevalence of diabetes mellitus, hypertension, angina and cardiac insufficiency 
(Lima & Nussmacher, 1996).  
Frasure-Smith and Lesperance (1998) suggest that the association between cardiac diseases 
and depression is similar in men and women. However, the majority of research is performed 
on men, with a proportion of 2:1, even though the incidence of depression and anxiety is 
higher in women (Kubzansky & Kawachi, 2000; Perez, 2004). There are also few studies on the 
effect of hostility in women. The type A behavior pattern did not present an association with 
the incidence of coronary disease in women (Eaker, 1998). In contrast, Favarato and Aldrighi 
(2001) compared various aspects related to the quality of life during menopause and 
concluded that sadness, tearfulness, nervousness and dissatisfaction with life were more 
commonly reported by women with coronary pathologies than by the control group.  
The gender differences in the incidence of coronary artery disease and atherosclerosis are 
attributed to the effects of estrogen. Pre-menopausal women, or those on hormone replacement 
therapy, have relative protection from coronary disease, ischemic stroke and atherosclerosis 
(Lima & Nussmacher, 1996). However, it must be remembered that the curve of incidence of 
these pathologies in women has a delay of approximately 10 years when compared to men. It is 
assumed, therefore, that atherosclerosis progresses for years and the clinical symptoms 
observed in the menopause began years before (Perez, 2004; Rozanski et al., 1999).  
There are biological differences between men and women also in relation to platelet 
aggregation, a factor that predisposes to thrombus formation. In vitro studies found that 
aspirin, the most used drug to inhibit platelet aggregation in the clinical practice, inhibits 
this phenomenon in men but not in women (Lima & Nussmacher, 1996). 
Menopause is also reflected in the incidence of depression, due to estrogens being related to 
serotonin metabolism, in that, their presence would have a similar effect to antidepressants, 
with respect to neurotransmission (Almeida & Fráguas Jr., 1996). Evidence suggests that 
psychosocial stress causes hypothalamic hypogonadism and these ovarian abnormalities 
reduce levels of estrogen, with manifestations ranging from subclinical luteal phase defects 
with regular menstrual intervals to irregular cycles of amenorrhea, hypercholesterolemia, and 
other neuroendocrine and behavioral indicators. Atherosclerosis is therefore accelerated, 
predisposing to coronary artery disease and possibly ischemic stroke (Rozanski et al., 1999).  
The social roles of gender make the reactions different when faced with the same stimulus. 
Men and women may feel anger in the same proportions and for almost the same reasons. 
However, men more freely express their negative emotions, experiencing anger more 
frequently although they repress fear. They express emotions with higher levels of 
physiological activation. In contrast, women report a greater range of emotions and 
verbalize more intensely, repressing both the experience and the expression of anger, 
concern themselves more with the reactions of others. The suppression of anger determined 
by socialization, in women, causes the feeling or demonstration of this emotion to generate 
other negative emotions such as guilt, anxiety, shame and depression (Kubzansky & 
Kawachi, 2000; Lavoiea et al., 2001). This summation of emotions increases physiological 
reactivity, especially among adolescents and young women, a trend that decreases with age 
(Labouvie-Vief et al., 2003; Lavoiea et al., 2001). 
The studies that have investigated marriage as a source of social support found that, among 
men, marriage is a protective factor and among women there is little or no relationship 
between marriage and health. Similarly, divorce or widowhood is more harmful to the 
health of men (Glynn et al., 1999). 
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2.5 Type A behavior pattern 
The Type A behavior pattern (TABP) corresponds to a set of reactions of a person facing a 
situation that seems challenging (Laham, 2001). Friedman and Rosenman identified the 
TABP in the 1950s, and characterized it as a syndrome consisting of hostility, feelings of 
competition and exaggerated commitment to work (Rozanski et al., 1999). This behavioral 
pattern is seen to be more evident in the male gender, though easily identified in women 
when they have to perform competitive professional activities (Almeida & Fráguas Jr., 1996).  
Among the psychological aspects the following also stand out: hyperactivity, restlessness, 
rapidity, hurry, impatience, time urgency, hostility, competitiveness, low frustration 
tolerance, feeling of being under pressure, need to show competence, high sense of 
responsibility and inattention to symptoms of pain or fatigue. As fatigue is the earliest and 
most common symptom of an impending heart attack, the individual postpones seeking 
help by denying or ignoring it (Laham, 2001; Sirois & Burg, 2003).  
Interpersonal relationships are problematic, with characteristics of dominance, tension and 
emotional aggressivity, anger, marital and professional problems, and social mobility and 
inconsistency (Laham, 2001; Sirois & Burg, 2003). 
The physiological manifestations of the TABP are: a) higher cholesterol levels, even in young 
people; b) increased variability in arterial pressure; c) high levels of frequent and prolonged 
sympathetic stimulation; d) cardiovascular and biochemical changes harmful to the heart 
and blood vessels; e) intense discharge of catecholamines; f) greater progression of 
atherosclerosis; g) less decrease in platelet aggregation after ergometric testing; and h) 
greater acceleration of blood coagulation under stress (Laham, 2001). 
The TABP is two times more related to the increase of coronary artery disease and five times 
more related to the recurrence of myocardial infarction (Rozanski et al., 1999). 
Despite this evidence, several other studies have found no link between the TABP and the 
risk of coronary diseases (Rozanski et al., 1999). Studies with patients recovering from 
myocardial infarction suggest that the TABP has a protective effect and population studies 
have reported increases in the prevalence of the TABP simultaneous with decreases in the 
rates of coronary artery disease (Frasure-Smith & Lesperance, 1998).  
2.6 Stress 
Stress, through neurohormonal activation of the hypothalamic-pituitary-adrenal axis, has 
systemic effects that influence the processes of atherosclerosis and thrombogenesis, also 
suggesting associations between psychological stress and cardiac infarction in patients with 
idiopathic ventricular fibrillation. There is evidence that the more stressful events an 
individual experiences in a given period of time, the greater the possibility of an occurrence 
of cardiac events (Frasure-Smith & Lesperance, 1998; Lane et al., 2005).  
The studies on the subject distinguish three modalities of stress: chronic, subacute and acute. 
Chronic stress may be associated with decreased vagal tone, which in itself is an established 
risk factor for cardiac mortality (Lane et al., 2005). The type of chronic stress most studied in 
relation to coronary artery disease is that associated with work. Work activities with high 
demands and low pay are recognized as predictors of cardiac events, relating to greater 
progressions of carotid atherosclerosis and increasing by four times the risk of death 
(Rozanski et al., 1999). 
Subacute stress lasts for some months. Acute stress, in turn, is the type most investigated 
recently by means of longitudinal studies (Lucini et al., 2005; Rozanski et al., 1999). 
Epidemiological studies show an increase in cardiac events in situations of public calamity 
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postoperative complications are greater in women. In general, women have a greater age, 
and a higher prevalence of diabetes mellitus, hypertension, angina and cardiac insufficiency 
(Lima & Nussmacher, 1996).  
Frasure-Smith and Lesperance (1998) suggest that the association between cardiac diseases 
and depression is similar in men and women. However, the majority of research is performed 
on men, with a proportion of 2:1, even though the incidence of depression and anxiety is 
higher in women (Kubzansky & Kawachi, 2000; Perez, 2004). There are also few studies on the 
effect of hostility in women. The type A behavior pattern did not present an association with 
the incidence of coronary disease in women (Eaker, 1998). In contrast, Favarato and Aldrighi 
(2001) compared various aspects related to the quality of life during menopause and 
concluded that sadness, tearfulness, nervousness and dissatisfaction with life were more 
commonly reported by women with coronary pathologies than by the control group.  
The gender differences in the incidence of coronary artery disease and atherosclerosis are 
attributed to the effects of estrogen. Pre-menopausal women, or those on hormone replacement 
therapy, have relative protection from coronary disease, ischemic stroke and atherosclerosis 
(Lima & Nussmacher, 1996). However, it must be remembered that the curve of incidence of 
these pathologies in women has a delay of approximately 10 years when compared to men. It is 
assumed, therefore, that atherosclerosis progresses for years and the clinical symptoms 
observed in the menopause began years before (Perez, 2004; Rozanski et al., 1999).  
There are biological differences between men and women also in relation to platelet 
aggregation, a factor that predisposes to thrombus formation. In vitro studies found that 
aspirin, the most used drug to inhibit platelet aggregation in the clinical practice, inhibits 
this phenomenon in men but not in women (Lima & Nussmacher, 1996). 
Menopause is also reflected in the incidence of depression, due to estrogens being related to 
serotonin metabolism, in that, their presence would have a similar effect to antidepressants, 
with respect to neurotransmission (Almeida & Fráguas Jr., 1996). Evidence suggests that 
psychosocial stress causes hypothalamic hypogonadism and these ovarian abnormalities 
reduce levels of estrogen, with manifestations ranging from subclinical luteal phase defects 
with regular menstrual intervals to irregular cycles of amenorrhea, hypercholesterolemia, and 
other neuroendocrine and behavioral indicators. Atherosclerosis is therefore accelerated, 
predisposing to coronary artery disease and possibly ischemic stroke (Rozanski et al., 1999).  
The social roles of gender make the reactions different when faced with the same stimulus. 
Men and women may feel anger in the same proportions and for almost the same reasons. 
However, men more freely express their negative emotions, experiencing anger more 
frequently although they repress fear. They express emotions with higher levels of 
physiological activation. In contrast, women report a greater range of emotions and 
verbalize more intensely, repressing both the experience and the expression of anger, 
concern themselves more with the reactions of others. The suppression of anger determined 
by socialization, in women, causes the feeling or demonstration of this emotion to generate 
other negative emotions such as guilt, anxiety, shame and depression (Kubzansky & 
Kawachi, 2000; Lavoiea et al., 2001). This summation of emotions increases physiological 
reactivity, especially among adolescents and young women, a trend that decreases with age 
(Labouvie-Vief et al., 2003; Lavoiea et al., 2001). 
The studies that have investigated marriage as a source of social support found that, among 
men, marriage is a protective factor and among women there is little or no relationship 
between marriage and health. Similarly, divorce or widowhood is more harmful to the 
health of men (Glynn et al., 1999). 
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2.5 Type A behavior pattern 
The Type A behavior pattern (TABP) corresponds to a set of reactions of a person facing a 
situation that seems challenging (Laham, 2001). Friedman and Rosenman identified the 
TABP in the 1950s, and characterized it as a syndrome consisting of hostility, feelings of 
competition and exaggerated commitment to work (Rozanski et al., 1999). This behavioral 
pattern is seen to be more evident in the male gender, though easily identified in women 
when they have to perform competitive professional activities (Almeida & Fráguas Jr., 1996).  
Among the psychological aspects the following also stand out: hyperactivity, restlessness, 
rapidity, hurry, impatience, time urgency, hostility, competitiveness, low frustration 
tolerance, feeling of being under pressure, need to show competence, high sense of 
responsibility and inattention to symptoms of pain or fatigue. As fatigue is the earliest and 
most common symptom of an impending heart attack, the individual postpones seeking 
help by denying or ignoring it (Laham, 2001; Sirois & Burg, 2003).  
Interpersonal relationships are problematic, with characteristics of dominance, tension and 
emotional aggressivity, anger, marital and professional problems, and social mobility and 
inconsistency (Laham, 2001; Sirois & Burg, 2003). 
The physiological manifestations of the TABP are: a) higher cholesterol levels, even in young 
people; b) increased variability in arterial pressure; c) high levels of frequent and prolonged 
sympathetic stimulation; d) cardiovascular and biochemical changes harmful to the heart 
and blood vessels; e) intense discharge of catecholamines; f) greater progression of 
atherosclerosis; g) less decrease in platelet aggregation after ergometric testing; and h) 
greater acceleration of blood coagulation under stress (Laham, 2001). 
The TABP is two times more related to the increase of coronary artery disease and five times 
more related to the recurrence of myocardial infarction (Rozanski et al., 1999). 
Despite this evidence, several other studies have found no link between the TABP and the 
risk of coronary diseases (Rozanski et al., 1999). Studies with patients recovering from 
myocardial infarction suggest that the TABP has a protective effect and population studies 
have reported increases in the prevalence of the TABP simultaneous with decreases in the 
rates of coronary artery disease (Frasure-Smith & Lesperance, 1998).  
2.6 Stress 
Stress, through neurohormonal activation of the hypothalamic-pituitary-adrenal axis, has 
systemic effects that influence the processes of atherosclerosis and thrombogenesis, also 
suggesting associations between psychological stress and cardiac infarction in patients with 
idiopathic ventricular fibrillation. There is evidence that the more stressful events an 
individual experiences in a given period of time, the greater the possibility of an occurrence 
of cardiac events (Frasure-Smith & Lesperance, 1998; Lane et al., 2005).  
The studies on the subject distinguish three modalities of stress: chronic, subacute and acute. 
Chronic stress may be associated with decreased vagal tone, which in itself is an established 
risk factor for cardiac mortality (Lane et al., 2005). The type of chronic stress most studied in 
relation to coronary artery disease is that associated with work. Work activities with high 
demands and low pay are recognized as predictors of cardiac events, relating to greater 
progressions of carotid atherosclerosis and increasing by four times the risk of death 
(Rozanski et al., 1999). 
Subacute stress lasts for some months. Acute stress, in turn, is the type most investigated 
recently by means of longitudinal studies (Lucini et al., 2005; Rozanski et al., 1999). 
Epidemiological studies show an increase in cardiac events in situations of public calamity 
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such as earthquakes or war. Thus, during the 1994 earthquake in Los Angeles, rates of 
mortality due to coronary artery disease increased from an average of 4.6 in the previous week 
to 24 on the day of the earthquake (Burg et al., 2004; Lampert et al., 2002; Rozanski et al., 1999). 
During the Korean War autopsies were carried out on soldiers whose average age was 22 
years and coronary lesions were found in 77% of the cases analyzed (Giannotti, 2002). 
The hypothesis that stress causes myocardial ischemia, increased blood pressure or 
electrophysiological changes can be investigated in the laboratory by means of exposure to 
controllable stressors, such as mental arithmetic and verbal fluency tests (Rozanski et al., 1999). 
Approximately half of the patients with symptomatic coronary artery disease present left 
ventricular dysfunction when subjected to mental stress tests (Jain et al., 2001). James et al. 
(2000) found that psychological stress caused by cognitive tests resulted in 
electrophysiological responses in patients with coronary stenosis, but not in patients with 
normal coronary arteries. 
The mental stress tests caused sympathetic activation, increased cardiac rate and arterial 
pressure and reduced left ventricular ejection fraction, however did not produce change in 
the parasympathetic tone (Jain et al., 2001). Even when the cardiac rate increases are small, 
the increases in arterial pressure are substantial when compared to those resulting from 
physical exercise (Rozanski et al., 1999). Previous studies had demonstrated that ischemia 
induced by mental stress is associated with the greatest risk, when compared with ischemia 
induced by exercise (Blumenthal et al., 2005). The increase of the adrenalin serum levels 
seems to relate psychological stress to platelet aggregation (Kubzansky & Kawachi, 2000). 
Patients who present myocardial ischemia when subjected to physical stress tend to also 
present it when subjected to mental stress in laboratory tests. However, myocardial ischemia 
produced by mental stress is not usually perceptible to the conventional electrocardiogram 
and is clinically silent, usually occurring with low heart rate elevations compared with 
physical exercise (Rozanski et al., 1999). 
The frequency and magnitude of ischemia induced by mental stress vary according to the 
type of stressor. When the stressor has a greater emotional load, or is personally relevant, 
such as the task of reporting personal errors or remembering episodes of anger, it results in 
greater increases in the frequency and magnitude of abnormalities of the left ventricular 
wall than those caused by non-specific mental stressors, such as mental arithmetic. It was 
also found that mental stress causes increased coronary vasoconstriction and that the 
coronary microcirculation does not dilate sufficiently (Rozanski et al., 1999). 
Lampert et al. (2002) investigated the occurrence of arrhythmias in situations of daily life. 
Some activities showed potential association with the occurrence of arrhythmias, such as 
driving, discussing and receiving bad news. Physical activity was associated with the period 
preceding the arrhythmia and there was no interaction between physical activity and 
emotions. 
Negative emotions and stress are interconnected, because in determining whether an event 
is stressful, one must know the interpretation of this event for the individual and its 
significance (Kubzansky & Kawachi, 2000). The emotional and psychological involvement of 
the participant is an important component of the mental stress tests. However, studies that 
use cognitive tests as mental stressors found inconsistent results which were difficult to 
replicate. Jain et al. (2001) believe that this is due to the attenuation of the responses caused 
by familiarization, conditioning or adaptation of the participant to the repetition of the tests. 
Recent experimental findings suggests that sympathetic overstimulation resulting from 
stress can increase the concentration of protein kinase C in the central cerebral structures, 
 
Psychological Approach to the Cardiac Arrhythmias: A Focus on the Emotions 
 
313 
such as the prefrontal lobe, leading to a deregulation of the thinking, mood or behavior 
(Lucini et al., 2005). 
2.6.1 Tako-Tsubo syndrome or broken-heart syndrome 
Since the 1990s, the so-called Tako-Tsubo syndrome has been reported in the literature. It is 
also known as ventricular apical ballooning syndrome, transitional broken heart syndrome 
and stress cardiomyopathy. Its pathophysiology is still not sufficiently understood, and the 
syndrome is characterized by chest pain and clinical, electrocardiographic and 
echocardiographic changes that mimick an acute myocardial infarction. It is different of the 
latter condition in that the coronary arteries do not show obstructions and there is 
significant recovery of the ventricle. In general, the syndrome affects women after 
menopause age, between 60 and 75 years old, although cases in children have also been 
reported (Finn et al., 2005; Lemos et al. 2008; Merli et al., 2006).  
It persists for a few weeks and its onset can be precipitated by intense emotional stress such 
as death or illness of a family member, distressing events, arguments with relatives or 
friends, traffic accidents, financial losses, termination of employment and change of 
residence. There is also an increased incidence after natural disasters, such as the 2004 
earthquakes in Japan. Other psychosocial impacts of major events, such as wars and sport 
matches, are frequently associated. Approximately 1-2% of cases of hospitalization because 
of signs of acute myocardial infarction account for this syndrome (Núñez Gil et al., 2009).   
2.7 Depression 
Depression is strongly associated with the neurohormonal imbalance related to the 
pathogenesis of the cardiac diseases and is considered both a primary and secondary risk 
factor (Frasure-Smith & Lesperance, 1998; Pinton et al., 2006). It includes feelings of sadness, 
loneliness, hopelessness, guilt and shame, and has well-defined diagnostic criteria. It occurs 
frequently associated with some type of loss, characterized by a behavioral inhibition, with 
decreased mobilization of the physiological resources (Kubzansky & Kawachi, 2000; 
Rozanski et al., 1999). Depression is twice as common among women (Lavoiea et al., 2001), 
among single people and those without close friends (Almeida & Fráguas Jr., 1996; Perez et 
al., 2005). 
Even with all the evidence associating depression to the cardiac diseases, cardiologists still 
have difficulties in making this association, because the somatic symptoms of fatigue, lack of 
energy, loss or increase in appetite and sleep disturbances are common and can be confused 
with symptoms of the cardiopathy (Perez et al., 2005). 
Not only is depression as a diagnostic entity related to disease. The presence of depressive 
symptoms is also related to the occurrence of cardiac events (Rozanski et al., 1999) and 
increases the risk of mortality by between two and four times (Pinton et al., 2006). 
Depressive symptoms are significantly associated with psychological factors such as 
hopelessness, despondency, apathy, intolerance to frustration and cognitive distortions 
(Perez et al., 2005; Shnek et al., 2001; Sirois & Burg, 2003). Several studies have suggested 
that depression is associated with decreased survival in the short and long term in survivors 
of myocardial infarction (Pitzalis et al., 2001). 
The prevalence of depression is approximately three times higher in patients with coronary 
disease than in the general population (Rozanski et al. 1999; Sirois & Burg, 2003). It is 
estimated that the prevalence of clinically significant depressive disorders in cardiac 
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such as earthquakes or war. Thus, during the 1994 earthquake in Los Angeles, rates of 
mortality due to coronary artery disease increased from an average of 4.6 in the previous week 
to 24 on the day of the earthquake (Burg et al., 2004; Lampert et al., 2002; Rozanski et al., 1999). 
During the Korean War autopsies were carried out on soldiers whose average age was 22 
years and coronary lesions were found in 77% of the cases analyzed (Giannotti, 2002). 
The hypothesis that stress causes myocardial ischemia, increased blood pressure or 
electrophysiological changes can be investigated in the laboratory by means of exposure to 
controllable stressors, such as mental arithmetic and verbal fluency tests (Rozanski et al., 1999). 
Approximately half of the patients with symptomatic coronary artery disease present left 
ventricular dysfunction when subjected to mental stress tests (Jain et al., 2001). James et al. 
(2000) found that psychological stress caused by cognitive tests resulted in 
electrophysiological responses in patients with coronary stenosis, but not in patients with 
normal coronary arteries. 
The mental stress tests caused sympathetic activation, increased cardiac rate and arterial 
pressure and reduced left ventricular ejection fraction, however did not produce change in 
the parasympathetic tone (Jain et al., 2001). Even when the cardiac rate increases are small, 
the increases in arterial pressure are substantial when compared to those resulting from 
physical exercise (Rozanski et al., 1999). Previous studies had demonstrated that ischemia 
induced by mental stress is associated with the greatest risk, when compared with ischemia 
induced by exercise (Blumenthal et al., 2005). The increase of the adrenalin serum levels 
seems to relate psychological stress to platelet aggregation (Kubzansky & Kawachi, 2000). 
Patients who present myocardial ischemia when subjected to physical stress tend to also 
present it when subjected to mental stress in laboratory tests. However, myocardial ischemia 
produced by mental stress is not usually perceptible to the conventional electrocardiogram 
and is clinically silent, usually occurring with low heart rate elevations compared with 
physical exercise (Rozanski et al., 1999). 
The frequency and magnitude of ischemia induced by mental stress vary according to the 
type of stressor. When the stressor has a greater emotional load, or is personally relevant, 
such as the task of reporting personal errors or remembering episodes of anger, it results in 
greater increases in the frequency and magnitude of abnormalities of the left ventricular 
wall than those caused by non-specific mental stressors, such as mental arithmetic. It was 
also found that mental stress causes increased coronary vasoconstriction and that the 
coronary microcirculation does not dilate sufficiently (Rozanski et al., 1999). 
Lampert et al. (2002) investigated the occurrence of arrhythmias in situations of daily life. 
Some activities showed potential association with the occurrence of arrhythmias, such as 
driving, discussing and receiving bad news. Physical activity was associated with the period 
preceding the arrhythmia and there was no interaction between physical activity and 
emotions. 
Negative emotions and stress are interconnected, because in determining whether an event 
is stressful, one must know the interpretation of this event for the individual and its 
significance (Kubzansky & Kawachi, 2000). The emotional and psychological involvement of 
the participant is an important component of the mental stress tests. However, studies that 
use cognitive tests as mental stressors found inconsistent results which were difficult to 
replicate. Jain et al. (2001) believe that this is due to the attenuation of the responses caused 
by familiarization, conditioning or adaptation of the participant to the repetition of the tests. 
Recent experimental findings suggests that sympathetic overstimulation resulting from 
stress can increase the concentration of protein kinase C in the central cerebral structures, 
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such as the prefrontal lobe, leading to a deregulation of the thinking, mood or behavior 
(Lucini et al., 2005). 
2.6.1 Tako-Tsubo syndrome or broken-heart syndrome 
Since the 1990s, the so-called Tako-Tsubo syndrome has been reported in the literature. It is 
also known as ventricular apical ballooning syndrome, transitional broken heart syndrome 
and stress cardiomyopathy. Its pathophysiology is still not sufficiently understood, and the 
syndrome is characterized by chest pain and clinical, electrocardiographic and 
echocardiographic changes that mimick an acute myocardial infarction. It is different of the 
latter condition in that the coronary arteries do not show obstructions and there is 
significant recovery of the ventricle. In general, the syndrome affects women after 
menopause age, between 60 and 75 years old, although cases in children have also been 
reported (Finn et al., 2005; Lemos et al. 2008; Merli et al., 2006).  
It persists for a few weeks and its onset can be precipitated by intense emotional stress such 
as death or illness of a family member, distressing events, arguments with relatives or 
friends, traffic accidents, financial losses, termination of employment and change of 
residence. There is also an increased incidence after natural disasters, such as the 2004 
earthquakes in Japan. Other psychosocial impacts of major events, such as wars and sport 
matches, are frequently associated. Approximately 1-2% of cases of hospitalization because 
of signs of acute myocardial infarction account for this syndrome (Núñez Gil et al., 2009).   
2.7 Depression 
Depression is strongly associated with the neurohormonal imbalance related to the 
pathogenesis of the cardiac diseases and is considered both a primary and secondary risk 
factor (Frasure-Smith & Lesperance, 1998; Pinton et al., 2006). It includes feelings of sadness, 
loneliness, hopelessness, guilt and shame, and has well-defined diagnostic criteria. It occurs 
frequently associated with some type of loss, characterized by a behavioral inhibition, with 
decreased mobilization of the physiological resources (Kubzansky & Kawachi, 2000; 
Rozanski et al., 1999). Depression is twice as common among women (Lavoiea et al., 2001), 
among single people and those without close friends (Almeida & Fráguas Jr., 1996; Perez et 
al., 2005). 
Even with all the evidence associating depression to the cardiac diseases, cardiologists still 
have difficulties in making this association, because the somatic symptoms of fatigue, lack of 
energy, loss or increase in appetite and sleep disturbances are common and can be confused 
with symptoms of the cardiopathy (Perez et al., 2005). 
Not only is depression as a diagnostic entity related to disease. The presence of depressive 
symptoms is also related to the occurrence of cardiac events (Rozanski et al., 1999) and 
increases the risk of mortality by between two and four times (Pinton et al., 2006). 
Depressive symptoms are significantly associated with psychological factors such as 
hopelessness, despondency, apathy, intolerance to frustration and cognitive distortions 
(Perez et al., 2005; Shnek et al., 2001; Sirois & Burg, 2003). Several studies have suggested 
that depression is associated with decreased survival in the short and long term in survivors 
of myocardial infarction (Pitzalis et al., 2001). 
The prevalence of depression is approximately three times higher in patients with coronary 
disease than in the general population (Rozanski et al. 1999; Sirois & Burg, 2003). It is 
estimated that the prevalence of clinically significant depressive disorders in cardiac 
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patients is around 14% to 27%. Psychiatric evaluations showed that 16% of the patients 
studied by Lane et al. (2005) presented moderate or severe depression in the three months 
preceding the cardiac episodes.  
Depression predicts the occurrence of myocardial infarction, angina, angioplasty and/or 
myocardial revascularization surgery, as well as presenting itself as an independent risk 
factor for mortality, with the same prognosis as left ventricular dysfunction and history of 
previous myocardial infarction (Sirois & Burg, 2003). Longitudinal studies have found 
between 1.5 and 2.0 times higher risk for coronary events in people diagnosed with 
depression or with self-reported depressive symptoms (Kubzansky & Kawachi, 2000).  
3. Emotions and their effects on cardiac rhythm 
3.1 Negative emotions and positive emotions 
The conceptual and theoretical description of the emotions has been the subject of much 
debate. However, most experts agree that the emotions comprise affective, cognitive, 
behavioral and neurobiological components which sustain the adaptive behavior (Gallo & 
Mathews, 2003; Kubzansky & Kawachi, 2000). Emotions are perceived as internal 
phenomena that cause external manifestations or signs, being organic or behavioral. 
Emotional experiences must be distinguished from emotional disorders, which are 
psychiatric disorders that encompass diverse symptoms, behavior and cognitive and 
affective processes, occurring infrequently when compared with the emotional experiences 
(Gallo & Mathews, 2003). 
The emotions can be grouped into the positive and negative, however, the specialists still 
disagree about whether these groups are two poles of the same dimension, or form distinct 
dimensions (Gallo & Mathews, 2003). Richman et al. (2005) identified four families of 
positive emotions: joy, interest, contentment and love. Shaver et al. (1987, as cited in Hupka 
et al., 1999) defined six categories of emotions subordinate to the general classification of 
negative and positive emotions: anger, fear, sadness, joy, love and surprise. Within these 
categories, they distributed the emotional lexicons of the English language in several 
subcategories: affection, lust, longing, cheerfulness, zest, contentment, pride, optimism, 
enthrallment, relief, amazement, irritation, exasperation, rage, disgust, envy, torment, 
suffering, sadness, disappointment, shame, neglect, sympathy, horror and nervousness. 
Emotions rarely occur in isolation and there is great variability of expression. Thus, in 
response to stimuli with the same emotional load, some individuals are more responsive 
than others and this tendency has been termed emotional reactivity (Carels et al., 1999). The 
hyperactivity of the sympathetic nervous system leading to exaggerated responses of 
cardiac rate and arterial pressure in situations of engagement, dispute or aversiveness is 
called, by some authors, cardiovascular reactivity (Rozanski et al., 1999). 
The literature suggests that when the style of regulation is more expressive and 
externalized, physiological reactivity is lower (Labouvie-Vief et al., 2003). Specialists also 
suggest that emotional reactivity that deviates from the norm in both directions is related to 
a risk of hypertension and probably also to arrhythmia (Carels et al., 1999; Kubzansky & 
Kawachi, 2000).  
Several measures and criteria have been used in studies regarding emotions, including 
clinical diagnoses of pathologies such as, for example, the definition of depression and 
anxiety (Kubzansky & Kawachi 2000). The majority of studies on emotions use self-reports, 
although this tends toward inaccuracy, because it involves remembering and reconstructing. 
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Some adopt methods of inducing emotions in the laboratory, but the generalization of the 
results cannot be determined (Thomas & Diener, 1990). Longitudinal studies separate the 
participants into “exposed” and “unexposed” to the risk factor and relate the two groups to 
the emergence of the target pathology, however, there is no way to determine if a person 
was exposed or not to a particular emotion (Kubzansky & Kawachi, 2000).  
Even with so many limitations, associations have been found between emotions and disease. 
Emotions can influence the onset of specific diseases or may result from diseases, 
influencing their prognosis. The relationship between emotions and cardiovascular health is, 
therefore, bidirectional, with the cumulative effect over time (Kubzansky & Kawachi, 2000). 
Studies have shown that patients with ambulatory ischemia during routine activities are 
more likely to have experienced negative emotions in the hours prior to the ischemic 
episode. Individuals with high emotional reactivity are 2.5 times more likely to show 
myocardial ischemia in the quotidian, 3.0 times more likely to manifest it in the laboratory 
and almost 4.0 times more likely to manifest it on two occasions (Carels et al., 1999).  
Emotions, especially the negative ones, alter cardiovascular reactivity and neuroendocrine 
functioning, affecting the autonomic nervous system and hypothalamic-pituitary-adrenal 
axis acting on the cardiovascular system. These changes cause hypercholesterolemia, 
elevation of the level of catecholamines in the plasma and urine, impaired platelet 
functioning favoring platelet aggregation, thrombosis and rupture of existing plaques, 
impairment in vagal control functioning, increased cardiac rate, alterations in the electrical 
stability of the heart and reduction of cardiac variability, with a negative impact on the 
prognosis for coronary disease (Kubzansky & Kawachi, 2000; Perez et al., 2005; Richman et 
al., 2005; Sirois & Burg, 2003). Excessive or chronic emotional activation increases the levels 
of adrenalin and noradrenalin, increasing the quantity of free fatty acids, the arterial 
pressure, the cardiac rate and total peripheral resistance (Kubzansky & Kawachi, 2000). 
Sudden death of cardiac origin has been associated with intense and prolonged emotions 
(Lampert et al., 2002). Furthermore, intense transient emotional states can cause the 
detachment of atherosclerotic plaques, initiating acute cardiac events, such as sudden death 
(Kubzansky & Kawachi, 2000).  
There is still no consistent evidence of this association in relation to cardiac arrhythmias 
(Lampert et al., 2002), even knowing that “negative emotions such as anxiety and 
depression can affect the electrical stability of the heart by altering the autonomic regulation 
(specifically, reducing the cardiac rate variability)” (Kubzansky & Kawachi, 2000, p. 330) 
and that behavioral factors cause excessive sympathetic activation, triggering arrhythmias 
(Rozanski et al., 1999).  
The arrhythmias of behavioral origin are caused by the sum of three conditions: a) 
myocardial electrical instability, usually due to previous coronary disease, b) an acute 
triggering event, often related to mental stress, and c) a chronic intense psychological state, 
which often include depression and hopelessness (Rozanski et al., 1999). 
There is evidence that different emotions are related to different patterns of cardiac 
response. Studies show that anger increases the cardiac rate by between 5.0 and 9.0 beats per 
minute (bpm), fear increases it by between 5.5 and 8.0 bpm, sadness by between 4.0 and 7.0 
bpm and joy by between 2.0 to 3.0 bpm (Labouvie-Vief et al., 2003). A study conducted with 
resident physicians showed an increase of unsustainable atrial and ventricular ectopic 
arrhythmias due to the stress of receiving an emergency call (Burg et al., 2004; Lampert et 
al., 2002).  
 
Cardiac Arrhythmias – New Considerations 
 
314 
patients is around 14% to 27%. Psychiatric evaluations showed that 16% of the patients 
studied by Lane et al. (2005) presented moderate or severe depression in the three months 
preceding the cardiac episodes.  
Depression predicts the occurrence of myocardial infarction, angina, angioplasty and/or 
myocardial revascularization surgery, as well as presenting itself as an independent risk 
factor for mortality, with the same prognosis as left ventricular dysfunction and history of 
previous myocardial infarction (Sirois & Burg, 2003). Longitudinal studies have found 
between 1.5 and 2.0 times higher risk for coronary events in people diagnosed with 
depression or with self-reported depressive symptoms (Kubzansky & Kawachi, 2000).  
3. Emotions and their effects on cardiac rhythm 
3.1 Negative emotions and positive emotions 
The conceptual and theoretical description of the emotions has been the subject of much 
debate. However, most experts agree that the emotions comprise affective, cognitive, 
behavioral and neurobiological components which sustain the adaptive behavior (Gallo & 
Mathews, 2003; Kubzansky & Kawachi, 2000). Emotions are perceived as internal 
phenomena that cause external manifestations or signs, being organic or behavioral. 
Emotional experiences must be distinguished from emotional disorders, which are 
psychiatric disorders that encompass diverse symptoms, behavior and cognitive and 
affective processes, occurring infrequently when compared with the emotional experiences 
(Gallo & Mathews, 2003). 
The emotions can be grouped into the positive and negative, however, the specialists still 
disagree about whether these groups are two poles of the same dimension, or form distinct 
dimensions (Gallo & Mathews, 2003). Richman et al. (2005) identified four families of 
positive emotions: joy, interest, contentment and love. Shaver et al. (1987, as cited in Hupka 
et al., 1999) defined six categories of emotions subordinate to the general classification of 
negative and positive emotions: anger, fear, sadness, joy, love and surprise. Within these 
categories, they distributed the emotional lexicons of the English language in several 
subcategories: affection, lust, longing, cheerfulness, zest, contentment, pride, optimism, 
enthrallment, relief, amazement, irritation, exasperation, rage, disgust, envy, torment, 
suffering, sadness, disappointment, shame, neglect, sympathy, horror and nervousness. 
Emotions rarely occur in isolation and there is great variability of expression. Thus, in 
response to stimuli with the same emotional load, some individuals are more responsive 
than others and this tendency has been termed emotional reactivity (Carels et al., 1999). The 
hyperactivity of the sympathetic nervous system leading to exaggerated responses of 
cardiac rate and arterial pressure in situations of engagement, dispute or aversiveness is 
called, by some authors, cardiovascular reactivity (Rozanski et al., 1999). 
The literature suggests that when the style of regulation is more expressive and 
externalized, physiological reactivity is lower (Labouvie-Vief et al., 2003). Specialists also 
suggest that emotional reactivity that deviates from the norm in both directions is related to 
a risk of hypertension and probably also to arrhythmia (Carels et al., 1999; Kubzansky & 
Kawachi, 2000).  
Several measures and criteria have been used in studies regarding emotions, including 
clinical diagnoses of pathologies such as, for example, the definition of depression and 
anxiety (Kubzansky & Kawachi 2000). The majority of studies on emotions use self-reports, 
although this tends toward inaccuracy, because it involves remembering and reconstructing. 
 
Psychological Approach to the Cardiac Arrhythmias: A Focus on the Emotions 
 
315 
Some adopt methods of inducing emotions in the laboratory, but the generalization of the 
results cannot be determined (Thomas & Diener, 1990). Longitudinal studies separate the 
participants into “exposed” and “unexposed” to the risk factor and relate the two groups to 
the emergence of the target pathology, however, there is no way to determine if a person 
was exposed or not to a particular emotion (Kubzansky & Kawachi, 2000).  
Even with so many limitations, associations have been found between emotions and disease. 
Emotions can influence the onset of specific diseases or may result from diseases, 
influencing their prognosis. The relationship between emotions and cardiovascular health is, 
therefore, bidirectional, with the cumulative effect over time (Kubzansky & Kawachi, 2000). 
Studies have shown that patients with ambulatory ischemia during routine activities are 
more likely to have experienced negative emotions in the hours prior to the ischemic 
episode. Individuals with high emotional reactivity are 2.5 times more likely to show 
myocardial ischemia in the quotidian, 3.0 times more likely to manifest it in the laboratory 
and almost 4.0 times more likely to manifest it on two occasions (Carels et al., 1999).  
Emotions, especially the negative ones, alter cardiovascular reactivity and neuroendocrine 
functioning, affecting the autonomic nervous system and hypothalamic-pituitary-adrenal 
axis acting on the cardiovascular system. These changes cause hypercholesterolemia, 
elevation of the level of catecholamines in the plasma and urine, impaired platelet 
functioning favoring platelet aggregation, thrombosis and rupture of existing plaques, 
impairment in vagal control functioning, increased cardiac rate, alterations in the electrical 
stability of the heart and reduction of cardiac variability, with a negative impact on the 
prognosis for coronary disease (Kubzansky & Kawachi, 2000; Perez et al., 2005; Richman et 
al., 2005; Sirois & Burg, 2003). Excessive or chronic emotional activation increases the levels 
of adrenalin and noradrenalin, increasing the quantity of free fatty acids, the arterial 
pressure, the cardiac rate and total peripheral resistance (Kubzansky & Kawachi, 2000). 
Sudden death of cardiac origin has been associated with intense and prolonged emotions 
(Lampert et al., 2002). Furthermore, intense transient emotional states can cause the 
detachment of atherosclerotic plaques, initiating acute cardiac events, such as sudden death 
(Kubzansky & Kawachi, 2000).  
There is still no consistent evidence of this association in relation to cardiac arrhythmias 
(Lampert et al., 2002), even knowing that “negative emotions such as anxiety and 
depression can affect the electrical stability of the heart by altering the autonomic regulation 
(specifically, reducing the cardiac rate variability)” (Kubzansky & Kawachi, 2000, p. 330) 
and that behavioral factors cause excessive sympathetic activation, triggering arrhythmias 
(Rozanski et al., 1999).  
The arrhythmias of behavioral origin are caused by the sum of three conditions: a) 
myocardial electrical instability, usually due to previous coronary disease, b) an acute 
triggering event, often related to mental stress, and c) a chronic intense psychological state, 
which often include depression and hopelessness (Rozanski et al., 1999). 
There is evidence that different emotions are related to different patterns of cardiac 
response. Studies show that anger increases the cardiac rate by between 5.0 and 9.0 beats per 
minute (bpm), fear increases it by between 5.5 and 8.0 bpm, sadness by between 4.0 and 7.0 
bpm and joy by between 2.0 to 3.0 bpm (Labouvie-Vief et al., 2003). A study conducted with 
resident physicians showed an increase of unsustainable atrial and ventricular ectopic 
arrhythmias due to the stress of receiving an emergency call (Burg et al., 2004; Lampert et 
al., 2002).  
 
Cardiac Arrhythmias – New Considerations 
 
316 
3.1.1 Anger and hostility 
Evidence for the association between anger and cardiac disease is still limited, however, 
suggestive. Studies show that high levels of anger precede the cardiac diseases, while others 
suggest that both the suppression and expression of anger have cardiac consequences 
(Kubzansky & Kawachi, 2000). 
Anger is an emotional experience that ranges from an irritation or mild annoyance to a full 
fury (Sirois & Burg, 2003). It occurs in response to events perceived as unfair and 
accompanies physiological activation, leading to aggressive behavior, being strongly 
interlinked with hostility (Kubzansky & Kawachi, 2000). Anger, its expression, and hostility 
may influence the incidence of recurrent depression among women (Lavoiea et al., 2001). 
The manifestation of anger and hostility, while stable personality traits, are associated with 
increased ischemia (Burg et al., 2004). An anger-trait is defined as the disposition to perceive 
situations as annoying or frustrating and the tendency to respond to these situations with 
higher frequencies of anger (Spielberger, 1998, as cited in Richman et al., 2005).  
Stimuli that generate responses of anger are more likely to provoke abnormalities in the 
cardiac rhythm (Rozanski et al., 1999), conferring risk for cardiac diseases through the 
persistence of exaggerated cardiovascular reactivity (Lavoiea et al., 2001). The emotions  
of anger and anxiety can precipitate arrhythmias due to increased sympathetic activity.  
It is therefore possible that anger and anxiety, present in a chronic form, increase the risk 
of arrhythmias due to the influence on the sympathetic-parasympathetic equilibrium 
(Burg et al., 2004). Not only the expression of anger, but also its inhibition and the 
inability to discuss feelings of anger are related to cardiac diseases (Kubzansky & 
Kawachi, 2000).  
Anger not only contributes to the development of atherogenesis and to cardiac disease but 
also triggers acute coronary events (Chang et al., 2002; Kubzansky & Kawachi, 2000). Both 
anger and physical exercise can cause non-fatal myocardial infarctions and/or transient 
ischemia (Lampert et al., 2002), however, in the two hours subsequent to episodes of anger, 
the relative risk of myocardial infarction increases by more than two times (Rozanski et al. 
1999; Sirois & Burg, 2003). In the study by Lampert et al. (2002) anger episodes of moderate 
intensity were reported preceding 15% of the cardiac events studied.  
The phenomenon of arrhythmias triggered by anger can be observed both in patients with 
recurrent episodes as well as those with single episodes, however, the study of the 
association between anger and cardiac arrhythmias is difficult because in a study it is 
virtually impossible to select participants with different tendencies (Lampert et al., 2002).  
3.1.2 Anxiety 
Anxiety is characterized by the perception of the inability to predict, control or obtain 
results in circumstances evaluated as threatening and covers physiological responses (Carels 
et al. 1999; Kubzansky & Kawachi, 2000). Patients who presented ventricular arrhythmias 
associated with emotions obtained scores above the average of the general population in 
anxiety tests (Burg et al., 2004). 
Anxiety has been shown to be related to the occurrence of cardiac events by affecting the 
autonomic cardiac control, which could increase the risk of fatal ventricular arrhythmias 
(Sirois & Burg, 2003) and reduce the R-R variability (Rozanski et al., 1999). In addition, acute 
states of anxiety may lead to hyperventilation, which in turn triggers coronary vasospasm 
(Kubzansky & Kawachi, 2000).  
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Initially it was not possible to relate anxiety with cardiac diseases (Kubzansky & Kawachi, 
2000). However, more recent studies, which used self-reporting, have suggested that the 
mere presence of symptoms may be a risk factor, without the need to meet the diagnostic 
criteria for anxiety. The experience of moderate intensity anxiety can trigger potentially 
fatal arrhythmias in patients with ischemic cardiac disease. Patients with higher scores in 
Spielberger’s anxiety tests also reported anxiety in the 15 minutes prior to an ischemic 
event (Burg et al., 2004). Similarly, Denollet and Brutsaert (1998, cited in Sirois & Burg, 
2003) found that individuals with high scores in the State-Trait Anxiety Inventory and in 
the social inhibition scale of the Heart Patients Psychological Questionnaire suffered more 
cardiac events during the eight years of follow-up, regardless of ventricular function 
impairment.  
Large-scale surveys were conducted to better demonstrate the relationship between anxiety 
and cardiac events. The Determinants of Myocardial Infarction Onset Study observed an 
increased relative risk of myocardial infarction in the two hours following an episode of 
anxiety. Both the Normative Aging Study and the Framingham Heart Study associated 
symptoms of anxiety with an increased risk of fatal coronary heart diseases (Kubzansky & 
Kawachi, 2000).   
However, the studies that relate anxiety and autonomic control of the heart do not have 
consistent results, probably due to the different measures used and because anxiety is often 
associated with depression (Pitzalis et al., 2001). 
Few studies have examined the prognostic significance of anxiety in patients diagnosed 
with cardiac disease. 
3.1.3 Positive emotions 
The studies regarding emotions has flourished in recent years, however research into 
positive emotions has not kept pace.  Possibly, due to the difficulties in conceptualization 
and definition and because the positive emotions seem to be more diffuses. In fact, 
taxonomies of basic emotions only identify one positive emotion for every three or four 
negative emotions. Thus, there is little consensus about what can be considered a positive 
emotion. Another factor that certainly complicates the study of positive emotions is to 
realize that for specific negative emotions there are specific facial expressions and that this 
does not occur with the positive emotions, which share the facial expression of the smile 
between them. Furthermore, different autonomic responses were demonstrated related to 
negative emotions, however, the same was not verified in situations of positive emotion 
(Fredrickson, 1998). 
A form of positive emotion that has received certain attention is curiosity, a term used to 
describe hypothetical mechanisms that serve to guide or attract an organism in the direction 
of new stimuli (Swan & Carmelli, 1996). Curiosity is defined as an affective state or trait that 
appears closely related to interest, being related to wanting to investigate, learn and 
incorporate new experiences. Thus, Richman et al. (2005) followed, for two years, a 
population composed of 4,027 men aged between 55 and 69 years to verify the relationship 
between hope, curiosity and hypertension, diabetes mellitus and respiratory infections.  For 
each unit increase in curiosity test scores, the researchers perceived a 57% decrease in the 
risk of developing hypertension. This decrease was 40% for the scores of the hope tests in 
the first year of follow-up. In the second year of follow-up, patients with higher scores in the 
hope tests had a 48% reduction. 
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Positive emotions may have the potential to reduce the effects of stress on the 
cardiovascular system even faced with inevitable negative life events. Concepts such as 
optimism and positive attitude can cause negative events to be viewed with the confidence 
that the future holds something positive and better. The internally generated, positive 
emotional state seems to modify the adverse effects of prolonged exposure to negative 
emotions (Danner et al., 2001; Richman et al., 2005). 
3.2 The Holter Examination: An investigation regarding activities and emotions 
Autonomic dysregulation in the context of stress has been investigated both in animals and 
in laboratory conditions, however, few studies have been conducted in everyday situations, 
probably due to the difficulty of making accurate measurements in the midst of multiple 
environmental factors and because of the perceptual variability between subjects (Lucini et 
al., 2005). It is important to consider that, under experimental conditions, the occurrence is 
restricted of emotions still little known. Therefore, recognition of the influence of other 
emotions in the arrhythmogenesis is also restricted. Thus, the study of emotional changes 
that occur in the quotidian of people with ambulatory electrocardiographic monitoring can 
better clarify important research questions. Additionally, from the standpoint of diagnostic 
evaluation, this feature is relatively simple and accessible.   
In view of these scientific and clinical interests, a study was conducted with the following 
objectives: a) to identify emotions simultaneous to arrhythmias at different times of the day; 
b) to verify that the same activity can be presented simultaneously to arrhythmias at 
different times of day; c) to verify the occurrence of similar arrhythmias in individuals with 
similar emotional reports; d) to identify aspects of daily experience that occur 
simultaneously to arrhythmias, e) to verify whether people that conduct similar activities 
present similar arrhythmias and f) to describe and analyze the association between emotions 
and activities reported during the 24-hour Holter Examination (Sánchez, 2007; Bonomo & 
Araujo, 2009). 
A total of 13 men and 17 women participated in the investigation, aged between 48 and 69 
years, with complete high school education as the minimum level of schooling, who did 
not use antiarrhythmic medication, antipsychotics or beta blockers and had the ability to 
communicate orally and in writing. The data obtained during the examination were first 
transferred to a memory card, coupled to the Holter device. As usual, after receiving 
guidance on how to proceed within the 24 hour period, the return was scheduled for the 
following day with a view to removing the device at the same time. The recorded 
electrocardiographic information were processed by computer, generating a Tabular 
Report. 
In the Daily Report, in addition to recording the activities performed during period of the 
examination, the participants were asked to record the concomitant emotions. If different 
emotions occurred during the same activity, they should register this emotional change, its 
intensity and the time. After removal of the device and evaluation by a cardiologist, they 
were interviewed by the psychologist researcher using a previously prepared script. These 
reports were audio recorded and later transcribed. The Daily Report data were paired, hour 
by hour, with the Tabular Report data. Those periods which, even after completion of the 
interview, remained without comment, were registered as “without report”. 
Initially, the data found in the Daily Reports and Tabular Reports were analyzed by means 
of descriptive statistics, using the arithmetic mean of the reports. It is worth explaining that 
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the analysis was focused on the waking period, with reports being excluded where patients 
said they were asleep, since there are limitations for the participant to record this 
experience. The daily activities and the emotional reports were organized into categories 
and subcategories. Subsequently, the software Alceste - Analyse de Lexèmes Concurrents dans 
les Énnoncés Simples d'un Texte - was used for content analysis of the interviews.  
3.2.1 Distribution of the ventricular and supraventricular arrhythmias 
The women presented more arrhythmias, both ventricular (mean = 121.82) and 
supraventricular (mean = 265.59). The men presented a mean of 68.15 ventricular 
arrhythmias and 67.69 supraventricular arrhythmias. That is, the women presented more 
than twice the number of supraventricular than ventricular arrhythmias, however, these 
arrhythmias were distributed differently throughout the examination period (Bonomo & 
Araujo, 2009). 
3.2.2 Distribution of arrhythmias by activity category 
The activities were organized into three categories: a) physical activity, b) mental activity 
and c) travelling. Figure 1 shows that, among the women, the physical activities were more 
associated with ventricular arrhythmias and less with supraventricular arrhythmias. In the 
men, the exact opposite occurred. It can also be seen that in both men and women the 
mental activities were associated more with supraventricular arrhythmias than with 
ventricular arrhythmias. Regarding travelling, the association with supraventricular 
arrhythmias was higher in the female group. 
 
 
Fig. 1. Distribution of the mean of the reports of ventricular and supraventricular 
arrhythmias by category of activity.  
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by hour, with the Tabular Report data. Those periods which, even after completion of the 
interview, remained without comment, were registered as “without report”. 
Initially, the data found in the Daily Reports and Tabular Reports were analyzed by means 
of descriptive statistics, using the arithmetic mean of the reports. It is worth explaining that 
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the analysis was focused on the waking period, with reports being excluded where patients 
said they were asleep, since there are limitations for the participant to record this 
experience. The daily activities and the emotional reports were organized into categories 
and subcategories. Subsequently, the software Alceste - Analyse de Lexèmes Concurrents dans 
les Énnoncés Simples d'un Texte - was used for content analysis of the interviews.  
3.2.1 Distribution of the ventricular and supraventricular arrhythmias 
The women presented more arrhythmias, both ventricular (mean = 121.82) and 
supraventricular (mean = 265.59). The men presented a mean of 68.15 ventricular 
arrhythmias and 67.69 supraventricular arrhythmias. That is, the women presented more 
than twice the number of supraventricular than ventricular arrhythmias, however, these 
arrhythmias were distributed differently throughout the examination period (Bonomo & 
Araujo, 2009). 
3.2.2 Distribution of arrhythmias by activity category 
The activities were organized into three categories: a) physical activity, b) mental activity 
and c) travelling. Figure 1 shows that, among the women, the physical activities were more 
associated with ventricular arrhythmias and less with supraventricular arrhythmias. In the 
men, the exact opposite occurred. It can also be seen that in both men and women the 
mental activities were associated more with supraventricular arrhythmias than with 
ventricular arrhythmias. Regarding travelling, the association with supraventricular 
arrhythmias was higher in the female group. 
 
 
Fig. 1. Distribution of the mean of the reports of ventricular and supraventricular 
arrhythmias by category of activity.  
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3.2.3 Distribution of arrhythmias by emotion category 
It was verified that only the reports of worry and sadness were similar between the two 
groups. Joy was the emotion that obtained the highest difference in the means of the reports, 
being more perceived by the women (see Table 1). 
 
 
Categories Subcategories WOMEN MEN Total % Total % 
Positive 
Blessed 5 3.1% 1 0.7% 
Joy 27 17.0% 3 2.2% 
Satisfaction 8 5.0% - - 
Security - - 3 2.2% 
Neutral Tranquility 68 42.8% 81 60.5% 
Negative 
Anxiety 14 8.8% 9 6.7% 
Worry 16 10.1% 17 12.7% 
Anger 9 5.7% 12 9.0% 
Surprise 1 0.6% - - 
Sadness 11 6.9% 8 6.0% 
 Total 159 100% 134 100% 
Table 1. Categories and subcategories of emotions reported by the participants  
3.2.4 Emotions simultaneous to ventricular arrhythmias 
The subcategory feeling blessed was the most frequently associated with ventricular 
arrhythmias in both genders (Figure 2). In the women, worry was related more with 
ventricular arrhythmias than anxiety and in the men this relationship was exactly the inverse. 





Fig. 2. Mean of ventricular arrhythmias in each subcategory of emotions reported. 
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Sadness was not simultaneous with ventricular arrhythmias in either gender. In the 
situations accompanied by reports of tranquility, ventricular arrhythmias were recorded 
more frequently in the women than in the men, possibly due to the activities that the 
women were performing. 
3.2.5 Emotions simultaneous to supraventricular arrhythmias 
Almost all the emotions that were recorded by both genders appeared simultaneously more 
frequently among women (see Figure 3). 
 
 
Fig. 3. Mean of supraventricular arrhythmias in each subcategory of emotions reported. 
In summary, the majority of the emotions reported by the participants were presented more 
simultaneously to supraventricular than to ventricular arrhythmias. Both for men and 
women, the mean of the reports of sorrow concomitant to ventricular arrhythmias were very 
low. Anger differed from all the other emotions, it was simultaneous to more ventricular 
arrhythmias in the men and to supraventricular arrhythmias in the women. Surprise was 
the least identified category. This may reflect the difficulty in conceptualizing it, which 
indicates the need for more studies. 
The analysis of the interviews also revealed the need for recognition of the efforts performed 
on behalf of the family members. When this recognition was not perceived by the 
participants, frustration occurred. It is worth mentioning that the majority attributed their 
organic disorders to external factors, having difficulty linking them clearly to their behavior 
or emotions. The men and women reported similar emotions in different social situations. 
The women said they were happy in situations of interaction with the family and the men 
when they were with friends. In fact, the men reported less interaction with the family, 
which in most cases, was limited to discussion of problems with the wife. 
This study showed that the 24-hour Holter examination enables the identification of the 
simultaneity between emotions, daily life and cardiac arrhythmias. 
4. Conclusions  
It is considered that if knowledge about the participation of the emotions in 
arrhythmogenesis is continually improved, it will be possible to generate support for 
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psychological guidance based more on, and tailored to, the daily routine of the patients. For 
example, meditation, which reduces the frequency of premature ventricular contractions 
(Giannotti-Hallage, 1990), could be recommended at times of circadian peak.  
In summary, disease prevention and health promotion depends on knowledge regarding 
the psychosocial determinants of risk behaviors and of the psychosocial processes that affect 
the triggering and experience of the chronic diseases. Therefore, to comprehend how the 
emotional factors trigger the functional imbalance of the heart may contribute to the 
planning of more effective therapeutic strategies. Certainly, the contribution of Applied 
Psychology to the area of Cardiology is increasingly promising concerning innovations for 
the work of the professionals of various categories integrated in interdisciplinary teamwork.  
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Before anything else, is essential to define what is the electrical cardiac systole. Especially 
when there are so many discrepancies among different authors. 
Includes cardiac electrical systole from the beginning of the P wave (atrial depolarization) to 
the end of the T wave (ventricular repolarization). 
Would cover thus the P wave, PR interval, QRS complex, ST segment, T wave. 
For other authors, this one only would include from the beginning of QRS complex to the 
end of the T wave. 
There are several changes, especially in its length, that can cause a sudden death in case that 
they are not adequately diagnosed and, thus, with the properly treated. 
2. Standard values (in length) 
P-wave: 0.06-0.09 seconds in length. 
PR- interval: 0.12 to 0.20 seconds in length. 
QRS- complex: 0.06 to 0.10 seconds in length. 
QT- interval (corrected): 0.40 to 0.44 seconds in length. 
RR- interval: 0.60-1.00 seconds in length. 
Normal duration of cardiac electric systole: 35-45% of total duration of the cardiac cycle 
(R-R interval) 
(The length of cardiac electrical systole is considered normal until reaching 45% of the overall 
length of cardiac cycle: a greater value is considered as prolonged and lesser is considered as 
shortened) 
The sudden death is defined for most authors as a natural death that happens very 
instantaneously or within the first hour from the beginning of the symptoms, in a patient 
with well-known previous disease or without her, but is unexpected totally. Although we 
do not agree with some nuances of such definition, we will give it as acceptable. 
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Consequently, any sudden death should be considered either of cardiac origin when the 
heart is the affected organ, structurally or without macroscopic alterations of its structure.  
The cardiac problems are the main cause of unexpected death. It is estimated that occurs 
about 1 case of sudden death for every 100,000 young athletes each year (under 35). Even 
though exercise is beneficial for health, sport of competition increases the risk of sudden 
death [Brignole M, et al 2004]. 
 
CARDIAC COMMOTION. 
CORONARY ARTERY ANOMALY. 
LEFT VENTRICULAR HYPERTROPHY OF UNDETERMINED CAUSE. 
MYOCARDITIS. 
RUPTURE OF AORTIC ANEURYSM. 
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY. 
BYPASS CORONARY ARTERY. 
AORTIC VALVE STENOSIS. 
ATHEROSCLEROTIC DISEASE OF THE CORONARY ARTERY. 
DILATED CARDIOMYOPATHY. 




OTHER CARDIOVASCULAR CAUSES. 
LONG QT SYNDROME. 
RUPTURED BRAIN ANEURYSM. 
CARDIAC SARCOIDOSIS.  
TRAUMATIC CARDIAC INJURY. 
[Thijs, RD., 2005] 
Table 1. The most frequent causes of sudden death in overall.  
The three most common causes for sudden cardiac death are:  
1. Hypertrophic cardiomyopathy (HCM). [Figure 1]:  
It is a disease of the myocardium in which a portion of the myocardium is hypertrophied 
(thickened) without any obvious cause. It is perhaps most well-known as a leading cause of 
sudden cardiac death in young athletes. The occurrence of Hypertrophic cardiomyopathy is 
a significant cause of sudden unexpected cardiac death in any age group and as a cause of 
disabling cardiac symptoms [Richardson P., 1996]. Younger people are likely to have a more 
severe form of Hypertrophic cardiomyopathy. HCM is frequently asymptomatic until 
sudden cardiac death, and for this reason, some suggest routinely screening certain 
populations for this disease [Doerer JJ., 2009]. 
A cardiomyopathy is a primary disease that affects the muscle of the heart. With 
Hypertrophic cardiomyopathy (HCM), the sarcomeres (contractile elements) in the heart 
replicate causing heart muscle cells to increase in size, which results in the thickening of the 
heart muscle. In addition, the normal alignment of muscle cells is disrupted, a phenomenon 
known as myocardial disarray. HCM also causes disruptions of the electrical functions of 
the heart. HCM is most commonly due to a mutation in one of 9 sarcomeric genes that 
results in a mutated protein in the sarcomere, the primary component of the myocyte (the 
muscle cell of the heart) [Maron BJ ., 2010]. 
While most literature so far focuses on European, American, and Japanese populations, 
HCM appears in all racial groups. The prevalence of HCM is about 0.2% to 0.5% of the 
general population [Kuller LH., 1980] 
 




Fig. 1. ECG is abnormal., 80-90% of cases. Abnormal Q-waves in inferior leads. Increasing 
the voltage in medium or left precordial (V3-V6). ST segment depression, negative T- waves 
in precordial leads, middle and left. Less often: Increasing in the left atrium, left axis, Giant 
negative T waves, atrial fibrillation, ventricular extra-systoles, ventricular tachycardia in 
severe cases.  
2. Arrhythmogenic right ventricle cardiomyopathy (ARVD). [Figure 2] 
Arrhythmogenic right ventricular dysplasia (ARVD), also called arrhythmogenic right 
ventricular cardiomyopathy (ARVC) or arrhythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVD/C), is an inherited heart disease. ARVD is caused by 
genetic defects of the parts of heart muscle known as desmosomes, areas on the surface of 
heart muscle cells which link the cells together [Lahtinen, AM., 2011]. The desmosomes 
are composed of several proteins, and many of those proteins can have harmful 
mutations. The disease is a type of non-ischemic cardiomyopathy that involves primarily 
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the right ventricle. It is characterized by hypokinetic areas involving the free wall of the 
right ventricle, with fibro fatty replacement of the right ventricular myocardium, with 
associated arrhythmias originating in the right ventricle. ARVD is often found in 
association with diffuse palmo-plantar keratoderma, and woolly hair, because their genes 
are nearby and often inherited together. ARVC/D is an important cause of ventricular 
arrhythmias in children and young adults. It is seen predominantly in males, and 30-50% 
of cases have a familial distribution. 
 
 
Fig. 2. 90% of individuals with ARVD have some EKG abnormality. The most common EKG 
abnormality seen in ARVD is T wave inversion in leads V1 to V3. However, this is a non-
specific finding, and may be considered a normal variant in right bundle branch block 
(RBBB), women, and children under 12 years old. RBBB itself is seen frequently in 
individuals with ARVD. This may be due to delayed activation of the right ventricle, rather 
than any intrinsic abnormality in the right bundle branch. The epsilon wave is found in 
about 50% of those with ARVD. This is described as a terminal notch in the QRS complex. It 
is due to slowed intraventricular conduction. The epsilon wave may be seen on a surface 
EKG; however, it is more commonly seen on signal averaged EKGs. Ventricular ectopy seen 
on a surface EKG in the setting of ARVD is typically of left bundle branch block (LBBB) 
morphology, with a QRS axis of -90 to +110 degrees. The origin of the ectopic beats is 
usually from one of the three regions of fatty degeneration (the "triangle of dysplasia"): the 
RV outflow tract, the RV inflow tract, and the RV apex. 
3. Arrhythmogenic sudden death syndrome: 
It is a generic name that includes many alterations in cardiac electrical conduction capable of 
produce instant death.  
This syndrome includes all sudden cardiac deaths wherein the cause of death could not be 
diagnosed, even after the necropsy. It is the cause of more 5% of all sudden cardiac deaths. 
That is, if we discard the non-cardiac causes and structural heart problems, this problem is 
denominated as arrhythmogenic sudden death syndrome from a generic form. As the 
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diagnostic techniques are being more appropriate each day, these numbers grows 
exponentially [Strickberger SA., 2006]. 
Here, would be included all events from our chapter proposal : Alterations in electrical 
cardiac systole and its impact on sudden cardiac death.  
3. Other disorders in electrical cardiac systole as cause for sudden cardiac 
death 
As we have said previously, the electrical cardiac systole originates from the beginning of 
the P wave (atrial depolarization) to the end of the descending branch of the T wave 
(ventricular repolarization). Are included, therefore, the succession of P-QRS-T and its 
corresponding intervals and segments: PQ, ST and QT. The mathematical possibilities in the 
variation on length of electrical systole of the heart may be several. It is well documented 
and demonstrated that such changes in length can cause that be more vulnerable and 
unstable all myocardial cells, and can also cause serious cardiac arrhythmias, several 
syncope episodes and even sudden death for this motive. Even today, many of these 
disorders are poorly understood and, too many times, its clinical manifestations are 
categorized as "episodes of epilepsy"; other times (most) are classified within a "common 
sack" called "channelopathies”, when -actually- is the alteration from electrical cardiac 
systole the true etiology of them.  
All these disorders can cause syncopal episodes and a sudden cardiac death. 
The measures and lengths of the different components of electrical cardiac systole, 
considered for most authors as normal are these:  
PR-interval: 0.120- 0.200 seconds. 
QRS complex: 0.08-0.120 seconds. 
QT-interval (corrected): 0.350-0.450 seconds. (Here, there is much disagreement among 
different authors). The most used methods for QT interval correction, since it is frequency-
dependent, are Bazett, Fridericia. 
When the PR-interval is lesser than 0.120 seconds, we call it a short PR-interval. In contrast, 
when is greater than 0,200 seconds, we call it a first-degree AV block. When the QRS 
complex is lesser than 0.08 seconds, we call it "narrow QRS" but when is greater than 0,120 
seconds, we call it "wide QRS". Likewise, when the corrected QT- interval length is lesser 
than 0,350 seconds, we call it Short QT- interval and when is greater than 0,450 seconds, we 
call it a Long QTc- interval. 
It is clear that there may be, in the same ECG recording, a combination of them all. 
Some of these disorders, we will explain briefly below. 
3.1 Wolff-Parkinson-White’s syndrome (WPWS) 
Wolff-Parkinson-White syndrome (WPWS) is a congenital heart disease (PRKAG2. Genetic 
map 7q36) characterized by a premature ventricular depolarization caused by an abnormal 
atrioventricular accessory pathway, between the atria and ventricles, known as Kent’s bundle. 
However, even today, is called into question the real cause of Wolff-Parkinson-White, there are 
some authors who believe that, PRKAG2 mutations, are caused by a glycogen storage 
cardiomyopathy associated with WPWS, because the overwhelming majority of accessory 
pathways occur in individuals without structural heart disease, and probably without this 
mutation. The pathogenesis of accessory pathway formation in PRKAG2 may be completely 
different, and some authors believe it is due to an inflammation of myocardial cells that occur 
in the atrial-ventricular connections [L. Wolff., 1930].  
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In fact, do not even know if the accessory pathways are mediated genetically or due to 
environmental exposures or randomly. 
A short PR interval, a delta wave, a wide QRS complex (greater than 120 ms) and, 
occasionally, alterations in the ventricular repolarization are its main electrocardiographic 
characteristics on the ECG. Its incidence varies between 0, 1% and 3% in the general 
population.  
It is essential to achieve the right differential diagnosis between: 
 
 Wolff-Parkinson-White’s syndrome or real ventricular pre-excitation. 
 Lown-Ganong-Levine syndrome or accelerated atrioventricular conduction. 
 Mahaim’s syndrome. 
 “Short PR alongside short QT” intervals in the same person. (Breijo's Pattern). 
3.1.1 Typical ECG image of the Wolff-Parkinson-White 
 
 
In this context of ECG recording, that has a normal heart rate, a short PR interval, a delta-
wave and an early ventricular repolarization can be seen. 
3.2 Lown-Ganong-Levine syndrome (LGL) 
This syndrome was described in 1952 by Lown, Ganong, and Levine, forming the famous 
now used to describe it. It is considered a preexcitation syndrome [Lown B, Ganong WF, 
Levine SA., 1952].  
We now know four types of pre-excitation syndrome:  
 Wolff-Parkinson-White or ventricular preexcitation true.  
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 Acquired . 
 Congenital :  
 Inherited. 
 Not inherited. 
The familial form is inherited, as an autosomal dominant genetic trait has been associated 
with the PRKAG2 gene that encodes the activated AMP protein kinase, responsible for 
transport and store energy from the heart. A mutation in this gene could explain the 
susceptibility of the heart to the crises of tachycardia. Mutation has been identified on the 
long arm of chromosome 7 (7q34-q36).  
The Lown-Ganong-Levine may affect approximately 1 in every 50,000 people.  
Several structural abnormalities have been proposed as the possible basis for LGL, including 
the presence of James's fibbers, Mahaim's fibbers, Brechenmacher and underdeveloped 
anatomic sinus node (hypoplastic).  
Each of these fibbers can only be identified histologically.  
Thus, unless other studies demonstrate definitive- structural or functional -abnormalities, 
the diagnosis of LGL remains a clinical diagnosis.  
In the absence of significant structural heart disease, the mortality rate appears to be very low.  
Patients may present with an acute episode of tachycardia or a history of symptoms 
suggestive of paroxysmal tachycardia.  
In diagnosis is necessary to make: 
1. A standard test for tachycardia, including an ECG to document the rhythm.  
2. Serum electrolytes, calcium, magnesium levels, and levels of serum thyroid hormone-
stimulating hormone (TSH). Lithemy.  
3. History suggestive of recurrent paroxysms of tachycardia,  
4. A Holter monitor or event recorder may be useful to document the rhythm during 
acute symptomatic episodes.  
5. An ergometric study.  
6. In rare cases, an implantable monitor for pace may be helpful.  
7. Family History. (Screening).  
3.2.2 Differential diagnosis with Wolf-Parkinson-White  
Although apparently similar, there are differences, which, in our opinion, are critical with 
respect to drug treatment elective. The key differences are:  
- The LGL is a PR- interval shortened due to, the presence of accessory pathway, 
prevents the AV node but normal QRS because the accessory pathway (James fibbers) 
binds directly to the sinus and depolarizes the ventricles not directly, but does so by 
typical pathway, by the Hiss-Purkinje system.  
- Not displayed "Delta waves -" in D1, aVL, V5 and V6.  
- The QRS complexes tend to be narrow because there is usually no interventricular 
conduction disturbance.  
- It is not be as frequent the association of atrial fibrillation during concomitant crisis. 
3.2.3 Prognosis 
No studies have shown an increased risk of sudden death or reduced survival for patients 
meeting the criteria for the diagnosis of LGL.  
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3.2.4 Current therapeutic bases  
Rarely, the drug medical therapy can have failures usually, but there are patients in who 
there is not effective (for patients who continue to have recurrent and intolerable 
symptoms). In such extreme cases are used:  
- Radiofrequency ablation (RF).  
- The external pacemaker.  
- The Implantable Cardioverter Defibrillators (ICDs).  
This destroys the accessory pathway using a catheter (tube) inserted into the body to reach 
the heart. The success rate of this procedure ranges between 85 and 95% depending on the 
location of the extra or additional route.  
Digoxin, verapamil and beta-blockers (other drugs commonly used to treat other types of 
tachycardia) can increase the frequency of episodes of tachycardia in some people with this 
syndrome. Beta-blockers may increase cardiac depression.  
We can use drugs such as adenosine (Inpatient), and amiodarone to control or prevent 
episodes of tachycardia.  
For the control of tachycardia is usually proceed according to the severity of the 
implementation of vagal maneuvers carotid massage type and Valsalva maneuver (forced 
expiratory made with the nose and mouth closed).  
3.2.5 Typical ECG image of the Lown-Ganong-Levine 
 
 
3.3 Short PR-interval alongside short QT-interval on the same person  
(Breijo's pattern) 
In 2006, Breijo-Marquez, Pardo Ríos et al. evaluated a series of young patients, who had had, 
since childhood, many episodes of nocturnal palpitations, chest pain, full loss of consciousness 
(syncope), and which were accompanied by tonic-clonic seizures. All had been diagnosed and 
treated as epileptic episodes. Treatment outcomes were null. They were always considered as 
normal, in every cardiac studies performed absolutely [Breijo-Marquez, FR., 2008]. 
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However, all these patients had an ECG recording common:  
“A PR-interval lesser than 0,120 seconds with a QTc-interval equal to or lesser than 
0.350 seconds”. 
That is, a pattern of short PR and QTc in the same person.  
The correct treatment was begun (beta-blockers and, in some cases, an implantable cardio 
defibrillator, ICD.). Was removed all treatment from epilepsy.  
The outcome to date is satisfactory. 
Although we don’t know, with certainty, the etiology of this pattern of ECG to date, we 
know that there were two important confusions: 
First. - The physicians mistook to syncopal episode, with an epileptic episode. 
Second. - The syncopal episodes are due to a cardiac disorder (was a cardiogenic syncope 
due to a cardiac electrical systole's alteration).  
This ECG recording may be easily confused with a Lown-Ganong-Levine, since both have a 
short PR-interval. Nevertheless, in this type of ECG pattern there is also a short QTc-
interval. 
Unfortunately, both entities are confused with epileptic episodes too often.  
Sudden cardiac death is extremely frequent in this type of event.  
3.3.1 Typical ECG image of the “short PR alongside short QT” intervals in the same 
person (Breijo's Pattern) 
 
 
This ECG recording was the first with 12 leads that was obtained from our Hospital from 
Boston. MA. The patient was a 17 years-old male. We can see a shortening of the PR and QT 
intervals (Bazett), especially in inferior and left precordial leads. PR-interval length is lesser 
than 0.120 seconds and QTc length is lesser than 0.350 seconds. Patient had the symptoms 
exposed previously. He was also diagnosed for epileptic episodes. However, he had 
syncopal episodes and two cardiac arrests by cardiological disturbances. 
3.4 Mahaim syndrome 
Mahaim syndrome is characterized by: 
The PR- interval with a standard length. Presence of pseudo-delta wave in the initial phase of the 
QRS complex because the sinus stimulus enters to AV node where physiological suffers a delay 
and then depolarizes the ventricles by an abnormal way: Mahaim fibers [Mahaim, I., 1937]  
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 PR-interval with a normal length. 
 Wide QRS complexes. 
3.4.1 Typical ECG image of the Mahaim’s syndrome 
 
 
4. Differential diagnosis among various entities with alterations in electrical 
cardiac systole 
 
ENTITY. PR-interval QRS complex QTc -interval 
W.P.W Short. Wide (δ-wave) Normal 
L.G.L Short Normal Normal 
Mahaim Normal or Short Normal or wide Normal 
Breijo’s Pattern Short Normal Short 
Differential diagnosis, based on the characteristics from the different intervals and complex. 
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5. Some variations in electrical cardiac systole that can cause sudden death 
(All these examples were discovered by Breijo-Marquez, FR. et al. They are still very 
underdiagnosed). 
1. WOLFF-PARKINSON-WHITE AND PROLONGED“Q-T”PATTERNS IN THE SAME 
ELECTROCARDIOGRAPHIC RECORD [Breijo-Marquez, FR., 2011].  
Wolff-Parkinson-White syndrome (WPWS) is a congenital heart disease (PRKAG2. Genetic map 
7q36) characterised by a premature ventricular depolarisation caused by an abnormal 
atrioventricular accessory pathway known as Kent’s bundle. Prolonged QT syndrome (PQTS) 
consists of an abnormal prolongation of the QT interval on the ECG, which can be both inherited 
and acquired. This anomaly is known to favour the occurrence of malign cardiac arrhythmias, 
above all polymorphic ventricular tachycardia, ventricular fibrillation and “torsade de pointes”. 
When taken separately, both syndromes have little incidence, which leads us to expect this 
incidence to be even lower when they are found on the same electrocardiogram. Incidentally, 
the current medical literature contains no publications on this topic. This clinical case aims to 
establish the existence of an electrocardiographic pattern characterised by WPW and a PQTS 
pattern on an ECG record. With a high susceptibility to crisis of tachycardia, especially at 
night, several episodes of syncope, even cardiac arrest and sudden cardiac death. 
The patient is a 24 old- years man. Since childhood, he has suffered from more than four 
tachycardia attacks, three documented syncope episodes, as well as two cardiac arrests 
recovered, for which he was treated with electric discharges. Afterwards, he was treated 




We can see a typical ECG recording of an intermittent WPW and a Long QT-interval 
together in a patient with several syncopal episodes and a recovered cardiac arrest. 
2. ECG PATTERNS WITH SHORT PR INTERVAL TOGETHER TO A LONG QT (A) AND 
FIRST-DEGREE AV BLOCK ALONGSIDE A LONG QT (B: INCREASED OF CARDIAC 
ELECTRICAL SYSTOLE). [Breijo Marquez, FR., 2009]. 
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In this exposition, we present the ECG record of two patients with an obvious diversity and 
variability of alterations in the electrical system of heart. These electrical cardiac 
disturbances could explain completely the symptomatology from patients: nocturnal 
palpitations, several syncopal episodes. 
In Figure A, we can see the presence of a short PR-interval together to a Long QT-interval. In 
Figure B, we can also see an ECG recording with a Long PR-interval alongside a Long QT-
interval. 
3. PRESENCE OF A CRITICAL STENOSIS IN LEFT ANTERIOR DESCENDING 
CORONARY ARTERY ALONGSIDE A SHORT “P-R” AND “Q-T” PATTERN, IN THE 
SAME ELECTROCARDIOGRAPHIC RECORD [Breijo-Márquez, FR., 2010].  
The knowledge of the heart and its functions is increasing every day. However, many 
cardiac dysfunctions remain undocumented. 
One of them might be the presence of the Wellens' sign, minimally elevated or isoelectric ST 
segments, and inverted T waves in the precordial leads, without changes in the QRS 
complex, together with a shortened of “P-R and Q-T intervals” in the same 
electrocardiographic record. Both patterns are greatly underdiagnosed. The risk implied by 
the aforementioned underdiagnosis could have lethal consequences because the inherent 
problems in a short “P-R”-“Q-T” pattern could be added to those inherent in Wellens' sign.  
Hereby, we set out to show both the description of the clinical case and the electrocardiogram 
(ECG) recording of a male having previously mentioned collection of symptoms. 
The patient is a 42-year-old single man, previously diagnosed with unstable angina, who is 
an occasional smoker with arterial hypertension and who was prescribed a felodipine  
(5 mg/d) and ramipril (5 mg/d) treatment. The patient was complaining about an intense, 
oppressive, and progressive pain in the chest, which bore no relation to physical effort. The 
pain radiated toward both jaws and was accompanied by acute autonomic symptoms. 
The sublingual administration of nitrates proved to be effective and led to a reduction of the 
pain as well as an improvement in the alterations the patient was showing. The ECG at 
presentation showed ST-segment elevations by more than 2 mm in all the precordial leads 
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except lead one. The laboratory tests verified myocardial injury: L-lactate dehydrogenase, 
1.220 UI/L (reference range, 230-460 UI/L);creatine kinase, 560 U/L (reference range,  
37-290 U/L); creatine kinase], 1.85-14.45 U/L); aspartate transaminase, 376 U/L (reference 
range, 3-40 UI/L); alanine transaminase, 121 U/L (reference range, 5-37 UI/L); and troponin, 
3.5 μg/L (Reference range, 0-0.1 ng/mL). 
In spite of the elevated biochemical markers of myocardial injury, the case was classified as 
an unstable angina variant.  
The patient made full recovery as well as radical improvement of the clinical manifestations after 
the administration of nitrates (b30 minutes). As soon as the patient was clinically stabilized and 
the enzymatic levels regained their stability, the patient was discharged. He was also given a 
medical appointment in the hospital 10 days later so that he could be submitted to a new 
evaluation (We must add that, we do not know why the patient was not studied according to 
international guidelines during his first cardiac evaluation: angiography study within 24 hours at 
least). The patient showed no symptoms whatsoever when he returned home. 
However, the patient returned to the hospital before his appointment was scheduled, 
describing similar symptoms to those, he had previously been afflicted by, but complaining, 
they were more acute and persistent. 
That is the reason why the patient was automatically transferred to intensive care, where he 
was diagnosed with Wellens' sign.  
After the patient was clinically and hemodynamically stabilized, he underwent a battery of 
diagnostic tests, which included an angiographic study, an echocardiogram and a single-
photon emission computed tomography (SPECT) study. 
Interestingly enough, the patient was reported to have had 3 short syncope attacks, from 
which he had fully recovered. He also had several nocturnal palpitation episodes, which 
were diagnosed as idiopathic supraventricular tachycardia.  
As far as his family clinical history is concerned, an uncle on his father's side is known to 
have died of sudden death at the age of 46. His father had a history of acute coronary 
syndrome with ECG changes confined to the anterolateral leads. 
The Wellens' sign represents an evolutionary stage of ST elevation acute coronary syndrome. 
Today, most of the patients are classified as non-ST elevation myocardial infarction, as they will 
have elevated troponin levels. Some patients are classified as unstable angina. The patients have 
similar symptoms: severe oppressive chest pain and radiation of the pain to different segments 
over a short period, but they usually respond to the administration of nitrates very quickly. 
Electrocardiographically speaking, the patients have very characteristic patterns: T-wave 
symmetrical inversion, with occasionally very deep T waves in precordial derivations, especially 
in V3 to V4, although these characteristics may extend to all the precordial derivations. 
The Wellens' sign is associated with a critical stenosis in the left anterior descending coronary 
artery. Before the widespread implementation of invasive cardiology and effective 
antithrombotic therapy, 3 of 4 patients with this ECG pattern developed a usually extensive 
anterior myocardial infarction within a few weeks of admission. Our patient had bypass surgery. 
Breijo et al. described the pattern of short “P-R and Q-T” intervals in 2006. It is characterized by 
the presence of an ECG with a P-R interval lesser than 0.12 seconds and the Q-T interval lesser 
than 0.350 seconds and, which, in more than 80% of cases, is accompanied by syncope episodes, 
nocturnal tachycardia, and occasionally, by ventricular fibrillation and even sudden death. 
The key to an accurate diagnosis of both dysfunctions must begin with a detailed analysis of 
all the symptoms reported by the patient. The ECG recording provides an almost definitive 
confirmation: 
- The T-wave characteristics in precordial derivations. 
- The duration of P-R and Q-T intervals.  
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5.2 Thoughts about the patterns described above 
All have a clear variation in the electrical cardiac systole. 
All have a strong tendency to produce events of tachycardia / ventricular fibrillation. 
Hence, all have a great capacity to produce cardiac arrest which, if not adequately 
diagnosed and treated, will inevitably occur sudden cardiac death.  
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1. Introduction 
Bradycardia in association with anaesthesia may lead to insufficient cardiac output and 
decreased delivery of oxygen to vital organs. In children the heart rate is the dominant 
factor for cardiac output, since the developing heart is less compliant and contractile and 
stroke volume cannot increase much. Thus, when bradycardia occurs in children during 
anaesthesia, cardiac output falls and may lead to serious cardiac arrhythmias and even 
cardiac arrest. In this chapter, the incidence, causes and risk factors, as well as the 
consequences and possible treatment of bradycardia in children during general anaesthesia 
are described and discussed. A focus is made on the incidence and causes of bradycardia in 
children undergoing adenotonsillectomy under general anaesthesia. 
2. Bradycardia and general anaesthesia in children 
2.1 Physiology  
The normal heart rate decreases with increasing age in children (Figure 1). Therefore, a heart 
rate less then 100 beats per minute in very young children is a bradycardia by definition. For 
children 3 years of age, this means a heart rate less then 65 beats per minute. In the first 
months after birth, the risk for bradycardia is even higher as a result of an autonomic 
imbalance in the heart innervation (Rothrock, 2004).  
Causes for bradycardia can be either intrinsic (e.g. cardiac abnormalities), or extrinsic (e.g. 
medication). During general anaesthesia children are at an increased risk of bradycardia in 
case of hypoxemia or hypervagotonia. Hypoxemia can be caused by administration of 
anaesthetics or other medication. Hypervagotonia can be evoked by oesophageal or nasal 
stimulation as a consequence of anaesthesia, for example in case of endotracheal intubation. 
However, surgery can also cause hypervagotonia by manipulation of the head or neck 
region, which is especially the case in otolaryngology. Among otolaryngology surgical 
procedures, adenotonsillectomy is a procedure likely to be responsible for direct stimulation 
of the vagal nerve. This stimulation is caused by placement of the mouth gag and the 
instruments used during the surgical procedure and the manipulation in the mouth and 
oropharynx. Together with placement of ventilation tubes, adenotonsillectomy is one of the 
most frequently performed types of surgery in children worldwide. 
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Fig. 1. Heart rate values in centiles from birth to age 18. (Fleming et al, 2011) 
2.2 Aetiology 
Bradycardia during general anaesthesia can have different causes, and depending on patient 
characteristics and conditions, the sequelae can be serious. Especially in children, 
bradycardia can lead to failure of cardiac output and may also lead to serious cardiac 
arrhythmias and even cardiac arrest. In a study performed by the Australian Patient Safety 
Foundation, the first 4000 incidents reported to the Australian Incident Monitoring Study 
(AIMS) were analysed for the incident bradycardia. A total of 265 reports describing 
bradycardia in both adults and children during anaesthesia were extracted and studied 
(Watterson et al., 2005). In general, bradycardia was associated with hypotension in 51% of 
cases, cardiac arrest in 25% of cases and hypertension in one case. In 22% of reports 
apparent desaturation or an abnormality of ventilation was described. The authors 
concluded that cardiopulmonary events causing bradycardia are more likely than other 
causes to be associated with cardiac arrest. The causes of bradycardia were drug events in 
28% of cases, airway related events in 16%, autonomic reflexes in 14%, and regional 
anaesthesia in 9% of the cases. Most episodes of bradycardia occurred during surgery (61%), 
whereas 20% was observed before and during induction. 
In 43 of these 265 reports, bradycardia occurred in children under the age of 14 years. The 
distribution of ASA grading in children was similar to that of adults, but the haemodynamic 
profile was different for children as compared to adults. Whereas in adults airway and drug 
events together were responsible for 44% of causes, in children up to 75% of bradycardias 
were associated with airway and drug events. Airway events were the predominant cause 
of bradycardia in children (47%). In 51% of children studied there was no abnormality of 
blood pressure, which was attributed to the high incidence of airway events, in which 
hypoxaemia was associated with rapid deterioration in heart rate. Hypotension was present 
in 21% of the cases, but cardiac arrest was described in 32% of the cases. Whereas a good 
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outcome was reported in 63% of both adults and children, in only 48% of incidents 
concerning children a good outcome was reported. This might indicate that an incident 
during general anaesthesia with bradycardia in children has an important risk of poor 
outcome.  
An epidemiologic study by Keenan and co-workers on bradycardia during anaesthesia 
concluded from data abstracted from almost 8,000 anaesthetic records of children 0-4 years 
of age that the frequency of bradycardia was 1.27% in the age group 0-1 years of age. This 
was considerably less in the older age groups, that is 0.65% and 0.16% in the 3rd and 4th year 
of age, respectively (Keenan et al., 1994). Causes of bradycardia included disease or surgery 
in 35%, inhalation anaesthetics in 35%, and hypoxaemia in 22% of children. Hypotension 
was observed in 10% of patients, whereas asystole of ventricular fibrillation occurred in 
10%. All children underwent non-cardiac surgery and brdaycardia was defined as heart rate 
lower than 100 beats per minute. The study population was considerably younger than in 
the study described by Watterson. The authors concluded that bradycardia was more 
frequent in very young children aged 0-1 years undergoing anaesthesia, and that it was 
associated with substantial morbidity such as hypotension and asystole. 
2.3 Airway related 
The laryngeal reflex prevents foreign substances from entering into the lower airway and 
maintaining upper airway integrity. However, in some circumstances the laryngeal reflexes 
can induce cardiorespiratory events, that can even lead to life-threatening events such as 
apnea or even death. Gastroesophageal and pharyngolaryngeal refluxes are associated with 
both bradycardia and apnea, and may play a role in acute life threatening events (ALTE) or 
sudden infant death syndrome (SIDS). In airway management during general anaesthesia 
the laryngeal reflex can cause bradycardia by vagal stimulation and apnoea (Reix et al., 
2007). In procedures especially during induction of anaesthesia, such as intubation, 
bradycardia and apnoea can be provoked. Other manoeuvres, like inserting a nasal feeding 
tube or head manipulation after endotracheal intubation, can induce bradycardia in a later 
phase of anaesthesia. In newborns and infants the upper airway sensitivity is even increased 
due to the immaturity of the chemo- and mechanoreceptors in the larynx. The innervation of 
the larynx is displayed in Figure 2. 
In airway management during anaesthesia, the incidence of bradycardia is reported to be 
0.5-4.2%, and the risk is increased when children are younger (Keenan et al., 1994, Fastle and 
Roback, 2004; Gencorelli et al., 2010). In an analysis of bradycardia incidents during 
anaesthesia, 20% of bradycardia events occurred in the pre-induction or induction phase 
(Watterson et al. 2005). In a large study population of 1070 children aged 3–12 years who 
underwent rapid sequence induction for intubation, bradycardia was observed in 5 patients 
(0.5%). Bradycardia was defined as a heart rate lower than 60 beats per minute. In the same 
study group, moderate hypoxemia with SaO2 of 80-89% was observed in 20 patients (1.9%) 
and 18 patients (1.7%) developed severe hypoxemia with SaO2 lower than 80%. The risk for 
hypoxemia was increased when the weight was below 20 kg (Gencorelli et al., 2010). In 
another group of 163 children undergoing rapid sequence induction for intubation, the 
incidence of bradycardia was 4%. The median age was 12 months (range 3 months to 19 
years), which might explain the higher incidence of bradycardia. Definition of bradycardia 
was a heart rate falling two standard deviations below normal for age as described by the 
American Heart Association (Table 1). 
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Fig. 2. Innervation of the larynx, reproduced from Reix et al, 2007 
 
Age Heart Rate 
0-3 months 85-205 
3 months to 2 years 100-190 
2-10 years 60-140 
>10 years 60-100 
Table 1. The 95% confidence interval for normal heart rates in children (American Heart 
Association). 
Analysis of the children with bradycardia showed hypoxemia prior to the bradycardia in 4 
out of 6 patients. Most of the patients were intubated for respiratory disease (45%), trauma 
(19%), or seizures (12%). All bradycardia episodes resolved with ventilation or after 
endotracheal intubation (Fastle and Roback, 2004). In a series of 475 children (aged 1–22 
years) who underwent operative intervention for post-tonsillectomy haemorrhage, 
bradycardia during rapid sequence induction was observed in 20 (4.2%) of patients. 
Bradycardia was defined as a heart rate lower than 60 beats per minute, appearing in at least 
two consecutive recorded vital signs, 15 seconds apart. In total 9.9% of the studied cohort 
had a moderate or severe hypoxemic event. Moderate hypoxemia was defined as SaO2 < 
90%, and severe hypoxemia was defined as SaO2 < 80%. All bradycardia events resolved 
without pharmacological intervention (Fields et al., 2010). 
2.4 Medication related 
Many drugs used in the operating theatre can cause bradycardia. Calcium-channel blockers 
and ß-blockers are specifically used to slow heart rate. Also amiodarone has calcium channel 
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and ß-blocking properties. Most anaesthetics used during general anaesthesia have the 
potential of inducing bradycardia. In an extensive meta-analysis, propofol was associated 
with increased risk of bradycardia, also when compared to other anaesthetics (Tramèr et al., 
1997), an odds ratio of 2.3 is thereby reported. Although it is difficult to compare the 
different trials, it seems clear that propofol carries an evident risk of bradycardia. The risk of 
death after bradycardia during propofol anaesthesia was 1.4/100.000. However, propofol is 
often administered together with opioids and muscle relaxants, which are also associated 
with bradycardia. By stimulation of the muscarinic receptors of the heart, suxamethonium (a 
depolarizing muscle relaxant) can cause bradycardia. Case reports on the occurrence of 
bradycardia or even asystole with the use of succinylcholine have been published (Delphin 
et al., 1987). However, incidence numbers are lacking. Also other non-depolarizing muscle 
relaxants and opioids like fentanyl or remifentanil have been associated with development 
of bradycardia in a meta-analysis of 85 randomised, controlled trials (Komatsu et al., 2007). 
Clonidine, an -2-receptoragonist which is frequently used in addition to local anaesthesia, 
can also elicit bradycardia  (Pöpping et al., 2009).  From the vapour anaesthetics, halothane 
has been associated with the most cardiovascular changes, including bradycardia especially 
in adenotonsillectomy (van Nouhuys, 1973; Slappendel & Rutten, 1989). Data on 
bradycardia and the use of sevoflurane, isoflurane and desflurane is scarce.  Thus, many 
drugs used in the perioperative period have been more or less associated with bradycardia. 
It is however difficult to elucidate which drugs contribute most to this risk, as randomized 
trials are lacking and most drugs are administered simultaneously.  
2.5 Premedication with atropine 
As discussed before, children that need endotracheal intubation commonly develop 
bradycardia. In literature there is discussion about the effect of premedication with atropine 
in children under the age of 5. Some authors advise atropine as pretreatment in all children 
under 1 year of age receiving succinylcholine and all patient with profound bradycardia 
during intubation. As stated earlier, bradycardia during intubation is probably due to 
combined vagal response and hypoxia. During intubation the vagal nerve is activated and 
because the parasympathetic-sympathetic imbalance in young children, this reaction is more 
profound in children. This imbalance disappears at the age of one year (Rothrock and 
Pagane, 2005). By administrating atropine, or other anticholinergic medication, the incidence 
of bradycardia could decrease. Atropine inhibits the binding of acetylcholine on the 
muscarinereceptors, thereby diminishing the vagal response and bradycardia. On the other 
hand, atropine can induce dysrhythmias, such as tachycardia. It has some side-effects that 
could be unwanted, such as malignant hyperthermia, seizure and an increased risk of 
aspiration by relaxation of the lower oesophageal sphincter. In case of underdosing of 
atropine, there is a chance of provoking bradycardia. In case of overdosing, ventricular 
dysrhythmias and tachyarrhythmia may occur. 
The review of Fleming and co-workers is a good overview of the evidence pro and contra 
the use of atropine. Most evidence for the use of atropine as a standard in all children under 
the age of 18 is from before 1990. Halothane and repeated succinylcholine was often used in 
that period. Therefore there was an increased risk for bradycardia. Nowadays, incidence of 
bradycardia is decreased because other anaesthetics showing less side-effects are used. 
Considering the disadvantage of atropine, it can be stated that standard premedication is 
not advised (Fleming et al., 2005). 
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2.6 Physical status 
Infants with a poor physical status have an increased risk for bradycardia. A higher ASA 
score is associated with more bradycardia, especially with an ASA score higher than 3. 
Infants with congenital diseases, especially heart disease may develop bradycardia easier 
and more prominent. Formally pre-mature infants have considerably more risk for apnoea 
and bradycardia. This can be associated with cardiac arrest and death. To reduce this risk, 
elective surgery should be postponed until after 55 weeks of post conceptual age. For 
explanation of ASA score, see Table 2.  
 
ASA score  
1 A normal healthy patient 
2 A patient with mild systemic disease 
3 A patient with severe systemic disease 
4 A patient with severe systemic disease that is a constant threat to life 
5 A moribund patient who is not expected to survive without the operation 
6 A declared brain-dead patient whose organs are being removed for donor 
purposes 
Table 2. ASA classification system according to the American Society of Anaesthesiologists. 
Children with Down syndrome have an increased risk of developing bradycardia during 
anaesthesia. Up to 50% of them have congenital cardiac abnormalities. But irrespective of 
the presence or absence of congenital heart disease, bradycardia as well as hypotension 
during anaesthetic induction in children with Down syndrome (n=567) occurred more 
frequently as compared to controls (Kraemer et al., 2010).  Although patients with Down 
syndrome develop bradycardia at the same time after induction, the decrease in heart rate 
from baseline was greater in patients with Down syndrom as compared to healthy children 
(Bai et al., 2010). 
The presence of obstructive sleep apnea-hyppopnea syndrome (OSAS) can influence the 
heart rate in children. Bradycardia is a common feature in children with OSAS during 
overnight sleep (Huang et al., 2008). Children woth OSAS undergoing adenotonsillectomy 
had more respiratory complications (Sanders et al., 2006).  
2.7 Age  
Cardiovascular and respiratory factors are the major causes of cardiopulmonary arrest in the 
pediatric population during anesthesia. Data from the American Society of Anesthesiologist 
Closed Claims Project showed that cardiopulmonary arrest during anesthesia in the 
pediatric population was different than in the adult population. In the pediatric population, 
cardiopulmonary arrest during anesthesia was commonly caused by respiratory events 
(inadequate ventilation with cyanosis and/or bradycardia proceding the cardiac arrest) and 
is more likely to result in mortality than in the adult cases. As known from the in 1994 
founded Pediatric Perioperative Cardiac Arrest (POCA) registry anesthesia related 
cardiopulmonary arrest is fortunately an uncommon event, that is 1.4 per 10,000. It must, 
however, be emphasized that although cardiac arrest is rare significant, bradyarrhythmias 
must be treated immediately to prevent an irreversible cardiac arrest which occurs in 26% 
and have a mortality rate of 72% (Morray, 2010). Special precaution measurement should be 
considered in patients less than 1 year with severe underlying or concurrent disease having 
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emergency surgery as they are the most at risk for a fatal outcome.  In patients who are ASA 
1 or 2, 64% of the cardiac arrests are medication-related arrests. In these patients 
conservative management includes removing or reducing the dose of drugs known to 
inhibit the sinus atrial node or removing the surgical stimulus (i.e oculocardia reflex). If this 
is not effective or possible, anticholinergics like atropine or sympathicomimetics (i.e. 
ephedrine, epinephrine, isoproterenol) must be considered. The risk of bradycardia and 
cardiovascular complications in children is inversely proportional to age. 
2.8 Temperature 
Lowering temperature is a risk for developing bradycardia, in children as well as in adults. 
In extreme cases of hypothermia (less than 32 C), extreme bradycardia with a heart rate of 
less than 40 beats per minute may occur. In a case report concerning a child with an extreme 
bradycardia of 30 beats per minute at a temperature of 24.8C, no serious effects in 
neurological outcome were observed (Balagna et al., 1999). In adults hypothermia is often 
deliberately used in patients after cardiac arrest to protect their brain. These patients have a 
better neurological outcome. In these adults, bradycardia is often monitored. Usually there 
is no decreased myocardial contractility (Polderman and Herold, 2009). 
3. The incidence of bradycardia in children undergoing adenotonsillectomy 
3.1 Incidence and surgical technique 
Adenotonsillectomy is one of the most frequently performed types of surgery in children 
worldwide. The surgical rate in United States and England is approximately 50-65 per 
10,000, respectively.  In the Netherlands the surgical rate in 1998 was 115, and was even 
higher in the decades before (Van den Akker et al., 2004). In the last decade, the incidence of 
adenotonsillectomy has decreased to a surgical rate of 110 per 10,000 in 2008 (Prismant, 
2010). In The Netherlands, the most frequently used surgical technique for 
adenotonsillectomy is the guillotine technique as described by Sluder in 1911. One of the 
advantages of the guillotine technique as compared to traditional dissection is a shorter 
duration of surgery (Mulder et al., 1995). Moreover, several studies have shown that the 
guillotine technique is less painful (Homer et al., 2000). Finally, there is less blood loss 
during surgery, and the incidence of postoperative haemorrhage is lower (Wake et al., 1989; 
Ünlü et al., 1992; Scheenstra et al., 2007; Lowe et al., 2007). The guillotine technique can be 
performed intubated and nonintubated under inhalation anaesthesia. A nonintubated 
adenotonsillectomy can be performed either in supine of sitting position.  
Whereas the traditional dissection technique for adenotonsillectomy is the dominant 
technique worldwide, in The Netherlands guillotine adenotonsillectomy is most frequently 
performed, and in the majority of patients the surgery is performed nonintubated under 
inhalation anaesthesia (Tjon Pian Gi et al., 2010). For several years, there has been discussion 
about the ideal anaesthesia technique for adenotonsillectomy, either intubated or 
nonintubated. Those in favor of the intubated technique, claim that the most important 
reason to use endotracheal intubation is that the airway is secured, thus allowing the 
administration of inhalation anaesthetics and/or oxygen. Moreover, intubation could 
decrease the incidence of aspiration of blood or tissue, for example of the adenoid or tonsils. 
However, there is no evidence whether intubation indeed decreases the risk of aspiration of, 
for example, blood. In the nonintubated child, the short duration of anaesthesia and the fact 
that no intravenous muscle relaxantia are used, may allow the child to recover more quickly 
 
Cardiac Arrhythmias – New Considerations 
 
348 
2.6 Physical status 
Infants with a poor physical status have an increased risk for bradycardia. A higher ASA 
score is associated with more bradycardia, especially with an ASA score higher than 3. 
Infants with congenital diseases, especially heart disease may develop bradycardia easier 
and more prominent. Formally pre-mature infants have considerably more risk for apnoea 
and bradycardia. This can be associated with cardiac arrest and death. To reduce this risk, 
elective surgery should be postponed until after 55 weeks of post conceptual age. For 
explanation of ASA score, see Table 2.  
 
ASA score  
1 A normal healthy patient 
2 A patient with mild systemic disease 
3 A patient with severe systemic disease 
4 A patient with severe systemic disease that is a constant threat to life 
5 A moribund patient who is not expected to survive without the operation 
6 A declared brain-dead patient whose organs are being removed for donor 
purposes 
Table 2. ASA classification system according to the American Society of Anaesthesiologists. 
Children with Down syndrome have an increased risk of developing bradycardia during 
anaesthesia. Up to 50% of them have congenital cardiac abnormalities. But irrespective of 
the presence or absence of congenital heart disease, bradycardia as well as hypotension 
during anaesthetic induction in children with Down syndrome (n=567) occurred more 
frequently as compared to controls (Kraemer et al., 2010).  Although patients with Down 
syndrome develop bradycardia at the same time after induction, the decrease in heart rate 
from baseline was greater in patients with Down syndrom as compared to healthy children 
(Bai et al., 2010). 
The presence of obstructive sleep apnea-hyppopnea syndrome (OSAS) can influence the 
heart rate in children. Bradycardia is a common feature in children with OSAS during 
overnight sleep (Huang et al., 2008). Children woth OSAS undergoing adenotonsillectomy 
had more respiratory complications (Sanders et al., 2006).  
2.7 Age  
Cardiovascular and respiratory factors are the major causes of cardiopulmonary arrest in the 
pediatric population during anesthesia. Data from the American Society of Anesthesiologist 
Closed Claims Project showed that cardiopulmonary arrest during anesthesia in the 
pediatric population was different than in the adult population. In the pediatric population, 
cardiopulmonary arrest during anesthesia was commonly caused by respiratory events 
(inadequate ventilation with cyanosis and/or bradycardia proceding the cardiac arrest) and 
is more likely to result in mortality than in the adult cases. As known from the in 1994 
founded Pediatric Perioperative Cardiac Arrest (POCA) registry anesthesia related 
cardiopulmonary arrest is fortunately an uncommon event, that is 1.4 per 10,000. It must, 
however, be emphasized that although cardiac arrest is rare significant, bradyarrhythmias 
must be treated immediately to prevent an irreversible cardiac arrest which occurs in 26% 
and have a mortality rate of 72% (Morray, 2010). Special precaution measurement should be 
considered in patients less than 1 year with severe underlying or concurrent disease having 
 
Bradycardia in Children During General Anaesthesia 
 
349 
emergency surgery as they are the most at risk for a fatal outcome.  In patients who are ASA 
1 or 2, 64% of the cardiac arrests are medication-related arrests. In these patients 
conservative management includes removing or reducing the dose of drugs known to 
inhibit the sinus atrial node or removing the surgical stimulus (i.e oculocardia reflex). If this 
is not effective or possible, anticholinergics like atropine or sympathicomimetics (i.e. 
ephedrine, epinephrine, isoproterenol) must be considered. The risk of bradycardia and 
cardiovascular complications in children is inversely proportional to age. 
2.8 Temperature 
Lowering temperature is a risk for developing bradycardia, in children as well as in adults. 
In extreme cases of hypothermia (less than 32 C), extreme bradycardia with a heart rate of 
less than 40 beats per minute may occur. In a case report concerning a child with an extreme 
bradycardia of 30 beats per minute at a temperature of 24.8C, no serious effects in 
neurological outcome were observed (Balagna et al., 1999). In adults hypothermia is often 
deliberately used in patients after cardiac arrest to protect their brain. These patients have a 
better neurological outcome. In these adults, bradycardia is often monitored. Usually there 
is no decreased myocardial contractility (Polderman and Herold, 2009). 
3. The incidence of bradycardia in children undergoing adenotonsillectomy 
3.1 Incidence and surgical technique 
Adenotonsillectomy is one of the most frequently performed types of surgery in children 
worldwide. The surgical rate in United States and England is approximately 50-65 per 
10,000, respectively.  In the Netherlands the surgical rate in 1998 was 115, and was even 
higher in the decades before (Van den Akker et al., 2004). In the last decade, the incidence of 
adenotonsillectomy has decreased to a surgical rate of 110 per 10,000 in 2008 (Prismant, 
2010). In The Netherlands, the most frequently used surgical technique for 
adenotonsillectomy is the guillotine technique as described by Sluder in 1911. One of the 
advantages of the guillotine technique as compared to traditional dissection is a shorter 
duration of surgery (Mulder et al., 1995). Moreover, several studies have shown that the 
guillotine technique is less painful (Homer et al., 2000). Finally, there is less blood loss 
during surgery, and the incidence of postoperative haemorrhage is lower (Wake et al., 1989; 
Ünlü et al., 1992; Scheenstra et al., 2007; Lowe et al., 2007). The guillotine technique can be 
performed intubated and nonintubated under inhalation anaesthesia. A nonintubated 
adenotonsillectomy can be performed either in supine of sitting position.  
Whereas the traditional dissection technique for adenotonsillectomy is the dominant 
technique worldwide, in The Netherlands guillotine adenotonsillectomy is most frequently 
performed, and in the majority of patients the surgery is performed nonintubated under 
inhalation anaesthesia (Tjon Pian Gi et al., 2010). For several years, there has been discussion 
about the ideal anaesthesia technique for adenotonsillectomy, either intubated or 
nonintubated. Those in favor of the intubated technique, claim that the most important 
reason to use endotracheal intubation is that the airway is secured, thus allowing the 
administration of inhalation anaesthetics and/or oxygen. Moreover, intubation could 
decrease the incidence of aspiration of blood or tissue, for example of the adenoid or tonsils. 
However, there is no evidence whether intubation indeed decreases the risk of aspiration of, 
for example, blood. In the nonintubated child, the short duration of anaesthesia and the fact 
that no intravenous muscle relaxantia are used, may allow the child to recover more quickly 
 
Cardiac Arrhythmias – New Considerations 
 
350 
and thus decrease the risk of aspiration of blood, since laryngeal reflexes will be earlier as 
compared to intubated patients due to the use of more anaesthetics. This, among others, 
may be in favor of performing adenotonsillectomy nonintubated under inhalation 
anaesthesia. As already mentioned, the duration of surgery is substantially shorter. 
Moreover, the amount of inhalated anaesthetics administered to the child is less as 
compared to children undergoing adenotonsillectomy intubated. Only inhalation 
anaesthetics (sevoflurane) are necessary, whereas for the intubated technique muscle 
relaxantia are required. In a Dutch study performed by Mulder, it was found that the 
incidence of postoperative fever and pain was lower in children undergoing 
adenotonsillectomy under inhalation anaesthesia and nonintubated as compared to those 
undergoing the adenotonsillectomy intubated (Mulder et al., 1995). An explanation for this 
observation could be that intubation through an infection upper airway (tonsils) might 
facilitate spread of microorganisms to the lower respiratory tract. Another explanation was 
that the children undergoing adenotonsillectomy nonintubated had better laryngeal and 
tracheal reflexes, thus allowing a more effective removal of aspirated fluids by coughing 
direct postoperatively. 
3.2 Hypoxemia and bradycardia in children undergoing adenotonsillectomy 
Cardiac arrhythmias as a consequence of bradycardia have been described in children 
undergoing adenotonsillectomy with inhalation anaesthesia (Van Nouhuys, 1973; 
Slappendel and Rutten, 1989). The inhalation anaesthetics used in these studies were nitrous 
oxide, halothane and trichloroethylene. Although nitrous oxide is still used nowadays, the 
used of trichloroethylene and halothane has been decreased significantly. The different 
types of inhalation anaesthetics, and the specific type of surgery may well contribute to the 
occurrence of bradycardia. Only few studies have compared different anaesthesia 
techniques, nonintubated versus intubated, and comparison of the supine versus sitting 
position. In a prospective, randomised trial three groups of patients were compared (Knape, 
1988). The first group of patients (n=42) underwent adenotonsillectomy with Sluder 
technique nonintubated, in a sitting position. In a second group of patients (n=42), the 
adenotonsillectomy was performed intubated. The third group (n=38) underwent 
circumcision nonintubated. Oxygen levels were registered using pletysmography. In this 
study, the pulse rate was not assessed. The incidence of hypoxemia was measured for each 
group. Hypoxemia was defined as SaO2 lower than 90% and severe hypoxemia as SaO2 
lower than 75%. Nitrous oxide was used as inhalation anaesthetic, together with halothane, 
for all patients including those undergoing adenotonsillectomy intubated. The number of 
episodes per 100 patients was calculated for hypoxemia. In the nonintubated group 
undergoing adenotonsillectomy in a sitting position, the number of hypoxemia episodes 
was 331 per 100 patients, which was significantly higher than the incidence of hypoxemia in 
the group undergoing adenotonsillectomy with intubation, 29 per 100 patients. The 
incidence of hypoxemia in the control group undergoing circumcision was 32 per 100 
patients. Severe hypoxemia with SaO2 lower than 75% was only observed in the patients 
undergoing adenotonsillectomy in a sitting position and nonintubated. The incidence of 
severe hypoxemia was 117 per 100 patients. Hypoxemia occurred at the end of surgery and 
direct postoperatively in the nonintubated group undergoing adenotonsillectomy in a 
sitting position, whereas hypoxemia in the intubated group was seen after extubation. In the 
control group undergoing circumcision nonintubated hypoxemia was observed at the time 
the child got awake, indicating laryngospasm. In the study by van der Werff, a total of four 
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groups were compared with different anaesthesia techniques (van der Werff et al., 1991). 
Children underwent adenotonsillectomy with Sluder technique nonintubated (n=20), 
adenoidectomy (n=20), adenotonsillectomy with Sluder technique nonintubated with 
placement of grommets (n=20), or only placement of grommets (n=20). All patients 
underwent surgery in a supine position. In none of the patient groups severe hypoxemia 
with SaO2 lower than 75% was observed. In the group of patients undergoing 
adenotonsillectomy with Sluder technique nonintubated with placement of grommets, the 
mean SaO2 was 94% versus 97% for the other groups. Wagemans performed continuous 
SaO2 registration and assessment of pulse rate in 37 children undergoing 
adenotonsillectomy or placement of grommets under inhalation anaesthesia (Wagemans et 
al., 1991). Adenotonsillectomy was performed nonintubated, in a sitting position. Both 
groups received nitrous oxide and halothane as inhalation anaesthetics.  Hypoxemia was 
defined as SaO2 lower than 90% and bradycardia was defined as a heart frequency under 70 
beats per minute. In the patients undergoing adenotonsillectomy, a mean SaO2 of 94.7% was 
found, as compared to a mean SaO2 of 96.5% in the patient group undergoing placements of 
grommets. This was not significantly different. In only one patient (5.3%) undergoing 
adenotonsillectomy a single SaO2 lower than 90% was observed. The time of hypoxemia was 
35 seconds and the lowest registration value of SaO2 was 74%. Bradycardia was not 
observed in both groups. These findings were considerably different from those described 
by Knape, who found in 80% of patients hypoxemia with a SaO2 lower than 90%. The 
authors concluded that the duration of surgery was increasingly shorter in their study 
population for adenotonsillectomy: 24 seconds versus 80 seconds in the patients studies by 
Knape. They concluded that the interaction between the anaesthesiologist and 
otolaryngologist was of great importance, resulting in a shorter duration of surgery. This 
leads to their conclusion that performing adenotonsillectomy under inhalation anaesthesia 
nonintubated in a sitting position, is a safe procedure. Based on these studies the Dutch 
Association of Otolaryngology and Head & Neck Surgery, in cooperation with the Dutch 
Institute for Healthcare Improvement (CBO) published the practice guideline 'Adenoid and 
tonsil disorders in secondary care' in 2008 (CBO, 2008). In this practice guideline, the advice 
was given to perform adenotonsillectomy using guillotine technique according to Sluder in 
a supine position if nonintubated inhalation anaesthesia is given.  
In a study recently performed by our departments, we retrospectively analysed the 
incidence of hypoxemia and bradycardia in children undergoing adenotonsillectomy 
(Kretzschmar et al., 2010). Analysis was performed on a total of 2963 children who 
underwent adenotonsillectomy nonintubated in a sitting position. Hypoxemia was defined 
as a SaO2 lower than 85% with a duration longer than 60 seconds. Incidental desaturation 
was defined as SaO2 lower than 90%, with a duration shorter than 60 seconds. Bradycardia 
was defined as a heart frequency under 60 beats per minute, for longer than 30 seconds. 
Incidental bradycardia was defined as a heart frequency lower than 60 beats per minute for 
a duration shorter than 30 seconds. For both incidental desaturation and bradycardia, the 
incidence per 100 patients was calculated in order to compare our data with earlier studies 
described above. Sevoflurane was used as inhalation anaesthetic. Hypoxemia occurred in 
132 patients (4.5%) and the incidence of incidental desaturations (SaO2 lower than 90%) was 
217 per 100 patients. In 1724 patients no incidental desaturations at all were seen. In 280 
patients (9.4%) bradycardia was observed. The incidence of incidental bradycardia, a heart 
frequency lower than 60 beats per second but shorter than 30 seconds, was 234 per 100 
patients. In 2683 patients (90.6%) bradycardia with a heart rate lower than 60 and a duration 
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and thus decrease the risk of aspiration of blood, since laryngeal reflexes will be earlier as 
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group. Hypoxemia was defined as SaO2 lower than 90% and severe hypoxemia as SaO2 
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sitting position, whereas hypoxemia in the intubated group was seen after extubation. In the 
control group undergoing circumcision nonintubated hypoxemia was observed at the time 
the child got awake, indicating laryngospasm. In the study by van der Werff, a total of four 
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Children underwent adenotonsillectomy with Sluder technique nonintubated (n=20), 
adenoidectomy (n=20), adenotonsillectomy with Sluder technique nonintubated with 
placement of grommets (n=20), or only placement of grommets (n=20). All patients 
underwent surgery in a supine position. In none of the patient groups severe hypoxemia 
with SaO2 lower than 75% was observed. In the group of patients undergoing 
adenotonsillectomy with Sluder technique nonintubated with placement of grommets, the 
mean SaO2 was 94% versus 97% for the other groups. Wagemans performed continuous 
SaO2 registration and assessment of pulse rate in 37 children undergoing 
adenotonsillectomy or placement of grommets under inhalation anaesthesia (Wagemans et 
al., 1991). Adenotonsillectomy was performed nonintubated, in a sitting position. Both 
groups received nitrous oxide and halothane as inhalation anaesthetics.  Hypoxemia was 
defined as SaO2 lower than 90% and bradycardia was defined as a heart frequency under 70 
beats per minute. In the patients undergoing adenotonsillectomy, a mean SaO2 of 94.7% was 
found, as compared to a mean SaO2 of 96.5% in the patient group undergoing placements of 
grommets. This was not significantly different. In only one patient (5.3%) undergoing 
adenotonsillectomy a single SaO2 lower than 90% was observed. The time of hypoxemia was 
35 seconds and the lowest registration value of SaO2 was 74%. Bradycardia was not 
observed in both groups. These findings were considerably different from those described 
by Knape, who found in 80% of patients hypoxemia with a SaO2 lower than 90%. The 
authors concluded that the duration of surgery was increasingly shorter in their study 
population for adenotonsillectomy: 24 seconds versus 80 seconds in the patients studies by 
Knape. They concluded that the interaction between the anaesthesiologist and 
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Institute for Healthcare Improvement (CBO) published the practice guideline 'Adenoid and 
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patients. In 2683 patients (90.6%) bradycardia with a heart rate lower than 60 and a duration 
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of more than 30 seconds did not occur. In 25 patients (0.8%) bradycardia and hypoxemia 
both occurred. The bradycardia was registered at the same moment or directly after 
hypoxemia in 3 of these 25 patients. All episodes were reversible and in none of the patients 
peri-operative complications due to hypoxemia or bradycardia were observed. 
 
 No Hypoxemia Hypoxemia Total 
No Bradycardia 2576 (86.9%) 107 (3.6%) 2683 (90.6%) 
Bradycardia 255 (8.6%) 25 (0.8%) 280 (9.4%) 
Total 2831 (95.5%) 132 (4.5%) 2963 (100%) 
Table 3. Incidence of hypoxemia and bradycardia in patients undergoing 
adenotonsillectomy. Hypoxemia was defined as a SaO2 lower than 85% with a duration 
longer than 60 seconds. Bradycardia was defined as a heart frequency under 60 beats per 
minute, for longer than 30 seconds. 
Different explanations for the occurrence of bradycardia can be given. Bradycardia as a 
direct consequence of hypoxemia is one of these, and can indicate severe problems during 
anesthesia. This was only observed in 3 of the patients (0.001%), and was reversible in all of 
them. It seems that the specific type of surgery is more likely to cause the bradycardia. Due 
to the placement of the mouth gag and guillotine procedure with manipulation of the tissue 
of the pharyngeal wall it is likely that the vagus nerve is stimulated leading to a reflex of 
lowering the heart rate.  
We concluded that bradycardia and hypoxemia both occur during adenotonsillectomy 
nonintubated in a sitting position. Both bradycardia and hypoxemia have shown to be 
reversible and do not lead to perioperative complications. The incidence of bradycardia 
directly during or after an episode of hypoxemia is extremely rare, in our study the 
incidence was 0.001%. However, bradycardia does occur relatively often, that is in 9.5% of 
patients. One of the most important explanations is the specific kind of surgery, where 
stimulation of the vagal nerve leads to bradycardia.  
4. Discussion 
Cardiac output is determined by the product of heart rate and left ventricular stroke 
volume. Bradycardia may result in an insufficient rate to sustain cardiac output and hence 
oxygen delivery to tissue beds. This is particularly so in the case of young children in whom 
cardiac output is more affected by changes in heart rate than stroke volume. A prompt 
appropriate response to bradycardia under anaesthesia is important as some causes are rare 
and/or obscure and homeostatic mechanisms may be impaired by anaesthetic agents. 
Hamilton and co-workers suggest in a recent meta-analysis that a preemptive targeted 
approach to the management of hemodynamics in the perioperative period may reduce 
morbidity and mortality for high-risk surgical patients (Hamilton et al., 2011). Flick et al 
reported that postoperative cardiac arrest occurred most often in children with congenital 
heart disease as a result of factors not related to anesthesia. While cardiac surgery accounted 
for only 5% of all procedures, 87.5% of all arrests occurred in patients with congenital heart 
disease, usually during cardiac surgery as a result of failure to wean from cardiopulmonary 
bypass. Anesthesia factors were related in only 7.5% of all arrests, with an incidence of 0.65 
per 10,000 anesthetics. Only six anesthesia-related arrests occurred in noncardiac cases 
during the 17-yr study period (Flick et al., 2007).  
 




Fig. 3. Registration results of SaO2 (green line, right axis, SaO2 in %) and heart rate (red line, 
left axis, in beats per minute) as measured in time (horizontal-axis, in seconds) during 
inhalation anaesthesia in a 6-years old child undergoing adenotonsillectomy in sitting 
position.  
During adenotonsillectomy under inhalation anaesthesia, bradycardia and hypoxemia both 
occur. In our study on children undergoing adenotonsillectomy in a sitting position 
nonintubated, both bradycardia and hypoxemia have shown to be reversible and do not 
lead to perioperative complications. The incidence of bradycardia directly during or after an 
episode of hypoxemia was extremely rare (0.001%). However, bradycardia does occur 
relatively often, in 9.5% of patients undergoing adenotonsillectomy in a sitting position 
nonintubated. An explanation might be a combination of study population, relatively young 
children, as well as the anaesthetics used, and the specific type of surgery leading to 
stimulation of the vagal nerve. Further research is necessary to compare different anesthesia 
techniques for adenotonsillectomy, with and without intubation. 
5. Conclusion 
Both bradycardia and hypoxemia occur relatively often during adenotonsillectomy, 
performed nonintubated in a sitting position under inhalation anaesthesia. The incidence of 
bradycardia in these children is 9.5%. Both bradycardia and hypoxemia are reversible and 
do not lead to perioperative complications. The incidence of bradycardia directly during or 
after an episode of hypoxemia is extremely rare. In general, in the pediatric population 
cardiovascular and respiratory factors are the major causes of cardiopulmonary arrest 
during anesthesia. The major causes of anesthesia-related cardiac arrest in the pediatric 
population are hypovolemia, preoperative anemia, pharmacological toxicity, 
hypoventilation and airway obstruction. Cardiopulmonary arrest during anesthesia in the 
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of more than 30 seconds did not occur. In 25 patients (0.8%) bradycardia and hypoxemia 
both occurred. The bradycardia was registered at the same moment or directly after 
hypoxemia in 3 of these 25 patients. All episodes were reversible and in none of the patients 
peri-operative complications due to hypoxemia or bradycardia were observed. 
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anesthesia. This was only observed in 3 of the patients (0.001%), and was reversible in all of 
them. It seems that the specific type of surgery is more likely to cause the bradycardia. Due 
to the placement of the mouth gag and guillotine procedure with manipulation of the tissue 
of the pharyngeal wall it is likely that the vagus nerve is stimulated leading to a reflex of 
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reversible and do not lead to perioperative complications. The incidence of bradycardia 
directly during or after an episode of hypoxemia is extremely rare, in our study the 
incidence was 0.001%. However, bradycardia does occur relatively often, that is in 9.5% of 
patients. One of the most important explanations is the specific kind of surgery, where 
stimulation of the vagal nerve leads to bradycardia.  
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Cardiac output is determined by the product of heart rate and left ventricular stroke 
volume. Bradycardia may result in an insufficient rate to sustain cardiac output and hence 
oxygen delivery to tissue beds. This is particularly so in the case of young children in whom 
cardiac output is more affected by changes in heart rate than stroke volume. A prompt 
appropriate response to bradycardia under anaesthesia is important as some causes are rare 
and/or obscure and homeostatic mechanisms may be impaired by anaesthetic agents. 
Hamilton and co-workers suggest in a recent meta-analysis that a preemptive targeted 
approach to the management of hemodynamics in the perioperative period may reduce 
morbidity and mortality for high-risk surgical patients (Hamilton et al., 2011). Flick et al 
reported that postoperative cardiac arrest occurred most often in children with congenital 
heart disease as a result of factors not related to anesthesia. While cardiac surgery accounted 
for only 5% of all procedures, 87.5% of all arrests occurred in patients with congenital heart 
disease, usually during cardiac surgery as a result of failure to wean from cardiopulmonary 
bypass. Anesthesia factors were related in only 7.5% of all arrests, with an incidence of 0.65 
per 10,000 anesthetics. Only six anesthesia-related arrests occurred in noncardiac cases 
during the 17-yr study period (Flick et al., 2007).  
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population are hypovolemia, preoperative anemia, pharmacological toxicity, 
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pediatric population is different as compared to the adult population. In children, 
cardiopulmonary arrest during anesthesia is commonly caused by respiratory events and is 
more likely to result in mortality than in the adults. Anesthesia related cardiopulmonary 
arrest is fortunately an uncommon event, but it must be emphasized that significant 
bradyarrhythmias must be treated immediately to prevent an irreversible cardiac arrest. 
Special precaution measurement should be considered in patients less than 1 year with 
severe underlying or concurrent disease having emergency surgery as they are the most at 
risk for a fatal outcome. Finally, it must be clear that children should be cared for in facilities 
with adequate skilled medical and nursing staff and appropriately sized equipment. 
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pediatric population is different as compared to the adult population. In children, 
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more likely to result in mortality than in the adults. Anesthesia related cardiopulmonary 
arrest is fortunately an uncommon event, but it must be emphasized that significant 
bradyarrhythmias must be treated immediately to prevent an irreversible cardiac arrest. 
Special precaution measurement should be considered in patients less than 1 year with 
severe underlying or concurrent disease having emergency surgery as they are the most at 
risk for a fatal outcome. Finally, it must be clear that children should be cared for in facilities 
with adequate skilled medical and nursing staff and appropriately sized equipment. 
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The propagation of electrical waves through cardiac tissue is a very important phenomenon
to study since those waves activate the mechanisms for cardiac contraction, responsible to
pump blood to the body. An electrical wave of excitation, called also an action potential
wave, is initiated periodically at a place called the sinoatrial node, the natural pacemaker of
the heart. This wave, propagates throughout the atria where it arrives at the atrioventricular
node, where after some time delay, it propagates to the ventricles via the Purkinje fibers
(Zaret et al., 1992). In normal conditions, this process is repeated approximately 70 to 100
times each minute and is commonly referred to as a heartbeat. The condition at which
abnormal generation or propagation of excitation waves during the process described above,
is termed as arrhythmia.
One of the proposed mechanisms involved in the development of certain type of arrhythmias,
are spiral waves, a particular form of functional reentry (Fenton et al., 2002; Veenhuyzen et al.,
2004). Spiral waves, are self sustained waves of excitation that rotate freely or around an
obstacle, reactivating the same area of tissue at a higher frequency than the normal SA
node would do, increasing the normal heartbeat rate. In the worst scenario, a spiral wave
might break up into smaller spiral waves giving uncoordinated contractions of the heart in a
phenomenon known as fibrillation. When this phenomenon occurs in the ventricles, the heart
quivers and looses its strength to pump blood to the body leading to immediate cardiac arrest
(Fenton et al., 2002; Zaret et al., 1992). Fibrillation, is the main cause of death in industrialized
countries (Fenton et al., 2002; Priori et al., 2002; Tang et al., 2005; Zipes, 2005).
An important research area is the study of the interaction of spiral waves in cardiac tissue with
obstacles. Obstacles in cardiac tissue can be partially excitable or non excitable. Examples
of partially excitable obstacles are scar tissue (Starobin et al., 1996) or ionic heterogeneities
(Starobin et al., 1996; Tusscher & Panfilov, 2002; Valderrábano et al., 2000), whereas examples
of non excitable obstacles are arteries (Valderrábano et al., 2000) or the natural orifices in the
atria (Azene et al., 2001).
It has been observed that an obstacle in cardiac tissue might act as a stabilizer of
spiral wave dynamics (Davidenko et al., 1992; Ikeda et al., 1997; Kim et al., 1999; Lim et al.,
2006; Pertsov et al., 1993; Valderrábano et al., 2000), as it provides a transition between
meandering spiral waves (Ikeda et al., 1997) or multiple spiral waves (Shajahan et al., 2007;
Valderrábano et al., 2000) into a simple rotation spiral, which is attached to the obstacle. This
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to study since those waves activate the mechanisms for cardiac contraction, responsible to
pump blood to the body. An electrical wave of excitation, called also an action potential
wave, is initiated periodically at a place called the sinoatrial node, the natural pacemaker of
the heart. This wave, propagates throughout the atria where it arrives at the atrioventricular
node, where after some time delay, it propagates to the ventricles via the Purkinje fibers
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An important research area is the study of the interaction of spiral waves in cardiac tissue with
obstacles. Obstacles in cardiac tissue can be partially excitable or non excitable. Examples
of partially excitable obstacles are scar tissue (Starobin et al., 1996) or ionic heterogeneities
(Starobin et al., 1996; Tusscher & Panfilov, 2002; Valderrábano et al., 2000), whereas examples
of non excitable obstacles are arteries (Valderrábano et al., 2000) or the natural orifices in the
atria (Azene et al., 2001).
It has been observed that an obstacle in cardiac tissue might act as a stabilizer of
spiral wave dynamics (Davidenko et al., 1992; Ikeda et al., 1997; Kim et al., 1999; Lim et al.,
2006; Pertsov et al., 1993; Valderrábano et al., 2000), as it provides a transition between
meandering spiral waves (Ikeda et al., 1997) or multiple spiral waves (Shajahan et al., 2007;
Valderrábano et al., 2000) into a simple rotation spiral, which is attached to the obstacle. This
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transition is clinically important because as it has been shown, fibrillation like activity changes
to a tachycardia regime (Kim et al., 1999).
The interaction of spiral waves with obstacles and its relationship with the transition
between different arrhythmic regimes has been experimentally and computationally
studied by different researchers (Azene et al., 2001; Comtois & Vinet, 2005; Ikeda et al., 1997;
Shajahan et al., 2007; 2009; Valderrábano et al., 2000). Valderrabano et al. (Valderrábano et al.,
2000) studied in a cardiac tissue preparation the transition between ventricular fibrillation
and ventricular tachycardia due to the presence of obstacles; Ikeda et al. (Ikeda et al., 1997),
also considered the transition of different arrhythmic regimes due to the attachment of a
spiral wave to an obstacle of minimum size. Shajahan et al. (Shajahan et al., 2007) used the
Luo-Rudy and Panfilov models to study the transition of spiral turbulence to a simple rotating
spiral wave due to the presence of an obstacle, which again provides a transition between
different arrhythmic regimes; Xie et al. (Xie et al., 2001) presented a computational study of
the effects of regional ischemia on the stability of a spiral wave; Azene et al. (Azene et al.,
2001) carried out a computational study of the attachment and detachment of wavefronts to
obstacles based on the Luo-Rudy model; Olmos (Olmos, 2010) studied the interaction of spiral
waves in a particular case of the meandering regime, with rectangular obstacles. The aim in
that work was to understand better necessary conditions in order to obtain attachment of the
meandering spiral wave to the obstacle.
However, the interaction of spiral waves with obstacles and its relationship with transitions
between different arrhythmic regimes, is a topic that has not been completely understood. For
example, the interaction of a spiral wave in the meandering regime with an obstacle, has not
previously being considered. Such interactions can be very complex (Olmos & Shizgal, 2008;
Yermakova & Pertsov, 1986), and the determination of the conditions for which a meandering
spiral wave attaches to an obstacle is an important endeavor. On the other hand, it has been
considered that the presence of obstacles can be only of a stabilizing nature, which is not
always the case. Therefore, the main objective of this work is to present a numerical study of
the interaction of spiral waves with obstacles and to show the existence of different transitions
due to the presence of obstacles.
By considering non-excitable and partially excitable obstacles we will show that obstacles
cannot only stabilize the dynamics as shown in (Ikeda et al., 1997; Kim et al., 1999; Lim et al.,
2006), but also, they can act as destabilizers. In both cases and by different mechanisms, the
obstacle might act as a switch between two arrhythmic regimes, in which one is less dangerous
than the other. In the case of non-excitable obstacles, it is shown that under certain conditions
like the size of the obstacle, a more complex arrhythmia might appear.
To this end, this work will consist in the following sections. We start by presenting a general
background about generation and propagation of action potentials (Section 2). In Section
3, we describe the model equations considered in the simulations. Then, in Section 4 the
formation of a spiral wave is discussed. In the same section, we discuss the concepts of
meandering and drift of spirals, which will be essential in explaining the results in this work.
We follow this section by presenting the results obtained with partially excitable obstacles and
non-excitable obstacles (Sections 5 and 6). We finish this work with Section 7 by presenting
some conclusions, limitations and open questions in this topic.
2. Generation and propagation of an action potential
An important electrical property of atrial and ventricular cells is excitability. At rest, a
ventricular cell has a transmembrane potential of about u = −84mV (Beeler & Reuter, 1977),
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which is called the resting membrane potential (RMP). If a short time pulse of current is
applied such that the new potential is below −60mV, the value of u will return to the RMP
immediately. However, if the potential is raised above u = −60mV, the transmembrane
potential will undergo a large excursion raising its value approximately to 28mV, generating
a peak, then a plateau and finally return to the RMP (Fig. 1). This phenomenon is called
an action potential (AP) and cells with this property are called excitable cells. The value of
u above which an AP is elicited, which in this case is u ≈ −60mV, is called the threshold
potential value uth.































Fig. 1. Membrane potential u versus time during an AP. Representative mechanisms
involved in the generation of an AP in a cardiac cell.
Changes in the membrane potential are due mainly to the passage of Na+, K+ and Ca++
ions via ion channels and other mechanisms through the cell membrane. The ion channels
are membrane proteins which allow the passage across the membrane of specific type of ions
between the interior and exterior of the cell. An essential part of the work by Hodgkin and
Huxley (Hodgkin & Huxley, 1952) was to establish that the Na, K and Ca channels can be
opened or closed, and that state depends on the membrane potential at a given time.
The general mechanism by which an AP is generated is as follows: Initially the cell is at rest
i.e. the potential across the cell membrane is at the RMP value. When the current is applied
such that the new potential is above uth, Na channels open in a fast time scale and a flux of
Na+ inside the cell, follows (Fig. 1A). The Na current is responsible for the rapid change in
u, which changes dramatically from −60mV to 28mV in a phenomenon called depolarization.
In Fig. 1B, K channels open in a slow time scale compared to the time scale of the Na channels
opening, and K+ flow outside the cell. In Fig. 1C, the Na channels close and the K+ current
lowers the membrane potential generating a peak in the AP. After that, Ca channels open in a
slow time scale and a flow of Ca++ from outside to inside the cell occurs (Fig. 1D). During this
stage, K and Ca currents move in the opposite direction, generating what is called a plateau
(Fig. 1E). Finally, both channels close and the membrane potential returns to the RMP value
(Fig. 1F).
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transition is clinically important because as it has been shown, fibrillation like activity changes
to a tachycardia regime (Kim et al., 1999).
The interaction of spiral waves with obstacles and its relationship with the transition
between different arrhythmic regimes has been experimentally and computationally
studied by different researchers (Azene et al., 2001; Comtois & Vinet, 2005; Ikeda et al., 1997;
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2001) carried out a computational study of the attachment and detachment of wavefronts to
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waves in a particular case of the meandering regime, with rectangular obstacles. The aim in
that work was to understand better necessary conditions in order to obtain attachment of the
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example, the interaction of a spiral wave in the meandering regime with an obstacle, has not
previously being considered. Such interactions can be very complex (Olmos & Shizgal, 2008;
Yermakova & Pertsov, 1986), and the determination of the conditions for which a meandering
spiral wave attaches to an obstacle is an important endeavor. On the other hand, it has been
considered that the presence of obstacles can be only of a stabilizing nature, which is not
always the case. Therefore, the main objective of this work is to present a numerical study of
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2006), but also, they can act as destabilizers. In both cases and by different mechanisms, the
obstacle might act as a switch between two arrhythmic regimes, in which one is less dangerous
than the other. In the case of non-excitable obstacles, it is shown that under certain conditions
like the size of the obstacle, a more complex arrhythmia might appear.
To this end, this work will consist in the following sections. We start by presenting a general
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which is called the resting membrane potential (RMP). If a short time pulse of current is
applied such that the new potential is below −60mV, the value of u will return to the RMP
immediately. However, if the potential is raised above u = −60mV, the transmembrane
potential will undergo a large excursion raising its value approximately to 28mV, generating
a peak, then a plateau and finally return to the RMP (Fig. 1). This phenomenon is called
an action potential (AP) and cells with this property are called excitable cells. The value of
u above which an AP is elicited, which in this case is u ≈ −60mV, is called the threshold
potential value uth.































Fig. 1. Membrane potential u versus time during an AP. Representative mechanisms
involved in the generation of an AP in a cardiac cell.
Changes in the membrane potential are due mainly to the passage of Na+, K+ and Ca++
ions via ion channels and other mechanisms through the cell membrane. The ion channels
are membrane proteins which allow the passage across the membrane of specific type of ions
between the interior and exterior of the cell. An essential part of the work by Hodgkin and
Huxley (Hodgkin & Huxley, 1952) was to establish that the Na, K and Ca channels can be
opened or closed, and that state depends on the membrane potential at a given time.
The general mechanism by which an AP is generated is as follows: Initially the cell is at rest
i.e. the potential across the cell membrane is at the RMP value. When the current is applied
such that the new potential is above uth, Na channels open in a fast time scale and a flux of
Na+ inside the cell, follows (Fig. 1A). The Na current is responsible for the rapid change in
u, which changes dramatically from −60mV to 28mV in a phenomenon called depolarization.
In Fig. 1B, K channels open in a slow time scale compared to the time scale of the Na channels
opening, and K+ flow outside the cell. In Fig. 1C, the Na channels close and the K+ current
lowers the membrane potential generating a peak in the AP. After that, Ca channels open in a
slow time scale and a flow of Ca++ from outside to inside the cell occurs (Fig. 1D). During this
stage, K and Ca currents move in the opposite direction, generating what is called a plateau
(Fig. 1E). Finally, both channels close and the membrane potential returns to the RMP value
(Fig. 1F).
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Point in refractory 
state (Cannot fire an
AP)
An AP has just passed.
Return to resting state.
Fig. 2. Propagation of an AP. The propagation is taken over a hypothetical large myocyte.
Each location of the cell membrane, once it has a response above uth, will experience an AP.
The AP generated in a cell location, with the proper conditions (Kléber & Rudy, 2004), will
propagate through the rest of the cell and through the cardiac tissue. The general mechanism
by which an AP travels through cardiac muscle can be explained by considering a large single
cell as shown in Fig. 2. In Fig. 2, it is considered that an AP is propagating only in the x
direction and from right to left. At location A, the membrane potential is at the RMP value
and it is ready to accept an AP. At point B, an AP has just been elicited. At point C, an AP is in
process and at this location the cell is in refractory state and another AP cannot be generated.
Durig this stage the Na channels, responsible for the depolarization of the cell, are closed and
remain inactive for a time called the refractory period. Finally, at location D, an AP has just
passed and at this location the membrane potential has almost returned to the RMP value.
Therefore, the propagation of the AP is as follows. At location B, where the AP has just been
elicited, Na ions are entering to the cell. These ions generate a current in the x direction due
to the concentration gradient in a neighborhood of point B. These ions move to location A,
increasing its corresponding u value until it reaches uth. Then, an AP is elicited at location A
and the AP advances in space. Therefore, propagation of the AP follows.
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3. The model equations
In order to make simulations we consider equations of the reaction-diffusion type given by
∂u
∂t
= ∇ · (D∇u)− 1
Cm
(Iion) (1)
where, u is the transmembrane potential, D is the conductivity tensor, Cm is the capacitance
and Iion is the sum of the different ionic currents. There are different forms in which Iion can be
chosen, depending on which cell type is considered. For example the Luo-Rudy (Luo & Rudy,
1994) or the Priebe-Beuckelmann (Priebe & Beuckelmann, 1998) models are considered for
ventricular cells, whereas the Courtemanche (Courtemanche et al., 1998) and the Nygren
(Nygren et al., 1998) models were developed for atrial cells. Other models are the Yanagihara
model for the sinoatrial node (Yanagihara et al., 1980), and the DiFrancesco- Noble model for
the Purkinje cells (DiFrancesco & Noble, 1985). A complete list of models can be found in
(Fenton & Cherry, 2008).
In this work, we consider the ionic currents given by Fenton and Karma (Fenton & Karma,
1998). This set of equations is a minimal model and was designed to mimic the behavior of
complex models with a minimum number of variables. The Fenton-Karma (FK) equations are
of the reaction diffusion type. They are given by
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where
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τ−v (u) = Θ(u − uv)τ−v1 + Θ(uv − u)τ−v2
(3)
In this case, u = u(x, t) measures the membrane potential at a location x and time t, whereas
v and w are gate variables. I f i, Iso and Isi denote fast inward, slow outward and slow inward
currents, respectively. Also D = 0.001, Cm = 1,τd = 0.403, τr = 50.0, τsi = 44.84, τo =
8.3, τ+v = 3.33, τ
−
v1 = 1000.0, τ
−
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+
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w = 11, uc = 0.13, uv = 0.055, u
si
c = 0.85.





Equations (2) are solved in a rectangular domain Ω = [−7, 7]× [−7, 7] using finite differences
with N = 512 points in each dimension. Advancing in time is done with Euler as in
(Fenton & Karma, 1998) with dt = 0.125. At the domain boundary and at the boundary of
non-excitable obstacles (Section 6), no-flux boundary conditions were imposed. Boundary
conditions at obstacles were implemented as done in (Morton & Mayers, 2005).
4. Generation of a spiral wave
Spiral waves have been observed to occur in cardiac tissue (Ikeda et al., 1997; Isomura et al.,
2008; Pertsov et al., 1993) and in computer models (Isomura et al., 2008; Olmos, 2010; Otani,
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Fig. 2. Propagation of an AP. The propagation is taken over a hypothetical large myocyte.
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Therefore, the propagation of the AP is as follows. At location B, where the AP has just been
elicited, Na ions are entering to the cell. These ions generate a current in the x direction due
to the concentration gradient in a neighborhood of point B. These ions move to location A,
increasing its corresponding u value until it reaches uth. Then, an AP is elicited at location A
and the AP advances in space. Therefore, propagation of the AP follows.
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2000). There are different ways in which a spiral wave might be generated. For example,
spiral waves arise when an unexcitable obstacle is stimulated with high frequency of AP
(Panfilov & Kenner, 1993); they can also be generated by using the method of cross-field
stimulation (Pertsov et al., 1993); and they might arise due to the appearance of ectopic beats
(Otani, 2000). Ectopic beats can arise due to abnormal calcium cycling (Benson & Holden,
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Fig. 3. Generation of a spiral wave due to ectopic activity. See text for details. The black bold
line is the contour plot u(x, y, t∗) = 0.1. The different colored regions represent different
levels of refractoriness of the medium. The region in white represents the medium
completely recovered and an AP can be elicited. The region in red is a completely
unexcitable region as an AP is occurring. The regions in orange and clear blue have a very
low excitability level. The region in dark blue is more excitable and an AP might propagate
in this region. The arrows point the direction of wave propagation. (x and y are in cm)
A particular and simple way in which the formation of a spiral wave can be explained, is
shown in Fig. 3, where a solution of Eq. (2) is shown for four different integration times.
In Fig. 3A, a pulse travels from left to right as shown by the direction of the arrows. After
the pulse has passed, an ectopic firing appears at the back of the pulse. The ectopic firing
starts propagating in all directions except at the back of the front where the region is still
in refractory state (Fig. 3B). The abnormal firing generates a curved front with a free end
that propagate downwards (Fig. 3C). The original AP moves to the right, disappears at the
right boundary and the region that was initially in refractory state is now ready to accept
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another AP. Then, the free end can propagate on the recovered region generating a spiral
wave (Fig. 3D). After a spiral wave has been generated, if its rotation frequency is faster than
the stimulation frequency from the sinoatrial node, then the spiral wave becomes the new
pacemaker of the heart (Lee, 1997).
4.1 Meandering and drift of a spiral wave
When a spiral wave evolves in excitable media in general, its dynamics are ruled by (i) the
local conducting mechanisms, and; (ii) the heterogeneities of the medium. The former gives
rise to a phenomenon called meandering, whereas the later to a phenomenon referred to as
drift of a spiral wave.
One way to get a better understanding of meandering and drift of a spiral wave, is by studying
the evolution of the position of its tip. The tip of a spiral wave can be defined in a variety of
ways and a resume can be found in (Fenton et al., 2002). In this work it is considered the
tip of the spiral wave as the point over the level curve u = 0.5 with zero normal velocity
(Fenton et al., 2002).
d0.430.400.34 0.37
Fig. 4. Tip trajectories of the spiral waves obtained with Eqns. (2), with uc = 0.13 and varying
the parameter τd from 0.34 to 0.43. An increase in the value τd implies a reduction in the
excitability of the medium.
4.1.1 Meandering of a spiral wave
In Fig. 4, different tip trajectories of spiral waves corresponding to different values of τd are
shown. The value τd controls the speed at which the depolarizing ions enter to the cell and is
a measure of the excitability of the cell (Efimov et al., 1995; Fenton et al., 2002). An increase in
the value τd implies a reduction in the excitability of the medium. When τd = 0.43 the tip of
the spiral wave traces a circumference. When the value of τd is reduced to 0.425 the radius of
the circular trajectory is reduced. However, when the value of τd is reduced to about 0.415 the
trajectory is no longer circular but a curve that resembles an epitrochoid (Fig. 5B). Decreasing
the value of τd increases the radius R (Fig. 5B) of the epitrochoidal trajectory. For τd = 0.3965
the value of R tends to infinity obtaining a trochoidal trajectory (Epitrochoid with R = ∞).
For smaller values of τd the tip trajectory resembles an hypotrochoid of radius R (Fig. 5A). For
values less than τd = 0.34 deformations of hypotrochoidal trajectories are obtained (Fig. 4).
The phenomenon shown in Fig. 4, is called meandering of the tip trajectory or meandering. In
order to understand the mechanisms behind meandering it is necessary to study the recovery
regions when the spiral wave is propagating in the medium. In Fig. 6, it is shown the contour
of the variable u(x, y, t∗) = 0.1 for a particular time t∗ (Labeled bold line in Fig. 6B); Also, are
shown different regions corresponding to the level of recovery of the medium, given by the
variable v in Eqns. 2, plotted also for the time t∗. The region in black means that the region is
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shown in Fig. 3, where a solution of Eq. (2) is shown for four different integration times.
In Fig. 3A, a pulse travels from left to right as shown by the direction of the arrows. After
the pulse has passed, an ectopic firing appears at the back of the pulse. The ectopic firing
starts propagating in all directions except at the back of the front where the region is still
in refractory state (Fig. 3B). The abnormal firing generates a curved front with a free end
that propagate downwards (Fig. 3C). The original AP moves to the right, disappears at the
right boundary and the region that was initially in refractory state is now ready to accept
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another AP. Then, the free end can propagate on the recovered region generating a spiral
wave (Fig. 3D). After a spiral wave has been generated, if its rotation frequency is faster than
the stimulation frequency from the sinoatrial node, then the spiral wave becomes the new
pacemaker of the heart (Lee, 1997).
4.1 Meandering and drift of a spiral wave
When a spiral wave evolves in excitable media in general, its dynamics are ruled by (i) the
local conducting mechanisms, and; (ii) the heterogeneities of the medium. The former gives
rise to a phenomenon called meandering, whereas the later to a phenomenon referred to as
drift of a spiral wave.
One way to get a better understanding of meandering and drift of a spiral wave, is by studying
the evolution of the position of its tip. The tip of a spiral wave can be defined in a variety of
ways and a resume can be found in (Fenton et al., 2002). In this work it is considered the
tip of the spiral wave as the point over the level curve u = 0.5 with zero normal velocity
(Fenton et al., 2002).
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trajectory is no longer circular but a curve that resembles an epitrochoid (Fig. 5B). Decreasing
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The phenomenon shown in Fig. 4, is called meandering of the tip trajectory or meandering. In
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of the variable u(x, y, t∗) = 0.1 for a particular time t∗ (Labeled bold line in Fig. 6B); Also, are
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variable v in Eqns. 2, plotted also for the time t∗. The region in black means that the region is












Fig. 5. (A) An hypotrochoid and; (B) an epitrochoid. From (Olmos, 2007)
completely unexcitable (v in this case is close to zero); As the region becomes clearer, the value
of v gets closer to 1 and therefore the region is able to accept more easily another AP. The line









































Fig. 6. Propagation of a spiral wave generated with Eqns. (2) with τd = 0.3965. The line in
blue represents the trajectory of the tip. The different coloured regions represents different
levels of refractoriness given by the v variable. For v close to 0 (black), the region is in its
maximum level of refractoriness and an AP cannot be elicited here. For v ≈ 1 (white), the
region is almost or totally recovered and an AP can be elicited in this region. (A) Formation
of a petal; (B) Formation of an arc. The blue dot filled in white, is the location of the tip of the
spiral.
In Figures 4 and 6, it is shown that the trajectory of the tip of the spiral wave has high and
low curvature in an alternate and periodic fashion. The part with high curvature is referred
to as a petal, whereas the part with low curvature, an arc. In Fig. 6A, the tip is tracing a petal,
whereas in Fig. 6B, an arc.
In Fig. 6A, it is shown the spiral wave at the time where the tip is tracing a petal. In
this case, the front that is close to the tip (blue dot filled in white) of the wave, propagates
through a region that is almost completely recovered giving a maximum in the curvature of
the trajectory. A different scenario occurs in Fig. 6B, where the tip is tracing an arc. Here,
it is clear that the front close to the tip of the spiral propagates through a region that is not
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completely recovered. This causes the front to propagate in another direction, where the
medium is more excitable. This deviation generates the low curvature part of the trajectory or
the arc. This process occurs periodically and the trajectory shown in Fig. 6 is obtained.
In order to give an explanation about the occurrence of the different trajectories obtained in
Fig. 4, we use the information of the previous paragraph and the facts that (i) 1/τd is the speed
at which the Na ions enter to the cell to depolarize it. For shorter τd the ions enter faster to the
cell, and; (ii) from Eqns. (2), changing the value of τd does not affect the threshold value uth.
Consider the case shown in Fig. 6, where τd = 0.3965, ie, when the tip trajectory is trochoidal.
In Fig. 6A, a petal is being traced. When the value of τd is reduced then the flux of Na ions
(In Eqns. (2), I f i is carried by Na ions) is increased. Therefore, the larger amount per time unit
of ions with a constant diffusion coefficient, makes that the spiral wave will trace a petal with
larger curvature than in the case with τd = 0.3965. In the same way, it will follow that the front
of the spiral wave will reach its own tail before than the case with τd = 0.3965. Therefore, it is
obtained an hypotrochoidal trajectory like the one shown in Fig. 4 with τd = 0.37. A similar
argument follows for epitrochoidal trajectories.
4.1.2 Drift of a spiral wave
Drift of a spiral wave is a directed change of its location with time in response to perturbations
(Biktashev, 2007). There are different ways in which drift might occur and an complete list
can be found in (Biktashev, 2007). In this work we focus on two different ways in which
drift occurs (Fig. 7). In Fig. 7A, it is shown the drift of a spiral wave due to the presence of
inhomogeneities. Initially, we considered a spiral wave with τd = 0.43. With this choice of τd,
the tip of the spiral wave traces a circumference. After some integration time, we changed the
value of τd to 0.39 for y < 0. The result of this change in the value of τd is shown in Fig. 7A. In
the figure, it is observed that the tip trajectory no longer traces a circumference but a trajectory
that resembles a spring. When the tip is far from the interphase y = 0, the trajectory traces
the usual circumference. However, when the tip hits the region above y = 0, the curvature
generated is higher than the curvature below y = 0 due to the decrease in τd. This causes
a drift of the position of the center of the circumference. It follows that the trajectory moves
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Fig. 7. Drift of a spiral wave due to (A) Inhomogeneities in the medium, and; (B) Interaction
with a boundary. In (A) τd = 0.43 for y ≥ 0 and τd = 0.39 for y < 0.
In Fig. 7B, it is shown the drift of a spiral wave due to the presence of a boundary. In this
case, when a spiral wave with a circular tip trajectory gets close enough to a boundary, there
is an increase in the curvature of the trajectory giving as a consequence drift of the center
of the circular trajectory. Therefore, the trajectory drifts along the boundary. The physical
mechanism by which the gain in curvature of the trajectory is observed, is apparently as
follows: The impermeable boundary prevents the spread of the current produced by the
spreading wavefront, which is equivalent to local rise in the excitability of the medium close
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levels of refractoriness given by the v variable. For v close to 0 (black), the region is in its
maximum level of refractoriness and an AP cannot be elicited here. For v ≈ 1 (white), the
region is almost or totally recovered and an AP can be elicited in this region. (A) Formation
of a petal; (B) Formation of an arc. The blue dot filled in white, is the location of the tip of the
spiral.
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whereas in Fig. 6B, an arc.
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through a region that is almost completely recovered giving a maximum in the curvature of
the trajectory. A different scenario occurs in Fig. 6B, where the tip is tracing an arc. Here,
it is clear that the front close to the tip of the spiral propagates through a region that is not
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Fig. 7. Drift of a spiral wave due to (A) Inhomogeneities in the medium, and; (B) Interaction
with a boundary. In (A) τd = 0.43 for y ≥ 0 and τd = 0.39 for y < 0.
In Fig. 7B, it is shown the drift of a spiral wave due to the presence of a boundary. In this
case, when a spiral wave with a circular tip trajectory gets close enough to a boundary, there
is an increase in the curvature of the trajectory giving as a consequence drift of the center
of the circular trajectory. Therefore, the trajectory drifts along the boundary. The physical
mechanism by which the gain in curvature of the trajectory is observed, is apparently as
follows: The impermeable boundary prevents the spread of the current produced by the
spreading wavefront, which is equivalent to local rise in the excitability of the medium close
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to the boundary (Yermakova & Pertsov, 1986), and therefore an increase in the curvature of
the trajectory (Subsection 4.1.1).
5. Partially excitable obstacles
Partially excitable obstacles are inhomogeneities in the tissue that originate from changes
in single-cell properties such as the conductance of ion channels (Shajahan et al., 2009).
Such inhomogeneities can arise from damaged or scar tissue (Starobin et al., 1996), when
a lesion is created via ablation (Azene et al., 2001) or by regional hyperkalemia (Xie et al.,
2001). These changes affect the propagation speed of the pulse (Kléber & Rudy, 2004), the
action potential duration (Beeler & Reuter, 1977; Efimov et al., 1995; Shajahan et al., 2009) and























Fig. 8. Tip trajectories of spiral waves obtained with Equations (2) with a partially excitable
circular obstacle (A) τd = 0.38 outside the circular obstacle and τd = 0.43 inside, r = 4; (B)
τd = 0.43 outside the obstacle and τd = 0.38 inside, r =
√
4.5.
The stability of spiral waves depending on inhomogeneities in the medium has been studied
by Shajahan (Shajahan et al., 2009) and Xie (Xie et al., 2001). In this work, we focus on partially
excitable obstacles of circular shape. A pair of simulations are shown in Fig. 8. In Figure 8A,
τd = 0.38 outside the circular obstacle and τd = 0.43 inside. The radius of the obstacle is
r = 4. In the previous section, the tip of the spiral wave followed the boundary between the
two regions. In Figure 8A, it is shown that the trajectory also follows such boundary, which
corresponds to the boundary of the inhomogeneity. In this case, it is shown that the tip traces
a curve that resembles an hypotrochoid. In the case where the value of τd is inverted, i.e. τd =
0.43 outside the inhomogeneity and τd = 0.38 inside, with a radius r =
√
4.5, we obtain the
trajectory shown in Fig. 8B. Here, the trajectory obtained resembles an epitrochoid. This last
result has been presented in (Biktashev, 2007) within a frame of drift due to inhomogeneities
where inside the obstacle the refractory period is longer than outside.
Now, consider varying the radius of the obstacle. In Fig. 9 we present the results of
considering the two cases presented in Fig. 8. In the top row, we show the case when the
trajectory resembles a hypotrochoid. In order to obtain these trajectories, we took τd = 0.43
inside the obstacle, such that inside the obstacle the trajectory is circular. Outside the obstacle
τd was taken as 0.38, such that the trajectory outside is hypotrochoidal. The radius of the
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obstacle is increased from left to right. When the radius of the obstacle is less than the radius
of the circumference traced by the tip trajectory, the trajectory is circular. As the radius of
the obstacle is increased, the trajectory changes from circular to hypotrochoidal. Then, by
considering an increase in the radius of the obstacle, the circular trajectory experiences a
bifurcation as the one periodic rotation changes to a two period rotation. This result was
reported by Mikhailov et al. (Mikhailov et al., 1994) where a circular domain with no flux
boundary conditions was considered.
Fig. 9. Trajectories obtained with Eqns. (2) with a partially excitable circular obstacle and
different radii. The red circle in each case, represents the boundary of the obstacle. Top row:
τd = 0.38 outside the circular obstacle and τd = 0.43 inside. Circular and hypotrochoidal
trajectories are obtained; Bottom row τd = 0.43 outside the obstacle and τd = 0.38.
Epitrochoidal trajectories are obtained
In the bottom row of Fig. 9 is shown the case when the trajectory traces an epitrochoid.
In this case, if we take a smaller radius, an epitrochoidal trajectory remains even by taking
R tending to zero. Additionally to this result, it is also clear that by considering partially
excitable obstacles it is possible to obtain the case of an epitrochoidal trajectory with R = ∞
and therefore a transition between the hypotrochoidal and epitrochoidal cases. Just like the
case of meandering discussed in subsection 4.1.1.
The results presented in the top row of Figure 9, have a completely different meaning from
those presented in (Mikhailov et al., 1994). As an example, consider the tip trajectory shown
in Fig. 10, which corresponds to the upper left case shown in Fig. 9. Initially, the tip of the
spiral wave is located outside of the obstacle. Because τd = 0.38 outside the obstacle, an
hypotrochoid is obtained. However, as soon as the trajectory hits the obstacle, the tip of the
spiral wave gets trapped by the obstacle and the trajectory becomes circular (Fig. 10).
Therefore, in this section we have shown that heterogeneities in the conducting properties of
the medium can give different results. (i) If inside the obstacle we take a value of τ1d such that
the tip trajectory is a circumference of radius r1 and outside the obstacle the value of τd is less
than τ2d < τ
1
d , where τ
2
d gives a circular trajectory with radius r2 < r1, then if the radius of
the obstacle is r ∈ [r2, r1] then a circular tip trajectory due to the interaction between the tip of
the spiral wave and the obstacle is obtained. Clearly, this case includes the situation of having
an epitrochoidal or hypotrochiodal trajectory outside the obstacle (with the values of τd given
in Fig. 4). (ii) Under the same conditions as above but the radius r of the obstacle larger
than r1, then the trapped trajectory will trace a hypotrochoid. Observe that in this regime, we
can obtain a transition from epitrochoidal (given by meandering) to hypotrochoidal trajectory
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to the boundary (Yermakova & Pertsov, 1986), and therefore an increase in the curvature of
the trajectory (Subsection 4.1.1).
5. Partially excitable obstacles
Partially excitable obstacles are inhomogeneities in the tissue that originate from changes
in single-cell properties such as the conductance of ion channels (Shajahan et al., 2009).
Such inhomogeneities can arise from damaged or scar tissue (Starobin et al., 1996), when
a lesion is created via ablation (Azene et al., 2001) or by regional hyperkalemia (Xie et al.,
2001). These changes affect the propagation speed of the pulse (Kléber & Rudy, 2004), the
action potential duration (Beeler & Reuter, 1977; Efimov et al., 1995; Shajahan et al., 2009) and























Fig. 8. Tip trajectories of spiral waves obtained with Equations (2) with a partially excitable
circular obstacle (A) τd = 0.38 outside the circular obstacle and τd = 0.43 inside, r = 4; (B)
τd = 0.43 outside the obstacle and τd = 0.38 inside, r =
√
4.5.
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a curve that resembles an hypotrochoid. In the case where the value of τd is inverted, i.e. τd =
0.43 outside the inhomogeneity and τd = 0.38 inside, with a radius r =
√
4.5, we obtain the
trajectory shown in Fig. 8B. Here, the trajectory obtained resembles an epitrochoid. This last
result has been presented in (Biktashev, 2007) within a frame of drift due to inhomogeneities
where inside the obstacle the refractory period is longer than outside.
Now, consider varying the radius of the obstacle. In Fig. 9 we present the results of
considering the two cases presented in Fig. 8. In the top row, we show the case when the
trajectory resembles a hypotrochoid. In order to obtain these trajectories, we took τd = 0.43
inside the obstacle, such that inside the obstacle the trajectory is circular. Outside the obstacle
τd was taken as 0.38, such that the trajectory outside is hypotrochoidal. The radius of the
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obstacle is increased from left to right. When the radius of the obstacle is less than the radius
of the circumference traced by the tip trajectory, the trajectory is circular. As the radius of
the obstacle is increased, the trajectory changes from circular to hypotrochoidal. Then, by
considering an increase in the radius of the obstacle, the circular trajectory experiences a
bifurcation as the one periodic rotation changes to a two period rotation. This result was
reported by Mikhailov et al. (Mikhailov et al., 1994) where a circular domain with no flux
boundary conditions was considered.
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different radii. The red circle in each case, represents the boundary of the obstacle. Top row:
τd = 0.38 outside the circular obstacle and τd = 0.43 inside. Circular and hypotrochoidal
trajectories are obtained; Bottom row τd = 0.43 outside the obstacle and τd = 0.38.
Epitrochoidal trajectories are obtained
In the bottom row of Fig. 9 is shown the case when the trajectory traces an epitrochoid.
In this case, if we take a smaller radius, an epitrochoidal trajectory remains even by taking
R tending to zero. Additionally to this result, it is also clear that by considering partially
excitable obstacles it is possible to obtain the case of an epitrochoidal trajectory with R = ∞
and therefore a transition between the hypotrochoidal and epitrochoidal cases. Just like the
case of meandering discussed in subsection 4.1.1.
The results presented in the top row of Figure 9, have a completely different meaning from
those presented in (Mikhailov et al., 1994). As an example, consider the tip trajectory shown
in Fig. 10, which corresponds to the upper left case shown in Fig. 9. Initially, the tip of the
spiral wave is located outside of the obstacle. Because τd = 0.38 outside the obstacle, an
hypotrochoid is obtained. However, as soon as the trajectory hits the obstacle, the tip of the
spiral wave gets trapped by the obstacle and the trajectory becomes circular (Fig. 10).
Therefore, in this section we have shown that heterogeneities in the conducting properties of
the medium can give different results. (i) If inside the obstacle we take a value of τ1d such that
the tip trajectory is a circumference of radius r1 and outside the obstacle the value of τd is less
than τ2d < τ
1
d , where τ
2
d gives a circular trajectory with radius r2 < r1, then if the radius of
the obstacle is r ∈ [r2, r1] then a circular tip trajectory due to the interaction between the tip of
the spiral wave and the obstacle is obtained. Clearly, this case includes the situation of having
an epitrochoidal or hypotrochiodal trajectory outside the obstacle (with the values of τd given
in Fig. 4). (ii) Under the same conditions as above but the radius r of the obstacle larger
than r1, then the trapped trajectory will trace a hypotrochoid. Observe that in this regime, we
can obtain a transition from epitrochoidal (given by meandering) to hypotrochoidal trajectory









Fig. 10. τd = 0.38 outside τd = 0.43 inside the obstacle. The radius of the obstacle is r = 1.
The simulation was done in the domain Ω = [−7, 7]× [−7, 7], but a zoom of the region of
interest is shown. x and y in cm.
(given by drift of the spiral wave). (iii) Finally, when the values of τd inside and outside the
obstacle are reverted, what is obtained is an epitrochoidal trajectory.
It is important to observe that two periodic rotations, named epitrochoidal and
hypotrochoidal trajectories, and transitions from circular to hypotrochoidal regimes, are also
obtained through drift. Therefore, the presence of partially excitable obstacles in cardiac tissue
may induce the existence of trajectories that mimic the meandering behavior.
6. Non-excitable obstacles
Obstacles in cardiac tissue have been modeled with regions where the zero flux condition
is imposed (Azene et al., 2001; Isomura et al., 2008; Panfilov & Kenner, 1993; Shajahan et al.,
2009; Starobin et al., 1996; Valderrábano et al., 2000). Arteries (Valderrábano et al., 2000) and
the natural orifices in the atria, (Azene et al., 2001) are examples of this type of obstacles. Also,
these obstacles can be artificially generated in experimental preparations by making cuts in
the tissue (Cabo et al., 1996; Ikeda et al., 1997).
The interaction of spiral waves with non excitable obstacles has been considered by different
authors (Azene et al., 2001; Ikeda et al., 1997; Isomura et al., 2008; Panfilov & Kenner, 1993;
Shajahan et al., 2009; Starobin et al., 1996; Valderrábano et al., 2000). Of particular interest is
the work by Ikeda (Ikeda et al., 1997), where it is observed that when a spiral wave attaches
to an obstacle, a transition between two different classes of arrhythmias is observed.
In the present section we extend the results observed by Ikeda (Ikeda et al., 1997) and show
that the presence of non excitable obstacles, just as the partially excitable ones, can stabilize
or destabilize spiral wave dynamics. Initially, it is considered a spiral wave in the circular
regime (τd = 0.426), with a circular obstacle with radius r = 1.7 and center in the origin.
In this regime, we placed the tip of the spiral wave near the obstacle. The result is shown
in Fig. 11. In this situation, it is observed that the spiral rotates and at the same time starts
moving around the obstacle. Due to the drift at an impermeable boundary plus the circular
shape of the obstacle, it is observed that the tip of the spiral traces a curve very similar to an
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epitrochoid. Therefore, the presence of a circular obstacle, has changed the simple rotation of
the spiral wave into a two periodic rotation. This phenomenon, was observed for obstacles of
all sizes above mesh partition. The speed of the drift was a decreasing function of the radius.
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Fig. 11. Drift of a spiral wave around a circular obstacle. τd = 0.426, radius r = 1.7.
In our second experiment, we considered a spiral wave in the epitrochoidal regime (τd =
0.405). In the same way, we placed the spiral wave in such way that the tip of the spiral
interacts with the obstacle. The results are shown in Fig. 12. In the figure, it is shown a spiral
wave in the epitrochoidal regime interacting with the circular obstacle at different integration
times. In Figs. 12A,B, it is shown that the spiral wave traces an epitrochoid. As soon as the
spiral wave hits the boundary, the tip trajectory changes its direction due to the boundary
effects (Olmos & Shizgal, 2008; Yermakova & Pertsov, 1986). In the figure, it is shown that the
tip of the spiral wave hits the boundary four times. In the first three interactions, it is observed
that the spiral bounces at the obstacle. However, in the fourth interaction it is observed that
the spiral wave attaches to the obstacle (Fig. 12C). A major consequence obtained is that the
two frequency rotation given by the epitrochoidal regime, changes after a transient, to a simple
rotation given by the circular regime.
The change from the two rotation period to simple rotation was due to attachment of the
spiral wave to the obstacle (Olmos, 2010). However, this experiment raises different questions.
When the tip of the spiral hits the obstacle, why in some cases bouncing is observed and
then attachment?, Does attachment always occur? Does attachment depend on the size of the
radius of the obstacle?, How long it takes to a spiral to attach to the obstacle? To answer these
questions is a very difficult task.
In order to show the complexity of this problem, we consider a previous analysis done in
(Olmos & Shizgal, 2008). We interact the tip of spiral waves in the trochoidal regime (R = ∞
in Fig.5) with a flat boundary. With these settings we remove the effect of the curvature of the
obstacle and the curvature of the epitrochoidal and hypotrochoidal regimes. We took initial
conditions such that the trajectory had an incident angle θi with respect to the boundary (Fig.
13A).
When the tip of a spiral wave interacts with a boundary, there are two possible outcomes. The
tip of the spiral wave bounces at the boundary as in Fig. 13A, or disappears at the boundary, in
which case the spiral wave also disappears from the domain (Olmos & Shizgal, 2008). When
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(given by drift of the spiral wave). (iii) Finally, when the values of τd inside and outside the
obstacle are reverted, what is obtained is an epitrochoidal trajectory.
It is important to observe that two periodic rotations, named epitrochoidal and
hypotrochoidal trajectories, and transitions from circular to hypotrochoidal regimes, are also
obtained through drift. Therefore, the presence of partially excitable obstacles in cardiac tissue
may induce the existence of trajectories that mimic the meandering behavior.
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Obstacles in cardiac tissue have been modeled with regions where the zero flux condition
is imposed (Azene et al., 2001; Isomura et al., 2008; Panfilov & Kenner, 1993; Shajahan et al.,
2009; Starobin et al., 1996; Valderrábano et al., 2000). Arteries (Valderrábano et al., 2000) and
the natural orifices in the atria, (Azene et al., 2001) are examples of this type of obstacles. Also,
these obstacles can be artificially generated in experimental preparations by making cuts in
the tissue (Cabo et al., 1996; Ikeda et al., 1997).
The interaction of spiral waves with non excitable obstacles has been considered by different
authors (Azene et al., 2001; Ikeda et al., 1997; Isomura et al., 2008; Panfilov & Kenner, 1993;
Shajahan et al., 2009; Starobin et al., 1996; Valderrábano et al., 2000). Of particular interest is
the work by Ikeda (Ikeda et al., 1997), where it is observed that when a spiral wave attaches
to an obstacle, a transition between two different classes of arrhythmias is observed.
In the present section we extend the results observed by Ikeda (Ikeda et al., 1997) and show
that the presence of non excitable obstacles, just as the partially excitable ones, can stabilize
or destabilize spiral wave dynamics. Initially, it is considered a spiral wave in the circular
regime (τd = 0.426), with a circular obstacle with radius r = 1.7 and center in the origin.
In this regime, we placed the tip of the spiral wave near the obstacle. The result is shown
in Fig. 11. In this situation, it is observed that the spiral rotates and at the same time starts
moving around the obstacle. Due to the drift at an impermeable boundary plus the circular
shape of the obstacle, it is observed that the tip of the spiral traces a curve very similar to an
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epitrochoid. Therefore, the presence of a circular obstacle, has changed the simple rotation of
the spiral wave into a two periodic rotation. This phenomenon, was observed for obstacles of
all sizes above mesh partition. The speed of the drift was a decreasing function of the radius.
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Fig. 11. Drift of a spiral wave around a circular obstacle. τd = 0.426, radius r = 1.7.
In our second experiment, we considered a spiral wave in the epitrochoidal regime (τd =
0.405). In the same way, we placed the spiral wave in such way that the tip of the spiral
interacts with the obstacle. The results are shown in Fig. 12. In the figure, it is shown a spiral
wave in the epitrochoidal regime interacting with the circular obstacle at different integration
times. In Figs. 12A,B, it is shown that the spiral wave traces an epitrochoid. As soon as the
spiral wave hits the boundary, the tip trajectory changes its direction due to the boundary
effects (Olmos & Shizgal, 2008; Yermakova & Pertsov, 1986). In the figure, it is shown that the
tip of the spiral wave hits the boundary four times. In the first three interactions, it is observed
that the spiral bounces at the obstacle. However, in the fourth interaction it is observed that
the spiral wave attaches to the obstacle (Fig. 12C). A major consequence obtained is that the
two frequency rotation given by the epitrochoidal regime, changes after a transient, to a simple
rotation given by the circular regime.
The change from the two rotation period to simple rotation was due to attachment of the
spiral wave to the obstacle (Olmos, 2010). However, this experiment raises different questions.
When the tip of the spiral hits the obstacle, why in some cases bouncing is observed and
then attachment?, Does attachment always occur? Does attachment depend on the size of the
radius of the obstacle?, How long it takes to a spiral to attach to the obstacle? To answer these
questions is a very difficult task.
In order to show the complexity of this problem, we consider a previous analysis done in
(Olmos & Shizgal, 2008). We interact the tip of spiral waves in the trochoidal regime (R = ∞
in Fig.5) with a flat boundary. With these settings we remove the effect of the curvature of the
obstacle and the curvature of the epitrochoidal and hypotrochoidal regimes. We took initial
conditions such that the trajectory had an incident angle θi with respect to the boundary (Fig.
13A).
When the tip of a spiral wave interacts with a boundary, there are two possible outcomes. The
tip of the spiral wave bounces at the boundary as in Fig. 13A, or disappears at the boundary, in
which case the spiral wave also disappears from the domain (Olmos & Shizgal, 2008). When


































Fig. 12. Interaction of a spiral wave in the epirtrochoidal regime with a circular obstacle for
different integration times. The arrow points at the place where the trajectory starts. (A)
shows the trajectory of the spiral wave meandering; (B) the spiral wave hits the obstacle and
bounces, and; (C) the spiral wave hits the obstacle and gets anchored. Note the difference in
the frequency of excitation between (A)-(B) and (C).
considering obstacles, the effect of bouncing is the same for a boundary and for the obstacle.
However, the effect of annihilation at a boundary becomes attachment of the spiral wave to the
obstacle (Olmos, 2010). In Fig. 13B, we show the probability of annihilation of a spiral wave at
the boundary as a function of the incident angle, following the procedure in (Olmos & Shizgal,
2008). From the figure, it is clear that for θi ∈ [0o, 60o ]
⋃
[160o , 180o ] the tip of the spiral wave
bounces at the boundary. For θi ∈ (60o , 160o) in some cases, there was observed bouncing but
also annihilation. As we increase the value of θi from 60o to 140o , there is an increase in the
proportion of spiral waves that annihilate at the boundary. For θi = 140o all the trajectories
considered in the simulations disappeared at the boundary giving annihilation. From there,
as the value of θi is increased up to θi = 160o , the proportion of spirals that bounced at the
boundary increased again.
Based on the previous information, we run several examples in the epitrochoidal regime (τd =
0.405) as the one shown in Fig. 12. We considered obstacles with three different radius, r = 0.8,
r = 1.1 and r = 1.7. From there, we took all the cases where attachment of the spiral wave
to the obstacle was obtained. It was observed from this numerical experiment that the angles
at which attachment occurred, ranged from 10o to 100o . From this observation and from Fig.
13B, it is shown that for incident angles θi ∈ [10o , 60o], annihilation at the flat boundary is not
possible, but attachment to the circular obstacle is possible.
The phenomenon of obtaining attachment for angles θi that in the flat boundary gave
bouncing might be expected from the studies in (Leal-Soto, 2011; Olmos, 2010), where a spiral
wave in the trochoidal regime interacted with the face of a square shaped obstacle. In these
studies, it is shown that a spiral wave that would experience bouncing in a flat boundary, will
experience attachment to the obstacle, as the interaction of the spiral wave takes place near
a corner of the obstacle. Therefore, when we consider a circular obstacle, the interactions of
the tip of the spiral wave with the obstacle can be thought as the interaction of the tip of a
spiral with a smoothed corner of a square shaped obstacle. This explains why attachment is
observed for angles less than θi = 60o observed in the simulations.
Attachment to the circular obstacle was observed to happen with angles θi between 10o to
100o . This does not imply that attachment is not possible for θi outside this range of values.
In fact, from the simulations, the interaction of the spiral wave with the obstacle rarely
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Fig. 13. (A) Interaction of a spiral wave in the trochoidal regime (R = ∞ in Fig. 5,
τd = 0.3965) with a boundary. θi is the angle of incidence. In the figure, the tip of the spiral
wave bounces at the boundary. (B) Probability of annihilation of the spiral wave at the
boundary for a particular angle of incidence θi.
occurs with angles greater than 100o . This basically happens because we are considering
epitrochoidal trajectories. If we consider hypotrochoidal trajectories, then interactions will
take place mostly with angles above 90o.
6.1 More complex dynamics
The interaction of a meandering spiral wave with an obstacle has different outcomes. In Fig.
14A, we show how complex dynamics can be. We took a spiral wave in the epitrochoidal
regime such that the tip touches the obstacle and bounces at it. The dynamics of the tip
trajectory are shown in Fig. 14A. From the figure it is clear that the trajectory hits the obstacle
repeatedly following no visible pattern. As seen in the figure, there is no attachment of
the spiral to the obstacle for large time integrations. Clearly, the activation of the tissue is
completely irregular and might be considered as being in a fibrillatory regime.
When we consider an obstacle of a very small size, and an epitrochoidal trajectory, it is
observed that the trajectory follows a more stable pattern (Fig. 14B). In this case, the trajectory
gets close to the obstacle periodically and it can be said that it happens each time the trajectory
traces an epitrochoid. As soon as the tip of the trajectory gets close to the obstacle, the
boundary effects induce an increase in the curvature of the trajectory, producing drift of the
spiral wave. It is important to note that the increase in the curvature is very small as the
size of the obstacle is also very small. This small perturbation in the tip trajectory allows the
trajectory to preserve the epitrochoidal trajectory as opposed in what is shown in Fig. 14A.
In this section, we have shown that obstacles might act as a switch between the one and two
periodic rotations. Therefore, it follows that the presence of obstacles does not necessarily
induce a more stable regime in the spiral wave. Moreover, if the spiral wave is in the
epitrochoidal regime, the result might be (i) A transition to a simple rotation scheme; (ii)


































Fig. 12. Interaction of a spiral wave in the epirtrochoidal regime with a circular obstacle for
different integration times. The arrow points at the place where the trajectory starts. (A)
shows the trajectory of the spiral wave meandering; (B) the spiral wave hits the obstacle and
bounces, and; (C) the spiral wave hits the obstacle and gets anchored. Note the difference in
the frequency of excitation between (A)-(B) and (C).
considering obstacles, the effect of bouncing is the same for a boundary and for the obstacle.
However, the effect of annihilation at a boundary becomes attachment of the spiral wave to the
obstacle (Olmos, 2010). In Fig. 13B, we show the probability of annihilation of a spiral wave at
the boundary as a function of the incident angle, following the procedure in (Olmos & Shizgal,
2008). From the figure, it is clear that for θi ∈ [0o, 60o ]
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[160o , 180o ] the tip of the spiral wave
bounces at the boundary. For θi ∈ (60o , 160o) in some cases, there was observed bouncing but
also annihilation. As we increase the value of θi from 60o to 140o , there is an increase in the
proportion of spiral waves that annihilate at the boundary. For θi = 140o all the trajectories
considered in the simulations disappeared at the boundary giving annihilation. From there,
as the value of θi is increased up to θi = 160o , the proportion of spirals that bounced at the
boundary increased again.
Based on the previous information, we run several examples in the epitrochoidal regime (τd =
0.405) as the one shown in Fig. 12. We considered obstacles with three different radius, r = 0.8,
r = 1.1 and r = 1.7. From there, we took all the cases where attachment of the spiral wave
to the obstacle was obtained. It was observed from this numerical experiment that the angles
at which attachment occurred, ranged from 10o to 100o . From this observation and from Fig.
13B, it is shown that for incident angles θi ∈ [10o , 60o], annihilation at the flat boundary is not
possible, but attachment to the circular obstacle is possible.
The phenomenon of obtaining attachment for angles θi that in the flat boundary gave
bouncing might be expected from the studies in (Leal-Soto, 2011; Olmos, 2010), where a spiral
wave in the trochoidal regime interacted with the face of a square shaped obstacle. In these
studies, it is shown that a spiral wave that would experience bouncing in a flat boundary, will
experience attachment to the obstacle, as the interaction of the spiral wave takes place near
a corner of the obstacle. Therefore, when we consider a circular obstacle, the interactions of
the tip of the spiral wave with the obstacle can be thought as the interaction of the tip of a
spiral with a smoothed corner of a square shaped obstacle. This explains why attachment is
observed for angles less than θi = 60o observed in the simulations.
Attachment to the circular obstacle was observed to happen with angles θi between 10o to
100o . This does not imply that attachment is not possible for θi outside this range of values.
In fact, from the simulations, the interaction of the spiral wave with the obstacle rarely










6 4 2 0 2 4 6
θi
Fig. 13. (A) Interaction of a spiral wave in the trochoidal regime (R = ∞ in Fig. 5,
τd = 0.3965) with a boundary. θi is the angle of incidence. In the figure, the tip of the spiral
wave bounces at the boundary. (B) Probability of annihilation of the spiral wave at the
boundary for a particular angle of incidence θi.
occurs with angles greater than 100o . This basically happens because we are considering
epitrochoidal trajectories. If we consider hypotrochoidal trajectories, then interactions will
take place mostly with angles above 90o.
6.1 More complex dynamics
The interaction of a meandering spiral wave with an obstacle has different outcomes. In Fig.
14A, we show how complex dynamics can be. We took a spiral wave in the epitrochoidal
regime such that the tip touches the obstacle and bounces at it. The dynamics of the tip
trajectory are shown in Fig. 14A. From the figure it is clear that the trajectory hits the obstacle
repeatedly following no visible pattern. As seen in the figure, there is no attachment of
the spiral to the obstacle for large time integrations. Clearly, the activation of the tissue is
completely irregular and might be considered as being in a fibrillatory regime.
When we consider an obstacle of a very small size, and an epitrochoidal trajectory, it is
observed that the trajectory follows a more stable pattern (Fig. 14B). In this case, the trajectory
gets close to the obstacle periodically and it can be said that it happens each time the trajectory
traces an epitrochoid. As soon as the tip of the trajectory gets close to the obstacle, the
boundary effects induce an increase in the curvature of the trajectory, producing drift of the
spiral wave. It is important to note that the increase in the curvature is very small as the
size of the obstacle is also very small. This small perturbation in the tip trajectory allows the
trajectory to preserve the epitrochoidal trajectory as opposed in what is shown in Fig. 14A.
In this section, we have shown that obstacles might act as a switch between the one and two
periodic rotations. Therefore, it follows that the presence of obstacles does not necessarily
induce a more stable regime in the spiral wave. Moreover, if the spiral wave is in the
epitrochoidal regime, the result might be (i) A transition to a simple rotation scheme; (ii)
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Fig. 14. Tip trajectories traced by a spiral wave solutions of Eqns. (2) when a circular obstacle
is imposed. (A) The trajectory does not follow a regular pattern; (B) When the size of the
obstacle is small enough a three periodic trajectory is obtained.
A transition to a more complex pattern, and; (iii) if the radius of the obstacle is sufficiently
small, a transition to a three period rotation 1.
7. Conclusions, limitations and open questions
In this work, it was considered the interaction of spiral waves in the circular and meandering
regime with partially and non excitable obstacles of circular shape. The aim was to understand
the transitions that occur between three different regimes: the circular, the epitrochoidal and
the hypotrochoidal. The presence of a spiral wave in the circular regime, provides a periodic
stimulation of the tissue in a more stable fashion than the other two regimes, as only one
excitation frequency is present. When a spiral wave attaches to an obstacle the arrhythmic
regime is the same as is the tip of a spiral wave were tracing a circle.
When partially excitable obstacles were considered (Section 5), it was shown that the presence
of such inhomogeneities induced the appearance of epitrochoidal and hypotrochoidal
trajectories, commonly associated to meandering. This implies that epitrochoidal and
hypotrochoidal trajectories might arise due to meandering or drift. It is important to point
out that tip trajectories obtained with meandering, like linear trajectories (Fenton et al., 2002),
were not obtained with drift. Nonetheless it is important to understand the nature of these
trajectories to apply the proper procedure to remove them.
Transitions between different spiral wave regimes were obtained when an obstacle was placed
in the medium (Sections 5 and 6). In Section 5, tip trajectories changed from epitrochoidal or
hypotrochoidal to circular ones. Also, the reversed process might be obtained, i.e. circular
trajectories can switch to epitrochoidal or hypotrochoidal trajectories. Finally, transitions from
epitrochoidal to hypotrochoidal might also be obtained. On the other hand, in Section 6, it was
shown that the presence of an obstacle, might act as a switch between two different arrhythmic
regimes. (i) Simple rotating spirals changed to a two period meandering spiral wave; (ii) Two
periodic meandering spiral waves changed to (a) simple rotating spiral; (b) Three periodic
meandering spiral wave and; (c) More complex trajectory with no regular pattern associated.
1 Strictly speaking, the trajectory is not three periodic, but there are three frequencies associated to the
tip motion.
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In general, it was shown that the presence of inhomogeneities in the medium not
only stabilizes the spiral wave dynamics as shown in (Ikeda et al., 1997; Kim et al., 1999;
Shajahan et al., 2007) but also might generate more complex dynamics, which implies that
the presence of obstacles might induce a more dangerous arrhythmic regime than the one
without the obstacle.
Drift of a spiral wave had been considered only for planar boundaries (Yermakova & Pertsov,
1986) and inside circular domains (Mikhailov et al., 1994). In this work, it was presented the
drift of a spiral wave around a circular obstacle which was not previously reported. Up to
now, there are still missing conditions for general shape obstacles that allow drift of the spiral
wave around the obstacle, when the spiral tip traces a circle. A similar analysis for partially
excitable obstacles is missing. i.e. which geometric properties must have an obstacle such that
the tip trajectory of a spiral wave will follow its boundary?
The study of attachment of meandering spiral waves to non-excitable obstacles is a very
difficult task, as there is not a clear a pattern that relates the radius of the obstacle and the
radius of the epitrochoid. Also, it is still the question of studying which type of trajectory,
epitrochoidal or hypotrochoidal, will attach more easily to an obstacle of a given size. In
this work it was not considered the study of hypotrochoidal trajectories and non-excitable
obstacles as the original study was to establish conditions to consider an obstacle as a switch
between the circular and epitrochoidal regime.
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1. Introduction   
Electrical storm (ES) is usually defined as a clustering of destabilizing episodes of 
ventricular tachycardia or ventricular fibrillation in a short period of time, requiring 
multiple cardioversions or defibrillations. Many criteria have been proposed to define ES 
since the early 1990s, when the term was first introduced to indicate a state of electrical 
instability with several ventricular tachycardias (VT) or ventricular fibrillations (VF) over a 
few hours. At present an official and widespread definition of ES is not available. ES has 
been defined differently, from two or more to twenty or more episodes within 24 hours. 
Some definitions were based on number of hemodynamically unstabilizing episodes, others 
relied on number of shocks needed (or just delivered, whether appropriate or not), and 
some others on time between each single episode. More imaginative definitions include “VT 
recurring immediately after termination”, “VT for an half  of each of three days” and “VT 
resulting in more total ventricular ectopic beats than sinus beats in 24 hours” (Israel et al, 
2007). Fortunately, nowadays most cardiologists define ES as recurrent VT or VF, at least 3 
in a 24 hours period, as this is probably the most appropriate and solid definition. This 
definition does not include the presence of haemodynamic instability, since the intervention 
of modern implanted cardioverter-defibrillator (ICD) usually terminates the arrhythmia 
before its clinical and hemodynamical consequences. 
Similarly to definitions, many names have been used as synonymous to ES, such as 
arrhythmic storm, recurrent short-term ventricular arrhythmia, VT clusters and electrical 
instability. In this chapter we will use the term ES, as the most used and widespread in 
clinical practice. 
ES is more frequently seen as an acute complication of myocardial infarction, as a not-so-
uncommon adverse event in ischemic and non ischemic dilated cardiomyopathy and in 
genetic arrhythmia syndromes, such as congenital long QT syndrome and Brugada 
syndrome. However, the highest incidence of ES is reported in heart failure patients with 
ICD. This incidence, which ranges from 4% to 60% according to different studies, is mainly 
due to two factors. First, ICD can detect the VT of VF underlying a clinical episode of 
dizziness, syncope or even aborted sudden cardiac death, thus making the diagnosis far 
easier. Second, and most important, it can effectively treat the first and second VT or VF, 
thus saving the patient from sudden cardiac death and making him able to withstand more 
arrhythmic episodes. 
The current chapter will summarize the current epidemiology and diagnosis of electrical 
storm, as well as give some insight on current recommendation regarding pharmacological 
and non pharmacological treatment. 
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2. Epidemiology of electrical storm 
2.1 Incidence of electrical storm and its different causative arrhythmias 





Author Year Definition Population % 
Wood 1995 ≥3 VT/VF ≤24 h ICD (secondary prevention) 10 
Kowey 1996 ≥2 VT/VF ≤24 h All ES patients - 
Villacastin 1996 ≥2 shocks for VT ICD (secondary prevention) 20 
Fries 1997 >2 VT ≤ 1 h ICD (secondary prevention) 60 
Credner 1998 ≥3 VT/VF ≤24 h ICD (secondary prevention) 10 
Nademanee 2000 ≥20 VT/VF ≤24 h ≥4 VT/VF ≤1 h All ES patients - 
Greene 2000 ≥3 VT/VF ≤24 h ICD (secondary prevention) 18 
Bansch 2000 ≥3 VT/VF ≤24 h ICD (secondary prevention) 28 
Exner 2001 ≥3 VT/VF ≤24 h ICD (secondary prevention) 20 
Verma 2004 ≥2 VT/VF ≤24 h ICD (secondary prevention) 10 
Arya 2005 ≥3 VT/VF ≤24 h ICD (30% primary prevention) 13 
Brigadeau 2006 ≥2 VT/VF  ≤24 h ICD (secondary prevention) 58 
Honhloser 2006 ≥3 VT/VF ≤24 h ICD (secondary prevention) 23 
Sesselberg 2007 ≥3 VT/VF ≤24 h ICD (primary prevention) 4 
Nordbeck 2010 ≥3 VT/VF ≤24 h ICD (55% primary prevention) 7 
Streinert 2011 ≥3 VT/VF ≤24 h ICD (81% primary prevention) 7 
Table 1. Incidence of electrical storm according to different definitions and populations. 
However, due to different definitions of ES and different populations, results vary widely. 
Most of the evidences come from ICD populations implanted after sustained ventricular 
arrhythmias, in which ES incidence ranges from 10 to 60 %. ICD recipients implanted for 
primary prevention, either with underlying ischemic or idiopathic dilated cardiomyopathy, 





Little is known about incidence after acute myocardial injury, except that is more common 
in acute ST-elevation myocardial infarction (STEMI), when STEMI is associated with an 
important left ventricular dysfunction and when reperfusion therapy (either fibrinolysis or 
percutaneous angioplasty) is late or ineffective. 
Similarly, exact incidence and prevalence of ES in genetic arrhythmic syndromes such as 
Brugada syndrome, familiar long QT syndrome, short-coupled variant of torsade de pointes 
and right ventricular arrhytmogenic cardiomyopathy is still unknown. Albeit they are all 
rare conditions, patients afflicted by genetic arrhythmic syndromes are tipically young and 
otherwise healthy subjects, therefore in immediate need for ES primary prevention. 
More than 8 out of 10 arrhythmic episodes constituting ES are monomorphic VT (mVT), 
with polymorphic VT (pVT) and VF far behind in prevalence (Table 2). 
 
 
Author Year mVT (%) pVT+VF (%) 
Credner 1998 71 29 
Greene 2000 97 3 
Bansch 2000 91 8 
Exner 2001 86 14 
Verma 2004 52 48 
Brigadeau 2006 90 10 
Honhloser 2006 91 9 
Sesselberg 2007 78 22 
Nordbeck 2010 85 15 
Streinert 2011 73 27 
Table 2. Prevalence of different ventricular arrhythmia types in ES. 
Sustained monomorphic VT is usually related to structural heart disease. Monomorphic VT 
self-propagation is made possible by a reentry mechanism around a fixed anatomic barrier, 
which is often represented by a myocardial scar from a previous MI. The same ischemic 
cardiomyopathy, as it progresses, leads to fibrosis which in turn leads to conduction 
slowdowns, creating the perfect pathway for reentrant VT. In this particular setting an 
otherwise harmless trigger such as a premature ventricular contraction is necessary to start 
monomorphic VT. Monomorphic reentrant VT does not require active ischemia as a trigger, 
and is an uncommon cause of ES in acute myocardial infarction. 
VF and pVT are due to different mechanisms, comprehending multiple activation of 
different ventricular foci (pVT) or chaotic activation of the whole endocardial ventricular 
surface (VF). These two arrhythmias are more common in acute myocardial infraction or 
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when a long QT interval is present. Therefore QT interval should be assessed in all 
patients with ES due to pVT or VF as soon as sinus rhythm has been restored. Acquired 
causes of long QT, such as hypokalemia, hypocalcemia, hypomagnesemia, 
hypothyroidism and medication known to prolong QT interval, should be corrected as 
soon as possible. Inherited causes of long QT should be suspected whether an acquired 
cause cannot be found. 
2.2 Short and long-term prognosis of electrical storm 
Available data strongly suggest that patients who experience an ES have a poor outcome. 
Only a few trials were inconclusive regarding the role of ES as a mortality marker, and those 
usually had a wider definition of ES or a shorter follow-up. In secondary prevention 
populations such as the one of the AVID trial (Exner et al, 2001), patients with ES had a 
higher risk for non-sudden cardiac death (OR 2.4). In a substudy of the MADIT-II trial, 
which enrolled primary prevention patients, the risk of death was even higher (OR 7.4). 
Consistent findings suggest that the increase in mortality is mainly due to the worsening of 
ventricular dysfunction leading to end stage heart failure, with only a small proportion of 
sudden cardiac or other deaths (Gatzoulis et al, 2005). This hypothesis is also supported by 
the fact that risk of death after ES reaches its peak around 2-3 months after the acute event. 
Another main clinical consequence of ES is hospitalization, which is required for a proper 
treatment in approximately 80% of patients (Bänsch et al, 2000). Hospitalization rates grow 
higher with each shock delivered, reaching 100% if 3 or more shocks are needed. 
Hospitalization is in turn associated with a poorer quality of life and higher costs. 
Patients who experience an ES are more likely to have multiple ES over time. Recent data 
showed that recurrence of ES happens in more than half of all patients with ES, and is more 
common within the first year after the original ES episode (Streitner et al, 2011). 
2.3 Pseudo-storm 
Sometimes multiple recurrent ICD discharges are not associated with ES but are due to 
device malfunctioning. Pseudo-storm is defined as recurrent inappropriate ICD discharges 
over 24 hours. Far from being a minor complication, pseudo-storm is usually physical and 
psychological harmful and potentially lethal. The most common causes of inappropriate 
ICD shock include supraventricular tachycardia with high ventricular response and 
oversening of peaked T waves, myopotentials or electrical noise (Gradaus et al, 2003). 
Recurrent ICD shocks can cause myocardial injury by direct electrocution cell injury and 
by activation of signaling pathways in the molecular cascade of HF, the most important of 
all being adrenergic neurohormonal system. Adrenergic iperactivity may then synergize 
with recurrent ventricular arrhythmias in exacerbating ventricular dysfunction and 
worsening heart failure. In a recent paper on a typical ICD population, Sweeney et al. 
demonstrated that electrical shocks were associated with an increased risk of death 
independently of underlying ventricular arrhythmia (Sweeney et al, 2010). Authors 
esteemed that for every delivered shock, whether appropriate or not, the risk of death 
increases by 20%. On the other hand, no increased risk was associated with anti-
tachycardia pacing (ATP) therapies. Pseudo-storm does not only cause myocardial 
damage, but can deplete a full device battery within hours, potentially leaving the patient 
unprotected from life-threatening arrhythmic events. Although a very rare complication, 





described a patient who, three months after an ICD replacement, received six consecutive 
shocks related to detection of noise interpreted as VF. Unfortunately, the sixth shock 
triggered a true VF, which was not treated due to the end of the therapeutic sequence, and 
which led to the patient’s death (Messali et al, 2004). 
Pseudo-storm should be treated by immediate intervention to suppress ICD shocks. 
Moreover, inappropriate discharges from ICD should be avoided at all cost by an optimal 
device programming. ATP therapy should be preferred over shock in the therapeutic 
sequence, due to its more favorable risk profile. 
3. Clinical presentation of electrical storm 
3.1 Electrical storm in acute myocardial infarction 
Electrical storm, when present, is often the initial manifestation of ischemia and usually 
starts in the first 48 hours of an ST-elevation MI. In that case, pVT is almost always the 
ventricular arrhythmia underlying ES. Ischemia and adrenergic activation increase Purkinje 
cell automaticity, thus letting multiple spontaneous firing. Necrosis, altered myocite 
membrane potential, electrolytic imbalance and even reperfusion damage can all contribute 
to increase dispersion of refractory periods between epicardium and endocardium, thus 
facilitating the propagation of multiple reentry waves. 
ES is a strong negative prognostic factor in acute myocardial infarction. In one study where 
ES was defined as ≥20 VT or VF episodes/day or ≥4 VT/VF episodes/hour, one-week 
incidence of non-sudden death was as high as 50%. The majority of patients who survived 
the acute phase, however, have a prognosis relatively comparable with other ES 
populations. Along with pharmacological therapy, swift and effective reperfusion is crucial 
to end arrhythmic episodes. Retrospective studies and registry data suggest the hypothesis 
that, with modern reperfusion therapy currently available, the incidence of ES could be 
associated with reperfusion time. 
3.2 Electrical storm in heart failure 
Heart failure is an important risk factor for ES. Most of the times, idiopathic dilated 
cardiomyopathy is the structural heart disease underlying heart failure in ES patients, 
followed in prevalence by ischemic cardiomyopathy (Gasparini et al, 2008). Hypertrophic 
cardiomyopathy and valvular cardiomyopathy, albeit uncommon, has been associated with 
heart failure worsening leading to ES (Credner et al, 1998). 
Left ventricular ejection fraction (LVEF) is the most widespread and easy to obtain marker 
of systolic dysfunction and has been used to test the association between heart failure and 
ES. Several studies have found an altered LVEF as an independent risk factor for ES, along 
with older age, chronic renal failure, causative arrhythmia and electrolytic imbalances 
(Exner et al, 2001 and Brigadeau et al, 2006). On the other hand, Streitner and coworkers 
found that a LVEF lower than 30% was not predictive for the initial ES event, but brought a 
2.2-fold increased risk for ES recurrence (Streitner et al, 2011). 
Current evidence suggests that, more than the presence or absence of heart failure by itself, 
it is the progression of heart failure and structural cardiomyopathy the real factor in 
promoting ES and ES recurrence. Therefore, prevention of further systolic function 
deterioration after an initial ES is mandatory and must be achieved through optimization of 
medical and resynchronization therapy. 
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3.3 Electrical storm in patients with congenital pro-arrhythmic diseases 
Genetic arrhythmic syndromes or inherited arrhythmic disorders comprise a group of 
syndromes with unique genetic abnormalities and presentations but with very similar 
clinical outcomes, the most terrifying of which are life-threatening arrhythmias and sudden 
cardiac death. Some of them, such as Brugada syndrome and long QT syndrome, affect 
structural normal hearts, whereas others, such as arrhythmogenic right ventricular 
cardiomyopathy and left ventricular non-compaction affect deeply the myocardial tissue, 
and are included in the cardiomyopathies classification. ES has been described in the 
Brugada syndrome, in the familiar long QT syndrome, in the short-coupled variant of 
torsade de pointes, in catecholaminergic polymorphic ventricular tachycardia, in 
arrhythmogenic right ventricular cardiomyopathy and in myocardial non-compaction. 
Overall, these syndromes are quite rare, being Brugada syndrome the most prevalent with 5 
cases out of 10.000, and association with ES in even rarer. However, patients affected by 
these syndromes are typically young and otherwise completely healthy, making diagnosis 
and treatment of these conditions challenging. 
4. Laboratory and electrical storm 
Although electrolytic imbalances, such as hypokalemia, hyperkalemia and hypomagnesemia 
are a well known risk factors for ventricular arrhythmias and hence ES, many papers report 
that an evident trigger in a majority of patients cannot be identified by laboratory alone. 
Credner et al. underlined the presence of hypokalemia, along with acute coronary syndrome 
and worsening heart failure as potential triggers in 26% of the patients in his case-records 
(Credner et al, 1998). Similarly, Bänsch et al. found hypokalemia as a potential cause of ES in 
20% of their cohort. According to the SHIELD trial, electrolytic imbalance was responsible for 
storm triggering in only 4% of patients (Hohnloser et al, 2006). 
In 2006 for the first time Brigadeau et al. highlighted a possible role of creatinine in 
predicting ES, identifying a storm trigger in 36% of the whole cohort. Among most common 
triggers (such as acute coronary syndrome, high body temperature, hypokalemia or 
hyperkalemia, hyperthyroidism and acute heart failure) chronic renal failure, identified as a 
creatinine clearance lower than 60 ml/min, was independently associated with ES 
occurrence. Thus, this study concluded that the patients with a defibrillator who are likely to 
undergo electrical storm are those who have both low left ventricular ejection fraction and 
chronic renal failure (Brigadeau et al, 2006). In a recent MADIT II chronic kidney disease 
was associated with a 2.1–fold increase in risk for ES in both primary and secondary 
prevention patient (Sesselberg et al., 2007). 
Thyroid disorders (both hypothyroidism and hyperthyroidism) have been suggested as a 
trigger for ES. However, at present there is scarce evidence of an important role of thyroid 
hormones in ventricular arrhythmias pathogenesis. In one case report ES was attributed to 
amiodarone-induced thyrotoxicosis (Marketou et al, 2001). The patient was unresponsive to 
medical therapy and the ES was successfully terminated by thyroidectomy. 
In conclusion, in an ES setting laboratory could play an important role. Electrolytic 
abnormalities such as hypokalemia, hyperkalemia and hypomagnesemia should be 
promptly diagnosed and corrected, as potential triggers of arrhythmic events. High serum 
levels of BNP, creatinine and PCR are valid markers for respectively decompensated heart 
failure, chronic renal insufficiency and pro-inflammatory state, and should be assessed in 
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repeated boluses at half the above doses for breakthrough episodes) blocks fast sodium 
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incidence of torsades de pointes is low in such patients despite the potential significant 
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threshold testing. Patients who have episodes of electrical storm despite amiodarone 
therapy may benefit from β-blockers adjunctive therapy or undergo RF ablation. 
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β-blockers play a key role in the management of electrical storm. Their effects were 
discovered in the 1970s, when they were studied as therapy for acute MI. First evidences 
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al, 1983). All β-blockers increased 6-fold the fibrillation threshold and made the animals less 
susceptible to fibrillation under ischemic and non-ischemic conditions. The improvement 
was greater with the use of more potent β-blockers and with those that antagonized both β1 
and β2 receptors. Although several β-blockers decrease susceptibility to VF, most of the 
studies have focused on propranolol. Propranolol consistently decreases the incidences of 
fatal VF during acute MI and sudden cardiac death after MI (Tsagalou et al, 2005). In 
patients with congestive heart failure, propranolol decreases sympathetic outflow more than 
does metoprolol, perhaps because β2 receptors prevail in failing hearts (Newton et al, 1996). 
The lipophilic nature of propranolol enables active penetration of the central nervous 
system and the blockade of central and prejunctional receptors in addition to peripheral β 
receptors. Propranolol may effectively suppress an electrical storm even when metoprolol 
has failed (Tsagalou et al, 2005). Therefore, propranolol, given at a dose of 0.15 mg/kg 
intravenous bolus over 10 minutes followed by a 3-5 mg dose every 6 hours, is a first line 
therapy in emergency ES setting. Nademanee and coworkers investigated the efficacy of 
sympathetic blockade in electrical storm comparing propranolol, esmolol, and left stellate 
ganglionic blockade to combined lidocaine, procainamide, and bretylium therapy 
(Nademanee et al, 2000). All their patients have experienced a recent MI and more than 20 
episodes of VT within 24 hours or more than 4 episodes per hour. Sympathetic blockade 
provided a marked survival advantage (78% versus 18% at one week, and 67% versus 5% at 
one year). Despite the high doses of propranolol, an increase in heart failure progression 
was not reported in this study, although it is known from previous studies that propranolol 
can exacerbate heart failure in patients with poor systolic function and use in these patients 
should be carefully monitored. The short acting intravenous esmolol may also be used but 
its dosing and titration are somewhat more complicated. Miwa et al. have demonstrated that 
landiolol, an ultra-short acting β1-selective blocker is useful as a life-saving drug for 
amiodarone-resistant ES (Miwa et al, 2010). Landiolol in ES is used intravenously with an 
initial dose of 2.5 µg/kg*min, which can be doubled every 10 minutes if first dose is 
ineffective, up to a maximum dose of 80 µg/kg*min. Landiolol has a shorter plasma half-life 
(4 minutes) than esmolol (9 minutes) or propanolol (2 hours) and higher β1 selectivity. 
These properties suggest that adverse respiratory effects, such as bronchial asma, are less 
likely to develop and to persist with landiolol, which make it more suitable for emergency 
medical care. When amiodarone was ineffective, landiolol inhibited ES in 33 patients (79%) 
at a mean dose of 7.5 µg/kg*min. All patients in whom landiolol was ineffective died of 
arrhythmia. Of the 33 patients in whom landiolol was effective, 25 survived and were 
discharged (60% of all patients). At present, landiolol is not available in most European 
countries and its safety profile in ES still needs to be assessed, making this drug a promising 
alternative to propranolol when amiodarone alone is ineffective. 
5.1.3 Lidocaine 
Intravenous sodium-channel blockers (lidocaine, procainamide) are minimally effective in 
suppressing shock-resistant VT/VF and ES (Credner et al, 1996 and Nademanee et al, 2000). 
Lidocaine binds to fast sodium channels in a use-dependent fashion. Binding increases 
under cellular conditions that are common in ischemic VT, such as reduced pH, faster 
stimulation rate and reduced membrane potential. However, lidocaine has relatively weak 
antiarrhythmic properties outside the ischemic setting: conversion rates from VT to sinus 





resistant VT or VF, only 12% of those randomized to lidocaine survived to hospital 
admission, versus 23% who received amiodarone. On the basis of this and other findings, 
amiodarone has replaced lidocaine as first line therapy for refractory VT and VF. Actual 
recommendations suggest intravenous lidocaine only in the treatment of polymorphic VT 
associated with acute ischemia. If lidocaine is used, it should be administered as an 
intravenous bolus of 0.5 to 0.75 mg/kg that is repeated every 5 to 10 min as needed. A 
continuous intravenous infusion of 1 to 4 mg/min maintains therapeutic levels. The 
maximum total dose is 3 mg/kg over 1 hr. 
5.1.4 Procainamide 
Procainamide blocks fast sodium channels in a use-dependent fashion and is metabolized to 
N-acetylprocainamide, which in turn blocks potassium channels and accounts for much of 
the antiarrhythmic effect in vivo. When given as a loading dose of 100 mg over 5 min, 
procainamide is a reasonable choice for terminating monomorphic VT. In patients with 
depressed systolic function procainamide can cause hypotension or prolong QRS width by 
more than 50%, either of which would necessitate discontinuation of the drug. Procainamide 
prolongs the QT interval and therefore could cause torsade de pointes. Its use is 
contraindicated in patients with impaired renal function, because N-acetylprocainamide is 
excreted by the kidneys. 
5.1.5 Azimilide 
Azimilide is an experimental class III antiarrhythmic drug that blocks calcium channels and 
prolongs the energy potential and refractory periods. The recently published SHIELD trial 
showed that azimilide is effective and helps to reduce the number of ICD discharges, 
though not mortality (Stefan et al, 2006). A secondary analysis of the SHIELD data found 
that during a prospective one-year follow up azimilide significantly reduced the incidence 
of ES in comparison with placebo. Azimilide could become an alternative for the treatment 
of ES whenever it becomes commercially available. 
5.1.6 Polypharmacological approach 
Optimization of β-blocker therapy is the first important step, particularly when the electrical 
storm is triggered by ischemia or increased sympathetic tone. The next step is initiating anti-
arrhythmic therapy if patient still experiences ES. In the absence of contraindications (such 
as QT lengthening or polymorphic ventricular tachycardia), amiodarone is generally the 
antiarrhythmic drug of choice and has been validated in numerous clinical trials (Kowey et 
al, 1995 and Wood et al, 1995). Most of the time, optimized β-blocker therapy plus 
intravenous amiodarone will control the electrical storm within 24 to 48 hours. This appears 
to be the most effective therapy for electrical storm. If the intravenous combination of 
amiodarone and β-blockers proves inefficacious, the addition of lidocaine is a reasonable 
option. Although controlled data are not available, combination of anti-arrhythmic drug 
allows lower and better tolerated doses of individual drugs, and offers the potential of 
synergistic effects. 
5.1.7 Sedation 
The physical and emotional stress that patients experience in association with electrical 
storm and multiple electrical cardioversions increases adrenergic tone and often perpetuates 
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arrhythmias. All patients who have electrical storm should be sedated. Sedation or general 
anesthesia are needed in resistant cases where repeated shocks or anti-tachicardia 
transthoracic pacing are needed. Short-acting anesthetics such as propofol, benzodiazepines, 
and some agents of general anesthesia have been associated with the conversion and 
suppression of VT (Burjorjee & Milne, 2002). Left stellate ganglion blockade and thoracic 
epidural anesthesia have also suppressed electrical storms that were refractory to multiple 
antiarrhythmic agents and β blockade (Nademanee et al, 2000). These therapeutic 
approaches directly target nerve fibers that innervate the myocardium, and a reduced 
adrenergic tone is most likely responsible for the reported efficacy. Is currently unknown 
whether sedative and anesthetic agents may have direct antiarrhythmic effects. 
5.2 Implantable defibrillators: First-line therapy and first-line diagnostic? 
ES is quite common in ICD recipients. In different studies the incidence of ES in patients 
with an ICD ranges from 10 to 60% when ICDs are implanted for secondary prevention 
(Arya A et al, 2005) and 4% to 7% when ICDs are implanted for primary prevention 
(Sesselberg et al, 2007). A higher incidence of ES in ICD patients is related to an higher 
cardiovascular mortality and morbidity among ICD recipients. As previously said the 
presence of ICD allows the physician to recognize more arrhythmias and the patient to 
survive the arrhythmia and hence manifest more episodes. 
Occurrence of ES after ICD implant has changed over time. A paper from the late 1990s 
reported the peak of incidence of ES between 4 and 5 months after implant (Credner et al, 
1998). On the other hand recent evidences pushed the onset of ES to 26 months after implant 
(Streitner et al, 2011). Total number of episodes varied over time too: as much as 55 mean 
episodes per patient have been reported (Greene et al, 2000), whereas more recent papers 
describe far less VT/VF per single patient (Streitner et al, 2011). Both these findings could be 
explained by changes in antiarrhythmic therapy and ICD technology occurred in this last 
decade which in turn led to fewer total arrhythmic episodes and improved overall prognosis. 
There is a multitude of etiologies of ES in ICD patients: hypokalemia or other electrolytic 
imbalance, drugs (diuretics, b-adrenergic drugs, alcohol), ischemia, medication 
noncompliance and less common causes such as fever or stress (Huang et al, 2005 and Israel 
et al, 2007). The most common cause of ES in ICD patients is exacerbation of heart failure, as 
underlying ischemic or idiopathic dilated cardiomyopathy could progress despite medical 
therapy and arrhythmic prevention. Nevertheless, most ES have no clear etiology and even 
an exhaustive search for acute cause may prove fruitless. 
Clinical presentation can vary dramatically depending on arrhythmias typology 
(monomorphic VT, polymorphic VT or VF) and patient’s characteristics (EF, NYHA class, 
comorbidities). The presence of syncope associated with arrhythmia depends both on 
hemodynamic factors and on ICD settings (mostly shock charging time). The most 
important acute consequence related to ES is hospitalization that is required in more than 
80% of patients, particularly when shocks are delivered (Bansch et al, 2000). ICD patients 
presenting ES have higher morbidity and mortality, hence determination of predictors is 
needed to identify high risk patients. 
Data on risk factors of ES are far from comprehensive or conclusive but most studies 
consider low EF and secondary prevention as major risk factors for developing ES in ICD 
recipients. High NT-proBNP and hs-CRP, history of atrial fibrillation before implant or 






ICD patients who experienced a first ES are also more likely to experience one or more ES 
recurrence. Recurrence rate is as high as 80% within 12 months after the first episode, 
according to Steinert, who described LVEF < 30%, age > 65 years, chronic obstructive 
pulmonary disease and lack of ACE inhibitors therapy as independent predictors of ES 
recurrence (Steinert et al, 2011). 
Most authors report poor prognosis associated whit ES with a risk of death increased from 
1.9 to 17.8 fold. Death rate is usually low during hospitalization and acute episode but 
increases afterward, particularly during the first year after ES. 
Lately, new tools have become available to detect and manage ES in ICD patients. All major 
ICD companies now offer some sort of home or remote monitoring along with their devices. 
Home monitoring offers the physician reports for arrhythmic events, device battery and 
parameters status in real-time. Asymptomatic or lightly symptomatic ES could be then 
promptly recognized and the patient immediately called in for a check-up without the need 
to wait for the next programmed ambulatory visit. Figure 1 shows how an ES looks like on 
auto-generated home monitoring report: the patient experienced 37 arrhythmic episodes in 
less than 24 hours, 36 VT terminated with a shock after ATP sequence was ineffective and 1 
VF episode terminated with ATP. 
Figure 2 shows how EGM can be seen and interpreted via remote monitoring. In this EGM 
VT has been correctly detected and treated by ICD shock. 
5.3 Is cardiac resynchronization therapy useful in preventing electrical storm? 
Cardiac resynchronization therapy (CRT) is a well established therapy for treatment of 
moderate to severe heart failure. Several studies assessed benefits from biventricular pacing 
resulting in prevention of left ventricular remodeling and improvement of hemodynamic, 
ejection fraction, NYHA class, quality of life, morbidity and mortality (Cleeland et al, 2005). 
Effects of CRT on ventricular arrhythmias are less well established. Some evidence suggests 
that pacing itself might cause arrhythmias and some authors reported an increase in 
incidence of atrial fibrillations, ventricular arrhythmias or even electrical storms after 
biventricular pacing (Kantharia et al, 2006). However, currently available large-scale trials 
showed no significant proarrhythmic effects of CRT. On the other hand, there is no strong 
evidence of a direct antiarrhythmic effect of CRT over single or dual chamber pacing either. 
Nordbeck et al. compared incidence of ES in 168 CRT and 561 ICD patients. They found 
significant lower incidence of ES in CRT group (0.6% versus 7%), suggesting that, beside the 
well known hemodynamic improvements, cardiac resynchronization therapy may reduce 
the arrhythmia burden in heart failure patients (Nordbeck et al, 2010). An Italian group 
found a higher incidence of ES (11.3% vs 5.3%) in patients non responder to CRT therapy, 
defined as minor improvement in NYHA class and ejection fraction (Gasparini et al, 2008). 
These data support the hypothesis that CRT may have an indirect antiarrhythmic effect, due 
to factors which are still unclear. Nordbeck suggests that the reduction of arrhythmic 
burden could be due to improvement of cardiac output and ejection fraction from CRT, as 
ejection fraction is a known risk factor for ventricular arrhythmias. Another hypothesis by 
Kowal found some evidences in clinical cases reporting a specific role of cardiac pacing site 
in development or suppression of VT. He hypothesized that the mechanism of arrhythmia 
suppression under biventricular pacing could be ascribed to preexcitation of the area of 
slow conduction responsible for the reentrant arrhythmia (Kowal et al, 2004). 
Nevertheless, electrophysiologic effects of CRT are still poorly understood. Biventricular 
pacing remains a major therapeutic tool in the treatment of heart failure but additional data 
are required to assess its efficacy as antiarrhythmic therapy. 
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Fig. 1. 78 year-old patient with dilated idiopathic cardiomyopathy. In this report the patient 
experienced 37 arrhythmic episodes in less than 24 hours. Physicians can check the report 






Fig. 2. One of the arrhythmic episodes reported in Fig.1. In this EGM a ventricular 
tachycardia in VT zone starts abruptly following a premature ventricular contraction. Atrio-
venticular dissociation is easily visible. ATP was ineffective whereas 15J delivered shock 
successfully terminated VT. 
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5.4 Specific therapy in congenital pro-arrhythmic diseases 
Although electrical storm associated with Brugada syndrome is exceptional, it is a major 
and life threatening event that requires rapid and effective treatment. In most cases 
presented to date, infusion of isoproterenol (as a 1-2 µg bolus injection followed by 
continuous infusion at 0.15 µg/min, or at a rate of about 0.003 µg/kg/min tritated to result 
in a 20% increase in heart rate), was used to terminate electrical storm. Other cases reported 
intravenous orciprenaline infusion or quinidine as effective in terminating ES. Direct β 
adrenergic stimulation by isoproterenol and orciprenaline increases the L-type calcium 
current, which restores the epicardial action potential dome, normalizes ST segment 
elevations and suppresses ventricular arrhythmias. It should be emphasized that 
orciprenaline or quinidine use as last resort approach in ES is limited to cases of confirmed 
Brugada syndrome, while in the majority of ES associated with ischemic or dilated 
cardiomyopathy, orciprenaline or quinidine application may result in fatal outcome. 
In the congenital long QT syndrome, high dose β-blockers can suppress the occurrence of ES 
and frequent ICD discharges. In refractory cases, left cardiac sympathetic denervation 
results in marked reduction in ES incidence. 
In the ES associated with the short-coupled variant of torsade de pointes ventricular 
tachycardia, verapamil or the combination of verapamil and mexiletine is somewhat 
effective. Intravenous magnesium and overdrive pacing are the treatment of choice for 
drug-induced torsade de pointes. 
Arrhythmogenic right ventricular cardiomyopathy and myocardial non-compaction deeply 
modify heart structure, and ES associated with these conditions is usually resistant to 
medical therapy. Heart transplantation represents nowadays the only viable option for 
terminating recurrent, haemodynamically destabilizing arrhythmias in these patients. 
5.5 Last resource therapies. Radio-frequency ablation and heart transplantation 
5.5.1 Radio-frequency ablation 
Although radiofrequency catheter ablation (CA) has an established role in the treatment of 
recurrent VT, only recently it has been suggested as a method of choice in management of 
ES, especially when pharmacological and ICD therapies fail. The best candidates for CA are 
those ventricular arrhythmias in which the initiating beat or premature ventricular 
contractions morphologically identical to the initiating beat can be localized with 
electroanatomical mapping. In patients affected with ischemic cardiomyopathy the typical 
site of the initiating beat is around the border zone of the scar tissue. The procedure can be 
performed under light anesthesia or deep sedation, according to the hemodynamic state of 
the patient. If the VT is not incessant, a stimulation protocol from right and left ventricle and 
up to three extrastimuli is usually applied to induce clinical VT and determine its 
characteristics. Mapping and ablation is usually performed by an irrigated-tip catheter 
introduced into the right ventricle or left ventricle by direct femoral vein approach or 
retrograde transaortic or transseptal approach, respectively. Electroanatomical mapping is 
nowadays the standard of care, being safe and effective. 
The largest series of patients undergoing CA for refractory ES has been described by 
Carbucicchio and coworkers. Solid electrophysiological evidence of the effective treatment 
of the presenting VT was achieved in 89% of patients, whereas a transient effect of CA 
causing short-term stabilization but ineffective in long-term ES prevention was observed in 





as a temporary bailout, with no impact on ES recurrence. In a recent Czech study RF 
ablation proved effective in suppression of ES in 84% of cases; however, repeated 
procedures were necessary in 1 out of 4 patients (Kozeluhova et al, 2011). Severely 
depressed left ventricular ejection fraction, highly-dilated left ventricle, renal insufficiency, 
and ES recurrence after previous ablation procedure were independently associated with 
adverse outcome within the first 6 months after the procedure. Is it still unclear whether 
inducibility testing of the VT at the end of the study is predictive of mortality and 
arrhythmic recurrences, as currently available data are controversial. 
Successful CA of refractory ES in the absence of a detectable trigger has also been described. 
Schreieck and colleagues reported a case series of 5 ischemic patients with unmappable 
recurrent VTs, in which CA was attempted targeting delayed local potentials guided by 
voltage mapping and pace mapping (Schreieck et al, 2004). These isolated delayed potentials 
are found exclusively in areas of dense scar, making this kind of technique ineffective in 
idiopathic dilated cardiomyopathy. 
On a side note, patients with pseudo-storm due to inappropriate ICD shocks induced by 
atrial tachyarrhythmias can benefit from CA of atrial flutter, atrial fibrillation or even AV 
node ablation. 
5.5.2 Heart transplantation 
Patients with no significant comorbidities except for recurrent ES who experienced no 
improvements from pharmacological, device-related and surgical treatment should be 
considered for cardiac transplantation. Patients with refractory ES associated with a genetic 
arrhythmia syndromes may also be reasonable candidates for heart transplantation as these 
patients are typically young, otherwise healthy individuals with good quality of life and 
prognosis. 
In haemodynamically instable patients, intraaortic balloon pump and cardiac assist devices 
should be used as bridge-to-transplant, as potentially lifesaving. 
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1. Introduction  
Acute spinal cord injury (SCI) is most commonly traumatic in origin but may also result 
from degenerative spine disease, ischemia, demyelination, inflammation, or rapidly 
expanding neoplastic, hemorrhagic, or pyogenic masses (Ghezzi et al, 2001). In the United 
States, traumatic SCI with or without bony injury has an annual incidence of 28 to 55 per 
million, with an average of 10,000 new cases a year and a prevalence of 200,000 (Sekhon & 
Fehlings, 2001). The average age at the time of injury is 32 years and the male/female ratio is 
4:1. More than half (55%) of traumatic SCI involves the cervical cord. The most common 
causes of SCI are traffic accidents (motor vehicle, bicycle, pedestrian) (40%– 50%), assault 
(10%–25%), falls (20%), work-related injuries (10%–25%), and sports/recreation-related 
injuries (10%–25%) (Cheung et al, 2002; Surkhin et al, 2000). In traumatic cervical SCI, 3-
month mortality is 20% to 21%. The independent predictors of mortality are level of cord 
injury, Glasgow Coma Scale, respiratory failure, and age. Principal causes of death are 
respiratory disorders, cardiovascular disorders, pulmonary embolism, infections, and 
suicide (Claxton et al, 1998; DeVivo et al, 1999, Yeo et al, 1998). Cardiovascular disorders are 
responsible for 40.5% of deaths, being the most common cause of mortality in patients with 
SCI (Garshick et al, 2005). 
2. Cardiovascular instability  
Cardiovascular instability is a frequent complication of SCI, especially when the upper 
thoracic or cervical cord is involved (Figure 1). Peripheral sympathetic denervation results 
in arteriolar dilation and pooling of blood in the venous compartment, while interruption 
of cardiac sympathetic innervation (T1– T4) promotes bradycardia (Figure 2) and reduces 
myocardial contractility. The autonomic nervous system modulates cardiac 
electrophysiology, and, consequently, autonomic dysfunction can lead to ventricular 
arrhythmias. Concomitantly, parasympathetic input to the heart (from the vagus nerve, 
cranial nerve [CN] X) remains intact and may frequently result in bradycardia, especially 
with cervical SCI. Less commonly, cardiac arrest has been documented. Bradycardia is 
often precipitated by tracheal stimulation (for example, during suctioning) and hypoxia 
(Mathias et al, 1976; Piepmeier et al, 1985). Reflex bradycardia and cardiac arrest occur 
due to a vago–vagal reflex. Under normal circumstances, this reflex is opposed by 
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sympathetic activity. As a compensatory response to hypoxia, a pulmonary–vagal reflex 
occurs, designed to increase respiratory rate and pulmonary inflation. However, in 
patients with SCI, compensatory sympathetic activity is eliminated, leaving 
parasympathetic activity unopposed, leading to severe bradycardia and potentially 
cardiac arrest. Studies of cardiovascular abnormalities after SCI show that as many as 
100% of patients with motor complete cervical injuries (American Spinal Injury 
Association [ASIA] grades A and B) develop bradycardia, 68% are hypotensive, 35% 
require pressors, and 16% have primary cardiac arrest. Of persons with motor incomplete 
cervical injuries (ASIA grades C and D), 35-71% develop bradycardia, but few have 
hypotension or require pressors. Among patients with thoracolumbar injuries, 13-35% 
have bradycardia (Lehmann et al, 1987; Wirth et al, 2007). Bradycardia is more frequently 
encountered in the acute phase, and is more severe in the first 2–6 weeks after trauma 
(Krassioukov et al, 2007; McKinley et al, 2006). Cardiovascular dysfunctions improve in 
time. The reasons are not well understood, but synaptic reorganization or 









Fig. 1. Spinal cord and level of injury. 
 





Fig. 2. Sinus Bradycardia during cervical SCI. 
Cardiovascular control in acute and chronic SCI has been investigated by measuring the 
response to a variety of cardiovascular markers (blood pressure, heart rate, and plasma 
levels of norepinephrine and epinephrine) before ,during and after application of noxious 
stimuli below the level of the lesion. In acute SCI, noxious stimuli ( eg. bladder 
stimulation) caused minimal changes in heart rate and plasma norepinephrine and 
epinephrine levels. In chronic SCI, noxious stimuli induced bradycardia and elevation in 
plasma norepinephrine but not in epinephrine levels. Resting plasma norepinephrine and 
epinephrine levels in both the acute and chronic SCI were lower than in normal subjects 
(Mathias et al, 1979).  
The tilt test has been used to evaluate and delineate alterations in sympathetic 
cardiovascular compensation, which reflect the degree of autonomic dysfunction. 
Autonomic and cardiovascular responses to tilt test are blunted in persons with 
quadriplegia or paraplegia (Welch et al, 2005). Such tests could be used to noninvasively 
assess autonomic dysfunction in persons with SCI, determine the degree of sympathetic 
disruption, and assess the risk of developing cardiac arrhythmias, especially bradycardia. 
However, there are very few studies on these bedside tests upon which to solidly base 
conclusions and recommendations. 
3. Treatment  
3.1 Pharmacotherapy  
Although bradycardia after cervical SCI usually resolves within 6 to 8 weeks after injury, 
it may progress to complete heart block and cardiac arrest. As such, the acute 
management and maintenance of cardiovascular stability in these patients  may range 
from  a practical clinical chore  to a potentially lifesaving responsibility. There is limited 
data available regarding the optimal and best treatment available for symptomatic 
bradycardia in this patient population (Table 1). All data on therapeutic management of 
bradycardia secondary to cervical spinal cord injury is based on case reports, case series 
and observational studies. 
Atropine, an anticholinergic agent, is generally recommended as the first-line agent for 
bradycardia after cervical spinal cord injury. Atropine improves conduction through the 
atrioventricular (AV) node by reducing vagal tone through muscarinic receptor blockade. 
The dose ranges from 0.4 to 0.6 mg, administered intravenously every 4 hours for short-term 
therapy (Abd & Braun, 1989; Pansoori & Leesar, 2004; Piepmeier et al, 1985; Sadaka et al, 
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2010; Sakamoto et al, 2007; Schulz-Stubner, 2005; Weant et al, 2007; Whitman et al, 2008; 
Winslow et al, 1986). Atropine should be kept readily available at the bedside at all times 
with this patient population, as acute episodes of bradycardia and hypotension may occur 
suddenly and without warning in the immediate few hours and days following injury. 
 
   
Modality Route of administration Mechanism of action 
   
   
Atropine IV reduces vagal tone by muscarinic receptor blockade 
   
Dopamine IV infusion Beta1 receptors on the heart 
   
Epinephrine IV infusion Beta1 receptors on the heart 
   
Aminophylline IV 
inhibition of PDE enzyme thus 
increasing c-AMP with subsequent rise 
in catecholamines 
   
Theophylline Enteral or parenteral 
inhibition of PDE enzyme thus 
increasing c-AMP with subsequent rise 
in catecholamines 
   
Propantheline Enteral postganglionic parasympathetic acetylcholine receptor blocker 
   
Permanent 
Pacemeker invasive  
Table 1. Therapeutic modalities for bradycardia secondary to cervical SCI. 
Another frequently utilized category of intravenous medications includes sympathomimetic 
agents such as  Dopamine or Epinephrine  which increase heart rate through action on Beta1 
receptors in the heart. Continuous infusions of dopamine at a rate of 2 to 10 mcg/kg/min or 
epinephrine at a rate of 0.01 to 0.1 mcg/kg/min has been used in the acute setting (Abd & 
Braun, 1989; Piepmeier et al, 1985; Sadaka et al, 2010; Winslow et al, 1986). Complications 
include tachyarrythmias, angina pain, palpitations, vasoconstriction, nausea, vomiting and 
headache. 
When intermittent boluses of atropine or continuous infusions of sympathomimetic drugs 
have failed to prevent  recurrent symptomatic bradycardia, or reverse high or complete 
heart block , permanent pacemaker placement has  often been used as the next therapeutic 
alternative  (Franga et al, 2006; Ruiz-Arango et al, 2006). Cardiac pacemaker implantation is 
advocated for patients with high cervical spinal cord injuries with persistent bradycardia 
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not responding to medical management (Giloff et al,1991). However, specific criteria for 
placement of a pacemaker are not well defined. The reported number of SCI patients 
requiring a pacemaker varies from 9 to 17% (Abd & Braun, 1989; Lehmann et al, 1987). 
Complications of permanent pacemakers include infection, lead malfunction, death during 
attempted insertion, and death associated with failure to capture. 
The methylxanthine agents, including aminophylline and theophylline, have been used 
effectively for the management of refractory symptomatic bradycardia when other agents 
have failed (Pansoori & Leesar, 2004; Sadaka et al, 2010; Sakamoto et al, 2007; Schulz-
Stubner, 2005; Weant et al, 2007; Whitman et al, 2008). In addition, there are recent reports 
of methylxanthines used specifically as a successful first line treatment for bradycardia 
associated with cervical spinal cord injury. None of the patients in the case series needed a 
pacemaker placement and none of the patients developed drug related side effects 
(Sadaka et al, 2010). The proposed mechanism for the chronotropic effect of these drugs is 
via inhibition of phosphodiesterase (PDE) enzyme thus increasing the cyclic adenosine 
monophosphate with subsequent rise in catecholamines. A clear benefit of these agents is 
that they may be administered on a fixed schedule as an enteral preparation. An oral (or 
intravenous)  loading dose between 200 and 300 mg was administered in most cases with 
maintenance doses starting at 100 mg three  times daily and continued for up to 12 weeks. 
Drug serum levels were variable and differed widely among patients. The effective dose 
of theophylline resulted in serum levels that were below the therapeutic range defined in 
the literature (10-20 mcg/ml), and ofcourse below the toxic range (>25 mcg/ml). Since no 
therapeutic index for symptomatic bradycardia has been established, the methylxanthine 
dose was titrated according to clinical response.  The main side effects of these agents are 
nausea, vomiting, tremor, headache, and seizures. However, No adverse effects were 
noted in any of the reports. Nonetheless until more experience is gained with this 
modality, careful attention should be made to monitor drug levels and avoid toxicity. 
Methylxanthine has also been associated with diaphragmatic strengthening in animal 
models, another potential beneficial effect to consider in spinal cord injury patients 
(Whitman et al, 2008).  
In patients requiring long-term therapy, there are case reports of successful treatment with 
propantheline 7.5 to 30 mg every 4 to 6 hours (Abd & Braun, 1989; Winslow et al, 1986). 
Propantheline competitively blocks the action of acetylcholine at postganglionic 
parasympathetic receptors. The main side effect reported from chronic propantheline 
therapy is a reduction in gastrointestinal motility due to its anticholinergic effects. 
3.2 Anticipation, prevention & positioning  
Bradycardia and potential for cardiac arrest should be anticipated in any patient with spinal 
cord injury. Bedside care providers should be alerted to the fact that life threatening events 
occur more frequently with high spinal cord lesions.  Personnel should anticipate and 
document triggers for serious bradycardic episodes. Hyperoxygenation and ambu 
“bagging” may be helpful prior to tracheal suctioning.  Prophylactic atropine administration 
before tracheal suction, laryngoscopy, or oral intubation has been shown to minimize 
severity of events (Frankel et al, 1974; Mathias ,1976;Welphy et al, 1975). Theophylline may 
also be started at the first indication of bradycardia. Particular attention should be paid to 
other potential exacerbating factors, including rapid changes in positioning, prolonged 
recumbency, drug adverse effects, underlying infection, and hypovolemia. 
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Before moving the patient out of supine position, abdominal binder, thigh-high stockings, 
and elastic bandages to the lower extremities can be applied. These measures decrease 
venous pooling in the lower extremities and splanchnic vasculature. The patient can be 
moved slowly, from a supine position to a relatively upright position. A tilt table can be 
used to slowly bring the patient to the upright position.  
3.3 Rehabilitation measures 
Active arm exercises can be used to maintain blood pressure while the patient is on the tilt 
table (Mckinley et al, 2006). Bilaterally functional electric stimulation to lower-limb muscles, 
quadriceps, hamstrings, tibialis anterior and gastrocnemius during tilting improves 
orthostatic tolerance in patients with cervical SCI. Functional electric muscle stimulation 
during tilting maneuver, significantly increases heart rate (Chao et al, 2005). 
4. Conclusion 
Spinal cord injury is a very common and devastating disease process that can occur as a 
consequence of motor vehicle collisions, falls or other traumatic injuries. Cardiac disorders 
are common consequences following SCI. Cardiovascular disturbances are the leading 
causes of morbidity and mortality in both acute and chronic phases of SCI. Disruption of 
descendent pathways from superior centers to spinal sympathetic neurons, originating into 
the intermediolateral nuclei of T1- L2 spinal cord segments results in a reduced overall 
sympathetic activity and unopposed parasympathetic activity. As a result, the most 
common cardiac dysrrhythmia is bradycardia. There are a few well established therapeutic 
modalities (Table 1) for the treatment of bradycardia associated with cervical SCI. All 
therapeutic options are based on anecdotal reports and small retrospective reviews. 
Atropine should be kept readily available at the bedside at all times. Based on recent 
evidence with methylxanthines, we recommend further studies to establish the role of these 
agents as a first line therapy in this specific patient population. Optimal dose and duration 
of therapy need to be established. Theophylline’s use via entral route as a first line therapy 
for spinal cord injury-related bradycardia can help avoid the long term use of inotropic and 
chronotropic infusions and their associated risks and complications, as well as prevent 
and/or decrease the use of cardiac pacemaker placement and its associated procedural risks 
and complications. We further recommend the study of xanthine derivates as prophylactic 
treatment for the first 2-6 weeks of the injury based on the frequency of bradycardia in 
patients with cervical SCI which is reported to be 100%. Currently, there are no established 
guidelines regarding permanent pacemaker placement in this patient population. 
Permanent pacemaker should still be considered in patients with refractory or recurrent 
bradycardia more than two weeks after the injury. In addition, the incidence of bradycardia 
after cervical SCI may be decreased by proper prophylactic measures, cardiac exercises and 
appropriate rehabilitation. 
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1. Introduction 
Electromagnetic mapping has made possible the routine approach to complex arrhythmia 
mapping. Originally, it was developed to facilitate accessory pathway location, but it only 
complicated solitary pathway ablation. Especially, with the introduction of atrial fibrillation 
ablation, the electromagnetic mapping has become an irreplaceable component of this 
procedure. Latter, this 3-dimentional mapping method facilitated ventricular foci ablation in 
patients with ventricular tachycardia. During the last decade, the application of this mapping 
method is continuously extended and applied to a large number of complex arrhythmia cases. 
The electromagnetic mapping is based on minimal magnetic field generation around the tip 
of the catheter and several antennas, located in a special hardware, called location pad, 
detect this field. In the near future the location pad will be replaced by an intracardiac 
detection system. As multiple antennas record the signal, the location pad precisely localizes 
the catheter tip. By apposition of a location on the endocardial surface and the catheter tip, a 
virtual map of the cardiac chamber is obtained. Multiple points are represented in space and 
finally, a continuous wall is completed. Moreover, the catheter records the electrical activity 
in its vicinity, and the electrical flow can be superimposed on the location in the space. A 
color-coding localizes the starting point of the arrhythmia and the current flow from it.  
As of today, an advanced generation is used and data from other imaging systems are 
merged with the electromagnetic picture. First, magnetic resonance data was merged with 
the electroanatomic mapping, but today cardiac computed tomography and echo picture 
might also be merged. Using these merged pictures the anatomical presentation more 
accurately represents the anatomical structure.  
2. A brief history of catheter ablation 
The first type of energy used for catheter ablation to cure cardiac arrhythmias was the direct 
current (DC) shock delivered through the catheter tip in apposition to the desired site of 
ablation. By ablating the AV junction in supraventricular tachycardia, a reasonable rate 
control was achieved (Scheinman MM et al, 1982). The ablation of well-defined positioned 
accessory pathways could also be achieved by DC ablation (Morady F & Scheinman MM, 
1984). The DC shock can be adjusted by delivering different amplitude of shocks, but as 
soon as it was delivered there was no more way to titrate or cancel it. To achieve a titratable 
energy, a different source is needed and the radiofrequency energy has fulfilled this 
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condition. At the end of 1980’s the radiofrequency energy has been introduced into the 
clinical electrophysiology. With the advent of specific pathways ablation, the clinical 
electrophysiology has become a continuously extending brunch of the cardiology. The 
radiofrequency energy in opposite to the direct current shock, can be titrated, limited, 
suddenly discontinued and reapplied. For this reason, the RF energy is easily applied in 
clinical practice. The first accessory pathways ablations and AV Nodal pathways ablations 
were performed during the late 1980’s and published for the first time in 1991 (Jackman WM 
et al, 1991: Calkins H et al, 1991). Since than, a vast amount of literature was published on 
this subject and almost all type of arrhythmia has become feasible for ablation. In Table 2.1 a 
list of ablatable arrhythmic substrates is presented.  
 
Arrhythmia Type Fist performed Publication 
WPW 1989 Jackman WM et al 1991; Clakins H at al, 1991 
ANRT 1989 Lee MA at al, 1991 
A Flutter 1992 Feld GK et al, 1992; Cosio FG et al, 1993 
A Tachycardia 1992 Kall JG& Wilber DJ, 1992; Walsh EP et al, 1992 
VT idiopathic 1991-1992 Kuck KH et al, 1991; Klein LS et al, 1992 
VT in Heart Disease 1992 Morady F et al, 1993 
A Fibrillation 1996 Haissaguerre M et al, 1998 
VF idiopathic 2001 Takatsuki S et al, 2001, Haissaguerre M et al, 2002 
Abbreviations: WPW-Wolf Parkinson White Syndrome; AVNRT- AV Nodal Reentrant Tachycardia;  
A Flutter-Atrial Flutter; A Tachycardia-Atrial Tachycardia; VT-Ventricular Tachycardia; A Fibrillation- 
Atrial fibrillation; VF- Ventricular Fibrillation 
Table 2.1. The table summarizes the types of arrhythmia treated with catheter ablation. 
In accessory pathway ablation, the presumed location is meticulously mapped with a special 
developed steerable tip catheter. The pathways are located on the mitral or tricuspid rings, 
or in the septum separating the left and right heart. When the recoding from this site is 
satisfactory, RF energy is delivered for certain duration. If the accessory pathway conducts 
electricity in both directions, or at least, in the antegrade direction (from the atrium to the 
ventricle), the resting ECG shows a typical preexcitation pattern. Short PR interval and a 
widening of the QRS characterize this preexcitation. A typical delta wave is preceding the 
QRS and its direction depends on the location of the pathway. Wolf, Parkinson and White 
described this type of ECG in 1930 and if it is associated with palpitation is called Wolff-
Parkinson-White syndrome (Wolff L et al, 1930). During the RF energy delivery the 
preexcitation disappears and the ECG becomes normal. After the ablation, during 
temporary blockage of the AV node with intravenous adenosine injection, AB block is 
achieved, demonstrating the remaining conduction only through the AV junction. 
However, in 50% of the patients the resting ECG is normal, but still the patient can develop 
supraventricular tachycardia. In this case, the accessory pathway conducts the electricity 
only in the retrograde direction (from the ventricle to the atrium) and is called concealed 
Wolff-Parkinson-White syndrome. The mapping is completed either during tachycardia or 
ventricular pacing. RF energy application eliminates the retrograde conduction without 
affecting the resting ECG. 
Patients with dual AV Nodal conduction may develop supraventricular tachycardia based on 
reentry circuit in the AV Node. One of the pathways has slow conduction of the electricity and 
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the other has fast conduction. If the refractoriness of these pathways and the conduction times 
are appropriate, the electric impulse may be conducted in a circuit constituted by this two 
pathways and the clinical expression will be supraventricular tachycardia with short VA time. 
A premature beat during unidirectional block in one of the pathways initiates the tachycardia. 
Different duration of refractoriness of these pathways creates the unidirectional block. 
Blocking one of these pathways will prevent induction of the tachycardia. RF ablation is based 
on the same principle: selective elimination of the conduction on one of these pathways. In the 
late 1980’s the fast pathway was ablated (Lee MA et al, 1991). These fast pathways are located 
in the anterior site of the AV node very near to the proximal His Bundle. Although the success 
rate was very high, special attention was needed to avoid complete AV Block. After a year, the 
slow pathway ablation was described (Jackman WM et al, 1992). The slow pathway is located 
in the posterior AV nodal area, relatively far from the His Bundle. The ablation of these slow 
pathways is safer and today is routinely performed in most of the electrophysiology 
laboratories. After the ablation, the AV refractoriness prolongs and the AH interval (atrial-His 
conduction time) remains short immediately before the blocking. 
The third classical ablation is that of typical atrial flutter (Feld GK et al, 1992, Cosio FG et al, 
1993). In typical atrial flutter, a single electrical wavefront circulates in the perimeter of the 
right atrium. The area between the lower pole of the tricuspid valve and the inferior vena 
cava is called isthmus. A multipolar catheter on the lateral wall of the right atrium 
demonstrates the counter-clockwise or clockwise rotation during the flutter. Complete 
blocking of the isthmus, terminates the flutter. After the successful ablation, pacing at the 
coronary sinus osteum demonstrates the block, by conduction to the lateral wall only from 
above the tricuspid annulus.  
In atrial tachycardia, idiopathic or peri-scar, and idiopathic ventricular tachycardia from right 
outflow tract or the basal left ventricle (fascicular), the atrial or the ventricular foci are ablated. 
The first three ablations, the accessory pathway (WPW) ablation, the selective or non selective 
AV Nodal pathways ablation and typical atrial flutter ablation are the classical ablations, 
which rarely if at all need other mapping methods, like the three-dimensional mapping 
methods. The atrial and ventricular tachycardia foci ablation is feasible in the majority of cases 
with “simple” electrophysiology mapping, like early activity, bracketing, entrainment, pace 
mapping, multi-pole catheter mapping, etc. However, occasionally, this mapping is not 
sufficient and three-dimensional mapping is needed (Marchlinski FE et al, 1998; Leonelli FM et 
al, 2001; Peichl P et al, 2003; Dong J et al, 2005). As we can notice, in the classical ablations, both 
the diagnostic test and the ablation procedure are focused on electrophysiology parameters. In 
atrial and ventricular tachycardia, although there are well defined electrophysiology 
maneuvers as previously mentioned, the more exact location of the focus and the 
demonstration of the ablation results demands the advanced electroanatomic mapping.  
3. The development of the electroanatomic mapping and the electroanatomic 
mapping guided ablation 
In the early 1990’s, Ben Haim and his colleagues developed a new method of three-
dimensional mapping of a tubular or spherical organ. First it was presented in the NASPE 
meeting in 1996 (Smeets J et al, 1996; Ben-Haim SA et al, 1996a; Hayam G et al, 1996; 
Gepstein L et al, 1996), than published as a new method evaluated in animal model and 
human subjects (Ben-Haim SA et al, 1996b; Gepstein L et al, 1997, Shpun S et al, 1997; 
Gepstein L et al, 1998). In this method, the locator pads, located beneath the operating table, 
generate a week magnetic field. The magnetic field strength is between 5x10-6 and 5x10-5 
tesla. A miniature sensor embedded in the body of the distal catheter collects these magnetic 
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the other has fast conduction. If the refractoriness of these pathways and the conduction times 
are appropriate, the electric impulse may be conducted in a circuit constituted by this two 
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Different duration of refractoriness of these pathways creates the unidirectional block. 
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late 1980’s the fast pathway was ablated (Lee MA et al, 1991). These fast pathways are located 
in the anterior site of the AV node very near to the proximal His Bundle. Although the success 
rate was very high, special attention was needed to avoid complete AV Block. After a year, the 
slow pathway ablation was described (Jackman WM et al, 1992). The slow pathway is located 
in the posterior AV nodal area, relatively far from the His Bundle. The ablation of these slow 
pathways is safer and today is routinely performed in most of the electrophysiology 
laboratories. After the ablation, the AV refractoriness prolongs and the AH interval (atrial-His 
conduction time) remains short immediately before the blocking. 
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right atrium. The area between the lower pole of the tricuspid valve and the inferior vena 
cava is called isthmus. A multipolar catheter on the lateral wall of the right atrium 
demonstrates the counter-clockwise or clockwise rotation during the flutter. Complete 
blocking of the isthmus, terminates the flutter. After the successful ablation, pacing at the 
coronary sinus osteum demonstrates the block, by conduction to the lateral wall only from 
above the tricuspid annulus.  
In atrial tachycardia, idiopathic or peri-scar, and idiopathic ventricular tachycardia from right 
outflow tract or the basal left ventricle (fascicular), the atrial or the ventricular foci are ablated. 
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AV Nodal pathways ablation and typical atrial flutter ablation are the classical ablations, 
which rarely if at all need other mapping methods, like the three-dimensional mapping 
methods. The atrial and ventricular tachycardia foci ablation is feasible in the majority of cases 
with “simple” electrophysiology mapping, like early activity, bracketing, entrainment, pace 
mapping, multi-pole catheter mapping, etc. However, occasionally, this mapping is not 
sufficient and three-dimensional mapping is needed (Marchlinski FE et al, 1998; Leonelli FM et 
al, 2001; Peichl P et al, 2003; Dong J et al, 2005). As we can notice, in the classical ablations, both 
the diagnostic test and the ablation procedure are focused on electrophysiology parameters. In 
atrial and ventricular tachycardia, although there are well defined electrophysiology 
maneuvers as previously mentioned, the more exact location of the focus and the 
demonstration of the ablation results demands the advanced electroanatomic mapping.  
3. The development of the electroanatomic mapping and the electroanatomic 
mapping guided ablation 
In the early 1990’s, Ben Haim and his colleagues developed a new method of three-
dimensional mapping of a tubular or spherical organ. First it was presented in the NASPE 
meeting in 1996 (Smeets J et al, 1996; Ben-Haim SA et al, 1996a; Hayam G et al, 1996; 
Gepstein L et al, 1996), than published as a new method evaluated in animal model and 
human subjects (Ben-Haim SA et al, 1996b; Gepstein L et al, 1997, Shpun S et al, 1997; 
Gepstein L et al, 1998). In this method, the locator pads, located beneath the operating table, 
generate a week magnetic field. The magnetic field strength is between 5x10-6 and 5x10-5 
tesla. A miniature sensor embedded in the body of the distal catheter collects these magnetic 
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fields. As the fields vectors have different directions, computer integration of the data 
resolves the location and orientation of the sensor in space. During the same time, the distal 
electrodes, located on the catheter tip, record the electrical activity behind it. By collecting 
multiple points, the heart chamber anatomy and the local electrical impulse in amplitude 
and timing are superimposed. With higher number of points added, higher precision is 
achieved. The resolution of the sensor location in space is < 1 mm.  Finally, the electrical 
field propagation is presented on the virtual reconstruction of the heart chamber anatomy. If 
the amplitude is expressed, scar anatomy is obtained based on very low electrical activity on 
the scar. Moreover, a transitional region with increasing amplitude will interpose between 
the scar and normal tissue. In this type of mapping, invagination of conducting tissue in the 
scar, gaps and marginal zones may present the substrate of arrhythmias. Early in the 
development of the electroanatomic mapping, the scar mapping contributed to the 
understanding of the arrhythmia substrate and made possible non-specific scar ablation 
(Stevenson WG et al, 1998a; Stevenson WG et al, 1998b; Marchlinski FE et al, 2000; Sra J et al, 
2001). However, the main development of the electroanatomic mapping happened with the 
use in atrial fibrillation ablation. After discovery of the triggers in the pulmonary veins, focal 
ablation was suggested, but the application of this ablation is limited and associated with an 
increased incidence of complication (Haissaguerre M et al, 1998). The use of electro-
anatomic guided ablation offered ablation lines in the antrum of the veins and in this way 
the ablation is far from the vein itself and also significant debalking is added (Pappone C et 
al, 1999; Pappone C et al, 2000; Oral H et al, 2003). The ablation was extended to persistent 
atrial fibrillation and even to long-standing persistent cases (Nademanee K et al, 2004; Oral 
H et al, 2006; Takahashi Y et al, 2007).  This addition contributed to development of this 
mapping. Additional mapping methods were developed and promoted in parallel with the 
original electromagnetic mapping, the CARTO mapping. Finally, the list of ablatable 
substrates has continuously increased and today includes beside atrial fibrillation and 
ventricular tachycardia in patients with or without structural heart disease, also atrial 
tachycardia, recurrent and refractory atrial flutter, idiopathic ventricular fibrillation (Knecht S et 
al, 2009) and more recently, the substrate of Brugada syndrome (Nademanee K et al, 2011). The 
following sections will describe in details the use of the mapping in each of these indications. 
4. Right atrial tachycardia 
The mechanism of right atrial tachycardia may be an autonomic focus or reentry around a 
physical obstacle, most commonly an iatrogenic scar or a post-infectious scar. 
4.1 Right atrial tachycardia-reentrant type 
For mapping the scar, bipolar voltage mapping is needed. Figure 4.1 shows two views 
obtained during atrial tachycardia ablation in a 32 year old man, who had a remote atrial 
septal closure surgery. During the surgery the lateral wall in the right atrium was opened 
and the septal defect was closed. On a recent echo, no interatrial shunt could be seen 
demonstrating lack of atrial septal defect and late success of the surgery. However the 
patient developed incessant and persistent atrial tachycardia. During the electrophysiology 
study, the right atrium was mapped using bipolar voltage mapping. This technique allows 
determination of the scar, as on the scar the electrical activity is practically non-existent. We 
defined everything bellow 0.04V as scar and assigned with red color. The normal tissue is 
defined everything above 0.47V and assigned with purple. The tissue in between them is the 
transition zone. As evident from the picture, the two red areas were connected with a 
continuous ablation line obtained with a point-by-point ablation.  
 




Fig. 4.1. The picture shows the voltage mapping of the right atrium with two scars on the 
lateral wall, a large (Scar A) and a small one (Scar B). The small one (Scar B) is connected to 
the Inferior Vena Cava. A small strip on normal myocardium separates the scars and this 
strip was transected with the ablation line. Annotations: AP- antero-posterior (the left 
picture); RL- Right lateral (the right picture). For further explanation see the text. 
 
 
Fig. 4.2. Schematic presentation of picture 4.1; the picture shows the two scars, a large and a 
small one. The IVC ring limits the small one. To interrupt to reentry circle the ablation line 
connects the two scars. 
 
Cardiac Arrhythmias – New Considerations 
 
408 
fields. As the fields vectors have different directions, computer integration of the data 
resolves the location and orientation of the sensor in space. During the same time, the distal 
electrodes, located on the catheter tip, record the electrical activity behind it. By collecting 
multiple points, the heart chamber anatomy and the local electrical impulse in amplitude 
and timing are superimposed. With higher number of points added, higher precision is 
achieved. The resolution of the sensor location in space is < 1 mm.  Finally, the electrical 
field propagation is presented on the virtual reconstruction of the heart chamber anatomy. If 
the amplitude is expressed, scar anatomy is obtained based on very low electrical activity on 
the scar. Moreover, a transitional region with increasing amplitude will interpose between 
the scar and normal tissue. In this type of mapping, invagination of conducting tissue in the 
scar, gaps and marginal zones may present the substrate of arrhythmias. Early in the 
development of the electroanatomic mapping, the scar mapping contributed to the 
understanding of the arrhythmia substrate and made possible non-specific scar ablation 
(Stevenson WG et al, 1998a; Stevenson WG et al, 1998b; Marchlinski FE et al, 2000; Sra J et al, 
2001). However, the main development of the electroanatomic mapping happened with the 
use in atrial fibrillation ablation. After discovery of the triggers in the pulmonary veins, focal 
ablation was suggested, but the application of this ablation is limited and associated with an 
increased incidence of complication (Haissaguerre M et al, 1998). The use of electro-
anatomic guided ablation offered ablation lines in the antrum of the veins and in this way 
the ablation is far from the vein itself and also significant debalking is added (Pappone C et 
al, 1999; Pappone C et al, 2000; Oral H et al, 2003). The ablation was extended to persistent 
atrial fibrillation and even to long-standing persistent cases (Nademanee K et al, 2004; Oral 
H et al, 2006; Takahashi Y et al, 2007).  This addition contributed to development of this 
mapping. Additional mapping methods were developed and promoted in parallel with the 
original electromagnetic mapping, the CARTO mapping. Finally, the list of ablatable 
substrates has continuously increased and today includes beside atrial fibrillation and 
ventricular tachycardia in patients with or without structural heart disease, also atrial 
tachycardia, recurrent and refractory atrial flutter, idiopathic ventricular fibrillation (Knecht S et 
al, 2009) and more recently, the substrate of Brugada syndrome (Nademanee K et al, 2011). The 
following sections will describe in details the use of the mapping in each of these indications. 
4. Right atrial tachycardia 
The mechanism of right atrial tachycardia may be an autonomic focus or reentry around a 
physical obstacle, most commonly an iatrogenic scar or a post-infectious scar. 
4.1 Right atrial tachycardia-reentrant type 
For mapping the scar, bipolar voltage mapping is needed. Figure 4.1 shows two views 
obtained during atrial tachycardia ablation in a 32 year old man, who had a remote atrial 
septal closure surgery. During the surgery the lateral wall in the right atrium was opened 
and the septal defect was closed. On a recent echo, no interatrial shunt could be seen 
demonstrating lack of atrial septal defect and late success of the surgery. However the 
patient developed incessant and persistent atrial tachycardia. During the electrophysiology 
study, the right atrium was mapped using bipolar voltage mapping. This technique allows 
determination of the scar, as on the scar the electrical activity is practically non-existent. We 
defined everything bellow 0.04V as scar and assigned with red color. The normal tissue is 
defined everything above 0.47V and assigned with purple. The tissue in between them is the 
transition zone. As evident from the picture, the two red areas were connected with a 
continuous ablation line obtained with a point-by-point ablation.  
 




Fig. 4.1. The picture shows the voltage mapping of the right atrium with two scars on the 
lateral wall, a large (Scar A) and a small one (Scar B). The small one (Scar B) is connected to 
the Inferior Vena Cava. A small strip on normal myocardium separates the scars and this 
strip was transected with the ablation line. Annotations: AP- antero-posterior (the left 
picture); RL- Right lateral (the right picture). For further explanation see the text. 
 
 
Fig. 4.2. Schematic presentation of picture 4.1; the picture shows the two scars, a large and a 
small one. The IVC ring limits the small one. To interrupt to reentry circle the ablation line 
connects the two scars. 
 
Cardiac Arrhythmias – New Considerations 
 
410 
During two-year follow-up the patients is free of any arrhythmia. This case demonstrates 
the of electro-anatomic mapping used for scar dependent atrial tachycardia ablation. 
4.2 Right atrial tachycardia-automatic focus type 
The next case will exemplify the ablation of automatic paroxysmal atrial tachycardia. The 
patient is a 17-year-old male patient with a history of palpitation and documented 
supraventricular tachycardia. Electrophysiology study demonstrated supraventricular 
tachycardia with long VA time and the ventricular rate was dictated by the atrial rate. 
Occasionally 2:1 AV conduction and even Wenkebach conduction was documented. The 
final diagnosis was right atrial tachycardia originating in the inferior third of the crista 
terminalis. Ablation was focused on the earliest atrial activity using a duodecapolar catheter. 
The tachycardia terminated during the RF application and has become noninducible. 
However, after 2 weeks the patient again experienced palpitation and again a similar 
arrhythmia was documented. The patient was referred for a second ablation this time 
CARTO guided. The tachycardia was again easily induced with atrial overdrive pacing, but 
not with atrial premature beats. Figure 4.3 shows the CARTO mapping.  
 
 
Fig. 4.3. Right Atria Tachycardia with the origin at the Inferior Vena Cava (IVC) area and the 
activation terminating at the Superior Vena Cava (SVC) area. This is a propagation map and 
the colors define the timing at each area. The red is the earliest time (-88 msec) and the purple 
the latest time (+23 msec) compared to the reference catheter. The white line with the arrow 
shows the activation direction. The red points in the origin area show the Radiofrequency 
application sites, which terminated the tachycardia rendering it non-inducible. 
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In this case, voltage mapping cannot be used as no scar could be mapped and the patient 
had no any previous cardiac procedure except the ablation procedure. For this reason, a 
propagation mapping was used. During this mapping the virtual reconstruction of the 
right atrium is completed parallel with accurate timing detection by comparing the 
activation time with the timing on a reference catheter, in this case in the coronary sinus 
osteum. The timing of the points located with the mapping catheter is compared with the 
reference catheter and is assigned with red color if it is early and purple if it is late. In 
between are the other colors like yellow, green and blue. Finally, a cine presentation 
shows the flow of the electrical activity, starting at the red point and terminating at the 
blue points. The red points are the area focused for ablation. As evident in Figure 4.3, the 
origin is well determined and ablation at this point again terminated the tachycardia 
leaving it noninducible. During the follow-up the patient is asymptomatic, practicing non-
professional sportive activity. 
These two cases exemplify not only two types of right atrial tachycardia, but also two 
methods of mapping. If a scar is to be mapped, the amplitude of the electrical activity will 
discriminate it from the normal tissue with clear demarcation. The reentry can be completed 
around a scar and by connecting the scar to a non-conducting tissue will prevent the 
reentry. This map is called, voltage-map, or scar mapping. In contrary, if the tachycardia is 
generated by an automatic focus, the earliest activation will reveal the origin of the 
tachycardia and the ablation may be focused to it. This is achieved by determining the 
timing at each point and the map is called, flow-map. 
These two cases are presenting the classical types of atrial tachycardias. However, 
occasionally the diagnosis is not so simple and the first impression may be misleading. The 
electro anatomic mapping may elucidate the diagnosis and make possible the correct 
ablation. In the next subsection such a complex case is presented. 
4.3 Atrial flutter or not flutter that is the question 
A 28-year-old man presented with an ECG showing typical atrial flutter and was referred to 
radiofrequency ablation. He was in sinus rhythm when admitted for the ablation and the 
inferior isthmus (between the tricuspid ring and the inferior vena cava) was ablated using a 
10 mm tip ablation catheter, a duodeca mapping catheter on the lateral wall and a 
quadripolar pacing-mapping catheter in the proximal coronary sinus.  The ablation was 
performed during coronary sinus pacing and the original collision on the lateral wall was 
abolished demonstrating the block bellow the valve. Pacing from the coronary sinus and 
from above the inferior vena cava approved the block in the isthmus. Although the 
bidirectional block was persistent the patient had additional episode of “typical atrial 
flutter”. In a second electrophysiology study the block in the isthmus was persistent and the 
patient had still inducible arrhythmia (Figures 4.4 and 4.5). Although the diagnosis of atrial 
flutter was attempting the duodeca catheter recording showed a big delay in the isthmus 
area during the tachycardia. This is not acceptable in typical atrial flutter or at least during 
an isthmus dependent flutter. Figure 4.5 shows details of the duodeca catheter recording 
during the atrial tachycardia-the last 10 tracings on Figure 4.4. The earliest point on the 
lateral wall is on pole D5-6. Pole D1-2 records from the median site of the isthmus block and 
pole D3-4 from the lateral site. The double arrow shows the big delay demonstrating the 
isthmus block during the tachycardia and non-isthmus dependent tachycardia. For this 
reason, CARTO mapping was initiated. 
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Fig. 4.4. The tracing shows a regular tachycardia, recorded at 100 mm/sec. The first 5 tracing 
are surface electrograms L1, L2, L3, AVR and V1. The next two belong to the right atrial 
tracing as reference for the CARTO mapping (not recording temporarily), than the mapping 
catheter and finally 10 tracings from the duodeca catheter deployed on the right lateral wall 
of the right atrium. The tracing on the duodeca catheter reveals unidirectional conduction 
suggesting atrial flutter. However, the tracing at DD1-2 is extremely delayed. As DD1-2 is 
medial to the isthmus block line and DD3-4 lateral, this delay demonstrates isthmus block 
during the tachycardia (See also Fig 4.5) 
 
 
Fig. 4.5. The figure shows the tracing on the duodeca catheter at 200 ms/min recording 
speed. The cartoon inserted on the tracing shows the right atrium, IVC, SVC and CS. The 
isthmus block line is also depicted. The position of 10 bipolar poles is also shown. DD 1-2 is 
medial to the block line and all the other 9 poles are lateral to the line. On the tracing, a long 
delay is between DD 1-2 and 3-4 demonstrating the persistence of the block during the 
tachycardia, which is not compatible with typical atrial flutter. 
A CARTO mapping demonstrated tachycardia originating from the lateral border of the 
block line in the isthmus (Figure 4.6) and was abolished by focal ablation using the area 
determined by the flow-map (Figure 4.7 and 4.8). The surface ECG was misleading and the 
real arrhythmia was atrial tachycardia and not atrial flutter! The electro-anatomic mapping 
made possible the correct diagnosis and finally the appropriate treatment.  
 




Fig. 4.6. Flow map during the tachycardia showing the early activation lateral to the isthmus 
line (purple color). The white arrows depict the current flow, simulating the flutter 
activation pattern except in the area between the origin (red color) and isthmus line (purple 
color) where a slow conduction in the opposite direction is clearly revealed. The isthmus is 
invaded from both sites.  
 
 
Fig. 4.7. The flow map from right lateral view is superimposed with the ablation mark signs. 
During the applications in this area the tachycardia terminated as shown in Figure 4.8. 
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Fig. 4.7. The flow map from right lateral view is superimposed with the ablation mark signs. 
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This is an illustration of the importance of electro-anatomic mapping in this case as the 
surface ECG suggested typical atrial flutter and apparent recurrence after successful 
ablation of the cavo-tricuspid isthmus. At the first glance, the recording suggests atrial 
flutter, but there is a sudden delay between DD 3-4 and DD 1-2. This is possible only if the 
isthmus block is persistent and the catheter is laid over the block line with the tip over the 
line and the rest of poles before the block line. If the tachycardia can continue despite the 
block in the isthmus, it cannot be isthmus-dependent flutter. The electro-anatomic mapping 
revealed the correct diagnosis and made possible the appropriate ablation. 
 
 
Fig. 4.8. In this tracing during the radiofrequency energy application, the tachycardia 
terminates and at the right side of the tracing the first sinus beat is seen. Of note, the 
tachycardia termination is sudden and not caused by ectopic activity, but only by the 
ablation. During the termination the last recording is from DD 1-2, demonstrating that the 
origin was between DD 3-4 and 5-6 and the last activation is on DD 1-2 (See Figure 4.6). 
5. Left atrial tachycardia 
Left atrial tachycardia may be of the same origin like the right atrial tachycardia. The 
automatic form mostly originates in the pulmonary veins, but the reentry forms originate in 
the atrial tissue like the reentry tachycardia in the right atrium. The most common form 
today is related to catheter ablation of atrial fibrillation, which will be discussed and 
presented within a next section on atrial fibrillation ablation. A rare form is the para-septal 
atrial tachycardia, which interestingly is associated with patent foramen ovale. For this 
reason, to map and ablate it, the septum is easily passed and the left atrium is easily 
mapped. The next presentation will exemplify it and will present the use of electro-anatomic 
mapping to determine the earliest activation point.  
A 48 year old woman was referred because a persistent form of atrial tachycardia. First right 
atrium was mapped and the earliest activation was on the septal area. The activation time 
was at about zero time when compared to the reference catheter located in the coronary 
sinus osteum. By mapping the septum at the fosa ovalis, the catheter passed to the left 
atrium without need for standard septal puncture. The left atrium was mapped. A fast map 
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was obtained, than the activation was superimposed on it. An early activation was mapped 
on the anterior wall, immediately above the mitral ring (Figure 5.1). At this point the 
ablation terminated the incessant atrial tachycardia. 
 
 
Fig. 5.1. The picture shows the left atrial flow map during incessant tachycardia. The 
activation time in the anterior wall and above the mitral ring was -43 msec (red color). On 
the posterior wall the activation times were all longer than 0 msec  (compared to the 
reference catheter at the coronary sinus osteum. The area above the right pulmonary vein is 
as late as 53 msec after the activation on the reference catheter (purple color). 
 
 
Fig. 5.2. The figure shows the virtual reconstruction of the left atrium during the tachycardia 
with the earliest point in red color. The catheter tip is pointing to that area. The ablation sites 
are shown. The tachycardia terminated with these ablation points. 
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This is an illustration of the importance of electro-anatomic mapping in this case as the 
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line and the rest of poles before the block line. If the tachycardia can continue despite the 
block in the isthmus, it cannot be isthmus-dependent flutter. The electro-anatomic mapping 
revealed the correct diagnosis and made possible the appropriate ablation. 
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As of today, the published information on electro-anatomic mapping during atrial 
tachycardia ablation is scars and limited. However, the clinical application is well known 
and rich and the accumulated and published knowledge is worth to mention. Atrial 
tachycardia is encounter in both pediatric and adult patients. We have information on the 
use of electro-magnetic mapping in both groups. In right atrial tachycardia, the use of this 
mapping adds a significant degree of accuracy and, just like in our patient described in 
subsection 4.3, rarely the electro-magnetic mapping adds to the correct diagnosis. In patients 
with incessant focal tachycardia, the electrophysiological maneuvers may be enough but in 
patients with scar related tachycardia, this mapping has irreplaceable value. In incessant 
focal tachycardia, the earliest activation in the Crista Terminalis area or along the tricuspid 
ring will reveal the origin and radiofrequency energy application will terminate it and total 
cure is achieved. However, if the tachycardia persists or reoccurs, 3D mapping is justified 
(Subsection 4.2). As previously mentioned, the activation map helps to localize the origin of 
the tachycardia. In scar related reentrant tachycardia, the scar is delineated and a narrow 
isthmus in between them is ablated (Subsection 4.1). Voltage mapping delineates the scar, 
and amplitude lower than 0.14 mV suggests scar. 
The published studies involved a limited number of patients, 7 to 120. Focal tachycardias in 
the right atrium are ablatable with success rate >90% (Kottkamp H et al, 1997; Marchlinski F 
et al, 1998; Iwai S et al, 2002). The same success rate may be achieved in macroreentrant 
atrial tachycardia related to post-surgical scar (Iwai S et al, 2002). In the left atrium, focal 
tachycardias were localized to mitral annulus, roof, posterior wall, appendage and septum 
(Dong J et al, 2005). Left septal atrial tachycardia is rare and the electroanatomic mapping 
facilitates its ablation (Marrouche NF et al, 2002). Atrial tachycardia originating in the mitral 
annulus is also rare and the electro-anatomic mapping also facilitates its ablation (Kistler PM 
et al, 2003). Our patient presented in section 5 had also tachycardia originating from the 
mitral annulus (Figures 5.1 and 5.2). In pediatric patients, the acute success is significantly 
higher with the electro-anatomic mapping compared to standard electrophysiological 
mapping and the recurrence rate was lower (Cummings RM, 2008).  
In all these conditions, the electroanatomic mapping for ablation of all types of atrial 
tachycardia in the clinical practice is firmly established.  
6. Atrial fibrillation ablation 
Atrial fibrillation is the most common arrhythmia an presents a great challenge for any 
cardiologist and even more for the clinical electrophysiologist. This arrhythmia has a very 
erratic response to antiarrhythmic treatment and for this reasons a non-medical treatment is 
demanded. Device therapy did not prove to be an effective alternative to the mediocre 
medical treatment. For this reason, the ablative opinion is an attractive alternative.  
Haissaguerre and his colleagues, by investigating the mode of initiation of paroxysmal 
atrial fibrillation, discovered that the trigger for this type of arrhythmia originates, in the 
majority of the cases, in the pulmonary veins (Haissaguerre M et al, 1998). Focal ablation 
of these foci, as a logical next step, turned to be complicated with damage to the vein, 
narrowing with significant and symptomatic increase in the pulmonary pressure. The 
electrical connection between the pulmonary vein and left atrium is through distinct 
pathways (Ehrlich JR et al, J Physiol 2003). Electrical disconnection of these veins avoided 
this damage and offered the same result.  However, the recurrence and occasional 
pulmonary stenosis were still encountered. In 1999, Pappone and his colleagues suggested 
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a different approach to disconnect electrically the pulmonary veins (Pappone C et al, 1999; 
Pappone C et al, 2000; Pappone et al, 2004). This method is based on electroanatomic 
mapping. The left atrium is approached by passing the inter atrial septum using the 
Brockenbrough method and the left atrial mapping is completed by virtual reconstruction 
of the atrial walls and tagging the veins and the mitral annulus. The ablation includes 
circles around the pulmonary veins and lines connecting the mitral annulus with the 
ablation line around the left lower pulmonary vein and lines connecting the left and right 
ablation rings around the veins. In patients with paroxysmal atrial fibrillation, this type of 
ablation was superior to the pulmonary vein disconnection, with higher success rate and 
lower recurrence rate after one year (Oral H et al, 2003). Moreover, in patients with 
persistent atrial fibrillation, circumferential pulmonary vein ablation was superior to 
amiodarone treatment in preventing recurrence of the fibrillation (Oral H et al, 2006; 
Pappone C et al, 2006). Multiple escalated methods exemplify the problematicity of the 
ablation in patients with long persistent atrial fibrillation (Oral H et al, 2006; Takahashi Y 
et al, 2007; Satomi K et al, 2008).  However, consensus was achieved on the necessity of 
catheter ablation of atrial fibrillation (Calkins H at al, 2007).  




Fig. 6.1. The picture shows the ablation lines around the common left entrance and the two 
right veins. The lines are continuous. 
SB 74 year old woman with a long history of paroxysmal atrial fibrillation on multiple 
antiarrhythmic medication including beat blockers, calcium channel blockers, Propafenon, 
Flecainide, Amiodarone all turned to be ineffective. The etiology of the atrial fibrillation was 
hypertension treated with multiple drugs. Finally she was referred to catheter ablation of atrial 
fibrillation. In the mean time the fibrillation converted to persistent. An ECHO showed normal 
systolic left ventricular function with decreased diastolic function, enlarged left ventricle with 
minimal mitral regurgitation. Patten Foramen Ovale with small left to right shunt was 
demonstrated. During the ablation, the septum was easily passed and the left atrium was 
reconstructed using anatomical map as she was in atrial fibrillation. The veins were tagged 
and the mitral annulus was reconstructed. The veins were circumvented with ablation points 
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SB 74 year old woman with a long history of paroxysmal atrial fibrillation on multiple 
antiarrhythmic medication including beat blockers, calcium channel blockers, Propafenon, 
Flecainide, Amiodarone all turned to be ineffective. The etiology of the atrial fibrillation was 
hypertension treated with multiple drugs. Finally she was referred to catheter ablation of atrial 
fibrillation. In the mean time the fibrillation converted to persistent. An ECHO showed normal 
systolic left ventricular function with decreased diastolic function, enlarged left ventricle with 
minimal mitral regurgitation. Patten Foramen Ovale with small left to right shunt was 
demonstrated. During the ablation, the septum was easily passed and the left atrium was 
reconstructed using anatomical map as she was in atrial fibrillation. The veins were tagged 
and the mitral annulus was reconstructed. The veins were circumvented with ablation points 
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and the roofline and mitral isthmus lines were completed. When the radiofrequency was 
delivered in the junction between the roofline and right superior pulmonary vein the patient 
converted to sinus rhythm after 2 months of atrial fibrillation. Figure 6.1 shows the ring 
around the left veins and the right veins; Figure 6.2 shows the posterior view of the left atrium 
after the ablation. The mapping and ablation were done with CARTO EXP 7. She was in sinus 
rhythm 5 years after the ablation and during her last follow-up 3 years ago. 
 
 
Fig. 6.2. The enlarged left atrium in a posterior view shows the rings around the pulmonary 
veins, the roofline and the mitral isthmus line. At least two lines connect the peri venous 
ring to the mitral annulus. There are 3 large left veins with a common entrance to the left 
atrium. The mapping is an anatomical map different from the mappings in atrial 
tachycardia ablation (Sections 4 and 5).  
MD is 81-year-old man with persistent atrial fibrillation failing multiple medical treatments. 
He had long history of supraventricular tachycardia and had a successful slow pathway 
ablation 8 years ago. Two years ago presented with symptomatic atrial fibrillation. Medical 
treatment with beta-blockers, Propafenon, Flecainide were not effective and Amiodarone 
was discontinued because hyperthyroidism. As medical treatment had to discontinued 
because lack of efficacy or side effects he was referred to catheter ablation. At the admission 
he was in persistent atrial fibrillation for 3 months and without antiarrhythmic treatment. 
The transseptal catheterization was performed safely under intra cardiac echo guidance. 
After the ablation he converted to sinus bradycardia. Figure 6.3 shows the ablations lines in 
the left atrium and presents new modes of mapping (fast map). 
SS is a 68-year-old man with long history of atrial flutter and fibrillation and hypertension. In 
2002 he had a successful atrial flutter ablation. In 2004 he had catheter ablation of atrial 
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fibrillation using the point-by-point method. Until recently he was in stable sinus rhythm 
when 3 months ago presented in the follow-up clinic with atrial fibrillation. Anticoagulation 
was started and referred for a second ablation. In the new mapping there was no electrical 
activity in the veins, on the posterior wall, but at several points around the veins was a low 
amplitude regular activity and all this places were ablated again. In the next figures the two 
mappings will be compared in the same patients emphasizing the advance in the mapping 
methods. The patient has common entrance of both left and right pulmonary veins. The 
intracardiac echo used during the second ablation in 2011 approved this anatomical variance. 
 
 
Fig. 6.3. The figure shows 20 degree left anterior view of the left atrium. The appendage covers 
the ablation ring around the left veins. The atrium is minimally enlarged. There is a common 
right entrance and two separate left veins. This map was performed using the fast map mode, 
a new future of the electro-anatomic mapping. The atrial anatomy much more resembles the 
other imaging models.  The lines are continuous and the veins are completely isolated with no 
residual electrical activity in the veins or posterior wall. The mode is new and for this reason 
the follow up after the ablation is only 3 months, however the patient is in sinus rhythm. 
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Fig. 6.4. The figure shows the anterior view of the left atrium recorded in 2004 using the 
point-by point method. The patient was in sinus rhythm during the procedure. A large 
number of ablation sites are seen through the mitral valve from inside the atrium. The left 
atrium is not enlarged. The left ablation lines are heavy and the right ablation lines are 
discrete. The roofline is slightly posterior an not present in this picture. 
 
 
Fig. 6.5. This is a posterior view recorded during the first ablation procedure. The ablation 
lines are clearly seen and are heavy in the left side and discrete in the right side. The voltage 
amplitude in the posterior wall is low (red color). 
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The next figure (6.5) shows the ablation lines in the posterior view and also the roofline 
not seen in Figure 6.4. Following the ablation the atrial fibrillation was not inducible.  
The areas around the veins were quiescent from any electrical activity. As the patient had 
a previous cavo-tricuspid isthmus line ablation, atrial flutter could also not be induced.  
As mentioned above, after 7 years the patient developed again atrial fibrillation, this  
time persistent and not paroxysmal. The following pictures will exemplify the second 




Fig. 6.6. The picture shows the left atrium using the fast map technique. This is the same left 
atrium like in Figures 6.4 and 6.5, just obtained 7 years latter and using more advanced 
method of mapping. The veins with common entrance are in colors, left with yellow and 
right with green. The mitral isthmus was reinforced with several ablation points and the left 
upper vein is also reinforced at the junction with the roofline were low amplitude relatively 
slow and regular activity was recorded. The ablation canceled this activity and the entire 
vein was free of any electrical activity. The next figure will show the areas with residual 
activity on the right side. 
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Fig. 6.7. The figure shows the posterior wall recoded with the fast map method. In the 
lower-posterior border of the right vein and on the junction point with the roofline 
additional application eliminated the activity and left the entire vein free of any electrical 
activity. The right vein different from the left, had multiple brunches and with common 
entrance into the left atrium. The anatomy was approved with the intra-cardiac echo 
recorded simultaneously with CARTO mapping. The posterior wall also free of electrical 
activity like in box-ablation (lines anterior to the veins completed with roofline and another 
line in the low atrium on the posterior wall). 
7. Ventricular tachycardia ablation 
A vast amount of information was accumulated during the last decades of the 20th Century 
supporting the superiority of implantable defibrillators (ICD) over any medical treatment in 
saving patients with high risk for sudden cardiac death (Ezekowitz JA et al, 2003). However, 
the defibrillator cannot guaranty the quality of life especially in patients with frequent ICD 
therapy. Moreover, patients may develop clusters of ventricular fibrillation, called VT storm. 
Some studies even suggest that repeated shock is associated with increased death rate 
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(Exner DV et al, 2001; Poole JE et al, 2008; Daubert JP et al, 2008; van Rees JB et al, 2011). It is 
still not clarified if the presence of high number of VT or the shocks signals the imminent 
death. When both the ICD and adjuvant antiarrhythmic treatment (mainly Sotalol or 
Amiodarone) cannot prevent frequent recurrence of VT, the only option is the ablation (Sra J 
et al, 2001). The next step in the strategy is ablation before the storm or frequent recurrence 
of VT (Reddy V et al, 2007; Stevenson WG et al, 2008; Tung R et al, 2010; Kuck KH et al, 
2010; Natale A et al, 2010). The main problem is that patients with structural heart disease 
have multiple VT foci, large scars with many possible reentry circles. For this reason, focal 
ablation may be only a temporary step. Occasionally, these patients with reduced left 
ventricular function may not tolerate hemodynamically the VT and focal ablation may not 
be feasible. To resolve this problem, scar ablation was suggested (Marchlinski FE et al, 2000; 
Sra J et al, 2001). The following 4 patients will exemplify these methods in different types of 
structural heart disease.  
AA is a 60-year-old patient with coronary artery disease, large anterior myocardial 
infarction in the recent past, and ventricular tachycardia. A cardioverter-defibrillator was 
implanted. As the tachycardia reoccurred, amiodarone treatment was added. Amiodarone 
did not control the tachycardia and the symptomatic cardioverter-defibrillator therapy and 
the patient was frequently re-hospitalized. 
For this reason, the patient was brought to the electrophysiology laboratory in purpose to 
study the ventricular tachycardia and to attempt an ablation procedure. The tachycardia 
was easily and reproducible induced with two premature beats. Although the tachycardia, 
on chronic amiodarone treatment, was relatively slow, the patient did not tolerate it 
hemodynamically. Propagation mapping was not applicable and the only option remained 
the scar/voltage mapping. Interestingly, the mapping revealed two scars, a large one and a 
small one with a small and narrow strip of myocardium between them. The small scar 
extended until the mitral annulus and no continuous myocardium surrounded it. The only 
reentry circuit for the slow tachycardia could be the large scar and by blocking the narrow 
myocardial strip between the scars necessarily will interfere with the current wave passage 
around the large scar, too.   
The flowing pictures exemplify the scars and the ablation (Figures 7.1, 7.2 and 7.3) 
The tachycardia has become not inducible after the ablation and during the 1 year follow-
up since the ablation the patient was free of ICD therapies. As we can see, in this case a 
clear delineation of the reentry circle was revealed by the scar mapping without an intend 
to map the activation. Scar mapping is the option when the patient cannot tolerate the 
tachycardia (Marchlinski FE et al, 2000; Sra J et al, 2001). A narrow conduction tissue in 
the scar serves the tachycardia (Figure 7.2 and 7.3). The strategy is to block this tissue, 
however it is important to connect the scar to a non-conducting structure like valve 
annulus, otherwise the ablation will only increase the reentry circle and may render the 
tachycardia more incessant. In our patient the smaller scar was already connected to the 
mitral annulus (Figure 7.3) leaving the only possible reentry circle around the large scar 
and the target of the ablation the narrow myocardial strip in between them. This patient 
presents an ideal ablatable reentry circle. Eliminating the conduction only on a single 
possible pathway eliminates also the VT substrates and the patient continues to be 
without ICD therapy for one year. Identification of the channel was crucial in this 
procedure and is discussed in recent published literature (Arenal A et al, 2004; Hsia HH et 
al, 2006). 
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(Exner DV et al, 2001; Poole JE et al, 2008; Daubert JP et al, 2008; van Rees JB et al, 2011). It is 
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Fig. 7.1. The picture shows the antero-posterior projection of the enlarged left ventricle with 
a large scar on almost all the anterior wall. Any voltage bellow 0.5 mV (red color) was 
considered scar and any voltage above 1.5 mV were considered normal myocardium 
(purple color). In between them three transitional tissues are collared in yellow, green and 
blue. No tissue penetrated the scar and no central pathways could be mapped. The arrows 
show the large reentry cycle around the scar. Normal myocardium is around the scar and 
constitutes the reentry circle. The ablation points (red dots) block the isthmus between two 
scars (see Figure 6.2) 
 




Fig. 7.2. The picture shows the antero-lateral projection of the left ventricle. In this voltage 
mapping two scars are evident: the large anterior scar and a smaller basal lateral scar. The 
scars delineate in between them a slowly conducting myocardial tissue called isthmus 
(arrow). The isthmus is blocked by the ablation points. As we will see in the next picture, the 
basal scar is extending until the mitral annulus the reason why the reentry could not be 
closed around it. 
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Fig. 7.3. This picture shows the superior projection of the left ventricle with the aortic and 
mitral annuli. The basal lateral scar is confluent with the mitral ring and this confluence 
prevents closure of the reentry around this lateral scar leaving only the anterior scar open to 
permit the reentry. The ablation blocked the isthmus leaving the tachycardia non inducible.  
Scar ablation is an accepted approach to ablate ventricular tachycardia. Electromagnetic 
mapping is indispensable in delineating the scar and magnetic resonance imaging (MRI), 
three-dimensional computer topographies (CT) and positron emission topographies combined 
with CT (PET/CT) pictures may enhance it and makes possible evaluation of the exact trans-
mural dispersion (Codreanu A et al, 2008; Dickfeld T et al, 2008, Tian J et al. 2010). 
The second patient is AG; 61-year-old man with dilated cardiomyopathy, sustained 
ventricular tachycardia and was referred for CRTD (cardiac resynchronization therapy-
defibrillator) implantation. Interestingly, during the implantation, at the left lead pacing 
threshold measurement, the patient developed ventricular tachycardia. This suggested a 
tachycardia focus near the pacing area in the left basal posterior-lateral wall.  
After the implantation he developed frequent episodes of VT not suppressed by adjuvant 
medical treatment with amiodarone and mexiletine (Figure 7.4). For this reason he was taken 
to the electrophysiology laboratory and the left ventricle was mapped during ventricular 
tachycardia (Figure 7.5 and 7.6). Only a partial mapping was needed (overall 27 points) and 
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the tachycardia origin was located on the basal posterior wall (Figure 7.6), just like suggested 
by the induction during the implantation. After 4 radiofrequency application on this site the 
tachycardia terminated and has become non inducible. Of note, the ECG (Figure 7.4 and 7.5) 
suggested the basal posterior location of the origin and the QRS during the tachycardia had 
RBBB (Right Bundle Brunch Block), inferior and rightward axis (Figure 7.4 and 7.5). 
 
 
Fig. 7.4. The clinical VT in non-sustained form, but with the same morphology of RBBB, 
inferior and rightward axis 
 
 
Fig. 7.5. The figure shows the ECG of the VT during the ablation. This VT had RBBB 
configuration and inferior and rightward axis. This configuration is suggesting a left 
ventricular VT with the origin in the basal area. 
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Fig. 7.6. The picture shows the potero-anterior projection of a part of the left ventricle during 
the VT. The earliest points are located on the basal posterior wall (red area) and the VT is 
propagated to the apical are as shown by the arrows (blue area). Ablation in this area 
terminated the VT and rendered it non-inducible. 
 
 
Fig. 7.7. The figure shows the ECG of the second VT during the ablation two weeks after the 
first one. The QRS has an RBBB configuration and superior axis. When compared with the 
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first VT (Figure 7.5), the rightward axis is less expressed (L1 compared in the two ECGs, and 
AVL in the first ECG is negative and in the second is positive). There are also differences in 
the chest leads available (V3 is strongly positive in the first VT and clearly negative in the 
second VT). The rates of the VTs are similar.  
Although the ablation was successful as exemplified by the previous pictures, the patient 
presented after two weeks with a second VT (Figure 7.7). He was taken again to the 
electrophysiology laboratory and the VT was mapped, again with CARTO (Figure 7.8). This 
time the VT had an RBBB configuration and superior axis! (Figure 7.7) 
It was evident that the two VTs are not coming from the same area and again a limited 
map was completed (to avoid hemodynamic compromise during prolonged mapping). As 
Figure 7.8 exemplifies, the second VT originated from the apical septum. This are was 
ablated (Figure 7.9) and interestingly, after the ablation at the earliest point the 
tachycardia terminated, but was reinduced. This time the second ablation site at this 




Fig. 7.8. The picture shows an antero-posterior projection of the left ventricular flow map 
during VT at the second ablation procedure. The left ventricular perimeter is shown with 
the white lines, including the aortic annulus. The earliest points are originating on the 
septal area and propagate  in the anterior and posterior wall. There is collision on the 
inferior wall (pink color) and is tagged. The earliest points are -144 msec before the 
reference catheter in the right ventricle and the collision is 4 msec after the reference 
catheter. 
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Fig. 7.9. The picture shows the flow map of the left ventricle in postero-anterior projection. 
Two areas had to be ablated to terminate the VT, first the higher area and earliest one was 
ablated than the second more inferior are which has become early (not shown) and finally 
terminated the VT and left it non-inducible.  
At the end of the second ablation procedure a very fast VT (200 msec cycle length) was 
induced requiring DC shock termination (through the implanted ICD which was 
immediately activated). Two years after the second ablation the patient was free of any ICD 
therapy. Only rare non-sustained VT was stored by the ICD. In this patient we made several 
clinical decisions and observations during and around the ablation procedures: 
1. The left ventricle mapping was not completed, was quickly achieved and culminated 
with ablation 
2. Propagation mapping was done as this patient has dilated cardiomyopathy and no 
discrete scar can be mapped 
3. Although the ICD was deactivated during the procedure to prevent early termination of 
the VT during the mapping, it was immediately activated with the induction of the 
rapid VT (200 msec cycle length- ventricular flutter) 
4. The rapid VT-ventricular flutter was not clinical as was not recorded by the ICD during 
the long follow-up. 
5. The proarrhythmic effect of biventricular pacing, well known from the current 
literature (Nayak HM et al, 2008; Gasparini M et al, 2008, Nordbeck P et al, 2010) 
CH was a 59-year-old patient with a large anterior wall myocardial infarction, ventricular 
tachycardia and implantable defibrillator. 
 




Fig. 7.10. The picture shows the extremely enlarged left ventricle, scar mapping and 
multiple isthmuses ablation (3 shown on this antero-posterior projection). All the procedure 
was completed during sinus rhythm, without ventricular pacing. The defibrillator was 
deactivated during the procedure. 
The defibrillator was upgraded to CRTD. Two years after the upgrading, he presented with 
“VT storm” (more than 150 episodes of VT, majority treated with overdrive pacing and two 
of them with ICD shock). As medical treatment was not effective and the tachycardia has 
become resistant to overdrive pacing (including pacing from the RV lead, LV lead and 
biventricular), he was taken to the electrophysiology laboratory for catheter ablation. It was 
understood that no mapping during the VT can be completed because the hemodynamic 
imbalance. Scar mapping was attempted. The left ventricle was extremely enlarged and no 
catheter was available to complete to basal area mapping. After the ablation the VT 
frequency was significantly reduced, but not completely abolished and the patient had 
ventricular assist device implantation, but not survived until appropriate donor heart was 
available for him. 
BN is a 75 year-old-man with a history of a large anterior infarction at the end of 1980’s. He 
was treated with intravenous Streptokinase and despite apparent reperfusion the laboratory 
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tests suggested a large infarction. In the early 1990’s he developed aborted sudden cardiac 
death and a defibrillator was implanted. Occasionally, he had successfully treated episodes 
of ventricular tachycardia and was resolved with adjuvant amiodarone treatment. In 2008 
the defibrillator was upgraded to cardiac resynchronization therapy-defibrillator (CRT-D). 
Recently he was admitted with incessant tachycardia with a rate between 135-140 beats per 
minute with relative hemodynamic stability. No medical treatment could suppress the 
tachycardia, including amiodarone reloading, additional mexiletine, beta-blockers and 
carvedilol. A coronary angiogram revealed no new coronary lesions and no target for 
revascularization. As the tachycardia was still incessant, the patient was taken to the 
electrophysiology laboratory for an ablation attempt. The left ventricle was approached 
through the aortic valve and the left ventricle was mapped using the fast map technique. 
The patient was all this time in his slow ventricular tachycardia. As evident in Figure 7.11, 
the left ventricle is enlarged with a large apical aneurysm and a large scar on the antero-
lateral wall. The origin of the tachycardia was in the apical area at the border of the large 
scar (Figure 7.11). Ablation in this site terminated the tachycardia and was returned to the 
Cardiology Ward in sinus rhythm.    
 
 
Fig. 7.11. The picture shows the voltage mapping of the left ventricle in two projections: A. 
antero-posterior; B. left anterior oblique; the ventricle is enlarged with a large apical 
aneurysm and a large antero-lateral scar. The ablation site is shown in both projections and 
the ablation was completed during incessant ventricular tachycardia (135 BPM) and 
propagation mapping. With the two lateral applications the tachycardia terminated 
spontaneously. 
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Although the tachycardia was not anymore incessant, the patient still had episodes of 
tachycardia at a faster rate (150-160 beats per minute). As this tachycardia was not tolerated, he 
was returned to the electrophysiology laboratory for a “scar ablation”. This time the 
tachycardia was not induced and the mapping was completed in sinus rhythm (paced 
rhythm). Using slightly different definitions (scar in the first mapping was defined as <0.18 
mV and during the second mapping as <0.54 mV), a large golf of myocardial tissue was 
revealed in the anterior basal area (Figure 7.12). This area was isolated from the surrounding 
normal tissue and the ablation area was continued until the mitral annulus to avoid any 
possible large reentry around the whole scar. Although the endocardial surface was 
completely blocked, the tachycardia was still inducible with impression of multiple 
breakthrough points suggesting epicardial origin. However, no real mapping could be 
completed because the hemodynamic instability during the VT. For this reason, he was 
scheduled for an epicardial ablation. During the epicardial mapping the origin of the VT was 
on the apical area and wide area ablation terminated the tachycardia. This epicardial site was 
almost the same with the successful site during the first mapping. During 3 months follow up 
the defibrillator recorded and stored only 4 episodes of VT successfully treated with overdrive 
pacing and not recalled by the patient. He continued the combination of amiodarone and 
carvedilol treatment. This patient also exemplifies the presence of multiple VT foci in a patient 
with ischemic cardiomyopathy and a large post myocardial infarction scar. 
 
 
Fig. 7.12. The picture shows the mapping during the second ablation attempt. This is an 
antero-posterior projection of the left ventricular voltage mapping. The normal tissue was 
defined as >1.5 mV (like in Figure 6.11), but the scar was defined as <0.5 mV. A large 
invagination of myocardium into the basal scar was revealed and ablated (see text). 
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In this patient, with poor left ventricular function and resynchronization therapy, a 
combined endocardial focal ablation, scar ablation and finally epicardial ablation completed 
the procedure and achieved an acceptable clinical outcome. The electro-anatomic mapping 
exemplifies the complexity of the ablation in this patient, and it was possible only using this 
advanced mapping.  
Four patients were presented, each one with a different condition and different mapping. 
The first patient had a well-defined scar with a clear narrow strip of myocardium dividing it 
into a large scar and a smaller basal scar limited by the mitral annulus. The second patient 
has dilated cardiomyopathy without discrete scar and two different foci ablated in two 
consecutive procedures. The third patient had an extreme ischemic cardiomyopathy, with 
uncontrollable ventricular tachycardia storm and labile hemodynamic condition. Only scar 
ablation was possible, because the extremely dilated left ventricle. The fours patient had an 
enlarged left ventricle, with a large apical aneurysm. The same patient has endocardial focal 
ablation, scar ablation and finally epicardial ablation.  
8. Theoretical aspects 
As mentioned in the introduction, first DC shock ablations than RF ablation of solitary 
pathways in the AV Node or outside it is practiced in clinical electrophysiology. However, 
DC was used for the first AV Nodal ablation, well-defined origin of WPW and ventricular 
tachycardia foci. Radiofrequency replaced the DC shock. During 2-3 years first the AV 
Nodal and AV pathways were ablated. Subsequently, idiopathic VT foci and atrial flutter 
and focal tachycardia were ablated. In the early 1990’s, ventricular tachycardia in structural 
heart disease, atrial fibrillation and idiopathic ventricular fibrillation were not considered 
candidates for ablation. Electro-anatomic mapping open the possibility to ablate this 
complex arrhythmia foci. (Exception was atrial fibrillation where first focal ablation than 
point ablation guided by special catheters- lasso- preceded the electro-anatomic mapping).  
8.1 Atrial tachycardia ablation 
In large branching scar, the ablation requires electroanatomic mapping. Patients after 
corrective surgery of congenital heart disease may develop large scars in the atrium and 
frequently develop incisional reentry tachycardia. As early as in 2001, several institutions 
reported small groups or case reports describing the use of electroanatomic mapping (Leonelli 
FM et al, 2001; Peichl P et al, 2003). Before the use of this mapping, electrophysiological 
definition of the slow isthmus, called central pathway, was needed. This was a long procedure 
with limited success. The electro-anatomic mapping delineates the scar, and delineates the 
isthmus in between scars or in the scar itself. Blocking these pathways, or as occasional called, 
channels, will prevent induction or spontaneous recurrence of the tachycardia. Interestingly, 
the number of publication describing the use of electroanatomic mapping for ablation of focal 
tachycardia ablation is much larger (Kottkamp H et al, 1997; Marchlinski FE et al, 1998; 
Cummings RM et al, 2008). There is also ample of information on the use of this mapping in 
the ablation of different left atrial tachycardias (Iwai S et al, 2002; Marrouche NF et al, 2002; 
Kistler PM et al, 2003; Dong J et al, 2005). Left atrial tachycardias may originate on the septum, 
along the mitral annulus and from the pulmonary veins. Correct mapping may localize the 
origin and ensure successful ablation.  
Two arrhythmias were extensively discussed in the literature: atrial fibrillation ablation and 
ablation of ventricular tachycardia in patients with structural heart disease.  
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8.2 Atrial fibrillation ablation 
After the description of the pulmonary vein as trigger in atrial fibrillation, ablation was 
attempted, first focal, than pulmonary vein isolation (Haissaguerre M et al, 1998). A special 
catheter was developed- the lasso catheter- to permit mapping of the pulmonary vein 
osteum and to localize the pathway connecting electrically the vein with the left atrium. This 
site was ablated and pacing from the coronary sinus could prove the electrical disconnection 
of the veins (Takahashi Y et al, 2007). This treatment was indicated for patients with 
paroxysmal atrial fibrillation and not for the other forms of chronic atrial fibrillation, like 
persistent and permanent. Atrial fibrillation ablation based on electro-anatomic mapping 
has become an accepted alternative to the pulmonary vein disconnection (Pappone C et al 
1999; Pappone C et al, 2000; Pappone C et al 2004; Oral H et al 2006, pappone et al, 2006). 
Developed at the beginning of this century, this approach offered already at the beginning 
of its implementation, a possible ablation also for persistent atrial fibrillation and even for 
long standing persistent type (more then 1 year). The pulmonary vein isolation is achieved 
by circle ablation in the antrum of the veins. Line ablations in the roof and in the mitral 
isthmus (between the mitral annulus and the left lower pulmonary vein) completes the 
procedure and are necessary to avoid left atrial flutter/tachycardia around the ablation 
rings in the pulmonary vein antrum. One first advantage of the left atrial ablation is the 
sparing of the vein and by this to reduce to minimum the possible damage to the vessel. 
This damage may result in pulmonary vein stenosis/occlusion, pulmonary hypertension 
and symptomatic shortness of breath. The correct and exact reconstruction of the left atrium 
and its appendages is a prerequisite not only for successful isolation of the pulmonary veins, 
but also for preventing the above-mentioned damage. Following the original introduction of 
the electro-anatomic approach to atrial fibrillation ablation, this method was compared with 
the original pulmonary vein disconnection and both the acute success and the recurrence 
rate after 1 year was in advantage of the left atrial ablation (Oral H et al, 2003). Moreover, 
the method was evaluated in patients with long-persistent atrial fibrillation and a 
significantly higher number of patient in the ablation group was in sinus rhythm after 1 
year-77% versus 53% (Oral H et al, 2006a). A large percent of the control group moved to the 
ablation group and the symptomatic improvement was significantly higher in the ablation 
group. An additional approach to atrial fibrillation ablation was targeted to complex atrial 
electrograms. This method is accepted as adjuvant to the left atrial ablation. Finally, even if 
the first method is use to disconnect the pulmonary veins, the procedure is escalated and 
elements of the second and third procedure are added (Oral H et al, 2006b; Takahashi Y et 
al, 2007). Although, we are still not at the end of the way in the development of atrial 
fibrillation ablation methods, the place of the electroanatomic mapping is well established. 
The most complex ablation is probably that of ventricular tachycardia in patients with 
structural heart disease.  
8.3 Ventricular tachycardia ablation 
Ventricular tachycardia ablation is going back to 1983 when DC shock was delivered to the 
ablation site (Hartzler GO, 1983). Soon after the presentation of ablation using 
radiofrequency energy, it was applied to patients with idiopathic ventricular tachycardia 
(Kuck KH et al, 1991; Klein LS et al, 1992) and subsequently to ventricular tachycardia in 
structural heart disease (Morady F et al, 1993). Different methods of pacing helped to 
localize a critical area in the tachycardia circle or focus pending on the type of heart disease. 
Although this method was successful, the procedure was prolonged, required a long time to 
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be in ventricular tachycardia and the recurrence rate or new tachycardias generation were 
high. It has become accepted as an adjuvant to other treatments and focused to the 
tachycardia causing repeated defibrillator therapy, ventricular tachycardia storm or 
intolerable shock therapy. The electroanatomic mapping opened to possibility to delineate 
the scar and reveal any narrow strips of myocardium bridging through the scar. These strips 
are targeted in the ablation and they are necessary parts of the tachycardia circle. In patients 
with tolerated tachycardia, the propagation map points to the tachycardia origin. This origin 
may be the exit point of the reentry circle or the other non-reentry focus (like in patients 
with dilated or hypertrophic cardiomyopathy). The ablation may be targeted to this early 
point. There is no need to hold the patient in prolonged tachycardia and no need for the 
pacing techniques. Moreover, in patients with non-tolerated tachycardia the scar is mapped 
and is isolated and connected to the valve annulus. Ablation, before defibrillation 
implantation, may reduce significantly the defibrillator therapy, when compared to non-
ablation control group. This approach was called SMASH-VT (Reddy V et al, 2007, Kuck KH 
et al, 2010). Finally, endocardial ablation may be completed with epicardial ablation 
(Tedrow U & Stevenson WG, 2009; Sacher F et al, 2010). In patients with post myocardial 
infarction scars, most of the tachycardia reentry circle is endocardial, but in patients with 
dilated cardiomyopathy it may be epicardial (Nakahara S et al, 2010).  
8.4 Future ablations 
There are several other ablation targets recently added to the electrophysiology treatment 
armamentarium. The first arrhythmia is the idiopathic ventricular fibrillation. Patient with 
idiopathic ventricular fibrillation may need daily shock therapies and no medical treatment 
can suppress it. For these patients ablation of the initiating beats origin may reduce the 
number of treatments needed. These sites are characterized by high density of Purkinje 
fibers. Clinically, fascicular spikes may be recorded at the successful site in the ventricle 
(Knecht S et al, 2009; Natale A et al, 2010). If this approach will be applicable in patients with 
aborted sudden cardiac death and structural heart disease is still on evaluation. The second 
group with possible future application of electro-anatomic mapping is in patients with 
Brugada Syndrome. Epicardial fractionated electrograms in the RV outflow may be targeted 
and after the ablation, the ECG normalizes (Nademanee K et al, 2011). Occasionally, the site 
may be approached from the endocardium. Of note, the ventricular wall in the RV outflow 
is relatively thin.  
If these two ablations will be implemented in routine practice, the future years will let us 
know.  
9. Conclusions 
Complex ablation has become routine in the clinical electrophysiology. Although these 
arrhythmias originally were approached with classical electrophysiology methods, the 
electroanatomic mapping simplified them and opened these ablations before rapidly 
increasing number of electrophysiology centers.  
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1. Introduction 
1.1 The burden of complex arrhythmias 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 9% of the 
population over 70 years of age (Feinberg, Blackshear et al. 1995). It is characterised by an 
irregular pulse, leading to symptoms of shortness of breath, dizziness, palpitations, chest 
pain, lethargy and an increased risk of stroke (Kannel, Abbott et al. 1982).  Current widely 
accepted indications for catheter ablation of AF are significant symptoms uncontrolled by 
anti-arrhythmic medications, however more recent European Guidelines have suggested 
catheter ablation may be used as a first line treatment for symptomatic paroxysmal AF in 
patients with no or minimal heart disease. Randomised trials from 2003 - 2010 have shown a 
range of success rates for catheter ablation of AF from 56 - 89% (freedom from AF off anti-
arrhythmic drugs) compared to the use of AADs alone ranging from 4 - 43% (Camm, 
Kirchhof et al. ; Kannel, Abbott et al. 1982).  
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after an episode of spontaneous sustained VT however the first ICD therapy appears to be the 
most important predictor of subsequent therapy in this population and is likely to occur 
within the first two years of implant (Koa-Wing M et al 2007). VT ablation has been shown to 
reduce therapies from ICDs, but in its current state, is technically challenging and time 
consuming with procedural times up to 8 hours (Cao et al 1996). 
1.2 The challenges of complex arrhythmias 
1.2.1 Atrial Fibrillation 
Several models have been proposed to explain the continuous irregular atrial activation of 
clinical AF. It is widely accepted that the initiation of AF is from an atrial ectopic ‘trigger’ 
originating from the pulmonary veins (Haissaguerre, Jais et al. 1998). The ‘trigger’ can continue 
to act as ‘a focal driver’ maintaining AF or can establish a self-sustaining spiral wave (or rotor) 
in a localised region of the myocardium leading to fibrillatory activation in the remaining atria 
(Haissaguerre, Jais et al. 1998; Jalife, Berenfeld et al. 2002; Sahadevan, Ryu et al. 2004).  
Pulmonary vein isolation to remove the ‘trigger’ has been shown to be effective in 
paroxysmal AF (Haissaguerre, Jais et al. 1998) (Pappone, Santinelli et al. 2004). However, 
triggers outside the pulmonary veins have also been identified in the superior vena cava 
and coronary sinus and these have been more challenging to identify and treat. Linear 
ablation has been performed in both paroxysmal and persistent AF along the principles of 
the Cox Maze surgical procedures, but these have not achieved the same success as the 
surgical approach (Cox, Boineau et al. 1995; Cox, Schuessler et al. 1996; Hsu, Jais et al. 2004).  
Linear ablation at the roof of the left atrium (Hocini, Jais et al. 2005) and the mitral isthmus 
between the left lower pulmonary vein and annulus has been shown to improve outcomes 
when there is proven conduction block of these lines (Jais, Hocini et al. 2004; Willems, 
Klemm et al. 2006). However, conduction block is difficult to achieve due to lack of catheter 
stability and failure to achieve transmurality.  
More recently, catheter-based substrate modification has targeted regions of highly 
fractionated electrograms that others suggest as drivers for persistent AF (Lellouche, Buch et 
al. 2007). Nadamanee et al achieved an 81% success rate for ablation after up to 4 procedures 
targeting only areas of complex fractionated atrial electrograms (CFAE) (Nademanee, 
Schwab et al. 2008). However several other groups have failed to reproduce these success 
rates with CFAE ablation alone (Estner, Hessling et al. 2008). Speculation as to the 
mechanistic basis for CFAE has implicated regions of autonomic innervations termed the 
ganglionated plexi, as these were noted to be co-located with regions of CFAE in animal 
studies. Alternatively, they may originate from regions of atrial scarring or fibrosis, and are 
thought to represent a combination of wavefronts approaching the recording electrode from 
multiple directions. Integration of delayed-enhancment MRI imaging, particularly 
containing information relating to scar, may provide greater insight on the origin of CFAE. 
This is discussed in more detail later in this chapter. 
Wide area circumferential ablation with pulmonary vein isolation, designed to encircle the PVs at 
a distance from the ostia, is a widely accepted technique for AF ablation and appears to achieve 
greater success rates than segmental PVI. (Marrouche, Martin et al. 2003; Pappone, Rosanio et al. 
2003; Ouyang, Bansch et al. 2004) The most widely practiced approach is to use a 3D-navigation 
system to recreate a virtual left atrium and move around the chamber delivering lesions around 
the pulmonary veins and marking lesion points on the virtual anatomy.(Pappone, Oreto et al. 
1999) The 3D geometry aids the operator in manipulating catheters around the complex anatomy 
of the left atrium which can vary significantly from patient to patient. This can prove particularly 
challenging with only 2D fluoroscopy for navigation.  
 




Example of virtual left atrium and points marked (red balls) during wide area 
circumferential ablation 
Despite these novel approaches, published success rates for single procedure AF ablation 
range remain around 50% to 88% (Lim, Matsuo et al. 2007; Matsuo, Lim et al. 2007; Natale, 
Raviele et al. 2007; O'Neill, Jais et al. 2007; Marchlinski 2008) which are still not comparable 
to the >95% success rates expected from ablations for other arrhythmias.  
1.2.2 Atrial Tachycardia 
Endocardial activation allows categorisation of ATs into focal and macro-rentrant. However in 
the era of persistant AF ablation the presence of “micro-reentry” circuits particularly within 
regions of previous complex fractionated atrial electrograms (CFAE) ablation scar must be 
acknowledged. It is therefore imperative to clarify the mechanism of the underlying AT during 
electrophysiological procedures to guide ablation therapy. Currently established techniques 
for guiding ablation in complex atrial tachycardias include activation and/or entrainment 
mapping. Routinely the tachycardia is displayed as an activation map on a recreated atrial 
geometry from endocardial location points collected using 3-D mapping technology. However, 
activation mapping is limited by a point-by-point acquisition process which is not always 
systematic, is often time-consuming and can miss small areas crucial to the circuit.  Detailed 
mapping often requires >150-200 points with each circuit potentially involving multiple loops 
and figure-of-8 circuits.  In order to identify the critical isthmus maintaining the tachycardia a 
trained operator is required to set an accurate “window of interest” and collect activation data, 
which requires significant processing to ensure all collected points have been correctly 
annotated to the chosen reference. In addition conventionally established entrainment 
manoeuvres are often used to confirm the diagnosis represented by activation mapping 
however these can have limitations if there is a variation in the tachycardia cycle length 
particularly in scarred atria with multiple regions of block and slow conduction. 
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The most commonly recognised mechanisms seen post-AF ablation are macro re-entrant roof-
dependant and mitral isthmus dependant tachycardias however with increasing linear and 
CFAE ablation lesions, micro-reentrant circuits must also be appreciated. In these situations 
diagnostic yield from mapping and entrainment can test the most skilled electrophysiologist 
and although acute success rates have been reported ranging from 88-100%, recurrences are 
disappointing with rates ranging from 0-47% over a mean follow-up of 2 to 16 months 
(Gerstenfeld 2004; Chugh 2005; Deisenhofer 2006; Mesas 2004; Haïssaguerre 2005).  
Several other circuits capable of sustaining re-entrant tachycardias are seen following 
cardiac surgery, particularly congenital heart disease.    
These are typically a challenge to map and ablate due to the unpredictable location and 
extent of the underlying iatrogenic scar exposing the limitations of the aforementioned 
diagnostic techniques. 
1.2.3 Ventricular Tachycardia 
The biggest challenge in VT ablation remains scar-related VT including ischaemic and dilated 
cardiomyopathy. The substrate for post-infarct VT is produced by channels of slow conduction 
within the scar border (the diastolic pathway), created by anatomical and functional lines of 
block. Identification and ablation of these diastolic pathways is required for successful VT 
ablation (Koa-Wing, Ho SY et al 2007; Stevenson, Khan et al 1993). Conventional techniques to 
identify the diastolic pathway consist of performing activation mapping followed by entrainment 
manoeuvres to locate areas within the scar that participate in the re-entrant circuit (Stevenson, 
Khan et al 1993; Huang & Wood 2006; Bogun, Good et al 2006), but non-inducibility, difficulty 
capturing scarred myocardium during entrainment, multiple different morphologies of VT, 
haemodynamic instability and circuit components deep to the sub-endocardium make this 
approach unreliable and prolonged with disappointingly high recurrence rates. 
These limitations have led to a change in practice from targeting specific circuits to substrate 
modification of the scar by linear ablation in an attempt to transect potential diastolic 
pathways and render the VT non-inducible (Marchlinski, Callans et al 2000). Although acute 
ablation success rates at elimination of the “clinical” tachycardia have improved from 71-
74% (Morady et al 1993, Gonska et al 1994, Kim et al 1994) in the mid-1990s to 90% in the 
2000s (Sacher et al 2008) long-term outcomes remain unsatisfactory. This is despite the 
introduction of cardiac mapping systems, irrigated tip catheters and substrate based 
ablation strategies. Up to 31% of patients with an acutely successful ablation outcome of the 
“clinical” VT have arrhythmia recurrence. Ablation to non-inducibility of any VT has been 
reported with success rates approaching 65% but with recurrence rates of 29% during a 
median follow-up of 1 month (Sacher et al. 2008).  The potential causes of recurrence or 
failure at the index procedure include inadequate mapping techniques of, often small, 
isthmi in a complex anatomic substrate and failure to achieve transmurality of lesions in 
those with circuits traversing the subendocardium and epicardium. Although epicardial 
circuits can be targeted percutaneously, this is not possible in up to 85% of patients with 
previous cardiac surgery (Sacher F, Roberts-Thomson K, et al. 2010). 
2. Mapping 
The development of intra-cardiac mapping was based on the use of individual contact 
catheters. Despite being able to record information from different sites using multipolar 
catheters, complex arrhythmias and complex substrates pose significant challenges using 
these techniques. 3-D electrophysiological mapping systems were developed to aid the 
 
Novel Technologies for Mapping and Ablation of Complex Arrhythmias 
 
447 
localisation of the source of focal tachycardias and the critical isthmi of re-entrant circuits 
(Stevenson, Delacretaz et al 1998; Marchlinski, Callans et al 1998; Earley, Showkathali et al 
2006; Schilling, Peters et al 1999; Shah, Jais et al 1997) Conventionally, these systems display 
electrical data from mapping catheters as either local activation time (isochronal) or local 
voltage (isopotential) maps. These methods indicate the parameter being displayed using a 
colour-scale on a 3D representation of the cardiac chamber of interest.  
The current versions of these mapping systems are not only significantly more accurate but 
they offer many more features to facilitate mapping of complex arrhythmias; voltage 
mapping, propagation maps, rapid mapping using multipolar catheters and mapping of 
fractionated electrograms and the input of anatomical data from pre-operative CT or MRI 
scans of the heart or rotational angiograms. The latest feature allowing 4-dimensional 
mapping, ‘ripple-mapping’, will also be discussed in this chapter. 
The use of mapping systems has not been shown to reduce the duration of the procedure or 
the efficacy of the procedure(Sporton, Earley et al. 2004), however, it has been shown to 
significantly reduce the fluoroscopy time, thereby reducing the exposure of patients and lab 
staff to harmful radiation.(Scaglione, Biasco et al.) 
2.1 Current mapping systems 
Current electroanatomic mapping systems build a 3-dimensional geometry of a cardiac 
chamber by recording sequential positional co-ordinates from the catheter tip in contact 
with the myocardium and combining this information with concomitantly acquired 
electrogram data. Low voltage areas and scar can be easily identified to develop a picture of 
the underlying substrate for arrhythmogensis.  Electrogram timings with respect to a stable 
reference catheter, enables an activation map to be created, which is colour coded to 
differentiate between ‘early’ and ‘late’ signals. 
 
 
Colour coded activation map of a clockwise isthmus dependent right atrial flutter. 
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Colour coded activation map of a clockwise isthmus dependent right atrial flutter. 
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Alternatively, this can be displayed as a propagation map, which demonstrates activation of 
the excitatory wavefront as it advances across the chamber geometry. Maps can be rotated 
and viewed in multiple orientations at the same time so that the wavefront can be followed 
throughout the cardiac cycle. Electroanatomic mapping systems are primarily used for 
mapping stable tachycardias, however they can also facilitate substrate mapping during 
sinus rhythm, which is particularly useful when mapping VTs which cause significant 
haemodynamic compromise. Additionally, these systems facilitate encirclement of cardiac 
structures, the best example of which is the encirclement of pulmonary veins as part of the 
treatment for ablation of atrial fibrillation (AF).  Areas targeted may lie between important 
scar boundaries (e.g. linear ablation lesions to transect the diastolic pathway in VT circuits) 
or between inert structures (e.g. linear ablation between the mitral valve annulus and the 
left inferior pulmonary vein in mitral isthmus-dependent atrial tachycardia).  
2.2 Integration with robotic navigation 
New Cohesion™ 3D visualisation module available with the Hansen Robotic Navigation 
system allows integration of the electroanatomic mapping system NavX or Velocity (St Jude 
Medical™) This facilitates navigation of the robotic catheter by producing an intuitive 
driving plane according to the orientation of the virtual geometry within the mapping 
system. This removes the requirement for the operator to re-orientate him or herself when 
using the virtual geometry of the left atrium to guide navigation. This has been tested in 
clinical studies and shown to reduce fluoroscopy times for robotic navigation and ablation 




Example of Cohesion, Hansen Robotic navigation system fully integrated with NavX 
mapping system to provide intuitive driving in the orientation of the virtual LA geometry 
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2.3 Integration with MRI / CT imaging 
The CARTOTM and NavXTM systems can both integrate digital computed tomography (CT) 
or magnetic resonance imaging (MRI) images of the heart into a mapping study, allowing 
navigation of “virtual” catheters within a high resolution model of the patient’s anatomy. 
CT / MRI studies can either be imported and segmented via the image processing platforms 
available in both mapping systems, or can be segmented offline by an experienced operator 
for direct import to the mapping system at the time of the procedure. Registration of the 
segmented chamber to the patient orientation is performed using fluoroscopy. Fixed 
anatomical landmarks close to the chamber of interest are acquired and subsequently 
registered with their corresponding sites on the CT/MRI image. The identified landmarks 
are then “merged” together to complete the registration process so that the catheter tip can 
be navigated within the detailed anatomical shell created on CT / MRI. 
Electroanatomical mapping with CT/MRI image integration is particularly useful in 
patients with unusual or complex anatomy such as those with congenital heart disease and 
previous cardiac surgery. Detailed chamber anatomy is also helpful in pulmonary vein 
isolation procedures, by delineating the location, size and orientation of the pulmonary vein 
ostia. However, CT / MRI integration does not improve acute procedural efficacy or long 
term success rates.(Kistler, Rajappan et al. 2008)  
2.4 Imaging of myocardial scar and integration with mapping systems 
Delayed-enhanced Magnetic Resonance Imaging (DE-MRI) has been used for almost a 
decade to identify regions of ventricular scar. An increase in extracellular space within 
myocardial scar allows for an accumulation and prolonged wash-out time of the contrast 
agent, gadolinium.(Saraste, Nekolla et al. 2008). Information regarding ventricular or atrial 
scar can be obtained from voltage readings using intra-cardiac catheters. However, the 
integration of DE-MRI data may eliminate the need for acquisition of a detailed voltage 
map, and prevent inaccurate readings due to poor catheter contact.  
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Example of Cohesion, Hansen Robotic navigation system fully integrated with NavX 
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histochemical staining in animal models (Kim RJ et al 1999). Heterogeneous tissue 
surrounding areas with dense LGE are hypothesized to be the imaging equivalent of slow 
conduction zones in patients with ischemic cardiomyopathy (Yan AT, Shayne AJ et al. 
2006; Roes SD, Borleffs CJ et al 2009) although this is not a consistent finding. Until higher 
resolution images are possible we must accept the reality that the currently visualized 
“infarct core” and “heterogeneous tissue” is a mixture of true infarct core, true 
heterogeneous tissue, and artifacts, particularly those produced by volume averaging of 
infarct core with healthy tissue.  
Utilising the technique described by Yan et al, Perez-David et al. demonstrated the 
connection between heterogeneous tissue on CMR and slow conduction zones identified by 
endocardial mapping. Furthermore, they confirmed that sites identified as critical VT isthmi 
by electrophysiological manoeuvres often reside in heterogeneous tissue identified by CMR. 
2.4.2 Atrial scar in AF and AT 
More recently, as scanners and scanning quality have improved, attention has turned to 
visualising atrial myocardium, in particular looking for regions of pre-existing fibrosis and 
iatrogenic scar following catheter ablation procedures.(Kim, Hillenbrand et al. 2000; Kim, 
Wu et al. 2000) Several recent studies have shown that high-spatial-resolution delayed 
enhancement MR (DE-MRI) imaging allows identification of scar induced by RF ablation in 
the left atrium(Peters, Wylie et al. 2007; McGann, Kholmovski et al. 2008; Badger, Adjei-
Poku et al. 2009). Badger et al showed, however, that chronic atrial scar may not be formed 
and visible on MRI until up to 3 months following the ablation procedure. (Badger, Oakes et 
al. 2009)  Integration of data from DE-MRI regarding location of scarred regions may benefit 
procedures such as repeat AF ablations and post-ablation atrial tachycardias. In particular, it 
may help identify the location of gaps within lines which are providing the substrate for 
ongoing AF / AT. 
Methods for improved patient selection and non-invasive evaluation of the LA wall to 
assess the extent permanent tissue injury created by ablation, may be an important tool in 
improving ablation technique and increasing procedural success. Oakes et al demonstrated 
that the presence of left atrial fibrosis prior to ablation can also be detected using DE-MRI 
and that patients with higher levels of fibrosis had lower procedural success rates.(Oakes, 
Badger et al. 2009) On this basis they hypothesised that a further possible use of DE-MRI 
may be that of patient selection for atrial fibrillation ablation.  
2.5 Novel mapping systems: CARTO Ripple 
Despite the aforementioned advantages of current mapping systems there remain shortfalls 
and limitations to their use. The conversion of the raw electrical data to ‘clean’ activation 
maps requires operator expertise with the potential introduction of errors by incorrect 
assignment of local activation times or voltage thresholds. Furthermore interpolation of data 
within unmapped regions can lead to the display of false information. The introduction of 
integrated multielectrode mapping catheters should reduce this error by allowing creation 
of dense maps. This integration should also improve the rapidity with which maps are 
created with a likely increase in diagnostic yield (Patel et al 2008). Additionally, colour-
spectrum isochronal maps are often converted to propagation maps that display moving 
activation wave fronts that are interpreted more intuitively but are mathematically 
extrapolated from the points collected and can give the operator a false sense of the 
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resolution of the map. Isopotential maps created by grouping far-field reconstructed 
electrograms (Ensite Array) that are above a pre-specified activation threshold voltage to 
create activation wave fronts are prone to errors due to the subjective variation introduced 
by voltage threshold adjustments. In addition the hardware is limited by far-field 
reconstruction of low voltage electrograms.  
Intracardiac electrograms provide unique site-specific data about local electrical activation 
and in-vitro studies have demonstrated that underlying anatomical substrate can be 
deduced from the electrogram morphology (Spach MS, Miller WT et al 1979). Electrograms 
are categorised by largely binary descriptors; simple or complex, early or late, high or low 
amplitude. Potentially crucial information contained within electrograms is lost to 
interpretation with current 3D mapping systems. CARTO does not assign any characteristics 
to potentials (diastolic or late systolic) within ventricular scar and is unable to appropriately 
display valuable data contained within complex fractionated electrograms often 
representing regions of slow conduction which may play a pivotal role in scar related artial 
arrhythmias. As the system can only assign a single value for the local activation time, 
isochronal and activation maps can be flawed if complex fractionated electrogams are 
annotated incorrectly.  
ENSITE can collect simultaneous global activation data but is prone to far-field noise 




The top panel shows increasing Ripple bar height in correlation to the increasing magnitude 
of the electrogram voltage in the annotation window (shown in the lower window).  
The bar height and colour are clearly visible. These can be correlated to the conventional 
reference colour bar from CARTO seen to the left of the panel with low voltage represented 
by red and high voltage represented by purple 
The conventional 2D method for displaying electrograms is deflection from a baseline 
according to a voltage scale. The overall sequence of directions and rates of change and 
amplitudes of deflections define the electrogram “morphology”. A new visualisation 
algorithm, Ripple Mapping, has allowed the reproduction of this 2D process on a 3D hull 
using a bar moving out from the cardiac surface conveying location, timing and electrogram 
morphology simultaneously (Linton, Koa-Wing. 2009). Multiple points collected in a small 
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resolution of the map. Isopotential maps created by grouping far-field reconstructed 
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area will display bars, which change according to the local voltage change and in a 
temporally accurate sequence producing a ‘ripple’ effect which conveys the direction of 
wave propagation without any operator annotation. The program avoids interpolation and 
as it does not use a single local activation time, all the components of the electrogram are 
preserved and displayed. Therefore a sequence of small potentials and complex 
electrograms can be temporally related to adjacent electrograms. This method has the 
benefit of using high quality contact electrograms capable of demonstrating low amplitude 
signals with accurate 3D localisation, enabling the assessment of electrogram morphology 
within scar. 
During the proof-of-concept study this novel method of cardiac mapping showed low-
amplitude continuous activity in four of five tachycardias at the site of successful ablation, 
consistent with a re-entrant mechanism. Cardiac Ripple Mapping has been integrated onto an 




Left panel: Displays a left atrial CARTO-XP local activation time (LAT) map of a patient 
with left atrial tachycardia following circumferential pulmonary vein isolation for 
paroxysmal atrial fibrillation. Analysis of the LAT map suggests the possibility of a focal 
tachycardia origination from the posterior wall near the right pulmonary veins.  
Right panel: The same atrial tachycardia as seen on the corresponding unaltered Ripple map 
(left lateral view) shows a roof dependant atrial tachycardia which was confimed by 
conventional entrainment manoeuvres. 
3. Ablation of complex arrhythmias 
The achievement of transmurality of ablation lesions for permanent VT abolition and 
pulmonary vein isolation is one of the ongoing challenges of ventricular tachycardia and 
atrial fibrillation ablation (Haissaguerre, Shah et al. 2000; Pappone, Santinelli et al. 
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2004);(Kosmidou, Inada et al. 2011 ; Willems, Steven et al. 2010). The Hansen robotic 
system was designed to improve catheter tip stability, lesion quality and clinical outcomes. 
3.1 The Hansen robotic navigation system 
The Hansen Sensei electromechanical robotic navigation system is capable of remotely 
steering a guide catheter to enable precise positioning and manipulation of any type of 
electrophysiological catheter within the heart for mapping and ablation. The Sensei system 
has been described in detail previously.(Saliba, Cummings et al. 2006; Kanagaratnam, Koa-
Wing et al. 2008)  In brief, the system comprises three linked components: the physician’s 
workstation (Sensei™ robotic control system), remote catheter manipulator (RCM) and 
steerable guide catheter (Artisan™ Sheath). The steerable guide catheter comprises an outer 
(14F) and inner (10.5F) steerable sheath through which any 8.5F or less ablation catheter can 
be placed. The outer guide can be inserted, deinserted and can bend up to 90 degrees, 
whereas the inner guide is controlled by the 3D joystick and can be directed anywhere 
within the toroidal workspace. The Artisan sheath maintains the catheter position by the 
tensile strength of four pullwires so that the shape adopted by the sheath is uniquely suited 
to the point of interest to which the catheter is being positioned.(Kanagaratnam, Koa-Wing 
et al. 2008) This is in contrast to the manual approach, where the operator has to 
dynamically apply torque and flexion to prevent the catheter displacing from the point of 
interest. The Sensei™ robotic control system also incorporates a pressure sensor 
(Intellisense™), which calculates the contact force at the tip of the catheter using the 
differential resistance when continuously dithering the catheter in and out of the Artisan 
sheath. This tissue contact pressure enhances the validation of tissue contact and also 
provides for the ability to identify a pressure curve for optimal lesion production. 




Hansen Robotic Artisan steerable sheath.  
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The Sensei system is currently compatible with all 8.5F or less mapping and irrigated 
ablation catheters. The physicians work station comprises 3 screens which can display any 
selected data including fluoroscopy, intracardiac echocardiography, electroanatomic 
mapping systems (Carto Biosense Webster, NavX St Jude Medical, Rotational Angiography 
imaging Philips ElectroNav etc.), and electrogram display systems (Bard Lab System Pro 
etc.) The free standing physician’s work station and remote catheter manipulation system 
mounted on the patient table can be moved between laboratories and do not require any 
floor reinforcement such as that required for magnetic remote navigation systems. 
The intended benefit of robotic catheter manipulation is that the catheter position is 
maintained once the physician has released the 3D joystick providing increased stability 
throughout the duration of RF delivery. In addition, the Intellisense system can confirm 
catheter contact during ablation.  
3.1.1 Atrial and ventricular ablation 
Several studies have been performed in animals to investigate whether the theoretical benefits 
of robotic ablation are translated into improved measurable parameters of lesion quality. In a 
study comparing robotic (Sensei) and manual ablation in 7 pig atria, robotic ablation reduced 
local electrogram amplitude to a greater degree than manual ablation (49+/- 2.6% vs 29 +/- 
4.5% signal reduction after one minute p=0.0002) The incidence of >50% signal reduction was 
also greater for robotic (37%) than manual (21%) (p=0.0001).(Koa-Wing, Kojodjojo et al. 2009) 
Koa-Wing et al also noted that macroscopically the robotic lesions were more consistently 
transmural compared to the manual lesions, with no evidence of charring or perforation with 
either modality. In other in-vitro studies, 45W at 20-30g for 40secs, 83% of lesions were 
transmural, however 33% of lesions were associated with char formation. Using 30W and 20-
30g pressure 0% were associated with char formation, however only 16% were associated with 
transmural lesion formation. (Di Biase, Natale et al. 2009), 
Previous human studies comparing robotic and manual ablation have been non-randomised 
and have shown no significant difference in clinical outcomes. The primary aim of these 
studies was to prove safety and feasibility, however it is important to try to understand the 
potential reasons why these studies did not deliver the anticipated benefits of increased 
catheter precision and stability. (Willems, Steven et al 2010; Di Biase, Wang et al. 2009)  The 
two studies both quoted using the same settings for both robotic and manual ablation (45W 
for 20secs and 20-25W for 60s) lesions. Interestingly, both reports comment on how robotic 
ablation required shorter radiofrequency duration. Therefore, in both series it appears that 
operators adjusted power according to anatomical location and local signal attenuation. 
Therefore, if the same target was being used for both manual and robotic arms, it is 
unsurprising that the clinical outcomes were similar.  
The ability to titrate force and improve tissue contact are important attributes required 
during ablation in the ventricle which can be over a centimetre thick. Furthermore greater 
transmurality of delivered lesions should negate the need to gain epicardial access in this 
patient population who have often previously undergone cardiac surgery, making 
percutaneous access less practical. The reduction in operator radiation exposure during 
these long procedures is of added value. There are no large scale trials of robotic VT ablation 
however acute feasibility is suggested by occasional single case reports (Duncan, Johns et al 
2010; Koa-Wing, Linton et al. 2009) Larger scale studies should help clarify the role of this 
technology in ablation of complex arrhythmias.  
 




With the rapidly progressing field of catheter ablation, advances in mapping and ablation 
technologies will lead to improved therapeutic outcomes in complex cardiac arrhythmias. 
Innovative methods of assessing, displaying and integrating the underlying substrate of 
complex scar with electrophysiological data will further streamline our current practice in 
these challenging cases.  
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Several studies have been performed in animals to investigate whether the theoretical benefits 
of robotic ablation are translated into improved measurable parameters of lesion quality. In a 
study comparing robotic (Sensei) and manual ablation in 7 pig atria, robotic ablation reduced 
local electrogram amplitude to a greater degree than manual ablation (49+/- 2.6% vs 29 +/- 
4.5% signal reduction after one minute p=0.0002) The incidence of >50% signal reduction was 
also greater for robotic (37%) than manual (21%) (p=0.0001).(Koa-Wing, Kojodjojo et al. 2009) 
Koa-Wing et al also noted that macroscopically the robotic lesions were more consistently 
transmural compared to the manual lesions, with no evidence of charring or perforation with 
either modality. In other in-vitro studies, 45W at 20-30g for 40secs, 83% of lesions were 
transmural, however 33% of lesions were associated with char formation. Using 30W and 20-
30g pressure 0% were associated with char formation, however only 16% were associated with 
transmural lesion formation. (Di Biase, Natale et al. 2009), 
Previous human studies comparing robotic and manual ablation have been non-randomised 
and have shown no significant difference in clinical outcomes. The primary aim of these 
studies was to prove safety and feasibility, however it is important to try to understand the 
potential reasons why these studies did not deliver the anticipated benefits of increased 
catheter precision and stability. (Willems, Steven et al 2010; Di Biase, Wang et al. 2009)  The 
two studies both quoted using the same settings for both robotic and manual ablation (45W 
for 20secs and 20-25W for 60s) lesions. Interestingly, both reports comment on how robotic 
ablation required shorter radiofrequency duration. Therefore, in both series it appears that 
operators adjusted power according to anatomical location and local signal attenuation. 
Therefore, if the same target was being used for both manual and robotic arms, it is 
unsurprising that the clinical outcomes were similar.  
The ability to titrate force and improve tissue contact are important attributes required 
during ablation in the ventricle which can be over a centimetre thick. Furthermore greater 
transmurality of delivered lesions should negate the need to gain epicardial access in this 
patient population who have often previously undergone cardiac surgery, making 
percutaneous access less practical. The reduction in operator radiation exposure during 
these long procedures is of added value. There are no large scale trials of robotic VT ablation 
however acute feasibility is suggested by occasional single case reports (Duncan, Johns et al 
2010; Koa-Wing, Linton et al. 2009) Larger scale studies should help clarify the role of this 
technology in ablation of complex arrhythmias.  
 




With the rapidly progressing field of catheter ablation, advances in mapping and ablation 
technologies will lead to improved therapeutic outcomes in complex cardiac arrhythmias. 
Innovative methods of assessing, displaying and integrating the underlying substrate of 
complex scar with electrophysiological data will further streamline our current practice in 
these challenging cases.  
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1. Introduction  
Severe disorders of the heart rhythm that can lead to sudden cardiac death (SCD) are often 
treated by radio-frequency (RF) catheter ablation. Using fluoroscopy as an imaging guide, 
the procedure consists of inserting a catheter inside the heart, near the area from which 
originates the abnormal cardiac electrical activity, then delivering RF currents through the 
catheter tip to ablate the arrhythmogenic area. Fluoroscopy is a conventional mapping 
technique that has been extremely useful in understanding and managing simpler 
arrhythmias. While the fluoroscopic procedure is still used in over 90% of ablations, its 
limitation in providing a reliable 3D geometry is evident when working upon complex cases 
like ventricular tachycardia (VT) or atrial fibrillation (AF) ablation. In turn, this results in 
impaired efficacy and length of the procedure lasting for several hours. Even though 
operator experience has decreased procedure times, radiation hazards still remain a major 
issue for the patient.  
Recent 3D systems which integrate electrophysiological signals with anatomy to provide 
(3D+ t) geometry are extremely useful in situations where radiation needs to be limited as 
much as possible, and to increase the efficiency and shorten the duration of RF catheter 
ablation. During intracardiac mapping, it is not unusual to find sites at which the operator 
feels ablation is likely to succeed. Three-dimensional systems not only allow the surgeon to 
mark precise ablation points but also facilitate fixing reference points if the ablation process 
has to be repeated (Rajnish, 2009). 
This chapter will summarize the most recent developments in catheter navigation and three-
dimensional electroanatomic mapping.  Conventional fluoroscopy techniques will be 
described followed by the CARTO and Ensite non-fluoroscopic mapping systems. Advances 
in ultrasound imaging for cardiac ablation guidance, and futuristic remote navigation 
technologies such as the Stereotaxis Magnetic Navigation system and the Hansen Sensei 
Robotic Catheter system will conclude the read.   
2. Conventional catheter mapping 
Every clinical electrophysiology (EP) laboratory is equipped with an X-ray system designed 
to provide fluoroscopic imaging of the heart. For many years this was the only form of 
procedural imaging available. A common characteristic of all X-ray images is that the soft 
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tissue of the myocardium cannot be visualized (Figure 1), nevertheless, the walls of the left 
atrium can be indirectly assessed by bolus injection of contrast, which can be augmented by 
manoeuvres that minimize atrial emptying such as adenosine or rapid ventricular pacing. 
However, the major disadvantage of using X-ray fluoroscopy as the sole imaging modality 
is that all images obtained are two-dimensional representations of three-dimensional 




Fig. 1. A conventional fluoroscopy image showing a multielectrode basket array and other 
standard catheters inside the right atrium. Letters A to H identify basket splines and ABL 
indicates ablation catheter.  
Image taken from Schmitt et al., 1999. (doi: 10.1161/01.CIR.99.18.2414). 
2.1 Rotational angiography  
Recently, three-dimensional rotational angiography (3DRA) has been introduced as  
an intraoperative modality for 3D imaging during cardiac ablation. In 3DRA, the  
C-arm typically performs a 200° rotation around the patient (Figure 2). Its cone-shaped 
radiation beam projects on a large flat-panel detector placed on the other end of the C-arm. 
A large number of two-dimensional projections are acquired over the course of the rotation. 
Reconstruction algorithms construct these into 3D images by volume or surface rendering. 
With adequate contrast agent administration and cardiac motion reduction (Figure 3),  
the image quality delivered by 3DRA has been shown to be comparable to or even 
exceeding classical cardiac computerized tomography (Wielandts et al., 2010). Three-
dimensional rotational angiography images are more likely to represent the true  
anatomy than a remotely acquired image, such as CT or MRI, because of factors such as  
the patient’s breathing and heart motion. This technique also reduces the financial  
and administrative burden of scheduling adjunctive and expensive imaging studies.  
In the case of patient movement, the geometry needs to be fully re-acquired; this can be 
promptly managed, but the consistent iodinated contrast agent load and radiation dose 
typically preclude the use of rotational angiography more than twice in a study (Casella et 
al., 2010). 
 





Fig. 2. A three-dimensional imaging sequence consists of 248 frames, imaged over a  
200° rotation of the C-arm fluoroscope. Using advanced algorithms, a subsequent 3D 
volume reconstruction of the atrium is generated.  




Fig. 3. Direct injection into the left atrium following segmentation of the resulting dataset. 
The subsequent 3D anatomical shell can then be superimposed on the live fluoroscopy. 
Image taken from D’Silva & Wright, 2011. 
3. Electroanatomic mapping: CARTO  
CARTO (Biosense-Webster Inc, Diamond Bar, CA) consists of a mapping catheter with 
miniaturized coils at the tip, a magnetic field generator located underneath the patient, a 
unit which analyses the current generated by the coils in the catheter-tip and a post-
processing graphical display unit. The location pad fixed beneath the patient table has 
three coils that generate low magnetic fields (Figure 4). The emitted fields possess well-
known temporal and spatial distinguishing characteristics that encode the mapping space 
around the patient’s chest. The location is mapped in three-dimensions with reference to a 
fixed point. Each of the sensor locations is determined by its distance from the location 
pad. Three dimensional reconstruction is performed by calculating the distance between 
the two sensors. In case the patient moves, the distance of each sensor from the location 
pad is changed; however, the distance between the sensors is retained. The three distances 
determine the location, orientation and rotation of the catheter (Rajnish, 2009). Accuracy 
of the catheter tip location has been estimated to be within 0.54 ± 0.05mm (LaPage & Saul, 
2011).  
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Fig. 4. Three electromagnetic fields originating from location pad coils. Spatial location of the 
catheter tip is accurately found by the electromagnetic fields, by determining the distance of 
the sensor on the catheter tip from each coil. This information is instantly computed to 
generate a real-time position of the catheter tip. Image courtesy of Biosense Webster. 
The CARTO system is termed a point-by-point technology; multiple positions of the 
magnetic tip catheter are required inside the heart chamber to create a complete three-
dimensional depiction of the chamber of interest (Figure 5). The activation time is referenced 




Fig. 5. Three dimensional anatomical reconstruction with superposition of activation times 
using the point-by-point CARTO technology. Earliest activation times are depicted in red. 
Image courtesy of Biosense Webster. 
3.1 CARTO 3TM 
(Kabra & Singh, 2010) have recently reviewed the CARTO 3TM technology and some of the 
highlights of the system follow. First, the CARTO 3 System is the third generation 
technology from Biosense Webster. Multiple catheter tips and curves can now be 
visualized on the electroanatomic map when compared to the traditional CARTO 
mapping system (Figure 6). In addition, CARTO 3 uses a magnetic technology that 
calibrates the current-based technology, thereby minimizing distortions at the periphery 
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of the electrical field. Mapping is performed in two steps. Initially, the magnetic mapping 
permits precise localization of the catheter with the sensor. As the catheter with the sensor 
moves around a chamber, multiple locations are created and stored by the system. The 
system then integrates the current based points with their respective magnetic locations, 
resulting in a calibrated current based field that permits accurate visualization of catheters 
and their locations (Kabra & Singh, 2010). Each electrode emits a unique frequency 
allowing each to be clearly distinguished, especially when in close proximity to one 
another. Both the catheters with and without the magnetic sensors can be visualized 
without spatial distortions. Lastly, CARTO 3 has 'Fast Anatomical Mapping' (FAM) 
feature that permits rapid creation of anatomical maps. Unlike point-by-point 
electroanatomical mapping, volume data can be collected with FAM. Catheters such as 
the multi-polar Lasso can further enhance the collection of points and increase the 




Fig. 6. The CARTO 3TM system with individually reconstructed catheters without spatial 
distortions. Image courtesy of Biosense Webster. 
3.2 CARTOMerge  
The major development for electroanatomic mapping in recent years has been the fusion of 
imaging technologies – MRI/CT – and electroanatomic mapping systems (Figure 7). The 
process of incorporating CT or MRI images into the electroanatomic mapping system 
involves 3D/3D registration of the catheter obtained geometry with the CT image. 
Typically, specific landmarks in the chamber are localized with the catheter and these points 
are then used to orient the CT/MRI image properly. (Rossillo et al, 2009) compared this 
method with a focused registration process during which they obtained multiple mapping 
points at each pulmonary vein using intracardiac echo guidance. They concluded that the 
focused registration process was a superior technique. 
3.3 Advantages/disadvantages 
The strengths of the CARTO technology are: (i) accurate heart chamber reconstruction,  
(ii) creation of linear ablations, (iii) color-coded activation maps, (iv) scar and ablation 
tagging capabilities. The weaknesses include: (i) incompatibility with other mapping 
catheters, (ii) limited utility in non-sustained arrhythmias, and (iii) orthogonal appearing 
volumes. 
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Fig. 7. The CARTOMerge technology allows the electroanatomic map of the left atrium 
using CARTO to be integrated with the CT/MRI images using CARTOMerge module. The 
circles depict the corresponding points on the two maps. Image taken from Thornton et al., 
2008. (doi: doi:10.1093/europace/eun080) 
3.4 Clinical study  
In a recently published randomized study of 3DRA versus CARTO during atrial fibrillation 
ablation, the radiation exposure, procedural times and clinical outcomes at 10 months were 
similar in the groups investigated (Knecht et al, 2010). However the use of contrast makes it 
a less appealing option for patients with heart failure or renal failure. In addition, 3DRA was 
sensitive to patient movements during the study period. However further refinements are 
needed before it can be widely adopted. These include incorporation of respiratory and 
cardiac motion compensation and the ability to display electrogram data on the 3D (Kabra & 
Singh, 2010). 
4. Electroanatomic mapping: ENSITE  
The ENSITE system (Endocardial Solutions, St. Jude Medical, Inc., St. Paul, MN, USA) has two 
different techniques for mapping: the contact mapping system, wherein points assimilate 
anatomic and physiologic information in reference to five location patches applied to the 
skin at different places, and the non-contact mapping by a balloon array.  
 
 
Fig. 8. Electroanatomical map acquired by the NavX system. (Top) Activation map of the left 
atrium during sinus rhythm, AP and PA views. (Bottom) Simultaneously-acquired voltage 
map of the left atrium. Image taken from Bhakta & Miller, 2008. 
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The contact mapping system, NavXTM, is capable of displaying 3D positions of many 
catheters. This is achieved by applying a 5.6 kHz current through orthogonally-located skin 
patches on the patient. The recorded voltage and impedance at each catheter's electrodes 
generated from this current allows their distance from each skin patch to be triangulated 
with the help of a reference electrode. This determines their positions in space and the three-
dimensional images of each catheter can then be displayed (Figure 8). Chamber geometry 
can be determined thereafter by moving a mapping catheter along the endocardial surface 
(Bhakta & Miller, 2008).  
The non-contact mapping proceeds by using a multi electrode array (MEA). The array is 
comprised of 64 braided surgical-steel wires with a polyimide coating. The unipolar 
electrodes are created by removing a small area of insulation for each wire. The MEA is 
introduced into the body, like any other catheter through the femoral veins, and is inflated 
to 7.5 ml after positioning it at the centre of the chamber of interest (Figure 9).  
 
 
Fig. 9. Multielectrode array balloon catheter and in its deployed state. Image courtesy of 
Endocardial Solutions. 
The balloon electrodes make galvanic contact with the blood and sense the electrical 
potentials induced upon them by the electrical fields generated by myocardial activity. Two 
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focused studies on noncontact mapping. They used the array in 20 patients with idiopathic 
ventricular tachycardia from the right ventricular outflow tract, left ventricle, or aortic root 
and achieved acute success in 17 of 18 patients for whom ablation was attempted with only 
three recurrences (LaPage & Saul, 2011). Previous versions of Ensite have been accurate 
within 0.7 ± 1.5mm. 
 
 
Fig. 10. Electroanatomic maps acquired by using a MEA. (Left) Activation map of macro-re-
entrant LA flutter. The arrows depict wave front propagation within the flutter circuit. 
(Right) Anatomical reconstruction of the RA. Image taken from Bhakta & Miller, 2008. 
4.1 Advantages/disadvantages 
The strengths of the ENSITE technology are: (i) accurate heart chamber reconstruction, (ii) 
ability to use with any other catheter, (iii) respiratory and cardiac motion compensation, (iv) 
multiple catheter location display, and (v) useful in treating poorly sustained arrhythmias. 
The weaknesses include: (i) inaccurate anatomical reconstructions, (ii) limited utility in non-
sustained arrhythmias, and (iii) difficult balloon deployment. 
4.2 Clinical study  
Recently, two clinical studies were performed to assess the impact of the NavX mapping 
system when compared to conventional fluoroscopy ablation.  
The first study (Kwong et al, 2011) sought to assess the impact on paediatric catheter ablation 
fluoroscopy times. The authors retrospectively analysed the procedural data during a 7-year 
period (2002–2008), which spanned the transition between the standard fluoroscopic 
mapping and adoption of routine NavXTM mapping for catheter ablation of atrioventricular 
nodal re-entrant tachycardia (AVNRT) and right-/left-sided accessory pathways (RAP/LAP). 
Overall, success rates were similar between the two mapping systems (95.7% for conventional 
vs. 95.9% for NavXTM). Secondly, NavXTM mapping significantly reduced the ablation fluoro 
time (15.9 + 14.3 min vs. 11.0 + 8.9 for NavXTM) with a trend towards a decrease in total fluoro 
time (26.4 + 15.6 min vs. 23.8 +11.1 for NavXTM). Lastly, the total procedure time was not 
significantly different between the two methods (210.1 + 66 vs. 222.8 + 61 min for NavXTM, P ¼ 
0.7). (Kwong et al, 2011) concluded that the NavXTM mapping reduced ablation fluoro times 
during paediatric catheter ablation, particularly in accessory pathways. 
The second study (Liu et al., 2011) was to probe the feasibility and safety of non-fluoroscopic 
radiofrequency catheter ablation of atrioventricular nodal re-entrant tachycardia guided by 
Ensite NavX system. Non-fluoroscopic radiofrequency catheter ablation navigated by NavX 
system was performed in 18 cases (mean age 52.8 + 16.1 years, range 24–77 years) of 
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atrioventricular nodal re-entrant tachycardia with normal cardiac anatomy. Using NavX, right 
atrial and coronary sinus geometries were reconstructed. Diagnostic electrophysiological 
study and radiofrequency catheter ablation were performed in all patients without use of 
fluoroscopy. Each site with His bundle potential were mapped and marked in the 3D 
geometry before ablation. The real-time position of ablation catheter was confirmed by the 
relative position between CS catheter and ablation catheter, which were monitored 
simultaneously in the Ensite NavX system. The authors show the success rate of procedure 
was 100%. The fluoroscopic duration of each case was zero. The average procedure duration 
was 97.5 + 19.8 min (55–125 min, the coronary sinus access was obtained in 13.4 + 7.3 min 
(8–30 min). (Liu et al., 2011) conclude that the preliminary study suggests that non-
fluoroscopic catheter navigation for radiofrequency catheter ablation of atrioventricular nodal 
re-entrant tachycardia is safe and feasible. 
5. Remote navigation systems 
Is robotic guidance for cardiac ablation procedures the future? We attempt to answer this 
question in this section. Remote navigation systems or robotic cardiac catheter ablation was 
essentially developed to eliminate potential errors in catheter manipulation. Also, the use of 
robots could systematically decrease clinician fatigue and fluoroscopy exposure. Some 
electrophysiologists agree that areas between mitral valves and pulmonary veins are 
typically difficult to reach and position correctly the mapping catheter. Robotics can thus 
provide more accuracy in these cases. Currently there are two robotic systems –the Niobe 
Stereotaxis Magnetic Navigation System (Stereotaxis, Inc., St Louis, Missouri, USA) and the 
Hansen Sensei Robotic Catheter System (Hansen Medical, Mountain View, California, USA) 
depicted in Figure 11 and Figure 12. Both systems allow the physician to perform the 
mapping and ablation procedure while sitting in a control room remote from the patient 
[LaPage & Saul, 2011]. 
 
 
Fig. 11. The Hansen Sensei Robotic catheter system. Image taken from Hansen Medical. 
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Fig. 12. Stereotaxis' Remote Magnetic Navigation System. Image taken from Stereotaxis.com. 
The Stereotaxis system has been around for nearly a decade. Multiple studies have been 
published regarding its utility and several excellent review papers on the technology have 
been published (Xu et al., 2009; Wu et al., 2010 ; Thornton et al., 2010 ). The catheter has a 
magnet near the distal tip that can be oriented in any position using the fields produced by 
two magnets positioned bilaterally to the patient (LaPage & Saul, 2011). As an example 
application of Stereotaxis, (Azizian & Patel, 2011) used a magnetic tracking device to track 
the distal part of the ablation catheter in real time and a master-slave robot-assisted system 
is developed for actuation of a steerable catheter. The Sensei system facilitates catheter 
navigation through two coaxial sheaths steered with a pull wire mechanism controlled 
through a joystick remote control. The system is relatively novel and no pediatric applicable 
studies have been published. (Schmidt et al., 2009) achieved a high success rate using it for 
atrial fibrillation ablation and found the system equally compatible with both the CARTO 
and ENSITE systems. (LaPage & Saul, 2011) Both of these technologies have been integrated 
with electroanatomic mapping systems to store catheter location information for semi-
automated re-navigation to regions of interest. These systems translate the operator’s 
manipulation of a handle into precise movements of the catheter, thus allowing barely 
accessible regions of the heart to be reached, to create detailed electroanatomic mappings 
and precise ablation lesions (Casella et al., 2010). 
5.1 Advantages/disadvantages 
The strengths of the Sensei Hansen technology are: (i) can be used with any electroanatomic 
mapping system described previously, (ii) no fidelity devices or distortion effects, and (iii) 
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catheter stability. The limitations include: (i) sheath diameter and lengths and (ii) no catheter 
restriction. 
The strengths of the Niobe Stereotaxis technology include: (i) low risk of perforation in 
anatomy, (ii) numerous experiments and trials published, (iii) semiautomatic mapping, and 
(iv)no fidelity devices or distortion effects. The limitations include: (i) restricted to expensive 
magnetic catheters, (ii) non real-time movement, and (iii) patients that have implanted 
devices. 
5.2 Clinical study  
(Chong et al., 2011a) performed two clinical studies using the Niobe Stereotaxis system. The 
first study aimed at determining the effectiveness and safety of single magnetic-guided 
catheter in the ablation of outflow tract tachycardias. At the outset of the clinical study, 
patients with symptomatic outflow tract tachycardia on surface ECG and without structural 
heart disease were recruited. Electrophysiology study and ablation were performed with the 
use of a single Navistar RMT Thermocool 8F ablation catheter. Both activation and pace 
mapping of ventricular tachycardia were performed. Three dimensional localization, using 
CARTO, was performed during activation mapping. As comparison, the patients were 
compared with a cohort of similar patients undergoing conventional catheter ablation via 
fluoroscopy. The results demonstrated that ablation was successful in all patients. Secondly, 
there was no difference in median procedure time between Niobe Stereotaxis (153 min) and 
conventional fluoroscopy (136 min) ablation groups. Nevertheless, the median fluoroscopy 
time was significantly reduced in the Niobe Stereotaxis group (8 vs. 29 min). (Chong et al., 
2011a) concluded that the ablation of outflow tract ventricular tachycardia with a single 
magnetic-guided catheter is feasible, safe, and reduces fluoroscopy time. 
In their second study, (Chong et al., 2011b) aimed at outlining their experiences in the 
ablation of incessant ventricular tachycardia with the use of the remote Niobe Stereotaxis 
magnetic-guided catheter system. In the course of the 1-year study, three patients with 
incessant ventricular tachycardia were recruited. All underwent ablation with Navistar 
RMT Thermocool 8F catheter guided via the Niobe Stereotaxis system and three 
dimensional localization using CARTO. Upon completion of procedure two of the 
patients’ ventricular tachycardia could no longer be induced after successful ablation, and 
after a 12 month period, there was no recurrence. The third patient had ventricular 
ectopics and non-sustained ventricular tachycardia (NSVT) noted from two further sites 
these were ablated as well and there were no significant complications. Total fluoroscopy 
time was 17.4, 18.2, and 15.2 min, respectively, whereas the total procedure time was 3, 2, 
and 5 h, respectively. (Chong et al., 2011b) concluded that magnetic-guided catheter 
ablation is effective in the ablation of patients with incessant haemodynamically stable 
ventricular tachycardia. 
(Zvereva et al., 2011) performed a prospective study to compare the incidence of 
oesophageal lesions using either the remote navigation system from Hansen Sensei to a 
manual approach for pulmonary vein isolation using a radiofrequency catheter. A total of 33 
patients were recruited, 14 of which underwent manual approach. The oesophageal probe 
was placed and integrated with NavXTM. When temperature rose to .39 FXC, ablation was 
immediately stopped until temperature decreased. Lastly, endoscopy was performed within 
24 h after pulmonary vein isolation. Results demonstrated that in 2 of 19 patients with 
Hansen Sensei treatment had an oesophageal lesion found compared to only lesion found 
for 1 of 14 patients using the manual approach. Altogether, patients were comparable with 
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respect to arterial hypertension, incidence of paroxysmal and persistent atrial fibrillation, or 
left atrial diameter. The oesophageal lesions showed brisk healing after re-endoscopy within 
2 weeks in all patients. (Zvereva et al., 2011) concluded that the incidence of oesophageal 
lesions in patients using Hansen Sensei compared with manually performed ablation is 
similar when low power settings at the posterior wall are used.  
6. Ultrasound 
The flexibility and ease of use of ultrasound has made it the imaging modality of choice in 
many intraoperative surgery rooms and laboratories worldwide. In this section we discuss 
specific applications of the common ultrasound instrumentation used in the electrophysiology 
laboratory. 
6.1 CARTOSound  
An extension to the CARTO mapping technology enabling ultrasound integration was 
created recently and termed, CARTOSound (Biosense Webster Inc., Diamond Bar, California, 
USA). It creates a three-dimensional image of a specific heart chamber undergoing cardiac 
ablation by utilizing an intracardiac ultrasound catheter. A first study (Schwartzman, & 
Zhong, 2010) evaluated the use of CARTOSound for left atrial navigation during atrial 
fibrillation ablation. The authors first integrated the images obtained from CARTOSound 
into a preoperative CT (Figure 13) and then assessed the accuracy of the CARTOSound 
volume representation of the left atrium from each of four different ultrasound positions 
(RA, left atrium, coronary sinus, and esophagus). It turns out that the most accurate 
representation of the chamber was obtained with the ultrasound catheter placed in the left 
atrium. Hence, at first sight, the CARTOSound chamber representation was found to be as 
accurate as the CT image (LaPage & Saul, 2011). 
 
 
Fig. 13. The CARTOSound mapping technology that fused ultrasound images into the 
reconstructed volume. Image taken from Knecht et al., 2008. (doi: 10.1093/europace/eun227) 
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6.2 TEE imaging  
Recently, real-time 3D transoesophageal echocardiography (TEE) has become available for 
clinical practice, offering clear and detailed rendering of the cardiac anatomy. The 3D TEE 
probe (Matrix 3DTEE, Philips, Inc., Andover, MA) allows for both 2D and 3D real-time imaging 
of both the left atrium and pulmonary veins. 3D TEE also provides excellent visualisation of 
the interatrial septum (Chierda et al., 2008a). A small study implied that 3D TEE guidance 
might provide safer trans-septal puncture in patients with unusual anatomy (Chierda et al., 
2008b), as it offers the benefit of recognising some shapes of the atrial septum that are not well 
characterised by conventional two dimensional TEE. Despite these promising features, post-
acquisition image processing is necessary and time-consuming. Moreover, general anaesthesia 
along with endotracheal intubation would be mandatory (Casella et al., 2010). 
 
 
Fig. 14. The TEE probe and its tip sensor used to image left atrium or pulmonary veins 
during ablation procedures. Also shown is the TEE probe visible in X-ray. Image taken from 
King et al., 2010. 
 
 
Fig. 15. (First column) the TEE volume shows a deca-polar catheter positioned in right atrium 
and dots highlight the position of the deca-polar catheter in the background of the X-ray 
image. (Second column), a lasso catheter was inserted into the left atrium with TEE volumes 
registered to X-ray images. Image taken from King et al., 2010. 
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2008b), as it offers the benefit of recognising some shapes of the atrial septum that are not well 
characterised by conventional two dimensional TEE. Despite these promising features, post-
acquisition image processing is necessary and time-consuming. Moreover, general anaesthesia 
along with endotracheal intubation would be mandatory (Casella et al., 2010). 
 
 
Fig. 14. The TEE probe and its tip sensor used to image left atrium or pulmonary veins 
during ablation procedures. Also shown is the TEE probe visible in X-ray. Image taken from 
King et al., 2010. 
 
 
Fig. 15. (First column) the TEE volume shows a deca-polar catheter positioned in right atrium 
and dots highlight the position of the deca-polar catheter in the background of the X-ray 
image. (Second column), a lasso catheter was inserted into the left atrium with TEE volumes 
registered to X-ray images. Image taken from King et al., 2010. 
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6.3 ICE imaging  
The first catheter-based 2D echocardiography systems were developed in the late 20th 
century for intracoronary imaging. They had high frequencies (20–40 MHz) and limited 
depth of penetration, making them suitable only for intravascular applications (Robinson & 
Hutchinson, 2010). Over the years, there has been a significant improvement in the 
technology with the advent of low frequency (12.5 - 9 MHz) and more recently the phased 
array (5.5 - 10 MHz) transducers which have been miniaturized and mounted on the 
catheters capable of percutaneous insertion (Pandian et al, 1990; Packer et al. 2002). Phased 
array ICE imaging uses a 64-element transducer on the distal end of an 8-10 French catheter. 
These catheters are capable of M-mode, pulsed, continuous wave and color Doppler 
(Daoud, 2005; Ren et al., 2002; Verma et al., 2002; Ferguson et al., 2009; Kabra & Singh, 2010.) 
During intervention, once transseptal access is achieved, ICE facilitates visualization of the 
left atrial and pulmonary venous anatomy. It also helps to assess the electrode-tissue 
contact. The images of ICE can be integrated with the electroanatomic mapping systems 
(CARTOSound) to generate the geometry of left atrium. A recent study demonstrated the 
feasibility of catheter ablation of atrial fibrillation without fluoroscopy using intracardiac 
echocardiography and electroanatomic mapping (Ferguson, 2009). Advances in intracardiac 
echocardiography include creation of accurate, real time three-dimensional ultrasound 
geometries that may obviate the need for pre-procedure CT/MRI imaging for catheter 
ablation of atrial fibrillation (Okumura, 2008). Other advantages over CT and MRI include 
ICE offering the advantage of showing the real-time detailed anatomy of the cardiac 
chambers that can be updated multiple times during the procedure. Furthermore, creating a 
3D reconstruction without entering the LA may reduce procedural time, enhance the safety 
of catheter ablation procedures and eliminate geometrical distortion resulting from 
distension of the tissue. However, this technology bears an important financial burden 
because of the employment of expensive non-reusable ICE catheters (Casella et al., 2010). 
 
 
Fig. 16. ICE image showing left and right atriums, interatrial septum, needle tenting and left 
pulmonary veins. Image taken from Robinson & Hutchinson, 2010. 
 




In summary, this chapter presented the latest findings involving several electroanatomical 
mapping systems that are available to assist electrophysiologists in treating arrhythmias. 
Techniques are still evolving to address the challenge of a catheter-based cure. The 
chapter indicates that the registration of MRI/CT images to the existing fluoroscopy 
image or 3D anatomical map can facilitate navigation of the ablation catheter. In addition, 
robotic catheter navigation is now available as well. Each method, whether it is the 
conventional fluoroscopic treatment or the more sophisticated remote navigation systems 
has its own merits and weaknesses. While all these systems provide a wealth of data and 
reduce fluoroscopy times slightly, they cannot replace careful interpretation of data and 
strict adherence to electrophysiologic principles. Although these benefits are achieved at a 
greater cost, there may be long-term benefits to the community and catheter laboratory 
staff. 
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1. Introduction 
Despite advances in emergency response and critical care, good neurologic outcome after 
cardiac arrest is difficult to achieve, and interventions during the resuscitation phase and 
treatment within the first hours after the event are crucial. Although recommended by 
organizations such as the American Heart Association (AHA) and the International Liaison 
Committee on Resuscitation (ILCOR), implementation of induced mild therapeutic 
hypothermia for survivors of cardiac arrest in the United States has been slow, at least in 
part, because of the perception that this therapy is technically difficult, especially at the 
community level. In this chapter, we review the pathophysiology, cooling techniques, 
clinical evidence and uses (including costs), and effectiveness of induced mild therapeutic 
hypothermia in adult patients after cardiopulmonary resuscitation, using any cooling 
method applied within six hours of arrest. Neurologic outcome, survival and adverse events 
are the main outcome parameters outlined here. In addition, we also include a discussion of 
the applicability of mild therapeutic hypthermia for both academic health centers and 
community hospitals, as well as areas of uncertainty, guidelines, and recommendations.  
2. Epidemiology of cardiac arrest 
The incidence of out-of-hospital sudden cardiac arrest in industrialized countries is about 62 
cases per 100,000 a year making sudden cardiac arrest a major cause of death in the United 
States amounting to more than 300,000 occurrences of cardiac arrests outside of hospital each 
year (Adler et al, 2011). Resuscitation is attempted on roughly 100,000 of these arrest patients 
but results in only 40,000 patients who survive upon arrival to the hospital (Holzer, 2010). 
Despite advances in emergency medical services the mortality and morbidity associated 
with out-of hospital cardiac arrest is high. In 2006, the National Registry of 
Cardiopulmonary Resuscitation (CPR) published statistics on 19,819 adults and 524 children 
with return of spontaneous circulation after cardiac arrest. The mortality rates were 67% 
among adults and 55% among children (Jacobshagen et al, 2010). Currently, less than half of 
cardiac arrest patients survive to discharge and less than a third of those discharged have a 
good neurologic outcome as defined by the Cerebral Performance Category (CPS) Scale 
(Adler et al, 2011). The cost of caring for patients with poor neurologic function within the 
first six months alone can range anywhere from $10,000 to $300,000, with an increasing 
morbidity generally associated with increasing cost (Merchant et al, 2009). 
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3. Pathophysiology of induced mild therapeutic hypothermia  
The brain receives approximately 15% of the human resting cardiac output despite 
comprising 1-2% of our total body weight, illustrating the high metabolic demands 
associated with the brain. During cardiac arrest the blood supply is interrupted leading to 
global cerebral ischemia. 
Ischemic events are especially detrimental to the brain and are a major cause of morbidity in 
cardiac arrest survivors. Areas such as the hippocampus, neocortex, cerebellum, corpus 
striatium, and thalamus are the most vulnerable to global ischemia. Necrosis and apoptosis 
have both been reported in cardiac arrest victims and it still is unclear the extent to which 
each of these processes contribute to neuronal cell death. The brain is damaged through an 
ischemic cascade of events occurring on a time scale of minutes-to-days after cardiac arrest 
and is summarized below.  
A lack of oxygen hinders the neurons ability to produce ATP. Consequently, cells switch to 
anaerobic metabolism which consumes glucose and produces lactic acid. As glucose 
concentrations are exhausted, ion transporters using ATP fail to function. Cells become 
depolarized allowing ions, including calcium, to flow into the cell. Due to the lack of ATPase 
activities, cells cannot pump calcium out of the intracellular space, and as intracellular 
calcium levels rise they trigger the release of excitatory neurotransmitters. Glutamate, one of 
the excitatory neurotransmitters, acts on AMPA and NMDA receptors to allow more 
calcium into cells and thereby increases the intracellular calcium leading to production of 
neurotoxic chemicals such as free radicals, reactive oxygen species and calcium-dependent 
enzyme (Sinclair & Andrews, 2010). This process is referred to as excitotoxicity. Calcium-
dependent enzymes such as calpain, endonucleases, and phospholipases break down cells 
making them more permeable to harmful chemicals and leads to damage of the 
mitochondrial membrane, ultimately causing release of pro-apoptotic factors that stimulate 
the caspase cascade and inducing cell suicide. Cells that die due to necrosis cause a release 
of glutamate and other neurotoxic compounds that act on surrounding cells and perpetuate 
excitotoxicty.  
Hypothermia exerts its effect on the ischemic cascade mentioned above to improve 
neurologic outcome after cardiac arrest. The following discussion will elaborate on mild 
therapeutic hypothermia and how it mitigates the pathologic processes involving: 1) blood-
brain barrier permeability and edema, 2) inflammation, 3) metabolism, 4) excitotoxicity, 5) 
intracellular calcium-dependent signaling 6) cerebral vascular effects, and 7) neuronal cell 
death. 
3.1 Blood-brain barrier permeability and edema 
The blood-brain barrier displays increased permeability after ischemia and allows the 
entrance of water, electrolytes, and potentially toxic substances into the brain 
parenchyma. Hypothermia has been shown to decrease the extravasation of certain 
protein markers such as horseradish peroxidase from the serum into the brain. Studies 
have also demonstrated that treatment with hypothermia in focal ischemia results in a 
decrease in brain water content as measured by MRI, and leads to a reduction in the 
diffusion of water into the brain and a consequent reduction in vasogenic edema by 
alleviating blood-brain barrier injury (Sinclair & Andrews, 2010). Vasogenic edema is a 
result of damage to the blood-brain barrier and the passage of large osmotically-active 
proteins like albumin into the brain. 
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The attenuation of matrix metalloproteases is another effect of hypothermia that reduces the 
permeability of the blood-brain barrier. Matrix metalloproteases are important for the 
extravasation of several substances into the brain including immunologic and other 
inflammatory cells. Reducing movement of these cells into the brain decreases deleterious 
edema associated with inflammatory immune responses to ischemia and neuronal cell 
injury. 
3.2 Inflammation and immune response 
Hypothermia mitigates the inflammation response by reducing the leukocyte extravasation 
as well as the endogenous inflammatory response of the brain to ischemia. Astrocytes and 
microglia respond to tissue damage in the brain by proliferating and secreting large 
quantities of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-1 
which recruit cells of the immune system. Hypothermia reduces the activation of astrocytes 
and microglia thereby reducing the pro-inflammatory signaling and the ensuing immune 
response (Sinclair & Andrews, 2010). 
The inflammatory response in the brain also results in the release of reactive oxygen species 
by astrocytes and microglia. Hypothermia, therefore, also reduces the levels of potentially 
damaging free radicals such as superoxide, nitric oxide, and hydroxyl radicals within the 
brain by decreasing their secretion from microglia and astrocytes. Hypothermia also 
increases the levels of superoxide dismutase, the enzyme that clears superoxide from the 
body, and decreases nitric oxide synthase, the enzyme responsible for production of nitric 
oxide. This reduction in reactive oxygen species production and increase in reactive oxygen 
species scavenger enzymes results in decreased neuronal damage.  
3.3 Metabolism 
Hypothermia has been proven to decrease glucose utilization. Studies implementing 2-
deoxyglucose, a glucose analog that can be taken up by glucose transporters but not 
digested, has shown that hypothermia decreases utilization of glucose when compared to 
normothermia. Global ischemia affects the brain more than the liver due to the small stores 
of glycogen found in the brain compared to large stores found in the liver. Therefore, any 
reduction in glucose utilization will attenuate the damaging effects of poor cerebral 
perfusion. Hypothermia reduces the metabolic demands of the cell, preserving cellular ATP 
concentration more effectively when compared to normothermia. Reducing core 
temperature 1°C decreases metabolic rate by approximately 6%-8% (Adler et al, 2011). 
The cell’s ability to maintain electrochemical gradients depends heavily upon ATP 
concentrations. Loss of transmembrane electrochemical gradients directly precedes failure of 
synaptic transmission and axonal conduction. Hypothermia’s ability to reduce metabolic 
demands, preserve ATP, and potentiate electrochemical gradients translates to better 
neurologic outcomes after recovery from cardiac arrest.  
3.4 Excitotoxicity 
The metabolic depletion of ATP associated with ischemia in cardiac arrest results in an 
inappropriate release of excitatory neurotransmitters such as glutamate. A reduction in the 
blood flow to the brain allows levels of glutamate to build up in the extracellular space 
around neurons. This rise in glutamate leads to activation of glutamatergic receptors AMPA 
(alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and NMDA (N-methyl d-
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aspartate). Glutamate acts through AMPA and NMDA to produce an influx of calcium from 
the extracellular fluid to the intracellular fluid. This inflow of calcium can injure the cell by 
initiating several cascades within the cell including, free radical generation, mitochondrial 
injury, and ultimately apoptosis (Nolan et al, 2008). Hypothermia inhibits the release of 
glutamine and dopamine while also inducing neurotrophic factors that further reduce 
glutamine release. 
3.5 Intracellular calcium-dependent signaling 
Global ischemia leads to an increase in intracellular calcium, thereby affecting normal 
signaling protein kinases in the cell. Proteins such as calmodulin-dependent kinase II 
(CaMKII) and protein kinase C (PKC) are rescued by hypothermia (Sinclair & Andrews, 
2010). These proteins, as well as other signaling factors, are temperature-sensitive. 
Controlling signaling factors and proteins such as CaMKII and PKC through hypothermia 
influences neuronal injury and normal cell signaling. 
3.6 Cerebral vascular and cellular effects 
Hypothermia affects secretion of vasoactive substances such as endothelin, thromboxane A2, 
and prostaglandin I2 in the brain. Endothelin and thromboxane A2 have vasoconstrictive 
effects while prostaglandin I2 is a vasodilator. Thromboxane A2, endothelin, and 
prostaglandin I2 mediate vascular homeostasis in the brain; during ischemic and traumatic 
events homeostatic balance is shifted towards vasoconstriction, hypoperfusion, and thrombus 
formation. Hypothermia has been shown in animal models and small clinical studies to alter 
the response to injury by attenuating the vasconstrictive response. However, regulation of 
cerebral perfusion is complex and dependent on several factors including the presence or 
absence of cerebral autoregulation, ventilator settings, serum blood gas levels, systemic blood 
pressure, osmotic therapy, etc (Sinclair & Andrews, 2010). 
Necrosis and apoptosis are the result of prolonged tissue ischemia and can be influenced by 
hypothermia. Several gene families associated with apoptosis are temperature-sensitive. 
Brain cells can sense irreversible injury and begin the process of self-destruction. 
Hypothermia leads to a delayed response of the cell to injury and this slowed response is 
mediated by a delay in genetic regulation (Sinclair & Andrews, 2010). Ultimately, 
hypothermia slows secondary injury and apoptosis through delaying the cells initial 
reaction to damage. Apoptosis occurs over the time frame of hours-to-days making 
hypothermia a major factor in mitigating apoptosis during the post-resuscitation phase. 
4. Cooling methods 
Several different cooling techniques are available for use in therapeutic hypothermia; 
however, all of the various techniques fall into two general categories: surface cooling and 
core cooling. Surface cooling can be carried out in two ways; the first utilizes pre-cooled 
pads while the second makes use of heat-exchanging mattresses or pads. Surface cooling 
was used in the two hallmark clinical trials carried out in 2003 in Europe and Australia that 
first demonstrated the beneficial effects of hypothermia on witnessed cardiac arrest 
survivors (Bernard et al, 2003; Holzer & Sterz, 2003). 
Core cooling can be achieved with the use of intravascular cooling catheters filled with cold 
saline or by intravenous injection of cold fluids. Devices for core cooling and surface cooling 
have been specifically designed for use in therapeutic hypothermia but the ultimate goal, 
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whether using either surface or core cooling methods, is to rapidly cool the patient and 
maintain a stable temperature between 32-34°C for at least 24 hours. 
Various measurements and devices may be used to monitor relevant core body 
temperature including esophageal probes, endotracheal tube cuff monitors, and non-
invasive continuous cerebral temperature monitoring (Zeiner et al, 2010; Haugk et al, 
2010). During the initial phase of head and neck cooling, jugular bulb temperature (Tjb), 
(which may reflect brain temperature) appears to be lower than esophageal temperature 
(Wandaller et al, 2009). 
4.1 Surface cooling 
4.1.1 Ice packs 
Ice packs are an inexpensive and easy technique to initiate cooling. However, they can be 
messy and less effective at cooling and maintaining target temperature. Ice packs can be 
placed all over the body, but are more effectively placed in anatomic areas that have large 
heat-exchange capability due to their blood flow. These areas include the head, neck, axillae, 
and groin. The average temperature drop attained by using ice packs is between 0.03-0.98°C 
per hour (Adler et al., 2011). 
4.1.2 Blankets or surface heat-exchange devices 
Conventional surface cooling blankets are not ideal because of poor surface contact with the 
patient’s skin. Generally, water-circulating cooling devices and ice packs used in 
combination can be effective at rapidly cooling patients. Many clinical studies have used this 
combination as their cooling technique. The patient is sandwiched between two blankets or 
cooling devices and ice packs are then applied. Once target temperature is achieved, the ice 
packs are removed and the blanket or cooling devices are used alone to maintain the target 
temperature. Newer cooling devices, specific for use in therapeutic hypothermia, use an 
adhesive gel to facilitate heat exchange that make them more effective at obtaining and 
maintaining target temperature. 
Weihs and coworkers (2011) used adult, human-sized pigs to study the importance of 
surface area for the cooling efficacy of mild therapeutic hypothermia. Each of five adult, 
human-sized pigs (88-105 kg) was randomly cooled in three phases with pads that covered 
different areas of the body surface corresponding to humans (100% or 30% [thorax and 
abdomen] or 7% [neck]). The cooling pads were effective and safe for rapid induction of 
mild hypothermia in these porcine simulators. depending on the percentage of body surface 
area covered. Extrapolating to humans, covering only the neck, chest, and abdomen may 
achieve satisfactory cooling rates. 
Convective-immersion surface cooling using a continuous shower of 2 degrees C water 
(ThermoSuit System) has also been found to be a rapid, effective method of inducing 
therapeutic hypothermia (Howes et al, 2010) and demonstrated improvement in survival 
and neurologic outcome in swine compared to normothermia (Weihls et al, 2008).  
4.1.3 Cooling helmet 
Helmet cooling devices are also available and have been used in some clinical trials. These 
helmets contain a solution of glycerol that facilitates heat exchange. Although this method is 
effective in cooling the brain it is much slower at reducing overall body temperature when 
compared to other methods. 
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4.2 Core cooling 
4.2.1 Catheter-based technologies 
Catheter-based technologies are usually placed in the femoral vein and provide heat 
exchange between the cooled saline that passes through a large coil in the catheter and the 
blood. The coiling provides a mechanism to increase surface area, thereby increasing the 
heat exchange between blood passing over the catheter. Internal cooling and rewarming is 
much faster and superior to other techniques in tightly regulating target temperature; it is 
possible to cool patients by 1.46°C - 1.59°C per hour (Jacobshagen et al, 2010). A potential 
advantage of using catheter-based cooling combined with anxiolytics is that it may avoid 
the need to use paralytics to decrease the shiver seen in surface cooling techniques.  
4.2.2 Cold fluid infusion 
Several studies have made use of intravenous cold fluid infusion for the induction of 
hypothermia. The rates of infusion differ between studies but the overall outcome is rapid 
cooling of the patient. Cold fluid infusion is a means of inducing hypothermia and cannot be 
used in the long-term maintenance of hypothermia. Usually, cold fluid infusions are used in 
conjunction with surface cooling methods to regulate and maintain patient body 
temperature. Most studies have used either normal saline or lactated Ringer solution as their 
cooling fluids. Evidence from reports using cold fluid infusion have not been associated 
with increased venous pressure, left atrial filling pressures, pulmonary pressures, 





Cooling Advantages Disadvantages 
Surface 
Cooling 
Ice packs Inexpensive can be implemented very quickly. 
Slow rate of cooling and provides 





Fair regulation of target 
temperature once it is 
obtained. 
Slow rate of cooling unless used in 
conjunction with other techniques.  
Cooling helmet 
Fair regulation of target 
temperature once it is 
obtained. 
Slowest rate of cooling among 
techniques unless used in 





Rapid rate of cooling, tight 
target temperature regulation, 
minimize shiver and possible 
avoidance of paralytic usage. 
Increased chance of thrombus 
formation 
Infusion of cold 
fluids Rapid rate of cooling 
Poor regulation of target 
temperature 
Table 1. Cooling Technique Summary 
5. Clinical evidence and uses 
5.1 Clinical studies 
The abovementioned landmark clinical trials from Europe and Australia, respectively, in 
2003 established the benefits of hypothermia and have served as the basis for subsequent 
therapeutic hypothermia guidelines and clinical trials. Most clinical trials evaluate the 
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benefits of hypothermia by scoring patients on the CPC Scale, a tool that rates a patient’s 
neurologic status, or by measuring survival rates. 
The European trial enrolled 275 patients whose cardiac arrest was caused by ventricular 
fibrillation or pulseless ventricular tachycardia. Patients were randomly assigned to either 
hypothermic (n = 137) or normothermic (n = 138) groups. Hypothermic subjects were cooled 
to between 32-34°C for 24 hours with a cold air mattress. The primary endpoint of this study 
was to establish a favorable neurologic outcome in patients six months after cardiac arrest. 
The authors found that 55% of surviving hypothermic patients had a favorable neurologic 
outcome, as defined by a score of 1 or 2 on the CPC Scale, compared to 39% of surviving 
normothermic patients. A secondary endpoint was to evaluate complications within the first 
seven days after cardiac arrest, and mortality rate at six months. The European study 
demonstrated that neurologic outcome, as well as patient survival at six months (55% vs. 
41%), both significantly improved in the hypothermic group as compared to the 
normothermic group (Holzer, 2002). 
In the Australian trial, 77 comatose cardiac arrest survivors with ventricular fibrillation or 
pulseless ventricular tachycardia as the initial rhythm were similarly assigned to 
normothermic (n = 34) or hypothermic (n = 43) groups based on randomization. The 
hypothermic group was cooled to 33°C with ice packs for 12 hours and showed a 49% 
survival with favorable neurologic outcome (i.e., discharged home or to a rehabilitation 
facility, with no or moderate disability ), while the normothermic group had a 26% survival 
with favorable neurologic outcome at hospital discharge (Bernard et al, 2002).  
In 2009, Arrich and colleagues performed a Cochrane systematic review and meta-analysis 
to assess the effectiveness of therapeutic hypothermia in patients after cardiac arrest. 
Neurologic outcome, survival and adverse events were the main outcome parameters. The 
authors included all randomized controlled trials assessing the effectiveness of the 
therapeutic hypothermia in patients after cardiac arrest without language restrictions. 
Studies were restricted to adult populations cooled with any cooling method applied within 
six hours of cardiac arrest. Four trials and one abstract reporting on 481 patients were 
included in the systematic review. Quality of the included studies was good in three out of 
five included studies. For the three comparable studies on conventional cooling methods all 
authors provided individual patient data. With conventional cooling methods patients in 
the hypothermia group were more likely to reach a best cerebral performance category score 
of 1 or 2 (CPC, 5-point scale; 1 -- good cerebral performance, to 5 -- brain death) during 
hospital stay (individual patient data; RR, 1.55; 95% CI 1.22 to 1.96) and were more likely to 
survive to hospital discharge (individual patient data; RR, 1.35; 95% CI 1.10 to 1.65) 
compared to standard post-resuscitation care. Across all studies, there was no significant 
difference in reported adverse events between hypothermia and control. The authors 
concluded that conventional cooling methods to induce mild therapeutic hypothermia seem 
to improve survival and neurologic outcome after cardiac arrest, and their review supports 
the current best medical practice as recommended by the International Resuscitation 
Guidelines. 
Testori and colleagues (2011) retrospectively studied 347 cardiac arrest survivors aged > 
18 years suffering a witnessed out-of-hospital cardiac arrest with asystole or pulseless 
electric activity as the first documented rhythm, for whom hypothermia was induced in 
135 patients. They found that subjects who were treated with mild therapeutic 
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much faster and superior to other techniques in tightly regulating target temperature; it is 
possible to cool patients by 1.46°C - 1.59°C per hour (Jacobshagen et al, 2010). A potential 
advantage of using catheter-based cooling combined with anxiolytics is that it may avoid 
the need to use paralytics to decrease the shiver seen in surface cooling techniques.  
4.2.2 Cold fluid infusion 
Several studies have made use of intravenous cold fluid infusion for the induction of 
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benefits of hypothermia by scoring patients on the CPC Scale, a tool that rates a patient’s 
neurologic status, or by measuring survival rates. 
The European trial enrolled 275 patients whose cardiac arrest was caused by ventricular 
fibrillation or pulseless ventricular tachycardia. Patients were randomly assigned to either 
hypothermic (n = 137) or normothermic (n = 138) groups. Hypothermic subjects were cooled 
to between 32-34°C for 24 hours with a cold air mattress. The primary endpoint of this study 
was to establish a favorable neurologic outcome in patients six months after cardiac arrest. 
The authors found that 55% of surviving hypothermic patients had a favorable neurologic 
outcome, as defined by a score of 1 or 2 on the CPC Scale, compared to 39% of surviving 
normothermic patients. A secondary endpoint was to evaluate complications within the first 
seven days after cardiac arrest, and mortality rate at six months. The European study 
demonstrated that neurologic outcome, as well as patient survival at six months (55% vs. 
41%), both significantly improved in the hypothermic group as compared to the 
normothermic group (Holzer, 2002). 
In the Australian trial, 77 comatose cardiac arrest survivors with ventricular fibrillation or 
pulseless ventricular tachycardia as the initial rhythm were similarly assigned to 
normothermic (n = 34) or hypothermic (n = 43) groups based on randomization. The 
hypothermic group was cooled to 33°C with ice packs for 12 hours and showed a 49% 
survival with favorable neurologic outcome (i.e., discharged home or to a rehabilitation 
facility, with no or moderate disability ), while the normothermic group had a 26% survival 
with favorable neurologic outcome at hospital discharge (Bernard et al, 2002).  
In 2009, Arrich and colleagues performed a Cochrane systematic review and meta-analysis 
to assess the effectiveness of therapeutic hypothermia in patients after cardiac arrest. 
Neurologic outcome, survival and adverse events were the main outcome parameters. The 
authors included all randomized controlled trials assessing the effectiveness of the 
therapeutic hypothermia in patients after cardiac arrest without language restrictions. 
Studies were restricted to adult populations cooled with any cooling method applied within 
six hours of cardiac arrest. Four trials and one abstract reporting on 481 patients were 
included in the systematic review. Quality of the included studies was good in three out of 
five included studies. For the three comparable studies on conventional cooling methods all 
authors provided individual patient data. With conventional cooling methods patients in 
the hypothermia group were more likely to reach a best cerebral performance category score 
of 1 or 2 (CPC, 5-point scale; 1 -- good cerebral performance, to 5 -- brain death) during 
hospital stay (individual patient data; RR, 1.55; 95% CI 1.22 to 1.96) and were more likely to 
survive to hospital discharge (individual patient data; RR, 1.35; 95% CI 1.10 to 1.65) 
compared to standard post-resuscitation care. Across all studies, there was no significant 
difference in reported adverse events between hypothermia and control. The authors 
concluded that conventional cooling methods to induce mild therapeutic hypothermia seem 
to improve survival and neurologic outcome after cardiac arrest, and their review supports 
the current best medical practice as recommended by the International Resuscitation 
Guidelines. 
Testori and colleagues (2011) retrospectively studied 347 cardiac arrest survivors aged > 
18 years suffering a witnessed out-of-hospital cardiac arrest with asystole or pulseless 
electric activity as the first documented rhythm, for whom hypothermia was induced in 
135 patients. They found that subjects who were treated with mild therapeutic 
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hypothermia at a temperature of 32-34°C for 24 hours were more likely to have good 
neurologic outcomes in comparison to patients who were not treated with hypothermia, 
with an odds ratio of 1.84 (95% confidence interval: 1.08-3.13). In addition, the rate of 
mortality was significantly lower in the hypothermia group (odds ratio: 0.56; 95% 
confidence interval: 0.34-0.93).  
While shortening the delay from spontaneous circulation to hypothermic target temperature 
has been theorized as a way of improving survival and neurologic outcome, randomized 
controlled trials and clinical registries have not shown evidence of whether the time to 
target temperature correlates with neurologic outcome. A recent study has reported that in 
comatose cardiac arrest patients treated with therapeutic hypothermia after return of 
spontaneous circulation, a faster decline in body temperature to the 34°C target appears to 
predict an unfavorable neurologic outcome (Haugk, 2011). Among 588 survivors of cardiac 
arrest managed with therapeutic hypothermia, the median time from restoration of 
spontaneous circulation to reaching a temperature of less than 34°C was 209 minutes 
(interquartile range [IQR]: 130-302) in patients with favorable neurologic outcomes 
compared to 158 minutes (IQR: 101-230) (p < 0.01) in patients with unfavorable neurologic 
outcomes. The adjusted odds ratio for a favorable neurologic outcome with a longer time to 
target temperature was 1.86 (95% CI 1.03 to 3.38, p = 0.04). Whether faster cooling is 
detrimental or patients with more severe neurologic damage show a faster cooling rate has 
to be further evaluated.  
Animal and human studies have suggested that hypothermia impairs renal function. Zeiner 
et al (2004) reported that 24 hours of mild therapeutic hypothermia was associated with a 
delayed improvement in renal function that was not reflected in serum creatinine values, 
and this transient impaired renal function appeared to be completely reversible within 4 
weeks. In trying to determine the  relationship between acute kidney injury on survivors of 
cardiac arrest treated with therapeutic hypothermia we found that the incidence of acute 
kidney injury in patients with a CPS 1 or 2 score was 13.6% compared to 86.4% in patients 
with a CPS score > 2 (p < 0.001) (J. Prior, personal communication). Stage 3 acute kidney 
injury correlated with poor neurologic outcome (p = 0.04) but there was no correlation 
between Stages 1 and 2 and neurologic recovery. A longer duration of cardiac arrest was 
predictive of the subsequent development of acute kidney injury (p = 0.01). In summary, the 
presence of acute kidney injury in survivors of cardiac arrest treated with therapeutic 
hypothermia appears to be associated with poorer neurologic function determined at the 
time of hospital discharge. Acute kidney injury in this population may serve as a marker for 
the severity of anoxic injury incurred during arrest.  
5.2 Indications and contraindications 
5.2.1 Indications  
The AHA has recommended that therapeutic hypothermia is indicated in adult patients 
with out-of-hospital cardiac arrests and who have an initial rhthym of ventricular fibrillation 
or nonperfusing ventricular tachycardia, that are comatose or have a Glasgow coma score < 
8, that are hemodynamically stable, and lack a verbal response. Although these are the 
criteria for which hypothermia is recommended, there are other patients that may benefit 
from therapeutic hypothermia such as post-resuscitation patients having initial rhthyms 
other than ventricular fibrillation or nonperfusing ventricular tachycardia, as well as in-
hospital cardiac arrest patients. 
 





 Survivors of witnessed out-of-hospital cardiac arrest of suspected cardiac origin 
 
 Persons with a Glasgow Coma Scale < 8  
    
 Persons with ventricular fibrillation or non-perfusing ventricular tachycardia 
 (those with other rhythyms such as asystole or electomechanical dissociatrion may  
 also benefit although firm data is lacking) 
  
 Persons who are hemodynamically stable (those in cardiac shock may also benefit 
 although firm data is lacking)  
  
 Consider for survivors of in-hospital cardiac arrest (although firm data is lacking) 
 _________________________________________________________________________ 
* Adapted from Holzer 2010. 
Table 2. Summary of indications for induced therapeutic hypothermia in comatose survivors 
of cardiac arrest.  
5.2.2 Contraindications 
Exclusion criteria for the use of therapeutic hypothermia are based upon increased risks to the 
patient. Studies have reported increased but non-significant increases in risk for the following 
patients: having major surgery within the previous 14 days; having systemic infections or 
sepsis, in a coma which is non-cardiac in origin, having active known bleeding or inherited 
bleeding disorder, being pregnant or terminally ill, those with a do-no-resuscitate (DNR) 
order, or having a tympanic temperature < 30°C upon admission (Oommen & Menon, 2011).  
6. Outcomes 
Various methods have been used to try and determine the likelihood of neurologic recovery 
after cardiac arrest, but no single test is effective in accurately predicting neurologic 
outcome post-resuscitation. Clinical trials have established that combining examinations, 
laboratory tests and accounting for co-morbidities is often more accurate in determining 
neurologic outcome. Precise predictors of neurologic recovery are lacking and seriously 
limit the way clinicians assess patient prognosis, develop appropriate plans of care, and 
counsel family members. Therefore, more clinical studies are required to determine a 
uniform protocol for predicting neurologic outcome. 
6.1 Modalities predicting neurological outcome 
6.1.1 Neurologic examination 
A neurologic examination is a fairly reliable predictor of neurological outcome after cardiac 
arrest. The presence of neurologic function during or immediately after return of spontaneous 
circulation (ROSC) roughly predicts a good neurologic outcome. Conversely, patients with a 
Glasgow Coma motor score of ≤ 2 or absent pupillary or corneal reflex at 72 hours can be 
predicted to have a poor neurologic outcome. The CPC Scale has also been classically used to 
predict patient outcome. Patients with a CPC scale score of 1 and 2 are likely to have good 
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hypothermia at a temperature of 32-34°C for 24 hours were more likely to have good 
neurologic outcomes in comparison to patients who were not treated with hypothermia, 
with an odds ratio of 1.84 (95% confidence interval: 1.08-3.13). In addition, the rate of 
mortality was significantly lower in the hypothermia group (odds ratio: 0.56; 95% 
confidence interval: 0.34-0.93).  
While shortening the delay from spontaneous circulation to hypothermic target temperature 
has been theorized as a way of improving survival and neurologic outcome, randomized 
controlled trials and clinical registries have not shown evidence of whether the time to 
target temperature correlates with neurologic outcome. A recent study has reported that in 
comatose cardiac arrest patients treated with therapeutic hypothermia after return of 
spontaneous circulation, a faster decline in body temperature to the 34°C target appears to 
predict an unfavorable neurologic outcome (Haugk, 2011). Among 588 survivors of cardiac 
arrest managed with therapeutic hypothermia, the median time from restoration of 
spontaneous circulation to reaching a temperature of less than 34°C was 209 minutes 
(interquartile range [IQR]: 130-302) in patients with favorable neurologic outcomes 
compared to 158 minutes (IQR: 101-230) (p < 0.01) in patients with unfavorable neurologic 
outcomes. The adjusted odds ratio for a favorable neurologic outcome with a longer time to 
target temperature was 1.86 (95% CI 1.03 to 3.38, p = 0.04). Whether faster cooling is 
detrimental or patients with more severe neurologic damage show a faster cooling rate has 
to be further evaluated.  
Animal and human studies have suggested that hypothermia impairs renal function. Zeiner 
et al (2004) reported that 24 hours of mild therapeutic hypothermia was associated with a 
delayed improvement in renal function that was not reflected in serum creatinine values, 
and this transient impaired renal function appeared to be completely reversible within 4 
weeks. In trying to determine the  relationship between acute kidney injury on survivors of 
cardiac arrest treated with therapeutic hypothermia we found that the incidence of acute 
kidney injury in patients with a CPS 1 or 2 score was 13.6% compared to 86.4% in patients 
with a CPS score > 2 (p < 0.001) (J. Prior, personal communication). Stage 3 acute kidney 
injury correlated with poor neurologic outcome (p = 0.04) but there was no correlation 
between Stages 1 and 2 and neurologic recovery. A longer duration of cardiac arrest was 
predictive of the subsequent development of acute kidney injury (p = 0.01). In summary, the 
presence of acute kidney injury in survivors of cardiac arrest treated with therapeutic 
hypothermia appears to be associated with poorer neurologic function determined at the 
time of hospital discharge. Acute kidney injury in this population may serve as a marker for 
the severity of anoxic injury incurred during arrest.  
5.2 Indications and contraindications 
5.2.1 Indications  
The AHA has recommended that therapeutic hypothermia is indicated in adult patients 
with out-of-hospital cardiac arrests and who have an initial rhthym of ventricular fibrillation 
or nonperfusing ventricular tachycardia, that are comatose or have a Glasgow coma score < 
8, that are hemodynamically stable, and lack a verbal response. Although these are the 
criteria for which hypothermia is recommended, there are other patients that may benefit 
from therapeutic hypothermia such as post-resuscitation patients having initial rhthyms 
other than ventricular fibrillation or nonperfusing ventricular tachycardia, as well as in-
hospital cardiac arrest patients. 
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Table 2. Summary of indications for induced therapeutic hypothermia in comatose survivors 
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bleeding disorder, being pregnant or terminally ill, those with a do-no-resuscitate (DNR) 
order, or having a tympanic temperature < 30°C upon admission (Oommen & Menon, 2011).  
6. Outcomes 
Various methods have been used to try and determine the likelihood of neurologic recovery 
after cardiac arrest, but no single test is effective in accurately predicting neurologic 
outcome post-resuscitation. Clinical trials have established that combining examinations, 
laboratory tests and accounting for co-morbidities is often more accurate in determining 
neurologic outcome. Precise predictors of neurologic recovery are lacking and seriously 
limit the way clinicians assess patient prognosis, develop appropriate plans of care, and 
counsel family members. Therefore, more clinical studies are required to determine a 
uniform protocol for predicting neurologic outcome. 
6.1 Modalities predicting neurological outcome 
6.1.1 Neurologic examination 
A neurologic examination is a fairly reliable predictor of neurological outcome after cardiac 
arrest. The presence of neurologic function during or immediately after return of spontaneous 
circulation (ROSC) roughly predicts a good neurologic outcome. Conversely, patients with a 
Glasgow Coma motor score of ≤ 2 or absent pupillary or corneal reflex at 72 hours can be 
predicted to have a poor neurologic outcome. The CPC Scale has also been classically used to 
predict patient outcome. Patients with a CPC scale score of 1 and 2 are likely to have good 
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outcomes, while patients scoring 3, 4 or 5 have a significantly higher chance of having a poor 
neurologic outcome or death (Nolan et al, 2008). It is worth noting that the neurologic exam 
and CPC score can be influenced by the physiologic circumstances of the patient such as 
hypotension, shock, and severe metabolic dysfunction. Interventions such as paralytics, 
sedatives, and hypothermia also influence the findings of a neurologic examination and must 
be taken into account. Cranial nerve findings and motor response to pain are the best physical 
features estimating neurologic status and recovery.  
 
1 Good cerebral performance: conscious, alert, able to work, might have mild neurologic or psychologic deficit. 
2 Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of daily life. Able to work in sheltered environment. 
3 
Severe cerebral disability: conscious, dependent on others for daily 
support because of impaired brain function. Ranges from ambulatory state 
to severe dementia or paralysis. 
4 
Coma or vegetative state: any degree of coma without the presence of all 
brain death criteria. Unawareness, even if appears awake (vegetative state) 
without interaction with environment; may have spontaneous eye opening 
and sleep/awake cycles. Cerebral unresponsiveness. 
5 Brain death: apnea, areflexia, EEG silence, etc. 
Note: If patient is anesthetized, paralyzed, or intubated, use “as is” clinical condition to calculate scores. 
Table 3. Cerebral Performance Categories Scale (CPC Scale) 
6.1.2 Neurophysiologic tests 
Electroencephalography (EEG) has been used to characterize the degree of brain damage 
after cardiac arrest. Various EEG patterns have been associated with poor neurologic 
outcome such as generalized suppression, burst-suppression patterns with generalized 
epileptiform activity, and generalized periodic complexes on a flat background. 
Nevertheless, EEG alone is likely to be insufficient to prognosticate neurologic recovery. The 
EEG requires a physician with experience in its interpretation and knowledge of the 
influence of drugs and metabolic disorders on its results.  
Madl & Holzer (2004) reviewed the literature on the pathophysiology of brain injury caused 
by cardiac arrest and the beneficial effect of therapeutic hypothermia on neurologic outcome. 
They summarized that electrophysiologic techniques and molecular markers of brain injury 
allow the accurate assessment and prognostication of long-term outcome in cardiac arrest 
survivors. In particular, somatosensory evoked potentials (SSEPs) appear to have the highest 
prognostic reliability; a systematic review of 18 studies analyzed the predictive ability of SSEPs 
performed early after onset of coma and found that absence of cortical SSEPs identify patients 
not returning from anoxic coma, with a specificity of 100%. Somatosensory-evoked potentials 
test the patency of the neuronal pathways, and are less affected by common drugs and 
metabolic disorders, making them a more reliable predictor of neurologic outcome than other 
modalities (Nolan et al, 2008). However, use of SSEPs in post-resuscitation patients requires 
advanced neurologic training which is usually restricted to specialized centers. 
6.1.3 Neuroimaging 
Neuroimaging is often performed to define structural brain injury related to cardiac arrest 
(either as a cause or consequence), including hemorrhage and cerebral vascular occlusion. 
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Most clinical studies evaluating neurologic outcome after use of therapeutic hypothermia do 
not make use of neuroimaging. The most common type of neuroimaging employed has been 
cranial computed tomography (CT), predominately because of the technical difficulties in 
performing magnetic resonance imaging (MRI) and positron emission tomography (PET) 
scans in the setting of arrest. Limited studies have shown that diffusion-weighted imaging 
(DWI), fluid attenuated inversion recovery (FLAIR), abnormalities in PET, and magnetic 
resonance spectroscopy can help predict poor neurologic outcome (Nolan et al, 2008).  
6.1.4 Biochemical markers 
Biochemical markers derived from the cerebrospinal fluid (CSF) and peripheral circulation, such 
as creatine phosphokinase (CPK) and neuron-specific enolase (NSE) respectively, have been used 
to predict neurologic outcome after cardiac arrest. The ease of obtaining blood compared to CSF 
has favored blood-based biochemical markers. Neuron-specific enolase is easily measured in the 
blood after injury to the brain and is, therefore, a good marker for neurologic outcome. Studies 
have shown that values of NSE > 33µg/L are predictor of poor neurologic outcome.  
A calcium-binding protein from astroglia and Schwann cells, S100β, may also be a marker of 
neurologic outcome. An S100 β concentration > 1.2 µg/L, drawn between 24 and 48 hours 
after ROSC, is indicative of poor neurologic recovery (Nolan et al, 2008). Biomarker 
threshold values established in clinical trials vary based on the time blood and CSF are 
drawn after ROSC and the method for measuring the biomarker. Therefore, standardization 
must be applied in future clinical trials so that true threshold values can be elucidated and 
used to predict patient outcome. 
6.1.5 Co-morbidities 
We previously reported that the risk of poor neurologic outcome among patients treated with 
mild therapeutic hypothermia was related to the number of risk factors present (Table 4) 
(Vanston et al, 2010). A first rhythm of non-ventricular tachycardia/ventricular fibrillation 
after cardiac arrest, acute kidney injury within the first 72 hours of intensive care, and any 
treated cardiac arrhythmia were factors significantly associated with poor neurologic outcome 
and death (Table 4).  
 
 
a CPS. Pittsburgh Cerebral Performance Scale; C.I. = confidence intervals 
b Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.004). 
c Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.002). 
d Include first rhythym other than ventricular fibrillation/ ventricular tachycardia, any arrhythmia,  
and acute kidney injury.  
Table 4. Risk of poor neurologic outcome among patient treated with mild therapeutic 
hypothermia, according to number of risk factors present.a 
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outcomes, while patients scoring 3, 4 or 5 have a significantly higher chance of having a poor 
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be taken into account. Cranial nerve findings and motor response to pain are the best physical 
features estimating neurologic status and recovery.  
 
1 Good cerebral performance: conscious, alert, able to work, might have mild neurologic or psychologic deficit. 
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Note: If patient is anesthetized, paralyzed, or intubated, use “as is” clinical condition to calculate scores. 
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6.1.2 Neurophysiologic tests 
Electroencephalography (EEG) has been used to characterize the degree of brain damage 
after cardiac arrest. Various EEG patterns have been associated with poor neurologic 
outcome such as generalized suppression, burst-suppression patterns with generalized 
epileptiform activity, and generalized periodic complexes on a flat background. 
Nevertheless, EEG alone is likely to be insufficient to prognosticate neurologic recovery. The 
EEG requires a physician with experience in its interpretation and knowledge of the 
influence of drugs and metabolic disorders on its results.  
Madl & Holzer (2004) reviewed the literature on the pathophysiology of brain injury caused 
by cardiac arrest and the beneficial effect of therapeutic hypothermia on neurologic outcome. 
They summarized that electrophysiologic techniques and molecular markers of brain injury 
allow the accurate assessment and prognostication of long-term outcome in cardiac arrest 
survivors. In particular, somatosensory evoked potentials (SSEPs) appear to have the highest 
prognostic reliability; a systematic review of 18 studies analyzed the predictive ability of SSEPs 
performed early after onset of coma and found that absence of cortical SSEPs identify patients 
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Most clinical studies evaluating neurologic outcome after use of therapeutic hypothermia do 
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a CPS. Pittsburgh Cerebral Performance Scale; C.I. = confidence intervals 
b Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.004). 
c Significantly greater than the risk of poor neurologic outcome amongs patients with no predictive 
factors (p = 0.002). 
d Include first rhythym other than ventricular fibrillation/ ventricular tachycardia, any arrhythmia,  
and acute kidney injury.  
Table 4. Risk of poor neurologic outcome among patient treated with mild therapeutic 
hypothermia, according to number of risk factors present.a 
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6.2 Adverse effects 
Adverse effects of mild induced therapeutic hypothermia are either directly related to the 
cooling device or due to hypothermia itself. In 41 clinical trials using therapeutic 
hypothermia the overall rate of adverse events related to a cooling device was 1% (Holzer, 
2010). These adverse effects included three cases of bleeding, eight cases of infection, ten 
cases of deep venous thrombosis, and eight cases of pulmonary edema. The cases of deep 
venous thrombosis were seen in patients that were cooled with a catheter-based device, 
while the cases of pulmonary edema occurred in patients that were cooled with cold 
intravenous fluid. 
Hypothermia causes a decrease in insulin secretion, as well as insulin resistance in many 
patients. This state of hyperglycemia requires administration of insulin to maintain glucose 
levels within an acceptable range. More importantly, during the re-warming phase patients 
can regain appropriate sensitivity to insulin rapidly, making them susceptible to 
hypoglycemia if insulin administration is not reduced accordingly. Glycemic lability is one 
of several reasons why re-warming rates after hypothermia are typically slow and 
controlled. 
Some of the adverse effects most commonly associated with therapeutic hypothermia 
include pneumonia, shivering hyperglycemia, cardiac arrhythmias, seizures, and electrolyte 
disorders. Less frequently seen complications are sepsis, coagulopathy, and metabolic 
disturbances. Many of these effects can be easily managed by proper patient monitoring. In 
a study compiling data from major clinical trials on adverse effects unrelated to the cooling 
devices, such events occurred in 74% of patients who were treated with hypothermia (223 
events in 300 patients) and in 71% of 285 patients given standard, normothermic treatment 
(Holzer, 2010). The incidences of cardiac arrhythmia, hemodynamic instability, bleeding, 
pneumonia, sepsis, renal failure, seizures, and pancreatitis were not significantly different 
between the two groups. 
7. Slow implementation 
Although its use is becoming more widespread, therapeutic hypothermia is still not 
appropriately initiated for a majority of eligible patients. Concerns with the ease of use, 
efficacy, and cost have limited use in the community setting. The current level of 
implementation of therapeutic hypothermia is difficult to measure, although hypothermia 
registries are attempting to bridge the gap. The AHA, along with some local communities, is 
advocating for the care of all patients with cardiac arrest at centers specializing in post-
arrest care in order to provide the best possible outcomes. Such centers would have the 
capability to perform therapeutic hypothermia, perform percutaneous coronary 
intervention, and utilize standardized protocols for the treatment of cardiac arrest survivors, 
as well as pay close attention to related aspects of overall management including 
hemodynamic stability, ventilator support (with timely normalization of FiO2 and pCO2), 
thromboembolic prophylaxis, and glycemic control. 
8. Ongoing and potential future research  
8.1 Neurologic prognosis 
In patients managed with therapeutic hypothermia clinical research is ongoing regarding 
clinical modeling and the use of aspects of the neurologic exam and acute and chronic 
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medical co-morbidities in predicting neurologic recovery. We have previously found that 
several simple and reproducible clinical markers (i.e., first rhythm at cardiac arrest; the 
presence of acute kidney injury in the ICU; any treated cardiac arrhythmia after admission; 
and Glasgow Coma Score < 8 determined 12 hours after re-warming) can help predict 
neurologic prognosis during and after treatment, in patients managed with therapeutic 
hypothermia for cardiac arrest (Vanston, 2010). Additional investigation is neded to 
examine the potential role of other exam techniques, and electrophysiologic and 
neurobiochemical tests in reliably predicting neurologic outcomes, and to determine the 
correlation between laboratory values or exam scores and time after return of spontaneous 
circulation. 
8.2 Non-shockable rhythms/ other cardiac  
Small randomized trials and registries have begun to collect data on the use of therapeutic 
hypothermia in cardiac arrests with non-shockable rhythms and in-hospital cardiac arrests. 
Recently, in a retrospective cohort study treatment with mild therapeutic hypothermia at a 
temperature of 32-34°C for 24 hours was associated with improved neurologic outcome and 
a reduced risk of death following out-of-hospital cardiac arrest in 135 with non-shockable 
rhythms (Testori et al, 2011). To date, the level of evidence is inadequate to firmly 
recommend therapeutic hypothermia for these patients; nevertheless, many of these patients 
are treated with therapeutic hypothermia in the community if their arrest is thought to be of 
cardiac origin or if the initial rhythm after arrest is unknown. Further research is needed to 
determine the potential role of therapeutic hypothermia for these subsets of patients. The 
ILCOR currectly advocates the use of therapeutic hypothermia following perinatal 
asphyxia-related cardiac arrest in term newborns.  
At least one study (a retrospective analysis of the Hypothermia after Cardiac Arrest 
(HACA) trial) suggested that cooling after successful resuscitation for ventricular fibrillation 
cardiac arrest did not influence infarct size (Koreny et, 2009). The authors contended that 
cautious interpretation of the subgroup analysis may indicate a favorable trend for early 
cooling, and thus additional research is indicated. 
8.3 Non-cardiac applications 
Clinical trials are still revealing further application of therapeutic hypothermia. It is likely 
that recommendations and the use of therapeutic hypothermia will expand to encompass 
several other pathologies such as traumatic brain and spinal cord injury and acute ischemic 
stroke. Currently, therapeutic hypothermia is not approved by an advisory panel for any 
other use besides comatose patients after return of spontaneous circulation due to 
ventricular fibrillation or pulseless ventricular tachycardia (Adler et al, 2011). 
8.4 Aspects of treatment 
Current and potential future areas of clinical research on treatment aspects of therapeutic 
hypothermia include, among others: 
 Optimal target temperature, duration, onset, cooling rates, and re-warming rates 
 Use of external, internal, or mixed modality cooling techniques 
 Pharmacologic uses and standardized drug protocols i.e. (analgesics, sedatives, 
paralytics, etc.) 
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9. Areas of uncertainty 
Some persistent unexposed topics that relate to the pathophysiology of therapeutic 
hypothermia include the precise mechanism(s) of greatest importance for good neurologic 
recovery, the mechanism(s) through which hypothermia exerts the most influence, the 
effects of co-morbidities in reducing the efficacy of therapeutic hypothermia, and the time 
course of cellular cascades and the ability to attenuate these processes (Holzer, 2010). 
10. Guidelines 
Sedation, analgesia, and paralysis should be initiated prior to hypothermia to prevent 
shivering which can increase oxygen consumption, promote labored breathing, increase 
heart rate, delay hypothermic induction, and increase patient discomfort. 
The ILCOR and the AHA recommend that core body temperature of unconscious adult 
patients with spontaneous circulation after an out-of- hospital ventricular fibrillation cardiac 
arrest should be lowered to 32-34°C. The cooling process should be started in the pre-
hospital setting or as soon as possible and continued for 12-24 hours. Core temperature 
should be continuously monitored via the esophagus, rectum, trachea or bladder. General 
management of hypothermia patients includes concurrent measurement of mean arterial 
pressure, central venous pressure, urine output, arterial blood gases, central venous oxygen 
saturation, serum lactate, blood glucose, electrolytes, and complete blood count, and 
continuous ECG monitoring and stabilization.  
After hypothermia, patients should be re-warmed at a rate of 0.5°C per hour with avoidance 
of hyperthermia. Potassium administraction should be stopped to avoid hyperkalemia 
during the re-warming phase. After re-warming to 36°C, sedation and paralytic agents 
should be discontinued and the patient should be weened off ventilator support 
(Jacobshagen et al, 2010). Neurologic recovery can take several hours after discontinuation 
of hypothermia. Therefore, it is important to wait until the patient is completely re-warmed 
and stabile before evaluating patients with prognositic neurologic exams like the Glasgow 
Coma Scale. 
11. Conclusions 
Mild therapeutic hypothermia is indicated for use in witnessed out-of-hospital cardiac arrest 
patients with a return of spontaneous circulation, for persons with an initial rhythm of 
ventricular fibrillation or non-perfusing ventricular tachycardia, for persons who are 
comatose or have a Glasgow coma score < 8, those who are hemodynamically stable, and 
those who lack a verbal response. Clinical evidence has shown that mild hypothermia 
decreases mortality and increases the proportion of patients with a favorable neurologic 
outcome (score of 1 or 2 on the CPC Scale) with mininimal risk of adverse effects. 
Therapeutic hypothermia is a relatively inexpensive treatment modality with an incremental 
cost-effectiveness ratio of $47,168 (Merchant et al, 2009) and can be implemented in a variety 
of settings from rural community-based hospitals to specialized cardiac and neurologic 
centers. The indications for mild therapeutic hypothermia will broaden in the future as more 
clinical trials are conducted. It is important to understand the pathophysiologic processes 
involved in the post-cardiac arrest syndrome, as well as the concominant changes in human 
physiology during induced mild therapeutic hypothermia. 
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1. Introduction 
Pregnancies, as well as the post-partum period, are characterized by important metabolic 
changes. A lot of physiological changes affect the circulating blood volume, peripheral 
vascular compliance and resistance, myocardial function, heart rate and the neuro-hormonal 
system. These changes are well known in normal pregnancies, due to thorough examination 
and intense study; however there are still some questions related to the differences between 
women with and without structural diseases. Tocolitic medication used in pregnancy can 
cause cardiac complications in a healthy woman.   
The presence of cardiovascular diseases in pregnancy must not be ignored because: 
 Cardiovascular diseases are top causes of non-obstetrical maternal death (Sullivan, 
1990). 
 The modern possibilities of investigation improved diagnosis of cardiac diseases. 
 The modern therapy can help women with cardiovascular diseases to have a good 
pregnancy outcome. Until recently, pregnancy was forbidden in those women. 
 Women with repaired congenital heart defects. These women will have an increased 
risk of arrhythmias during pregnancy (Tateno, 2003). These types of patients usually 
have fragile hemodynamics and need additional therapy in most of the cases.  
2. Physiological changes during pregnancy  
The antepartum period is characterized by three main changes: an increased blood volume 
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than in the pre-pregnant state (Lind, 1985). However, this value is not constant. Studies have 
shown that there are increases from 20% to 100% above pre-pregnant blood volume (Pirani, 
1973). It has been demonstrated that the blood volume increases at least until mid-pregnancy. 
The period, when the blood pressure plateaus, is arguable: some studies consider that it 
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term (Lund, 1967). Blood volume increases considerably in a twin pregnancy (Thomsen, 1994). 
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anemia”, as a consequence of hemodilution (there is a proportional greater increase in the 
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plasma volume than in the red blood cell mass, the latter being around 40% above pre-
pregnancy levels) (Pirani 1973). Hypervolemia is caused by hormonal factors like: prolactin, 
placental lactogen, growth hormone, and estrogen or peptides like the prostaglandins. 
Considering women without heart disease, the cardiac filling pressures are not higher in 
women at term compared to women 11-13 weeks’ postpartum (Clark, 1989). The vascular 
resistance differs from one pregnancy state to another. A fall in systemic vascular resistance 
has been described in the 5th week of gestation; a nadir between the 20th and 32nd week was 
followed by a slowly increase. The overall fall in the systemic vascular resistance occurs 
because of the changes in the resistance and flow in multiple vascular beds, such as the 
uteroplacental, renal, muscular, cutaneous and mammary bed. There are no changes in the 
hepatic or the cerebral blood flow. Variations in the renal and unteroplacental blood flow are 
primarily caused by positional changes (Jurkovic, 1991). For example, in the supine position in 
case of a pregnant woman, there is a compression of the inferior vena cava. An obstruction of 
the abdominal aorta and iliac arteries may also occur because of the uterus (Bieniarz, 1969). 
The resistance of these vascular beds is decreased due to the great amount of secreted 
vasodilators for example prostacyclin. 
The systemic arterial pressure has a similar behavior: it decreases in the first semester and 
reaches its nadir at mid-pregnancy. Thereafter it increases and, in some cases, its level is higher 
than the pre-pregnancy level. The cardiac output is the most common measure of cardiac 
performance. Cardiac output, which is dependent on the heart rate and stroke volume, is 
gradually increasing by about 30-50% (Clark, 1989; and Rubler S, 1977) in the 5th week of 
gestation, reaching its peak at approximately the end of the second trimester (Robson, 1989) or 
in the third trimester (Bader, 1955). Afterwards, it is either constant until term or it decreases 
slightly near term. Although the amount of the oxygen in the blood is proportional with the 
cardiac output; there is no relation between the cardiac output and oxygen consumption, the 
last, increasing progressively by 20-30% at term (Elkus, 1992). Studies show different results 
when the ejection fraction is debated: some indicate that there are no alterations in the left 
ventricular ejection fraction (Katz, 1978 and Geva T, 1997), meanwhile other demonstrate 
increases in ejection fraction (Robson, 1989). This may be a result of the different loading 
conditions. The ratio of early to late diastolic flow velocity has been shown to be lower during 
the third semester compared with postpartum (Sadaniantz, 1992). 
There is a wide individual variation of heart rate; however it usually increases by 10-20 
beats; peaking in the late second trimester or early third trimester. Most pregnant women 
remain in sinus rhythm; but premature atrial and ventricular complexes may frequently 
occur.  
Hemodynamic changes are also a cause of neurohormonal responses. The most important 
are the vasodilators: nitric oxide and prostaglandins, which cause, on one hand decreases in 
the peripheral resistance and, on the other hand, changes in the uterine and renal blood 
flow. Decreased cerebral blood flow activates the sympathetic nervous system. Conversely, 
plasma volume expansion suppresses catecholamine levels.  
Neurohormones also activate the renin-angiotensin-aldosterone system that is responsible 
for the regulation of the salt and water homeostasis in the body (August, 1990). Pregnancy is 
characterized by increased levels of renin and angiotensin. The increased level of renin is 
not dependent on the extracellular volume. 
Natriuretic peptides (also activated by neurohormones) are associated with cardiovascular 
and renal functions. The level of the two main natriuretic peptides (the atrial natriuretic-
ANP and the brain natriuretic-BNP) is increased during pregnancy (Yoshimura, 1994). Their 
release is caused by atrial and ventricular distension. 
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During the peripartum period the hemodynamics will radically change, due to pain, anxiety 
and uterine contractions. For example, uterine contractions will increase the blood volume 
up to 500 mL (Ueland, 1969). The blood loss will be associated to the type of delivery. If in 
vaginal delivery there is a 10% blood loss; in caesarian delivery there may be a loss of up to 
29% of the total blood volume (Ueland, 1976). Research has demonstrated that the 
circulation is not influenced by the placental separation. With every contraction the cardiac 
output increases up to 7-15%, consequently increasing the basal blood pressure. Early after 
delivery, cardiac output may continue to increase to as much as 80% above pre-labour 
values. Cardiac output will return to pre-labour levels about 1 hour post-partum. In labour 
the amount of the catecholamine increase. As a result, the heart rate will have high values. 
These values are not constant, and depend on many factors such as: position or anesthesia. 
Hemodynamic parameters need around 6 months to return to their normal values. 
Immediately after delivery, the cardiac output increases by as much as 80%, followed by a 
decrease in 24 weeks. Within the first 3 days after delivery the blood volume will decrease 
by 20%, however the hematocrit needs 2 weeks to be stabilized. Also, within 2 weeks after 
delivery the systemic vascular resistance increases by 30 % (Robson, 1987), and the heart 
rate will return to baseline levels. Stroke volume decreases for the first 24 weeks after 
delivery. Systolic and diastolic blood pressures remain unaltered from late pregnancy until 
12 weeks post-partum (Campos, 1996). 
2.1 Prevalence of arrhythmias in pregnancy 
The elevated levels of estrogen and b-choral gonadotropine appear, from experimental 
models, to affect the expression of cardiac ion channels. By functioning in a proarrhythmic 
way, pregnancy gives rise to significant problems concerning the diagnosis and treatment of 
certain arrhythmias, especially when drugs and/or non pharmaceutical therapeutic 
methods are required (Mark, 2002). 
Palpitations, fatigue and syncope are common in pregnancy. The sinus rate increases by 
about 10 beats/minute during pregnancy, and sinus tachycardia greater than 100 beats/min 
is common (Conti, 2005). Extrasystoles, intermittent sinus tachycardia and non-sustained 
arrhythmia are encountered in more than 50% of pregnant women are investigated for 
symptoms of arrhythmia (Gowda, 2003). Some arrhythmias occuring during pregnancy 
represent a recurrence of a pre-existing problem, but a substantial number of cases appear 
for the first time in pregnancy. Bradyarrhythmias presenting during pregnancy are rare 
with a prevalence of about 1–20 000, and are usually caused by sinoatrial disease or 
congenital complete heart block (Lee, 1995). Atrial fibrillation and flutter are rarely 
encountered during pregnancy unless organic heart disease or endocrine disorders are 
present. Episodes of such arrhythmias appearing for the first time during pregnancy require 
further evaluation for possible congenital heart disease, rheumatic valvular disease or 
hyperthyroidism (Leung, 1998).  
3. Mechanisms of arrhythmia in pregnancy 
The management of the arrhythmia is not different in pregnant women. However, 
hemodynamic conditions should be considered. 
The cardiovascular system undergoes significant changes in adaptation to pregnancy, 
including an increased heart rate and cardiac output, reduced systemic resistance, increased 
plasma catecholamine concentrations and adrenergic receptor sensitivity, atrial stretch and 
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plasma volume than in the red blood cell mass, the latter being around 40% above pre-
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Considering women without heart disease, the cardiac filling pressures are not higher in 
women at term compared to women 11-13 weeks’ postpartum (Clark, 1989). The vascular 
resistance differs from one pregnancy state to another. A fall in systemic vascular resistance 
has been described in the 5th week of gestation; a nadir between the 20th and 32nd week was 
followed by a slowly increase. The overall fall in the systemic vascular resistance occurs 
because of the changes in the resistance and flow in multiple vascular beds, such as the 
uteroplacental, renal, muscular, cutaneous and mammary bed. There are no changes in the 
hepatic or the cerebral blood flow. Variations in the renal and unteroplacental blood flow are 
primarily caused by positional changes (Jurkovic, 1991). For example, in the supine position in 
case of a pregnant woman, there is a compression of the inferior vena cava. An obstruction of 
the abdominal aorta and iliac arteries may also occur because of the uterus (Bieniarz, 1969). 
The resistance of these vascular beds is decreased due to the great amount of secreted 
vasodilators for example prostacyclin. 
The systemic arterial pressure has a similar behavior: it decreases in the first semester and 
reaches its nadir at mid-pregnancy. Thereafter it increases and, in some cases, its level is higher 
than the pre-pregnancy level. The cardiac output is the most common measure of cardiac 
performance. Cardiac output, which is dependent on the heart rate and stroke volume, is 
gradually increasing by about 30-50% (Clark, 1989; and Rubler S, 1977) in the 5th week of 
gestation, reaching its peak at approximately the end of the second trimester (Robson, 1989) or 
in the third trimester (Bader, 1955). Afterwards, it is either constant until term or it decreases 
slightly near term. Although the amount of the oxygen in the blood is proportional with the 
cardiac output; there is no relation between the cardiac output and oxygen consumption, the 
last, increasing progressively by 20-30% at term (Elkus, 1992). Studies show different results 
when the ejection fraction is debated: some indicate that there are no alterations in the left 
ventricular ejection fraction (Katz, 1978 and Geva T, 1997), meanwhile other demonstrate 
increases in ejection fraction (Robson, 1989). This may be a result of the different loading 
conditions. The ratio of early to late diastolic flow velocity has been shown to be lower during 
the third semester compared with postpartum (Sadaniantz, 1992). 
There is a wide individual variation of heart rate; however it usually increases by 10-20 
beats; peaking in the late second trimester or early third trimester. Most pregnant women 
remain in sinus rhythm; but premature atrial and ventricular complexes may frequently 
occur.  
Hemodynamic changes are also a cause of neurohormonal responses. The most important 
are the vasodilators: nitric oxide and prostaglandins, which cause, on one hand decreases in 
the peripheral resistance and, on the other hand, changes in the uterine and renal blood 
flow. Decreased cerebral blood flow activates the sympathetic nervous system. Conversely, 
plasma volume expansion suppresses catecholamine levels.  
Neurohormones also activate the renin-angiotensin-aldosterone system that is responsible 
for the regulation of the salt and water homeostasis in the body (August, 1990). Pregnancy is 
characterized by increased levels of renin and angiotensin. The increased level of renin is 
not dependent on the extracellular volume. 
Natriuretic peptides (also activated by neurohormones) are associated with cardiovascular 
and renal functions. The level of the two main natriuretic peptides (the atrial natriuretic-
ANP and the brain natriuretic-BNP) is increased during pregnancy (Yoshimura, 1994). Their 
release is caused by atrial and ventricular distension. 
 
Arrhythmias in Pregnancy 
 
499 
During the peripartum period the hemodynamics will radically change, due to pain, anxiety 
and uterine contractions. For example, uterine contractions will increase the blood volume 
up to 500 mL (Ueland, 1969). The blood loss will be associated to the type of delivery. If in 
vaginal delivery there is a 10% blood loss; in caesarian delivery there may be a loss of up to 
29% of the total blood volume (Ueland, 1976). Research has demonstrated that the 
circulation is not influenced by the placental separation. With every contraction the cardiac 
output increases up to 7-15%, consequently increasing the basal blood pressure. Early after 
delivery, cardiac output may continue to increase to as much as 80% above pre-labour 
values. Cardiac output will return to pre-labour levels about 1 hour post-partum. In labour 
the amount of the catecholamine increase. As a result, the heart rate will have high values. 
These values are not constant, and depend on many factors such as: position or anesthesia. 
Hemodynamic parameters need around 6 months to return to their normal values. 
Immediately after delivery, the cardiac output increases by as much as 80%, followed by a 
decrease in 24 weeks. Within the first 3 days after delivery the blood volume will decrease 
by 20%, however the hematocrit needs 2 weeks to be stabilized. Also, within 2 weeks after 
delivery the systemic vascular resistance increases by 30 % (Robson, 1987), and the heart 
rate will return to baseline levels. Stroke volume decreases for the first 24 weeks after 
delivery. Systolic and diastolic blood pressures remain unaltered from late pregnancy until 
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The elevated levels of estrogen and b-choral gonadotropine appear, from experimental 
models, to affect the expression of cardiac ion channels. By functioning in a proarrhythmic 
way, pregnancy gives rise to significant problems concerning the diagnosis and treatment of 
certain arrhythmias, especially when drugs and/or non pharmaceutical therapeutic 
methods are required (Mark, 2002). 
Palpitations, fatigue and syncope are common in pregnancy. The sinus rate increases by 
about 10 beats/minute during pregnancy, and sinus tachycardia greater than 100 beats/min 
is common (Conti, 2005). Extrasystoles, intermittent sinus tachycardia and non-sustained 
arrhythmia are encountered in more than 50% of pregnant women are investigated for 
symptoms of arrhythmia (Gowda, 2003). Some arrhythmias occuring during pregnancy 
represent a recurrence of a pre-existing problem, but a substantial number of cases appear 
for the first time in pregnancy. Bradyarrhythmias presenting during pregnancy are rare 
with a prevalence of about 1–20 000, and are usually caused by sinoatrial disease or 
congenital complete heart block (Lee, 1995). Atrial fibrillation and flutter are rarely 
encountered during pregnancy unless organic heart disease or endocrine disorders are 
present. Episodes of such arrhythmias appearing for the first time during pregnancy require 
further evaluation for possible congenital heart disease, rheumatic valvular disease or 
hyperthyroidism (Leung, 1998).  
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The management of the arrhythmia is not different in pregnant women. However, 
hemodynamic conditions should be considered. 
The cardiovascular system undergoes significant changes in adaptation to pregnancy, 
including an increased heart rate and cardiac output, reduced systemic resistance, increased 
plasma catecholamine concentrations and adrenergic receptor sensitivity, atrial stretch and 
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increased end‐diastolic volumes due to intravascular volume expansion, as well as 
hormonal and emotional changes (Adamson, 2007). Pregnancies with abnormal uterine 
perfusion and subsequent pathological outcomes are paralleled by changes in ventricular 
repolarization, that precede clinical symptoms (Baumert, 2010). Repolarization of the 
ventricular myocardium might be affected in pregnancy due to changes in circulating 
hormones, electrolyte imbalances and increased sympathetic tone.  
It is important to determine if the arrhythmia has clinical conequences such as deterioration 
of the underlying cardiac condition. Arrhythmogenic effects are linked to the type of 
arrhythmia. There is a high risk of maternal and fetal morbidity in women with repaired 
CHD (chronic heart diseases). Studies have demonstrated that simple tachyarrhythmia does 
not lead to death. However, death may occur if this type of arrhythmia is associated with 
structural diseases. New research suggests that women with cyanosis and CHD may 
experience still birth or miscarriage. In this situation, the best case scenario is a low birth 
weight infant. 
4. Signs, investigations and diagnosis 
4.1 Symptoms 
Palpitations, the most common presenting symptom, are usually intermittent and only 
rarely indicate a serious problem. Patients with arrhythmia may also present with fatigue, 
breathlessness, peripheral edema and chest discomfort resulting from cardiac failure. 
Symptoms of thromboembolism may be the presenting feature of atrial fibrillation or atrial 
flutter. Patients complaining of palpitations, but without documented arrhythmia, have a 
low likelihood for having a life-threatening arrhythmia, and no further evaluation is 
warranted (Andreson, 1997). A history of previous heart disease increases the likelihood of 
life threatening arrythmias. Inquiry should be made about the family history, particularly 
with reference to cases of premature sudden death.  
The severity of the symptoms allows the physician to judge whether the risks of therapy 
outweigh the benefits. The only difference in pregnancy is that the physician must consider 
the risk/benefit ratio for both the mother and the fetus. An arrhythmia that is 
hemodynamically compromising to the mother constitutes a major concern because of 
inadequate maternal, as well as placental, blood flow (Anderson, 1997). 
4.2 Examination 
The pulse may be abnormal during symptoms; the clinician should focus on looking for 
signs of heart disease that may be associated with arrhythmia, including scars from 
previous surgery, murmurs of structural heart disease and signs of cardiac failure. It is 
also important to look for systemic problems such as thyrotoxicosis that may cause 
arrhythmia.  The diagnosis of heart disease in pregnancy is often difficult due to the 
anatomical and physiological changes in the cardiovascular system. Many symptoms and 
signs of normal pregnancy can mimic heart disease. Dyspnea is especially common, with 
75% of women complaining of breathlessness by 31 weeks (Elkos, 1992). Orthopnea may 
also occur in the advanced stages of pregnancy and is due to pressure exerted on the 
diaphragm by the gravid uterus. Light-headedness and syncope can result from 
venocaval compression by the enlarged uterus causing supine hypotensive syndrome. 
Palpitations are common and are related to the increased heart rate and to women being 
more aware of their heart beat.  
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Abnormal findings which may warrant further evaluation include the following: (1) a 
laterally displaced apex beat (more than 2 cm beyond the mid-clavicular line) and (2) non-
physiological murmurs such as diastolic murmurs, pan-systolic murmurs, late systolic 
murmurs, ejection systolic murmurs with intensities of grade 3 or more or those associated 
with ejection clicks. The radiation dose associated with a chest X-ray is very small (<0.005 
rads) and the risk to the fetus is minimal with proper shielding. There should be no 
hesitancy in performing a chest X-ray when it is clinically indicated.  
4.3 ECG 
Several electrocardiographic changes have been described in pregnant patients (Gowda, 
2003). Caution should be exercised when interpreting the electrocardiographic abnormalities 
in pregnant women, and must account for the normal physiological changes occuring in 
pregnancy. This may results in decreased PR, QRS, and QT intervals, but usually there is no 
change in the amplitude of the P wave, QRS complex, and T wave. There is an increase of 
the heart rate (about 10 beats/minute). The electrical axis shift can occur, more commonly 
leftward, due to rotation of the heart secondary to the enlargement of the gravid uterus. 
Premature atrial and ventricular contractions are common during pregnancy (Stein, 1999). 
Supraventricular tachycardia may occur as new onset paroxysmal supraventricular 
tachycardia or exacerbation during pregnancy, cause probably by the hyperdynamic state 
(Gowda, 2003). Wolf-Parkinson White (WPW) syndrome may first occur during pregnancy 
or the frequency of episodes may increase in women with previously diagnosed WPW 
syndrome. Atrial fibrillation and flutter are rare in pregnant patients and are secondary to 
congenital or valvular heart disease, electrolyte imbalances or metabolic disorders. 
Ventricular tachycardia raises usually the suspicion of underlying cardiovascular disease, 
but physical or physiological stresses may precipitate ventricular arrhythmias in pregnant 
women without structural heart disease. Bradyarrhythmias are uncommon in pregnancy.   
A patient without previous heart disease will usually have a normal ECG between episodes 
of arrhythmia. Infrequently, a patient may have 12-lead ECG abnormalities indicative of 
primary ‘electrical’ disease, such as frequent ectopic beats or Wolff–Parkinson–White 
syndrome. A patient with previous heart disease may have an abnormal resting ECG,  
reflecting their condition and any surgical intervention they may have received in the past. 
Arrhythmia symptoms are typically intermittent and a 12-lead ECG recording during 
symptoms may not be available. Prolonged ECG monitoring with either inpatient bedside 
monitoring or a portable Holter monitor may pick up an episode in a patient with frequent 
symptoms. Where symptoms are less frequent, it is appropriate for the patient to wear a 
cardiac rhythm event monitor for 7 days or longer, with a patient-activation function for use 
during episodes of symptoms. It is helpful for the patient to keep a diary of symptoms, 
which can then be related to the recorded rhythm. Most types of devices will also record 
asymptomatic episodes when the heart rate falls outside certain preprogrammed limits. The 
patient should be encouraged to pursue all her normal activities during the recording, in 
particular those activities that previously triggered her symptoms. 
4.4 Echocardiography and Doppler 
Echocardiography is of undisputed value in the diagnosis and follow-up of structural and 
functional heart disease, and should be considered an integral part of the investigation of 
any pregnant patient with arrhythmia. It is noninvasive and poses no risk to the fetus. It is 
the best way to exclude puerperal cardiomyopathy. Changes include slight increases in 
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increased end‐diastolic volumes due to intravascular volume expansion, as well as 
hormonal and emotional changes (Adamson, 2007). Pregnancies with abnormal uterine 
perfusion and subsequent pathological outcomes are paralleled by changes in ventricular 
repolarization, that precede clinical symptoms (Baumert, 2010). Repolarization of the 
ventricular myocardium might be affected in pregnancy due to changes in circulating 
hormones, electrolyte imbalances and increased sympathetic tone.  
It is important to determine if the arrhythmia has clinical conequences such as deterioration 
of the underlying cardiac condition. Arrhythmogenic effects are linked to the type of 
arrhythmia. There is a high risk of maternal and fetal morbidity in women with repaired 
CHD (chronic heart diseases). Studies have demonstrated that simple tachyarrhythmia does 
not lead to death. However, death may occur if this type of arrhythmia is associated with 
structural diseases. New research suggests that women with cyanosis and CHD may 
experience still birth or miscarriage. In this situation, the best case scenario is a low birth 
weight infant. 
4. Signs, investigations and diagnosis 
4.1 Symptoms 
Palpitations, the most common presenting symptom, are usually intermittent and only 
rarely indicate a serious problem. Patients with arrhythmia may also present with fatigue, 
breathlessness, peripheral edema and chest discomfort resulting from cardiac failure. 
Symptoms of thromboembolism may be the presenting feature of atrial fibrillation or atrial 
flutter. Patients complaining of palpitations, but without documented arrhythmia, have a 
low likelihood for having a life-threatening arrhythmia, and no further evaluation is 
warranted (Andreson, 1997). A history of previous heart disease increases the likelihood of 
life threatening arrythmias. Inquiry should be made about the family history, particularly 
with reference to cases of premature sudden death.  
The severity of the symptoms allows the physician to judge whether the risks of therapy 
outweigh the benefits. The only difference in pregnancy is that the physician must consider 
the risk/benefit ratio for both the mother and the fetus. An arrhythmia that is 
hemodynamically compromising to the mother constitutes a major concern because of 
inadequate maternal, as well as placental, blood flow (Anderson, 1997). 
4.2 Examination 
The pulse may be abnormal during symptoms; the clinician should focus on looking for 
signs of heart disease that may be associated with arrhythmia, including scars from 
previous surgery, murmurs of structural heart disease and signs of cardiac failure. It is 
also important to look for systemic problems such as thyrotoxicosis that may cause 
arrhythmia.  The diagnosis of heart disease in pregnancy is often difficult due to the 
anatomical and physiological changes in the cardiovascular system. Many symptoms and 
signs of normal pregnancy can mimic heart disease. Dyspnea is especially common, with 
75% of women complaining of breathlessness by 31 weeks (Elkos, 1992). Orthopnea may 
also occur in the advanced stages of pregnancy and is due to pressure exerted on the 
diaphragm by the gravid uterus. Light-headedness and syncope can result from 
venocaval compression by the enlarged uterus causing supine hypotensive syndrome. 
Palpitations are common and are related to the increased heart rate and to women being 
more aware of their heart beat.  
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Abnormal findings which may warrant further evaluation include the following: (1) a 
laterally displaced apex beat (more than 2 cm beyond the mid-clavicular line) and (2) non-
physiological murmurs such as diastolic murmurs, pan-systolic murmurs, late systolic 
murmurs, ejection systolic murmurs with intensities of grade 3 or more or those associated 
with ejection clicks. The radiation dose associated with a chest X-ray is very small (<0.005 
rads) and the risk to the fetus is minimal with proper shielding. There should be no 
hesitancy in performing a chest X-ray when it is clinically indicated.  
4.3 ECG 
Several electrocardiographic changes have been described in pregnant patients (Gowda, 
2003). Caution should be exercised when interpreting the electrocardiographic abnormalities 
in pregnant women, and must account for the normal physiological changes occuring in 
pregnancy. This may results in decreased PR, QRS, and QT intervals, but usually there is no 
change in the amplitude of the P wave, QRS complex, and T wave. There is an increase of 
the heart rate (about 10 beats/minute). The electrical axis shift can occur, more commonly 
leftward, due to rotation of the heart secondary to the enlargement of the gravid uterus. 
Premature atrial and ventricular contractions are common during pregnancy (Stein, 1999). 
Supraventricular tachycardia may occur as new onset paroxysmal supraventricular 
tachycardia or exacerbation during pregnancy, cause probably by the hyperdynamic state 
(Gowda, 2003). Wolf-Parkinson White (WPW) syndrome may first occur during pregnancy 
or the frequency of episodes may increase in women with previously diagnosed WPW 
syndrome. Atrial fibrillation and flutter are rare in pregnant patients and are secondary to 
congenital or valvular heart disease, electrolyte imbalances or metabolic disorders. 
Ventricular tachycardia raises usually the suspicion of underlying cardiovascular disease, 
but physical or physiological stresses may precipitate ventricular arrhythmias in pregnant 
women without structural heart disease. Bradyarrhythmias are uncommon in pregnancy.   
A patient without previous heart disease will usually have a normal ECG between episodes 
of arrhythmia. Infrequently, a patient may have 12-lead ECG abnormalities indicative of 
primary ‘electrical’ disease, such as frequent ectopic beats or Wolff–Parkinson–White 
syndrome. A patient with previous heart disease may have an abnormal resting ECG,  
reflecting their condition and any surgical intervention they may have received in the past. 
Arrhythmia symptoms are typically intermittent and a 12-lead ECG recording during 
symptoms may not be available. Prolonged ECG monitoring with either inpatient bedside 
monitoring or a portable Holter monitor may pick up an episode in a patient with frequent 
symptoms. Where symptoms are less frequent, it is appropriate for the patient to wear a 
cardiac rhythm event monitor for 7 days or longer, with a patient-activation function for use 
during episodes of symptoms. It is helpful for the patient to keep a diary of symptoms, 
which can then be related to the recorded rhythm. Most types of devices will also record 
asymptomatic episodes when the heart rate falls outside certain preprogrammed limits. The 
patient should be encouraged to pursue all her normal activities during the recording, in 
particular those activities that previously triggered her symptoms. 
4.4 Echocardiography and Doppler 
Echocardiography is of undisputed value in the diagnosis and follow-up of structural and 
functional heart disease, and should be considered an integral part of the investigation of 
any pregnant patient with arrhythmia. It is noninvasive and poses no risk to the fetus. It is 
the best way to exclude puerperal cardiomyopathy. Changes include slight increases in 
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systolic and diastolic left ventricular dimensions, moderate increases in the size of the right 
atrium, right ventricle and left atrium, progressive dilatation of the pulmonary, tricuspid 
and mitral valve annuli with functional regurgitation (Campos, 2009). 
4.5 Genetic testing 
Several cardiac conditions increase the vulnerability to arrhythmias and have a defined 
genetic basis. Although routine genetic testing for these conditions is not currently available 
for the evaluation of arrhythmia risk in pregnancy, a detailed family history should always 
be taken, and include specific questioning about premature sudden death. Counseling about 
the risk of transmission of these conditions to offspring is essential, and it is likely that there 
will be an increasing role for pre-implantation diagnosis of these conditions in affected 
families (Ueda, 2004). 
4.6 Laboratory tests 
Laboratory tests are not effective in diagnosis of syncope, but it can reveal some of its causes. 
Blood tests like complete blood count, electrolyte panel, and chemistry panel can lead to 
causes of arrhythmia. The blood test count is used to detect anemia or acute blood loss. 
Electrolyte panel may reveal the level of hydration. As far as the chemistry panel is concerned, 
thyroid stimulating hormone and serum drug levels should be assessed. Studies have shown 
that routine blood tests are not always necessary or fruitful (Olshansky, 2008). Besides blood 
tests, there are more precise diagnostic tests, like HUTT used by clinicians to assess patients 
who present syncope (Bendit et al. 1996). Used first by the NASA, HUTT emerged in 
cardiology in 1980 (NASA 1999, Baron-Esquivas et al 2003). The design of the HUTT was 
based on the following physiological mechanism: due to gravity, in a up-ward position, the 
blood will be displaced downwards. Consequently, the venous system will expand. The 
sympathetic system will increase the PVR and the skeletal muscle tone, the latter being an 
important component in maintaining the upright posture and also helping the venous blood to 
return to the heart and brain (Brignole, 2005). The role of the HUTT is to inhibit the skeletal 
muscle pump in the extremities that are responsible for the upright posture or orthostatic 
stress. In normal conditions; skeletal muscles contraction does not occur when venous pooling 
starts. However, individuals presenting excessive venous pooling, difficulty with PVR or 
sensitivity to diminish venous return, may experience difficulty in maintaining the upright 
posture on HUTT. The number of HUTT protocols varies, but the main idea is to induce 
venous pooling either through passive upright position or using vasodilators (protenerol, 
nitroglycerin, and adenosine) which inhibit the innate skeletal muscle pump. Guidelines 
(American College of Cardiology 1996) state that HUTT is efficient in cases such as: recurrent 
syncope or single episode in a high-risk patient; no evidence of the structural heart disease; 
structural heart diseases, as long as other causes have been excluded by the diagnostic testing. 
There are also conditions in which HUTT has proved to be inefficient. The most common are 
syncope episodes without injury and not in high risk setting and syncope with identified cause 
and identification of NCS would not alter therapy. There are some cases in which the use of 
HUTT is forbidden (syncope with ventricular outflow obstruction, critical mitral stenosis, and 
critical cerebral vascular stenosis).  
5. Treatment 
Due to the fact that physiological changes of pregnancy affect drug absorption as well as the 
metabolism in several ways, it may be difficult to obtain adequate therapeutic drug levels 
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and to avoid toxicity. This may explain why some women experience recurrence of 
symptoms of arrhythmia during pregnancy despite continuing therapy that had previously 
been effective (Tan, 2001). 
Arrhythmias in pregnancy are treated conservatively. After determining the type of 
arrhythmia, the physician will evaluate for underlying causes. If symptoms are minimal, 
rest and vagal maneuvers may be used to help slow the heart rate. Vagal maneuvers include 
carotid massage, applying ice to the face, and the Valvsalva maneuver, which is the most 
successful in stopping tachycardias (Zu-Chi, 1998). When the arrhythmia causes symptoms 
or a drop in blood pressure, antiarrhythmic medications may be used. No anti-arrhythmic 
medication is completely safe during pregnancy; therefore medications are avoided during 
the first trimester, if possible, to limit risk to the fetus. Drugs with the longest safety record 
should be tried first. Propranolol, metoprolol, digoxin, and adenosine have been tested and 
shown to be well tolerated and safe during the second and third trimester (Ferrero, 2004). 
When a cardiac disease is identified in a pregnant woman, we must keep in mind the 
following (ACOG, 1992): 
 The blood volume and the cardiac output increase with approximately 50% at the 
beginning of the first trimester of pregnancy. 
 There are big changes of the circulated volume and of the cardiac output during the 
birth and in the period after. 
 The peripheral vascular resistance decreases in pregnancy and returns to minimum in 
the second trimester. After that it increases, up to 20% referred to normal, during late 
pregnancy. 
 Hypercoagulability is present in pregnancy. This is very important, particularly in 
patients requiring anticoagulant therapy outside the pregnancy. 
Pregnancies with any cardiac problem must be managed by a complex team, consisting of 
an obstetrician, a cardiologist and, if necessarily, an intensive therapy specialist and/or a 
fetal medicine specialist.  The aforementioned are compulsory in order to obtain an excellent 
outcome both for mother and for the child.  
5.1 Arrhythmia prevention 
In pregnancy, risk of cardiac disease or arrhythmias should be eliminated by: 
- Making healthy lifestyle choices 
Living a "heart healthy" life is the best way to decrease the chances of developing heart 
disorders. Exercising regularly (brisk walking, running, bicycling, swimming) and eating 
healthy are the most important. According to the American Heart Association, a heart-
healthy diet includes high amounts of fruits and vegetables (at least five servings a day) and 
of whole grain foods. It includes lean protein sources like fish, beans, and low-fat dairy 
products, derives most of its fat from unsaturated fats like olive oil, and avoids saturated 
fats, trans-fats, and cholesterol. 
- Maintaining a healthy weight 
It's important to balance the eaten calories with burned calories through daily activity and 
exercise. Obesity is linked to heart disease. 
- Smoking cessation and limiting the intake of caffeine or alcohol 
Tobacco contributes to as much as one-third of all cardiovascular disease. It is necessary to 
avoid or limit the intake of caffeine, alcohol, and other substances that may contribute to 
arrhythmias or heart disease. The American Heart Association recommends restriction of 
the use of alcohol to one drink a day for women and two a day for men (a drink equals 12 
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systolic and diastolic left ventricular dimensions, moderate increases in the size of the right 
atrium, right ventricle and left atrium, progressive dilatation of the pulmonary, tricuspid 
and mitral valve annuli with functional regurgitation (Campos, 2009). 
4.5 Genetic testing 
Several cardiac conditions increase the vulnerability to arrhythmias and have a defined 
genetic basis. Although routine genetic testing for these conditions is not currently available 
for the evaluation of arrhythmia risk in pregnancy, a detailed family history should always 
be taken, and include specific questioning about premature sudden death. Counseling about 
the risk of transmission of these conditions to offspring is essential, and it is likely that there 
will be an increasing role for pre-implantation diagnosis of these conditions in affected 
families (Ueda, 2004). 
4.6 Laboratory tests 
Laboratory tests are not effective in diagnosis of syncope, but it can reveal some of its causes. 
Blood tests like complete blood count, electrolyte panel, and chemistry panel can lead to 
causes of arrhythmia. The blood test count is used to detect anemia or acute blood loss. 
Electrolyte panel may reveal the level of hydration. As far as the chemistry panel is concerned, 
thyroid stimulating hormone and serum drug levels should be assessed. Studies have shown 
that routine blood tests are not always necessary or fruitful (Olshansky, 2008). Besides blood 
tests, there are more precise diagnostic tests, like HUTT used by clinicians to assess patients 
who present syncope (Bendit et al. 1996). Used first by the NASA, HUTT emerged in 
cardiology in 1980 (NASA 1999, Baron-Esquivas et al 2003). The design of the HUTT was 
based on the following physiological mechanism: due to gravity, in a up-ward position, the 
blood will be displaced downwards. Consequently, the venous system will expand. The 
sympathetic system will increase the PVR and the skeletal muscle tone, the latter being an 
important component in maintaining the upright posture and also helping the venous blood to 
return to the heart and brain (Brignole, 2005). The role of the HUTT is to inhibit the skeletal 
muscle pump in the extremities that are responsible for the upright posture or orthostatic 
stress. In normal conditions; skeletal muscles contraction does not occur when venous pooling 
starts. However, individuals presenting excessive venous pooling, difficulty with PVR or 
sensitivity to diminish venous return, may experience difficulty in maintaining the upright 
posture on HUTT. The number of HUTT protocols varies, but the main idea is to induce 
venous pooling either through passive upright position or using vasodilators (protenerol, 
nitroglycerin, and adenosine) which inhibit the innate skeletal muscle pump. Guidelines 
(American College of Cardiology 1996) state that HUTT is efficient in cases such as: recurrent 
syncope or single episode in a high-risk patient; no evidence of the structural heart disease; 
structural heart diseases, as long as other causes have been excluded by the diagnostic testing. 
There are also conditions in which HUTT has proved to be inefficient. The most common are 
syncope episodes without injury and not in high risk setting and syncope with identified cause 
and identification of NCS would not alter therapy. There are some cases in which the use of 
HUTT is forbidden (syncope with ventricular outflow obstruction, critical mitral stenosis, and 
critical cerebral vascular stenosis).  
5. Treatment 
Due to the fact that physiological changes of pregnancy affect drug absorption as well as the 
metabolism in several ways, it may be difficult to obtain adequate therapeutic drug levels 
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and to avoid toxicity. This may explain why some women experience recurrence of 
symptoms of arrhythmia during pregnancy despite continuing therapy that had previously 
been effective (Tan, 2001). 
Arrhythmias in pregnancy are treated conservatively. After determining the type of 
arrhythmia, the physician will evaluate for underlying causes. If symptoms are minimal, 
rest and vagal maneuvers may be used to help slow the heart rate. Vagal maneuvers include 
carotid massage, applying ice to the face, and the Valvsalva maneuver, which is the most 
successful in stopping tachycardias (Zu-Chi, 1998). When the arrhythmia causes symptoms 
or a drop in blood pressure, antiarrhythmic medications may be used. No anti-arrhythmic 
medication is completely safe during pregnancy; therefore medications are avoided during 
the first trimester, if possible, to limit risk to the fetus. Drugs with the longest safety record 
should be tried first. Propranolol, metoprolol, digoxin, and adenosine have been tested and 
shown to be well tolerated and safe during the second and third trimester (Ferrero, 2004). 
When a cardiac disease is identified in a pregnant woman, we must keep in mind the 
following (ACOG, 1992): 
 The blood volume and the cardiac output increase with approximately 50% at the 
beginning of the first trimester of pregnancy. 
 There are big changes of the circulated volume and of the cardiac output during the 
birth and in the period after. 
 The peripheral vascular resistance decreases in pregnancy and returns to minimum in 
the second trimester. After that it increases, up to 20% referred to normal, during late 
pregnancy. 
 Hypercoagulability is present in pregnancy. This is very important, particularly in 
patients requiring anticoagulant therapy outside the pregnancy. 
Pregnancies with any cardiac problem must be managed by a complex team, consisting of 
an obstetrician, a cardiologist and, if necessarily, an intensive therapy specialist and/or a 
fetal medicine specialist.  The aforementioned are compulsory in order to obtain an excellent 
outcome both for mother and for the child.  
5.1 Arrhythmia prevention 
In pregnancy, risk of cardiac disease or arrhythmias should be eliminated by: 
- Making healthy lifestyle choices 
Living a "heart healthy" life is the best way to decrease the chances of developing heart 
disorders. Exercising regularly (brisk walking, running, bicycling, swimming) and eating 
healthy are the most important. According to the American Heart Association, a heart-
healthy diet includes high amounts of fruits and vegetables (at least five servings a day) and 
of whole grain foods. It includes lean protein sources like fish, beans, and low-fat dairy 
products, derives most of its fat from unsaturated fats like olive oil, and avoids saturated 
fats, trans-fats, and cholesterol. 
- Maintaining a healthy weight 
It's important to balance the eaten calories with burned calories through daily activity and 
exercise. Obesity is linked to heart disease. 
- Smoking cessation and limiting the intake of caffeine or alcohol 
Tobacco contributes to as much as one-third of all cardiovascular disease. It is necessary to 
avoid or limit the intake of caffeine, alcohol, and other substances that may contribute to 
arrhythmias or heart disease. The American Heart Association recommends restriction of 
the use of alcohol to one drink a day for women and two a day for men (a drink equals 12 
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ounces of beer, 4 ounces of wine or 1 ounce of 100-proof spirits). A single episode of heavy 
consumption can trigger arrhythmias like atrial fibrillation.  Stimulants, both legal and 
illegal, can contribute to the development of heart arrhythmias. Caffeine and nicotine may, 
in some cases, cause premature ventricular contractions, which, over time, may develop into 
more serious arrhythmias. Cocaine and amphetamines also accelerate the heart rate, in some 
cases leading to ventricular fibrillation and sudden death. Supplements or some herbal 
remedies may increase the risk of arrhythmias. For instance, Ephedra, the herbal 
supplement once promoted as a diet aid and energy booster, increases the risk of 
arrhythmia. In 2004 the FDA pulled it from the shelves for that very reason.  
- Avoiding unnecessary stress, such as anger, anxiety or fear, and finding ways to manage 
or control stressful situations that cannot be avoided.  
- Avoiding stimulant medications  
Many drugs may cause arrhythmias. Over-the-counter cough and cold medicines may 
speed up the heart. And approximately 50 FDA-approved medications have the potential to 
prolong the QT interval—the measure of time it takes for the electrical system in the 
ventricles to recharge after each heartbeat—and thus cause the acquired form of long QT 
syndrome (LQTS), in which the heart's mechanical or pumping function is normal but its 
recharging system is slow or ineffective. Those medications include certain antibiotics, 
antidepressants, antifungal, antihistamines, psychotropic medications, oral hypoglycemic 
(medications for diabetes), anesthetic agents, and even drugs used to treat heart disease like 
lipid-lowing drugs and diuretics. Patients with inherited LQTS should always ask 
physicians and pharmacists if a prescribed drug has the potential to aggravate the condition. 
Women have a longer QT interval on the electrocardiogram compared to men, despite 
higher heart rates.  
Tocolitics may induce arrhythmias. Corrected QT and Tpeak-Tend intervals were 
unchanged from pre-operative values after induction of spinal anaesthesia in women 
undergoing caesarian section, but increased significantly after oxytocin injection.  The risk-
benefit balance of oxytocin bolus during caesarean delivery should be discussed with 
women with a history of long QT syndrome. (Guillon, 2010). Women with a long QT 
syndrome are more susceptible to ventricular arrythmias during pregnancy, labour, 
delivery and postpartum (Drake, 2007; Seth, 2007).  
- Having regular physical exams and promptly reporting any unusual symptoms to a 
physician. The Centers for Disease Control and Prevention suggests that families with a 
history of arrhythmias or sudden cardiac arrest consider screening younger family 
members.  
- Seeking treatment for underlying health problems that may contribute to arrhythmias and 
heart disease.  
Any of the following conditions can increase the likelihood of developing arrhythmias: 
coronary artery disease, congenital heart disease, heart failure, stroke, atherosclerosis, heart 
valve damage, high blood pressure, high cholesterol, diabetes, obesity, thyroid disease, 
advancing age  
5.2 Monitoring and treating existing heart disorders 
Effectively treating any existing heart disorder is the best way to prevent it from becoming 
more severe. This can be done by: 
 Having regular check ups 
 Understanding how various conditions increase the risk of arrhythmias.  
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 Learning about heart disorders, tests, and treatment options, and discussing them with 
caregivers.  
 Finding out if the heart's electrical system and its ability to pump blood efficiently have 
been affected by heart muscle damage from a heart attack or another cause.  
 Learning the importance of an ejection fraction (EF). EF is a measure of the proportion, 
or fraction, of blood the heart pumps out with each beat. An abnormally low EF is the 
single most important factor in predicting the risk of Sudden Cardiac Arrest (SCA).  
 Following treatment plans. 
 Reporting any new symptoms or changes in existing symptoms to physicians as soon as 
possible.   
5.3 Treatment 
When the treatment plan is conceived, the physician has to consider factors like: the severity 
of the arrhythmia, the severity of patient’s symptoms, if the patient has other health 
problems/medications that the patient takes, patient’s age, overall health, and personal and 
family medical history of the patient. 
Arrhythmia treatments may include one or more of the following:  
1. Medicine to prevent and control arrhythmias and to treat related conditions such as 
high blood pressure, coronary artery disease and heart failure  
2. Anticoagulant medication to reduce the risk of blood clots and stroke  
3. A pacemaker that uses batteries to help the heart to beat more regularly  
4. Cardiac defibrillation and implanted cardioverter defibrillators (ICDs)  
5. Cardiac ablation; cryoablation (the defective cells are detected with the help of 
computerized mapping techniques and destroyed with a cold probe). 
6. Surgery  
7. Cardioversion 
8. Other therapies. 
In association with the effect on the human body, heart medication is categorized into two 
groups: "rate control" medicines, are used to slow the heart rate to less than 100 beats per 
minute or "rhythm control" medications (antiarrhythmic/cardioversion drugs) used in order 
to restore your heart's normal sinus rhythm. The aforementioned drugs are being used less, 
with more care and often in conjunction with implantable cardioverter defibrillators (ICDs) 
or cardiac ablation.  
Many of the prescription medications reviewed here are also used to treat other kinds of 
heart-related conditions, including heart failure, high blood pressure, and angina (chest 
pain).  
5.3.1 Rate control heart medication 
Rate control heart medicine may include beta or calcium channel blockers. The first group of 
medication reduces the heart rate and cardiac output by lowering the blood pressure by 
blocking adrenalin. The most used beta blockers are: Acebutolol, Atenolol, Betaxolol, 
Bisoprolol/hydrochlorothiazide, Carteolol, Esmolol, Metoprolol, Nadolol, Penbutolol, 
Pindolol, Propranolol and Timolol. Calcium channel blockers, also called "calcium 
antagonists”, work by interrupting the movement of calcium into heart and blood vessel 
tissue, slowing the heart rate. They are used in other disorders like: angina and arrhythmias.  
Examples of calcium channel blockers: Amlodipine, Diltiazem, Felodipine, Isradipine, 
Nicardipine, Nifedipine, Nimodipine, Nisoldipine and Verapamil.  
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ounces of beer, 4 ounces of wine or 1 ounce of 100-proof spirits). A single episode of heavy 
consumption can trigger arrhythmias like atrial fibrillation.  Stimulants, both legal and 
illegal, can contribute to the development of heart arrhythmias. Caffeine and nicotine may, 
in some cases, cause premature ventricular contractions, which, over time, may develop into 
more serious arrhythmias. Cocaine and amphetamines also accelerate the heart rate, in some 
cases leading to ventricular fibrillation and sudden death. Supplements or some herbal 
remedies may increase the risk of arrhythmias. For instance, Ephedra, the herbal 
supplement once promoted as a diet aid and energy booster, increases the risk of 
arrhythmia. In 2004 the FDA pulled it from the shelves for that very reason.  
- Avoiding unnecessary stress, such as anger, anxiety or fear, and finding ways to manage 
or control stressful situations that cannot be avoided.  
- Avoiding stimulant medications  
Many drugs may cause arrhythmias. Over-the-counter cough and cold medicines may 
speed up the heart. And approximately 50 FDA-approved medications have the potential to 
prolong the QT interval—the measure of time it takes for the electrical system in the 
ventricles to recharge after each heartbeat—and thus cause the acquired form of long QT 
syndrome (LQTS), in which the heart's mechanical or pumping function is normal but its 
recharging system is slow or ineffective. Those medications include certain antibiotics, 
antidepressants, antifungal, antihistamines, psychotropic medications, oral hypoglycemic 
(medications for diabetes), anesthetic agents, and even drugs used to treat heart disease like 
lipid-lowing drugs and diuretics. Patients with inherited LQTS should always ask 
physicians and pharmacists if a prescribed drug has the potential to aggravate the condition. 
Women have a longer QT interval on the electrocardiogram compared to men, despite 
higher heart rates.  
Tocolitics may induce arrhythmias. Corrected QT and Tpeak-Tend intervals were 
unchanged from pre-operative values after induction of spinal anaesthesia in women 
undergoing caesarian section, but increased significantly after oxytocin injection.  The risk-
benefit balance of oxytocin bolus during caesarean delivery should be discussed with 
women with a history of long QT syndrome. (Guillon, 2010). Women with a long QT 
syndrome are more susceptible to ventricular arrythmias during pregnancy, labour, 
delivery and postpartum (Drake, 2007; Seth, 2007).  
- Having regular physical exams and promptly reporting any unusual symptoms to a 
physician. The Centers for Disease Control and Prevention suggests that families with a 
history of arrhythmias or sudden cardiac arrest consider screening younger family 
members.  
- Seeking treatment for underlying health problems that may contribute to arrhythmias and 
heart disease.  
Any of the following conditions can increase the likelihood of developing arrhythmias: 
coronary artery disease, congenital heart disease, heart failure, stroke, atherosclerosis, heart 
valve damage, high blood pressure, high cholesterol, diabetes, obesity, thyroid disease, 
advancing age  
5.2 Monitoring and treating existing heart disorders 
Effectively treating any existing heart disorder is the best way to prevent it from becoming 
more severe. This can be done by: 
 Having regular check ups 
 Understanding how various conditions increase the risk of arrhythmias.  
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 Learning about heart disorders, tests, and treatment options, and discussing them with 
caregivers.  
 Finding out if the heart's electrical system and its ability to pump blood efficiently have 
been affected by heart muscle damage from a heart attack or another cause.  
 Learning the importance of an ejection fraction (EF). EF is a measure of the proportion, 
or fraction, of blood the heart pumps out with each beat. An abnormally low EF is the 
single most important factor in predicting the risk of Sudden Cardiac Arrest (SCA).  
 Following treatment plans. 
 Reporting any new symptoms or changes in existing symptoms to physicians as soon as 
possible.   
5.3 Treatment 
When the treatment plan is conceived, the physician has to consider factors like: the severity 
of the arrhythmia, the severity of patient’s symptoms, if the patient has other health 
problems/medications that the patient takes, patient’s age, overall health, and personal and 
family medical history of the patient. 
Arrhythmia treatments may include one or more of the following:  
1. Medicine to prevent and control arrhythmias and to treat related conditions such as 
high blood pressure, coronary artery disease and heart failure  
2. Anticoagulant medication to reduce the risk of blood clots and stroke  
3. A pacemaker that uses batteries to help the heart to beat more regularly  
4. Cardiac defibrillation and implanted cardioverter defibrillators (ICDs)  
5. Cardiac ablation; cryoablation (the defective cells are detected with the help of 
computerized mapping techniques and destroyed with a cold probe). 
6. Surgery  
7. Cardioversion 
8. Other therapies. 
In association with the effect on the human body, heart medication is categorized into two 
groups: "rate control" medicines, are used to slow the heart rate to less than 100 beats per 
minute or "rhythm control" medications (antiarrhythmic/cardioversion drugs) used in order 
to restore your heart's normal sinus rhythm. The aforementioned drugs are being used less, 
with more care and often in conjunction with implantable cardioverter defibrillators (ICDs) 
or cardiac ablation.  
Many of the prescription medications reviewed here are also used to treat other kinds of 
heart-related conditions, including heart failure, high blood pressure, and angina (chest 
pain).  
5.3.1 Rate control heart medication 
Rate control heart medicine may include beta or calcium channel blockers. The first group of 
medication reduces the heart rate and cardiac output by lowering the blood pressure by 
blocking adrenalin. The most used beta blockers are: Acebutolol, Atenolol, Betaxolol, 
Bisoprolol/hydrochlorothiazide, Carteolol, Esmolol, Metoprolol, Nadolol, Penbutolol, 
Pindolol, Propranolol and Timolol. Calcium channel blockers, also called "calcium 
antagonists”, work by interrupting the movement of calcium into heart and blood vessel 
tissue, slowing the heart rate. They are used in other disorders like: angina and arrhythmias.  
Examples of calcium channel blockers: Amlodipine, Diltiazem, Felodipine, Isradipine, 
Nicardipine, Nifedipine, Nimodipine, Nisoldipine and Verapamil.  
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5.3.2 Rhythm control heart medications 
Rhythm control medication includes sodium channel blockers, beta blockers, class III 
antiarrhythmics that slow the electrical conductivity of the heart to improve rhythm 
problems. This type of medication can be administrated intravenously in emergency 
situations and orally in long term situations: Amiodarone, Bepridil Hydrochloride, 
Disopyramide, Dofetilide, Flecainide, Ibutilide, Lidocaine, Procainamide, Propafenone, 
Propranolol, Quinidine, Sotalol and Tocainide. 
5.3.3 Drug administration 
All medications have potential side effects and risks. Antiarrhythmic drugs must be taken daily 
and indefinitely. There are also side effects that are hard to manage. These side effects may 
include proarrhythmia, which means drug-related arrhythmia. When medication proves 
unsuccessful, the American College of Cardiology and the American Heart Association suggest 
catheter (cardiac) ablation or surgical ablation as a safe and effective treatment option.  
The greatest risk is however drug-induced congenital malformation, that is most prone to 
occur during fetal organogenesis, a process which is completed by the end of the first 
trimester. Thereafter, the risk is mainly of impaired growth and functional development, or 
direct toxicity to fetal tissues. Drugs given shortly before term or during labour may have 
adverse effects on labour or the neonate after delivery. Most antiarrhythmic drugs are 
categorized by the US Food and Drug Administration (FDA) as category C during 
pregnancy which signifies that: risk (to the fetus) cannot be ruled out. Adequate well-
controlled human studies are lacking, and animal studies have shown a risk to the fetus or 
are lacking as well. There is a chance of fetal harm if the drug is administered during 
pregnancy; but the potential benefits may outweigh the risks (Blomstrom-Lundqvist, 2003). 
Drug treatment is not required for a benign tachycardia that is well tolerated. A low dose 
should be used initially with titration according to response, and this must be accompanied 
by regular monitoring. The selection of an appropriate drug depends on knowledge of the 
arrhythmia mechanisms, and only drugs with a safe track record in pregnancy should be 
used. The most common drugs are: Adenosine, Digoxine, and Beta Blockers.  
Research showed that Adenosine is useful for the emergency management of SVT and 
broad QRS complex tachycardias, and has been used safely in pregnant women (Blomstrom-
Lundqvist, 2003). It is administered as a bolus dose and it has a very short duration of action 
of no more than 5–10 s. The role of this medication is to depress sinus and AV nodal 
function causing transient bradycardia and AV block in the mother, but it has no detectable 
effect on the fetal cardiac rhythm. Adenosine is contraindicated in patients with brittle 
asthma, in whom it may cause bronchospasm, and in those taking dipyridamole because of 
the risk of prolonged asystole. 
There is a long history of digoxin use during pregnancy and it is considered to be safe 
(Blomstrom-Lundqvist, 2003). It crosses the placenta, but is not teratogenic. It is cleared by 
the kidney, although renal excretion is inhibited by concomitant use of amiodarone. It is 
mainly used for the control of ventricular rate in patients with persistent atrial fibrillation, 
but may also be effective in some cases of focal atrial tachycardia. 
Propranolol is the beta blocker with the longest track record and is considered safe in 
pregnancy (Blomstrom-Lundqvist, 2003). Beta blockers are not teratogenic, but beta1-
selective blockers, such as atenolol or metoprolol, may be preferred because they may 
interfere less with beta2-receptor-mediated uterine relaxation. However, beta1-selective 
agents achieve less complete cardiac beta blockade because there are functional beta2-
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receptors on cardiac myocytes, and these may, therefore, be less effective anti-arrhythmic 
agents. There have been reports linking beta blockers to fetal bradycardia, hypotonia, 
hypoglycemia and intrauterine growth retardation. 
Sotalol is a combined beta blocker and class III anti-arrhythmic drug. It does cross the 
placenta and is excreted renally. It has achieved class B classification with the FDA and its 
use in pregnant patients has been reported with no adverse outcome (Blomstrom-Lundqvist, 
2003). 
Flecainide has been used frequently during pregnancy and is a reasonable choice for 
patients with a structurally normal heart (Blomstrom-Lundqvist, 2003). It should probably 
be avoided in those with myocardial disease, and in particular patients with ventricular 
tachycardia or vulnerability to myocardial ischemia. 
The conflict between the interests of the mother and the well-being of the fetus is thrown 
into sharp relief with Amiodarone. Amiodarone is a very effective anti-arrhythmic drug to 
treat and prevent life-threatening ventricular arrhythmias in patients with ventricular 
disease. Amiodarone crosses the placenta and achieves fetal concentrations of around 10% 
of maternal serum values (Ovadia, 1994). Maternal amiodarone use may cause a goiter, 
which in turn compromises the upper airway in the neonate. Amiodarone is prone to cause, 
neonatal hypothyroidism, and fetal growth retardation.  For these reasons, amiodarone 
should be used only when the mother’s life is significantly threatened and no other agent 
will do (Chow, 1998). 
There are no reports of teratogenicity, but verapamil does cross the placenta and may have 
fetal cardiovascular effects (Klein, 1984). Intravenous verapamil is a useful alternative to 
adenosine for emergency termination of SVT, and oral verapamil may be used in patients to 
prevent SVT recurrence when beta blockers are contraindicated or not tolerated (Klein, 
1984). 
Anticoagulant medications help to prevent new clots appearance in the blood or existing 
clots from getting larger. They are often prescribed for patients with atrial fibrillation to help 
reduce stroke risk. Aspirin also is often recommended for these patients in addition to or 
instead of prescription anticoagulants. 
The pacemaker is a small device that's surgically placed under the skin at the collarbone; 
wires lead from it to the atrium and ventricle(s). The pacemaker sends small electric signals 
through the wires to control the speed of the heartbeat. Most pacemakers contain a sensor 
that activates the device only when the heartbeat is abnormal. 
An ICD (Implantable Cardioverter Defibrillator) provides automatic electrical therapy on a 
chronic basis for patients suffering from recurrent tachycardias. (When an episode of fast, 
irregular heartbeat begins, the device delivers a shock to end the tachycardia, preventing the 
heart from going into ventricular fibrillation, which is frequently fatal). The device is 
connected to leads positioned inside or on the surface of the heart. These leads sense cardiac 
rhythm, provide necessary electrical shocks when necessary, and at times - pace the heart as 
needed. Various leads are connected to a pulse generator implanted in a pouch beneath the 
skin of the chest or abdomen. Newer devices are smaller, with simpler lead systems and can 
be installed through blood vessels. 
Women with an implanted cardioverter defibrillator (ICD) may undergo pregnancy 
successfully with a good reported outcome. Potentially threatening arrhythmias are 
promptly detected and automatically terminated by an ICD by, either a series of rapid 
pacing impulses delivered via an endocardial right ventricular pacing lead, or delivery of a 
synchronized shock between a coil electrode in the right ventricular cavity and a second 
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5.3.2 Rhythm control heart medications 
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by regular monitoring. The selection of an appropriate drug depends on knowledge of the 
arrhythmia mechanisms, and only drugs with a safe track record in pregnancy should be 
used. The most common drugs are: Adenosine, Digoxine, and Beta Blockers.  
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Lundqvist, 2003). It is administered as a bolus dose and it has a very short duration of action 
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selective blockers, such as atenolol or metoprolol, may be preferred because they may 
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electrode formed by the ICD box, which is located in the pre-pectoral position on the left. 
Prompt detection and termination of an arrhythmia by an ICD minimize the hemodynamic 
disturbance and thereby limit the risk of harm to the fetus. ICDs are configured to 
concentrate the maximal electrical field strength to the mother’s ventricular myocardium, 
and the electrical energy to which the fetus is exposed is minimal. Delivered energies  
(2–40 J) are about a tenth of those used for external DC cardioversion. Research found 
Cardioversion safe for the entire pregnancy state therefore, it can be used, if necessary 
(Blomstrom, 2003). Also, there is not additional risk (excepting patients with underlying 
heart condition) to develop ICD complications, during pregnancy (Natale, 1997). 
Ablation is a nonsurgical technique that neutralizes parts of the abnormal electrical pathway 
(tissue) that is causing the arrhythmia. The technique utilizes a variety of imaging and 
monitoring systems that navigate flexible wires (catheters) to the heart through an artery or 
vein, locate the abnormal electrical activity (where ablation is needed), and evaluate their 
progress.  
Once in the heart, one or more catheters are used to pinpoint the source of the abnormal 
electrical signals. When the source of the arrhythmia is located, the catheter delivers bursts 
of high-energy waves that eliminate the abnormal areas.  
There are two techniques of ablation: radiofrequency ablation and transcatheter technique. 
In this first technique, a catheter with an electrode at its tip is guided to the damaged 
portion of heart muscle and mild, painless radiofrequency energy is transmitted to the site 
of the pathway, killing a few cells (about 1/5 of an inch). Consequently, these cells stop 
conducting the extra impulses that caused the rapid heartbeats. This non-surgical procedure 
is used to treat patients suffering from atrial fibrillation, atrial flutter, atrial tachycardia and 
supraventricular tachycardia. The second technique, however, electrocauterization is 
performed at a targeted spot in the heart. This technique is generally used to treat 
supraventricular tachycardia. 
Most patients who receive this treatment experience a long-term reduction in the number of 
episodes of arrhythmia and the severity of symptoms, or a permanent return to normal 
heart rhythm.  
Sometimes, surgery is used to treat arrhythmia. Often this is done when surgery is already 
being performed for another reason, such as repair of a heart valve. One type of surgery for 
atrial fibrillation is called "maze" surgery. In this operation, the surgeon makes small cuts or 
burns in the atria, which prevent the spread of disorganized electrical signals. Ventricular 
resection implies the removal of a part of the heart’s muscle, where the arrhythmia 
originates. 
Coronary artery bypass surgery may be needed for arrhythmias caused by coronary artery 
disease. The operation improves blood supply to the heart muscle. 
Cardioversion treatment can be chemical (implemented through fast-acting drugs) or 
electric (implemented through a direct current using paddles over the chest) and is used 
to restore the heart's normal rhythm. DC cardioversion may be used to terminate 
sustained tachycardias. It should be carried out with general anesthesia, or deep sedation 
with midazolam or diazepam. Traditionally, the cardioversion electrodes are placed at the 
right sternal edge and cardiac apex, but for atrial fibrillation, it may be more effective to 
use an anterior–posterior configuration. Firm downward pressure on the sternal paddle 
reduces the electrode separation and increases the intensity of the electrical field, thus 
maximizing the chance of success. A waveform that reverses polarity during delivery 
(biphasic waveform) achieves cardioversion at energy thresholds that are half those 
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required when a monophasic waveform is used. For all tachyarrhythmias, except 
ventricular fibrillation, the shock should be synchronized to the R wave, to minimize the 
risk of inducing ventricular fibrillation. Patients with atrial flutter or fibrillation are 
particularly vulnerable to systemic thromboembolism after restoration of sinus rhythm. 
DC cardioversion should not be carried out on patients who have been in atrial fibrillation 
for longer than 24 hours unless the arrhythmia results in serious cardiovascular 
compromise, or the patient has been fully anticoagulated since the onset of arrhythmia, or 
the absence of thrombus in the left atrium has been verified by transesophageal 
echocardiography. Anticoagulation should be continued for a minimum of 4 weeks after 
DC cardioversion. DC cardioversion seems to be quite safe in all stages of pregnancy 
because the intensity of the electrical field to which the fetus is exposed is low. 
Nevertheless, the fetus should be carefully monitored throughout the procedure. In the 
later stages of pregnancy, full general anesthesia and intubation are used, considering the 
increased risk of gastric aspiration. 
Vagal maneuvers are another arrhythmia treatment. These are simple exercises that 
sometimes can stop or slow down certain types of supraventricular arrhythmias. They stop 
the arrhythmia by affecting the vagus nerve, which controls the heart rate. Some vagal 
maneuvers include: 
 Gagging  
 Holding breath and bearing down (Valsalva maneuver)  
 Immersing the face in ice-cold water  
 Coughing  
 Putting the fingers on the own eyelids and pressing down gently.  
6. Management of specific arrhythmias during pregnancy, labour and 
delivery 
Dynamic changes in maternal physiology, as well as concern for the fetal well-being, are 
factors that complicate the treatment of arrhythmia. Premature atrial and ventricular 
contractions associated with a structurally normal heart are considered to be benign. 
However, in order to prevent them, exacerbating factors (dehydration, caffeine, sleep 
deprivation) should be avoided. Also, nonpharmacologic vagal maneuvers are 
recommended in atrial tachycardias. In the aforementioned case, drug therapy is indicated 
as long as the patient present refractory symptoms. In order to prevent recurrence, digoxin 
and beta-blockers are recommended. If the patient does not respond to these, flecainide and 
propafenone should be taken into consideration. Cardioversion or intravenous adenosine is 
indicated in acute management. Arrhythmias in association with the Wolf-Parkinson-White 
syndrome should be treated with Prosainamide, during pregnancy.  
Records demonstrating the safety usage of digoxin and beta-blockers have determined the 
specialists to use these drugs in diseases like atrial flutter and fibrillation. In these cases, 
there are some who appeal to a rate or rhythm control strategy, similar to the nonpregnant 
state.   
The management of ventricular arrhythmias is closely associated to the underlying heart 
condition; for instance patients suffering from idiopathic ventricular tachycardia (VT), but 
whith a structurally normal heart will receive, as first line therapy, beta-blockers, with IC 
agents or sotalol as second-line agents. 
In pregnancy, congenital heart diseases have a complex prognosis. In most cases, long QT or 
hypertrophic cardiomyopathy are associated with ventricular arrhythmias. Sustained VT 
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Prompt detection and termination of an arrhythmia by an ICD minimize the hemodynamic 
disturbance and thereby limit the risk of harm to the fetus. ICDs are configured to 
concentrate the maximal electrical field strength to the mother’s ventricular myocardium, 
and the electrical energy to which the fetus is exposed is minimal. Delivered energies  
(2–40 J) are about a tenth of those used for external DC cardioversion. Research found 
Cardioversion safe for the entire pregnancy state therefore, it can be used, if necessary 
(Blomstrom, 2003). Also, there is not additional risk (excepting patients with underlying 
heart condition) to develop ICD complications, during pregnancy (Natale, 1997). 
Ablation is a nonsurgical technique that neutralizes parts of the abnormal electrical pathway 
(tissue) that is causing the arrhythmia. The technique utilizes a variety of imaging and 
monitoring systems that navigate flexible wires (catheters) to the heart through an artery or 
vein, locate the abnormal electrical activity (where ablation is needed), and evaluate their 
progress.  
Once in the heart, one or more catheters are used to pinpoint the source of the abnormal 
electrical signals. When the source of the arrhythmia is located, the catheter delivers bursts 
of high-energy waves that eliminate the abnormal areas.  
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In pregnancy, congenital heart diseases have a complex prognosis. In most cases, long QT or 
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can develop into peripartum cardiomyopathy or vasospastic coronary artery disease. In 
each case daily evaluation is compulsory. If VT is unstable hemodynamically, emergent 
cardioversion is recommended. Well tolerated VT is treated with lidocaine, however if VT is 
sustained or recurrent, procainamide, flacainide, propafenone, sotalol or amiodarone are 
required.  
Conservatory management is the best option for asymptomatic bradycardia. In pregnancy, 
pacemakers’ insertions are tolerated.  
During labour as well as delivery, hemodynamic changes occur, due to pain, anxiety. These 
hemodynamic changes increase the risk of arrhythmia. 
Holter monitorization of the pregnancies with arrhythmias showed a high incidence of  
ventricular and/or atrial extrasystoles, with no consequences on the future mother or on the 
child. They will gradually disappear in post-partum.       
7. Conclusion 
Pregnancy increases cardiac output, heart rate and prevalence of dysrrhythmias in normal 
healthy women. The factors that can promote arrhythmias during pregnancy are: the direct 
electrophysiological effects of the hormones, the increased sympathetic tone and sensitivity, 
hemodynamic changes, electrolyte imbalances, atrial stretch, increased end-diastolic 
volumes and underlying heart diseases.  
The most important problem in patients diagnosed with cardiac arrhythmia in pregnancy is 
the early detection, a multidisciplinary monitorization and an adequate therapy. The 
purpose is to decrease the cardiovascular complications in pregnancy and to have a good 
pregnancy outcome.                              
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can develop into peripartum cardiomyopathy or vasospastic coronary artery disease. In 
each case daily evaluation is compulsory. If VT is unstable hemodynamically, emergent 
cardioversion is recommended. Well tolerated VT is treated with lidocaine, however if VT is 
sustained or recurrent, procainamide, flacainide, propafenone, sotalol or amiodarone are 
required.  
Conservatory management is the best option for asymptomatic bradycardia. In pregnancy, 
pacemakers’ insertions are tolerated.  
During labour as well as delivery, hemodynamic changes occur, due to pain, anxiety. These 
hemodynamic changes increase the risk of arrhythmia. 
Holter monitorization of the pregnancies with arrhythmias showed a high incidence of  
ventricular and/or atrial extrasystoles, with no consequences on the future mother or on the 
child. They will gradually disappear in post-partum.       
7. Conclusion 
Pregnancy increases cardiac output, heart rate and prevalence of dysrrhythmias in normal 
healthy women. The factors that can promote arrhythmias during pregnancy are: the direct 
electrophysiological effects of the hormones, the increased sympathetic tone and sensitivity, 
hemodynamic changes, electrolyte imbalances, atrial stretch, increased end-diastolic 
volumes and underlying heart diseases.  
The most important problem in patients diagnosed with cardiac arrhythmia in pregnancy is 
the early detection, a multidisciplinary monitorization and an adequate therapy. The 
purpose is to decrease the cardiovascular complications in pregnancy and to have a good 
pregnancy outcome.                              
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1. Introduction 
Atrial fibrillation (AF) is one of the major health risks for strokes, and has been found to 
increase the risk of ischemic stroke fivefold (Wolf et al., 1987). Strokes with AF are more 
severe, cause greater disability and have worse outcomes than those without (Jørgensen et 
al., 1996; Lin et al., 1996). Approximately 15–20% of all strokes are due to AF but the 
percentage increases up to 40% for patients over the age of 90 (Marini et al., 2005). As the 
risk of initial strokes in these patients can be reduced up to 64% by long-term treatment with 
anti-coagulants (Hart et al., 2007), accurate and timely detection of AF is essential in high-
risk elderly populations. Paroxysmal AF (PAF) is defined as an AF episode that lasts longer 
than 2 min but less than 7 days. Most PAF episodes terminate spontaneously within 24 h. 
Although PAF is short-lived, it shares similar stroke risks with long-lasting persistent AF 
(Friberg et al., 2010). Furthermore, the rare and asymptomatic manifestation of AF episodes 
makes a definitive diagnosis of PAF even harder to provide. Holter or event recorder 
devices are used conventionally to capture actual episodes of AF. Using 24-h Holter 
monitoring, only 23% of cases were detected among PAF patients whose diagnosis was 
confirmed by continuous bedside electrocardiograph (ECG) monitoring (Rizos et al., 2010), 
which indicates an underestimated detection of PAF leading to inadequate treatment. Using 
7-day event-loop recording, 5.7% of cases that were missed by 24-h Holter monitoring were 
revealed to be PAF (Jabaudon et al., 2004). Thus, prolonged ECG monitoring by event 
recorders improves the detection rates of PAF cases. However, event recorders may not be 
appropriate for all patients, and depend on patient compliance. The extended use of Holter 
monitors is not commonly practiced in clinics, and few technical guidelines are currently 
available for the improvement of PAF detection by a short-term use of Holter monitors. 
Prediction methods have been studied in order to suppress PAF episodes through atrial 
pacing techniques and to provide the clinical benefit of maintaining normal sinus rhythm 
(NSR) in, for example, drug-refractory AF patients (Delfaut et al., 1998). Most of the 
methods developed were inspired by earlier physiological findings that were associated 
with the triggering mechanisms of PAF, namely, activated ectopic nodes in abnormal atrial 
tissue and the imbalance of the autonomic nervous system (ANS) via increased sympathetic 
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appropriate for all patients, and depend on patient compliance. The extended use of Holter 
monitors is not commonly practiced in clinics, and few technical guidelines are currently 
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Prediction methods have been studied in order to suppress PAF episodes through atrial 
pacing techniques and to provide the clinical benefit of maintaining normal sinus rhythm 
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with the triggering mechanisms of PAF, namely, activated ectopic nodes in abnormal atrial 
tissue and the imbalance of the autonomic nervous system (ANS) via increased sympathetic 
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or parasympathetic tone. A hypothetical transition period has been proposed during which 
the triggering mechanisms are activated, forcing NSR to change to PAF. During the 
transition, the number of premature atrial complexes (PAC), runs of atrial bigeminy and 
trigeminy, and length of paroxysmal atrial tachycardia were increased before PAF onset 
(Thong et al., 2004). Spectral analysis revealed a significant increase in ANS activity in both 
the sympathetic and parasympathetic branches, which were represented by increased low-
frequency (LF) and high-frequency (HF) components in the power spectrum density of the 
heartbeat intervals (RR intervals) (Chesnokov et al., 2008; Kim et al., 2008a). Heart rate 
variability (HRV) features in time domain analysis were also significantly changed during 
the transition (Kim et al., 2008a), again indicating a change in ANS activity. The complexity 
of RR interval dynamics decreased before the onset of PAF episodes (Chesnokov, 2008; 
Vikman et al., 1999). Poincaré plots depicting the correlation between two successive RR 
intervals in a two-dimensional diagram were also found to be closely related to ANS activity 
and to exhibit highly heterogeneous patterns during the transition (Duong et al., 2009). 
Recently, recurrence plots representing the frequency of two RR intervals in close proximity 
were investigated to discover dynamic behaviors during the transition that were not 
uncovered by earlier methods (Mohebbi & Ghassemian, 2011). In these studies, prediction 
models were derived by running pattern classification algorithms on learning sets that 
consisted of two types of ECG data: one distant and the other immediately before the onsets, 
representing NSR and the transition period, respectively (available from the PhysioBank’s 
MIT-BIH AF Prediction Database as 30-min ECG data sets). These prediction models were 
able to detect the transition to PAF events at rates of 70–97%. Some of PAF prediction 
reports are summarized in Table 1. Recent reviews of these techniques and their 
performance are also available (Sahoo et al., 2011; Mohebbi & Ghassemian, 2011). To apply 
these methods to atrial pacing techniques, ECG data need to be sampled continuously.  
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Due to the low detection rates of PAF events provided by Holter devices, alternative 
approaches have been motivated by the physiological findings of different dynamics of heart 
rate controls in PAF subjects, even when AF is not actually occurring. Thus, instead of relying 
on the capture of PAF episodes, prediction methods have been developed to provide a 
diagnostic assessment of PAF cases that display either no episodes of AF or a small number of 
episodes (Hickey et al., 2004; Kikillus et al., 2008; Kim et al., 2008a). Although these prediction 
models were motivated by the similar findings and methods explained above, they were 
evaluated against public databases that provide long-term ECG data from PAF and NSR 
subjects (available from the PhysioBank’s MIT-BIH AF and NSR Databases). The AF Database 
provides 25 ECG data sets of 10-h recordings obtained from patients with PAF. The NSR 
Database provides 18 ECG data sets of 24-h recordings obtained from healthy persons with no 
arrhythmias. Numerous approaches have been reported because multiple representations of 
heart rate dynamics were feasible at different time-points of the day or night. Each short 
segment was classified by a first-stage classifier who relied on the detection of abnormal HRV 
features and PAC. To incorporate prediction results made at different time-points into one 
assessment, a second-stage classifier inquired whether an empirical rule was satisfied. For 
example, a subject was classified as PAF if at least 10% of the segments were classified as PAF 
segments and the average probability of PAF was at least 0.35 (Hickey et al., 2004). For this 
approach, finding the empirical rule was critical to evaluate the performance of the classifier. 
The performance of this prediction model may be directly related to not only how often a PAF 
patient experiences a physiological condition resembling the transition period, but also how 
often actual PAF episodes occur immediately after the presumed transition period. However, 
no information is available on the frequency of a transition period being followed by an actual 
PAF event. Furthermore, the performance of these prediction models over a long-term 
monitoring period has not yet been investigated.  
In contrast, if the sampling of ECG data as learning sets is not confined to the transition period, 
then a prediction model may be less sensitive to whether a subject experiences the transition 
period or not and still performs as anticipated. Instead of confining learning set samples to the 
transition period, 1-h ECG segments were sampled from all available time-points and evaluated 
by a classifier based on a risk assessment of HRV analysis and Poincaré plot analysis performed 
on all samples (Kikillus et al., 2008). Because the test sets included the AF episodes, the 
classification performance was sensitive to the length of AF episodes included in the data. 
Alternatively, multiple ultra-short 3-min segments were sampled from different time periods of 
the day and classified using two different formulas designed for day or evening time (Kim et al., 
2008a, 2008b). This method did not contain AF episodes in the test data, and thus the prediction 
accuracy relates exclusively to detecting the transition period. In addition, transition periods 
were treated differently depending on the time of their occurrence (Kim et al., 2008b), which 
resulted in two time-dependent classifiers performing better than one classifier disregarding the 
occurrence time of transitions. These methods require ECG data to be continuously analyzed, 
that may demand some extraordinary functional capabilities from wireless devices and data 
networks in mobile healthcare systems.  For instance, a limited battery time is common in 
potable wireless gateway devices such as personal data assistant (PDA) or cellular phones.  
Network congestion and loss should be avoided or reliably handled in a medical sensor 
network (MSN) (Hu & Xiao, 2009) that may monitors large number of mobile subjects.  As a 
strategy that alleviates these requirements of future mobile healthcare devices and networks, an 
intermittent data sampling and its relevance to clinical decision makings could be considered. 
Thus, we propose that intermittently sampled ECG data (but devoid of any arrhythmic 
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or parasympathetic tone. A hypothetical transition period has been proposed during which 
the triggering mechanisms are activated, forcing NSR to change to PAF. During the 
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the transition (Kim et al., 2008a), again indicating a change in ANS activity. The complexity 
of RR interval dynamics decreased before the onset of PAF episodes (Chesnokov, 2008; 
Vikman et al., 1999). Poincaré plots depicting the correlation between two successive RR 
intervals in a two-dimensional diagram were also found to be closely related to ANS activity 
and to exhibit highly heterogeneous patterns during the transition (Duong et al., 2009). 
Recently, recurrence plots representing the frequency of two RR intervals in close proximity 
were investigated to discover dynamic behaviors during the transition that were not 
uncovered by earlier methods (Mohebbi & Ghassemian, 2011). In these studies, prediction 
models were derived by running pattern classification algorithms on learning sets that 
consisted of two types of ECG data: one distant and the other immediately before the onsets, 
representing NSR and the transition period, respectively (available from the PhysioBank’s 
MIT-BIH AF Prediction Database as 30-min ECG data sets). These prediction models were 
able to detect the transition to PAF events at rates of 70–97%. Some of PAF prediction 
reports are summarized in Table 1. Recent reviews of these techniques and their 
performance are also available (Sahoo et al., 2011; Mohebbi & Ghassemian, 2011). To apply 
these methods to atrial pacing techniques, ECG data need to be sampled continuously.  
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episodes) may be used as learning sets for calculating a PAF prediction model. Our driving 
hypothesis remains the same as that stated in previous reports: the non-episodic state of PAF 
subjects is different to that of NSR subjects (Kikillus et al., 2008; Kim et al., 2008a). 
The recurrence rate of silent AF is high even when the patient has undergone apparently 
successful ablation or drug therapy. Patients who had been treated with atrial ablation and 
circumferential pulmonary vein ablation were reported to have a 26.7% recurrence rate after 13 
months and a rate of 31% after 19 months, respectively (Berruezo et al., 2007; Grubitzsch et al., 
2008). Patients who underwent chemical or electrical cardioversion also showed high 
recurrence rates of 30–43% after 0.5–42 months (Aytemir et al., 1999; Lombardi et al., 2001). The 
recurrence of silent AF in stroke victims can also be as high as the percentage reported in these 
earlier studies. If clinicians and patients can be alarmed by the early diagnosis of AF to take 
appropriate measures and avoid the recurrence of ischemic strokes, tens of thousands of 
recurrent stroke victims can be saved each year. In this study, we first sought to develop a 
detection method for PAF subjects using HRV patterns obtained from intermittently sampled 
ECG. Based on this model, we then sought to predict recurrent PAF subjects among patients 
who had been successfully treated for AF previously and were currently under anti-arrhythmic 
medication. In addition, we have implemented our algorithms to a remote real-time heartbeat 
analysis system that consists of a portable ECG sensor with a three-axis accelerometer, a smart 
phone, and a data analysis server. This internet-based system should provide a developmental 
platform to investigate the detection of PAF further through the use of long-term monitoring.   
2. Methods and subjects 
2.1 Subjects and data acquisition 
The 24-h ECG data of 50 cases were obtained from the archive storage in Chungnam National 
University Hospital, Department of Cardiology. Subjects visited the clinic due for a variety of 
complaints with symptoms that might have been related to underlying cardiac diseases. Data 
were included if the subject was older than 35 years, had visited the clinic during the past 2 
years, and were free of any cardiovascular disease. All ECG data were obtained by using the 
same type of Holter monitors for 24 h. The use of patient ECG data was approved by the 
internal review board of the hospital.  
Thirty-nine patients with previously diagnosed AF were recruited for 48-h Holter monitoring 
in the same department. Patients completed the consent form for the use of experimental data 
and a stress questionnaire (Koh et al., 2001). Six patients were excluded due to the failure of 48-
h Holter monitoring (n = 3) and the loss of ECG data during data handling (n = 3). A total of 33 
patients had been under AF management for the past 1.5 years on average (15 women: age 
range, 39–82 years, median age, 66 years; and 18 men: age range, 43–78 years, median age, 66 
years). This experiment was approved by the internal review board of the hospital.  
2.2 Data processing 
2.2.1 Preparation of ECG data 
ECG signals were sampled at 125 samples per second by Holter recorders (Marquette MARS 
PC Holter monitor, GE Healthcare) and screened for arrhythmic events first by the computer 
software and then by two cardiologists. A 24-h binary record (in .bin format) was transformed 
into four 6-h text-based records using a software tool called “rdsamp.exe” available at the 
Physionet. Each record represented four different time periods of the day (namely morning 
from 6 am to 12 noon, afternoon from noon to 6 pm, evening from 6 pm to 12 midnight, and 
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night from midnight to 6 am). ECG segments that contained arrhythmic episodes were also 
removed based on medical records. Noisy parts of ECG data were automatically removed by a 
cut-off value that represented the maximum value of local heterogeneity of ECG signals (data 
not shown). The percentage of ECG signals detected as noise was also recorded. 
2.2.2 RR interval detection 
Time intervals between two successive QRS complexes (RR intervals) were obtained using the 
previous ECG analysis software for a mobile application (Salahuddin & Kim, 2006). Java-based 
analysis software was developed to detect RR intervals and calculate the HRV features. The 
analysis algorithm was mainly adapted from a derivative method (Pan & Tompkins, 1985) but 
several modifications had to be added to ensure the detection of true RR intervals in noisy 
ECG signals. Briefly, a tophat operation was performed on the band-pass waveforms to 
suppress noisy peaks and remove the baseline shift. A set of rules was applied to avoid 
detecting R peaks from unusually high or low amplitude parts and noisy parts of ECG signals. 
After detecting R peaks, another set of rules was applied to avoid extracting RR intervals that 
were too short or too long compared with average RR intervals calculated from accumulated 
RR intervals. The analysis algorithm was divided into three phases: a pre-processing, an R 
peak decision and a post-processing. During the pre-processing phase, the ECG signal (Figure 
1a) was passed through a band-pass filter — a 60th order finite impulse response digital filter 
using a Hamming window — with a cut-off frequency ranging from 8 to 12 Hz (Figure 1b). 
The band-passed signal was then filtered through a tophat operation that consisted of a series 
of minimum and maximum operations and a subtraction operation (Figure 1c). Since the size 
of the tophat filter was set to equal the average width at half maximum of the R peaks (seven 
time-points), tophat filtering preferentially enhanced RR intervals and suppressed noisy small 
peaks and large T peaks. The subtraction of the minimum-maximum filtered waveforms from 
the original waveforms eliminated baseline drifts completely. The tophat-processed ECG 
signal was differentiated so that RR interval signals resulted in two wave peaks with relatively 
larger amplitudes (Figure 1d). The resultant signal was squared to amplify the part of the 
signal with larger amplitude to a greater extent (Figure 1e). An integral waveform was 
generated by a moving window of 30 time-points in width (Figure 1f). The integral waveform 
was compared with the adaptive thresholds that were continuously updated estimates of the 
peak signal level (Figure 1g) and the peak noise level (data not shown) (Pan & Tompkins, 
1985). In our algorithm, the search back (or dual thresholds) technique (Pan & Tompkins, 1985) 
was not used since it did not seem to contribute significantly to the detection of the RR 
intervals of our ECG signals. The adaptive threshold produced a series of time-point ranges 
(rectangular wave tops), representing possible locations of R peak candidates (Figure 1h). The 
local maximum of band-passed waveform within each range was found to be an R peak 
candidate (shown as arrowheads in Figure 1i). During the R peak decision phase, a true R peak 
was found if the following two conditions were satisfied at the time-point of the R peak 
candidate: 1) if the amplitude of the raw signal was less than 1000; and 2) if the amplitude of 
tophat-filtered signal was greater than 30. During the post-processing phase, some RR 
intervals were often found to be unreasonably short or long due to errors such as detecting 
spurious peaks or missing true peaks. An RR interval was considered as valid if it satisfied the 
following two conditions: 1) if the RR interval was longer than 0.75 times; and 2) if the RR 
interval was shorter than 1.5 times the accumulated RR interval average to avoid unusually 
short or long RR intervals caused by noisy signals or missing R peaks, respectively.  
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night from midnight to 6 am). ECG segments that contained arrhythmic episodes were also 
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Fig. 1. Processing steps of R peak detection algorithm. (a) the input signal, (b) the output of 
bandpass filtering, (c) tophat, (d) differentiator, (e) squaring; (f) moving-window integration, 
(g) locally adaptive thresholding, (h) possible QRS complex ranges, (i) QRS complex 
candidates detected from band-passed waveform. (Permission from Salahuddin & Kim, 2006). 
2.2.3 HRV calculation 
From each 6-h RR interval record, four 30-min RR records were randomly selected. The 
baseline trend in heart rates introduced by postural change or movement was removed 
using a linear curve-fitting method. Detrended time series were cubically interpolated and 
re-sampled at 4 Hz, and the fast Fourier transform was windowed with 256-sample-width 
Hamming windows with 50% overlap. All HRV features were calculated from the 
detrended RR interval series. 
In each RR interval set, the following HRV features were calculated using the ECG analysis 
software (also available at http://mhealth.kaist.ac.kr/afdectection): mean heart rate (mean 
HR), mean heartbeat intervals (mean RR), standard deviation of NN interval (SDNN), 
coefficient of variation (CV), root mean square of successive differences (RMSSD), and 
percentage heartbeat intervals with difference in successive heartbeat intervals greater than 
50 ms (PNN50) as time domain features; HRV index (bin width of 8.0 ms), triangular 
interpolation of heartbeat interval histogram (TINN), and stress index (SI) (Lednev et al., 
2008) as geometrical analysis features; and LF (LF 0.04-0.09 Hz), HF (HF >0.1 Hz), the ratio 
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of LF to HF (LF/HF), normalized LF (LFnu) and normalized HF (HFnu) components as 
frequency domain features (Task Force, 1996). Among the HRV features, the RMSSD is 
worthy of further mention because it has been used to indicate the levels of mental or 
physical stress of a subject (Task Force, 1996). In preparing the learning sets, RMSSD was 
used as basis to estimate the activity level of a subject during daily activity. 
2.2.4 Poincaré plot pattern analysis 
The Poincaré plot is a two-dimensional scatter plot of each heartbeat interval plotted against 
the subsequent interval, and thus depicts the correlation between successive heartbeat 
intervals (Woo et al., 1992). Recently, Poincaré plots of arrhythmic ECG data were 
systematically investigated to discover 10 distinctive prototypical patterns that represent 
different kinds of arrhythmias from 24-h Holter ECG data (Esperer et al., 2008). For 
example, fan-shaped Poincaré plots were typical in subjects with AF; multiple side lobe 
patterns specified the presence of atrial premature beats or ventricular premature beats; 
while an island pattern was highly correlated with atrial flutter or atrial tachycardia 
(Esperer et al., 2008). Poincaré plots were generated to calculate Poincaré plot features and 
classify them into different patterns such as torped, island, multiple side lobes, and fan 
pattern (Duong et al., 2009). Finally, standard deviations of the minor axis (SD1) and major 
axis (SD2), the ratio of SD1 to SD2 (SD1/SD2), standard deviation of the RR intervals (SDRR), 
standard deviation of the successive differences of the RR intervals (SDSD), and 
autocorrelation function of the RR intervals (rRR) were calculated from the Poincaré plot 
(Brennan et al., 2001). In addition to the previously reported conventional descriptors, new 
cluster descriptors were calculated by analyzing the Poincaré plots as an image (Duong et 
al., 2009). In brief, Poincaré plot images (Figure 2A) were thresholded at the gray level of 0 
(Figure 2B). Second, binary plot images were eroded once with the 3×3 structuring element, 
reconstructed with respect to the binary plot, and seed-filled (Figure 2C) (Serra, 1984). A 
cluster was defined as an isolated group of connected points containing more than 12 points 
that effectively represented highly correlated heartbeat interval events. Then, the cluster was 
described by using shape attributes, such as form factor and minor to major axis ratio; 
texture attributes, such as entropy and contrast; and location attributes, such as the number 
of clusters on the diagonal line. Torpedo, island, and multi-sided lobe patterns were 
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Circadian rhythm (CR) represents physiological phenomena repeatedly occurring during a 
time period of approximately 24 h. In humans, almost every physiological function displays 
CR to some degree and the mechanism can be endogenous, exogenous or a combination of 
both. The cardiovascular system also exhibits a pronounced CR which is influenced by both 
external stimuli and endogenous homoeostatic control mechanism with the latter playing a 
more important role than the former (Guo & Stein, 2002). Circadian variations are found in a 
number of electrophysiological parameters such as heart rate, QT interval, sinus node 
recovery time, and atrial refractory periods (Guo & Stein, 2002). Although detailed genetic 
or epigenetic mechanisms are not fully understood, numerous cardiovascular and 
cerebrovascular diseases show circadian variations. For example, paroxysmal and persistent 
atrial arrhythmia occurs more frequently during the evening time (Mitchell et al., 2002), 
whereas sudden cardiac death (Savopoulos et al., 2006) and myocardial ischemia (Li, 2003) 
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occur predominantly in the morning. In previous studies, we reported circadian variations 
of HRV features in NSR and PAF subjects (Kim et al., 2008a) and CR parameters such as 
amplitudes, phase, and shift obtained from a least square fitting of sinusoidal functions to 
various HRV features. On the day of onset of PAF, CR of PAF subjects were affected and 
significantly different from those of NSR subjects. The CR parameters obtained from the 
non-episodic data for that day were used to detect PAF patients with an accuracy of 84.6% 
(Olemann & Kim, 2011). 
 
 
Fig. 2. The Poincaré plot of island pattern (A), its binary plot (B), opening by reconstruction 
and closing (C), and cluster boundary overlaid onto the binary plot (D). (Permission from 
Duong et al., 2009). 
To obtain CR parameter patterns of HRV features, a non-linear curve-fitting method known 
as the Levenberg-Marquardt algorithm (Levenberg, 1944) was applied (Statgraphics Plus 
V4.1 Professional System®, Manugistics, Inc., Rockville, MD, USA) to each HRV feature set 
that consisted of at least six time-points which represents a time span of at least 6 h. The 
initial values for the regression were set by trial and error and were maintained constant for 
both the NSR and PAF group. The CR parameters obtained were the amplitude, the shift 
and the phase, from the following sinusoidal equation used for the curve fitting: 
 H (t) = b  cosine ( w t + p) + a             (1) 
where H(t) represents the HRV feature, b represents amplitude, p represents phase (in 
degrees), a represents shift, t represents time of the day (in hours), and w represents 15/h. 
The final amplitude was obtained by taking the absolute value. The final phase was 
modified to restrict its phase value between 0 and 180 using the following formula:  
Development of Computer Aided  
Prediction Technology for Paroxysmal Atrial Fibrillation in Mobile Healthcare 
 
523 
 Phase = 180/phi  cosine−1(b  cosine (p  phi/180 )/  b  )         (2) 
While performing the sinusoidal curve fitting, time-points that showed unusual residuals 
(Studentized residual > |3.0|) were removed from the analysis.  
2.3 Data analysis  
2.3.1 Preparation of learning sets  
Before preparing the learning sets, based on the pattern recognition algorithms of Poincaré 
plots, feature sets showing noisy plots that consist of most of events out of the clusters were 
also removed since these were caused by the poor contact of electrodes (Figure 3). Feature 
sets showing island, multi-sided lobe, and fan patterns were removed from learning sets of 
NSR group since they represent arrhythmic events (Esperer et al., 2006). However, only 
records showing fan shapes were removed from learning sets of PAF group. To divide 
learning sets according to the level of physical or mental activity, an arbitrary cut-off value 
of RMSSD (in sec) was selected to assign each 30-min RR interval to two types of ANS 
conditions: one representing the activated state of the vagal nervous system (RMSSD > 0.040 
sec) and the other representing the suppressed state of the vagal nervous system due to 
mental or physical activity (RMSSD <0.040 sec) experienced by the subject during daily 
activity. HRV feature sets from different subject groups were compared by Mann-Whitney 
signed rank test (Statgraphics Plus V 4.1). Test results were considered significant if the p-
value was less than 0.05 (95% confidence level).  
From the prepared learning sets, the CR curve fittings were performed according to the 
procedure described in the section above. The calculated CR parameters were compared 
between NSR and PAF groups based on median values by the Mann-Whitney test 
(Statgraphics Plus V 4.1). The results were considered significantly different if p-values were 
less than 0.05. 
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Fig. 3. Flow diagram for data processing and analysis used in the study. 
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2.3.2 Derivation of prediction models  
Significant HRV and Poincaré plot features were selected from the learning sets by 
evaluating the worth of a feature based on the value of the chi-squared statistic with respect 
to the class (Weka 6.1, The University of Waikato, Hamilton, New Zealand). Naïve Bayesian, 
logistic regression, and support vector machine (SVM) analyses were performed to derive 
classification models that detect 30-min RR intervals of PAF subjects (Weka 6.1). Because 
this first classification was based on 30-min segments of RR interval data, it was called the 
segment-based classification. Once each 30-min segment was annotated, a second phase of 
classification was derived from a heuristic rule. Because annotation results for each subject 
were used, it was called the subject-based classification. A similar approach of two-phase 
classification has been reported previously (Hickey et al., 2006). According to the clinical 
definition of PAF, a subject would be diagnosed with PAF if at least one 30-min segment 
contained AF episodes. However, because our learning sets did not contain any segments 
with AF episodes (fan-shaped plots were removed), the empirical rule in this study was 
modified to classify subjects as PAF if any of four time periods had two or more segments 
annotated as PAF within the same time period.  
Significant CR features were selected from the learning sets by the chi-squared test (Weka 
6.1). Naïve Bayesian, logistic regression, and SVM analyses were performed to derive 
classification models that detect PAF subjects using CR features (Weka 6.1). 
2.3.3 Preparation of test sets  
Before preparing the test sets, the records showing noisy Poincaré plots were removed from 
further analysis. Testing sets were divided according to the RMSSD cut-off. The segment-
based classification was performed using the classification algorithm that produced the best 
accuracy. These outputs were further tested using the subject-based classification rule with 
different segment sampling methods: two, three, or four 30-min samples per time period to 
determine the dependence of classification accuracy on the number of sample segments. 
Cases classified as NSR were tested using the CR classification (Figure 3). 
3. Results 
3.1 Establishment of PAF prediction models using data from the 24-h study 
3.1.1 Segment-based model and subject-based model 
A total of 299 and 319 items of RR interval data were obtained from 20 NSR and 24 PAF 
patients, respectively, and were processed for HRV calculation. HRV features that differed 
significantly between two types of data were initially screened by the Mann-Whitney test at 
a significance level of p = 0.05. Most HRV features were higher in the PAF groups except for 
SD2, SI, and HFnu, which were lower (data not shown, p<0.01). Similar outcomes have also 
been reported in previous studies (Kim et al., 2008a, 2008b) using NSR and AF databases 
available at Physionet. These HRV features were further ranked based on their contribution 
to a prediction model (chi-squared feature selection method, Weka 6.1). The top nine HRV 
features (RMSSD, SDSD, SD1, SDRatio, rRR, %Cluster, SDNN, CV, and PNN50) were then 
used to generate a prediction model that represented the segment-based classification 
model. The accuracy of each classification method is summarized in Table 2. The logistic 
regression analysis produced the highest accuracy among three classification algorithms 
(71.4%) and was selected for the testing.  
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Based on this observation, a simple heuristic rule was applied to generate the subject-based 
classification. Two of 24 PAF cases were misclassified as NSR (false negative) and four of 20 
NSR cases (false positive) were misclassified (Table 3). False-negative cases showed only one 
record classified as PAF. All false-positive cases showed fan-shaped Poincaré plots. 
 
 
Classification methods Sensitivity Specificity Accuracy 
Naïve Bayesian 39.5% 96.0% 66.8% 
Logistic regression 
analysis 58.3% 85.3% 71.4% 
Support vector machine 49.5% 89.6% 68.9% 
Table 2. Performance of different classification algorithms for the segment based 




                                Predicted 
   Observed NSR PAF 
NSR (n=20) 16 (80%) 4 (20%) 
PAF (n=24) 2 (8%) 22 (92%) 
Table 3. Performance of the subject based classification using the results from the segment-
based classification by logistic regression analysis  
3.1.2 The CR model  
The phases of the HRV features of the two groups did not show significant differences (data 
not shown; p > 0.05), thereby suggesting that there was no significant difference in the time-
point of HRV peak occurrence. The CR amplitudes and shifts of rRR, HF, LF, HR and 
RMSSD showed significant differences between the two groups (data not shown; Mann-
Whitney test, p < 0.05). These CR features were further ranked based on their contribution 
to a prediction model (chi-squared feature selection method, Weka 6.1). The top three CR 
features (rRR shift, LF amplitude, and HR amplitude) were then used to generate a 
prediction model that represented the segment-based classification model. These three HRV 
features were curve-fitted and plotted to determine the circadian change in individual 
subjects (Figure 4). Logistic regression analysis was performed with the three CR features 
and produced an accuracy of 86% in predicting PAF cases (sensitivity of 79% classifying 
19/24 PAF cases and specificity of 95% classifying 19/20 NSR cases). The false-positive 
subject (n=1) seemed to show greater fluctuations, whereas false-negative subjects (n=5) 
showed fewer fluctuations in CR amplitudes. 
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Fig. 4. Circadian rhythms of selected HRV features were significantly different between NSR 
and PAF cases. HR: heart rates per min, LF: low frequency area (msec2) after logarithmic 
transform, and rRR: autocorrelation function of the RR intervals. 
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3.2 Prediction of AF recurrence using 48-h recordings 
ECG data from 48-h Holter monitoring were first screened for AF episodes using the 
software in the Holter system and software findings for AF were confirmed by two 
cardiologists (JHP, JHK). Nineteen of 33 subjects were diagnosed as NSR whose heart 
rhythms were successfully maintained for 48 h under drug treatment (normal group). Ten 
subjects were diagnosed as PAF and four as persistent AF (recurrent group; recurrence rate 
of 42%). Normal and recurrent groups did not differ significantly different in terms of age 
(Mann-Whitney test, p > 0.05), gender, or other diseases such as diabetes, hypertension, or 
past strokes (chi-squared test, p > 0.05).  
The noise detection algorithm detected four NSR cases and showed that more than 30% of 
the total ECG data were corrupted by noise possibly due to poor electrode contacts; these 
were removed from the test sets to avoid misinterpretation. When four ECG segments 
were sampled from each time period of ECG data, a total of 350 and 270 segments were 
obtained from 15 normal and 14 recurrent cases, respectively, and were processed for the 
calculation of HRV and Poincaré plot features. Using the segment-based classification and 
subject-based rule, 9/10 recurrent PAF patients were correctly identified, whereas 13/15 
normal subjects were correctly identified (data not shown). In addition, four persistent AF 
cases were all correctly identified. An illustrative example for the subject-based rule is 
described in Figure 5, in which a data point represents the probability density value of the 
segment based model at a given time-point. Data points for an NSR case remain higher 
than the empirical cut-off at all time-points, whereas those for a PAF case often fall below 
the cut-off even during the days when no episodes were evident (Figure 5). Subjects 
classified as normal cases by the subject-based rule (n = 14) were further tested with the 
CR-based model. One false-negative case was correctly identified as recurrent and all 
normal cases were correctly confirmed as normal cases. Therefore, the final classification 
resulted in a sensitivity of 100% (14/14 recurrent cases) and a specificity of 86% (13/15 
normal cases) (Table 4). The same classification procedure was applied to the data sets 
obtained by sampling two or three segments per time period and classification results are 
summarized in Table 4. The number of sampled segments did not change the 
classification outcomes drastically. 
4. Conclusion and discussion 
In this study, we have developed a new method for predicting PAF subjects using 
intermittently sampled ECG data and applied it to the identification of recurrent AF cases. 
The proposed method consists of an empirical rule and a CR-based classification. The 
empirical rule alone identified nearly 93% of recurrent cases (13/14 cases) and 86% of 
normal cases (13/15 cases). Because our aim was not to miss any recurrent cases, normal 
cases classified by the empirical rule were re-tested using the CR-based prediction model. 
The false-negative case was correctly identified as a recurrent case thus achieving a 100% 
sensitivity and no false-positive cases were generated thus maintaining the 86% specificity. 
Our results suggest that intermittently sampled ECG data could be used to detect the 
increased likelihood of PAF episodes. Since previous PAF prediction methods relied on the 
change during the transition from NSR to PAF, ECG needs to be analyzed continuously not 
to miss transition periods. Furthermore, somewhat higher degree of false positive errors 
may be expected in an actual implementation of long term ECG analysis since the likelihood 
of not having subsequent PAF episodes following a transition period is not known. 
 













































































Fig. 4. Circadian rhythms of selected HRV features were significantly different between NSR 
and PAF cases. HR: heart rates per min, LF: low frequency area (msec2) after logarithmic 
transform, and rRR: autocorrelation function of the RR intervals. 
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may be expected in an actual implementation of long term ECG analysis since the likelihood 
of not having subsequent PAF episodes following a transition period is not known. 
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Contrary to previous prediction methods, our classification models were not designed to 
detect the transition period prior to PAF episodes exclusively. Instead, they were aimed to 
evaluate the likelihood of a 24 hour period when PAF episodes may occur. Thus, the 
performance of our proposed method can be less sensitive to the continuity of ECG data but 
allows ECG recordings to be sampled over the whole day. Two samples gave results that 
were as accurate as those of four samples taken during four 6-h time periods (Table 4). 
Furthermore, our results indicated that the proposed methods tended to show an increased 
likelihood of detecting PAF cases even during the days when no PAF episodes were evident 
(Figure 5). Therefore, we conclude that our intermittent sampling strategy is as accurate for 
predicting recurrent PAF as previously reported methods.  
 
CLASS NSR PAF NSR PAF NSR PAF 
NSR (n = 15) 14 (93) 1 (7) 13 (86) 2 (14) 13 (86) 2 (14) 
PAF (n = 10) 0 (0) 10 (100) 0 (0) 10 (100) 0 (0) 10 (100) 
No. of samples 
taken in each 
time period  
(6 hrs) 
2 3 4 
Table 4. Performance of proposed methods for predicting PAF subjects using a subject-
based rule and a CR-based classification algorithm. Performance results were obtained 
when two, three, or four 30-min ECG records were sampled from each of four time periods 
during a day. 
The intermittent sampling approach might be more effective in mobile healthcare settings 
because the sensor may not need to be worn all day, which could effectively reduce many 
problems caused by poor sensor tolerance, limited battery life, and high data transmission 
costs of current technology. In general, mobile healthcare technology offers many attractive 
features such as convenient wearable ECG sensors, real-time feedback of abnormal heart 
rhythms, and timely intervention in the case of adverse events. However, the continuous 
measurement of ECG signals might not be ideal as a long-term monitoring solution in 
mobile healthcare settings because it requires long hours of wearing a sensor that may 
stigmatize a majority of patients and eventually influence the quality of the data. For 
example, Holter monitoring was regarded as inconvenient because of hygienic aspects, 
physical activity, night sleep, and skin reactions (Fensli & Boisen, 2009). Based on our 
understanding of current advances in low-power bioelectronics (Sarpeshkar, 2010), the 
proposed intermittent sampling of ECG signals is believed to provide an attractive 
alternative strategy to long-term monitoring in mobile healthcare settings. It could be 
specially adapted to work with wireless devices such as wearable sensors and gateway 
devices that consume battery power at high rates. In addition, the amount of data traffic 
would be minimized, which is also attractive in countries where wireless data transfer is 
costly. Thus, in developing a computer-aided prediction method for mobile healthcare 
settings, it seems important to consider human factors, such as patient acceptance of 
procedures, or device factors, such as battery time or data transfer costs. 
Development of Computer Aided  
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Fig. 5. Distribution of probability values from the segment-based model applied to two 
patient cases. Data points in the hollow circle are from a normal case (NSR). Data points in 
the solid square are from a PAF case on the day when PAF episodes were recorded, whereas 
those in the hollow square and triangle are from the same case during the previous and 
following days when no PAF episodes were recorded. The points in the area under the  
cut-off at 0.25 (broken line) were classified as PAF. 
It is becoming evident that a significant proportion of cryptogenic stroke is due to intermittent 
AF. By using 30-day cardiac event monitors, 20% of such strokes was found to be related to AF 
(Elijovich et al., 2009). Warfarin treatment was given to patients after the detection of 
intermittent AF (despite no detection of AF on ECG or in-patient telemetry monitoring in the 
majority of patients). Similarly to the detection of recurrent PAF, prevention of recurrent 
strokes related to PAF in particular may require long-term ECG monitoring. For these 
applications, our proposed intermittent sampling method should also be suitable as an initial 
screening method that generates a real-time alarm or trend report that enables timely 
intervention. For example, if the incidence of abnormal segments increases, then the ECG 
sampling strategy may be changed to a continuous monitoring mode to capture the PAF 
episodes. In this way, patients can be monitored in the long term to determine recurrence after 
conversion treatment or the origin of strokes, so that conventional Holter monitoring can be 
complemented or improved. For initial screening purposes, the ECG sensor used in this study 
can be replaced by a heartbeat sensor because all analytic features were calculated from RR 
interval data rather than the morphology of ECG signals. Current advances in microelectronics 
have provided a variety of heartbeat sensors ranging from conventional chest belt type to 
Doppler radar-based non-contact types. These sensors are usually equipped with a module of 
wireless data communication so they can transmit the signals to the gateway device that is 
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Fig. 6. (A) System components of web-based heartbeat analysis system. (B) Electrode 
attachment. (C) Poincaré plots were generated from wirelessly transmitted ECG data 
obtained from an NSR and an AF subject (Pictures in (A) and (B) were kindly provided by 
Alivetec Technologies Pty. Ltd.). 
4.1 Development of web-based real-time heartbeat analysis 
Currently, we are actively developing a remote real-time heartbeat analysis system that 
consists of a wearable ECG sensor (AliveECG monitor, Alive Technologies Pty. Ltd, 
Ashmore, Queensland, Australia) with a three-axis accelerometer, a smart phone (HD2, 
HTC Corporation, Taoyuan, Taiwan ROC), and a data analysis server (Microsoft Windows 
XP; Figure 6). The original server software (Cardiomobile, Alive Technologies) displays 
ECG, activity features, and global positioning system-based location in a web-based map in 
real time or in review mode. In addition to these functions, HRV features and outputs from 
a PAF prediction model are also calculated and displayed in our current version (Figure 7). 
A feasible scenario of using our system is that a wireless ECG sensor worn by a patient, and 
communicating to the smart phone through the near field Bluetooth, transmits ECG signals 
to the remote server through a wireless data streaming service. The remote server performs 
real-time analysis of transmitted ECG data and detects abnormal events (or trends). In the 
case of PAF prediction, a cardiology specialist at the hospital may be notified to interpret the 
remote monitoring and confirm the diagnosis. Compared with conventional Holter 
monitoring systems, a mobile healthcare solution can be designed to enable the patient to 
carry out normal daily activities, while still being under continuous monitoring.  
Development of Computer Aided  





Fig. 7. Real-time heartbeat analysis system for remote monitoring of ECG and HRV of 
patients. Heart rates, energy expenditure, physical activity, HRV (RMSSD), and abnormal 
heartbeats (Abnormality %) can be monitored by remote clinical staff in real time while a 
patient is exercising outdoors during daily activity. In the case of advent events, user 
location data from the global positioning system can be provided to paramedic staff  
(user’s current position is indicated by the avatar on the web-based map)  
(Cardiomobile is the trademark of Alivetec Technologies Pty. Ltd.   
The server software was kindly provided to be modified by us.) 
Since the patient may experience an arrhythmic episode during physical activity, mobile 
solutions may enhance the quality of data measured by enabling the patient to carry out 
normal daily routines. Currently, we are also implementing the CR analysis of HRV features 
and its related PAF prediction. This prototype system should help us to discover the “real 
problem” and the users’ requirements, demonstrate the actual functionality of a device, and 
provide many insights on how to design and build a more advanced system that should 
enable long-term ECG monitoring. The future system is being designed to provide 
additional benefits for stroke or heart disease rehabilitation patients. 
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